european journal of pharmacology

an international journal

ejp

Master Author and Keyword Indexes, Volumes 294–316, 1996

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1996

european journal of pharmacology

Author and Keyword Indexes, 1996
Volumes 294–316

ELSEVIER

AMSTERDAM — LAUSANNE — NEW YORK — OXFORD - SHANNON - TOKYO

Copyright © 1997 Elsevier Science B.V. All rights reserved.

ISSN 0014-2999/97/$17.00

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science B.V., and the following terms and conditions apply to their use:

Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

In the USA, users may clear permissions and make payment through the Copyright Clearance Center Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; Tel. (508) 7508-400; Fax (508) 7504 744. In the UK, users may clear permissions and make payment through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP. In other countries where a local copyright clearance centre exists, please contact it for information on required permissions and payments.

Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution.

Permission of the publisher is required for all other derivative works, including compilations and translations.

Electronic Storage
Permission of the publisher is required to store electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Notice
No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 17005, 1001 JA Amsterdam, The Netherlands.

Publication information
European Journal of Pharmacology (ISSN 0014-2999). As of 1996 the journal is no longer divided into sections. For 1997, volumes 317–339 are scheduled for publication. Volumes 317 and 318 appeared in 1996 but remain the first volumes of the 1997 subscription year.
Subscription prices are available upon request from the publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request.
Claims for missing issues must be made within six months of our publication (mailing) date.
For orders, claims, product enquiries (no manuscript enquiries) please contact the Customer Support Department at the Regional Sales Office nearest to you:
New York, Elsevier Science, P.O. Box 945, New York, NY 10159-0945, USA. Tel.: (1-212) 633-3730 (Toll Free number for North American Customers:1-888-4ES-INFO (437-4636)), Fax: (1-212) 633-3680; e-mail: usinfo-f@elsevier.com
Amsterdam, Elsevier Science, P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel.: (1-212) 485-3757; Fax: (1-212) 485-3432; e-mail: nlinfo-f@elsevier.nl
Tokyo, Elsevier Science, 9-15, Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan. Tel.: (81-3) 5561-5033; Fax: (81-3) 5561-5047; e-mail: kyf04035@niftyserve.or.jp
Singapore, Elsevier Science, No. 1 Temasek Avenue, #17-01 Millenia Tower, Singapore 039192. Tel.: (+65) 434-3727; Fax: (+65) 337-2230; e-mail: asiainfo@elsevier.com.sg
All questions arising after acceptance of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publisher, Elsevier Science B.V., Log-in Department, P.O. Box 2759, 1000 CT Amsterdam, The Netherlands (Fax: (31-20) 485-3239). Address for courier service: Molenwerf 1, 1014 AG Amsterdam, The Netherlands.
In the U.S.A. and Canada: For further information on this and other Elsevier journals please contact: Elsevier Science Inc., Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. (Tel.: 212-633-3750; Fax: 212-633-3764; Telex: 420.643 AEP UI).

Advertising information
Advertising orders and enquiries may be sent to:
International: Elsevier Science, Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK; Tel. (44-1865) 843-565; Fax (44-1865) 843-976.
USA & Canada: Weston Media Associates, Daniel Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110, USA; Tel. (1-203) 261-2500; Fax: (1-203) 261- 0101.
Japan: Elsevier Science Japan, Marketing Services, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106, Japan; Tel. (81-3) 5561-5033; Fax (81-3) 5561-5047.

US mailing info – European Journal of Pharmacology (ISSN 0014-2999) is published weekly by Elsevier Science NL (P.O. Box 211, 1000 AE Amsterdam, The Netherlands). Annual subscription rate in the USA US$ 6431.00 (valid in North, Central and South America), including air speed delivery. Periodicals postage paid at Jamaica, NY 11431.
USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.
AIRFREIGHT AND MAILING in the USA by Publications Expediting Inc., 200 Meacham Avenue, Elmont, NY 11003.

Printed in The Netherlands

♾ The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

ELSEVIER

European Journal of Pharmacology

ejp

Master author index to volumes 294–316 (1996)

Aas, P.
In vitro effects of toxogonin, HI-6 and HLö-7 on the release of [^{3}H]acetylcholine from peripheral cholinergic nerves in rat airway smooth muscle (301) 59
Abadie, P., Rioux, P., Scatton, B., Zarifian, E., Barré, L., Patat, A. and Baron, J.-C.
Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography (295) 35
Abassi, Z., see Gurbanov, K. (310) 193
Abbott, F.V., see Hong, Y. (301) 41
Abdel Salam, O.M.E., Szolcsányi, J., Pórszász, R. and Mózsik, G.
Effect of capsaicin and resiniferatoxin on gastrointestinal blood flow in rats (305) 127
Abdul-Hussain, M.N., Jia, Y.L. and Hussain, S.N.A.
Mechanisms mediating the vasodilatory effects of *N*-hydroxy-L-arginine in coronary arteries (305) 155
Abe, K., Watanabe, Y. and Saito, H.
Differential role of nitric oxide in long-term potentiation in the medial and lateral amygdala (297) 43
Abeywardena, M., see McLennan, P. (300) 83
Abraham, C., see Delagrange, P. (316) 195
Abreu, J.-N., see Friedrichs, G.S. (306) 99
Abu-Dalu, R., Zhang, J.M. and Hanani, M.
The actions of ketotifen on intestinal smooth muscles (309) 189
Acosta-Burruel, M., see Hawkinson, J.E. (304) 141
Acosta-Burruel, M., see Hawkinson, J.E. (307) 219
Acs, G., see Szallasi, A. (299) 221
Adachi, K., see Koshikawa, N. (308) 227
Adachi, Y., Hashimoto, K., Hisa, H., Yoshida, M., Suzuki-Kusaba, M. and Satoh, S.
Angiotensin II-induced renal responses in anesthetized rabbits: effects of N^{ω}-nitro-L-arginine methyl ester and losartan (308) 165
Adami, M., Bertorelli, R., Ferri, N., Foddi, M.C. and Ongini, E.
Effects of repeated administration of selective adenosine A_1 and A_{2A} receptor agonists on pentylenetetrazole-induced convulsions in the rat (294) 283
Ader, J.-L., see Praddaude, F. (294) 173
Adham, N., Gerald, C., Schechter, L., Vaysse, P., Weinshank, R. and Branchek, T.
[^{3}H]5-Hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT_4 receptor (304) 231
Adler-Graschinsky, E., see Lorenzo, P.S. (312) 203
Advenier, C., see Biyah, K. (308) 325
Aghajanian, G.K., see Marek, G.J. (305) 95
Ahlberg, S., see Dasgupta, S. (316) 325
Ahlenius, S., see Hillegaart, V. (295) 155
Ahlenius, S., see Salmi, P. (307) 27
Ahlenius, S., see Wadenberg, M.-L. (294) 247
Ahmmed, G.U., see Yoshida, A. (312) 115
Ahn, S.K., Shin, Y.K., Kang, H.J., Han, E.S. and Lee, C.S.
Effects of protein kinase inhibitors on the stimulated neutrophil responses by degraded immunoglobulin G (306) 175
Aïssa, J., Nathan, N., Arnoux, B. and Benveniste, J.
Biochemical and cellular effects of heparin-protamine injection in rabbits are partially inhibited by a PAF-acether receptor antagonist (302) 123
Ajuebor, M.N., see Cambridge, H. (301) 151
Akil, H., see Meng, F. (311) 285
Akima, M., see Tamura, K. (312) 195
Akiyama, K., see Yamagishi, R. (315) 73
Akuzawa, S., Miyake, A., Miyata, K. and Fukutomi, H.
Comparison of [^{3}H]YM060 binding to native and cloned rat 5-HT_3 receptors (296) 227
Alcaraz, M.J., see Payá, M. (312) 97
Aldasoro, M., see Medina, P. (300) 221
Alekseev, A.E., see Brady, P.A. (308) 343
Alescio-Lautier, B., Rao, H., Paban, V., Devigne, C. and Soumireu-Mourat, B.
Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V_1 receptor antagonist in mice (294) 763
Alexander, E., see Pennacchio, M. (305) 169
Aliev, G., see Ralevic, V. (313) 221
Allescher, H.-D., see Kurjak, M. (314) 165
Allescher, H.-D., see Willis, S. (315) 59
Allingham, K., see Spanagel, R. (305) 39
Alper, R.H., see Szabó, A. (315) 187
Alper, S.L., see Coupry, I. (295) 109
Altura, B.M., Zhang, A., Cheng, T.P.-O. and Altura, B.T.
Exposure of piglet coronary arterial muscle cells to low alcohol results in elevation of intracellular free Ca^{2+}: relevance to fetal alcohol syndrome (314) R9
Altura, B.T., see Altura, B.M. (314) R9
Alvarez, F.J., see Molina-Holgado, F. (316) 39
Álvarez, M., see Gil-Longo, J. (310) 175
Alves, A.C., Pires, A.L.A., Cruz, H.N., Serra, M.F., Diaz, B.L., Cordeiro, R.S.B., Lagente, V., Martins, M.A. and E Silva, P.M.R.
Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro (312) 89
Alves, A.C., see Diaz, B.L. (296) 173
Alves, R.V., see De Campos, R.O.P. (316) 277
Amalric, M., see Ouagazzal, A. (294) 137
Amann, R., Schuligoi, R., Lanz, I. and Peskar, B.A.
Effect of a 5-lipoxygenase inhibitor on nerve growth factor-induced thermal hyperalgesia in the rat (306) 89
Amano, T., see Momiyama, T. (310) 1
Amaro, A., see Molina-Holgado, F. (316) 39
Ambrosio, E., Tella, S.R., Goldberg, S.R., Schindler, C.W., Erzouki, H. and Elmer, G.I.
Cardiovascular effects of cocaine during operant cocaine self-administration (315) 43
Amemiya, M., see Iimura, O. (296) 319
Amenta, F., see Barili, P. (310) 129
Amenta, F., see Ricci, A. (301) 189

Ameri, A., see Gleitz, J. (315) 83
Amishima, M., see Nasuhara, Y. (296) 161
Amit, Z., see Wise, R.A. (307) 15
Ammer, H. and Schulz, R.
Chronic exposure of NG108-15 cells to inhibitory acting drugs reduces stimulatory prostaglandin E_1 receptor number (302) 199
Amoroso, S., see Di Renzo, G. (294) 11
Anacardio, R., see Guerrini, R. (302) 37
Andersen, P.H., Tygesen, C.K., Rasmussen, J.S., Søegaard-Nielsen, L., Hansen, A., Hansen, K., Kiemer, A. and Stidsen, C.E.
Stable expression of homomeric AMPA-selective glutamate receptors in BHK cells (311) 95
Anderson, J.J., Kask, A.M. and Chase, T.N.
Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists (295) 163
Anderson, J.L., see Zhu, S.-J. (299) 205
Andersson, R.G.G., see Mårtensson, L.G.E. (316) 273
Andrews, P., Torii, Y., Saito, H. and Matsuki, N.
The pharmacology of the emetic response to upper gastrointestinal tract stimulation in *Suncus murinus* (307) 305
Andrieux, J., see Shen, S. (307) 133
Angelucci, L., see Patacchioli, F.R. (299) 29
Angus, J.A., see Whorlow, S.L. (315) 11
Annunziato, L., see Di Renzo, G. (294) 11
Annunziato, L., see Taglialatela, M. (316) 373
Anouar, A., Clerget, M.-S., Durroux, T., Barberis, C. and Germain, G.
Comparison of vasopressin and oxytocin receptors in the rat uterus and vascular tissue (308) 87
Ansanay, H., Sebben, M., Bockaert, J. and Dumuis, A.
Pharmacological comparison between [^{3}H]GR 113808 binding sites and functional 5-HT_4 receptors in neurons (298) 165
Antkiewicz-Michaluk, L., Karolewicz, B., Michaluk, J. and Vetulani, J.
Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca^{2+} channels (294) 459
Antkiewicz-Michaluk, L., see Karolewicz, B. (313) 181
Antoine, M.-H., Ouedraogo, R., Sergooris, J., Hermann, M., Herchuelz, A. and Lebrun, P.
Hydroxylamine, a nitric oxide donor, inhibits insulin release and activates K^+_{ATP} channels (313) 229
Antonelli, T., see Ferraro, L. (306) 33
Antonicek, H., see Van der Staay, F.J. (294) 361
Antunes, E., see Costa, S.K.P. (298) 113
Antunes, E., see Ferreira, H.H.A. (310) 201
Anwyl, R., see Manahan-Vaughan, D. (294) 617
Appendino, G., see Szallasi, A. (299) 221
Arabia, A., see Bagetta, G. (294) 341
Arai, M., see Naito, Y. (294) 47
Araki, H., see Noguchi, K. (308) 53
Araki, T., Kato, H., Shuto, K., Fujiwara, T., Kogure, K. and Itoyama, Y.
Effects of cerebral ischemia on dopamine receptors in the gerbil striatum (306) 73
Araújo, C., see Lopes-Martins, R. (308) 287
Archer, S., see McLaughlin, J.P. (294) 201
Arenas, E., see Dasgupta, S. (316) 325
Aretha, C.W. and Galloway, M.P.
Dopamine autoreceptor reserve in vitro: possible role of dopamine D_3 receptors (305) 119
Argiolas, A., see Melis, M.R. (294) 1
Argiolas, L., see Fabi, F. (309) 41
Ari, G., Vardi, Y., Hoffman, A. and Finberg, J.P.M.
Possible role for endothelins in penile erection (307) 69
Arisawa, H., see Iga, Y. (308) 13
Arletti, R., see Benelli, A. (294) 505
Armsby, C.C., see Coupry, I. (295) 109
Armstead, W.M., see Wilderman, M.J. (309) 243
Arnould, T., Janssens, D., Michiels, C. and Remacle, J.
Effect of aescine on hypoxia-induced activation of human endothelial cells (315) 227
Arnoux, B., see Aïssa, J. (302) 123
Arnt, J., see Sánchez, C. (297) 1
Arnt, J., see Sánchez, C. (315) 245
Aroviita, L., see Riekkinen, M. (308) 243
Asaad, M.M., see Bird, J.E. (294) 183
Asano, M., Kuwako, M., Nomura, Y., Suzuki, Y., Shibuya, M., Sugita, K. and Ito, K.
Possible mechanism of the potent vasoconstrictor responses to ryanodine in dog cerebral arteries (311) 53
Asano, M., Matsunaga, K., Miura, M., Ito, K.M., Seto, M., Sakurada, K., Nagumo, H., Sasaki, Y. and Ito, K.
Selectivity of action of staurosporine on Ca^{2+} movements and contractions in vascular smooth muscles (294) 693
Asano, M., see Ohashi, T. (307) 315
Asano, Y., see Iimura, O. (296) 319
Ashizawa, T., see Nurmi, M. (315) 277
Ashton, C., see Gonsalves, S. (305) 181
Assié, M.-B. and Koek, W.
Effects of 5-HT_{1A} receptor antagonists on hippocampal 5-hydroxytryptamine levels: (*S*)-WAY100135, but not WAY100635, has partial agonist properties (304) 15
Astarie-Dequeker, C., see Gagnet, C. (310) 67
Astolfi, M., see Goso, C. (294) 239
Atef, N., Lafontan, M., Doublé, A., Hélary, C., Ktorza, A. and Pénicaud, L.
A specific β_3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats (298) 287
Attila, M., see Guerrini, R. (302) 37
Auer, B., see Wiedermann, C.J. (298) 335
Aulakh, C.S., see Mazzola-Pomietto, P. (308) 329
Ausina, P., Savineau, J.-P., Pinto, F.M., Martin, J.D. and Candenas, L.
Ca^{2+}-independent contraction induced by hyperosmolar K^+-rich solutions in rat uterus (312) 309
Aussel, C., see Hernvann, A. (314) 193
Auth, F., see Moor, E. (294) 155
Avenet, P., Léonardon, J., Besnard, F., Graham, D., Frost, J., Depoortere, H., Langer, S.Z. and Scatton, B.
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in *Xenopus* oocytes (296) 209
Avenet, P., see Biton, B. (294) 91
Avery, D., see Bane, A. (302) 7
Awane-Igata, Y., see Kitayoshi, T. (305) 137
Ayensu, W.K., see Pucilowski, O. (305) 57
Azuma, H., see Ohashi, T. (307) 315

Baba, A., see Suzuki, T. (310) 243
Babcock, D., see Frantz, K. (302) 1
Bach, N.J., see Fox, N. (308) 195
Bachelet, M., see De Castro, C.M.M.B. (294) 669
Baeyens, J.M., see Robles, L.-I. (295) 181
Bagetta, G., Rodinò, P., Paoletti, A.M., Arabia, A., Massoud, R. and Nisticò, G.
Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain (294) 341
Baker, K.M., see Thomas, W.G. (295) 119
Bakogeorgou, E., see Hatzoglou, A. (296) 199
Bakogeorgou, E., see Hatzoglou, A. (310) 217
Baldık, Y., see Ulugöl, A. (308) 49
Balducci, C., see Bono, G. (296) 233
Baldwin, B.A., see Wattanathorn, J. (313) 69

Balfour, D.J.K., Birrell, C.E., Moran, R.J. and Benwell, M.E.M.
Effects of acute D-CPPene on mesoaccumbens dopamine responses to nicotine in the rat (316) 153
Bali, J.-P., see Cuq, P. (315) 213
Balster, R.L., see Bowen, S.E. (312) 131
Balster, R.L., see Wiley, J.L. (294) 101
Bandarage, U.K., see Layer, R.T. (309) 159
Bandoh, T., Mitani, H., Niihashi, M., Kusumi, Y., Ishikawa, J., Kimura, M., Totsuka, T., Sakurai, I. and Hayashi, S.
Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery (315) 37
Bane, A., Rojas, D., Indermaur, K., Bennett, T. and Avery, D.
Adverse effects of dextromethorphan on the spatial learning of rats in the Morris water maze (302) 7
Banerjee, B. and Ganguly, D.K.
Thermodynamics of the interaction of *d*-tubocurarine with nicotinic receptors of mammalian skeletal muscle in vitro (310) 13
Banke, T., see Wahl, P. (308) 211
Banner, S.E., Smith, M.I., Bywater, D., Gaster, L.M. and Sanger, G.J.
Increased defaecation caused by 5-HT_4 receptor activation in the mouse (308) 181
Bao, L.-h., see Tanabe, T. (299) 187
Barajas-López, C., Peres, A.L., Espinosa-Luna, R., Reyes-Vázquez, C. and Prieto-Gómez, B.
Melatonin modulates cholinergic transmission by blocking nicotinic channels in the guinea-pig submucous plexus (312) 319
Barberis, C., see Anouar, A. (308) 87
Barcellini, W., see Nicoletti, F. (311) 213
Barf, T., Korte, S.M., Korte-Bouws, G., Sonesson, C., Damsma, G., Bohus, B. and Wikström, H.
Potential anxiolytic properties of *R*-(+)-8-OSO_2CF_3-PAT, a 5-HT_{1A} receptor agonist (297) 205
Barf, T., see Saxena, P.R. (312) 53
Barg, J., see Heldman, E. (297) 283
Barili, P., Zaccheo, D. and Amenta, F.
Pharmacological characterization and autoradiographic localization of dopamine receptors in the rat adrenal medulla (310) 129
Barlas, C., see Modi, P.I. (299) 213
Barnes, J.C., see Brown, J.D. (311) 305
Barnes, N.M., see Ge, J. (297) 299
Barnes, N.M., see Ge, J. (300) 113
Barnes, P.J., see Kidney, J.C. (296) 81
Barnes, P.J., see Mak, J.C.W. (302) 215
Baron, B.M., see Siegel, B.W. (296) 307
Baron, B.M., see Siegel, B.W. (312) 357
Baron, J.-C., see Abadie, P. (295) 35
Barré, L., see Abadie, P. (295) 35
Barrios, M., see Robles, L.-I. (295) 181
Barroso, N. and Rodriguez, M.
Action of β-phenylethylamine and related amines on nigrostriatal dopamine neurotransmission (297) 195
Bartfai, T., see Lundkvist, J. (309) 195
Barth, Z., Strauss, J.D., Dohet, C. and Rüegg, J.C.
The Ca^{2+} sensitizer EMD 53998 antagonizes the effect of 2,3-butanedione monoxime on skinned cardiac muscle fibres (296) 285
Barthelmebs, M., Krieger, J.-P., Grima, M., Nisato, D. and Imbs, J.-L.
Vascular effects of [Arg^8]vasopressin in the isolated perfused rat kidney (314) 325
Bartolini, A., see Galeotti, N. (308) 125
Bartsch, R., see Tober, C. (303) 163
Bascands, J.-L., see Praddaude, F. (294) 173
Bassi, A., see Di Renzo, G. (294) 11
Bastide, B., see Hervé, J.-C. (313) 243
Bates, J.N., see Lewis, S.J. (312) R3
Bateson, A.N., Jakiwczyk, O.M. and Schulz, R.
Rapid increase in inducible nitric oxide synthase gene expression in the heart during endotoxemia (303) 141
Bath, C.P., Farrell, L.N., Gilmore, J., Ward, M.A., Hicks, C.A., O'Neill, M.J. and Bleakman, D.
The effects of ifenprodil and eliprodil on voltage-dependent Ca^{2+} channels and in gerbil global cerebral ischaemia (299) 103
Battisti, C., see Federico, A. (304) 237
Bauer, V., see Mai, M.P. (315) 305
Bax, W.A., see Saxena, P.R. (312) 53
Bazan, E., Campbell, A.K. and Rapoport, R.M.
Erratum to 'Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta'. [Eur. J. Pharmacol. Mol. Pharmacol. Sect. 290 (1995) 253–257] (311) 101
Beart, P.M., see Cheung, N.S. (313) 159
Beart, P.M., see Larm, J.A. (314) 249
Beatty, M.F., see Chen, S.-W. (312) 241
Beaugé, F., see Naassila, M. (313) 273
Beaumont, K., see Vine, W. (314) 115
Becherer, U., see Zerr, P. (303) 101
Beck, B., see Stricker-Krongrad, A. (295) 27
Becker, H.C. and Jarvis, M.F.
Chronic ethanol exposure selectively increases diazepam-insensitive [^{3}H]RO15-4513 binding in mouse cerebellum (296) 43
Bédard, P.J., see Blanchet, P.J. (309) 13
Bedingfield, J.S., Jane, D.E., Kemp, M.C., Toms, N.J. and Roberts, P.J.
Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors (309) 71
Beenhakker, M., see Von Lubitz, D.K.J.E. (302) 43
Beenhakker, M., see Von Lubitz, D.K.J.E. (316) 171
Beglan, C.L., see Bell, J.A. (294) 289
Beglan, C.L., see Bell, J.A. (294) 297
Beile, A., see Gleitz, J. (315) 83
Beitner, R., see Glass-Marmor, L. (313) 265
Bélichard, P., see Pruneau, D. (297) 53
Bell, J.A. and Beglan, C.L.
Co-treatment with MK-801 potentiates naloxone-precipitated morphine withdrawal in the isolated spinal cord of the neonatal rat (294) 297
Bell, J.A. and Beglan, C.L.
MK-801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat (294) 289
Bell, R.L., see Namovic, M.T. (315) 81
Belladonna, M.L., see Campanile, F. (307) 191
Bellmann, R., see Kähler, C.M. (304) 135
Bellot, R.G., Camarini, R., Vital, M.A.B.F., Palermo-Neto, J., Leyton, V. and Frussa-Filho, R.
Monosialoganglioside attenuates the excitatory and behavioural sensitization effects of ethanol (313) 175
Belogi, L., see Tubaro, E. (294) 555
Beltrami, B., see Nicoletti, F. (311) 213
Ben-Ari, Y., see Charriaut-Marlangue, C. (310) 137
Bence, J.Zs., see Erdő, S.L. (314) 69
Bench, C.J., see Pike, V.W. (301) R5
Bendesky, R.J., see Chang, R.S.L. (294) 429
Benelli, A., Bertolini, A., Poggioli, R., Cavazzuti, E., Calzà, L., Giardino, L. and Arletti, R.
Nitric oxide is involved in male sexual behavior of rats (294) 505
Bengtsson, H.J., see Hjorth, S. (316) 43
Beninger, R.J., see Smith, I.D. (301) 7
Bennai, F., Greney, H., Vonthron, C., Bousquet, P. and Dontenwill, M.
Polyclonal anti-idiotypic antibodies to idazoxan and their interaction with human brain imidazoline binding sites (306) 211
Bennett, T., see Bane, A. (302) 7
Benveniste, J., see Aïssa, J. (302) 123

Benwell, M.E.M., see Balfour, D.J.K. (316) 153
Berdeu, D., Puech, R., Loubatières-Mariani, M.-M. and Bertrand, G.
Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed (308) 301
Berendsen, H.H.G., Kester, R.C.H., Peeters, B.W.M.M. and Broekkamp, C.L.E.
Modulation of 5-HT receptor subtype-mediated behaviours by corticosterone (308) 103
Beresford, I.J.M., see Hawcock, A.B. (294) 163
Beretta, C., see Paroni, R. (294) 737
Berg, G., see Mårtensson, L.G.E. (316) 273
Bergdahl, A., Nilsson, T., Cantera, L., Nilsson, L., Sun, X.-Y., Hedner, T., Erlinge, D., Valdemarson, S. and Edvinsson, L.
Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y_1 receptor (316) 59
Berge, R.K., see Brunvand, H. (314) 99
Bergman, J., see Gatch, M.B. (298) 31
Bergman, J., see Gatch, M.B. (312) 389
Berlin, K.D., see Pugsley, M.K. (294) 319
Bernardi, G., see Stefani, A. (307) 113
Bernardi, M., Bertolini, A., Szczawinska, K. and Genedani, S.
Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice (298) 51
Bernards, C.M.
Centrally mediated hemodynamic effects of cocaine in rabbits: the role of local anesthetic actions and biogenic amine re-uptake blockade (307) 33
Berning, B., see Rupprecht, R. (303) 227
Bertha, C.M., see Layer, R.T. (309) 159
Berthelot, P., see Kerr, D.I.B. (308) R1
Berti, F., see Bianchi, M. (294) 71
Berti, F., see De Gennaro Colonna, V. (314) 333
Bertolini, A., see Benelli, A. (294) 505
Bertolini, A., see Bernardi, M. (298) 51
Bertorelli, R., see Adami, M. (294) 383
Bertrand, G., see Berdeu, D. (308) 301
Bertrand, V., see Dufresne, M. (297) 165
Berzetei-Gurske, I.P., Schwartz, R.W. and Toll, L.
Determination of activity for nociceptin in the mouse vas deferens (302) R1
Besnard, F., see Avenet, P. (296) 209
Besson, J.-M., see Buritova, J. (303) 91
Beswick, P., see Brown, J.D. (311) 305
Bettelli, C., see Giardino, L. (312) 183
Better, O.S., see Gurbanov, K. (310) 193
Beubler, E., see Schirgi-Degen, A. (316) 257
Bezáková, Ž., see Mai, M.P. (315) 305
Bézie, Y., Mesnard, L., Longrois, D., Samson, F., Perret, C., Mercadier, J.-J. and Laurent, S.
Interactions between endothelin-1 and atrial natriuretic peptide influence cultured chick cardiac myocyte contractility (311) 241
Bhargava, H.N., Zhao, G.-M., House, R.V. and Thomas, P.T.
Effects of chronic administration of 7-benzylidene-7-dehydronaltrexone and naltriben on the antinociceptive actions of δ_1- and δ_2-opioid receptor agonists (311) 127
Bhounsule, S.A., D'Sa, S., Fernandes, N., Diniz D'Souza, R. and Dhume, V.G.
Gastrointestinal actions of buprenorphine: are different receptors involved? (316) 253
Bi, Y., see Iyo, M. (312) 163
Bianchi, C., see Calò, G. (311) R3
Bianchi, M., Rossoni, G., Sacerdote, P., Panerai, A.E. and Berti, F.
Carbamazepine exerts anti-inflammatory effects in the rat (294) 71
Bidlack, J.M., see McLaughlin, J.P. (294) 201
Bienkowski, P., Stefanski, R. and Kostowski, W.
Competitive NMDA receptor antagonist, CGP 40116, substitutes for the discriminative stimulus effects of ethanol (314) 277
Bienkowski, P., see Stefanski, R. (309) 141
Bieroń, K., see Gryglewski, R.J. (308) 61
Biggs, C.S., Fowler, L.J., Whitton, P.S. and Starr, M.S.
NMDA receptor antagonists increase the release of dopamine in the substantia nigra of reserpine-treated rats (299) 83
Bijak, M., Tokarski, K., Czyrak, A., Maćkowiak, M. and Wędzony, K.
Imipramine increases the 5-HT_{1A} receptor-mediated inhibition of hippocampal neurons without changing the 5-HT_{1A} receptor binding (305) 79
Billaud, G., see Héron, C. (301) 195
Bird, J.E., Webb, M.L., Giancarli, M.R., Chao, C.-c., Dorso, C.R. and Asaad, M.M.
A role for endothelin ET_A receptors in regulation of renal function in spontaneously hypertensive rats (294) 183
Birdsall, N.J.M., see Cohen, F.R. (309) 111
Birrell, C.E., see Balfour, D.J.K. (316) 153
Bischofberger, N., see Von Lubitz, D.K.J.E. (302) 43
Bischofberger, N., see Von Lubitz, D.K.J.E. (316) 171
Bisetti, A., see Ricci, A. (301) 189
Biton, B., Granger, P., Depoortere, H., Scatton, B. and Avenet, P.
Block of P-type Ca^{2+} channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells (294) 91
Biyah, K., Molimard, M., Emonds-Alt, X. and Advenier, C.
SR 140333 prevents potentiation by citric acid of plasma exudation induced by histamine in airways (308) 325
Björklund, M., see Jäkälä, P. (299) 47
Björklund, M., see Jäkälä, P. (316) 181
Black, J.L., see Yang, K.X.F. (315) 65
Black, S.C., see Friedrichs, G.S. (306) 99
Blackburn, T., see Lightowler, S. (296) 137
Blackham, A., see Liu, Y.J. (303) 187
Blackham, A., see Liu, Y.J. (304) 117
Blanchard, J.-C., see Boireau, A. (300) 237
Blanchard, J.-C., see Heuillet, E. (314) 229
Blanchet, P.J., Grondin, R., Bédard, P.J., Shiosaki, K. and Britton, D.R.
Dopamine D_1 receptor desensitization profile in MPTP-lesioned primates (309) 13
Blandizzi, C., Colucci, R., Carignani, D., Natale, G., Lazzeri, G., Crema, F. and Del Tacca, M.
Role of peripheral $GABA_B$ receptors in the regulation of pepsinogen secretion in anaesthetized rats (294) 191
Blazicek, P., see Vietor, I. (313) 119
Bleakman, D., see Bath, C.P. (299) 103
Blomqvist, O., Ericson, M., Johnson, D.H., Engel, J.A. and Söderpalm, B.
Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment (314) 257
Bloms-Funke, P. and Löscher, W.
The anticonvulsant gabapentin decreases firing rates of substantia nigra pars reticulata neurons (316) 211
Blumberg, P.M., see Szallasi, A. (298) 321
Blumberg, P.M., see Szallasi, A. (299) 221
Bo, X., see Vallejo, A.I. (312) 209
Bobbitt, J.L., see Fox, N. (308) 195
Bocheva, A., see Pencheva, N. (304) 99
Bockaert, J., see Ansanay, H. (298) 165
Boddeke, H.W.G.M., see Laurie, D.J. (296) R1
Boddeke, H.W.G.M., see Laurie, D.J. (302) 229
Bode, D.C., see De Garavilla, L. (313) 89
Boden, P.R., see Lee, K. (313) 163
Boege, F., see Jahns, R. (316) 111
Boehm, S., see Fröhlich, R. (315) 255
Boer, R., Ulrich, W.-R., Haas, S., Borchers, C., Gekeler, V., Boss, H., Przybylski, M. and Schödl, A.
Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein (295) 253
Boev, K.K., see Duridanova, D.B. (298) 159

Boeynaems, J.-M., see Motte, S. (307) 201
Bogdan, C., see Stenger, S. (294) 703
Bogoni, G., see Calò, G. (311) R3
Böhm, M., see Lenz, O. (294) 17
Bohus, B., see Barf, T. (297) 205
Bohus, B., see Korte, S.M. (301) 19
Bohus, B., see Korte, S.M. (309) 281
Böing, C., see Fink, K. (300) 79
Boireau, A., Malgouris, C., Burgevin, M.-C., Pény, C., Durand, G., Bordier, F., Meunier, M., Miquet, J.M., Daniel, M., Chevet, T., Jimonet, P., Mignani, S., Blanchard, J.-C. and Doble, A.
Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro (300) 237
Boja, J.W., see Fleckenstein, A.E. (311) 109
Bolaños-Jiménez, F., Manhães de Castro, R., Seguin, L., Cloëz-Tayarani, I., Monneret, V., Drieu, K. and Fillion, G.
Effects of stress on the functional properties of pre- and postsynaptic 5-HT_{1B} receptors in the rat brain (294) 531
Bolkenius, F.N., Verne-Mismer, J., Wagner, J. and Grisar, J.M.
Amphiphilic α-tocopherol analogues as inhibitors of brain lipid peroxidation (298) 37
Bonacci, D., see De Gennaro Colonna, V. (314) 333
Bonanno, L., see Bruno, V. (310) 61
Bonnet, J., Kucharczyk, N., Robineau, P., Lonchampt, M., Dacquet, C., Regoli, D., Fauchère, J.-L. and Canet, E.
A water-soluble, stable dipeptide NK_1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523 (310) 37
Bonnet, J.-J., see Héron, C. (301) 195
Bonnet, P., see Vandier, C. (295) 53
Bono, G., Balducci, C., Richelmi, P., Koob, G.F. and Pulvirenti, L.
Dopamine partial receptor agonists reduce ethanol intake in the rat (296) 233
Booz, G.W., see Thomas, W.G. (295) 119
Booze, R.M., see Wallace, D.R. (308) 283
Borbély, A.A., see Schwierin, B. (300) 163
Borcherding, D.R., see McWhinney, C.D. (310) 209
Borchers, C., see Boer, R. (295) 253
Bordi, F.
Reduced long-term potentiation in the dentate gyrus of $mGlu_1$ receptor-mutant mice in vivo (301) R15
Bordi, F., see Ugolini, A. (294) 403
Bordier, F., see Boireau, A. (300) 237
Borea, P.A., Dalpiaz, A., Gessi, S. and Gilli, G.
Thermodynamics of 5-HT_3 receptor binding discriminates agonistic from antagonistic behaviour (298) 329
Borea, P.A., see Dalpiaz, A. (312) 107
Borella, F., see Gorio, A. (311) 21
Borelli, G.P., see Tubaro, E. (294) 555
Borges, R., see Gandía, L. (298) 199
Borghi, M.O., see Nicoletti, F. (311) 213
Boric, M.P., Martínez, A., Donoso, M.V. and Huidobro-Toro, J.P.
Neuropeptide Y is a vasoconstrictor and adrenergic modulator in the hamster microcirculation by acting on neuropeptide Y_1 and Y_2 receptors (294) 391
Borman, R.A. and Burleigh, D.E.
Human colonic mucosa possesses a mixed population of 5-HT receptors (309) 271
Borowicz, K., see Gasior, M. (312) 27
Borrega, F., see Charriaut-Marlangue, C. (310) 137
Borrelli, F., see Izzo, A.A. (301) 137
Borsini, F., see Brambilla, A. (305) 115
Borsini, F., see Ceci, A. (312) 189
Borsini, F., see Pitsikas, N. (311) 115
Boser, M., see Höhle, S. (300) 119
Bosmans, J.M., Bult, H., Vrints, C.J., Kockx, M.M. and Herman, A.G.
Balloon angioplasty and induction of non-endothelial nitric oxide synthase in rabbit carotid arteries (310) 163
Boss, H., see Boer, R. (295) 253
Botero Cid, H.M., see Kostenis, E. (314) 385
Boucher, M., Chassaing, C. and Chapuy, E.
Cardiac electrophysiological effects of falipamil in the conscious dog: comparison with alinidine (306) 93
Boucher, M., Chassaing, C., Hamel, J.-D. and Poirier, J.-M.
Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog (315) 171
Boulton, R.M., see Reynolds, G.P. (301) R19
Bouman, S.D., see Korte, S.M. (301) 19
Bourdon, D.M., see Salvemini, D. (303) 217
Bourely, B., see Hernvann, A. (314) 193
Bourre, J.-M., see Francès, H. (298) 217
Bousquet, P., see Bennai, F. (306) 211
Bousquet, P., see Monassier, L. (305) 109
Bowen, S.E., Wiley, J.L. and Balster, R.L.
The effects of abused inhalants on mouse behavior in an elevated plus-maze (312) 131
Bowen, W.D., see Matsumoto, R.R. (301) 31
Bowen, W.D., see Torrence-Campbell, C. (304) 201
Bowery, N.G., see Malcangio, M. (299) 113
Bowery, N.G., see Teoh, H. (302) 27
Bowie, L.D., see Sodder, V.H. (315) 115
Bowlin, T.L., see McWhinney, C.D. (310) 209
Bowman, M., see Szabó, A. (315) 187
Boyd, M., see Von Lubitz, D.K.J.E. (316) 171
Bradberry, C.W., see Gruen, R.J. (309) 115
Bradshaw, M., see McWhinney, C.D. (310) 209
Brady, P.A., Zhang, S., López, J.R., Jovanovic, A., Alekseev, A.E. and Terzic, A.
Dual effect of glyburide, an antagonist of K_{ATP} channels, on metabolic inhibition-induced Ca^{2+} loading in cardiomyocytes (308) 343
Braga, M.F.M., see Henning, R.H. (301) 91
Braida, D., Paladini, E., Griffini, P., Lamperti, M., Maggi, A. and Sala, M.
An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors (302) 13
Brain, S.D., see Cambridge, H. (301) 151
Brain, S.D., see Costa, S.K.P. (298) 113
Brambilla, A., Prudentino, A., Grippa, N. and Borsini, F.
Pharmacological characterization of AMPA-induced biting behaviour in mice (305) 115
Branchek, T., see Adham, N. (304) 231
Brann, M.R., see Bräuner-Osborne, H. (295) 93
Brann, M.R., see Bräuner-Osborne, H. (313) 145
Brasseur, R., see Montenez, J.-P. (314) 215
Braun, C.J., see Szabó, A. (315) 187
Bräuner-Osborne, H. and Brann, M.R.
Pharmacology of muscarinic acetylcholine receptor subtypes (m1–m5): high throughput assays in mammalian cells (295) 93
Bräuner-Osborne, H., Ebert, B., Brann, M.R., Falch, E. and Krogsgaard-Larsen, P.
Functional partial agonism at cloned human muscarinic acetylcholine receptors (313) 145
Bredenbröker, D., see Wagner, U. (298) 265
Brémont, B., see Shen, S. (307) 133
Brenner, G.M., see Stevens, C.W. (316) 205
Breu, V., see McAuley, M.A. (307) 171
Briejer, M.R. and Schuurkes, J.A.J.
5-HT_3 and 5-HT_4 receptors and cholinergic and tachykininergic neurotransmission in the guinea-pig proximal colon (308) 173

Briley, M., see Moret, C. (295) 189
Brioni, J.D., Kim, D.J.B. and O'Neill, A.B.
Nicotine cue: lack of effect of the α7 nicotinic receptor antagonist methyllycaconitine (301) 1
Briscoe, R.J., see Gauvin, D.V. (294) 281
Britton, D.R., see Blanchet, P.J. (309) 13
Broadley, K.J., see Thorne, J.R. (316) 263
Broekkamp, C.L.E., see Berendsen, H.H.G. (308) 103
Bronson, M. and Chen, H.-C.
Time course of discriminative stimulus effects of bretazenil and chlordiazepoxide in rats (305) 7
Bronzetti, E., see Ricci, A. (301) 189
Brooks, D.P. and Contino, L.C.
Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist SB 209670 (294) 571
Brooks, R., see Keddie, J.R. (301) 107
Broquère, N., see Monteau, R. (314) 41
Brørs, O., see Stokke, M. (303) 115
Brotchie, J., see Fox, S. (301) 27
Brotchie, J.M., see Maneuf, Y.P. (308) 161
Broten, T.P., see Kivlighn, S.D. (294) 439
Brouwer, A., see Mensink, A. (310) 73
Brouwers-Ceiler, D.L., Nelissen-Vrancken, H.J.M.G. and Smits, J.F.M.
Effect of nitric oxide synthase inhibition on the acetylcholine response in the perfused hind limb of rats (307) 65
Brown, A.M., see Taglialatela, M. (316) 373
Brown, J.D., O'Shaughnessy, C.T., Kilpatrick, G.J., Scopes, D.I.C., Beswick, P., Clitherow, J.W. and Barnes, J.C.
Characterisation of the specific binding of the histamine H_3 receptor antagonist radioligand [^{3}H]GR168320 (311) 305
Brown, P., see Hinks, G.L. (312) 153
Brown, R.A., Savage, A.O. and Lloyd, T.C.
Acute and chronic effects of ethanol on papillary muscles from spontaneously hypertensive rats (302) 61
Brown, R.E., see McGregor, I.S. (313) 43
Brown, T., see Lightowler, S. (296) 137
Brownhill, V.R., Hourani, S.M.O. and Kitchen, I.
Differential distribution of adenosine A_2 receptors in the epididymal and prostatic portions of the rat vas deferens (303) 87
Browning, R., see Statnick, M. (299) 93
Brugnara, C., see Coupry, I. (295) 109
Bruguerolle, B., see Grignon, S. (315) 111
Bruhwyler, J., see Liégeois, J.-F. (310) 9
Brüne, B., see Meßmer, U.K. (302) 171
Brunet, A., see Gagnet, C. (310) 67
Bruno, V., Copani, A., Bonanno, L., Knoepfel, T., Kuhn, R., Roberts, P.J. and Nicoletti, F.
Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures (310) 61
Brunvand, H., Frøyland, L., Hexeberg, E., Rynning, S.E., Berge, R.K. and Grong, K.
Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury (314) 99
Brusasco, V., see Sannita, W.G. (300) 33
Brutesco, C., see Valette, H. (306) 133
Bryant, S.D., see Guerrini, R. (302) 37
Brzezińska-Błaszczyk, E., Mińcikiewicz, M. and Ochocki, J.
Effect of cisplatin and *cis*-platinum (II) phosphonate complex on murine mast cells (298) 155
Buccafusco, J.J., see Feldman, D.S. (313) 211
Buchholz, J.N., see García-Villalón, A.L. (314) 339
Buchholz, R.A., see De Garavilla, L. (313) 89
Buckner, S.A., Oheim, K.W., Morse, P.A., Knepper, S.M. and Hancock, A.A.
α_1-Adrenoceptor-induced contractility in rat aorta is mediated by the α_{1D} subtype (297) 241
Buczko, W., see Malinowska, B. (315) 159
Budhoo, M.R., Harris, R.P. and Kellum, J.M.
5-Hydroxytryptamine-induced Cl^- transport is mediated by 5-HT_3 and 5-HT_4 receptors in the rat distal colon (298) 137
Budhoo, M.R., Harris, R.P. and Kellum, J.M.
The role of the 5-HT_4 receptor in Cl^- secretion in human jejunal mucosa (314) 109
Büküşoğlu, C. and Sarlak, F.
Pregnenolone sulfate increases intracellular Ca^{2+} levels in a pituitary cell line (298) 79
Bult, H., see Bosmans, J.M. (310) 163
Bult, H., see Matthys, K.E. (298) 97
Bult, H., see Van Put, D.J.M. (294) 753
Bunn, S.J., see Loneragan, K. (311) 87
Bunney Jr., W.E., see Helmeste, D.M. (314) R3
Burcher, E., see Strigas, J. (311) 177
Burgevin, M.-C., see Boireau, A. (300) 237
Buritova, J., Chapman, V., Honoré, P. and Besson, J.-M.
Interactions between NMDA- and prostaglandin receptor-mediated events in a model of inflammatory nociception (303) 91
Burkman, A.M., see Konkar, A.A. (305) 63
Burleigh, D.E., see Borman, R.A. (309) 271
Burlet, C., see Stricker-Krongrad, A. (295) 27
Burnet, P.W.J., see McGowan, S. (306) 249
Burnstock, G., see Ralevic, V. (313) 221
Burnstock, G., see Vallejo, A.I. (312) 209
Burton, M.J., see Watson, J.M. (314) 365
Bustamante, D., see Gozariu, M. (313) 51
Butterworth, R.F., see Mousseau, D.D. (300) 191
Buwalda, B., see Korte, S.M. (301) 19
Buwalda, B., see Korte, S.M. (309) 281
Bywater, D., see Banner, S.E. (308) 181

Cabib, S., see Mele, A. (308) 1
Cabot, P.J., Cramond, T. and Smith, M.T.
Quantitative autoradiography of peripheral opioid binding sites in rat lung (310) 47
Caccia, S., see Mele, A. (308) 1
Cagnotto, A., Parotti, L. and Mennini, T.
In vitro affinity of piribedil for dopamine D_3 receptor subtypes, an autoradiographic study (313) 63
Cahill, C.M., White, T.D. and Sawynok, J.
Synergy between μ/δ-opioid receptors mediates adenosine release from spinal cord synaptosomes (298) 45
Cai, H., Yao, H., Ibayashi, S., Takaba, H. and Fujishima, M.
Amlodipine, a Ca^{2+} channel antagonist, modifies cerebral blood flow autoregulation in hypertensive rats (313) 103
Cai, M., Sakamoto, A. and Ogawa, R.
Inhibition of nitric oxide formation with L-canavanine attenuates endotoxin-induced vascular hyporeactivity in the rat (295) 215
Cai, S.-X., see Ilyin, V.I. (310) 107
Cailmail, S., see Pilette, C. (312) 63
Caine, S.B., see Wan, F.-J. (314) 9
Calapai, G., see Nava, F. (309) 223
Calignano, A., see Mancuso, F. (312) 327
Calixto, J.B., see De Campos, R.O.P. (316) 277
Calixto, J.B., see Gonçalves de Moraes, V.L. (312) 333
Calixto, J.B., see Teixeira, R.M. (311) 7
Callado, L.F., Gabilondo, A.M. and Meana, J.J.
[^{3}H]RX821002 (2-methoxyidazoxan) binds to α_2-adrenoceptor subtypes and a non-adrenoceptor imidazoline binding site in rat kidney (316) 359
Callado, L.F., see Grijalba, B. (310) 83
Callado, L.F., see Meana, J.J. (312) 385
Calò, G., Rizzi, A., Bogoni, G., Neugebauer, V., Salvadori, S., Guerrini, R., Bianchi, C. and Regoli, D.
The mouse vas deferens: a pharmacological preparation sensitive to nociceptin (311) R3

Calzà, L., see Benelli, A. (294) 505
Calzà, L., see Giardino, L. (312) 183
Camarasa, J., see Pubill, D. (303) 171
Camarini, R., see Bellot, R.G. (313) 175
Cambridge, H., Ajuebor, M.N. and Brain, S.D.
Investigation of 6-hydroxydopamine-induced plasma extravasation in rat skin (301) 151
Cameron, J.S., see Sodder, V.H. (315) 115
Cameron, N.E., see Love, A. (314) 33
Campa, M.J., McNutt, R.W., Hill, J.A., Patz, E.F. and Chang, K.-J.
Binding of [^{3}H](+)-BW373U86 to δ-opioid receptors in rat brain membranes (310) 263
Campanile, F., Giampietri, A., Grohmann, U., Belladonna, M.L., Fioretti, M.C. and Puccetti, P.
Evidence for tumor necrosis factor α as a mediator of the toxicity of a cyclooxygenase inhibitor in Gram-negative sepsis (307) 191
Campbell, A.K., see Bazan, E. (311) 101
Candenas, L., see Ausina, P. (312) 309
Cándido, A., see Torres, C. (314) 269
Canella, R., see Mazzari, S. (300) 227
Canet, E., see Bonnet, J. (310) 37
Canet, E., see Robineau, P. (294) 677
Canini, F., see Messaoudi, M. (299) 17
Cantera, L., see Bergdahl, A. (316) 59
Cantoni, L., see Tsankova, V. (294) 601
Cantoni, L., see Tsankova, V. (299) 197
Canudas, A.M., see Pubill, D. (303) 171
Cao, W., see Rupalla, K. (294) 469
Capasso, A., see Guerrini, R. (302) 37
Capasso, F., see Izzo, A.A. (301) 137
Caputi, A.P., see Nava, F. (309) 223
Cardelús, I., Gras, J., Jáuregui, J., Llenas, J. and Palacios, J.M.
Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors (299) 153
Cárdenas, A., see Gandía, L. (298) 199
Carelli, M., see Tsankova, V. (299) 197
Carignani, D., see Blandizzi, C. (294) 191
Carl, K.L., see Gauvin, D.V. (294) 281
Carlson, D.G., see Fox, N. (308) 195
Carlsson, P.-O., Sandler, S. and Jansson, L.
Influence of the neurotoxin capsaicin on rat pancreatic islets in culture, and on the pancreatic islet blood flow of rats (312) 75
Carmeliet, E., see Tytgat, J. (296) 189
Carroll, F.I., see Fleckenstein, A.E. (311) 109
Carroll, F.I., see Gatley, S.J. (296) 145
Carta, G., see Imperato, A. (302) 21
Carter, C., see Klarica, M. (308) 135
Carter, G.W., see Namovic, M.T. (315) 81
Carter, M.F., see Von Lubitz, D.K.J.E. (302) 43
Carvalho, A.P., see Ferreira, I.L. (302) 153
Carvalho, M.F., see DeFarias, F.P. (314) 123
Casalotti, S.O., see Wattanathorn, J. (313) 69
Casley, D., see Murone, C. (306) 237
Castanas, E., see Hatzoglou, A. (296) 199
Castanas, E., see Hatzoglou, A. (310) 217
Castañeda, E., see Neisewander, J.L. (305) 13
Castañeda-Hernández, G., see López-Muñoz, F.J. (308) 275
Castellano, C., see Mele, A. (308) 1
Casu, M.A., see Imperato, A. (302) 21
Casulari, L.A., see Maggi, R. (301) 169
Cataldi, M., see Di Renzo, G. (294) 11
Catelli, M., see Lopes-Martins, R. (308) 287
Catheline, G., Kayser, V. and Guilbaud, G.
Further evidence for a peripheral component in the enhanced antinociceptive effect of systemic morphine in mononeuropathic rats: involvement of κ-, but not δ-opioid receptors (315) 135
Cattaneo, L., see De Gennaro Colonna, V. (314) 333
Cavallo, G., see Tubaro, E. (294) 555
Cavazzuti, E., see Benelli, A. (294) 505
Cebere, A., see Hou, Y.-N. (309) 307
Cebers, G., see Hou, Y.-N. (309) 307
Ceci, A. and Borsini, F.
Effects of desipramine and maprotiline on the coeruleus-cortical noradrenergic system in anaesthetized rats (312) 189
Cerutis, D.R., see Zhu, S.-J. (299) 205
Cestari, I.N., see Uchida, I. (307) 89
Chai, S.Y., see Murone, C. (306) 237
Chai, Z., see Lundkvist, J. (309) 195
Chairungsrilerd, N., Furukawa, K.-I., Ohta, T., Nozoe, S. and Ohizumi, Y.
Pharmacological properties of α-mangostin, a novel histamine H_1 receptor antagonist (314) 351
Chakravarty, S., see De Campos, R.O.P. (316) 277
Champion, H.C., Garrison, E.A., Estrada, L.S., Potter, J.M. and Kadowitz, P.J.
Analysis of responses to angiotensin I and angiotensin I-(3–10) in the mesenteric vascular bed of the cat (309) 251
Chan, B., see Yoshihara, S. (296) 291
Chan, W., see Herdon, H. (314) R7
Chang, K.-J., see Campa, M.J. (310) 263
Chang, M.-C., see Sheu, J.-R. (294) 231
Chang, M.C., Yang, R.S., Lin, C.H. and Huang, T.F.
Integrin $\alpha_v\beta_3$ and phospholipase C regulate prostacyclin formation of endothelial cells caused by ancrod-generated fibrin (297) 129
Chang, R.S.L., Lotti, V.J., Chen, T.-B., O'Malley, S.S., Bendesky, R.J., Kling, P.J., Kivlighn, S.D., Siegl, P.K.S., Ondeyka, D., Greenlee, W.J. and Mantlo, N.B.
In vitro pharmacology of an angiotensin AT_1 receptor antagonist with balanced affinity for AT_2 receptors (294) 429
Chang, R.S.L., see Kivlighn, S.D. (294) 439
Chanut, E., see Shen, S. (307) 133
Chao, C.-c., see Bird, J.E. (294) 183
Chao, C.C.-K.
Cross-resistance to *cis*-diamminedichloroplatinum(II) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair (305) 213
Chapman, A.G., see De Sarro, G. (294) 411
Chapman, V., see Buritova, J. (303) 91
Chaput, C., see Newman-Tancredi, A. (307) 107
Chapuy, E., see Boucher, M. (306) 93
Charriaut-Marlangue, C., Margaill, I., Borrega, F., Plotkine, M. and Ben-Ari, Y.
N^G-Nitro-L-arginine methyl ester reduces necrotic but not apoptotic cell death induced by reversible focal ischemia in rat (310) 137
Chase, T.N., see Anderson, J.J. (295) 163
Chassaing, C., see Boucher, M. (306) 93
Chassaing, C., see Boucher, M. (315) 171
Chauvin, M., see Guirimand, F. (294) 651
Chayvialle, J.-A., see Miampamba, M. (308) 251
Cheah, T.B., see Loneragan, K. (311) 87
Chen, H.-C., see Bronson, M. (305) 7
Chen, J., see Chueh, S.-C. (305) 177
Chen, J.-C., Fine, R.E., Squicciarini, J. and Volicer, L.
Neurotoxicity of free-radical-mediated serotonin neurotoxin in cultured embryonic chick brain neurons (303) 109
Chen, L.D., see Melchiorri, D. (305) 239
Chen, R., see Gatley, S.J. (296) 145
Chen, S.-W., Maguire, P.A., Davies, M.F., Beatty, M.F. and Loew, G.H.
Evidence for μ_1-opioid receptor involvement in fentanyl-mediated respiratory depression (312) 241
Chen, T.-B., see Chang, R.S.L. (294) 429
Chen, T.-S., see Koutsilieri, E. (306) 181
Cheng, P.Y., see Szeto, H.H. (297) 77

Cheng, T.P.-O., see Altura, B.M. (314) R9
Cheng, X., see Palacios, B. (296) 75
Cherng, C.-H., see Wong, C.-S. (297) 27
Chéry-Croze, S., see Miampamba, M. (308) 251
Cheung, N.S., O'Callaghan, D., Ryan, M.C., Dutton, R., Wong, M.G. and Beart, P.M.
Structure-activity relationships of competitive NMDA receptor antagonists (313) 159
Cheung, N.S., see Larm, J.A. (314) 249
Chevet, T., see Boireau, A. (300) 237
Chevillard, C., see Hadj-Kaddour, K. (298) 145
Chhatwal, V.J.S., see Moochhala, S.M. (316) 287
Chi, L., see Friedrichs, G.S. (306) 99
Chiavarelli, M., see Fabi, F. (309) 41
Chiba, S., see Furukawa, Y. (300) 203
Chiba, S., see Ren, L.-M. (295) 61
Chiba, S., see Yamazaki, K. (297) 233
Chiba, S., see Yonezawa, T. (309) 51
Chiba, S., see Yonezawa, T. (315) 289
Chien, C.-C. and Pasternak, G.W.
(−)-Pentazocine analgesia in mice: interactions with a σ receptor system (294) 303
Childers, S.R., see Sim, L.J. (307) 97
Chimirri, A., see De Sarro, G. (294) 411
Chiu, T.H., see Zhao, T.-j. (306) 61
Chizh, B.A. and Headley, P.M.
Thyrotropin-releasing hormone facilitates spinal nociceptive responses by potentiating NMDA receptor-mediated transmission (300) 183
Cho, S., Duchemin, A.-M., Neff, N.H. and Hadjiconstantinou, M.
Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A (314) 51
Chobanian, A.V., see Moreland, R.S. (307) 55
Choi, D.-S., see Kim, Y.-B. (313) 107
Choi, S.-R., see Suh, H.-W. (307) 141
Choi, Y.-S., see Suh, H.-W. (307) 141
Choppin, A. and O'Connor, S.E.
Influence of vascular tone on vasoconstrictor responses to the 5-HT_1-like receptor agonist sumatriptan in anaesthetised rabbits (304) 87
Chow, L., Zakrzewska, K., De Gasparo, M., Cumin, F. and Levens, N.
Gastric acid secretion after blockade of angiotensin AT_1 receptors in the Na^+-depleted rat (294) 309
Chowdhury, S.A., Kawashima, T., Konishi, T., Niwa, M. and Matsunami, K.
Study of paired-pulse inhibition of transcallosal response in the pyramidal tract neuron in vivo (314) 313
Christie, M.J., see Nguyen, V.H. (311) 233
Christopoulos, A., see Lanzafame, A. (316) 27
Chrousos, G.P., see Stratakis, C.A. (315) 53
Chuan, P., see Medina, P. (300) 221
Chueh, S.-C., Guh, J.-H., Chen, J., Lai, M.-K., Ko, F.-N. and Teng, C.-M.
Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation (305) 177
Chung, K.F., see Kidney, J.C. (296) 81
Ciabattoni, G., see Montuschi, P. (313) R1
Ciccocioppo, R., see Polidori, C. (307) 259
Ciceri, S., see De Gennaro Colonna, V. (314) 333
Cini, M., see Speciale, C. (315) 263
Cirillo, R., see Polidori, C. (307) 259
Clark, E.A. and Hill, S.J.
Sensitivity of histamine H_3 receptor agonist-stimulated [^{35}S]GTPγ[S] binding to pertussis toxin (296) 223
Clarke, D.E., see Lachnit, W.G. (297) 83
Claustrat, B., see Deprés-Brummer, P. (312) 171
Clément, M., see Francès, H. (298) 217
Clerc, P., see Dufresne, M. (297) 165
Clerget, M.-S., see Anouar, A. (308) 87
Cliffe, I.A., see Pike, V.W. (301) R5
Clitherow, J.W., see Brown, J.D. (311) 305
Cloëz-Tayarani, I., see Bolaños-Jiménez, F. (294) 531
Cochrane, E.V., see Lahti, R.A. (301) R11
Coderre, T.J., see Fundytus, M.E. (300) 173
Cohen, F.R., Lazareno, S. and Birdsall, N.J.M.
The affinity of adenosine for the high- and low-affinity states of the human adenosine A_1 receptor (309) 111
Colao, A.M., see Di Renzo, G. (294) 11
Colleoni, M., see Costa, B. (313) 17
Collins, D.R., Smith, R.C. and Davies, S.N.
Interactions between arachidonic acid and metabotropic glutamate receptors in the induction of synaptic potentiation in the rat hippocampal slice (294) 147
Collins, K.A., see Tseng, L.F. (294) 345
Collins, S.M., see Hogaboam, C.M. (309) 261
Collis, M.G., see Keddie, J.R. (301) 107
Collu, M., see Diana, M. (312) 179
Colombo, S., see Letari, O. (306) 325
Colpaert, F.C., see Pauwels, P.J. (300) 137
Colpaert, F.C., see Pauwels, P.J. (300) 141
Colucci, R., see Blandizzi, C. (294) 191
Compton, D.R., see Moore, K.A. (311) 133
Compton, D.R., see Pertwee, R.G. (315) 195
Concha, J., see Neumann, V. (316) 123
Connolly, S., see Mullany, P. (309) 311
Conte Camerino, D., see De Luca, A. (296) 215
Conti, E., see Paroni, R. (294) 737
Contino, L.C., see Brooks, D.P. (294) 571
Contreras, E., see Germany, A. (310) 123
Contreras, E., see Neumann, V. (316) 123
Cools, A.R., see Koshikawa, N. (303) 13
Cools, A.R., see Koshikawa, N. (308) 227
Cools, A.R., see Koshikawa, N. (308) 235
Cooper, J.C., Gutbrod, O., Witzemann, V. and Methfessel, C.
Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in *Xenopus* oocytes (309) 287
Cooper, S.J., see Higgs, S. (313) 1
Copani, A., see Bruno, V. (310) 61
Corbett, R., see Kafka, S.H. (295) 147
Cordeiro, R., see Lopes-Martins, R. (308) 287
Cordeiro, R.S.B., see Alves, A.C. (312) 89
Cordeiro, R.S.B., see Diaz, B.L. (296) 173
Costa, B., Parolaro, D. and Colleoni, M.
Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat (313) 17
Costa, L.G., see Guizzetti, M. (297) 265
Costa, P., see Guizzetti, M. (297) 265
Costa, S.K.P., Moreno Jr., H., Brain, S.D., De Nucci, G. and Antunes, E.
The effect of *Phoneutria nigriventer* (armed spider) venom on arterial blood pressure of anaesthetised rats (298) 113
Costentin, J., see Héron, C. (301) 195
Costentin, J., see Vaugeois, J.-M. (316) R1
Cotter, M.A., see Love, A. (314) 33
Coudereau, J.-P., see Francès, H. (298) 217
Coulomb, B., see Le Panse, R. (307) 339
Coupar, I.M., see McLean, P.G. (312) 215
Coupry, I., Armsby, C.C., Alper, S.L., Brugnara, C. and Parini, A.
Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I_1 and I_2 binding sites (295) 109
Couraud, F., see Grignon, S. (315) 111
Courtoy, P.J., see Van Bambeke, F. (314) 203
Couture, R., see Poulat, P. (315) 327
Couvineau, A., see Gaudin, P. (302) 207
Cowan, A., see Ryan, R.R. (306) 307
Cowley, D.J., Lukovic, L. and Petty, M.A.
MDL 74,180 reduces cerebral infarction and free radical concentrations in rats subjected to ischaemia and reperfusion (298) 227

Cox, B.M., see Izenwasser, S. (297) 187
Cox, B.M., see Izenwasser, S. (297) 9
Cox, H.M., see Tough, I.R. (310) 55
Coy, D.H., see Lin, J.-T. (294) 55
Coy, D.H., see Martínez, V. (296) 153
Cozzi, N.V. and Nichols, D.E.
5-HT_{2A} receptor antagonists inhibit potassium-stimulated γ-amino-butyric acid release in rat frontal cortex (309) 25
Cozzolino, A., see Mancuso, F. (312) 327
Cramond, T., see Cabot, P.J. (310) 47
Cravotto, G., see Szallasi, A. (299) 221
Crawley, J.N., see Sills, T.L. (303) 177
Crema, F., see Blandizzi, C. (294) 191
Crimi, E., see Sannita, W.G. (300) 33
Cristello, A.F., see Wiley, J.L. (294) 101
Cronier, L., see Hervé, J.-C. (313) 243
Crossman, A.R., see Maneuf, Y.P. (308) 161
Cruz, H.N., see Alves, A.C. (312) 89
Csati, S., see Szilvassy, Z. (301) R17
Cua, M., see Geller, J.C. (294) 423
Cuéllar, B., see Lizasoain, I. (299) 41
Culman, J., see Höhle, S. (300) 119
Cumin, F., see Chow, L. (294) 309
Cuq, P., Zumbihl, R., Fischer, T., Rouot, B., Bali, J.-P. and Magous, R.
Involvement of $G_{\alpha q/11}$ in the contractile signal transduction pathway of muscarinic M_3 receptors in caecal smooth muscle (315) 213
Currie, M.G., see Salvemini, D. (303) 217
Currò, D., see Montuschi, P. (313) R1
Curzon, G., see O'Connell, M.T. (312) 137
Czerwiec, E., De Backer, J.-P., Flamez, A. and Vauquelin, G.
Identification and characterization of imidazoline-binding sites from calf striatum (315) 99
Czerwiec, E., De Backer, J.-P., Vauquelin, G. and Vanderheyden, P.M.L.
High-affinity binding of [^{3}H]neuropeptide Y to a polypeptide from the venom of *Conus anemone* (315) 355
Czuczwar, S.J., see Gasior, M. (312) 27
Czyrak, A., see Bijak, M. (305) 79

Da Costa Santos, W., see Jurkiewicz, N.H. (307) 299
Dacquet, C., see Bonnet, J. (310) 37
Dafny, N., see Gaytan, O. (300) 1
Dahl, S.G., see Kristiansen, K. (306) 195
Dailey, J., see Statnick, M. (299) 93
Dailey, J.W., see Yan, Q.-S. (301) 49
Dallaporta, M., see Himmi, T. (312) 273
Dallel, R., Luccarini, P., Molat, J.-L. and Woda, A.
Effects of systemic morphine on the activity of convergent neurons of spinal trigeminal nucleus oralis in the rat (314) 19
D'Alonzo, A.J., Darbenzio, R.B., Sewter, J.C., Hess, T.A., Grover, G.J., Sleph, P.G., Normandin, D.E. and Lodge, N.J.
A comparison between the effects of BMS-180448, a novel K^+ channel opener, and cromakalim in rat and dog (294) 271
Dalpiaz, A., Borea, P.A., Gessi, S. and Gilli, G.
Binding thermodynamics of 5-HT_{1A} receptor ligands (312) 107
Dalpiaz, A., see Borea, P.A. (298) 329
Damaj, M.I. and Martin, B.R.
Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice (300) 51
Damas, J., see Liégeois, J.-F. (310) 9
D'Amico, M., Rossi, F. and Warner, T.D.
Cardiovascular responses induced by injection of endothelin-1 into the superior colliculus of rats (316) 245
Damsma, G., see Barf, T. (297) 205
Danahay, H., see Thorne, J.R. (316) 263
Danhof, M., see Van Schaick, E.A. (308) 311
Daniel, J.L., see Ryan, R.R. (306) 307
Daniel, M., see Boireau, A. (300) 237
Danilo, Jr., P., see Geller, J.C. (294) 423
Danysz, W., see Hölter, S.M. (314) R1
Danysz, W., see Misztal, M. (296) 1
Danysz, W., see Zajaczkowski, W. (296) 239
Daoust, M., see Naassila, M. (313) 273
Darbenzio, R.B., see D'Alonzo, A.J. (294) 271
Darlington, C.L., see Hutchinson, M.A. (301) 83
Darlington, C.L., see Jerram, A.H. (307) 269
Dasgupta, S., Ferré, S., Kull, B., Hedlund, P.B., Finnman, U.-B., Ahlberg, S., Arenas, E., Fredholm, B.B. and Fuxe, K.
Adenosine A_{2A} receptors modulate the binding characteristics of dopamine D_2 receptors in stably cotransfected fibroblast cells (316) 325
Dastur, F.N., see McGregor, I.S. (313) 43
D'Aubioul, J., see Van de Water, A. (299) 127
Davies, J.A., see Srinivasan, J. (315) 285
Davies, M.F., see Chen, S.-W. (312) 241
Davies, M.P., McCurrie, J.R. and Wood, D.
Comparative effects of K^+ channel modulating agents on contractions of rat intestinal smooth muscle (297) 249
Davies, S.N., see Collins, D.R. (294) 147
Davis, D.A., see Neisewander, J.L. (305) 13
Davis, T.P., see Konkoy, C.S. (297) 47
De, M., see McWhinney, C.D. (310) 209
De Backer, J.-P., see Czerwiec, E. (315) 355
De Backer, J.-P., see Czerwiec, E. (315) 99
Debaert, M., see Kerr, D.I.B. (308) R1
De Beun, R., Lohmann, A., Schneider, R. and De Vry, J.
Comparison of the stimulus properties of ethanol and the Ca^{2+} channel antagonist nimodipine in rats (306) 5
DeBoer, P., see Moor, E. (294) 155
De Campos, R.O.P., Alves, R.V., Kyle, D.J., Chakravarty, S., Mavunkel, B.J. and Calixto, J.B.
Antioedematogenic and antinociceptive actions of NPC 18521, a novel bradykinin B_2 receptor antagonist (316) 277
De Castro, C.M.M.B., Nahori, M.-A., Dumarey, C.H., Vargaftig, B.B. and Bachelet, M.
Fenspiride: an anti-inflammatory drug with potential benefits in the treatment of endotoxemia (294) 669
De Champlain, J., see Poulat, P. (315) 327
De Clerck, F., see Van de Water, A. (299) 127
De Costa, B.R., see Matsumoto, R.R. (301) 31
Decrinis, M., see Stark, G. (310) 29
DeFarias, F.P., Carvalho, M.F., Lee, S.H., Kaczorowski, G.J. and Suarez-Kurtz, G.
Effects of the K^+ channel blockers, paspalitrem-C and paxilline, on mammalian smooth muscle (314) 123
Defrêne, E., see Pruneau, D. (297) 53
De Garavilla, L., Pagani, E.D., Buchholz, R.A., Dundore, R., Bode, D.C., Volberg, M.L., Jackson, K.N., Pratt, P. and Silver, P.J.
Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo (313) 89
De Gasparo, M., see Chow, L. (294) 309
De Gennaro Colonna, V., Rossoni, G., Bonacci, D., Ciceri, S., Cattaneo, L., Müller, E.E. and Berti, F.
Worsening of ischemic damage in hearts from rats with selective growth hormone deficiency (314) 333
De Kloet, E.R., see Korte, S.M. (301) 19
De Kloet, E.R., see Korte, S.M. (309) 281
De la Fuente, M.T., Maroto, R., Esquerro, E., Sánchez-García, P. and García, A.G.
The actions of ouabain and lithium chloride on cytosolic Ca^{2+} in single chromaffin cells (306) 219
Delagrange, P., Emerit, M.B., Merahi, N., Abraham, C., Morain, P., Rault, S., Renard, P., Pfeiffer, B., Guardiola-Lemaître, B. and Hamon, M.
Interaction of S 21007 with 5-HT_3 receptors. In vitro and in vivo characterization (316) 195
Delagrange, P., see Ying, S.-W. (296) 33

De la Lande, I.S., Philp, T., Stafford, I. and Horowitz, J.D.
Lack of inhibition of glyceryl trinitrate by diphenyleneiodonium in bovine coronary artery (314) 347
DeLander, G.E., see Keil II, G.J. (312) 7
Del Arco, C., see Pascual, J. (295) 271
Delarge, J., see Liégeois, J.-F. (310) 9
Delarue, C., see Esneu, M. (308) 187
Del Basso, P., see Fabi, F. (309) 41
Delehanty, J.M., see Lai, L.-P. (309) 235
Délèze, J., see Hervé, J.-C. (313) 243
De Lima, T.C.M., see Teixeira, R.M. (311) 7
Del Monte, F., see Wynne, D.G. (310) 235
Del Olmo, E., see Pascual, J. (295) 271
Del Papa, N., see Nicoletti, F. (311) 213
Del Pozo, E., see Robles, L.-I. (295) 181
Del Soldato, P., see Santini, G. (316) 65
Del Tacca, M., see Blandizzi, C. (294) 191
Delton-Vandenbroucke, I., Sarda, N., Molière, P., Lagarde, M. and Gharib, A.
Modulation of norepinephrine-stimulated cyclic AMP accumulation in rat pinealocytes by n-3 fatty acids (312) 379
De Luca, A., Pierno, S. and Conte Camerino, D.
Effect of taurine depletion on excitation-contraction coupling and Cl^- conductance of rat skeletal muscle (296) 215
De Meyer, G.R.Y., see Van Put, D.J.M. (294) 753
Demirdamar, R., see Gumusel, B. (306) 107
Demmer, A., Dunn, T., Hoof, T., Kubesch, P. and Tümmler, B.
Competitive inhibition of photoaffinity labelling of P-glycoprotein by anticancer drugs and modulators including S9788 (315) 339
De Mol, N.J., see Paulussen, J.J.C. (312) 121
De Neef, P., see Waelbroeck, M. (305) 187
Deng, H.-W., see Li, Y.-J. (311) 163
Den Hertog, A., see Sipma, H. (305) 207
Den Hertog, A., see Sipma, H. (306) 187
De Nucci, G., see Costa, S.K.P. (298) 113
De Nucci, G., see Ferreira, H.H.A. (310) 201
Depoortere, H., see Avenet, P. (296) 209
Depoortere, H., see Biton, B. (294) 91
Deprés-Brummer, P., Metzger, G., Morin, D., Urien, S., Touitou, Y., Tillement, J.-P., Claustrat, B. and Lévi, F.
Pharmacokinetically guided melatonin scheduling in rats with circadian system suppression (312) 171
D'Ercole, A.J., see Pucilowski, O. (305) 57
De Sarro, A., see De Sarro, G. (294) 411
De Sarro, A., see Nava, F. (309) 223
De Sarro, G., Chimirri, A., De Sarro, A., Gitto, R., Grasso, S., Giusti, P. and Chapman, A.G.
GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice (294) 411
Desmond, T., see Vander Borght, T. (294) 577
Deth, R.C., see Jinsi, A. (302) 183
Détolle-Sarbach, S., see Miampamba, M. (308) 251
De Vecchi, E., see Paroni, R. (294) 737
Devigne, C., see Alescio-Lautier, B. (294) 763
De Vries, P., see Saxena, P.R. (312) 53
De Vries, T.J., Schoffelmeer, A.N.M., Tjon, G.H.K., Nestby, P., Mulder, A.H. and Vanderschuren, L.J.M.J.
Mifepristone prevents the expression of long-term behavioural sensitization to amphetamine (307) R3
De Vry, J., see De Beun, R. (306) 5
Devynck, M.-A., see Gagnet, C. (310) 67
De Wildt, D.J., see Herz, R.C.G. (306) 113
De Wildt, D.J., see Van Bergen, P. (294) 795
De Wildt, D.J., see Van Buren, T. (296) 277
Dhume, V.G., see Bhounsule, S.A. (316) 253
Diana, M., Muntoni, A.L., Pistis, M., Collu, M., Forgione, A. and Gessa, G.L.
Chronic administration of *l*-sulpiride at low doses reduces A10 but not A9 somatodentritic dopamine autoreceptor sensitivity (312) 179
Diana, M., see Muntoni, A.L. (301) R9
Diaz, B.L., Serra, M.F., Alves, A.C., Cordeiro, R.S.B., Martins, M.A. and Silva, P.M.R.
Local exposure to salbutamol or Bt_2 cyclic AMP inhibits pleural exudation and leukocyte influx caused by antigen in rats (296) 173
Diaz, B.L., see Alves, A.C. (312) 89
Di Bello, S., see Palmer, S. (294) 83
Dickenson, J.M. and Hill, S.J.
Synergistic interactions between human transfected adenosine A_1 receptors and endogenous cholecystokinin receptors in CHO cells (302) 141
Diéguez, G., see Fernández, N. (294) 483
Diéguez, G., see García, J.L. (315) 179
Diener, M. and Hug, F.
Modulation of Cl^- secretion in rat distal colon by genistein, a protein tyrosine kinase inhibitor (299) 161
Di Giamberardino, M., see Santini, G. (316) 65
Di Giulio, A.M., see Gorio, A. (303) 21
Di Giulio, A.M., see Gorio, A. (311) 21
Di Grezia, R., see Orzi, F. (302) 49
Di Grezia, R., see Patacchioli, F.R. (299) 29
Dijkstra, D., see Lahti, R.A. (301) R11
Dik, I.E.M., see Sadeghi-Hashjin, G. (302) 109
Dillard, R.D., see Fox, N. (308) 195
Di Lorenzo, D., see Di Santo, E. (299) 179
Dimitrov, E., see Pencheva, N. (304) 99
Diniz D'Souza, R., see Bhounsule, S.A. (316) 253
Di Renzo, G., Amoroso, S., Bassi, A., Fatatis, A., Cataldi, M., Colao, A.M., Lombardi, G. and Annunziato, L.
Role of the Na^+-Ca^{2+} and Na^+-H^+ antiporters in prolactin release from anterior pituitary cells in primary culture (294) 11
Di Renzo, G., see Taglialatela, M. (316) 373
Di Santo, E., Sironi, M., Mennini, T., Zinetti, M., Savoldi, G., Di Lorenzo, D. and Ghezzi, P.
A glucocorticoid receptor-independent mechanism for neurosteroid inhibition of tumor necrosis factor production (299) 179
Dittrich, P., see Graier, W.F. (294) 221
Dobashi, K., see Mita, Y. (297) 121
Doble, A., see Boireau, A. (300) 237
Doble, A., see Heuillet, E. (314) 229
Dohet, C., see Barth, Z. (296) 285
Dohi, T., see Kitayama, S. (309) 107
Dökmeci, D., see Ulugöl, A. (308) 49
Dökmeci, İ., see Ulugöl, A. (308) 49
Domenach, V., see Waelbroeck, M. (305) 187
Donadoni, M.L., see Gorio, A. (311) 21
Dong, E., see Han, C. (294) 593
Donoso, M.V., see Boric, M.P. (294) 391
Dontenwill, M., see Bennai, F. (306) 211
Dordal, A., see Robles, L.-I. (295) 181
D'Orléans-Juste, P., see Poulat, P. (315) 327
Dorsa, D.M., see Poulin, P. (294) 29
Dorso, C.R., see Bird, J.E. (294) 183
Dossin, O., Hanoun, N. and Zajac, J.-M.
Involvement of locus coeruleus projections in opiate withdrawal but not in opiate tolerance in mice (308) 271
Doublé, A., see Atef, N. (298) 287
Doucet, J., see Pham, I. (296) 267
Draheim, S.E., see Fox, N. (308) 195
Dresse, A., see Liégeois, J.-F. (310) 9
Driessen, B. and Gonçalves, J.
Inhibition of neural ATP release by atrial natriuretic peptide in guinea-pig vas deferens (296) 261
Drieu, K., see Bolaños-Jiménez, F. (294) 531
Drijfhout, W.J., Grol, C.J. and Westerink, B.H.C.

Parasympathetic inhibition of pineal indole metabolism by prejunctional modulation of noradrenaline release (308) 117
Drukarch, B., see Nestby, P. (294) 771
D'Sa, S., see Bhounsule, S.A. (316) 253
Duarte, C.B., see Ferreira, I.L. (302) 153
Dubocovich, M.L., see Larson-Prior, L.J. (297) 181
Dubocovich, M.L., see Molinari, E.J. (301) 159
Duc, D., see Thoss, V.S. (297) 145
Duchemin, A.-M., see Cho, S. (314) 51
Duckles, S.P., see García-Villalón, A.L. (314) 339
Duckles, S.P., see McNeill, A.M. (308) 305
Dudley, M.W., see McWhinney, C.D. (310) 209
Dufresne, M., Escrieut, C., Clerc, P., Le Huerou-Luron, I., Prats, H., Bertrand, V., Le Meuth, V., Guilloteau, P., Vaysse, N. and Fourmy, D.
Molecular cloning, developmental expression and pharmacological characterization of the CCK_B/gastrin receptor in the calf pancreas (297) 165
Dumarey, C.H., see De Castro, C.M.M.B. (294) 669
Dumuis, A., see Ansanay, H. (298) 165
Dun, N.J., see Narita, M. (311) 121
Dun, S.L., see Narita, M. (311) 121
Duncalfe, L.L. and Dunn, S.M.J.
Mapping of $GABA_A$ receptor sites that are photoaffinity-labelled by [^{3}H]flunitrazepam and [^{3}H]Ro 15-4513 (298) 313
Duncan, C.J., see Harding, R.J. (316) 223
Dundore, R., see De Garavilla, L. (313) 89
Dunn, S.M.J., see Duncalfe, L.L. (298) 313
Dunn, T., see Demmer, A. (315) 339
Durand, G., see Boireau, A. (300) 237
Duridanova, D.B., Gagov, H.S. and Boev, K.K.
Ca^{2+}-induced Ca^{2+} release activates K^+ currents by a cyclic GMP-dependent mechanism in single gastric smooth muscle cells (298) 159
Durroux, T., see Anouar, A. (308) 87
Dušek, L., see Kozubík, A. (316) 349
Düsing, R., see Sachinidis, A. (309) 95
Düsing, R., see Weber, A.-A. (309) 209
Dutton, R., see Cheung, N.S. (313) 159
Duvauchelle, C.L., Fleming, S.M. and Kornetsky, C.
Involvement of δ- and μ-opioid receptors in the potentiation of brain-stimulation reward (316) 137
Dyer, D.C., see Nair, R. (312) 45
Dziedzicka-Wasylewska, M., see Maj, J. (304) 49

Eastwood, S.L., see McGowan, S. (306) 249
Eaton, M.J., Lookingland, K.J. and Moore, K.E.
The σ receptor ligand rimcazole alters secretion of prolactin and α-melanocyte stimulating hormone by dopaminergic and non-dopaminergic mechanisms (299) 171
Ebert, B., see Bräuner-Osborne, H. (313) 145
Ebert, V., see Scholze, P. (304) 155
Ebinger, G., see Sarre, S. (296) 247
Eblen, F., Löschmann, P.-A., Wüllner, U., Turski, L. and Klockgether, T.
Effects of 7-nitroindazole, N^G-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, *N*-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions (299) 9
Edmundson, R., see Wang, S.Z. (296) 113
Edvinsson, L., see Bergdahl, A. (316) 59
Edwards III, C.K., see McWhinney, C.D. (310) 209
Egido, J., see Gutierrez, S. (302) 191
Eglen, R.M., see Watson, N. (294) 779
Eigler, A., see Greten, T.F. (299) 229
Eilam, Y., see Ela, C. (295) 275
Ekindjian, O.G., see Hernvann, A. (314) 193
El-Fakahany, E.E., see Wang, S.Z. (296) 113
El-Haschimi, K., see Sachinidis, A. (307) 121
Ela, C., Hasin, Y. and Eilam, Y.
Apparent desensitization of a σ receptor sub-population in neonatal rat cardiac myocytes by pre-treatment with σ receptor ligands (295) 275
Elam, H., see Lai, L.-P. (309) 201
Elghozi, J.L., see Ponchon, P. (297) 61
El Hadri, K., Fève, B. and Pairault, J.
Developmental expression and functional activity of β_1- and β_3-adrenoceptors in murine 3T3-F442A differentiating adipocytes (297) 107
Elmer, G.I., see Ambrosio, E. (315) 43
Elson, H.J., see Neisewander, J.L. (305) 13
Eltze, M. and Ullrich, B.
Characterization of vascular P_2 purinoceptors in the rat isolated perfused kidney (306) 139
Eltze, M.
Functional evidence for an α_{1B}-adrenoceptor mediating contraction of the mouse spleen (311) 187
Eltze, M.
In functional experiments, risperidone is selective, not for the B, but for the A subtype of α_1-adrenoceptors (295) 69
Emadi-Khiav, B. and Pearce, F.L.
Some studies on the effects of α-chymotrypsin on mast cells from the rat and other species (295) 243
Emaduddin, M., Liu, G.J., Takeuchi, H. and Munekata, E.
Multiple intracellular signal transduction pathways mediating inward current produced by the neuropeptide, achatin-I (302) 129
Emerit, M.B., see Delagrange, P. (316) 195
Emond, C., see Praddaude, F. (294) 173
Emonds-Alt, X., see Biyah, K. (308) 325
Endo, H., see Hiyoshi, Y. (294) 117
Endo, S., see Huh, K.-H. (310) 225
Endo, T., see Taniguchi, H. (304) 147
Endo, T., see Taniguchi, H. (312) 227
Endoh, M., see Yang, H.-T. (296) 47
Endoh, M., see Yang, H.-T. (312) 281
Endres, S., see Greten, T.F. (299) 229
Engel, J.A., see Blomqvist, O. (314) 257
Engert, F., see Frank, C. (295) 87
Epping, P., see Sachinidis, A. (307) 121
Erdemli, G. and Krnjević, K.
Tolbutamide blocks Ca^{2+}- and voltage-dependent K^+ currents of hippocampal Ca1 neurons (304) 37
Erdő, S.L., Molnár, P., Lakics, V., Bence, J.Zs. and Tömösközi, Z.
Vincamine and vincanol are potent blockers of voltage-gated Na^+ channels (314) 69
Erdő, S.L., see Molnár, P. (311) 311
Ericson, M., see Blomqvist, O. (314) 257
Erlinge, D., see Bergdahl, A. (316) 59
Erradi, F., see Payá, M. (312) 97
Erzouki, H., see Ambrosio, E. (315) 43
Escrieut, C., see Dufresne, M. (297) 165
Escubedo, E., see Pubill, D. (303) 171
E Silva, P.M.R., see Alves, A.C. (312) 89
Esneu, M., Delarue, C., Fournier, A. and Vaudry, H.
Characterization of the receptor mediating the effect of calcitonin gene-related peptide in the frog adrenal gland (308) 187
Espinosa-Luna, R., see Barajas-López, C. (312) 319
Esquerro, E., see De la Fuente, M.T. (306) 219
Estato, V., see Lopes-Martins, R. (308) 287
Estival, A., see Hillegaart, V. (295) 155
Estrada, L.S., see Champion, H.C. (309) 251
Etienne, P., Parés-Herbuté, N. and Monnier, L.
Regulation of growth of cultured smooth muscle cells from diabetic rats by interleukin-1β: role of nitric oxide (311) 79

Eto, K., Xue, Y.-x. and Hashimoto, K.
Effects of MCI-154, a new cardiotonic Ca^{2+} sensitizer, on ventricular arrhythmias and membrane ionic currents (298) 247
Eto, T., see Osajima, A. (315) 319
Evans, R.J., see Jarvis, G.E. (315) 203

Fabi, F., Argiolas, L., Chiavarelli, M. and Del Basso, P.
Nitric oxide-dependent and -independent modulation of sympathetic vasoconstriction in the human saphenous vein (309) 41
Fadda, F., Melis, F. and Stancampiano, R.
Increased hippocampal acetylcholine release during a working memory task (307) R1
Fage, D., see Klarica, M. (308) 135
Fain, C., see Nicoletti, F. (311) 213
Falch, E., see Bräuner-Osborne, H. (313) 145
Falcone, J., see Grider, J. (313) 115
Fallgren, B., see Malmberg, A.B. (294) 609
Fan, T.-H.M., see Lai, L.-P. (309) 235
Fang, H., see Helmeste, D. (301) R1
Farina, N.K., Hodgson, W.C. and Widdop, R.E.
Vascular reactivity to angiotensin II in blood-perfused kidneys of hypertensive diabetic rats (310) 185
Farr, S., see Morley, J.E. (311) 15
Farr, S.A., see Morley, J.E. (305) 23
Farrell, L.N., see Bath, C.P. (299) 103
Farzin, D., see Zarrindast, M.-R. (298) 1
Fatatis, A., see Di Renzo, G. (294) 11
Fauchère, J.-L., see Robineau, P. (294) 677
Fauchère, J.-L., see Bonnet, J. (310) 37
Fdez-Grandal, D., see Gil-Longo, J. (310) 175
Federico, A., Battisti, C., Manneschi, L., Gaggelli, E., Tassini, M., Valensin, G. and Vivi, A.
Amiodarone affects membrane water permeability properties of human erythrocytes and rat mitochondria (304) 237
Fehmann, H.-C., see Wagner, U. (298) 265
Feldman, D.S., Terry Jr., A.V. and Buccafusco, J.J.
Spinal muscarinic cholinergic and nitric oxide systems in cardiovascular regulation (313) 211
Feldman, J., see Monassier, L. (305) 109
Felici, A., see Mele, A. (308) 1
Felici, L., see Ricci, A. (301) 189
Feller, D.R., see Konkar, A.A. (305) 63
Feller, D.R., see Lezama, E.J. (308) 69
Feltz, A., see Zerr, P. (303) 101
Fernandes, N., see Bhounsule, S.A. (316) 253
Fernández, A.G., see Silvestre, J.S. (309) 219
Fernández, N., Monge, L., García-Villalón, A.L., García, J.L., Gómez, B. and Diéguez, G.
Endothelin-1-induced in vitro cerebral venoconstriction is mediated by endothelin ET_A receptors (294) 483
Fernández, N., see García, J.L. (315) 179
Fernando, S.R., see Pertwee, R.G. (315) 195
Ferrándiz, M.L., see Payá, M. (312) 97
Ferrante, F., see Ricci, A. (301) 189
Ferraro, L., Tanganelli, S., O'Connor, W.T., Antonelli, T., Rambert, F. and Fuxe, K.
The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism (306) 33
Ferré, S., see Dasgupta, S. (316) 325
Ferré, S., see Popoli, P. (305) 123
Ferreira, H.H.A., Medeiros, M.V., Lima, C.S.P., Flores, C.A., Sannomiya, P., Antunes, E. and De Nucci, G.
Inhibition of eosinophil chemotaxis by chronic blockade of nitric oxide biosynthesis (310) 201
Ferreira, I.L., Duarte, C.B. and Carvalho, A.P.
Ca^{2+} influx through glutamate receptor-associated channels in retina cells correlates with neuronal cell death (302) 153
Ferri, N., see Adami, M. (294) 383
Fertel, R.H., see Konkar, A.A. (305) 63
Fertel, R.H., see Xia, Y. (316) 81
Feuerstein, G.Z., see Yue, T.-L. (294) 585
Fève, B., see El Hadri, K. (297) 107
Field, M., see Hinks, G.L. (312) 153
Field, M.J., see Singh, L. (307) 283
Fijał, K., see Wędzony, K. (305) 73
Fillion, G., see Bolaños-Jiménez, F. (294) 531
Finberg, J.P.M., see Ari, G. (307) 69
Finco, C., see Gorio, A. (311) 21
Fine, R.E., see Chen, J.-C. (303) 109
Fink, C.A., see Hu, S. (294) 357
Fink, K., Böing, C. and Göthert, M.
Presynaptic 5-HT autoreceptors modulate *N*-methyl-D-aspartate-evoked 5-hydroxytryptamine release in the guinea-pig brain cortex (300) 79
Finnman, U.-B., see Dasgupta, S. (316) 325
Fioretti, M.C., see Campanile, F. (307) 191
Fischer, M.J.E., see Paulussen, J.J.C. (312) 121
Fischer, T., see Cuq, P. (315) 213
Fisher, A., see Heldman, E. (297) 283
Fisher, L., see Fox, N. (308) 195
Fitzgerald, M.E.C., see Zagvazdin, Y. (303) 61
Flamez, A., see Czerwiec, E. (315) 99
Flanigan, T.P., see McGowan, S. (306) 249
Fleckenstein, A.E., Kopajtic, T.A., Boja, J.W., Carroll, F.I. and Kuhar, M.J.
Highly potent cocaine analogs cause long-lasting increases in locomotor activity (311) 109
Fleming, S.M., see Duvauchelle, C.L. (316) 137
Flesch, M., see Lenz, O. (294) 17
Fletcher, A., see Pike, V.W. (301) R5
Flood, J.F., see Morley, J.E. (305) 23
Flood, J.F., see Morley, J.E. (311) 15
Flores, C.A., see Ferreira, H.H.A. (310) 201
Flores-Murrieta, F.J., see López-Muñoz, F.J. (308) 275
Flouquet, N., see Kerr, D.I.B. (308) R1
Flower, R.J., see Malcangio, M. (299) 113
Foddi, M.C., see Adami, M. (294) 383
Folkerts, G., see Sadeghi-Hashjin, G. (302) 109
Ford, A.P.D.W., see Lachnit, W.G. (297) 83
Forgione, A., see Diana, M. (312) 179
Foster, Jr., H.E., see Saito, M. (310) 197
Fourmy, D., see Dufresne, M. (297) 165
Fournié-Zaluski, M.-C., see Pham, I. (296) 267
Fournié-Zaluski, M.-C., see Valverde, O. (312) 15
Fournier, A., see Esneu, M. (308) 187
Fowler, J.S., see Gatley, S.J. (296) 145
Fowler, L.J., see Biggs, C.S. (299) 83
Fowler, L.J., see Teoh, H. (302) 27
Fox, N., Song, M., Schrementi, J., Sharp, J.D., White, D.L., Snyder, D.W., Hartley, L.W., Carlson, D.G., Bach, N.J., Dillard, R.D., Draheim, S.E., Bobbitt, J.L., Fisher, L. and Mihelich, E.D.
Transgenic model for the discovery of novel human secretory non-pancreatic phospholipase A_2 inhibitors (308) 195
Fox, S. and Brotchie, J.
Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat (301) 27
Fozard, J.R., Pfannkuche, H.-J. and Schuurman, H.-J.
Mast cell degranulation following adenosine A_3 receptor activation in rats (298) 293
Francès, H., Coudereau, J.-P., Sandouk, P., Clément, M., Monier, C. and Bourre, J.-M.

Influence of a dietary α-linolenic acid deficiency on learning in the Morris water maze and on the effects of morphine (298) 217
Frank, C., Engert, F., Tokutomi, N. and Lux, H.D.
Different effects of baclofen and GTPγS on voltage-activated Ca^{2+} currents in rat hippocampal neurons in vitro (295) 87
Frankiewicz, T., see Misztal, M. (296) 1
Frantz, K., Babcock, D. and Van Hartesveldt, C.
The locomotor effects of a putative dopamine D_3 receptor agonist in developing rats (302) 1
Fraundorfer, P.F., see Konkar, A.A. (305) 63
Fredholm, B.B., see Dasgupta, S. (316) 325
Fredholm, B.B., see Sipma, H. (306) 187
Fredholm, B.B., see Zhang, Y. (313) 237
Freedman, J., see Siegel, B.W. (296) 307
Frei, K., see Lorenzl, S. (308) 335
Freund, W.-D., see Van der Staay, F.J. (294) 361
Frey, K., see Kilbourn, M. (307) 227
Frey, K., see Vander Borght, T. (294) 577
Friedhoff, A.J., see Gruen, R.J. (309) 115
Friedman, E., see Tilakaratne, N. (307) 211
Friedrichs, G.S., Abreu, J.-N., Black, S.C., Chi, L. and Lucchesi, B.R.
5-Hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death (306) 99
Friend, J.M., see Xue, B.G. (300) 125
Friese, J., see Gleitz, J. (315) 83
Fröhlich, R., Boehm, S. and Illes, P.
Pharmacological characterization of P_2 purinoceptor types in rat locus coeruleus neurons (315) 255
Frost, J., see Avenet, P. (296) 209
Frøyland, L., see Brunvand, H. (314) 99
Frussa-Filho, R., see Bellot, R.G. (313) 175
Frydryszak, H., see Van Kampen, J. (298) 7
Fu, M., see Modi, P.I. (299) 213
Fuentes, J.A., see Reche, I. (301) 75
Fuentes, J.A., see Reche, I. (312) 391
Fujii, E., Irie, K., Ogawa, A., Ohba, K.-i. and Muraki, T.
Role of nitric oxide and prostaglandins in lipopolysaccharide-induced increase in vascular permeability in mouse skin (297) 257
Fujii, E., Irie, K., Uchida, Y., Tsukahara, F., Ohba, K.-i., Ogawa, A. and Muraki, T.
Tolerance to lipopolysaccharide-induced increase in vascular permeability in mouse skin (313) 129
Fujii, M., see Mito, K. (304) 93
Fujiki, H., Mori, T., Yoshida, K., Imaizumi, T. and Tominaga, M.
OPC-18790, a novel positive inotropic agent, has both arterial and venous vascular dilating actions in the dog (313) 191
Fujimoto, Y., see Yoshida, A. (312) 115
Fujino, M., see Kitayoshi, T. (305) 137
Fujino, M., see Kusumoto, K. (296) 65
Fujishima, M., see Cai, H. (313) 103
Fujitani, B., see Minato, H. (315) 297
Fujiwara, A., see Kusumoto, K. (296) 65
Fujiwara, T., see Araki, T. (306) 73
Fukao, M., see Hattori, Y. (301) 99
Fukasawa, H., see Hotta, N. (311) 199
Fukasawa, H., see Hotta, N. (313) 201
Fukuda, S., see Szeto, H.H. (309) 183
Fukui, S., see Iyo, M. (312) 163
Fukunaga, Y., see Kishioka, S. (316) 7
Fukuta, H., see Xue, L. (294) 75
Fukutomi, H., see Akuzawa, S. (296) 227
Fukuyama, S., see Hirasawa, Y. (303) 55
Fulcrand, P., see Oiry, C. (294) 511
Fuller, R.W., see Hemrick-Luecke, S.K. (311) 207
Funada, M., Schutz, C.G. and Shippenberg, T.S.
Role of δ-opioid receptors in mediating the aversive stimulus effects of morphine withdrawal in the rat (300) 17
Funder, J., see Jefferys, D. (295) 131
Fundytus, M.E. and Coderre, T.J.
Chronic inhibition of intracellular Ca^{2+} release or protein kinase C activation significantly reduces the development of morphine dependence (300) 173
Furuhama, K., see Zafirov, D. (311) 61
Furukawa, K.-I., see Chairungsrilerd, N. (314) 351
Furukawa, S., see Nitta, A. (307) 1
Furukawa, Y., Xue, Y.-x., Chiba, S. and Hashimoto, K.
Effects of zatebradine on ouabain-, two-stage coronary ligation- and epinephrine-induced ventricular tachyarrhythmias (300) 203
Furukawa, Y., see Yamazaki, K. (297) 233
Furukawa, Y., see Yonezawa, T. (309) 51
Furukawa, Y., see Yonezawa, T. (315) 289
Fuseau, C., see Valette, H. (306) 133
Fuxe, K., see Dasgupta, S. (316) 325
Fuxe, K., see Ferraro, L. (306) 33
Fuxe, K., see Popoli, P. (305) 123

Gabel, R.A., see Kivlighn, S.D. (294) 439
Gabilondo, A.M., Krasel, C. and Lohse, M.J.
Mutations of Tyr^{326} in the β_2-adrenoceptor disrupt multiple receptor functions (307) 243
Gabilondo, A.M., see Callado, L.F. (316) 359
Gaggelli, E., see Federico, A. (304) 237
Gaginella, T.S., see Izzo, A.A. (301) 137
Gagnet, C., Brunet, A., Pernollet, M.-G., Devynck, M.-A. and Astarie-Dequeker, C.
Endothelin-3, Ca^{2+} mobilization and cyclic GMP content in human platelets (310) 67
Gagov, H.S., see Duridanova, D.B. (298) 159
Gainetdinov, R.R., Sotnikova, T.D., Grekhova, T.V. and Rayevsky, K.S.
In vivo evidence for preferential role of dopamine D_3 receptor in the presynaptic regulation of dopamine release but not synthesis (308) 261
Galas, M.-C. and Harden, T.K.
Cyclic AMP-induced desensitization of G-protein-regulated phospholipase C in turkey erythrocyte membranes (314) 157
Galeotti, N., Ghelardini, C. and Bartolini, A.
Effect of pertussis toxin on morphine, diphenhydramine, baclofen, clomipramine and physostigmine antinociception (308) 125
Galleyrand, J.-C., see Oiry, C. (294) 511
Galli Kienle, M., see Paroni, R. (294) 737
Galloway, M.P., see Aretha, C.W. (305) 119
Galloway, M.P., see West, A.R. (298) 241
Galzin, A.-M., see Riva, L. (305) 193
Gandía, L., López, M.G., Villarroya, M., Gilabert, J.A., Cárdenas, A., García, A.G. and Borges, R.
Blocking effects of otilonium on Ca^{2+} channels and secretion in rat chromaffin cells (298) 199
Ganguly, D.K., see Banerjee, B. (310) 13
Gantner, F., Uhlig, S. and Wendel, A.
Quinine inhibits release of tumor necrosis factor, apoptosis, necrosis and mortality in a murine model of septic liver failure (294) 353
Garcez do Carmo, L., see Jurkiewicz, N.H. (307) 299
García, A.G., see De la Fuente, M.T. (306) 219
García, A.G., see Gandía, L. (298) 199
Garcia-Barrado, M.-J., Jonas, J.-C., Gilon, P. and Henquin, J.-C.
Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca^{2+} in pancreatic B-cells (298) 279
García, J.L., Fernández, N., García-Villalón, A.L., Monge, L., Gómez, B. and Diéguez, G.
Coronary vasoconstriction by endothelin-1 in anesthetized goats: role of endothelin receptors, nitric oxide and prostanoids (315) 179
García, J.L., see Fernández, N. (294) 483
García-Sáinz, J.A., Romero-Avila, M.T. and González-Espinosa, C.
Coexpression of α_{1A}- and α_{1B}-adrenoceptors in the liver of the rhesus monkey (*Macaca mulatta*) (311) 277
García-Sevilla, J.A., see Grijalba, B. (310) 83

García-Sevilla, J.A., see Meana, J.J. (312) 385
García-Sevilla, J.A., see Olmos, G. (310) 273
García-Velasco, G., Sánchez, M., Hidalgo, A. and García de Boto, M.J.
Pharmacological dissociation of UTP- and ATP-elicited contractions and relaxations in isolated rat aorta (294) 521
García-Villalón, A.L., Buchholz, J.N., Krause, D.N. and Duckles, S.P.
Sex differences in the effects of 17β-estradiol on vascular adrenergic responses (314) 339
García-Villalón, A.L., see Fernández, N. (294) 483
García-Villalón, A.L., see García, J.L. (315) 179
García de Boto, M.J., see García-Velasco, G. (294) 521
Garratt, J.C., McEvoy, M.P. and Owen, D.G.
Blockade of two voltage-dependent potassium channels, mKv1.1 and mKv1.2, by docosahexaenoic acid (314) 393
Garrison, E.A., see Champion, H.C. (309) 251
Gasior, M., Borowicz, K., Starownik, R., Kleinrok, Z. and Czuczwar, S.J.
Ca^{2+} channel blockade and the antielectroshock activity of NMDA receptor antagonists, CGP 40116 and CGP 43487, in mice (312) 27
Gaskin, A.A., see MacLennan, A.J. (295) 103
Gassen, M., Glinka, Y., Pinchasi, B. and Youdim, M.B.H.
Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction (308) 219
Gaster, L.M., see Banner, S.E. (308) 181
Gasulla, D., see Pubill, D. (303) 171
Gatch, M.B., Liguori, A., Negus, S.S., Mello, N.K. and Bergman, J.
Corrigendum to 'Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in rhesus monkeys'. [Eur. J. Pharmacol. 298 (1996) 31–36] (312) 389
Gatch, M.B., Negus, S.S., Mello, N.K., Liguori, T. and Bergman, J.
Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in Rhesus monkeys (298) 31
Gater, P.R., Wasserman, M.A. and Renzetti, L.M.
Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea (304) 123
Gatley, S.J., Gifford, A.N., Volkow, N.D., Lan, R. and Makriyannis, A.
^{123}I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB_1 receptors (307) 331
Gatley, S.J., Volkow, N.D., Chen, R., Fowler, J.S., Carroll, F.I. and Kuhar, M.J.
Displacement of RTI-55 from the dopamine transporter by cocaine (296) 145
Gaudin, P., Couvineau, A., Maoret, J.-J., Rouyer-Fessard, C. and Laburthe, M.
Stable expression of the recombinant human VIP_1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties (302) 207
Gauthier, T.W., see Scalia, R. (296) 181
Gauvin, D.V., Carl, K.L., Briscoe, R.J., Vallett, M. and Holloway, F.A.
Cross-generalization between a cocaine cue and two antihistamines (294) 281
Gaytan, O., Swann, A.C. and Dafny, N.
Effects of amphetamine at the beginning of the light cycle on multiple indices of motor activity in the rat (300) 1
Ge, J. and Barnes, N.M.
Alterations in angiotensin AT_1 and AT_2 receptor subtype levels in brain regions from patients with neurodegenerative disorders (297) 299
Ge, J., Towers, P., Patel, A.C. and Barnes, N.M.
[^{125}I]S(−)-zacopride labels a novel 5-hydroxytryptamine sensitive recognition site in rat duodenum and ileum (300) 113
Géczy, J., see Liégeois, J.-F. (310) 9
Gedulin, B., see Vine, W. (314) 115
Gee, K.W., see Xue, B.G. (300) 125
Geiger, J.D., see Padua, R.A. (298) 185
Geiger, J.D., see Parkinson, F.E. (308) 97
Gekeler, V., see Boer, R. (295) 253
Geller, J.C., Cua, M., Prieto, L., Guo, S.-D., Danilo, Jr., P. and Rosen, M.R.
Chloroethylclonidine increases the incidence of lethal arrhythmias during coronary occlusion in anesthetized dogs (294) 423
Genedani, S., see Bernardi, M. (298) 51
George, S.R., see Ng, G.Y.K. (311) 45
Geppetti, P., see Yoshihara, S. (296) 291
Gerald, C., see Adham, N. (304) 231
Gergen, K.A., Zadina, J.E. and Paul, D.
Analgesic effects of Tyr-W-MIF-1: a mixed μ_2-opioid receptor agonist/μ_1-opioid receptor antagonist (316) 33
Gergen, K.A., Zadina, J.E., Kastin, A.J. and Paul, D.
Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by α_2-adrenoceptors (298) 235
Gerhardt, C.C., Leysen, J.E., Planta, R.J., Vreugdenhil, E. and Van Heerikhuizen, H.
Functional characterisation of a 5-HT_2 receptor cDNA [1] cloned from *Lymnaea stagnalis* (311) 249
Germain, G., see Anouar, A. (308) 87
Germany, A., González, P. and Contreras, E.
Possible role of nitric oxide in the antinociceptive action of intraventricular bradykinin in mice (310) 123
Gessa, G.L., see Diana, M. (312) 179
Gessa, G.L., see Imperato, A. (302) 21
Gessa, G.L., see Muntoni, A.L. (301) R9
Gessi, S., see Borea, P.A. (298) 329
Gessi, S., see Dalpiaz, A. (312) 107
Geurts, S., see Mensink, A. (310) 73
Gharib, A., see Delton-Vandenbroucke, I. (312) 379
Ghelardini, C., see Galeotti, N. (308) 125
Ghezzi, P., see Di Santo, E. (299) 179
Ghijsen, W.E.J.M., see Zuiderwijk, M. (307) 275
Ghisalberti, E.L., see Pennacchio, M. (305) 169
Giampietri, A., see Campanile, F. (307) 191
Giancarli, M.R., see Bird, J.E. (294) 183
Gianoulakis, C., see Guillaume, P. (316) 49
Giardino, L., Zanni, M., Bettelli, C., Savina, M.A. and Calzà, L.
Regulation of glutamic acid decarboxylase mRNA expression in rat brain after sertraline treatment (312) 183
Giardino, L., see Benelli, A. (294) 505
Gibson, R.E., see Kivlighn, S.D. (294) 439
Giesbers, I., see Liégeois, J.-F. (310) 9
Gifford, A.N., see Gatley, S.J. (307) 331
Gil-Longo, J., Fdez-Grandal, D., Álvarez, M., Sieira, M. and Orallo, F.
Study of in vivo and in vitro resting vasodilator nitric oxide tone in normotensive and genetically hypertensive rats (310) 175
Gilabert, J.A., see Gandía, L. (298) 199
Gilli, G., see Borea, P.A. (298) 329
Gilli, G., see Dalpiaz, A. (312) 107
Gillies, D.M., Mylecharane, E.J. and Jackson, D.M.
Effects of 5-HT_3 receptor-selective agents on locomotor activity in rats following injection into the nucleus accumbens and the ventral tegmental area (303) 1
Gilmore, J., see Bath, C.P. (299) 103
Gilon, P., see Garcia-Barrado, M.-J. (298) 279
Gingras, M.A., see Wise, R.A. (307) 15
Girard, J., Panizzon, K. and Wallis, R.A.
Azelastine protects against CA1 traumatic neuronal injury in the hippocampal slice (300) 43
Girolami, J.-P., see Praddaude, F. (294) 173
Gispen, W.H., see Van Buren, T. (296) 277
Gitto, R., see De Sarro, G. (294) 411
Giusti, P., see De Sarro, G. (294) 411
Glass-Marmor, L., Morgenstern, H. and Beitner, R.
Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells (313) 265

Gleitz, J., Friese, J., Beile, A., Ameri, A. and Peters, T.
Anticonvulsive action of (±)-kavain estimated from its properties on stimulated synaptosomes and Na^+ channel receptor sites (315) 83
Glen, A., see Lightowler, S. (296) 137
Glinka, Y., see Gossen, M. (308) 219
Godlewski, G., see Malinowska, B. (315) 159
Goldberg, S.R., see Ambrosio, E. (315) 43
Golembiowska, K., White, T.D. and Sawynok, J.
Adenosine kinase inhibitors augment release of adenosine from spinal cord slices (307) 157
Gołembiowska, K., see Wędzony, K. (305) 73
Gómez, B., see Fernández, N. (294) 483
Gómez, B., see García, J.L. (315) 179
Gómez-Garre, D., see Gutierrez, S. (302) 191
Gomi, Y., see Tsunobuchi-Ushijima, H. (295) 235
Gonçalves, J., see Driessen, B. (296) 261
Gonçalves, M.L. and Ribeiro, J.A.
Adenosine A_2 receptor activation facilitates $^{45}Ca^{2+}$ uptake by rat brain synaptosomes (310) 257
Gonçalves de Moraes, V.L., Rumjanek, V.M. and Calixto, J.B.
Jatrophone and 12-*O*-tetradecanoyl phorbol-13-acetate antagonism of stimulation of natural killer activity and lymphocyte proliferation (312) 333
Gonda, T., see Matsubara, K. (315) 145
Gonsalves, S., Watson, J. and Ashton, C.
Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK_1 receptor antagonist, in ferrets (305) 181
Gonzalez-Alvear, G.M. and Werling, L.L.
σ_1 Receptors in rat striatum regulate NMDA-stimulated [^{3}H]dopamine release via a presynaptic mechanism (294) 713
González, E., see Gutierrez, S. (302) 191
González-Espinosa, C., see García-Sáinz, J.A. (311) 277
Gonzalez, M.I., Patmore, L. and Wilson, C.A.
Effect of delequamine (RS15385) on female sexual behaviour in the rat (312) 1
González, M.I., see Molina-Holgado, F. (316) 39
González, P., see Germany, A. (310) 123
Gonzalez, W., see Pham, I. (296) 267
Goodfellow, C., see Namovic, M.T. (315) 81
Goodnough, D.B., see Hawkinson, J.E. (304) 141
Gordon, I., Weizman, R. and Rehavi, M.
Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter (298) 27
Gorio, A., Donadoni, M.L., Finco, C., Borella, F. and Di Giulio, A.M.
Alterations of protein mono-ADP-ribosylation and diabetic neuropathy: a novel pharmacological approach (311) 21
Gorio, A., Vergani, L., Malosio, M.L., Lesma, E. and Di Giulio, A.M.
Perinatal exposure to morphine: reactive changes in the brain after 6-hydroxydopamine (303) 21
Goshima, Y., Miyamae, T., Nakamura, S., Miki, K., Kosaka, K. and Misu, Y.
Ventral tegmental injection of nicotine induces locomotor activity and L-DOPA release from nucleus accumbens (309) 229
Goshima, Y., see Miyamae, T. (300) 105
Goso, C., Astolfi, M., Parlani, M. and Manzini, S.
[^{3}H][β-Ala^8]neurokinin A-(4–10): a novel, selective radioligand for the tachykinin NK_2 receptor (294) 239
Göthert, M., see Fink, K. (300) 79
Göthert, M., see Malinowska, B. (315) 159
Goto, K., see Miyauchi, T. (303) 193
Goto, Y., Miura, M. and Iijima, T.
Extrusion mechanisms of intracellular Ca^{2+} in human aortic endothelial cells (314) 185
Goudreau, N., see Jagerschmidt, A. (296) 97
Govitrapong, P., see Wattanathorn, J. (313) 69
Gozariu, M., Bustamante, D., Le Bars, D. and Willer, J.-C.
Effects of clonidine on a C-fibre reflex in the rat (313) 51
Graham, D., see Avenet, P. (296) 209
Graham, D.I., see McAuley, M.A. (307) 171
Graier, W.F., Grubenthal, I., Dittrich, P., Wascher, T.C. and Kostner, G.M.
Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation (294) 221
Granados-Soto, V., see López-Muñoz, F.J. (308) 275
Granger, P., see Biton, B. (294) 91
Grant, T.L., see Mayers, R.M. (295) 199
Gras, J., see Cardelús, I. (299) 153
Grasby, P.M., see Pike, V.W. (301) R5
Grasso, S., see De Sarro, G. (294) 411
Gray, A.M.
Effect of alprazolam on opiate withdrawal: a combined behavioural and microdialysis study (313) 73
Greenlee, W.J., see Chang, R.S.L. (294) 429
Greenlee, W.J., see Kivlighn, S.D. (294) 439
Gregg, K., see Rabin, B.C. (306) 51
Grekhova, T.V., see Gainetdinov, R.R. (308) 261
Greney, H., see Bennai, F. (306) 211
Greten, T.F., Sinha, B., Haslberger, C., Eigler, A. and Endres, S.
Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesis (299) 229
Grider, J., Falcone, J., Kilpatrick, E., Ott, C. and Jackson, B.
Effect of luminal vasopressin on NaCl transport in the medullary thick ascending limb of the rat (313) 115
Griffin, G., see Pertwee, R.G. (315) 195
Griffini, P., see Braida, D. (302) 13
Grignon, S., Levy, N., Couraud, F. and Bruguerolle, B.
Tyrosine kinase inhibitors and cycloheximide inhibit Li^+ protection of cerebellar granule neurons switched to non-depolarizing medium (315) 111
Grigorjev, C., see Navarro Becerra, N. (312) 83
Grijalba, B., Callado, L.F., Meana, J.J., García-Sevilla, J.A. and Pazos, A.
α_2-Adrenoceptor subtypes in the human brain: a pharmacological delineation of [^{3}H]RX-821002 binding to membranes and tissue sections (310) 83
Grijalba, B., see Meana, J.J. (312) 385
Grima, M., see Barthelmebs, M. (314) 325
Grippa, N., see Brambilla, A. (305) 115
Grisar, J.M., see Bolkenius, F.N. (298) 37
Grohmann, U., see Campanile, F. (307) 191
Grol, C.J., see Drijfhout, W.J. (308) 117
Grondin, R., see Blanchet, P.J. (309) 13
Grong, K., see Brunvand, H. (314) 99
Groschner, K., see Wakabayashi, I. (299) 139
Gross, S.S., see Hattori, Y. (296) 107
Grouls, R.J.E., see Van den Berg, R.J. (316) 87
Grover, G.J., see D'Alonzo, A.J. (294) 271
Grubenthal, I., see Graier, W.F. (294) 221
Gruber, B., see Kähler, C.M. (304) 135
Gruen, R.J., Wenberg, K., Selim, M., Friedhoff, A.J. and Bradberry, C.W.
Novelty-associated locomotion: correlation with cortical and subcortical $GABA_A$ receptor binding (309) 115
Gryglewski, R.J., Korbut, R., Święs, J., Kostka-Trąbka, E., Bieroń, K. and Robak, J.
Thrombolytic action of ticlopidine: possible mechanisms (308) 61
Gu, J.-L., see Yue, T.-L. (294) 585
Guardiola-Lemaître, B., see Delagrange, P. (316) 195
Guardiola-Lemaître, B., see Ying, S.-W. (296) 33
Guerrini, R., Capasso, A., Sorrentino, L., Anacardio, R., Bryant, S.D., Lazarus, L.H., Attila, M. and Salvadori, S.
Opioid receptor selectivity alteration by single residue replacement: synthesis and activity profile of [Dmt^1]deltorphin B (302) 37

Guerrini, R., see Calò, G. (311) R3
Guez, D., see Miampamba, M. (308) 251
Guh, J.-H., Yu, S.-M., Ko, F.-N., Wu, T.-S. and Teng, C.-M.
Antiproliferative effect in rat vascular smooth muscle cells by osthole, isolated from *Angelica pubescens* (298) 191
Guh, J.-H., see Chueh, S.-C. (305) 177
Guilbaud, G., see Catheline, G. (315) 135
Guillaume, P., Jankowski, M., Gutkowska, J. and Gianoulakis, C.
Effect of chronic moderate ethanol consumption on heart brain natriuretic peptide (316) 49
Guillaume-Rousselet, N., see Jagerschmidt, A. (296) 97
Guilloteau, P., see Dufresne, M. (297) 165
Guirimand, F., Chauvin, M., Willer, J.-C. and Le Bars, D.
Buprenorphine blocks diffuse noxious inhibitory controls in the rat (294) 651
Guizzetti, M., Costa, P., Peters, J. and Costa, L.G.
Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells (297) 265
Gumusel, B., Tel, B.C., Demirdamar, R. and Sahin-Erdemli, I.
Reactive oxygen species-induced impairment of endothelium-dependent relaxation in rat aortic rings: protection by L-arginine (306) 107
Guo, J.-L., see Ohkuma, S. (301) 179
Guo, L.j., see Singewald, N. (294) 787
Guo, S.-D., see Geller, J.C. (294) 423
Guo, T.-Z., see Rabin, B.C. (306) 51
Gurbanov, K., Rubinstein, I., Hoffman, A., Abassi, Z., Better, O.S. and Winaver, J.
Bosentan improves renal regional blood flow in rats with experimental congestive heart failure (310) 193
Gürün, M.S., see Savci, V. (309) 275
Gutbrod, O., see Cooper, J.C. (309) 287
Gutierrez, S., Palacios, I., Egido, J., Gómez-Garre, D., Hernández, P., González, E. and Herrero-Beaumont, G.
Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. (302) 191
Gutkowska, J., see Guillaume, P. (316) 49
Gynther, J., see Navajas, C. (304) 173
Györgyi, K., see Vegh, A. (305) 163
Gy Papp, J., see Vegh, A. (305) 163

Haas, A., see Petty, M.A. (307) 149
Haas, S., see Boer, R. (295) 253
Hacksell, U., see Yu, H. (303) 151
Hada, J., Kaku, T., Morimoto, K., Hayashi, Y. and Nagai, K.
Adenosine transport inhibitors enhance high K^+-evoked taurine release from rat hippocampus (305) 101
Haddad, E.-B., see Mak, J.C.W. (302) 215
Hadj-Kaddour, K., Michel, A. and Chevillard, C.
Different mechanisms involved in relaxation of guinea-pig trachea by endothelin-1 and -3 (298) 145
Hadjiconstantinou, M., see Cho, S. (314) 51
Hagan, J.J., Hatcher, J.P. and Slade, P.D.
The role of 5-HT_{1D} and 5-HT_{1A} receptors in mediating 5-hydroxytryptophan induced myoclonic jerks in guinea pigs (294) 743
Hagan, R.M., see Hawcock, A.B. (294) 163
Hagelin, E.M., see Stokke, M. (303) 115
Hagiwara, M., see Shimasue, K. (296) 347
Hajós-Korcsok, É. and Sharp, T.
8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT_{1A} and dopamine D_1 receptors (314) 285
Håkanson, R., see Wang, Z.-Y. (297) 157
Halonen, T., Nissinen, J., Jansen, J.A. and Pitkänen, A.
Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus (299) 69
Hamada, E., see Nakajima, T. (294) 625
Hamada, Y., see Hotta, N. (311) 199
Hamada, Y., see Hotta, N. (313) 201
Hamada, Y., see Nakamura, J. (294) 207
Hamel, J.-D., see Boucher, M. (315) 171
Hamon, M., see Delagrange, P. (316) 195
Han, B.-G., see Kim, Y.-B. (313) 107
Han, C., Yu, G., Zhang, Y., Xu, K., Qu, P. and Dong, E.
Alterations of α_1-adrenoceptor subtypes in the hearts of thyroxine-treated rats (294) 593
Han, E.S., see Ahn, S.K. (306) 175
Han, X.Y., see Salunga, T.L. (304) 163
Hanani, M., see Abu-Dalu, R. (309) 189
Hancock, A.A., see Buckner, S.A. (297) 241
Handrock, R. and Herzig, S.
Stereoselectivity of Ca^{2+} channel block by dihydropyridines: no modulation by the voltage protocol (309) 317
Haneda, T., see Miyata, S. (307) 81
Hanin, I., see Kim, S.Y. (316) 249
Hanoun, N., see Dossin, O. (308) 271
Hansen, A., see Andersen, P.H. (311) 95
Hansen, H.C., see Jackson, H.C. (308) 21
Hansen, K., see Andersen, P.H. (311) 95
Hara, M., see Yoshihara, S. (296) 291
Hara, T., see Hotta, N. (311) 199
Hara, T., see Hotta, N. (313) 201
Hara, T., see Nakamura, J. (294) 207
Hara, Y., see Oh-ishi, S. (300) 255
Hara, Y., see Yamamoto, T. (302) 53
Harden, F.A., Harrison, G.J., Headrick, J., Jordan, L.R. and Willis, R.J.
A biphasic response to adenosine in the coronary vasculature of the K^+-arrested perfused rat heart (307) 49
Harden, T.K., see Galas, M.-C. (314) 157
Harding, R.J. and Duncan, C.J.
Extracellular K^+ and protection against cellular damage in the rat heart (316) 223
Harding, S.E., see Wynne, D.G. (310) 235
Haroutunian, V., see Santucci, A.C. (295) 7
Harris, E.W., see Kinney, G.G. (294) 547
Harris, R.P., see Budhoo, M.R. (298) 137
Harris, R.P., see Budhoo, M.R. (314) 109
Harris, R.R., see Namovic, M.T. (315) 81
Harrison, G.J., see Harden, F.A. (307) 49
Harrison, P.J., see McGowan, S. (306) 249
Hartley, L.W., see Fox, N. (308) 195
Hartman, J.C., see Wall, T.M. (306) 165
Harvey, A.L., see Henning, R.H. (301) 91
Hasanvan, H., see Lundkvist, J. (309) 195
Hasegawa, T., see Nitta, A. (307) 1
Hasegawa, T., see Ohkuma, S. (301) 179
Hasegawa, Y. and Ono, H.
Effect of (±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide on spinal motor systems in anesthetized intact and spinalized rats (295) 211
Hasegawa, Y., see Kobayashi, H. (311) 29
Hasegawa, Y., see Wada, T. (312) 263
Hashii, M., see Katsumori, H. (311) 37
Hashimoto, K., see Adachi, Y. (308) 165
Hashimoto, K., see Eto, K. (298) 247
Hashimoto, K., see Furukawa, Y. (300) 203
Hashimoto, K., see Iyo, M. (312) 163
Hashimoto, K., see Murakami, N. (304) 129
Hashimoto, K., see Narita, N. (307) 117
Hashimoto, S., see Inoue, T. (311) 1
Hashimoto, S., see Izumi, T. (300) 25
Hashimoto, S., see Ohashi, T. (307) 315
Hashimoto, T., see Ito, K. (314) 143
Hashimoto, T., see Nakayama, T. (316) 157
Hasin, Y., see Ela, C. (295) 275

Haslberger, C., see Greten, T.F. (299) 229
Hassan, A.H.S., see Mousa, S.A. (311) 221
Hatano, A., Tang, R., Walden, P.D. and Lepor, H.
The α-adrenoceptor antagonist properties of the enantiomers of doxazosin in the human prostate (313) 135
Hatcher, J.P., see Hagan, J.J. (294) 743
Hattori, K., see Yoshida, A. (312) 115
Hattori, S., see Hattori, Y. (300) 147
Hattori, Y., Fukao, M., Houzen, H., Qi, F., Yamada, Y. and Kanno, M.
In vitro assessment for vascular selectivity of a new dihydropyridine derivative, NB-818 (301) 99
Hattori, Y., Murakami, Y., Hattori, S., Kuroda, H., Kasai, K. and Shimoda, S.-I.
Ursodeoxycholic acid inhibits the induction of nitric oxide synthase (300) 147
Hattori, Y., Nakanishi, N., Kasai, K., Shimoda, S.-I. and Gross, S.S.
Pyrrolidine dithiocarbamate inhibits immunostimulant-induced tetrahydrobiopterin synthesis in rat vascular smooth muscle (296) 107
Hatzidimitriou, G., see McCann, U.D. (312) R1
Hatzoglou, A., Bakogeorgou, E. and Castanas, E.
The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors (296) 199
Hatzoglou, A., Bakogeorgou, E., Hatzoglou, C., Martin, P.-M. and Castanas, E.
Antiproliferative and receptor binding properties of α- and β-casomorphins in the T47D human breast cancer cell line (310) 217
Hatzoglou, C., see Hatzoglou, A. (310) 217
Hauser, C.A.E., see Rupprecht, R. (303) 227
Hawcock, A.B., Beresford, I.J.M., Marshall, F.H. and Hagan, R.M.
Temperature and agonist dependency of tachykinin NK_1 receptor antagonist potencies in rat isolated superior cervical ganglion (294) 163
Hawkinson, J.E., Acosta-Burruel, M. and Wood, P.L.
The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase (307) 219
Hawkinson, J.E., Acosta-Burruel, M., Kimbrough, C.L., Goodnough, D.B. and Wood, P.L.
Steroid inhibition of [^{3}H]SR 95531 binding to the $GABA_A$ recognition site (304) 141
Hawksworth, G.M., see Pertwee, R.G. (296) 169
Hayakawa, H., see Takao, K. (294) 721
Hayama, T., see Woo, J.-T. (300) 131
Hayashi, K., Nagamatsu, T., Honda, S. and Suzuki, Y.
Butein (3,4,2′,4′-tetrahydroxychalcone) ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis (3) (316) 297
Hayashi, S., see Bandoh, T. (315) 37
Hayashi, T., see Takebayashi, M. (297) 137
Hayashi, Y., see Hada, J. (305) 101
Hayashi, Y., see Ito, K. (307) 291
Hayes, E., see Pugsley, M.K. (294) 319
Haynes, J.M., see Orre, M. (316) 229
Hazama, H., see Nakajima, T. (294) 625
Head, R., see McLennan, P. (300) 83
Headley, P.M., see Chizh, B.A. (300) 183
Headrick, J., see Harden, F.A. (307) 49
Healy, D.J. and Meador-Woodruff, J.H.
Receptor gene expression in hippocampus is differentially regulated by the NMDA receptor antagonist MK-801 (306) 257
Heath, M.F., see Jarvis, G.E. (315) 203
Hedberg, T.G. and Stanton, P.K.
Long-term plasticity in cingulate cortex requires both NMDA and metabotropic glutamate receptor activation (310) 19
Hedlund, P.B., see Dasgupta, S. (316) 325
Hedner, T., see Bergdahl, A. (316) 59
Hedner, T., see Malmberg, A.B. (294) 609
Hedqvist, P., see Zhang, Y. (313) 237
Heidbreder, C., Shoaib, M. and Shippenberg, T.S.
Differential role of δ-opioid receptors in the development and expression of behavioral sensitization to cocaine (298) 207
Heidbreder, Ch., see Shippenberg, T.S. (299) 33
Heiligers, J.P.C., see Saxena, P.R. (312) 53
Heinzel-Wieland, R., see Schneider, J. (302) 69
Hélary, C., see Atef, N. (298) 287
Heldman, E., Barg, J., Fisher, A., Levy, R., Pittel, Z., Zimlichman, R., Kushnir, M. and Vogel, Z.
Pharmacological basis for functional selectivity of partial muscarinic receptor agonists (297) 283
Heller, B., see Izenwasser, S. (297) 187
Helmeste, D., Tang, S.W., Fang, H. and Li, M.
Brain σ receptors labelled by [^{3}H]nemonapride (301) R1
Helmeste, D.M., Tang, S.W., Bunney Jr., W.E., Potkin, S.G. and Jones, E.G.
Decrease in σ but no increase in striatal dopamine D_4 sites in schizophrenic brains (314) R3
Helpap, B., see Van der Staay, F.J. (294) 361
Hemrick-Luecke, S.K. and Fuller, R.W.
Involvement of $5\text{-}HT_{2A}$ receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212 (311) 207
Henmi, S., Imaizumi, Y., Muraki, K. and Watanabe, M.
Time course of Ca^{2+}-dependent K^+ and Cl^- currents in single smooth muscle cells of guinea-pig trachea (306) 227
Henning, R.H., Rowan, E.G., Braga, M.F.M., Nelemans, A. and Harvey, A.L.
The prejunctional inhibitory effect of suramin on neuromuscular transmission in vitro (301) 91
Henquin, J.-C., see Garcia-Barrado, M.-J. (298) 279
Henricks, P.A.J., see Sadeghi-Hashjin, G. (302) 109
Henry, J.L., see Yashpal, K. (308) 41
Herchuelz, A., see Antoine, M.-H. (313) 229
Herdon, H., Jerman, J., Stean, T., Chan, W., Middlemiss, D. and Upton, N.
The novel anticonvulsant SB 204269 binds to a stereospecific site in the mouse brain (314) R7
Herman, A.G., see Bosmans, J.M. (310) 163
Herman, A.G., see Loenders, B. (296) 89
Herman, A.G., see Matthys, K.E. (298) 97
Herman, A.G., see Van Put, D.J.M. (294) 753
Hermann, M., see Antoine, M.-H. (313) 229
Hernández, P., see Gutierrez, S. (302) 191
Hernvann, A., Bourely, B., Le Maire, V., Aussel, C., Menkes, C.-J. and Ekindjian, O.G.
Action of anti-inflammatory drugs on interleukin-1β-mediated glucose uptake by synoviocytes (314) 193
Héron, C., Billaud, G., Costentin, J. and Bonnet, J.-J.
Complex ionic control of [^{3}H]GBR 12783 binding to the dopamine neuronal carrier (301) 195
Herrero-Beaumont, G., see Gutierrez, S. (302) 191
Hertel, P., see Mathé, J.M. (309) 1
Hervé, J.-C., Pluciennik, F., Bastide, B., Cronier, L., Verrecchia, F., Malassiné, A., Joffre, M. and Délèze, J.
Contraceptive gossypol blocks cell-to-cell communication in human and rat cells (313) 243
Herz, R.C.G., De Wildt, D.J. and Versteeg, D.H.G.
The effects of γ_2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion (306) 113
Herzig, J.W., see Palmer, S. (294) 83
Herzig, S.
Ca^{2+} channel activation by CGP 48506, a new positive inotropic benzodiazocine derivative (295) 113
Herzig, S., see Handrock, R. (309) 317
Hess, T.A., see D'Alonzo, A.J. (294) 271

Hettrick, D.A., Pagel, P.S., Lowe, D., Tessmer, J.P. and Warltier, D.C.
Increases in inotropic state without change in heart rate: Combined use of dobutamine and zatebradine in conscious dogs (316) 237
Hettrick, D.A., see Lowe, D. (304) 81
Heuillet, E., Petitet, F., Mignani, S., Malleron, J.-L., Lavayre, J., Néliat, G., Doble, A. and Blanchard, J.-C.
The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D_4 receptor (314) 229
Hexeberg, E., see Brunvand, H. (314) 99
Hey, J.A., see Rizzo, C.A. (294) 329
Hicks, C., see O'Neill, M.J. (310) 115
Hicks, C.A., see Bath, C.P. (299) 103
Hidaka, H., see Win, N.H.H. (299) 119
Hidaka, H., see Yasui, K. (316) 317
Hidaka, T., see Ishizuka, T. (312) 367
Hidalgo, A., see García-Velasco, G. (294) 521
Hietala, J., see Wong, G. (314) 319
Higashi, M., see Yamaguchi, Y. (312) 149
Higashida, H., see Katsumori, H. (311) 37
Higgs, S. and Cooper, S.J.
Hyperphagia induced by direct administration of midazolam into the parabrachial nucleus of the rat (313) 1
Higuchi, S., see Noguchi, K. (308) 53
Hilaire, G., see Monteau, R. (314) 41
Hildebrand, B.E., see Mathé, J.M. (309) 1
Hill, J.A., see Campa, M.J. (310) 263
Hill, R., see Sällström Baum, S. (314) 75
Hill, S.J., see Clark, E.A. (296) 223
Hill, S.J., see Dickenson, J.M. (302) 141
Hill, S.J., see Peakman, M.-C. (306) 281
Hillegaart, V., Estival, A. and Ahlenius, S.
Evidence for specific involvement of 5-HT_{1A} and 5-$HT_{2A/C}$ receptors in the expression of patterns of spontaneous motor activity of the rat (295) 155
Hiltscher, R., see Laurie, D.J. (296) R1
Hiltscher, R., see Laurie, D.J. (302) 229
Himmi, T., Dallaporta, M., Perrin, J. and Orsini, J.-C.
Neuronal responses to Δ^9-tetrahydrocannabinol in the solitary tract nucleus (312) 273
Hinks, G.L., Brown, P., Field, M., Poat, J.A. and Hughes, J.
The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat elevated X-maze (312) 153
Hirabayashi, A., Nishiwaki, K., Shimada, Y. and Ishikawa, N.
Role of neuropeptide Y and its receptor subtypes in neurogenic pulmonary edema (296) 297
Hiramatsu, M., Hyodo, T. and Kameyama, T.
U-50488H, a selective κ-opioid receptor agonist, improves carbon monoxide-induced delayed amnesia in mice (315) 119
Hiraoka, M., see Sunami, A. (312) 245
Hirasawa, Y., Sugimoto, T., Fukuyama, S., Kato, Y., Takamatu, H., Ohno, M., Nishino, S., Kato, M., Maeda, K., Seki, J. and Kita, Y.
Antianginal effects of FR144420, a novel slow nitric oxide-releasing agent (303) 55
Hirata, H., see Jurkiewicz, N.H. (307) 299
Hirayama, Y., see Yasumitsu, R. (300) 215
Hiroi, J., see Yasumitsu, R. (300) 215
Hirose, M., see Yonezawa, T. (315) 289
Hirst, S.J., see Mak, J.C.W. (302) 215
Hisa, H., see Adachi, Y. (308) 165
Hisamichi, N., Kawasaki, T., Suzuki, K.-i., Kaku, S., Sakai, Y., Taniuchi, Y., Sato, K., Inagaki, O., Tomioka, K., Yanagisawa, I., Takenaka, T., Yanagi, K. and Ohshima, N.
Synergistic effect of aurintricarboxylic acid and triflavin in a photochemically induced thrombosis model in rats (312) 69
Hisatome, I., see Yoshida, A. (312) 115
Hiyoshi, Y., Miura, H., Uemura, K., Endo, H., Ozawa, K., Maeda, N., Tamagawa, T. and Iguchi, A.
Effects of imidazoline antagonists of α_2-adrenoceptors on endogenous adrenaline-induced inhibition of insulin release (294) 117
Hjorth, S., Bengtsson, H.J. and Milano, S.
Raphe 5-HT_{1A} autoreceptors, but not postsynaptic 5-HT_{1A} receptors or β-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo (316) 43
Hjorth, S.
(−)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine (303) 183
Hliňák, Z., Vinšová, J. and Kasafírek, E.
Effect of alaptide, its analogues and oxiracetam on memory for an elevated plus-maze in mice (314) 1
Ho, A., see Zhou, Y. (315) 31
Ho, I.K., see Hoshi, K. (314) 301
Ho, I.K., see Kimura, T. (311) 265
Ho, I.K., see Suzuki, T. (295) 169
Ho, I.K., see Suzuki, T. (310) 243
Ho, I.K., see Tokuyama, S. (295) 123
Ho, S.-T., see Wong, C.-S. (297) 27
Hodgson, W.C., see Farina, N.K. (310) 185
Hodgson, W.C., see James, G.M. (294) 109
Hoffman, A., see Ari, G. (307) 69
Hoffman, A., see Gurbanov, K. (310) 193
Hoffman, P.L., see Szabó, G. (306) 67
Hoffmann, W.E., see Piercey, M.F. (312) 35
Hofmanová, J., see Kozubík, A. (316) 349
Höfner, G. and Schmidt, B.H.
Species differences in [^{3}H]linopirdine (DuP 996) binding to brain membranes (298) 307
Hogaboam, C.M., Muller, M.J., Collins, S.M. and Hunt, R.H.
An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis (309) 261
Hogg, J.E., Myers, J. and Hutson, P.H.
The human neuroblastoma cell line, IMR-32, expresses functional corticotropin-releasing factor receptors (312) 257
Hogg, J.E., see Hutson, P.H. (295) 45
Höhle, S., Culman, J., Boser, M., Qadri, F. and Unger, T.
Effect of angiotensin AT_2 and muscarinic receptor blockade on osmotically induced vasopressin release (300) 119
Hökfelt, T., see Szallasi, A. (298) 321
Hollingsworth, M., see Piper, A.S. (307) 183
Holloway, B.R., see Mayers, R.M. (295) 199
Holloway, F.A., see Gauvin, D.V. (294) 281
Holsboer, F., see Rupprecht, R. (303) 227
Hölscher, C.
Prostaglandins play a role in memory consolidation in the chick (294) 253
Hölter, S.M., Danysz, W. and Spanagel, R.
Evidence for alcohol anti-craving properties of memantine (314) R1
Hölter, S.M., see Spanagel, R. (305) 39
Holzgrabe, U., see Kostenis, E. (314) 385
Homma, Y., see Nasuhara, Y. (296) 161
Hon, W.-M., see Moochhala, S.M. (316) 287
Hönack, D., see Löscher, W. (299) 61
Honda, S., see Hayashi, K. (316) 297
Honda, Y., see Minato, H. (315) 297
Hong, Y. and Abbott, F.V.
Contribution of peripheral α_{1A}-adrenoceptors to pain induced by formalin or by α-methyl-5-hydroxytryptamine plus noradrenaline (301) 41
Honka, N., see Navajas, C. (304) 173
Honkanen, A., Vilamo, L., Wegelius, K., Sarviharju, M., Hyytiä, P. and Korpi, E.R.
Alcohol drinking is reduced by a μ_1- but not by a δ-opioid receptor antagonist in alcohol-preferring rats (304) 7
Honoré, P., see Buritova, J. (303) 91
Hoof, T., see Demmer, A. (315) 339
Hoogerhout, P., see Van Bergen, P. (294) 795

Hope, W., see White, P.J. (294) 215
Hora, M., see Yamagishi, R. (315) 73
Hori, T., see Suzuki, T. (310) 243
Horikawa, N., see Yamamoto, T. (302) 53
Horisaka, K., see Sugimoto, Y. (307) 75
Horisaka, K., see Sugimoto, Y. (316) 15
Horisaka, K., see Yamada, J. (316) 23
Hornfeldt, C.S., Kitto, K.F. and Larson, A.A.
Evidence that the NH_2-terminus of substance P modulates *N*-methyl-D-aspartate-induced activity by an action involving σ receptors (306) 15
Horowitz, J.D., see De la Lande, I.S. (314) 347
Hoshi, K., Ma, T. and Ho, I.K.
Precipitated κ-opioid receptor agonist withdrawal increases glutamate in rat locus coeruleus (314) 301
Hosoki, K., see Minato, H. (315) 297
Hosoki, K., see Yoshikawa, T. (301) 143
Hotta, K., see Ichikawa, T. (297) 87
Hotta, N., Koh, N., Sakakibara, F., Nakamura, J., Hamada, Y., Hara, T., Fukasawa, H., Kakuta, H. and Sakamoto, N.
Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats (311) 199
Hotta, N., Koh, N., Sakakibara, F., Nakamura, J., Hamada, Y., Hara, T., Mori, K., Naruse, K., Fukasawa, H., Kakuta, H. and Sakamoto, N.
Nerve function and blood flow in Otsuka Long-Evans Tokushima Fatty rats with sucrose feeding: effect of an anticoagulant (313) 201
Hotta, N., see Nakamura, J. (294) 207
Hou, X., see Waelbroeck, M. (303) 221
Hou, Y.-N., Cebers, G., Cebere, A., Terenius, L. and Liljequist, S.
N-Methyl-D-aspartate-induced enhancement of activator protein-1 DNA binding activity is blocked by ethanol in cerebellar granule cells (309) 307
Houdebine, L.-M., see Le Panse, R. (307) 339
Hourani, S.M.O., see Brownhill, V.R. (303) 87
House, R.V., see Bhargava, H.N. (311) 127
Houzen, H., see Hattori, Y. (301) 99
Hoversten, M.T., see Meng, F. (311) 285
Howe, P., see McLennan, P. (300) 83
Howse, K.M., see Roerig, S.C. (314) 293
Hoyano, Y., see Yonezawa, T. (309) 51
Hoyer, D., see Thoss, V.S. (297) 145
Hsiao, G., see Teng, C.-M. (303) 129
Hu, S., Kim, H.S. and Fink, C.A.
Differential effects of the BK_{Ca} channel openers NS004 and NS1608 in porcine coronary arterial cells (294) 357
Huang, T.-F., see Sheu, J.-R. (294) 231
Huang, T.F., see Chang, M.C. (297) 129
Hudson, A.L., see Lione, L.A. (304) 221
Hudson, A.L., see Reynolds, G.P. (301) R19
Hudzik, T.J., see Kinney, G.G. (294) 547
Hug, F., see Diener, M. (299) 161
Hughes, J., see Hinks, G.L. (312) 153
Hughes, R., see Kerr, D.I.B. (294) 349
Huh, K.-H., Endo, S. and Olsen, R.W.
Diazepam-insensitive $GABA_A$ receptors in rat cerebellum and thalamus (310) 225
Hui-Chan, C.W.Y., see Yashpal, K. (308) 41
Huidobro-Toro, J.P., see Boric, M.P. (294) 391
Hume, S.P., see Pike, V.W. (301) R5
Hundt, W., see Spanagel, R. (305) 51
Hunt, R.H., see Hogaboam, C.M. (309) 261
Hunter, J.C., see Singh, L. (307) 283
Hunter, L.W., Tyce, G.M. and Rorie, D.K.
Neuropeptide Y release and contractile properties: differences between canine veins and arteries (313) 79
Hur, G.-H., see Kim, Y.-B. (313) 107
Hussain, S.N.A., see Abdul-Hussain, M.N. (305) 155
Hutchinson, M.A., Smith, P.F. and Darlington, C.L.
Tolerance to the ataxic effects of diazepam in guinea pig is not associated with a reduced sensitivity of $GABA_A$ receptors in the vestibular nucleus (301) 83
Hutson, P.H. and Hogg, J.E.
Effects of and interactions between antagonists for different sites on the NMDA receptor complex on hippocampal and striatal acetylcholine efflux in vivo (295) 45
Hutson, P.H., see Hogg, J.E. (312) 257
Hymel, L.J., see Ruiz-Velasco, V. (296) 327
Hyodo, T., see Hiramatsu, M. (315) 119
Hyslop, D.K., see Piercey, M.F. (312) 35
Hyytiä, P., see Honkanen, A. (304) 7

Ibarra, M., see Villalobos-Molina, R. (298) 257
Ibayashi, S., see Cai, H. (313) 103
Ibbotson, T., see Lee, K. (313) 163
Ichikawa, T., Ishihara, K., Shibata, M., Yamaura, T., Saigenji, K. and Hotta, K.
Stimulation of mucin biosynthesis in rat gastric mucosa by FRG-8813 and its structural analogs (297) 87
Idänpään-Heikkilä, J.-J., see Mansikka, H. (297) 19
Idzu, T., see Matsubara, K. (315) 145
Ienaga, Y., see Katsumata, S. (312) 349
Iga, Y., Arisawa, H., Ise, M., Yasuda, H. and Takeshita, Y.
Modulation of rhythmical slow activity, long-term potentiation and memory by muscarinic receptor agonists (308) 13
Igawa, O., see Yoshida, A. (312) 115
Iguchi, A., see Hiyoshi, Y. (294) 117
Iida, Y., see Win, N.H.H. (299) 119
Iijima, T., see Goto, Y. (314) 185
Iimura, O., Kusano, E., Amemiya, M., Muto, S., Ikeda, U., Shimada, K. and Asano, Y.
Dipyridamole enhances interleukin-1β-stimulated nitric oxide production by cultured rat vascular smooth muscle cells (296) 319
Iizuka, K., see Yamagishi, R. (315) 73
IJzerman, A.P., Von Frijtag Drabbe Künzel, J.K., Kim, J., Jiang, Q. and Jacobson, K.A.
Site-directed mutagenesis of the human adenosine A_{2A} receptor. Critical involvement of Glu^{13} in agonist recognition (310) 269
IJzerman, A.P., see Van Schaick, E.A. (308) 311
Ikeda, K., see Ishibashi, T. (303) 247
Ikeda, M., see Ikeda, U. (314) 197
Ikeda, S., see Kitayoshi, T. (305) 137
Ikeda, S., see Kusumoto, K. (296) 65
Ikeda, U., Ikeda, M., Kano, S., Kanbe, T. and Kazuyuki Shimada,
Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells (314) 197
Ikeda, U., see Iimura, O. (296) 319
Ikeuchi, Y. and Nishizaki, T.
ATP-regulated K^+ channel and cytosolic Ca^{2+} mobilization in cultured rat spinal neurons (302) 163
Ikeuchi, Y., Nishizaki, T., Mori, M. and Okada, Y.
Adenosine activates the K^+ channel and enhances cytosolic Ca^{2+} release via a P_{2Y} purinoceptor in hippocampal neurons (304) 191
Illes, P., see Fröhlich, R. (315) 255
Ilyin, V.I., Whittemore, E.R., Tran, M., Shen, K.-Z., Cai, S.-X., Kher, S.M., Keana, J.F.W., Weber, E. and Woodward, R.M.
Pharmacology of ACEA-1416: a potent systemically active NMDA receptor glycine site antagonist (310) 107
Imai, S., see Takahashi, T. (295) 229
Imai, T., see Yasumitsu, R. (300) 215
Imaizumi, T., see Fujiki, H. (313) 191
Imaizumi, Y., see Henmi, S. (306) 227
Imamura, H., see Yamazaki, K. (297) 233
Imamura, H., see Yonezawa, T. (309) 51
Imamura, T., see Takada, Y. (308) 205

Imbs, J.-L., see Barthelmebs, M. (314) 325
Imperato, A., Obinu, M.C., Casu, M.A., Mascia, M.S., Carta, G. and Gessa, G.L.
Chronic morphine increases hippocampal acetylcholine release: possible relevance in drug dependence (302) 21
Imura, H., see Murakami, N. (304) 129
Inada, T., see Iyo, M. (312) 163
Inagaki, C., see Tanabe, T. (299) 187
Inagaki, C., see Tanabe, T. (314) 175
Inagaki, O., see Hisamichi, N. (312) 69
Inami, T., see Takada, Y. (308) 205
Indermaur, K., see Bane, A. (302) 7
Inoue, G., see Murakami, N. (304) 129
Inoue, K., see Ito, K. (314) 143
Inoue, M., see Tan-No, K. (314) 61
Inoue, N., see Kishioka, S. (316) 7
Inoue, T., Hashimoto, S., Tsuchiya, K., Izumi, T., Ohmori, T. and Koyama, T.
Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing (311) 1
Inoue, T., see Izumi, T. (300) 25
Irie, K., see Fujii, E. (297) 257
Irie, K., see Fujii, E. (313) 129
Ise, M., see Iga, Y. (308) 13
Ise, Y., see Suzuki, T. (314) 281
Ishibashi, T., Ikeda, K., Ishida, K., Yasui, J., Tojima, R., Nakamura, M. and Ohno, Y.
Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum (303) 247
Ishibashi, Y., see Tsuji, M. (313) 169
Ishida, K., see Ishibashi, T. (303) 247
Ishihara, H., see Takada, Y. (308) 205
Ishihara, K., see Ichikawa, T. (297) 87
Ishikawa, J., see Bandoh, T. (315) 37
Ishikawa, M., see Ozawa, Y. (298) 57
Ishikawa, N., see Hirabayashi, A. (296) 297
Ishikawa, T., see Miyauchi, T. (303) 193
Ishikawa, T., see Win, N.H.H. (299) 119
Ishiki, M., see Takada, Y. (308) 205
Ishine, T. and Lee, T.J.F.
Norepinephrine attenuates serotonin inhibition of pial venous tone (313) 97
Ishizuka, T., Suzuki, K., Kawakami, M., Hidaka, T., Matsuki, Y. and Nakamura, H.
Thromboxane A_2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells (312) 367
Isogaya, M., see Sato, Y. (315) 363
Ito, K., Nakazawa, K., Koizumi, S., Liu, M., Takeuchi, K., Hashimoto, T., Ohno, Y. and Inoue, K.
Inhibition by antipsychotic drugs of L-type Ca^{2+} channel current in PC12 cells (314) 143
Ito, K., Sakamoto, T., Hayashi, Y., Morishita, M., Shibata, E., Sakai, K., Takeuchi, Y. and Torii, S.
Role of tachykinin and bradykinin receptors and mast cells in gaseous formaldehyde-induced airway microvascular leakage in rats (307) 291
Ito, K., see Asano, M. (294) 693
Ito, K., see Asano, M. (311) 53
Ito, K., see Morishita, M. (298) 149
Ito, K.M., see Asano, M. (294) 693
Ito, S., see Tabo, M. (313) 151
Ito, T., see Suzuki, T. (295) 169
Ito, T., see Suzuki, T. (310) 243
Ito, Y., see Katsumori, H. (311) 37
Ito, Y., see Ohashi, T. (307) 315
Itoh, T., see Wada, K. (294) 377
Itoh, T., see Wada, K. (296) 335
Itoh, Z., see Tamura, T. (308) 315
Itoyama, Y., see Araki, T. (306) 73
Ivancheva, C., see Pencheva, N. (304) 99
Iwanishi, M., see Takada, Y. (308) 205
Iwatsubo, K., see Kawabata, A. (296) 23
Iyo, M., Bi, Y., Hashimoto, K., Inada, T. and Fukui, S.
Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram (312) 163
Izawa, T., see Komabayashi, T. (298) 299
Izenwasser, S., Heller, B. and Cox, B.M.
Continuous cocaine administration enhances μ- but not δ-opioid receptor-mediated inhibition of adenylyl cyclase activity in nucleus accumbens (297) 187
Izenwasser, S., Newman, A.H., Cox, B.M. and Katz, J.L.
The cocaine-like behavioral effects of meperidine are mediated by activity at the dopamine transporter (297) 9
Izumi, F., see Osajima, A. (315) 319
Izumi, T., Inoue, T., Tsuchiya, K., Hashimoto, S., Ohmori, T. and Koyama, T.
Effect of the selective CCK_B receptor antagonist LY288513 on conditioned fear stress in rats (300) 25
Izumi, T., see Inoue, T. (311) 1
Izzo, A.A., Gaginella, T.S., Mascolo, N., Borrelli, F. and Capasso, F.
N^G-Nitro-L-arginine methyl ester reduces senna- and cascara-induced diarrhoea and fluid secretion in the rat (301) 137

Jackson, B., see Grider, J. (313) 115
Jackson, D.M., see Gillies, D.M. (303) 1
Jackson, D.M., see Liu, Y.J. (303) 187
Jackson, D.M., see Liu, Y.J. (304) 117
Jackson, H.C., Hansen, H.C., Kristiansen, M., Suzdak, P.D., Klitgaard, H., Judge, M.E. and Swedberg, M.D.B.
Anticonvulsant profile of the imidazoquinazolines NNC 14-0185 and NNC 14-0189 in rats and mice (308) 21
Jackson, K.N., see De Garavilla, L. (313) 89
Jacobson, K.A., see IJzerman, A.P. (310) 269
Jacobson, K.A., see Van Schaick, E.A. (308) 311
Jacobson, K.A., see Von Lubitz, D.K.J.E. (302) 43
Jacobson, K.A., see Von Lubitz, D.K.J.E. (316) 171
Jagadish, M., Raviprakash, V., Telang, A.G. and Mishra, S.K.
Modulation of vascular K_{ATP} channels in hypothyroidism (309) 63
Jagerschmidt, A., Guillaume-Rousselet, N., Vikland, M.-L., Goudreau, N., Maigret, B. and Roques, B.-P.
His^{281} of the rat CCK_B receptor is essential for CCK_B versus CCK_A receptor antagonist selectivity (296) 97
Jahan, H., Kobayashi, S., Nishimura, J. and Kanaide, H.
Endothelin-1 and angiotensin II act as progression but not competence growth factors in vascular smooth muscle cells (295) 261
Jahns, R., Siegmund, C., Jahns, V., Reiländer, H., Maidhof, A., Müller-Esterl, W., Lohse, M.J. and Boege, F.
Probing human β_1- and β_2-adrenoceptors with domain-specific fusion protein antibodies (316) 111
Jahns, V., see Jahns, R. (316) 111
Jain, S., see Kolesnikov, Y. (296) 17
Jain, S., see Kolesnikov, Y. (310) 141
Jakab, I., see Szilvassy, Z. (301) R17
Jäkälä, P., Björklund, M. and Riekkinen Jr., P.
Suppression of neocortical high-voltage spindles by nicotinic acetylcholine and 5-HT_2 receptor stimulation (299) 47
Jäkälä, P., Björklund, M., Koivisto, E. and Riekkinen Jr., P.
The effects of cholinergic drugs on rat neocortical high-voltage spindles in ketanserin-treated rats (316) 181
Jakiwczyk, O.M., see Bateson, A.N. (303) 141
James, G.M. and Hodgson, W.C.
Attenuated 5-HT_2 receptor-mediated responses in hindquarters of diabetic rats (294) 109

Jane, D.E., see Bedingfield, J.S. (309) 71
Jane, D.E., see Kemp, M.C. (309) 79
Jang, D., Szabo, C. and Murrell, G.A.C.
S-Substituted isothioureas are potent inhibitors of nitric oxide biosynthesis in cartilage (312) 341
Jankowski, M., see Guillaume, P. (316) 49
Jansen, J.A., see Halonen, T. (299) 69
Janssen, L.H.M., see Paulussen, J.J.C. (312) 121
Janssen, P.M.L., see Van Bergen, P. (294) 795
Janssens, D., see Arnould, T. (315) 227
Jansson, L., see Carlsson, P.-O. (312) 75
Jarrott, B., see Lawrence, A.J. (315) 127
Jarvis, G.E., Evans, R.J. and Heath, M.F.
The role of ADP in endotoxin-induced equine platelet activation (315) 203
Jarvis, M.F., see Becker, H.C. (296) 43
Jáuregui, J., see Cardelús, I. (299) 153
Jefferys, D. and Funder, J.
Nitric oxide modulates retention of immobility in the forced swimming test in rats (295) 131
Jenck, F., see Lundkvist, J. (309) 195
Jeng, A.Y., see Tayag, E.C. (300) 261
Jensen, R.T., see Lin, J.-T. (294) 55
Jerman, J., see Herdon, H. (314) R7
Jerning, E., see Malmberg, Å. (303) 123
Jerram, A.H., Smith, P.F. and Darlington, C.L.
The effects of (+)-SKF10047 and ketamine hydrochloride on stereotyped behaviour, locomotor activity and ataxia in guinea pig (307) 269
Jia, Y.L., see Abdul-Hussain, M.N. (305) 155
Jiang, Q., see IJzerman, A.P. (310) 269
Jimonet, P., see Boireau, A. (300) 237
Jinsi, A., Paradise, J. and Deth, R.C.
A tyrosine kinase regulates α-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta (302) 183
Jirillo, E., see Mitolo-Chieppa, D. (309) 175
Jobe, P., see Statnick, M. (299) 93
Jobe, P.C., see Yan, Q.-S. (301) 49
Joe-Adigwe, G., see Pertwee, R.G. (296) 169
Joffre, M., see Hervé, J.-C. (313) 243
Johns, E.J., see Sattar, M.A. (294) 727
Johnson, D.H., see Blomqvist, O. (314) 257
Johnston, G.A.R., see Nguyen, V.H. (311) 233
Jonas, J.-C., see Garcia-Barrado, M.-J. (298) 279
Jones, B.J., see Watson, J.M. (314) 365
Jones, E.G., see Helmeste, D.M. (314) R3
Jongen, W.M.F., see Mensink, A. (310) 73
Joppa, M.A., see Meisel, R.L. (309) 21
Jordan, L.R., see Harden, F.A. (307) 49
Jorens, P.G., see Loenders, B. (296) 89
Jorens, P.G., see Matthys, K.E. (298) 97
Jovanovic, A., Lopez, J.R. and Terzic, A.
Cytosolic Ca^{2+} domain-dependent protective action of adenosine in cardiomyocytes (298) 63
Jovanovic, A., see Brady, P.A. (308) 343
Judge, M.E., see Jackson, H.C. (308) 21
Jun, X., see Katsura, M. (298) 71
Jung, J.-S., see Song, D.-K. (316) 165
Jurkiewicz, A., see Jurkiewicz, N.H. (307) 299
Jurkiewicz, N.H., Garcez do Carmo, L., Hirata, H., Da Costa Santos, W. and Jurkiewicz, A.
Functional properties of agmatine in rat vas deferens (307) 299

Kaczorowski, G.J., see DeFarias, F.P. (314) 123
Kadowitz, P.J., see Champion, H.C. (309) 251
Kachler, S., see Singewald, N. (294) 787
Kafka, S.H. and Corbett, R.
Selective adenosine A_{2A} receptor/dopamine D_2 receptor interactions in animal models of schizophrenia (295) 147
Kagaya, A., see Takebayashi, M. (297) 137
Kähler, C.M., Bellmann, R., Reinisch, N., Schratzberger, P., Gruber, B. and Wiedermann, C.J.
Stimulation of human skin fibroblast migration by the neuropeptide secretoneurin (304) 135
Kähler, C.M., see Wiedermann, C.J. (298) 335
Kai, T., Takahashi, S. and Kanaide, H.
Halothane counteracts acetylcholine-induced increase in Ca^{2+} sensitivity of the contractile apparatus in airway smooth muscle (315) 313
Kaku, S., see Hisamichi, N. (312) 69
Kaku, T., see Hada, J. (305) 101
Kakuta, H., see Hotta, N. (311) 199
Kakuta, H., see Hotta, N. (313) 201
Kaldenberg-Stasch, S., see Michel, M.C. (309) 87
Kalkman, E.A.J., Saxena, P.R. and Schoemaker, R.G.
Sensitivity to ischemia of chronically infarcted rat hearts; effects of long-term captopril treatment (298) 121
Kalkman, E.A.J., see Schoemaker, R.G. (298) 17
Kamata, K., Numazawa, T. and Kasuya, Y.
Characteristics of vasodilatation induced by acetylcholine and platelet-activating factor in the rat mesenteric arterial bed (298) 129
Kamata, K., Numazawa, T. and Kasuya, Y.
Mechanisms of desensitization of vasodilatation induced by platelet-activating factor in hypertensive rats (301) 121
Kamata, K., Sugiura, M., Kojima, S. and Kasuya, Y.
Restoration of endothelium-dependent relaxation in both hypercholesterolemia and diabetes by chronic taurine (303) 47
Kamato, T., see Nagakura, Y. (311) 67
Kamei, H., Kameyama, T. and Nabeshima, T.
(+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated σ_1 sites (299) 21
Kamei, H., Kameyama, T. and Nabeshima, T.
(+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated σ_1 sites (309) 149
Kamei, J. and Morita, K.
Antitussive effect of moguisteine on the enhanced coughing associated with enalapril in guinea-pig (312) 235
Kamei, J., Morita, K., Saitoh, A., Suzuki, T. and Nagase, H.
Antinociceptive and antitussive effects of morphine in the DA-bg/bg (Beige) rat (300) 75
Kameyama, T., see Hiramatsu, M. (315) 119
Kameyama, T., see Kamei, H. (299) 21
Kameyama, T., see Kamei, H. (309) 149
Kameyama, T., see Toyoshi, T. (294) 637
Kameyama, T., see Ukai, M. (313) 11
Kamisaki, Y., see Wada, K. (294) 377
Kamisaki, Y., see Wada, K. (296) 335
Kampine, J.P., see Mizoguchi, H. (309) 37
Kanaide, H., see Jahan, H. (295) 261
Kanaide, H., see Kai, T. (315) 313
Kanbe, T., see Ikeda, U. (314) 197
Kanda, T., see Takahashi, T. (295) 229
Kaneko, T., see Naito, Y. (294) 47
Kaneko, T., see Tanabe, M. (313) 187
Kanematsu, K., see Katsumata, S. (312) 349
Kanfer, J.N., see Sorrentino, G. (308) 81
Kang, H.J., see Ahn, S.K. (306) 175
Kang, J.X. and Leaf, A.
Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes (297) 97
Kangawa, K., see Osajima, A. (315) 319

Kanno, M., see Hattori, Y. (301) 99
Kano, S., see Ikeda, U. (314) 197
Kanthasamy, A.G., Vu, T.Q., Yun, R.J. and Truong, D.D.
Antimyoclonic effect of gabapentin in a posthypoxic animal model of myoclonus (297) 219
Karadağ, H.Ç., see Ulugöl, A. (308) 49
Karaki, H., see Kuwahara, M. (296) 55
Karaki, H., see Mito, K. (304) 93
Karaki, H., see Sudjarwo, S.A. (294) 261
Karaki, H., see Trongvanichnam, K. (303) 39
Karaki, H., see Trongvanichnam, K. (314) 83
Karim, K., see Khadour, F. (298) 271
Karolewicz, B., Antkiewicz-Michaluk, L., Michaluk, J. and Vetulani, J.
Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain (313) 181
Karolewicz, B., see Antkiewicz-Michaluk, L. (294) 459
Kasafírek, E., see Hliňák, Z. (314) 1
Kasai, K., see Hattori, Y. (296) 107
Kasai, K., see Hattori, Y. (300) 147
Kasama, M., see Yamazaki, K. (297) 233
Kasama, M., see Yonezawa, T. (309) 51
Kasbergen, C.M., see Van Buren, T. (296) 277
Kashyap, A., see Modi, P.I. (299) 213
Kask, A.M., see Anderson, J.J. (295) 163
Kaspareit, G., see Neumann, J. (294) 451
Kassiou, M., see Nguyen, V.H. (311) 233
Kastin, A.J., see Gergen, K.A. (298) 235
Kasuya, Y., see Kamata, K. (298) 129
Kasuya, Y., see Kamata, K. (301) 121
Kasuya, Y., see Kamata, K. (303) 47
Kato, A., see Nakatani, K. (315) 335
Kato, H., see Araki, T. (306) 73
Kato, H., see Ohashi, T. (307) 315
Kato, K., see Murakami, N. (304) 129
Kato, M., see Hirasawa, Y. (303) 55
Kato, M., see Win, N.H.H. (299) 119
Kato, T., see Tamura, K. (312) 195
Kato, Y., see Hirasawa, Y. (303) 55
Katsube, Y. and Sperelakis, N.
Na^+/Ca^{2+} exchange current: lack of effect of taurine (316) 97
Katsumata, S., Ienaga, Y., Minami, M., Nakagawa, T., Kanematsu, K. and Satoh, M.
Pharmacological characterization of KT-90 using cloned μ-, δ- and κ-opioid receptors (312) 349
Katsumori, H., Ito, Y., Higashida, H., Hashii, M. and Minabe, Y.
Anti- and proconvulsive actions of levcromakalim, an opener of ATP-sensitive K^+ channel, in the model of hippocampus-generating partial seizures in rats (311) 37
Katsura, M., Ohkuma, S., Jun, X. and Kuriyama, K.
Down-regulation of benzodiazepine receptors by ethyl β-carboline-3-carboxylate in cerebrocortical neurons (298) 71
Katsura, M., see Ohkuma, S. (301) 179
Katz, J.L., see Izenwasser, S. (297) 9
Kaur, S. and Starr, M.
Motor effects of lamotrigine in naive and dopamine-depleted mice (304) 1
Kawabata, A., Iwatsubo, K., Takaya, S. and Takagi, H.
Central antinociceptive effect of L-ornithine, a metabolite of L-arginine, in rats and mice (296) 23
Kawakami, M., see Ishizuka, T. (312) 367
Kawakami, Y., see Nasuhara, Y. (296) 161
Kawamura, M., see Osajima, A. (315) 319
Kawamura, Y., see Sato, N. (314) 373
Kawanabe, Y., see Nakatani, K. (315) 335
Kawasaki, K., see Takao, K. (294) 721
Kawasaki, T., see Hisamichi, N. (312) 69
Kawashima, T., see Chowdhury, S.A. (314) 313
Kawashima, Y., see Matsuno, K. (306) 271
Kayser, V., see Catheline, G. (315) 135
Kazuyuki Shimada, , see Ikeda, U. (314) 197
Keana, J.F.W., see Ilyin, V.I. (310) 107
Keddie, J.R., Poucher, S.M., Shaw, G.R., Brooks, R. and Collis, M.G.
In vivo characterisation of ZM 241385, a selective adenosine A_{2A} receptor antagonist (301) 107
Keenan, A.K., see McQuaid, K.E. (307) 233
Keil II, G.J. and DeLander, G.E.
Altered sensory behaviors in mice following manipulation of endogenous spinal adenosine neurotransmission (312) 7
Kellum, J.M., see Budhoo, M.R. (298) 137
Kellum, J.M., see Budhoo, M.R. (314) 109
Kelly, E., see Wickenden, A.D. (302) 79
Kelso, E., Spiers, P., McDermott, B., Scholfield, N. and Silke, B.
Dual effects of endothelin-1 on the L-type Ca^{2+} current in ventricular cardiomyocytes (308) 351
Kemp, M.C., Jane, D.E., Tse, H.-W. and Roberts, P.J.
Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices (309) 79
Kemp, M.C., see Bedingfield, J.S. (309) 71
Kennedy, R.H., see Williamson, A.P. (304) 73
Kennett, G., see Lightowler, S. (296) 137
Kerr, D.I.B., Ong, J., Hughes, R. and Prager, R.H.
3-Amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide, a new class of $GABA_B$ receptor antagonist in central and peripheral preparations (294) 349
Kerr, D.I.B., Ong, J., Vaccher, C., Berthelot, P., Flouquet, N., Vaccher, M.-P. and Debaert, M.
$GABA_B$ receptor antagonism by resolved (*R*)-saclofen in the guinea-pig ileum (308) R1
Kester, R.C.H., see Berendsen, H.H.G. (308) 103
Khadour, F., Karim, K. and Najim, R.
Drugs acting at central benzodiazepine receptors attenuate ethanol-induced gastric lesions in rats (298) 271
Kher, S.M., see Ilyin, V.I. (310) 107
Khoo, H.-E., see Moochhala, S.M. (316) 287
Kidney, J.C., Lötvall, J.O., Lei, Y., Chung, K.F. and Barnes, P.J.
The effect of inhaled K^+ channel openers on bronchoconstriction and airway microvascular leakage in anaesthetised guinea pigs (296) 81
Kiemer, A., see Andersen, P.H. (311) 95
Kiianmaa, K., see Nurmi, M. (315) 277
Kijjoa, A., see Payá, M. (312) 97
Kikuchi, K., see Miyata, S. (307) 81
Kikuchi, K., see Sato, N. (314) 373
Kikuchi, S., Umemura, K., Kondo, K. and Nakashima, M.
Tranilast suppresses intimal hyperplasia after photochemically induced endothelial injury in the rat (295) 221
Kilbourn, M. and Frey, K.
Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains (307) 227
Kilbourn, M., see Vander Borght, T. (294) 577
Kilpatrick, E., see Grider, J. (313) 115
Kilpatrick, G.J., see Brown, J.D. (311) 305
Kilter, H., see Lenz, O. (294) 17
Kim, D.J.B., see Brioni, J.D. (301) 1
Kim, H.O., see Van Schaick, E.A. (308) 311
Kim, H.S., see Hu, S. (294) 357
Kim, J., see IJzerman, A.P. (310) 269
Kim, K.-T., see Suh, B.-C. (314) 235
Kim, K.H., see Lee, S.-M. (294) 41
Kim, S.Y., Raikoff, K., Wülfert, E. and Hanin, I.
Mivazerol, a selective α_2-adrenoceptor agonist, attenuates tachycardia by intrathecal injection of *N*-methyl-D-aspartate in the rat (316) 249
Kim, Y.-B., Hur, G.-H., Choi, D.-S., Shin, S., Han, B.-G., Lee, Y.-S. and Sok, D.-E.

Effects of calmodulin antagonists and anesthetics on the skin lesions induced by 2-chloroethylethyl sulfide (313) 107
Kim, Y.-H., see Song, D.-K. (316) 165
Kim, Y.-H., see Suh, H.-W. (307) 141
Kimbrough, C.L., see Hawkinson, J.E. (304) 141
Kimura, K., see Matsubara, K. (315) 145
Kimura, M., see Bandoh, T. (315) 37
Kimura, T., Kuze, J., Watanabe, K., Kondo, S., Ho, I.K. and Yamamoto, I.
N^3-Phenacyluridine, a novel hypnotic compound, interacts with the benzodiazepine receptor (311) 265
Kindgen-Milles, D.
Effects of prostaglandin E_2 on the intensity of bradykinin-evoked pain from skin and veins of humans (294) 491
Kinney, G.G., Harris, E.W., Ray, R. and Hudzik, T.J.
σ_2 Site-mediated inhibition of electrically evoked guinea pig ileum longitudinal muscle/myenteric plexus contractions (294) 547
Kiran, B.K., see Savci, V. (309) 275
Kirchhefer, U., see Neumann, J. (294) 451
Kirstetter, P., see Pilette, C. (312) 63
Kisara, K., see Tan-No, K. (314) 61
Kishimoto, T., see Wei, E.T. (306) 161
Kishioka, S., Inoue, N., Nishida, S., Fukunaga, Y. and Yamamoto, H.
Diltiazem inhibits naloxone-precipitated and spontaneous morphine withdrawal in rats (316) 7
Kita, Y., see Hirasawa, Y. (303) 55
Kitagawa, S., Yamaguchi, Y., Shinozuka, K., Kwon, Y.M. and Kunitomo, M.
Dietary cholesterol enhances impaired endothelium-dependent relaxations in aortas of salt-induced hypertensive Dahl rats (297) 71
Kitamura, K., see Osajima, A. (315) 319
Kitamura, M., see Koshikawa, N. (303) 13
Kitamura, M., see Koshikawa, N. (308) 235
Kitamura, Y., Takahashi, H., Nomura, Y. and Taniguchi, T.
Possible involvement of Janus kinase Jak2 in interferon-γ induction of nitric oxide synthase in rat glial cells (306) 297
Kitamura, Y., see Takao, K. (294) 721
Kitano, M., see Wada, K. (294) 377
Kitayama, S., Morita, K. and Dohi, T.
Cocaine inhibits the release of MPP^+ but not dopamine through the rat dopamine transporter (309) 107
Kitayoshi, T., Ikeda, S., Kubo, K., Awane-Igata, Y., Watanabe, T. and Fujino, M.
Effects of a new endothelin receptor antagonist, TAK-044, on myocardial stunning in dogs (305) 137
Kitazawa, M., see Yamagishi, R. (315) 73
Kitazawa, T., see Nakajima, T. (294) 625
Kitchen, I., see Brownhill, V.R. (303) 87
Kits, K.S., see Mansvelder, H.D. (311) 293
Kitto, K.F., see Hornfeldt, C.S. (306) 15
Kiuchi, N., see Ohashi, H. (301) 129
Kivipelto, M., see Riekkinen, M. (308) 243
Kivlighn, S.D., Zingaro, G.J., Gabel, R.A., Broten, T.P., Chang, R.S.L., Ondeyka, D.L., Mantlo, N.B., Gibson, R.E., Greenlee, W.J. and Siegl, P.K.S.
In vivo pharmacology of an angiotensin AT_1 receptor antagonist with balanced affinity for angiotensin AT_2 receptors (294) 439
Kivlighn, S.D., see Chang, R.S.L. (294) 429
Klarica, M., Fage, D. and Carter, C.
Pharmacology of *N*-methyl-D-aspartate-evoked [^{3}H]noradrenaline release in adult rat spinal cord (308) 135
Kleinrok, Z., see Gasior, M. (312) 27
Kleven, M., Prinssen, E.P.M. and Koek, W.
Role of 5-HT_{1A} receptors in the ability of mixed 5-HT_{1A} receptor agonist/dopamine D_2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats (313) 25
Kling, P.J., see Chang, R.S.L. (294) 429
Klitgaard, H., see Jackson, H.C. (308) 21
Klockgether, T., Wüllner, U., Steinbach, J.P., Petersen, V., Turski, L. and Löschmann, P.-A.
Effects of the antiparkinsonian drug budipine on central neurotransmitter systems (301) 67
Klockgether, T., see Eblen, F. (299) 9
Knapp, R.J., see Li, X. (300) R1
Knepper, S.M., see Buckner, S.A. (297) 241
Knoepfel, T., see Bruno, V. (310) 61
Knott, P.J., see Santucci, A.C. (295) 7
Ko, F.-N., see Chueh, S.-C. (305) 177
Ko, F.-N., see Guh, J.-H. (298) 191
Ko, F.-N., see Teng, C.-M. (303) 129
Ko, Y., see Nickenig, G. (297) 307
Ko, Y., see Sachinidis, A. (307) 121
Ko, Y., see Sachinidis, A. (309) 95
Kobayashi, H., Hasegawa, Y. and Ono, H.
Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems (311) 29
Kobayashi, H., see Yamaguchi, Y. (312) 149
Kobayashi, I., see Takahashi, T. (295) 229
Kobayashi, M., see Koshikawa, N. (303) 13
Kobayashi, M., see Koshikawa, N. (308) 227
Kobayashi, M., see Koshikawa, N. (308) 235
Kobayashi, M., see Ohno, M. (307) 21
Kobayashi, M., see Takada, Y. (308) 205
Kobayashi, S., see Jahan, H. (295) 261
Kobayashi, T., see Matsuno, K. (312) 267
Kobayashi, T., see Senda, T. (315) 1
Kobayashi, T., see Ukai, M. (313) 11
Kobayashi, Y., see Matsubara, K. (315) 145
Kobori, T., see Woo, J.-T. (300) 131
Koch, T., see Sebens, J.B. (315) 269
Kocić, I.
Modulation of the contractility of guinea pig papillary muscle by the activation of ATP-sensitive K^+ channels (301) 115
Kockx, M.M., see Bosmans, J.M. (310) 163
Ködel, U., see Lorenzl, S. (308) 335
Koek, W., see Assié, M.-B. (304) 15
Koek, W., see Kleven, M. (313) 25
Koga, T., see Tamura, K. (312) 195
Kogo, H., see Komabayashi, T. (298) 299
Kogure, K., see Araki, T. (306) 73
Koh, N., see Hotta, N. (311) 199
Koh, N., see Hotta, N. (313) 201
Koh, N., see Nakamura, J. (294) 207
Kohara, A., see Okada, M. (309) 299
Koivisto, E., see Jäkälä, P. (316) 181
Koizumi, S., see Ito, K. (314) 143
Kojima, S., see Kamata, K. (303) 47
Kok-Van Esterik, J.A.E., see Paulussen, J.J.C. (312) 121
Kokkola, T., see Navajas, C. (304) 173
Kokubu, N., see Satoh, M. (308) 145
Kolesnikov, Y., Jain, S. and Pasternak, G.W.
Modulation of opioid analgesia by agmatine (296) 17
Kolesnikov, Y., Jain, S., Wilson, R. and Pasternak, G.W.
Peripheral κ_1-opioid receptor-mediated analgesia in mice (310) 141
Komabayashi, T., Sawada, H., Izawa, T. and Kogo, H.
Altered intracellular Ca^{2+} regulation in pancreatic acinar cells from acute streptozotocin-induced diabetic rats (298) 299
Komai, C., see Ozawa, Y. (298) 57
Komori, S., see Ohashi, H. (301) 129
Komuro, Y., see Oh-ishi, S. (300) 255
Komuro, Y., see Yamamoto, T. (302) 53
Kondo, K., see Kikuchi, S. (295) 221
Kondo, K., see Woo, J.-T. (300) 131
Kondo, M., see Naito, Y. (294) 47

Kondo, S., see Kimura, T. (311) 265
Kongsamut, S., see Tang, L. (300) 71
Konishi, T., see Chowdhury, S.A. (314) 313
Konkar, A.A., Fraundorfer, P.F., Fertel, R.H., Burkman, A.M., Miller, D.D. and Feller, D.R.
Pharmacological activities of trimetoquinol and 1-benzyl halogen-substituted analogues on rat β-adrenoceptor subtypes (305) 63
Konkar, A.A., see Lezama, E.J. (308) 69
Konkoy, C.S., Waters, S.M. and Davis, T.P.
Subchronic haloperidol administration decreases aminopeptidase N activity and [Met^5]enkephalin metabolism in rat striatum and cortex (297) 47
Koob, G.F., see Bono, G. (296) 233
Kooy, N.W. and Lewis, J.
Nitrotyrosine attenuates the hemodynamic effects of adrenoceptor agonists in vivo: relevance to the pathophysiology of peroxynitrite (310) 155
Kooy, N.W. and Lewis, S.J.
Elevation in arterial blood pressure following the development of tachyphylaxis to peroxynitrite (307) R5
Kooy, N.W. and Lewis, S.J.
The peroxynitrite product 3-nitro-L-tyros ne attenuates the hemodynamic responses to angiotensin II in vivo (315) 165
Kopajtic, T.A., see Fleckenstein, A.E. (311) 109
Korbut, R., see Gryglewski, R.J. (308) 61
Korf, J., see Sebens, J.B. (315) 269
Kornetsky, C., see Duvauchelle, C.L. (316) 137
Korpi, E.R., see Honkanen, A. (304) 7
Korpi, E.R., see Wong, G. (314) 319
Korsten, H.H.M., see Van den Berg, R.J. (316) 87
Korte-Bouws, G., see Barf, T. (297) 205
Korte, S.M., Buwalda, B., De Kloet, E.R. and Bohus, B.
Adrenaline release by the 5-HT$_{1A}$ receptor agonist 8-OH-DPAT is partly responsible for pituitary activation (309) 281
Korte, S.M., De Kloet, E.R., Buwalda, B., Bouman, S.D. and Bohus, B.
Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test (301) 19
Korte, S.M., see Barf, T. (297) 205
Kortezova, N., Mizhorkova, Z., Milusheva, E., Varga, G., Vizi, E.S. and Papasova, M.
Non-adrenergic non-cholinergic neuron stimulation in the cat lower esophageal sphincter (304) 109
Kosaka, K., see Goshima, Y. (309) 229
Koshikawa, N., Kitamura, M., Kobayashi, M. and Cools, A.R.
Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D$_2$ receptors in the shell of the nucleus accumbens; turning behaviour (308) 235
Koshikawa, N., Miwa, Y., Adachi, K., Kobayashi, M. and Cools, A.R.
Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D$_2$ receptors in the shell of the nucleus accumbens; jaw movements (308) 227
Koshikawa, N., Yoshida, Y., Kitamura, M., Saigusa, T., Kobayashi, M. and Cools, A.R.
Stimulation of acetylcholine or dopamine receptors in the nucleus accumbens differentially alters dopamine release in the striatum of freely moving rats (303) 13
Kosten, T.R., see Rosen, M.I. (307) 251
Kostenis, E., Botero Cid, H.M., Holzgrabe, U. and Mohr, K.
Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors (314) 385
Kostka-Trąbka, E., see Gryglewski, R.J. (308) 61
Kostner, G.M., see Graier, W.F. (294) 221
Kostowski, W., see Bienkowski, P. (314) 277
Kostowski, W., see Stefanski, R. (309) 141
Kotchabhakdi, N., see Wattanathorn, J. (313) 69
Koutsilieri, E., Chen, T.-S., Rausch, W.-D. and Riederer, P.
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium (306) 181
Kow, L.-M., see Zhang, C. (308) 153
Koyama, T., see Inoue, T. (311) 1
Koyama, T., see Izumi, T. (300) 25
Koyama, T., see Odagaki, Y. (300) 151
Kozubík, A., Hofmanová, J. and Dušek, L.
Eicosanoid inhibitors enhance synergistically the effect of transforming growth factor β1 on CCL 64 cell proliferation (316) 349
Krasel, C., see Gabilondo, A.M. (307) 243
Krause, D.N., see García-Villalón, A.L. (314) 339
Krause, D.N., see McNeill, A.M. (308) 305
Krause, J.E., see Robineau, P. (294) 677
Krause, W., Michael, N., Lübke, C., Livett, B.G. and Oehme, P.
Catecholamine release from fractionated chromaffin cells (302) 223
Kreek, M.J., see Zhou, Y. (315) 31
Krieger, J.-P., see Barthelmebs, M. (314) 325
Krieglstein, J., see Rupalla, K. (294) 469
Krieglstein, J., see Semkova, I. (315) 19
Kristiansen, K. and Dahl, S.G.
Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT$_{2C}$ receptor interactions (306) 195
Kristiansen, M., see Jackson, H.C. (308) 21
Krnjević, K., see Erdemli, G. (304) 37
Krogsgaard-Larsen, P., see Bräuner-Osborne, H. (313) 145
Krogsgaard-Larsen, P., see Wahl, P. (308) 211
Kronthaler, U.O. and Schmidt, W.J.
1*S*,3*R*-ACPD has cataleptogenic effects and reverses MK-801- and less pronounced, D,L-amphetamine-induced locomotion (316) 129
Krstew, E., see Lawrence, A.J. (315) 127
Ktorza, A., see Atef, N. (298) 287
Kubesch, P., see Demmer, A. (315) 339
Kubo, K., see Kitayoshi, T. (305) 137
Kucharczyk, N., see Bonnet, J. (310) 37
Kucharczyk, N., see Robineau, P. (294) 677
Kuehne, M.E., see Layer, R.T. (309) 159
Kuhar, M.J., see Fleckenstein, A.E. (311) 109
Kuhar, M.J., see Gatley, S.J. (296) 145
Kuhl, D., see Vander Borght, T. (294) 577
Kuhn, R., see Bruno, V. (310) 61
Kuhn-Regnier, F., see Lenz, O. (294) 17
Kuitunen, J., see Riekkinen Jr., P. (309) 121
Kuitunen, J., see Riekkinen, M. (300) 9
Kukovetz, W.R., see Wakabayashi, I. (299) 139
Kulick, A., see Ruzycky, A.L. (313) 257
Kull, B., see Dasgupta, S. (316) 325
Kumar, P., see Wickenden, A.D. (302) 79
Kumar, V.B., see Morley, J.E. (311) 15
Kunitomo, M., see Kitagawa, S. (297) 71
Kunos, G., see Varga, K. (310) 145
Kunz, D., see Walker, G. (306) 265
Kuoppamäki, M., see Wong, G. (314) 319
Kurachi, Y., see Nakajima, T. (294) 625
Kurashina, Y., see Yamagishi, R. (315) 73
Kuribara, H., Sekine, H. and Nakahara, Y.
Effect of haloperidol on the behavioral stimulation by *N*-cyanomethylmethamphetamine, a main product of smoking methamphetamine mixed with tobacco (305) 1
Kuribara, H.
Effects of interdose interval on ambulatory sensitization to methamphetamine, cocaine and morphine in mice (316) 1
Kuriyama, K., see Katsura, M. (298) 71
Kuriyama, K., see Ohkuma, S. (301) 179
Kurjak, M., Schusdziarra, V. and Allescher, H.-D.
Presynaptic modulation by VIP, secretin and isoproterenol of somatostatin release from enriched enteric synaptosomes: role of cAMP (314) 165
Kuroda, H., see Hattori, Y. (300) 147
Kuroda, S., see Ujike, H. (296) 123
Kuroiwa, A., see Osajima, A. (315) 319

Kurose, H., see Sato, Y. (315) 363
Kusano, E., see Iimura, O. (296) 319
Kusayama, T., Yamazaki, J. and Nagao, T.
Flow dependence of nitric oxide-mediated pressure change in rat mesenteric beds with different tonus (312) 301
Kushnir, M., see Heldman, E. (297) 283
Kusumi, T., see Ohizumi, Y. (310) 95
Kusumi, Y., see Bandoh, T. (315) 37
Kusumoto, K., Fujiwara, A., Ikeda, S., Watanabe, T. and Fujino, M.
Pharmacological characterization of cardiovascular responses induced by endothelin-1 in the perfused rat heart (296) 65
Kuwahara, M., Masuda, T., Tsubone, H., Sugano, S. and Karaki, H.
Cardiovascular responses mediated by two types of endothelin ET_B receptor in spontaneously hypertensive and Wistar-Kyoto rats (296) 55
Kuwahara, M., see Mito, K. (304) 93
Kuwako, M., see Asano, M. (311) 53
Kuze, J., see Kimura, T. (311) 265
Kuzmin, A., Semenova, S., Ramsey, N.F., Zvartau, E.E. and Van Ree, J.M.
Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca^{2+} channel modulators (295) 19
Kuzuya, H., see Murakami, N. (304) 129
Kvetnansky, R., see Vietor, I. (313) 119
Kwan, Y.W., see Yiu, M.-k. (302) 99
Kwon, O.-J., see Mak, J.C.W. (302) 215
Kwon, Y.M., see Kitagawa, S. (297) 71
Kyle, D.J., see De Campos, R.O.P. (316) 277

Laburthe, M., see Gaudin, P. (302) 207
Lachnit, W.G., Ford, A.P.D.W. and Clarke, D.E.
SDZ NVI 085, an α_{1A}-adrenoceptor agonist with 5-HT_{2A} receptor antagonist properties (297) 83
Lacković, Z., see Trkulja, V. (297) 93
Lafontan, M., see Atef, N. (298) 287
LaForge, K.S., see Zhou, Y. (315) 31
Lagarde, M., see Delton-Vandenbroucke, I. (312) 379
Lagente, V., see Alves, A.C. (312) 89
Lahti, R.A., Mutin, A., Cochrane, E.V., Tepper, P.G., Dijkstra, D., Wikström, H. and Tamminga, C.A.
Affinities and intrinsic activities of dopamine receptor agonists for the hD_{2l} and $hD_{4.4}$ receptors (301) R11
Lahtinen, H., Ylinen, A., Lukkarinen, U., Sirviö, J., Miettinen, R. and Riekkinen Sr., P.
Failure of carbamazepine to prevent behavioural and histopathological sequels of experimentally induced status epilepticus (297) 213
Lai, J., Ma, S.-w., Porreca, F. and Raffa, R.B.
Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells (316) 369
Lai, L.-P., Fan, T.-H.M., Delehanty, J.M., Yatani, A. and Liang, C.-s.
Elevated myocardial interstitial norepinephrine concentration contributes to the regulation of Na^+,K^+-ATPase in heart failure (309) 235
Lai, L.-P., Suematsu, M., Elam, H. and Liang, C.-s.
Differential changes of myocardial β-adrenoceptor subtypes and G-proteins in dogs with right-sided congestive heart failure (309) 201
Lai, M.-K., see Chueh, S.-C. (305) 177
Laitinen, J.T., see Navajas, C. (304) 173
Lakemond, C.M.M., see Mensink, A. (310) 73
Lakhe, M., see Yonezawa, T. (315) 289
Lakics, V., see Erdő, S.L. (314) 69
Lalonde, R., see Messaoudi, M. (299) 17
Lamarque, D. and Whittle, B.J.R.
Involvement of peroxynitrite in the lipid peroxidation induced by nitric oxide in rat gastric mucosa (313) R5
Lambert, D.G., see Smart, D. (305) 235
Lambert, G. and Michalicek, J.
Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation (311) 141
Lambrecht, G., see Waelbroeck, M. (303) 221
Lammertsma, A.A., see Pike, V.W. (301) R5
Lamperti, M., see Braida, D. (302) 13
Lan, R., see Gatley, S.J. (307) 331
Landgraf, R., see Spanagel, R. (305) 39
Langer, S.Z., see Avenet, P. (296) 209
Langlois, M., see Shen, S. (307) 133
Lanz, I., see Amann, R. (306) 89
Lanzafame, A., Christopoulos, A. and Mitchelson, F.
Interactions of agonists with an allosteric antagonist at muscarinic acetylcholine M_2 receptors (316) 27
La Riccia, M., see Orzi, F. (302) 49
Larm, J.A., Cheung, N.S. and Beart, P.M.
(*S*)-5-Fluorowillardiine-mediated neurotoxicity in cultured murine cortical neurones occurs via AMPA and kainate receptors (314) 249
La Rosée, K., see Lenz, O. (294) 17
Larson, A.A., see Hornfeldt, C.S. (306) 15
Larson-Prior, L.J., Siuciak, J.A. and Dubocovich, M.L.
Localization of 2-[^{125}I]iodomelatonin binding sites in visual areas of the turtle brain (297) 181
Latifpour, J., see Saito, M. (310) 197
Laurent, S., see Bézie, Y. (311) 241
Laurie, D.J., Boddeke, H.W.G.M., Hiltscher, R. and Sommer, B.
Erratum to '$HmGlu_{1d}$, a novel splice variant of the human type I metabotropic glutamate receptor'. [Eur. J. Pharmacol. 296 (1996) R1–R3] (302) 229
Laurie, D.J., Boddeke, H.W.G.M., Hiltscher, R. and Sommer, B.
$HmGlu_{1d}$, a novel splice variant of the human type I metabotropic glutamate receptor (296) R1
Lavayre, J., see Heuillet, E. (314) 229
Lawrence, A.J., Krstew, E. and Jarrott, B.
Actions of nitric oxide and expression of the mRNA encoding nitric oxide synthase in rat vagal afferent neurons (315) 127
Layer, R.T., Skolnick, P., Bertha, C.M., Bandarage, U.K., Kuehne, M.E. and Popik, P.
Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors (309) 159
Lazareno, S., see Cohen, F.R. (309) 111
Lazarus, L.H., see Guerrini, R. (302) 37
Lazzeri, G., see Blandizzi, C. (294) 191
Leaf, A., see Kang, J.X. (297) 97
Le Bars, D., see Gozariu, M. (313) 51
Le Bars, D., see Guirimand, F. (294) 651
Lebrec, D., see Pilette, C. (312) 63
Lebrun, P., see Antoine, M.-H. (313) 229
Lee, C.S., see Ahn, S.K. (306) 175
Lee, K., Ibbotson, T., Richardson, P.J. and Boden, P.R.
Inhibition of K_{ATP} channel activity by troglitazone in CRI-G1 insulin-secreting cells (313) 163
Lee, S.-M. and Kim, K.H.
Rebamipide ameliorates hepatic dysfunction induced by ischemia/reperfusion in rats (294) 41
Lee, S.-S., see Teng, C.-M. (303) 129
Lee, S.H., see DeFarias, F.P. (314) 123
Lee, T.J.F., see Ishine, T. (313) 97
Lee, Y.-S., see Kim, Y.-B. (313) 107
Leeuwin, R.S., Zeegers, A. and Van Wilgenburg, H.
Flunarizine but not theophylline modulates inotropic responses of the isolated rat heart to diazepam (315) 153
Leeuwin, R.S., Zeegers, A. and Van Wilgenburg, H.
PK 11195 antagonizes the positive inotropic response of the isolated rat heart to diazepam but not the negative inotropic response (299) 149
Lefebvre, R.A., see Smits, G.J.M. (303) 79

Lefer, A.M., see Scalia, R. (296) 181
Lefevour, A., see Shippenberg, T.S. (299) 33
Leff, P., see Liu, Y.J. (304) 117
Lehmann, J.C., see Tayag, E.C. (300) 261
Le Huerou-Luron, I., see Dufresne, M. (297) 165
Lei, Y., see Kidney, J.C. (296) 81
Leid, M., see Musser, B. (308) 357
Le Maire, V., see Hernvann, A. (314) 193
Le Meuth, V., see Dufresne, M. (297) 165
Lenz, O., Schmid, B., Kilter, H., La Rosée, K., Flesch, M., Kuhn-Regnier, F., Südkamp, M. and Böhm, M.
Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium (294) 17
Leon, A., see Mazzari, S. (300) 227
Léonardon, J., see Avenet, P. (296) 209
Le Panse, R., Mitev, V., Houdebine, L.-M. and Coulomb, B.
Protein kinase C-independent activation of mitogen-activated protein kinase by epidermal growth factor in skin fibroblasts (307) 339
Lepor, H., see Hatano, A. (313) 135
Leret, M.L., see Molina-Holgado, F. (316) 39
Lesma, E., see Gorio, A. (303) 21
Letari, O., Mennuni, L., Revel, L., Colombo, S. and Makovec, F.
Cytosolic Ca^{2+} evaluation in rabbit parietal cells: a novel method to screen gastrin receptor antagonists (306) 325
Levens, N., see Chow, L. (294) 309
Leventhal, L., see Rossi, G.C. (311) R7
Lévi, F., see Deprés-Brummer, P. (312) 171
Levy, N., see Grignon, S. (315) 111
Levy, R., see Heldman, E. (297) 283
Lewander, T., see Yu, H. (303) 151
Lewis, J., see Kooy, N.W. (310) 155
Lewis, S.J., Travis, M.D. and Bates, J.N.
Stereoselective *S*-nitrosocysteine recognition sites in rat brain (312) R3
Lewis, S.J., see Kooy, N.W. (307) R5
Lewis, S.J., see Kooy, N.W. (315) 165
Leysen, J.E., see Gerhardt, C.C. (311) 249
Leysen, J.E., see Nestby, P. (294) 771
Leyton, V., see Bellot, R.G. (313) 175
Leza, J.C., see Lizasoain, I. (299) 41
Lezama, E.J., Konkar, A.A., Salazar-Bookaman, M.M., Miller, D.D. and Feller, D.R.
Pharmacological study of atypical β-adrenoceptors in rat esophageal smooth muscle (308) 69
Li, M., see Helmeste, D. (301) R1
Li, X., Varga, E.V., Stropova, D., Zalewska, T., Malatynska, E., Knapp, R.J., Roeske, W.R. and Yamamura, H.I.
δ-Opioid receptor: the third extracellular loop determines naltrindole selectivity (300) R1
Li, Y., see Nowak, G. (295) 75
Li, Y.-J., Xiao, Z.-S., Peng, C.-F. and Deng, H.-W.
Calcitonin gene-related peptide-induced preconditioning protects against ischemia-reperfusion injury in isolated rat hearts (311) 163
Liang, C.-s., see Lai, L.-P. (309) 201
Liang, C.-s., see Lai, L.-P. (309) 235
Lichtenstein, A.H., see Moreland, R.S. (307) 55
Liégeois, J.-F., Scuvée-Moreau, J., Giesbers, I., Damas, J., Bruhwyler, J., Géczy, J., Delarge, J. and Dresse, A.
Dibenzoazepine analogues: the electrophysiological properties of JL3, a potential atypical antidepressant (310) 9
Lightowler, S., Wood, M., Brown, T., Glen, A., Blackburn, T., Tulloch, I. and Kennett, G.
An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats (296) 137
Liguori, A., see Gatch, M.B. (312) 389
Liguori, T., see Gatch, M.B. (298) 31
Liljequist, S., see Hou, Y.-N. (309) 307
Lima, C.S.P., see Ferreira, H.H.A. (310) 201
Lima-Leite, A.-C., see Oiry, C. (294) 511
Lin, C.H., see Chang, M.C. (297) 129
Lin, D.-T., see Teng, C.-M. (303) 129
Lin, J.-T., Coy, D.H., Mantey, S.A. and Jensen, R.T.
Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors (294) 55
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (302) 43
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (316) 171
Lin, W.W.
Erratum to 'Effects of protein kinase A activation on endothelin- and ATP-induced signal transduction' [Eur. J. Pharmacol. – Mol. Pharmacol. Sect. 291 (1995) 1–7] (296) 231
Lindemann, J.P., see Williamson, A.P. (304) 73
Lindén, A., see Yoshihara, S. (296) 291
Linden, J., see Musser, B. (308) 357
Linseman, D.A., see Wall, T.M. (306) 165
Lione, L.A., Nutt, D.J. and Hudson, A.L.
[^{3}H]2-(2-Benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I_2 receptors (304) 221
Liu, G.J., see Emaduddin, M. (302) 129
Liu, M., see Ito, K. (314) 143
Liu, Y., see Souverbie, F. (307) 347
Liu, Y., see Yu, H. (303) 151
Liu, Y.J., Jackson, D.M. and Blackham, A.
Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations (303) 187
Liu, Y.J., Jackson, D.M., Blackham, A. and Leff, P.
Partial agonist effects of BW A868C, a selective DP receptor antagonist, on Cl^- secretion in dog tracheal epithelium (304) 117
Livett, B.G., see Krause, W. (302) 223
Lizasoain, I., Leza, J.C., Cuéllar, B., Moro, M.A. and Lorenzo, P.
Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide (299) 41
Llenas, J., see Cardelús, I. (299) 153
Lloyd, K.C.K., see Martínez, V. (296) 153
Lloyd, T.C., see Brown, R.A. (302) 61
Lluch, S., see Medina, P. (300) 221
Lodge, D., see Nooney, J.M. (306) 41
Lodge, N.J., see D'Alonzo, A.J. (294) 271
Loenders, B., Jorens, P.G. and Herman, A.G.
Epithelial modulation of cholinergic responses in rabbit trachea is partly due to neutral endopeptidase activity (296) 89
Loew, G.H., see Chen, S.-W. (312) 241
Lohmann, A., see De Beun, R. (306) 5
Lohse, M.J., see Gabilondo, A.M. (307) 243
Lohse, M.J., see Jahns, R. (316) 111
Loiacono, R.E., see Whorlow, S.L. (315) 11
Loisel, L., see Vaugeois, J.-M. (316) R1
Lombardi, G., see Di Renzo, G. (294) 11
Lonchampt, M., see Bonnet, J. (310) 37
Lonchampt, M., see Robineau, P. (294) 677
Loneragan, K., Cheah, T.B., Bunn, S.J. and Marley, P.D.
The role of protein kinase C in nicotinic responses of bovine chromaffin cells (311) 87
Longrois, D., see Bézie, Y. (311) 241
Lonovics, J., see Szilvassy, Z. (301) R17
Lookingland, K.J., see Eaton, M.J. (299) 171
Lopes-Martins, R., Catelli, M., Araújo, C., Estato, V., Cordeiro, R. and Tibiriçá, E.
Pharmacological evidence of a role for platelet activating factor as a modulator of vasomotor tone and blood pressure (308) 287
Lopes da Silva, F.H., see Zuiderwijk, M. (307) 275
López, J.R., see Brady, P.A. (308) 343
Lopez, J.R., see Jovanovic, A. (298) 63
López, M.G., see Gandía, L. (298) 199

López-Muñoz, F.J., Castañeda-Hernández, G., Flores-Murrieta, F.J. and Granados-Soto, V.
Effect of caffeine coadministration and of nitric oxide synthesis inhibition on the antinociceptive action of ketorolac (308) 275
Lorenzl, S., Ködel, U., Frei, K. and Pfister, H.-W.
Effect of the bradykinin B_2 receptor antagonist Hoe140 in experimental pneumococcal meningitis in the rat (308) 335
Lorenzo, P., see Lizasoain, I. (299) 41
Lorenzo, P.S., Rubio, M.C., Medina, J.H. and Adler-Graschinsky, E.
Involvement of monoamine oxidase and noradrenaline uptake in the positive chronotropic effects of apigenin in rat atria (312) 203
Löscher, W. and Hönack, D.
Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats (299) 61
Löscher, W., see Bloms-Funke, P. (316) 211
Löscher, W., see Richter, A. (300) 197
Löschmann, P.-A., see Eblen, F. (299) 9
Löschmann, P.-A., see Klockgether, T. (301) 67
Lotti, V.J., see Chang, R.S.L. (294) 429
Lötvall, J.O., see Kidney, J.C. (296) 81
Loubatières-Mariani, M.-M., see Berdeu, D. (308) 301
Lovas, G., see Varga, K. (310) 145
Love, A., Cotter, M.A. and Cameron, N.E.
Nerve function and regeneration in diabetic and galactosaemic rats: antioxidant and metal chelator effects (314) 33
Lowe, D., Pagel, P.S., McGough, M.F., Hettrick, D.A. and Warltier, D.C.
Comparison of the cardiovascular effects of two novel superoxide dismutase mimetics, SC-55858 and SC-54417, in conscious dogs (304) 81
Lowe, D., see Hettrick, D.A. (316) 237
Lubatti, L., see Paroni, R. (294) 737
Lübke, C., see Krause, W. (302) 223
Luccarini, J.-M., see Pruneau, D. (297) 53
Luccarini, P., see Dallel, R. (314) 19
Lucchesi, B.R., see Friedrichs, G.S. (306) 99
Ludbrook, J., see Ventura, S. (294) 369
Lüddens, H., see Wong, G. (314) 319
Luk, H.-N., see Wong, C.-S. (297) 27
Lukkarinen, U., see Lahtinen, H. (297) 213
Lukovic, L., see Cowley, D.J. (298) 227
Lundberg, J.M., see Malmström, R.E. (294) 661
Lundberg, J.M., see Malmström, R.E. (305) 145
Lundberg, J.M., see Szallasi, A. (298) 321
Lundberg, J.M., see Szallasi, A. (299) 221
Lundkvist, J., Chai, Z., Teheranian, R., Hasanvan, H., Bartfai, T., Jenck, F., Widmer, U. and Moreau, J.-L.
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity (309) 195
Luodonpää, M., see Pelkonen, M. (304) 55
Lux, H.D., see Frank, C. (295) 87
Lynch, A.M., see See, R.E. (308) 279
Lynch, M.A., see McGahon, B. (309) 323
Lynch, M.A., see Mullany, P. (309) 311
Lyupina, Y.V., Sudakov, S.K. and Yarygin, V.N.
Inhibitors of Ca^{2+}-dependent endopeptidases modulate morphine-induced effects in rats (304) 23

Ma, S.-w., see Lai, J. (316) 369
Ma, T., see Hoshi, K. (314) 301
Maaß, A. and Mohr, K.
Opposite effects of alcuronium on agonist and on antagonist binding to muscarinic receptors (305) 231
Maas, M.A.W., see Zwaveling, J. (300) 91
MaassenVanDenBrink, A., see Saxena, P.R. (312) 53
MacGregor, D.P., see Murone, C. (306) 237
Maćkowiak, M., see Bijak, M. (305) 79
Maćkowiak, M., see Wędzony, K. (305) 73
MacLennan, A.J., Gaskin, A.A., Vinson, E.N. and Martinez, L.C.
Ciliary neurotrophic factor receptor α mRNA in NB41A3 neuroblastoma cells: regulation by cAMP (295) 103
Madsen, U., see Wahl, P. (308) 211
Maeda, J., see Suzuki, T. (314) 281
Maeda, K., see Hirasawa, Y. (303) 55
Maeda, N., see Hiyoshi, Y. (294) 117
Maes, J.H.R., Van Rijn, C.M. and Vossen, J.M.H.
Drug states as modulators of conditioned immobility in a latent discrimination procedure (309) 131
Maggi, A., see Braida, D. (302) 13
Maggi, C.A., see Patacchini, R. (303) 197
Maggi, R., Pimpinelli, F., Casulari, L.A., Piva, F. and Martini, L.
Antiprogestins inhibit the binding of opioids to μ-opioid receptors in nervous membrane preparations (301) 169
Maggos, C.E., see Zhou, Y. (315) 31
Magistrelli, A., see Tsankova, V. (294) 601
Magous, R., see Cuq, P. (315) 213
Maguire, P.A., see Chen, S.-W. (312) 241
Mai, M.P., Bauer, V., Nosáľová, V., Mátyás, Š. and Bezáková, Ž.
Effect of pentacaine and its derivatives on the contractile responses of smooth muscle in the guinea-pig stomach (315) 305
Maidhof, A., see Jahns, R. (316) 111
Maigret, B., see Jagerschmidt, A. (296) 97
Mainiero, F., see Tubaro, E. (294) 555
Maitra, R., see Reynolds, J.N. (314) 151
Maj, J., Dziedzicka-Wasylewska, M., Rogoż, R., Rogóż, Z. and Skuza, G.
Antidepressant drugs given repeatedly change the binding of the dopamine D_2 receptor agonist, [^{3}H]N-0437, to dopamine D_2 receptors in the rat brain (304) 49
Maj, J., Rogóż, Z., Skuza, G. and Mazela, H.
Neuropharmacological profile of EMD 57445, a σ receptor ligand with potential antipsychotic activity (315) 235
Mak, J.C.W., Nishikawa, M., Haddad, E.-B., Kwon, O.-J., Hirst, S.J., Twort, C.H.C. and Barnes, P.J.
Localisation and expression of β-adrenoceptor subtype mRNAs in human lung (302) 215
Makovec, F., see Letari, O. (306) 325
Makriyannis, A., see Gatley, S.J. (307) 331
Malassiné, A., see Hervé, J.-C. (313) 243
Malatynska, E., see Li, X. (300) R1
Malcangio, M., Bowery, N.G., Flower, R.J. and Perretti, M.
Effect of interleukin-1β on the release of substance P from rat isolated spinal cord (299) 113
Malcangio, M., see Teoh, H. (302) 27
Maldonado, A., see Torres, C. (314) 269
Maldonado, R., see Valverde, O. (312) 15
Malgouris, C., see Boireau, A. (300) 237
Malinowska, B., Godlewski, G., Buczko, W. and Göthert, M.
Facilitation by substance P and inhibition by (+)-tubocurarine of the 5-HT_3 receptor-mediated Bezold-Jarisch reflex in rats (315) 159
Malleron, J.-L., see Heuillet, E. (314) 229
Malmberg, Å., Jerning, E. and Mohell, N.
Critical reevaluation of spiperone and benzamide binding to dopamine D_2 receptors: evidence for identical binding sites (303) 123
Malmberg, Å., see Yu, H. (303) 151
Malmberg, A.B., Fallgren, B. and Hedner, T.
Antinociceptive effect of α-trinositol, a novel D-*myo*-inositol phosphate derivative, in the formalin test in rats (294) 609
Malmström, R.E. and Lundberg, J.M.
Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435 (294) 661
Malmström, R.E., Modin, A. and Lundberg, J.M.
SR 120107A antagonizes neuropeptide Y Y_1 receptor mediated sympathetic vasoconstriction in pigs in vivo (305) 145

Malosio, M.L., see Gorio, A. (303) 21
Manabe, I., see Yoshida, A. (312) 115
Manahan-Vaughan, D. and Reymann, K.G.
1*S*,3*R*-ACPD dose dependently induces a slow onset potentiation in the dentate gyrus in vivo (294) 497
Manahan-Vaughan, D., Anwyl, R. and Rowan, M.J.
The azapirone metabolite 1-(2-pyrimidinyl)piperazine depresses excitatory synaptic transmission in the hippocampus of the alert rat via 5-HT_{1A} receptors (294) 617
Mancuso, F., Calignano, A., Cozzolino, A., Metafora, S. and Porta, R.
Inhibition of zymosan-induced air-pouch inflammation by rat seminal vesicle protein and by its spermidine derivative (312) 327
Maneuf, Y.P., Nash, J.E., Crossman, A.R. and Brotchie, J.M.
Activation of the cannabinoid receptor by Δ^9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus (308) 161
Manhães de Castro, R., see Bolaños-Jiménez, F. (294) 531
Manneschi, L., see Federico, A. (304) 237
Manning, P., see Stenger, S. (294) 703
Manning, P.T., see Salvemini, D. (303) 217
Mano, M., see McLennan, P. (300) 83
Mansi, G., see Mitolo-Chieppa, D. (309) 175
Mansikka, H., Idänpään-Heikkilä, J.-J. and Pertovaara, A.
Different roles of α_2-adrenoceptors of the medulla versus the spinal cord in modulation of mustard oil-induced central hyperalgesia in rats (297) 19
Mansvelder, H.D., Stoof, J.C. and Kits, K.S.
Dihydropyridine block of ω-agatoxin IVA- and ω-conotoxin GVIA-sensitive Ca^{2+} channels in rat pituitary melanotropic cells (311) 293
Mantey, S.A., see Lin, J.-T. (294) 55
Mantlo, N.B., see Chang, R.S.L. (294) 429
Mantlo, N.B., see Kivlighn, S.D. (294) 439
Manzini, S., see Goso, C. (294) 239
Maoret, J.-J., see Gaudin, P. (302) 207
Marcolongo, G., see Mazzari, S. (300) 227
Marconi, M., see Speciale, C. (315) 263
Marcotte, E.R., see Modi, P.I. (299) 213
Marek, G.J. and Aghajanian, G.K.
α_{1B}-Adrenoceptor-mediated excitation of piriform cortical interneurons (305) 95
Marescau, B., see Matthys, K.E. (298) 97
Margaill, I., see Charriaut-Marlangue, C. (310) 137
Margioris, A.N., see Stratakis, C.A. (315) 53
Marley, P.D., see Loneragan, K. (311) 87
Maroto, R., see De la Fuente, M.T. (306) 219
Marsden, C.A., see Rowley, H.L. (294) 541
Marshall, F.H., see Hawcock, A.B. (294) 163
Mårtensson, L.G.E., Andersson, R.G.G. and Berg, G.
Melatonin together with noradrenaline augments contractions of human myometrium (316) 273
Martin, B.R., see Damaj, M.I. (300) 51
Martin, B.R., see Pertwee, R.G. (315) 195
Martin, J.D., see Ausina, P. (312) 309
Martin, K.F., see Rowley, H.L. (294) 541
Martin, P.-M., see Hatzoglou, A. (310) 217
Martínez, A., see Boric, M.P. (294) 391
Martinez, J., see Oiry, C. (294) 511
Martinez, L.C., see MacLennan, A.J. (295) 103
Martínez, M.C., see Medina, P. (300) 221
Martínez, V., Coy, D.H., Lloyd, K.C.K. and Taché, Y.
Intracerebroventricular injection of somatostatin sst_5 receptor agonist inhibits gastric acid secretion in rats (296) 153
Martini, L., see Maggi, R. (301) 169
Martins, M.A., see Alves, A.C. (312) 89
Martins, M.A., see Diaz, B.L. (296) 173
Mascia, M.S., see Imperato, A. (302) 21
Mascolo, N., see Izzo, A.A. (301) 137
Massarelli, R., see Sorrentino, G. (308) 81
Massi, M., see Polidori, C. (307) 259
Massoud, R., see Bagetta, G. (294) 341
Masuda, N., see Yamagishi, R. (315) 73
Masuda, T., see Kuwahara, M. (296) 55
Masuda, Y., see Minato, H. (315) 297
Masumiya, H., see Noguchi, K. (308) 53
Matešić, D., see Župan, G. (310) 103
Mathé-Allainmat, M., see Shen, S. (307) 133
Mathé, J.M., Nomikos, G.G., Hildebrand, B.E., Hertel, P. and Svensson, T.H.
Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens (309) 1
Matsubara, K., Idzu, T., Kobayashi, Y., Gonda, T., Okunishi, H. and Kimura, K.
Differences in dopamine efflux induced by MPP^+ and β-carbolinium in the striatum of conscious rats (315) 145
Matsuki, N., see Andrews, P. (307) 305
Matsuki, N., see Okada, F. (309) 33
Matsuki, Y., see Ishizuka, T. (312) 367
Matsumoto, H., see Naraba, H. (302) 117
Matsumoto, M., see Yoshioka, M. (294) 565
Matsumoto, R.R., Bowen, W.D., Walker, J.M., Patrick, S.L., Zambon, A.C., Vo, V.N., Truong, D.D., De Costa, B.R. and Rice, K.C.
Dissociation of the motor effects of (+)-pentazocine from binding to σ_1 sites (301) 31
Matsumura, N., see Mito, K. (304) 93
Matsunaga, K., see Asano, M. (294) 693
Matsunami, K., see Chowdhury, S.A. (314) 313
Matsunami, K.-i., see Salunga, T.L. (304) 163
Matsuno, K., Kobayashi, T., Tanaka, M.K. and Mita, S.
σ_1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test (312) 267
Matsuno, K., Nakazawa, M., Okamoto, K., Kawashima, Y. and Mita, S.
Binding properties of SA4503, a novel and selective σ_1 receptor agonist (306) 271
Matsuno, K., see Senda, T. (315) 1
Matsuo, A., see Shinoda, M. (305) 31
Matsuo, K., see Satoh, M. (308) 145
Matsuyama, K., see Naito, Y. (294) 47
Matsuzawa, A., see Yamagishi, R. (315) 73
Mattammal, M.B., see Morley, J.E. (311) 15
Matthys, K.E., Van Hove, C.E., Jorens, P.G., Rosseneu, M., Marescau, B., Herman, A.G. and Bult, H.
Dual effects of oxidized low-density lipoprotein on immune-stimulated nitric oxide and prostaglandin release in macrophages (298) 97
Mátyás, Š., see Mai, M.P. (315) 305
Mavunkel, B.J., see De Campos, R.O.P. (316) 277
Mayer, M.B., see Ruiz-Velasco, V. (296) 327
Mayers, R.M., Quayle, S.P., Thompson, A.J., Grant, T.L. and Holloway, B.R.
The acid metabolite of ZD7114 is a partial agonist of lipolysis mediated by the rat β_3-adrenoceptor (295) 199
Maze, M., see Rabin, B.C. (306) 51
Mazela, H., see Maj, J. (315) 235
Mazzari, S., Canella, R., Petrelli, L., Marcolongo, G. and Leon, A.
N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation (300) 227
Mazzola-Pomietto, P., Aulakh, C.S. and Murphy, D.L.
NMDA receptor antagonists block development of tolerance to m-CPP-induced increases in ACTH concentrations in rats (308) 329
McAllister, K.H.
The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats (314) 307
McAuley, M.A., Breu, V., Graham, D.I. and McCulloch, J.
The effects of bosentan on cerebral blood flow and histopathology following middle cerebral artery occlusion in the rat (307) 171

McAuley, M.A., see Patel, T.R. (307) 41
McCann, U.D., Hatzidimitriou, G. and Ricaurte, G.A.
Prolactin response to fenfluramine is independent of serotonin release (312) R1
McCarron, J.A., see Pike, V.W. (301) R5
McCulloch, J., see McAuley, M.A. (307) 171
McCulloch, J., see Patel, T.R. (307) 41
McCurrie, J.R., see Davies, M.P. (297) 249
McDermott, B., see Kelso, E. (308) 351
McEvoy, M.P., see Garratt, J.C. (314) 393
McGahon, B. and Lynch, M.A.
The synergism between ACPD and arachidonic acid on glutamate release in hippocampus is age-dependent (309) 323
McGough, M.F., see Lowe, D. (304) 81
McGowan, S., Eastwood, S.L., Mead, A., Burnet, P.W.J., Smith, C., Flanigan, T.P. and Harrison, P.J.
Hippocampal and cortical G protein ($G_s\alpha$, $G_o\alpha$ and $G_{i2}\alpha$) mRNA expression after electroconvulsive shock or lithium carbonate treatment (306) 249
McGregor, I.S., Dastur, F.N., McLellan, R.A. and Brown, R.E.
Cannabinoid modulation of rat pup ultrasonic vocalizations (313) 43
McLaughlin, J.P., Nowak, D., Sebastian, A., Schultz, A.G., Archer, S. and Bidlack, J.M.
Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors (294) 201
McLean, P.G. and Coupar, I.M.
Characterisation of a postjunctional 5-ht$_7$-like and a prejunctional 5-HT$_3$ receptor mediating contraction of rat isolated jejunum (312) 215
McLellan, R.A., see McGregor, I.S. (313) 43
McLennan, P., Howe, P., Abeywardena, M., Muggli, R., Raederstorff, D., Mano, M., Rayner, T. and Head, R.
The cardiovascular protective role of docosahexaenoic acid (300) 83
McMahon, T.J., see Rosen, M.I. (307) 251
McNeill, A.M., Duckles, S.P. and Krause, D.N.
Relaxant effects of 17ß-estradiol in the rat tail artery are greater in females than males (308) 305
McNutt, R.W., see Campa, M.J. (310) 263
McQuaid, K.E., Smyth, E.M. and Keenan, A.K.
Evidence for modulation of hydrogen peroxide-induced endothelial barrier dysfunction by nitric oxide in vitro (307) 233
McWhinney, C.D., Dudley, M.W., Bowlin, T.L., Peet, N.P., Schook, L., Bradshaw, M., De, M., Borcherding, D.R. and Edwards III, C.K.
Activation of adenosine A_3 receptors on macrophages inhibits tumor necrosis factor-α (310) 209
Mead, A., see McGowan, S. (306) 249
Meador-Woodruff, J.H., see Healy, D.J. (306) 257
Meana, J.J., Callado, L.F., Pazos, A., Grijalba, B. and García-Sevilla, J.A.
The subtype-selective α_2-adrenoceptor antagonists BRL 44408 and ARC 239 also recognize 5-HT$_{1A}$ receptors in the rat brain (312) 385
Meana, J.J., see Callado, L.F. (316) 359
Meana, J.J., see Grijalba, B. (310) 83
Medeiros, M.V., see Ferreira, H.H.A. (310) 201
Medina, J.H., see Lorenzo, P.S. (312) 203
Medina, P., Martínez, M.C., Aldasoro, M., Vila, J.M., Chuan, P. and Lluch, S.
Contractile responses of human deferential artery and vas deferens to vasopressin (300) 221
Meijerman, I., see Mensink, A. (310) 73
Meisel, R.L., Joppa, M.A. and Rowe, R.K.
Dopamine receptor antagonists attenuate conditioned place preference following sexual behavior in female Syrian hamsters (309) 21
Meissner, A., Szymanska, G. and Morgan, J.P.
Effects of dantrolene sodium on intracellular Ca^{2+}-handling in normal and Ca^{2+}-overloaded cardiac muscle (316) 333
Melchiorri, D., Reiter, R.J., Chen, L.D., Sewerynek, E. and Nisticò, G.
Melatonin affords protection against kainate-induced in vitro lipid peroxidation in brain (305) 239
Mele, A., Castellano, C., Felici, A., Cabib, S., Caccia, S. and Oliverio, A.
Dopamine–*N*-methyl-D-aspartate interactions in the modulation of locomotor activity and memory consolidation in mice (308) 1
Melis, F., see Fadda, F. (307) R1
Melis, M.R. and Argiolas, A.
Nitric oxide donors induce penile erection and yawning when injected in the central nervous system of male rats (294) 1
Mello, N.K., see Gatch, M.B. (298) 31
Mello, N.K., see Gatch, M.B. (312) 389
Mendelsohn, F.A.O., see Murone, C. (306) 237
Meng, F., Ueda, Y., Hoversten, M.T., Thompson, R.C., Taylor, L., Watson, S.J. and Akil, H.
Mapping the receptor domains critical for the binding selectivity of δ-opioid receptor ligands (311) 285
Menge, W., see Waelbroeck, M. (303) 221
Menkes, C.-J., see Hernvann, A. (314) 193
Mennini, T., see Cagnotto, A. (313) 63
Mennini, T., see Di Santo, E. (299) 179
Mennuni, L., see Letari, O. (306) 325
Mensink, A., Brouwer, A., Van den Burg, E.H., Geurts, S., Jongen, W.M.F., Lakemond, C.M.M., Meijerman, I. and Van der Wijk, T.
Modulation of intercellular communication between smooth muscle cells by growth factors and cytokines (310) 73
Merahi, N., see Delagrange, P. (316) 195
Mercadier, J.-J., see Bézie, Y. (311) 241
Mercer, A.D., see Salunga, T.L. (304) 163
Meroni, P.L., see Nicoletti, F. (311) 213
Meßmer, U.K. and Brüne, B.
Modification of macrophage glyceraldehyde-3-phosphate dehydrogenase in response to nitric oxide (302) 171
Mesnard, L., see Bézie, Y. (311) 241
Messaoudi, M., Tricoire, A., Lalonde, R., Canini, F. and Minn, A.
Effects of MPTP on lever-pressing for light extinction in rats (299) 17
Metafora, S., see Mancuso, F. (312) 327
Methfessel, C., see Cooper, J.C. (309) 287
Metzger, G., see Deprés-Brummer, P. (312) 171
Meunier, M., see Boireau, A. (300) 237
Meyer zu Brickwedde, M.K., see Sachinidis, A. (309) 95
Miampamba, M., Chéry-Croze, S., Détolle-Sarbach, S., Guez, D. and Chayvialle, J.-A.
Antinociceptive effects of oral clonidine and S12813-4 in acute colon inflammation in rats (308) 251
Michael, N., see Krause, W. (302) 223
Michalicek, J., see Lambert, G. (311) 141
Michaluk, J., see Antkiewicz-Michaluk, L. (294) 459
Michaluk, J., see Karolewicz, B. (313) 181
Michel, A., see Hadj-Kaddour, K. (298) 145
Michel, J.-B., see Pham, I. (296) 267
Michel, M.C., Kaldenberg-Stasch, S. and Wieland, T.
Cytoskeletal inhibitors impair Ca^{2+} elevations via neuropeptide Y and other G_i-coupled receptors (309) 87
Michiels, C., see Arnould, T. (315) 227
Michotte, Y., see Sarre, S. (296) 247
Middlemiss, D., see Herdon, H. (314) R7
Middlemiss, D.N., see Watson, J.M. (314) 365
Miettinen, R., see Lahtinen, H. (297) 213
Mignani, S., see Boireau, A. (300) 237
Mignani, S., see Heuillet, E. (314) 229
Mihelich, E.D., see Fox, N. (308) 195
Mikami, Y., see Tanabe, T. (299) 187
Miki, K., see Goshima, Y. (309) 229
Milano, S., see Hjorth, S. (316) 43
Millan, M.J., see Newman-Tancredi, A. (307) 107

Miller, A.S. and Walker, J.M.
Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus (304) 29
Miller, D.D., see Konkar, A.A. (305) 63
Miller, D.D., see Lezama, E.J. (308) 69
Milusheva, E., see Kortezova, N. (304) 109
Minabe, Y., see Katsumori, H. (311) 37
Minabe, Y., see Narita, N. (307) 117
Minami, M., see Katsumata, S. (312) 349
Minami, M., see Yabuuchi, K. (300) 59
Minato, H., Honda, Y., Masuda, Y., Fujitani, B. and Hosoki, K.
Prevention by the new Ca^{2+} channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats (315) 297
Mińcikiewicz, M., see Brzezińska-Błaszczyk, E. (298) 155
Mingeot-Leclercq, M.-P., see Montenez, J.-P. (314) 215
Mingeot-Leclercq, M.-P., see Van Bambeke, F. (314) 203
Minn, A., see Messaoudi, M. (299) 17
Miquet, J.M., see Boireau, A. (300) 237
Mirshahi, T., see Moore, K.A. (311) 133
Mirza, N.R., Pei, Q., Stolerman, I.P. and Zetterström, T.S.C.
The nicotinic receptor agonists (−)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens (295) 207
Misawa, M., see Suzuki, T. (314) 281
Misawa, M., see Takahashi, Y. (302) 89
Misawa, M., see Tsuda, M. (307) 7
Mishima, K., see Tanabe, T. (314) 175
Mishra, R.K., see Modi, P.I. (299) 213
Mishra, S.K., see Jagadish, M. (309) 63
Misu, Y., see Goshima, Y. (309) 229
Misu, Y., see Miyamae, T. (300) 105
Misztal, M., Frankiewicz, T., Parsons, C.G. and Danysz, W.
Learning deficits induced by chronic intraventricular infusion of quinolinic acid – protection by MK-801 and memantine (296) 1
Mita, S., see Matsuno, K. (306) 271
Mita, S., see Matsuno, K. (312) 267
Mita, S., see Senda, T. (315) 1
Mita, Y., Dobashi, K., Suzuki, K., Mori, M. and Nakazawa, T.
Induction of muscarinic receptor subtypes in monocytic/macrophagic cells differentiated from EoL-1 cells (297) 121
Mitani, H., see Bandoh, T. (315) 37
Mitani, Y., see Yoshida, A. (312) 115
Mitchell, W.M., see Mousa, S.A. (311) 221
Mitchelson, F., see Lanzafame, A. (316) 27
Mitev, V., see Le Panse, R. (307) 339
Mito, K., Fujii, M., Kuwahara, M., Matsumura, N., Shimizu, T., Sugano, S. and Karaki, H.
Antihypertensive effect of angiotensin I-converting enzyme inhibitory peptides derived from hemoglobin (304) 93
Mitolo-Chieppa, D., Serio, M., Potenza, M.A., Montagnani, M., Mansi, G., Pece, S., Jirillo, E. and Stoclet, J.-C.
Hyporeactivity of mesenteric vascular bed in endotoxin-treated rats (309) 175
Mitsiades, N.S., see Stratakis, C.A. (315) 53
Mitsui-Saito, M., see Trongvanichnam, K. (303) 39
Mitsui-Saito, M., see Trongvanichnam, K. (314) 83
Miura, H., see Hiyoshi, Y. (294) 117
Miura, M., see Asano, M. (294) 693
Miura, M., see Goto, Y. (314) 185
Miwa, I., see Murakami, N. (304) 129
Miwa, Y., see Koshikawa, N. (308) 227
Miyake, A., see Akuzawa, S. (296) 227
Miyamae, T., Yue, J.-L., Goshima, Y. and Misu, Y.
Depressor action of L-*threo*-dihydroxyphenylserine in the rat nucleus tractus solitarii (300) 105
Miyamae, T., see Goshima, Y. (309) 229
Miyamoto, S., see Muramatsu, I. (300) 155
Miyata, K., see Akuzawa, S. (296) 227
Miyata, K., see Nagakura, Y. (311) 67
Miyata, S., Haneda, T., Osaki, J. and Kikuchi, K.
Renin-angiotensin system in stretch-induced hypertrophy of cultured neonatal rat heart cells (307) 81
Miyauchi, T., Tomobe, Y., Ishikawa, T., Goto, K. and Sugishita, Y.
Vasoconstriction by endothelin-1 in resistance and conduit portions of isolated human mesenteric arteries (303) 193
Miyayasu, K., see Yasumitsu, R. (300) 215
Mizhorkova, Z., see Kortezova, N. (304) 109
Mizoguchi, H., Narita, M., Kampine, J.P. and Tseng, L.F.
Pretreatment with pertussis toxin spinally, but not supraspinally, blocks the cold water swimming-induced antinociception in the mouse (309) 37
Mizoguchi, H., see Narita, M. (310) R1
Mizoguchi, K., see Tanaka, T. (297) 35
Mizota, M., see Murakami, N. (304) 129
Mizuchi, A., see Wada, T. (312) 263
Mizumoto, A., see Tamura, T. (308) 315
Mo, L.-L., see Souverbie, F. (307) 347
Mocaër, E., see Ying, S.-W. (296) 33
Modi, P.I., Kashyap, A., Nair, V.D., Ross, G.M., Fu, M., Savelli, J.E., Marcotte, E.R., Barlas, C. and Mishra, R.K.
Modulation of brain catecholamine absorbing proteins by dopaminergic agents (299) 213
Modin, A., see Malmström, R.E. (305) 145
Mohell, N., see Malmberg, Å. (303) 123
Mohell, N., see Yu, H. (303) 151
Mohr, K., see Kostenis, E. (314) 385
Mohr, K., see Maaß, A. (305) 231
Molat, J.-L., see Dallel, R. (314) 19
Molière, P., see Delton-Vandenbroucke, I. (312) 379
Molimard, M., see Biyah, K. (308) 325
Molina-Holgado, F., Amaro, A., González, M.I., Alvarez, F.J. and Leret, M.L.
Effect of maternal Δ^9-tetrahydrocannabinol on developing serotonergic system (316) 39
Molina, V., see Zurita, A. (299) 1
Molinari, E.J., North, P.C. and Dubocovich, M.L.
2-[^{125}I]Iodo-5-methoxycarbonylamino-*N*-acetyltryptamine: a selective radioligand for the characterization of melatonin ML_2 binding sites (301) 159
Molnár, P. and Erdő, S.L.
Differential effects of five glycine site antagonists on NMDA receptor desensitisation (311) 311
Molnár, P., see Erdő, S.L. (314) 69
Moltzen, E., see Sánchez, C. (315) 245
Moltzen, E.K., see Sánchez, C. (297) 1
Momiyama, T., Amano, T., Todo, N. and Sasa, M.
Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area (310) 1
Monahan, M.E., see Rizzo, C.A. (294) 329
Monassier, L., Tibiriça, E., Roegel, J.-C., Feldman, J. and Bousquet, P.
MK-801 and memantine inhibit a centrally induced increase in myocardial oxygen demand in rabbits (305) 109
Monge, L., see Fernández, N. (294) 483
Monge, L., see García, J.L. (315) 179
Monier, C., see Francès, H. (298) 217
Monneret, V., see Bolaños-Jiménez, F. (294) 531
Monnier, L., see Etienne, P. (311) 79
Monstein, H.-J., see Wang, Z.-Y. (297) 157
Montagnani, M., see Mitolo-Chieppa, D. (309) 175
Monteau, R., Ptak, K., Broquère, N. and Hilaire, G.
Tachykinins and central respiratory activity: an in vitro study on the newborn rat (314) 41
Montenez, J.-P., Van Bambeke, F., Piret, J., Schanck, A., Brasseur, R.,

Tulkens, P.M. and Mingeot-Leclercq, M.-P.
Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies (314) 215
Montenez, J.-P., see Van Bambeke, F. (314) 203
Montuschi, P., Currò, D. and Ciabattoni, G.
Tachykinin NK_2 receptor antagonists decrease eicosanoid release in lung anaphylaxis (313) R1
Moochhala, S.M., Hon, W.-M., Chhatwal, V.J.S. and Khoo, H.-E.
Expression of inducible nitric oxide synthase in mice: Pharmacological evaluation of adenosine receptor agonists (316) 287
Moor, E., DeBoer, P., Auth, F. and Westerink, B.H.C.
Characterisation of muscarinic autoreceptors in the septo-hippocampal system of the rat: a microdialysis study (294) 155
Moore, C.X., see Vine, W. (314) 115
Moore, K.A., Mirshahi, T., Compton, D.R., Poklis, A. and Woodward, J.J.
Pharmacological characterization of BNMPA (α-benzyl-*N*-methylphenethylamine), an impurity of illicit methamphetamine synthesis (311) 133
Moore, K.E., see Eaton, M.J. (299) 171
Morain, P., see Delagrange, P. (316) 195
Morales, A., see Torres, C. (314) 269
Morales-Villagrán, A., Ureña-Guerrero, M.E. and Tapia, R.
Protection by NMDA receptor antagonists against seizures induced by intracerebral administration of 4-aminopyridine (305) 87
Moran, R.J., see Balfour, D.J.K. (316) 153
Moreau, J.-L., see Lundkvist, J. (309) 195
Moreau, R., see Pilette, C. (312) 63
Morel, E., see Sanger, D.J. (313) 35
Moreland, R.S., Lichtenstein, A.H. and Chobanian, A.V.
Effects of hypertension on hypercholesterolemia-induced changes in contraction of rabbit aorta and carotid artery (307) 55
Moreno, J.J.
Antiflammin-2, a nonapeptide of lipocortin-1, inhibits leukocyte chemotaxis but not arachidonic acid mobilization (314) 129
Moreno Jr., H., see Costa, S.K.P. (298) 113
Moret, C. and Briley, M.
Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain (295) 189
Morgan, J.P., see Meissner, A. (316) 333
Morgan, M.E., see Musser, B. (308) 357
Morgenstern, H., see Glass-Marmor, L. (313) 265
Mori, A., see Yoshida, A. (312) 115
Mori, K., see Hotta, N. (313) 201
Mori, K., see Nakamura, J. (294) 207
Mori, M., see Ikeuchi, Y. (304) 191
Mori, M., see Mita, Y. (297) 121
Mori, T., see Fujiki, H. (313) 191
Morikawa, K., see Ohashi, T. (307) 315
Morimoto, K., see Hada, J. (305) 101
Morin, C., see Sapena, R. (300) 159
Morin, D., see Deprés-Brummer, P. (312) 171
Morin, D., see Sapena, R. (300) 159
Morioka, H., see Takada, Y. (308) 205
Morishita, M., Sakamoto, T., Ito, K. and Torii, S.
Role of bradykinin B_2 receptors and mast cells in the bradykinin-induced skin response in the rat (298) 149
Morishita, M., see Ito, K. (307) 291
Morisset, S., Traiffort, E. and Schwartz, J.-C.
Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity (315) R1
Morita, K., see Kamei, J. (300) 75
Morita, K., see Kamei, J. (312) 235
Morita, K., see Kitayama, S. (309) 107
Mørk, A., see Petersen, B. (300) 67
Morley, J.E., Farr, S.A. and Flood, J.F.
Isatin inhibits food intake in mice (305) 23
Morley, J.E., Kumar, V.B., Mattammal, M.B., Farr, S., Morley, P.M.K. and Flood, J.F.
Inhibition of feeding by a nitric oxide synthase inhibitor: effects of aging (311) 15
Morley, P.M.K., see Morley, J.E. (311) 15
Moro, M., see Pérez-Vizcaíno, F. (314) 91
Moro, M.A., see Lizasoain, I. (299) 41
Moroji, T., see Sagi, N. (304) 185
Morot Gaudry-Talarmain, Y. and Moulian, N.
Cyclosporin A affects functions concerning acetylcholine release of cholinergic *Torpedo* synaptosomes (296) 341
Morse, P.A., see Buckner, S.A. (297) 241
Moryl, E., see Papp, M. (296) 129
Moryl, E., see Papp, M. (310) 99
Moryl, E., see Papp, M. (316) 145
Moshé, S.L., see Velíšková, J. (309) 167
Motohashi, N., see Takebayashi, M. (297) 137
Motte, S., Swillens, S. and Boeynaems, J.-M.
Evidence that most high-affinity ATP binding sites on aortic endothelial cells and membranes do not correspond to P_2 receptors (307) 201
Mottola, L., see Nicoletti, F. (311) 213
Moulian, N., see Morot Gaudry-Talarmain, Y. (296) 341
Mousa, S.A., Schäfer, M., Mitchell, W.M., Hassan, A.H.S. and Stein, C.
Local upregulation of corticotropin-releasing hormone and interleukin-1 receptors in rats with painful hindlimb inflammation (311) 221
Mousseau, D.D., Rao, V.L.R. and Butterworth, R.F.
Na^+,K^+-ATPase activity is selectively increased in thalamus in thiamine deficiency prior to the appearance of neurological symptoms (300) 191
Mózsik, G., see Abdel Salam, O.M.E. (305) 127
Mršić, J., see Župan, G. (310) 103
Muceniece, R., see Schiöth, H.B. (314) 381
Muggli, R., see McLennan, P. (300) 83
Mukherjee, K., see Parkinson, F.E. (308) 97
Mulder, A.H., see De Vries, T.J. (307) R3
Mulder, A.H., see Nestby, P. (294) 771
Mullany, P., Connolly, S. and Lynch, M.A.
Ageing is associated with changes in glutamate release, protein tyrosine kinase and Ca^{2+}/calmodulin-dependent protein kinase II in rat hippocampus (309) 311
Müller, E.E., see De Gennaro Colonna, V. (314) 333
Müller-Esterl, W., see Jahns, R. (316) 111
Müller-Esterl, W., see Murone, C. (306) 237
Muller, M.J., see Hogaboam, C.M. (309) 261
Munakata, M., see Nasuhara, Y. (296) 161
Munaro, N., see Navarro Becerra, N. (312) 83
Munekata, E., see Emaduddin, M. (302) 129
Muntoni, A.L., Diana, M. and Gessa, G.L.
Repeated naltrexone administration accelerates resolution of morphine somatic withdrawal signs in morphine-dependent rats (301) R9
Muntoni, A.L., see Diana, M. (312) 179
Murakami, N., Ohta, M., Hashimoto, K., Kato, K., Mizota, M., Miwa, I., Okuda, J., Inoue, G., Kuzuya, H., Nakao, K. and Imura, H.
Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent (304) 129
Murakami, Y., see Hattori, Y. (300) 147
Muraki, K., see Henmi, S. (306) 227
Muraki, T., see Fujii, E. (297) 257
Muraki, T., see Fujii, E. (313) 129
Muramatsu, I., Takita, M., Suzuki, F., Miyamoto, S., Sakamoto, S. and Ohmura, T.
Subtype selectivity of a new α_1-adrenoceptor antagonist, JTH-601: comparison with prazosin (300) 155
Muramatsu, I., see Nishio, M. (297) 293
Murata, K., see Takahashi, T. (295) 229
Murata, S., see Yamagishi, R. (315) 73

Murayama, T., see Yakushi, Y. (314) 243
Murohara, T., see Scalia, R. (296) 181
Murone, C., Perich, R.B., Schlawe, I., Chai, S.Y., Casley, D., MacGregor, D.P., Müller-Esterl, W. and Mendelsohn, F.A.O.
Characterization and localization of bradykinin B_2 receptors in the guinea-pig using a radioiodinated HOE140 analogue (306) 237
Murphy, D.L., see Mazzola-Pomietto, P. (308) 329
Murray, T.F., see Musser, B. (308) 357
Murrell, G.A.C., see Jang, D. (312) 341
Murúa, S., see Zurita, A. (299) 1
Musser, B., Morgan, M.E., Leid, M., Murray, T.F., Linden, J. and Vestal, R.E.
Corrigendum to 'Species comparison of adenosine and β-adrenoceptors in mammalian atrial and ventricular myocardium'. [Eur. J. Pharmacol. Mol. Pharmacol. Sect. 246 (1993) 105–111] (308) 357
Mutin, A., see Lahti, R.A. (301) R11
Muto, S., see Iimura, O. (296) 319
Mutoh, Y., see Osajima, A. (315) 319
Mutschler, E., see Waelbroeck, M. (303) 221
Myers, J., see Hogg, J.E. (312) 257
Mylecharane, E.J., see Gillies, D.M. (303) 1

Naassila, M., Roux, F., Beaugé, F. and Daoust, M.
Ethanol potentiates lipopolysaccharide- or interleukin-1β-induced nitric oxide generation in RBE4 cells (313) 273
Nabata, H., see Tamura, K. (312) 195
Nabeshima, T., see Kamei, H. (299) 21
Nabeshima, T., see Kamei, H. (309) 149
Nabeshima, T., see Nitta, A. (307) 1
Nadel, J.A., see Yoshihara, S. (296) 291
Nagai, K., see Hada, J. (305) 101
Nagai, Y., see Nakayama, T. (316) 157
Nagakura, Y., Naitoh, Y., Kamato, T., Yamano, M. and Miyata, K.
Compounds possessing 5-HT_3 receptor antagonistic activity inhibit intestinal propulsion in mice (311) 67
Nagamatsu, T., see Hayashi, K. (316) 297
Nagamatsu, T., see Nagao, T. (316) 73
Nagao, T., Nagamatsu, T. and Suzuki, Y.
Effect of DP-1904, a thromboxane A_2 synthase inhibitor, on passive Heymann nephritis in rats (316) 73
Nagao, T., see Kusayama, T. (312) 301
Nagao, T., see Sato, Y. (315) 363
Nagao, T., see Shimasue, K. (296) 347
Nagasaki, M., see Taniguchi, H. (304) 147
Nagasaki, M., see Taniguchi, H. (312) 227
Nagase, H., see Kamei, J. (300) 75
Nagase, H., see Tsuda, M. (307) 7
Nagashima, Y., see Yonezawa, T. (315) 289
Nagatani, T., see Takao, K. (294) 721
Nagumo, H., see Asano, M. (294) 693
Nagy, I., see Szilvassy, Z. (301) R17
Nagy, J.I., see Padua, R.A. (298) 185
Nahori, M.-A., see De Castro, C.M.M.B. (294) 669
Nair, R. and Dyer, D.C.
Pharmacological characterization of α_1-adrenoceptors in porcine uterine artery (312) 45
Nair, V.D., see Modi, P.I. (299) 213
Naito, Y., Yoshikawa, T., Matsuyama, K., Yagi, N., Arai, M., Nakamura, Y., Kaneko, T., Yoshida, N. and Kondo, M.
Effect of a novel histamine H_2 receptor antagonist, IT-066, on acute gastric injury induced by ischemia-reperfusion in rats, and its antioxidative properties (294) 47
Naitoh, Y., see Nagakura, Y. (311) 67
Najim, R., see Khadour, F. (298) 271
Nakagawa, T., see Katsumata, S. (312) 349
Nakagawa, Y., see Tsuji, M. (313) 169
Nakahara, K., see Yamamoto, N. (314) 137
Nakahara, Y., see Kuribara, H. (305) 1
Nakahata, N., see Ohkubo, S. (298) 175
Nakahata, N., see Tsukii, K. (298) 87
Nakajima, T., Kitazawa, T., Hamada, E., Hazama, H., Omata, M. and Kurachi, Y.
17β-Estradiol inhibits the voltage-dependent L-type Ca^{2+} currents in aortic smooth muscle cells (294) 625
Nakamoto, K., see Wada, K. (294) 377
Nakamoto, K., see Wada, K. (296) 335
Nakamura, H., see Ishizuka, T. (312) 367
Nakamura, J., Koh, N., Sakakibara, F., Hamada, Y., Wakao, T., Hara, T., Mori, K., Nakashima, E., Naruse, K. and Hotta, N.
Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats (294) 207
Nakamura, J., see Hotta, N. (311) 199
Nakamura, J., see Hotta, N. (313) 201
Nakamura, M., see Ishibashi, T. (303) 247
Nakamura, S., see Goshima, Y. (309) 229
Nakamura, S., see Yamagishi, R. (315) 73
Nakamura, Y., see Naito, Y. (294) 47
Nakane, T., see Ren, L.-M. (295) 61
Nakanishi, N., see Hattori, Y. (296) 107
Nakao, K., see Murakami, N. (304) 129
Nakashima, E., see Nakamura, J. (294) 207
Nakashima, M., see Kikuchi, S. (295) 221
Nakata, H., see Nishio, E. (301) 203
Nakata, K., see Senda, T. (315) 1
Nakatani, K., Kawanabe, Y., Kato, A. and Tanaka, T.
Interaction of propranolol with S100 proteins of the cardiac muscle (315) 335
Nakayama, T., Hashimoto, T. and Nagai, Y.
Involvement of glutamate and γ-aminobutyric acid (GABA)-ergic systems in thyrotropin-releasing hormone-induced rat cerebellar cGMP formation (316) 157
Nakazato, Y., see Tabo, M. (313) 151
Nakazawa, K. and Ohno, Y.
Dopamine and 5-hydroxytryptamine selectively potentiate neuronal type ATP receptor channels (296) 119
Nakazawa, K., see Ito, K. (314) 143
Nakazawa, M., see Matsuno, K. (306) 271
Nakazawa, T., see Mita, Y. (297) 121
Namer, I.J., see Petty, M.A. (307) 149
Namovic, M.T., Walsh, R.E., Goodfellow, C., Harris, R.R., Carter, G.W. and Bell, R.L.
Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats (315) 81
Naraba, H., Ueno, A., Matsumoto, H. and Oh-ishi, S.
Inhibitory effect of arachidonic acid on platelet-activating factor production in rat neutrophils (302) 117
Narihara, H., see Ohkuma, S. (301) 179
Narita, M., Dun, S.L., Dun, N.J. and Tseng, L.F.
Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord (311) 121
Narita, M., Mizoguchi, H. and Tseng, L.F.
Phorbol ester blocks the increase of a high affinity GTPase activity induced by δ_2-opioid receptor agonist in the mouse spinal cord (310) R1
Narita, M., see Mizoguchi, H. (309) 37
Narita, N., Hashimoto, K., Tomitaka, S.-i. and Minabe, Y.
Interactions of selective serotonin reuptake inhibitors with subtypes of σ receptors in rat brain (307) 117
Naruse, K., see Hotta, N. (313) 201
Naruse, K., see Nakamura, J. (294) 207
Nash, J.E., see Maneuf, Y.P. (308) 161
Nasuhara, Y., Munakata, M., Sato, A., Amishima, M., Homma, Y. and Kawakami, Y.
Mechanisms of epidermal growth factor-induced contraction of guinea pig airways (296) 161
Natale, G., see Blandizzi, C. (294) 191

Nathan, N., see Aïssa, J. (302) 123
Naumenko, N.V., see Urazaev, A.Kh. (316) 219
Nava, F., Calapai, G., De Sarro, A. and Caputi, A.P.
Interleukin-1 receptor antagonist does not reverse lipopolysaccharide-induced inhibition of water intake in rat (309) 223
Navajas, C., Kokkola, T., Poso, A., Honka, N., Gynther, J. and Laitinen, J.T.
A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor (304) 173
Navarro Becerra, N., Grigorjev, C. and Munaro, N.
Glutamic acid decarboxylase in rat olfactory bulb: effect of ovarian steroids or male pheromones (312) 83
Nawada, T., see Yoshida, A. (312) 115
Neff, N.H., see Cho, S. (314) 51
Negri, L., Noviello, L. and Noviello, V.
Antinociceptive and behavioral effects of synthetic deltorphin analogs (296) 9
Negus, S.S., see Gatch, M.B. (298) 31
Negus, S.S., see Gatch, M.B. (312) 389
Neisewander, J.L., Castañeda, E., Davis, D.A., Elson, H.J. and Sussman, A.N.
Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia (305) 13
Nekooeian, A.A. and Tabrizchi, R.
Effects of adenosine A_{2A} receptor agonist, CGS 21680, on blood pressure, cardiac index and arterial conductance in anaesthetized rats (307) 163
Nelemans, A., see Henning, R.H. (301) 91
Nelemans, A., see Sipma, H. (305) 207
Nelemans, A., see Sipma, H. (306) 187
Néliat, G., see Heuillet, E. (314) 229
Nelissen-Vrancken, H.J.M.G., see Brouwers-Ceiler, D.L. (307) 65
Nestby, P., Tjon, G.H.K., Visser, D.T.M., Drukarch, B., Leysen, J.E., Mulder, A.H. and Schoffelmeer, A.N.M.
Intermittent morphine treatment causes long-term desensitization of functional dopamine D_2 receptors in rat striatum (294) 771
Nestby, P., see De Vries, T.J. (307) R3
Neugebauer, V., see Calò, G. (311) R3
Neuhaus, T., see Weber, A.-A. (309) 209
Neumann, J., Kaspareit, G., Kirchhefer, U. and Scholz, H.
Sodium fluoride attenuates the negative inotropic effects of muscarinic M_2 and adenosine receptor agonists (294) 451
Neumann, V., Norris, B., Concha, J. and Contreras, E.
Influence of nitric oxide on transepithelial transport in toad skin: effects of cholinergic agents and morphine (316) 123
Nève, J., see Parij, N. (311) 259
Newman, A.H., see Izenwasser, S. (297) 9
Newman-Tancredi, A., Chaput, C., Verrièle, L. and Millan, M.J.
S 15535 and WAY 100,635 antagonise 5-HT-stimulated [^{35}S]GTPγS binding at cloned human 5-HT_{1A} receptors (307) 107
Ng, G.Y.K., O'Dowd, B.F. and George, S.R.
Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice (311) 45
Ngan, M.-p., see Yiu, M.-k. (302) 99
Nguyen, V.H., Kassiou, M., Johnston, G.A.R. and Christie, M.J.
Comparison of binding parameters of σ_1 and σ_2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes (311) 233
Nichols, D.E., see Cozzi, N.V. (309) 25
Nickenig, G., Sachinidis, A., Ko, Y. and Vetter, H.
Regulation of angiotensin AT_1 receptor gene expression during cell growth of vascular smooth muscle cells (297) 307
Nicoletti, F., Borghi, M.O., Barcellini, W., Fain, C., Beltrami, B., Del Papa, N., Schorlemmer, H.U., Mottola, L. and Meroni, P.L.
Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells (311) 213
Nicoletti, F., see Bruno, V. (310) 61
Nihonyanagi, K. and Oba, T.
Gold ion inhibits silver ion induced contracture and activates ryanodine receptors in skeletal muscle (311) 271
Niihashi, M., see Bandoh, T. (315) 37
Nijkamp, F.P., see Sadeghi-Hashjin, G. (302) 109
Niki, I., see Yasui, K. (316) 317
Nikolsky, E.E., see Urazaev, A.Kh. (316) 219
Nilsson, L., see Bergdahl, A. (316) 59
Nilsson, S., see Szallasi, A. (298) 321
Nilsson, T., see Bergdahl, A. (316) 59
Ninomiya, T., see Tanabe, T. (299) 187
Nisato, D., see Barthelmebs, M. (314) 325
Nishi, K., see Saito, M. (310) 197
Nishi, N., see Odagaki, Y. (300) 151
Nishida, S., see Kishioka, S. (316) 7
Nishikawa, M., see Mak, J.C.W. (302) 215
Nishimura, J., see Jahan, H. (295) 261
Nishimura, M., see Sato, N. (314) 373
Nishino, S., see Hirasawa, Y. (303) 55
Nishio, E., Tomiyama, K., Nakata, H. and Watanabe, Y.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell differentiation in cultured adipogenic cells (3T3-L1) (301) 203
Nishio, M., Muramatsu, I. and Yasumoto, T.
Na^+-permeable channels induced by maitotoxin in guinea-pig single ventricular cells (297) 293
Nishiwaki, K., see Hirabayashi, A. (296) 297
Nishiyori, A., see Yabuuchi, K. (300) 59
Nishizaki, T., see Ikeuchi, Y. (302) 163
Nishizaki, T., see Ikeuchi, Y. (304) 191
Nissinen, J., see Halonen, T. (299) 69
Nisticò, G., see Bagetta, G. (294) 341
Nisticò, G., see Melchiorri, D. (305) 239
Nitta, A., Ogihara, Y., Onishi, J., Hasegawa, T., Furukawa, S. and Nabeshima, T.
Propentofylline prevents neuronal dysfunction induced by infusion of anti-nerve growth factor antibody into the rat septum (307) 1
Niwa, M., see Chowdhury, S.A. (314) 313
Noguchi, K., Masumiya, H., Sasaki, T., Takahashi, K., Araki, H., Higuchi, S., Tanaka, H. and Shigenobu, K.
Relative selectivity for negative chronotropic and inotropic effects of a novel dihydropyridine derivative, CD-832 (308) 53
Noma, T., see Sugimoto, Y. (316) 15
Nomikos, G.G., see Mathé, J.M. (309) 1
Nomura, Y., see Asano, M. (311) 53
Nomura, Y., see Kitamura, Y. (306) 297
Nomura, Y., see Yakushi, Y. (314) 243
Nooney, J.M. and Lodge, D.
The use of invertebrate peptide toxins to establish Ca^{2+} channel identity of CA3-CA1 neurotransmission in rat hippocampal slices (306) 41
Normandin, D.E., see D'Alonzo, A.J. (294) 271
Norota, I., see Yang, H.-T. (296) 47
Norris, B., see Neumann, V. (316) 123
North, P.C., see Molinari, E.J. (301) 159
Nosálová, V., see Mai, M.P. (315) 305
Noviello, L., see Negri, L. (296) 9
Noviello, V., see Negri, L. (296) 9
Nowak, D., see McLaughlin, J.P. (294) 201
Nowak, G., Li, Y. and Paul, I.A.
Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment (295) 75
Nozoe, S., see Chairungsrilerd, N. (314) 351
Numazawa, R., see Yoshioka, M. (294) 565
Numazawa, T., see Kamata, K. (298) 129
Numazawa, T., see Kamata, K. (301) 121
Nunes, M.L., see Velíšková, J. (309) 167
Nunley, K.R., see Szabó, G. (306) 67

Nurmi, M., Ashizawa, T., Sinclair, J.D. and Kiianmaa, K.
Effect of prior ethanol experience on dopamine overflow in accumbens of AA and ANA rats (315) 277
Nutt, D.J., see Lione, L.A. (304) 221
Nutt, D.J., see Reynolds, G.P. (301) R19
Nylander, I., see Tan-No, K. (314) 61

Oba, T., see Nihonyanagi, K. (311) 271
Obinu, M.C., see Imperato, A. (302) 21
O'Brien, E., see Wanstall, J.C. (303) 71
O'Callaghan, D., see Cheung, N.S. (313) 159
Ochocki, J., see Brzezińska-Błaszczyk, E. (298) 155
O'Connell, M.T. and Curzon, G.
A comparison of the effects of 8-OH-DPAT pretreatment on different behavioural responses to 8-OH-DPAT (312) 137
O'Connor, S.E., see Choppin, A. (304) 87
O'Connor, W.T., see Ferraro, L. (306) 33
Oda, M., see Yamamoto, N. (297) 225
Odagaki, Y., Nishi, N. and Koyama, T.
Functional coupling between metabotropic glutamate receptors and G proteins in rat brain membranes (300) 151
Odièvre, C., see Vaugeois, J.-M. (316) R1
O'Dowd, B.F., see Ng, G.Y.K. (311) 45
Oehme, P., see Krause, W. (302) 223
Ogawa, A., see Fujii, E. (297) 257
Ogawa, A., see Fujii, E. (313) 129
Ogawa, R., see Cai, M. (295) 215
Ogawa, R., see Tanabe, T. (299) 187
Ogawa, R., see Tanabe, T. (314) 175
Ogihara, Y., see Nitta, A. (307) 1
Ogino, Y., Tanaka, K. and Shimizu, N.
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells (316) 105
O'Grady, S.M., see Sprunger, L.K. (314) 357
Oh-ishi, S., Utsunomiya, I., Yamamoto, T., Komuro, Y. and Hara, Y.
Effects of prostaglandins and cyclic AMP on cytokine production in rat leukocytes (300) 255
Oh-ishi, S., see Naraba, H. (302) 117
Ohashi, H., Tanaka, K., Kiuchi, N., Unno, T. and Komori, S.
Modulation of peristalsis by neurotensin in isolated guinea-pig intestinal segments (301) 129
Ohashi, T., Hashimoto, S., Morikawa, K., Kato, H., Ito, Y., Asano, M. and Azuma, H.
Potent inhibition of spontaneous rhythmic contraction by a novel β_2-adrenoceptor agonist, HSR-81, in pregnant rat uterus (307) 315
Ohba, K.-i., see Fujii, E. (297) 257
Ohba, K.-i., see Fujii, E. (313) 129
Ohba, Y., see Woo, J.-T. (300) 131
Oheim, K.W., see Buckner, S.A. (297) 241
Ohizumi, Y., Sasaki, S., Kusumi, T. and Ohtani, I.I.
Ptilomycalin A, a novel Na^+,K^+- or Ca^{2+}-ATPase inhibitor, competitively interacts with ATP at its binding site (310) 95
Ohizumi, Y., see Chairungsrilerd, N. (314) 351
Ohizumi, Y., see Ohkubo, S. (298) 175
Ohizumi, Y., see Tsukii, K. (298) 87
Ohkubo, S., Nakahata, N. and Ohizumi, Y.
ML-7 and W-7 facilitate thromboxane A_2-mediated Ca^{2+} mobilization in rabbit platelets (298) 175
Ohkuma, S., Katsura, M., Guo, J.-L., Narihara, H., Hasegawa, T. and Kuriyama, K.
Role of peroxynitrite in [^{3}H]γ-aminobutyric acid release evoked by nitric oxide and its mechanism (301) 179
Ohkuma, S., see Katsura, M. (298) 71
Ohmori, T., see Inoue, T. (311) 1
Ohmori, T., see Izumi, T. (300) 25
Ohmura, T., see Muramatsu, I. (300) 155
Ohno, H., see Takahashi, Y. (302) 89
Ohno, M. and Watanabe, S.
Interactive processing between glutamatergic and cholinergic systems involved in inhibitory avoidance learning of rats (312) 145
Ohno, M., Yoshimatsu, A., Kobayashi, M. and Watanabe, S.
β-Adrenergic dysfunction exacerbates impairment of working memory induced by hippocampal NMDA receptor blockade in rats (307) 21
Ohno, M., see Hirasawa, Y. (303) 55
Ohno, Y., see Ishibashi, T. (303) 247
Ohno, Y., see Ito, K. (314) 143
Ohno, Y., see Nakazawa, K. (296) 119
Ohoi, I. and Takeo, S.
Involvement of superoxide and nitric oxide in the genesis of reperfusion arrhythmias in rats (306) 123
Ohshima, N., see Hisamichi, N. (312) 69
Ohta, M., see Murakami, N. (304) 129
Ohta, T., see Chairungsrilerd, N. (314) 351
Ohta, T., see Tabo, M. (313) 151
Ohtani, I.I., see Ohizumi, Y. (310) 95
Oiry, C., Galleyrand, J.-C., Lima-Leite, A.-C., Fulcrand, P. and Martinez, J.
Are C-terminal octapeptide of cholecystokinin and [Leu^{11}]gastrin-(5–17) different in stimulating acid secretion in isolated rabbit gastric glands? (294) 511
Okada, F., Saito, H. and Matsuki, N.
Prophylactic effect of serotonin uptake inhibitors against motion sickness in *Suncus murinus* (309) 33
Okada, M., Kohara, A. and Yamaguchi, T.
Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected *Xenopus* oocytes (309) 299
Okada, Y., see Ikeuchi, Y. (304) 191
Okamoto, K., see Matsuno, K. (306) 271
Okamoto, K., see Senda, T. (315) 1
Okamura, T., see Zhang, J.-X. (311) 169
Okuda, J., see Murakami, N. (304) 129
Okuhara, M., see Yamamoto, N. (314) 137
Okunishi, H., see Matsubara, K. (315) 145
Okuyama, S., see Sagi, N. (304) 185
Olds, M.E.
Dopaminergic basis for the facilitation of brain stimulation reward by the NMDA receptor antagonist, MK-801 (306) 23
Oles, R.J., see Singh, L. (307) 283
Oliverio, A., see Mele, A. (308) 1
Olivier, B., see Zethof, T.J.J. (294) 125
Olmos, G., Ribera, J. and García-Sevilla, J.A.
Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain (310) 273
Olsen, R.W., see Huh, K.-H. (310) 225
O'Malley, S.S., see Chang, R.S.L. (294) 429
Omata, M., see Nakajima, T. (294) 625
Ondeyka, D., see Chang, R.S.L. (294) 429
Ondeyka, D.L., see Kivlighn, S.D. (294) 439
O'Neill, A.B., see Brioni, J.D. (301) 1
O'Neill, M.J., Hicks, C. and Ward, M.
Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia (310) 115
O'Neill, M.J., see Bath, C.P. (299) 103
Ong, J., see Kerr, D.I.B. (294) 349
Ong, J., see Kerr, D.I.B. (308) R1
Ongini, E., see Adami, M. (294) 383
Ongini, E., see Taglialatela, M. (316) 373
Onishi, J., see Nitta, A. (307) 1
Ono, H., see Hasegawa, Y. (295) 211
Ono, H., see Kobayashi, H. (311) 29
Ono, H., see Wada, T. (312) 263
Orallo, F., see Gil-Longo, J. (310) 175

Orre, M., Pennefather, J.N., Story, M.E. and Haynes, J.M.
The effects of P_2 purinoceptor agonists on the isolated portal vein of the guinea pig (316) 229
Orsini, J.-C., see Himmi, T. (312) 273
Orzi, F., Passarelli, F., La Riccia, M., Di Grezia, R. and Pontieri, F.E.
Intravenous morphine increases glucose utilization in the shell of the rat nucleus accumbens (302) 49
Osajima, A., Uezono, Y., Tamura, M., Kitamura, K., Mutoh, Y., Ueta, Y., Kangawa, K., Kawamura, M., Eto, T., Yamashita, H., Izumi, F., Takasugi, M. and Kuroiwa, A.
Adrenomedullin-sensitive receptors are preferentially expressed in cultured rat mesangial cells (315) 319
Osaki, J., see Miyata, S. (307) 81
Osborne, M.P., see Spencer, A.J. (303) 205
O'Shaughnessy, C.T., see Brown, J.D. (311) 305
Osman, S., see Pike, V.W. (301) R5
Ossowska, K.
The subsensitivity of striatal glutamate receptors induced by chronic haloperidol in rats (294) 685
Otani, H., see Tanabe, T. (299) 187
Otani, H., see Tanabe, T. (314) 175
Otsu, T., see Wada, T. (312) 263
Otsuki, S., see Ujike, H. (296) 123
Ott, C., see Grider, J. (313) 115
Ouagazzal, A. and Amalric, M.
Competitive NMDA receptor antagonists do not produce locomotor hyperactivity by a dopamine-dependent mechanism (294) 137
Ouedraogo, R., see Antoine, M.-H. (313) 229
Owen, D.G., see Garratt, J.C. (314) 393
Ozaki, H., see Trongvanichnam, K. (303) 39
Ozaki, H., see Trongvanichnam, K. (314) 83
Ozawa, K., see Hiyoshi, Y. (294) 117
Ozawa, Y., Komai, C., Sakitama, K. and Ishikawa, M.
Effects of NK433, a new centrally acting muscle relaxant, on masticatory muscle reflexes in rats (298) 57

Paban, V., see Alescio-Lautier, B. (294) 763
Padovano, R., see Santini, G. (316) 65
Padua, R.A., Nagy, J.I. and Geiger, J.D.
Subcellular localization of ryanodine receptors in rat brain (298) 185
Pagani, E.D., see De Garavilla, L. (313) 89
Pagel, P.S., see Hettrick, D.A. (316) 237
Pagel, P.S., see Lowe, D. (304) 81
Pairault, J., see El Hadri, K. (297) 107
Palacios, B., Cheng, X. and Pang, C.C.Y.
Reversal of in vitro lipopolysaccharide-induced suppression of contraction in rat aorta by N^G-nitro-arginine, diphenyleneiodonium and di-2-thienyliodonium (296) 75
Palacios, I., see Gutierrez, S. (302) 191
Palacios, J.M., see Cardelús, I. (299) 153
Palacios, J.M., see Silvestre, J.S. (309) 219
Paladini, E., see Braida, D. (302) 13
Palermo-Neto, J., see Bellot, R.G. (313) 175
Palkovits, M., see Varga, K. (310) 145
Pallàs, M., see Pubill, D. (303) 171
Palmer, S., Di Bello, S. and Herzig, J.W.
The effects of EMD 57033 on rigor tension in porcine skinned cardiac trabecula (294) 83
Panara, M.R., see Santini, G. (316) 65
Panerai, A.E., see Bianchi, M. (294) 71
Pang, C.C.Y., see Palacios, B. (296) 75
Panizzon, K., see Girard, J. (300) 43
Panizzon, K.L., see Wallis, R.A. (294) 475
Paoletti, A.M., see Bagetta, G. (294) 341
Papasova, M., see Kortezova, N. (304) 109
Papp, M. and Moryl, E.
Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression (316) 145
Papp, M., Moryl, E. and Willner, P.
Corrigendum to 'Pharmacological validation of the chronic mild stress model of depression' [Eur. J. Pharmacol. 296 (1996) 129–136] (310) 99
Papp, M., Moryl, E. and Willner, P.
Pharmacological validation of the chronic mild stress model of depression (296) 129
Paquet, J.-L., see Pruneau, D. (297) 53
Paradise, J., see Jinsi, A. (302) 183
Parés-Herbuté, N., see Etienne, P. (311) 79
Parij, N. and Nève, J.
Nonsteroidal antiinflammatory drugs interact with horseradish peroxidase in an in vitro assay system for hydrogen peroxide scavenging (311) 259
Parini, A., see Coupry, I. (295) 109
Park, T.-J., see Suh, B.-C. (314) 235
Parkinson, F.E., Mukherjee, K. and Geiger, J.D.
[^{3}H]Adenosine transport in DDT_1 MF-2 smooth muscle cells: inhibition by metabolites of propentofylline (308) 97
Parlani, M., see Goso, C. (294) 239
Parolaro, D., see Costa, B. (313) 17
Paroni, R., De Vecchi, E., Lubatti, L., Conti, E., Beretta, C., Rinaldi, P., Galli Kienle, M. and Trazzi, R.
Influence of the 21-aminosteroid U74389F on ischemia-reperfusion injury in the rat (294) 737
Parotti, L., see Cagnotto, A. (313) 63
Parratt, J.R., see Vegh, A. (305) 163
Parsons, C.G., see Misztal, M. (296) 1
Pasanen, M., see Pelkonen, M. (304) 55
Pascual, J., Del Arco, C., Romón, T., Del Olmo, E. and Pazos, A.
[^{3}H]Sumatriptan binding sites in human brain: regional-dependent labelling of 5-HT_{1D} and 5-HT_{1F} receptors (295) 271
Passarelli, F., see Orzi, F. (302) 49
Pasternak, G.W., see Chien, C.-C. (294) 303
Pasternak, G.W., see Kolesnikov, Y. (296) 17
Pasternak, G.W., see Kolesnikov, Y. (310) 141
Pasternak, G.W., see Rossi, G.C. (311) R7
Patacchini, R., Santicioli, P. and Maggi, C.A.
Effect of niflumic acid on electromechanical coupling by tachykinin NK_1 receptor activation in rabbit colon (303) 197
Patacchioli, F.R., Di Grezia, R. and Angelucci, L.
Arginine-aspartate and haloperidol-induced neurobehavioral effects in the rat (299) 29
Patat, A., see Abadie, P. (295) 35
Patel, A.C., see Ge, J. (300) 113
Patel, T.R., McAuley, M.A. and McCulloch, J.
Endothelin receptor mediated constriction and dilatation in feline cerebral resistance arterioles in vivo (307) 41
Patmore, L., see Gonzalez, M.I. (312) 1
Patrick, S.L., see Matsumoto, R.R. (301) 31
Patrignani, P., see Santini, G. (316) 65
Patz, E.F., see Campa, M.J. (310) 263
Paul, D., see Gergen, K.A. (298) 235
Paul, D., see Gergen, K.A. (316) 33
Paul, I.A., see Nowak, G. (295) 75
Paul, I.A., see Von Lubitz, D.K.J.E. (302) 43
Paul, I.A., see Von Lubitz, D.K.J.E. (316) 171
Paulussen, J.J.C., Fischer, M.J.E., Kok-Van Esterik, J.A.E., Tiemessen, R.C., De Mol, N.J. and Janssen, L.H.M.
Influence of the anti-allergic drug oxatomide on the signal transduction mechanism in a mast cell model (312) 121
Pauwels, P.J. and Colpaert, F.C.
Selective antagonism of human 5-HT_{1D} and 5-HT_{1B} receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935 (300) 141
Pauwels, P.J. and Colpaert, F.C.
Stereoselectivity of 8-OH-DPAT enantiomers at cloned human 5-HT_{1D} receptor sites (300) 137

Payá, M., Ferrándiz, M.L., Erradi, F., Terencio, M.C., Kijjoa, A., Pinto, M.M.M. and Alcaraz, M.J.
Inhibition of inflammatory responses by a series of novel dolabrane derivatives (312) 97
Pazos, A., see Grijalba, B. (310) 83
Pazos, A., see Meana, J.J. (312) 385
Pazos, A., see Pascual, J. (295) 271
Peakman, M.-C. and Hill, S.J.
Adenosine A_1 receptor-mediated inhibition of cyclic AMP accumulation in type-2 but not type-1 rat astrocytes (306) 281
Pearce, F.L., see Emadi-Khiav, B. (295) 243
Pearsall, H.R., see Rosen, M.I. (307) 251
Pearson, S.J., see Reynolds, G.P. (301) R19
Pece, S., see Mitolo-Chieppa, D. (309) 175
Peet, N.P., see McWhinney, C.D. (310) 209
Peeters, B.W.M.M., see Berendsen, H.H.G. (308) 103
Pei, Q., see Mirza, N.R. (295) 207
Pelkonen, M., Luodonpää, M., Vuolteenaho, O., Pasanen, M. and Ruskoaho, H.
Cocaine increases circulating levels of atrial natriuretic peptide and pro atrial natriuretic peptide N-terminal fragment in conscious rats (304) 55
Pencheva, N., Bocheva, A., Dimitrov, E., Ivancheva, C. and Radomirov, R.
[Cys(O_2NH_2)^2]enkephalin analogues and dalargin: selectivity for δ-opioid receptors (304) 99
Peng, C.-F., see Li, Y.-J. (311) 163
Peng, H.-C., see Sheu, J.-R. (294) 231
Pénicaud, L., see Atef, N. (298) 287
Pennacchio, M., Alexander, E., Syah, Y.M. and Ghisalberti, E.L.
The effect of verbascoside on cyclic 3′,5′-adenosine monophosphate levels in isolated rat heart (305) 169
Pennefather, J.N., see Orre, M. (316) 229
Pény, C., see Boireau, A. (300) 237
Peres, A.L., see Barajas-López, C. (312) 319
Pérez-Vizcaíno, F., Villamor, E., Moro, M. and Tamargo, J.
Pulmonary versus systemic effects of vasodilator drugs: an in vitro study in isolated intrapulmonary and mesenteric arteries of neonatal piglets (314) 91
Perich, R.B., see Murone, C. (306) 237
Pernollet, M.-G., see Gagnet, C. (310) 67
Perrault, G., see Sanger, D.J. (313) 35
Perret, C., see Bézie, Y. (311) 241
Perretti, M., see Malcangio, M. (299) 113
Perrin, J., see Himmi, T. (312) 273
Pertovaara, A., see Mansikka, H. (297) 19
Pertwee, R.G., Fernando, S.R., Griffin, G., Ryan, W., Razdan, R.K., Compton, D.R. and Martin, B.R.
Agonist-antagonist characterization of 6′-cyanohex-2′-yne-Δ^8-tetrahydrocannabinol in two isolated tissue preparations (315) 195
Pertwee, R.G., Joe-Adigwe, G. and Hawksworth, G.M.
Further evidence for the presence of cannabinoid CB_1 receptors in mouse vas deferens (296) 169
Peskar, B.A., see Amann, R. (306) 89
Peters, J., see Guizzetti, M. (297) 265
Peters, T., see Gleitz, J. (315) 83
Petersen, B. and Mørk, A.
Chronic treatment with citalopram induces noradrenaline receptor hypoactivity. A microdialysis study (300) 67
Petersen, V., see Klockgether, T. (301) 67
Petitet, F., see Heuillet, E. (314) 229
Petrelli, L., see Mazzari, S. (300) 227
Petty, M.A., Poulet, P., Haas, A., Namer, I.J. and Wagner, J.
Reduction of traumatic brain injury-induced cerebral oedema by a free radical scavenger (307) 149
Petty, M.A., see Cowley, D.J. (298) 227
Pèzzola, A., see Popoli, P. (305) 123
Pfaff, D.W., see Zhang, C. (308) 153
Pfaffendorf, M., see Zwaveling, J. (300) 91
Pfannkuche, H.-J., see Fozard, J.R. (298) 293
Pfeiffer, B., see Delagrange, P. (316) 195
Pfeilschifter, J., see Walker, G. (306) 265
Pfister, H.-W., see Lorenzl, S. (308) 335
Pham, I., Gonzalez, W., Doucet, J., Fournié-Zaluski, M.-C., Roques, B.P. and Michel, J.-B.
Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin (296) 267
Philippu, A., see Singewald, N. (294) 787
Philp, T., see De la Lande, I.S. (314) 347
Pidoplichko, V.I., Wilsch, V.W. and Reymann, K.G.
Fast desensitizing kainate-gated current resolved in whole-cell experiments on isolated rat hippocampal neurons (303) 145
Piercey, M.F., Hoffmann, W.E., Smith, M.W. and Hyslop, D.K.
Inhibition of dopamine neuron firing by pramipexole, a dopamine D_3 receptor-preferring agonist: comparison to other dopamine receptor agonists (312) 35
Pierno, S., see De Luca, A. (296) 215
Pignat, W., see Walker, G. (306) 265
Pike, V.W., McCarron, J.A., Lammertsma, A.A., Osman, S., Hume, S.P., Sargent, P.A., Bench, C.J., Cliffe, I.A., Fletcher, A. and Grasby, P.M.
Exquisite delineation of 5-HT_{1A} receptors in human brain with PET and [*carbonyl*-^{11}C]WAY-100635 (301) R5
Pilette, C., Moreau, R., Sogni, P., Kirstetter, P., Cailmail, S., Pussard, E. and Lebrec, D.
Haemodynamic and hormonal responses to long-term inhibition of nitric oxide synthesis in rats with portal hypertension (312) 63
Piletz, J.E., see Suzuki, T. (310) 243
Pimpinelli, F., see Maggi, R. (301) 169
Pinchasi, B., see Gassen, M. (308) 219
Pini, L.A., Sandrini, M. and Vitale, G.
The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain (308) 31
Pinto, F.M., see Ausina, P. (312) 309
Pinto, M.M.M., see Payá, M. (312) 97
Piper, A.S. and Hollingsworth, M.
ATP and β,γ-methylene ATP produce relaxation of guinea-pig isolated trachealis muscle via actions at P_1 purinoceptors (307) 183
Pires, A.L.A., see Alves, A.C. (312) 89
Piret, J., see Montenez, J.-P. (314) 215
Piret, J., see Van Bambeke, F. (314) 203
Pistis, M., see Diana, M. (312) 179
Pitkänen, A., see Halonen, T. (299) 69
Pitsikas, N. and Borsini, F.
Itasetron (DAU 6215) prevents age-related memory deficits in the rat in a multiple choice avoidance task (311) 115
Pittel, Z., see Heldman, E. (297) 283
Pittman, Q.J., see Poulin, P. (294) 29
Pittner, R., see Vine, W. (314) 115
Piva, F., see Maggi, R. (301) 169
Planta, R.J., see Gerhardt, C.C. (311) 249
Plotkine, M., see Charriaut-Marlangue, C. (310) 137
Pluciennik, F., see Hervé, J.-C. (313) 243
Poat, J.A., see Hinks, G.L. (312) 153
Poggioli, R., see Benelli, A. (294) 505
Poirier, J.-M., see Boucher, M. (315) 171
Poklis, A., see Moore, K.A. (311) 133
Poletayev, G.I., see Urazaev, A.Kh. (316) 219
Polidori, C., Ciccocioppo, R., Pompei, P., Cirillo, R. and Massi, M.
Functional evidence for the ability of angiotensin AT_1 receptor antagonists to cross the blood-brain barrier in rats (307) 259
Pompei, P., see Polidori, C. (307) 259
Poncet, A., see Shen, S. (307) 133
Ponchon, P. and Elghozi, J.L.
Contribution of the renin-angiotensin and kallikrein-kinin systems to

short-term variability of blood pressure in two-kidney, one-clip hypertensive rats (297) 61
Pontieri, F.E., see Orzi, F. (302) 49
Popik, P., Vetulani, J. and Van Ree, J.M.
Facilitation and attenuation of social recognition in rats by different oxytocin-related peptides (308) 113
Popik, P., see Layer, R.T. (309) 159
Popoli, P., Ferré, S., Pèzzola, A., Reggio, R., Scotti de Carolis, A. and Fuxe, K.
Stimulation of adenosine A_1 receptors prevents the EEG arousal due to dopamine D_1 receptor activation in rabbits (305) 123
Porreca, F., see Lai, J. (316) 369
Porreca, F., see Rao, R. (303) 209
Pórszász, R., see Abdel Salam, O.M.E. (305) 127
Porta, R., see Mancuso, F. (312) 327
Poso, A., see Navajas, C. (304) 173
Potenza, M.A., see Mitolo-Chieppa, D. (309) 175
Potkin, S.G., see Helmeste, D.M. (314) R3
Potter, J.M., see Champion, H.C. (309) 251
Poucher, S.M., see Keddie, J.R. (301) 107
Poucher, S.M., see Wickenden, A.D. (302) 79
Poulat, P., De Champlain, J., D'Orléans-Juste, P. and Couture, R.
Receptor and mechanism that mediate endothelin- and big endothelin-1-induced phosphoinositide hydrolysis in the rat spinal cord (315) 327
Poulet, P., see Petty, M.A. (307) 149
Poulin, P., Szot, P., Dorsa, D.M. and Pittman, Q.J.
Vasopressin-induced sensitization: involvement of neurohypophyseal peptide receptors (294) 29
Praddaude, F., Tack, I., Emond, C., Bascands, J.-L., Girolami, J.-P., Tran-Van, T., Regoli, D. and Ader, J.-L.
In vivo and in vitro homologous desensitization of rat glomerular bradykinin B_2 receptors (294) 173
Prager, R.H., see Kerr, D.I.B. (294) 349
Prats, H., see Dufresne, M. (297) 165
Pratt, P., see De Garavilla, L. (313) 89
Prehn, J.H.M.
Marked diversity in the action of growth factors on *N*-methyl-D-aspartate-induced neuronal degeneration (306) 81
Price, G.W., see Watson, J.M. (314) 365
Price, J.S., see Wei, E.T. (306) 161
Prieto-Gómez, B., see Barajas-López, C. (312) 319
Prieto, L., see Geller, J.C. (294) 423
Prinssen, E.P.M., see Kleven, M. (313) 25
Prior, H., see Wickenden, A.D. (302) 79
Proška, J. and Tuček, S.
Positive allosteric action of eburnamonine on cardiac muscarinic acetylcholine receptors (305) 201
Prost, J.-F., see Robineau, P. (294) 677
Prudentino, A., see Brambilla, A. (305) 115
Pruneau, D., Luccarini, J.-M., Defrêne, E., Paquet, J.-L. and Bélichard, P.
Characterisation of bradykinin receptors from juvenile pig coronary artery (297) 53
Przybylski, M., see Boer, R. (295) 253
Ptak, K., see Monteau, R. (314) 41
Pubill, D., Canudas, A.M., Gasulla, D., Pallàs, M., Escubedo, E. and Camarasa, J.
MK-801 enhances noradrenergic neurotransmission in rat vas deferens (303) 171
Puccetti, P., see Campanile, F. (307) 191
Pucilowski, O., Ayensu, W.K. and D'Ercole, A.J.
Insulin-like growth factor I expression alters acute sensitivity and tolerance to ethanol in transgenic mice (305) 57
Puech, R., see Berdeu, D. (308) 301
Pugsley, M.K., Saint, D.A., Hayes, E., Berlin, K.D. and Walker, M.J.A.
The cardiac electrophysiological effects of sparteine and its analogue BRB-I-28 in the rat (294) 319
Pulvirenti, L., see Bono, G. (296) 233
Pussard, E., see Pilette, C. (312) 63
Putzke, J., see Spanagel, R. (305) 45

Qadri, F., see Höhle, S. (300) 119
Qi, F., see Hattori, Y. (301) 99
Qu, P., see Han, C. (294) 593
Quack, G., see Zajaczkowski, W. (296) 239
Quayle, S.P., see Mayers, R.M. (295) 199

Rabin, B.C., Guo, T.-Z., Gregg, K. and Maze, M.
Role of serotonergic neurotransmission in the hypnotic response to dexmedetomidine, an α_2-adrenoceptor agonist (306) 51
Rabin, R.A. and Winter, J.C.
Ibogaine and noribogaine potentiate the inhibition of adenylyl cyclase activity by opioid and 5-HT receptors (316) 343
Radhakrishnan, R. and Sim, M.K.
Actions of D-amino acid-substituted analogues of des-Asp-angiotensin I on the central pressor action of angiotensin III (294) 337
Radomirov, R., see Pencheva, N. (304) 99
Rae, G.A., see Teixeira, R.M. (311) 7
Raederstorff, D., see McLennan, P. (300) 83
Raffa, R.B., see Lai, J. (316) 369
Raikoff, K., see Kim, S.Y. (316) 249
Ralevic, V., Aliev, G. and Burnstock, G.
Mesenteric and hepatic vascular reactivity in Donryu rats with and without a cholesterol-supplemented diet (313) 221
Ramage, A.G. and Wyllie, M.G.
A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats (294) 645
Rambert, F., see Ferraro, L. (306) 33
Ramsey, N.F., see Kuzmin, A. (295) 19
Rao, H., see Alescio-Lautier, B. (294) 763
Rao, R. and Porreca, F.
Epidermal growth factor protects mouse ileal mucosa from Triton X-100-induced injury (303) 209
Rao, V.L.R., see Mousseau, D.D. (300) 191
Rapoport, R.M., see Bazan, E. (311) 101
Rashed, S.M.K. and Songu-Mize, E.
Regulation of Na^+,K^+-ATPase activity by dopamine in cultured rat aortic smooth muscle cells (305) 223
Rasmussen, J.S., see Andersen, P.H. (311) 95
Raud, J., see Zhang, Y. (313) 237
Rault, S., see Delagrange, P. (316) 195
Rausch, W.-D., see Koutsilieri, E. (306) 181
Raviprakash, V., see Jagadish, M. (309) 63
Ray, R., see Kinney, G.G. (294) 547
Rayevsky, K.S., see Gainetdinov, R.R. (308) 261
Rayner, T., see McLennan, P. (300) 83
Razdan, R.K., see Pertwee, R.G. (315) 195
Reche, I., Fuentes, J.A. and Ruiz-Gayo, M.
A role for central cannabinoid and opioid systems in peripheral Δ^9-tetrahydrocannabinol-induced analgesia in mice (301) 75
Reche, I., Fuentes, J.A. and Ruiz-Gayo, M.
Erratum to 'A role for central cannabinoid and opioid systems in peripheral Δ^9-tetrahydrocannabinol-induced analgesia in mice'. [Eur. J. Pharmacol. 301 (1996) 75–81] (312) 391
Reddy, H., see Watson, N. (294) 779
Reggio, R., see Popoli, P. (305) 123
Regoli, D., see Bonnet, J. (310) 37
Regoli, D., see Calò, G. (311) R3
Regoli, D., see Praddaude, F. (294) 173
Regoli, D., see Robineau, P. (294) 677
Rehavi, M., see Gordon, I. (298) 27
Reid, A., see Sawynok, J. (298) 105
Reiländer, H., see Jahns, R. (316) 111
Reiner, A., see Zagvazdin, Y. (303) 61

Reinisch, N., see Kähler, C.M. (304) 135
Reinisch, N., see Wiedermann, C.J. (298) 335
Reis, D.J., see Sun, M.-K. (304) 63
Reiter, R.J., see Melchiorri, D. (305) 239
Reith, M.E.A., see Yan, Q.-S. (301) 49
Reith, M.E.A., see Zhang, L. (315) 345
Remacle, J., see Arnould, T. (315) 227
Ren, L.-M., Nakane, T. and Chiba, S.
Purinergic and adrenergic transmission and their presynaptic modulation in canine isolated perfused splenic arteries (295) 61
Renard, P., see Delagrange, P. (316) 195
Renard, P., see Ying, S.-W. (296) 33
Renzetti, L.M., see Gater, P.R. (304) 123
Reul, J.M.H.M., see Rupprecht, R. (303) 227
Revel, L., see Letari, O. (306) 325
Reyes-Vázquez, C., see Barajas-López, C. (312) 319
Reymann, K.G., see Manahan-Vaughan, D. (294) 497
Reymann, K.G., see Pidoplichko, V.I. (303) 145
Reynolds, G.P., Boulton, R.M., Pearson, S.J., Hudson, A.L. and Nutt, D.J.
Imidazoline binding sites in Huntington's and Parkinson's disease putamen (301) R19
Reynolds, J.N. and Maitra, R.
Propofol and flurazepam act synergistically to potentiate $GABA_A$ receptor activation in human recombinant receptors (314) 151
Ribeiro, J.A., see Gonçalves, M.L. (310) 257
Ribeiro, S.J., see Teixeira, R.M. (311) 7
Ribera, J., see Olmos, G. (310) 273
Ricaurte, G.A., see McCann, U.D. (312) R1
Ricci, A., Bisetti, A., Bronzetti, E., Felici, L., Ferrante, F., Veglio, F. and Amenta, F.
Pharmacological characterisation of Ca^{2+} channels of the L-type in human peripheral blood lymphocytes (301) 189
Ricciardolo, F.L.M., see Yoshihara, S. (296) 291
Rice, K.C., see Matsumoto, R.R. (301) 31
Richardson, P.J., see Lee, K. (313) 163
Richelmi, P., see Bono, G. (296) 233
Richens, A., see Srinivasan, J. (315) 285
Richter, A. and Löscher, W.
Antidystonic effects of L-type Ca^{2+} channel antagonists in a hamster model of idiopathic dystonia (300) 197
Riederer, P., see Koutsilieri, E. (306) 181
Riekkinen, M., Aroviita, L., Kivipelto, M., Taskila, K. and Riekkinen Jr., P.
Depletion of serotonin, dopamine and noradrenaline in aged rats decreases the therapeutic effect of nicotine, but not of tetrahydroaminoacridine (308) 243
Riekkinen, M., Stefanski, R., Kuitunen, J. and Riekkinen Jr., P.
Effects of combined block of α_1-adrenoceptors and NMDA receptors on spatial and passive avoidance behavior in rats (300) 9
Riekkinen, M., see Riekkinen Jr., P. (309) 121
Riekkinen Jr., P., Schmidt, B., Stefanski, R., Kuitunen, J. and Riekkinen, M.
Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats (309) 121
Riekkinen Jr., P., see Jäkälä, P. (299) 47
Riekkinen Jr., P., see Jäkälä, P. (316) 181
Riekkinen Jr., P., see Riekkinen, M. (300) 9
Riekkinen Jr., P., see Riekkinen, M. (308) 243
Riekkinen Sr., P., see Lahtinen, H. (297) 213
Riela, S., see Sannita, W.G. (300) 33
Rinaldi, P., see Paroni, R. (294) 737
Rink, T.J., see Vine, W. (314) 115
Rioux, P., see Abadie, P. (295) 35
Riva, E. and Traquandi, C.
Dose-response studies with idrapril in the rat heart during acute myocardial ischaemia and reperfusion (312) 293
Riva, L. and Galzin, A.-M.
Pharmacological characterization of a specific binding site for angiotensin IV in cultured porcine aortic endothelial cells (305) 193
Rivier, C., see Turnbull, A.V. (303) 213
Rizzi, A., see Calò, G. (311) R3
Rizzo, C.A., Tozzi, S., Monahan, M.E. and Hey, J.A.
Pharmacological characterization of histamine H_3 receptors in isolated guinea pig pulmonary artery and ileum (294) 329
Robak, J., see Gryglewski, R.J. (308) 61
Roberts, P.J., see Bedingfield, J.S. (309) 71
Roberts, P.J., see Bruno, V. (310) 61
Roberts, P.J., see Kemp, M.C. (309) 79
Robineau, P., Lonchampt, M., Kucharczyk, N., Krause, J.E., Regoli, D., Fauchère, J.-L., Prost, J.-F. and Canet, E.
In vitro and in vivo pharmacology of S 16474, a novel dual tachykinin NK_1 and NK_2 receptor antagonist (294) 677
Robineau, P., see Bonnet, J. (310) 37
Robles, L.-I., Barrios, M., Del Pozo, E., Dordal, A. and Baeyens, J.M.
Effects of K^+ channel blockers and openers on antinociception induced by agonists of $5\text{-}HT_{1A}$ receptors (295) 181
Rodeau, J.-L., see Zerr, P. (303) 101
Rodinò, P., see Bagetta, G. (294) 341
Rodriguez, M., see Barroso, N. (297) 195
Roegel, J.-C., see Monassier, L. (305) 109
Roerig, S.C. and Howse, K.M.
ω-Agatoxin IVA blocks spinal morphine/clonidine antinociceptive synergism (314) 293
Roeske, W.R., see Li, X. (300) R1
Rogoż, R., see Maj, J. (304) 49
Rogóż, Z., see Maj, J. (304) 49
Rogóż, Z., see Maj, J. (315) 235
Rojas, D., see Bane, A. (302) 7
Röllinghoff, M., see Stenger, S. (294) 703
Romero-Avila, M.T., see García-Sáinz, J.A. (311) 277
Rommelspacher, H., see Sällström Baum, S. (314) 75
Romón, T., see Pascual, J. (295) 271
Roques, B.-P., see Jagerschmidt, A. (296) 97
Roques, B.P., see Pham, I. (296) 267
Roques, B.P., see Valverde, O. (312) 15
Rorie, D.K., see Hunter, L.W. (313) 79
Rosadini, G., see Sannita, W.G. (300) 33
Rose'Meyer, R.B., see White, P.J. (294) 215
Rosen, M.I., McMahon, T.J., Woods, S.W., Pearsall, H.R. and Kosten, T.R.
A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal (307) 251
Rosen, M.R., see Geller, J.C. (294) 423
Rosenberg, H.C., see Zhao, T.-j. (306) 61
Ross, G.M., see Modi, P.I. (299) 213
Rosseneu, M., see Matthys, K.E. (298) 97
Rossi, F., see D'Amico, M. (316) 245
Rossi, G.C., Leventhal, L. and Pasternak, G.W.
Naloxone sensitive orphanin FQ-induced analgesia in mice (311) R7
Rossoni, G., see Bianchi, M. (294) 71
Rossoni, G., see De Gennaro Colonna, V. (314) 333
Rostock, A., see Tober, C. (303) 163
Rotondo, M.T., see Santini, G. (316) 65
Roumy, M. and Zajac, J.-M.
Effects of neuropeptide FF on intracellular Ca^{2+} in mouse spinal ganglion neurons (306) 291
Rouot, B., see Cuq, P. (315) 213
Roux, F., see Naassila, M. (313) 273
Rouyer-Fessard, C., see Gaudin, P. (302) 207
Rowan, E.G., see Henning, R.H. (301) 91
Rowan, M.J., see Manahan-Vaughan, D. (294) 617
Rowe, R.K., see Meisel, R.L. (309) 21
Rowley, H.L., Marsden, C.A. and Martin, K.F.

Differential effects of phenytoin and sodium valproate on seizure-induced changes in γ-aminobutyric acid and glutamate release in vivo (294) 541
Rubinstein, I., see Gurbanov, K. (310) 193
Rubio, M.C., see Lorenzo, P.S. (312) 203
Rüegg, J.C., see Barth, Z. (296) 285
Ruetten, H., see Wu, C.-C. (300) 99
Ruffolo, Jr., R.R., see Yue, T.-L. (294) 585
Ruiz-Gayo, M., see Reche, I. (301) 75
Ruiz-Gayo, M., see Reche, I. (312) 391
Ruiz-Velasco, V., Mayer, M.B. and Hymel, L.J.
Dihydropyridine-sensitive Ca^{2+} influx modulated by stretch in A7r5 vascular smooth muscle cells (296) 327
Rumjanek, V.M., see Gonçalves de Moraes, V.L. (312) 333
Rundfeldt, C., see Tober, C. (303) 163
Rupalla, K., Cao, W. and Krieglstein, J.
Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca^{2+} concentration (294) 469
Rupprecht, R., Berning, B., Hauser, C.A.E., Holsboer, F. and Reul, J.M.H.M.
Steroid receptor-mediated effects of neuroactive steroids: characterization of structure-activity relationship (303) 227
Rusak, B., see Ying, S.-W. (296) 33
Ruskoaho, H., see Pelkonen, M. (304) 55
Ruskoaho, H., see Taskinen, P. (308) 295
Rusnak, M., see Vietor, I. (313) 119
Russell, K., see Wickenden, A.D. (302) 79
Ruzycky, A.L. and Kulick, A.
Estrogen increases the expression of uterine protein kinase C isozymes in a tissue specific manner (313) 257
Ruzycky, A.L.
Effects of 17β-estradiol and progesterone on mitogen-activated protein kinase expression and activity in rat uterine smooth muscle (300) 247
Ryan, M.C., see Cheung, N.S. (313) 159
Ryan, R.R., Taylor, J.E., Daniel, J.L. and Cowan, A.
Pharmacological profiles of two bombesin analogues in cells transfected with human neuromedin B receptors (306) 307
Ryan, W., see Pertwee, R.G. (315) 195
Rynning, S.E., see Brunvand, H. (314) 99

Sabban, E.L., see Vietor, I. (313) 119
Sacerdote, P., see Bianchi, M. (294) 71
Sachinidis, A., El-Haschimi, K., Ko, Y., Seul, C., Epping, P. and Vetter, H.
Carbocyclic thromboxane A_2 enhances the angiotensin II-induced DNA synthesis in smooth muscle cells (307) 121
Sachinidis, A., Schulte, K.B., Ko, Y., Seul, C., Meyer zu Brickwedde, M.K., Düsing, R. and Vetter, H.
Oligodeoxynucleotides directed to early growth response gene-1 mRNA inhibit DNA synthesis in the smooth muscle cell (309) 95
Sachinidis, A., see Nickenig, G. (297) 307
Sachinidis, A., see Weber, A.-A. (309) 209
Sadegh, M., see Zarrindast, M.-R. (295) 1
Sadeghi, A.-I., see Zarrindast, M.-R. (306) 1
Sadeghi-Hashjin, G., Folkerts, G., Henricks, P.A.J., Van de Loo, P.G.F., Van der Linde, H.J., Dik, I.E.M. and Nijkamp, F.P.
Induction of guinea pig airway hyperresponsiveness by inactivation of guanylate cyclase (302) 109
Sagi, N., Yamamoto, H., Yamamoto, T., Okuyama, S. and Moroji, T.
Possible expression of a σ_1 site in rat pheochromocytoma (PC12) cells (304) 185
Sahin-Erdemli, I., see Gumusel, B. (306) 107
Saigenji, K., see Ichikawa, T. (297) 87
Saigusa, T., see Koshikawa, N. (303) 13
Saint, D.A., see Pugsley, M.K. (294) 319
Saito, H., see Abe, K. (297) 43
Saito, H., see Andrews, P. (307) 305
Saito, H., see Okada, F. (309) 33
Saito, H., see Yoshioka, M. (294) 565
Saito, M., Nishi, K., Foster, Jr., H.E., Weiss, R.M. and Latifpour, J.
Effect of experimental diabetes on rat prostate endothelin receptors (310) 197
Saito, N., see Win, N.H.H. (299) 119
Saitoh, A., see Kamei, J. (300) 75
Sakai, F., see Yamamoto, N. (314) 137
Sakai, K., see Ito, K. (307) 291
Sakai, K., see Vegh, A. (305) 163
Sakai, Y., see Hisamichi, N. (312) 69
Sakakibara, F., see Hotta, N. (311) 199
Sakakibara, F., see Hotta, N. (313) 201
Sakakibara, F., see Nakamura, J. (294) 207
Sakamoto, A., see Cai, M. (295) 215
Sakamoto, N., see Hotta, N. (311) 199
Sakamoto, N., see Hotta, N. (313) 201
Sakamoto, S., see Muramatsu, I. (300) 155
Sakamoto, T., see Ito, K. (307) 291
Sakamoto, T., see Morishita, M. (298) 149
Sakitama, K., see Ozawa, Y. (298) 57
Sakurada, C., see Tan-No, K. (314) 61
Sakurada, K., see Asano, M. (294) 693
Sakurada, S., see Tan-No, K. (314) 61
Sakurada, T., see Tan-No, K. (314) 61
Sakurai, I., see Bandoh, T. (315) 37
Sala, M., see Braida, D. (302) 13
Salazar-Bookaman, M.M., see Lezama, E.J. (308) 69
Sällström Baum, S., Hill, R. and Rommelspacher, H.
Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats (314) 75
Salmi, P. and Ahlenius, S.
Further evidence for clozapine as a dopamine D_1 receptor agonist (307) 27
Salunga, T.L., Han, X.Y., Wong, S.M., Takeuchi, H., Matsunami, K.-i., Upton, C. and Mercer, A.D.
Blocking effects of promethazine, triprolidine and their analogues on the excitation caused by the peptide, achatin-I (304) 163
Salvadori, S., see Calò, G. (311) R3
Salvadori, S., see Guerrini, R. (302) 37
Salvemini, D., Wang, Z.-Q., Bourdon, D.M., Stern, M.K., Currie, M.G. and Manning, P.T.
Evidence of peroxynitrite involvement in the carrageenan-induced rat paw edema (303) 217
Salzman, A.L., see Szabó, C. (315) 221
Samson, F., see Bézie, Y. (311) 241
Sancesario, G., see Zagvazdin, Y. (303) 61
Sánchez, C., Arnt, J. and Moltzen, E.
Assesment of relative efficacies of 5-HT_{1A} receptor ligands by means of in vivo animal models (315) 245
Sánchez, C., Arnt, J. and Moltzen, E.K.
The antiaggressive potency of (−)-penbutolol involves both 5-HT_{1A} and 5-HT_{1B} receptors and β-adrenoceptors (297) 1
Sánchez-García, P., see De la Fuente, M.T. (306) 219
Sánchez, M., see García-Velasco, G. (294) 521
Sandler, S., see Carlsson, P.-O. (312) 75
Sandouk, P., see Francès, H. (298) 217
Sandrini, M., see Pini, L.A. (308) 31
Sanger, D.J., Morel, E. and Perrault, G.
Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem (313) 35
Sanger, G.J., see Banner, S.E. (308) 181
Sannita, W.G., Crimi, E., Riela, S., Rosadini, G. and Brusasco, V.
Cutaneous antihistaminic action of cetirizine and dose-related EEG concomitants of sedation in man (300) 33
Sannomiya, P., see Ferreira, H.H.A. (310) 201

Sano, I., see Tamura, T. (308) 315
Santicioli, P., see Patacchini, R. (303) 197
Santini, G., Sciulli, M.G., Panara, M.R., Padovano, R., Di Giamberardino, M., Rotondo, M.T., Del Soldato, P. and Patrignani, P.
Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases (316) 65
Santoni, A., see Tubaro, E. (294) 555
Santos, A.R.S., see Teixeira, R.M. (311) 7
Santucci, A.C., Knott, P.J. and Haroutunian, V.
Excessive serotonin release, not depletion, leads to memory impairments in rats (295) 7
Sapena, R., Morin, D., Zini, R., Morin, C. and Tillement, J.-P.
Desipramine treatment differently down-regulates β-adrenoceptors of freshly isolated neurons and astrocytes (300) 159
Sarda, N., see Delton-Vandenbroucke, I. (312) 379
Sargent, P.A., see Pike, V.W. (301) R5
Sarlak, F., see Büküşoğlu, C. (298) 79
Sarre, S., Ebinger, G. and Michotte, Y.
Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists (296) 247
Sarviharju, M., see Honkanen, A. (304) 7
Sasa, M., see Momiyama, T. (310) 1
Sasaki, N., see Yoshida, A. (312) 115
Sasaki, S., see Ohizumi, Y. (310) 95
Sasaki, T., see Noguchi, K. (308) 53
Sasaki, Y., see Asano, M. (294) 693
Sato, A., see Nasuhara, Y. (296) 161
Sato, K., see Hisamichi, N. (312) 69
Sato, N., Nishimura, M., Kawamura, Y., Ward, C.A. and Kikuchi, K.
Block of Na^+ channel by bepridil in isolated guinea-pig ventricular myocytes (314) 373
Sato, R., see Yoshida, A. (312) 115
Sato, T., see Tan-No, K. (314) 61
Sato, Y., Kurose, H., Isogaya, M. and Nagao, T.
Molecular characterization of pharmacological properties of T-0509 for β-adrenoceptors (315) 363
Satoh, M., Matsuo, K., Kokubu, N. and Takayanagi, I.
Inhibitory effect of phorbol 12,13-dibutyrate on norepinephrine-induced contraction in rabbit iris dilator muscle (308) 145
Satoh, M., see Katsumata, S. (312) 349
Satoh, M., see Tamura, T. (308) 315
Satoh, M., see Yabuuchi, K. (300) 59
Satoh, S., see Adachi, Y. (308) 165
Satoh, Y., see Takada, Y. (308) 205
Sattar, M.A. and Johns, E.J.
α_1-Adrenoceptor subtypes mediating antinatriuresis in Wistar and stroke-prone spontaneously hypertensive rats (294) 727
Saunders, D., see Schneider, J. (302) 69
Savage, A.O., see Brown, R.A. (302) 61
Savage, P., see Tayag, E.C. (300) 261
Savci, V. and Ulus, I.H.
Central choline reverses hypotension caused by α-adrenoceptor or ganglion blockade in rats: the role of vasopressin (311) 153
Savci, V., Gürün, M.S., Ulus, I.H. and Kiran, B.K.
Effect of intracerebroventricularly injected choline on plasma ACTH and β-endorphin levels in conscious rats (309) 275
Savelli, J.E., see Modi, P.I. (299) 213
Savina, M.A., see Giardino, L. (312) 183
Savineau, J.-P., see Ausina, P. (312) 309
Savola, J.-M., see Savola, M.K.T. (306) 315
Savola, M.K.T. and Savola, J.-M.
[^{3}H]Dexmedetomidine, an α_2-adrenoceptor agonist, detects a novel imidazole binding site in adult rat spinal cord (306) 315
Savoldi, G., see Di Santo, E. (299) 179
Sawa, T., see Takada, Y. (308) 205
Sawada, H., see Komabayashi, T. (298) 299
Sawynok, J. and Reid, A.
Caffeine antinociception: role of formalin concentration and adenosine A_1 and A_2 receptors (298) 105
Sawynok, J., see Cahill, C.M. (298) 45
Sawynok, J., see Golembiowska, K. (307) 157
Saxena, P.R., De Vries, P., Heiligers, J.P.C., MaassenVanDenBrink, A., Bax, W.A., Barf, T. and Wikström, H.
Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential (312) 53
Saxena, P.R., see Kalkman, E.A.J. (298) 121
Saxena, P.R., see Van der Graaf, P.H. (300) 211
Scalia, R., Gauthier, T.W., Murohara, T. and Lefer, A.M.
Oligotide attenuates leukocyte-endothelial cell interaction via P-selectin in the rat mesenteric vascular bed (296) 181
Scarpignato, C., see Varga, G. (306) 153
Scatton, B., see Abadie, P. (295) 35
Scatton, B., see Avenet, P. (296) 209
Scatton, B., see Biton, B. (294) 91
Schäfer, M., see Mousa, S.A. (311) 221
Schanck, A., see Montenez, J.-P. (314) 215
Schechter, L., see Adham, N. (304) 231
Schilling, M., see Semkova, I. (315) 19
Schindler, C.W., see Ambrosio, E. (315) 43
Schiöth, H.B., Muceniece, R., Wikberg, J.E.S. and Szardenings, M.
Alternative translation initiation codon for the human melanocortin MC_3 receptor does not affect the ligand binding (314) 381
Schirgi-Degen, A. and Beubler, E.
Involvement of K^+ channel modulation in the proabsorptive effect of nitric oxide in the rat jejunum in vivo (316) 257
Schlawe, I., see Murone, C. (306) 237
Schmid, B., see Lenz, O. (294) 17
Schmidt, B., see Riekkinen Jr., P. (309) 121
Schmidt, B.H., see Höfner, G. (298) 307
Schmidt, W.J., see Kronthaler, U.O. (316) 129
Schmidt, W.J., see Tzschentke, T.M. (295) 137
Schneider, C., see Singewald, N. (294) 787
Schneider, J., Wnendt, S., Saunders, D., Heinzel-Wieland, R., Wilffert, B. and Steffens, G.
Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa/Hir) (302) 69
Schneider, R., see De Beun, R. (306) 5
Schöbitz, B., see Spanagel, R. (305) 45
Schödl, A., see Boer, R. (295) 253
Schoemaker, R.G., Kalkman, E.A.J. and Smits, J.F.M.
'Quality of life' after therapy in rats with myocardial infarction: dissociation between hemodynamic and behavioral improvement (298) 17
Schoemaker, R.G., see Kalkman, E.A.J. (298) 121
Schoepp, D.D., see Wright, R.A. (297) 275
Schoffelmeer, A.N.M., see De Vries, T.J. (307) R3
Schoffelmeer, A.N.M., see Nestby, P. (294) 771
Scholfield, N., see Kelso, E. (308) 351
Scholz, H., see Neumann, J. (294) 451
Scholze, P., Ebert, V. and Sieghart, W.
Affinity of various ligands for $GABA_A$ receptors containing $\alpha_4\beta_3\gamma_2$, $\alpha_4\gamma_2$, or $\alpha_1\beta_3\gamma_2$ subunits (304) 155
Schook, L., see McWhinney, C.D. (310) 209
Schorlemmer, H.U., see Nicoletti, F. (311) 213
Schousboe, A., see Wahl, P. (308) 211
Schratzberger, P., see Kähler, C.M. (304) 135
Schratzberger, P., see Wiedermann, C.J. (298) 335
Schrementi, J., see Fox, N. (308) 195
Schrör, K., see Weber, A.-A. (309) 209
Schudt, C., see Wagner, U. (298) 265
Schuligoi, R., see Amann, R. (306) 89
Schulte, K.B., see Sachinidis, A. (309) 95

Schultz, A.G., see McLaughlin, J.P. (294) 201
Schulz, R., see Ammer, H. (302) 199
Schulz, R., see Bateson, A.N. (303) 141
Schumpelick, V., see Willis, S. (315) 59
Schusdziarra, V., see Kurjak, M. (314) 165
Schusdziarra, V., see Willis, S. (315) 59
Schutz, C.G., see Funada, M. (300) 17
Schuurkes, J.A.J., see Briejer, M.R. (308) 173
Schuurman, H.-J., see Fozard, J.R. (298) 293
Schwarcz, R., see Speciale, C. (315) 263
Schwartz, J.-C., see Morisset, S. (315) R1
Schwartz, R.W., see Berzetei-Gurske, I.P. (302) R1
Schwarz, F., see Wagner, U. (298) 265
Schwarzl, I., see Stark, G. (310) 29
Schwierin, B., Borbély, A.A. and Tobler, I.
Effects of N^6-cyclopentyladenosine and caffeine on sleep regulation in the rat (300) 163
Sciulli, M.G., see Santini, G. (316) 65
Scopes, D.I.C., see Brown, J.D. (311) 305
Scotti de Carolis, A., see Popoli, P. (305) 123
Scuvée-Moreau, J., see Liégeois, J.-F. (310) 9
Sebastian, A., see McLaughlin, J.P. (294) 201
Sebben, M., see Ansanay, H. (298) 165
Sebens, J.B., Koch, T. and Korf, J.
Lack of cross-tolerance between haloperidol and clozapine towards Fos-protein induction in rat forebrain regions (315) 269
See, R.E. and Lynch, A.M.
Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats (308) 279
Seguin, L., see Bolaños-Jiménez, F. (294) 531
Seifen, E., see Williamson, A.P. (304) 73
Seki, J., see Hirasawa, Y. (303) 55
Sekine, H., see Kuribara, H. (305) 1
Selim, M., see Gruen, R.J. (309) 115
Selley, D.E., see Sim, L.J. (307) 97
Semenova, S., see Kuzmin, A. (295) 19
Semkova, I., Wolz, P., Schilling, M. and Krieglstein, J.
Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage (315) 19
Senda, T., Matsuno, K., Okamoto, K., Kobayashi, T., Nakata, K. and Mita, S.
Ameliorating effect of SA4503, a novel σ_1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats (315) 1
Sergooris, J., see Antoine, M.-H. (313) 229
Serio, M., see Mitolo-Chieppa, D. (309) 175
Serra, M.F., see Alves, A.C. (312) 89
Serra, M.F., see Diaz, B.L. (296) 173
Serraz, I., see Shen, S. (307) 133
Seto, M., see Asano, M. (294) 693
Seul, C., see Sachinidis, A. (307) 121
Seul, C., see Sachinidis, A. (309) 95
Seul, C., see Weber, A.-A. (309) 209
Sewerynek, E., see Melchiorri, D. (305) 239
Sewter, J.C., see D'Alonzo, A.J. (294) 271
Shafaghi, B., see Zarrindast, M.-R. (295) 1
Shan-Wu, X., see Ukai, M. (313) 11
Share, L., see Zagvazdin, Y. (303) 61
Sharifzadeh, M., see Zarrindast, M.-R. (306) 1
Sharp, J.D., see Fox, N. (308) 195
Sharp, T., see Hajós-Korcsok, É. (314) 285
Shaw, G.R., see Keddie, J.R. (301) 107
Shen, K.-Z., see Ilyin, V.I. (310) 107
Shen, S., Brémont, B., Serraz, I., Andrieux, J., Poncet, A., Mathé-Allainmat, M., Chanut, E., Trouvin, J.-H. and Langlois, M.
Structure–activity relationships for substrates and inhibitors of pineal 5-hydroxytryptamine-*N*-acetyltransferase: preliminary studies (307) 133
Sheng, J.-Z. and Wong, T.-M.
Chronic U50,488H abolishes inositol 1,4,5-trisphosphate and intracellular Ca^{2+} elevations evoked by κ-opioid receptor in rat myocytes (307) 323
Sheu, J.-R., Yen, M.-H., Peng, H.-C., Chang, M.-C. and Huang, T.-F.
Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments (294) 231
Shibata, E., see Ito, K. (307) 291
Shibata, M., see Ichikawa, T. (297) 87
Shibuya, M., see Asano, M. (311) 53
Shieh, G.-J. and Walters, D.E.
Stimulating dopamine D_1 receptors increases the locomotor activity of developing rats (311) 103
Shigemasa, C., see Yoshida, A. (312) 115
Shigenobu, K., see Noguchi, K. (308) 53
Shikano, T., see Taniguchi, H. (312) 227
Shimada, K., see Iimura, O. (296) 319
Shimada, M., see Tsuji, M. (313) 169
Shimada, Y., see Hirabayashi, A. (296) 297
Shimasue, K., Urushidani, T., Hagiwara, M. and Nagao, T.
Effects of anandamide and arachidonic acid on specific binding of (+)-PN200-110, diltiazem and (−)-desmethoxyverapamil to L-type Ca^{2+} channel (296) 347
Shimizu, N., see Ogino, Y. (316) 105
Shimizu, T., see Mito, K. (304) 93
Shimoda, S.-I., see Hattori, Y. (296) 107
Shimoda, S.-I., see Hattori, Y. (300) 147
Shin, S., see Kim, Y.-B. (313) 107
Shin, Y.K., see Ahn, S.K. (306) 175
Shinoda, M., Matsuo, A. and Toide, K.
Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion (305) 31
Shinozuka, K., see Kitagawa, S. (297) 71
Shiosaki, K., see Blanchet, P.J. (309) 13
Shippenberg, T.S., Heidbreder, Ch. and Lefevour, A.
Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics (299) 33
Shippenberg, T.S., see Funada, M. (300) 17
Shippenberg, T.S., see Heidbreder, C. (298) 207
Shiraishi, H., see Suzuki, T. (310) 243
Shoaib, M., see Heidbreder, C. (298) 207
Shuto, K., see Araki, T. (306) 73
Siegel, B.W., Freedman, J., Vaal, M.J. and Baron, B.M.
Activities of novel aryloxyalkylimidazolines on rat 5-HT_{2A} and 5-HT_{2C} receptors (296) 307
Siegel, B.W., Sreekrishna, K. and Baron, B.M.
Binding of the radiolabeled glycine site antagonist [^{3}H]MDL 105,519 to homomeric NMDA-NR1a receptors (312) 357
Sieghart, W., see Scholze, P. (304) 155
Sieghart, W., see Zezula, J. (301) 207
Siegl, P.K.S., see Chang, R.S.L. (294) 429
Siegl, P.K.S., see Kivlighn, S.D. (294) 439
Siegmund, C., see Jahns, R. (316) 111
Sieira, M., see Gil-Longo, J. (310) 175
Sigeizumi, S., see Woo, J.-T. (300) 131
Silberring, J., see Tan-No, K. (314) 61
Silke, B., see Kelso, E. (308) 351
Sills, T.L. and Crawley, J.N.
Individual differences in sugar consumption predict amphetamine-induced dopamine overflow in nucleus accumbens (303) 177
Silva, P.M.R., see Diaz, B.L. (296) 173
Silver, P.J., see De Garavilla, L. (313) 89

Silvestre, J.S., Fernández, A.G. and Palacios, J.M.
Effects of 5-HT_4 receptor antagonists on rat behaviour in the elevated plus-maze test (309) 219
Sim, L.J., Selley, D.E., Xiao, R. and Childers, S.R.
Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum (307) 97
Sim, M.K., see Radhakrishnan, R. (294) 337
Simonić, A., see Župan, G. (310) 103
Sinclair, J.D., see Nurmi, M. (315) 277
Singewald, N., Guo, L.j., Schneider, C., Kaehler, S. and Philippu, A.
Serotonin outflow in the hypothalamus of conscious rats: origin and possible involvement in cardiovascular control (294) 787
Singh, I.N., see Sorrentino, G. (308) 81
Singh, L., Field, M.J., Hunter, J.C., Oles, R.J. and Woodruff, G.N.
Modulation of the in vivo actions of morphine by the mixed $CCK_{A/B}$ receptor antagonist PD 142898 (307) 283
Sinha, B., see Greten, T.F. (299) 229
Siniscalchi, A., see Stefani, A. (307) 113
Sipma, H., Fredholm, B.B., Den Hertog, A. and Nelemans, A.
Plasma membrane Ca^{2+} pumping plays a prominent role in adenosine A_1 receptor mediated changes in $[Ca^{2+}]_i$ in DDT_1 MF-2 cells (306) 187
Sipma, H., Van der Zee, L., Den Hertog, A. and Nelemans, A.
Neomycin inhibits histamine and thapsigargin mediated Ca^{2+} entry in DDT_1 MF-2 cells independent of phospholipase C activation (305) 207
Sironi, M., see Di Santo, E. (299) 179
Sirviö, J., see Lahtinen, H. (297) 213
Sitte, B., see Wiedermann, C.J. (298) 335
Siuciak, J.A., see Larson-Prior, L.J. (297) 181
Skolnick, P., see Layer, R.T. (309) 159
Skuza, G., see Maj, J. (304) 49
Skuza, G., see Maj, J. (315) 235
Slade, P.D., see Hagan, J.J. (294) 743
Slany, A., see Zezula, J. (301) 207
Sleph, P.G., see D'Alonzo, A.J. (294) 271
Smart, D. and Lambert, D.G.
Tyr-D-Arg^2-Phe-$sarcosine^4$ activates phospholipase C-coupled μ_2-opioid receptors in SH-SY5Y cells (305) 235
Smith, C., see McGowan, S. (306) 249
Smith, C.B., see Yoshioka, M. (294) 565
Smith, I.D., Todd, M.J. and Beninger, R.J.
Glutamate receptor agonist injections into the dorsal striatum cause contralateral turning in the rat: involvement of kainate and AMPA receptors (301) 7
Smith, M.I., see Banner, S.E. (308) 181
Smith, M.T., see Cabot, P.J. (310) 47
Smith, M.W., see Piercey, M.F. (312) 35
Smith, P.F., see Hutchinson, M.A. (301) 83
Smith, P.F., see Jerram, A.H. (307) 269
Smith, R.C., see Collins, D.R. (294) 147
Smits, G.J.M. and Lefebvre, R.A.
Influence of age on cholinergic and inhibitory nonadrenergic noncholinergic responses in the rat ileum (303) 79
Smits, J.F.M., see Brouwers-Ceiler, D.L. (307) 65
Smits, J.F.M., see Schoemaker, R.G. (298) 17
Smyth, E.M., see McQuaid, K.E. (307) 233
Snyder, D.W., see Fox, N. (308) 195
Sodder, V.H., Bowie, L.D. and Cameron, J.S.
Trypsin alters ATP sensitivity of K_{ATP} channels in control and hypertrophied myocytes (315) 115
Söderpalm, B., see Blomqvist, O. (314) 257
Søegaard-Nielsen, L., see Andersen, P.H. (311) 95
Sogabe, K., see Takiguchi, Y. (309) 59
Sogni, P., see Pilette, C. (312) 63
Sok, D.-E., see Kim, Y.-B. (313) 107
Sommer, B., see Laurie, D.J. (296) R1
Sommer, B., see Laurie, D.J. (302) 229
Sonesson, C., see Barf, T. (297) 205
Song, D.-K., Suh, H.-W., Jung, J.-S., Wie, M.-B., Song, J.-H. and Kim, Y.-H.
Involvement of NMDA receptor in the regulation of plasma interleukin-6 levels in mice (316) 165
Song, D.-K., see Suh, H.-W. (307) 141
Song, J.-H., see Song, D.-K. (316) 165
Song, M., see Fox, N. (308) 195
Songu-Mize, E., see Rashed, S.M.K. (305) 223
Soong, Y., see Szeto, H.H. (297) 77
Soong, Y., see Szeto, H.H. (309) 183
Sorrentino, G., Singh, I.N., Massarelli, R. and Kanfer, J.N.
Stimulation of phospholipase C activity by norepinephrine, *t*-ACPD and bombesin in LA-N-2 cells (308) 81
Sorrentino, L., see Guerrini, R. (302) 37
Sotnikova, T.D., see Gainetdinov, R.R. (308) 261
Soumireu-Mourat, B., see Alescio-Lautier, B. (294) 763
Souverbie, F., Mo, L.-L., Liu, Y., Von Euler, G. and Sundström, E.
Pharmacological characterization of [^{3}H]MK-801 binding in the rat spinal cord (307) 347
Spadoni, F., see Stefani, A. (307) 113
Spanagel, R., Hölter, S.M., Allingham, K., Landgraf, R. and Zieglgänsberger, W.
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat (305) 39
Spanagel, R., Putzke, J., Stefferl, A., Schöbitz, B. and Zieglgänsberger, W.
Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat (305) 45
Spanagel, R., Zieglgänsberger, W. and Hundt, W.
Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat (305) 51
Spanagel, R., see Hölter, S.M. (314) R1
Spangler, R., see Zhou, Y. (315) 31
Speciale, C., Wu, H.-Q., Cini, M., Marconi, M., Varasi, M. and Schwarcz, R.
(*R,S*)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats (315) 263
Spencer, A.J., Osborne, M.P. and Stephen, J.
The effects of cisapride on elemental content in neonatal mouse small intestine in vivo (303) 205
Sperelakis, N., see Katsube, Y. (316) 97
Spiers, P., see Kelso, E. (308) 351
Sprunger, L.K., Stewig, N.J. and O'Grady, S.M.
Effects of charybdotoxin on K^+ channel (Kv1.2) deactivation and inactivation kinetics (314) 357
Squicciarini, J., see Chen, J.-C. (303) 109
Sreekrishna, K., see Siegel, B.W. (312) 357
Srinivasan, J., Richens, A. and Davies, J.A.
Effects of felbamate on veratridine- and K^+-stimulated release of glutamate from mouse cortex (315) 285
Stafford, I., see De la Lande, I.S. (314) 347
Stam, W.B., see Van der Graaf, P.H. (300) 211
Stancampiano, R., see Fadda, F. (307) R1
Stanton, P.K., see Hedberg, T.G. (310) 19
Stark, G., Schwarzl, I., Stark, U., Decrinis, M. and Tritthart, H.A.
Rate-dependent effects of ajmaline and propafenone on atrioventricular conduction (310) 29
Stark, U., see Stark, G. (310) 29
Starownik, R., see Gasior, M. (312) 27
Starr, M., see Kaur, S. (304) 1
Starr, M.S., see Biggs, C.S. (299) 83
Statnick, M., Dailey, J., Jobe, P. and Browning, R.
Neither intranigral fluoxetine nor 5,7-dihydroxytryptamine alter audiogenic seizures in genetically epilepsy-prone rats (299) 93
Stean, T., see Herdon, H. (314) R7

Stefani, A., Spadoni, F., Siniscalchi, A. and Bernardi, G.
Lamotrigine inhibits Ca^{2+} currents in cortical neurons: functional implications (307) 113
Stefanski, R., Bienkowski, P. and Kostowski, W.
Studies on the role of 5-HT_3 receptors in the mediation of the ethanol interoceptive cue (309) 141
Stefanski, R., see Bienkowski, P. (314) 277
Stefanski, R., see Riekkinen Jr., P. (309) 121
Stefanski, R., see Riekkinen, M. (300) 9
Steffens, G., see Schneider, J. (302) 69
Stefferl, A., see Spanagel, R. (305) 45
Stein, C., see Mousa, S.A. (311) 221
Steinbach, J.P., see Klockgether, T. (301) 67
Stenger, S., Thüring, H., Röllinghoff, M., Manning, P. and Bogdan, C.
L-N^6-(1-Iminoethyl)-lysine potently inhibits inducible nitric oxide synthase and is superior to N^G-monomethyl-arginine in vitro and in vivo (294) 703
Stephen, J., see Spencer, A.J. (303) 205
Stern, M.K., see Salvemini, D. (303) 217
Stevens, C.W. and Brenner, G.M.
Spinal administration of adrenergic agents produces analgesia in amphibians (316) 205
Stewig, N.J., see Sprunger, L.K. (314) 357
Stidsen, C.E., see Andersen, P.H. (311) 95
Stoclet, J.-C., see Mitolo-Chieppa, D. (309) 175
Stoessl, A.J., see Van Kampen, J. (298) 7
Stokke, M., Hagelin, E.M. and Brørs, O.
Effects of ATP on specific [^{3}H](+)-isradipine binding in rat ventricular cardiomyocytes (303) 115
Stolerman, I.P., see Mirza, N.R. (295) 207
Stoof, J.C., see Mansvelder, H.D. (311) 293
Story, M.E., see Orre, M. (316) 229
Stratakis, C.A., Mitsiades, N.S., Chrousos, G.P. and Margioris, A.N.
Dopamine affects the in vitro basal secretion of rat placenta opioids in an opioid and dopamine receptor type-specific manner (315) 53
Strauss, J.D., see Barth, Z. (296) 285
Stricker-Krongrad, A., Beck, B. and Burlet, C.
Enhanced feeding response to neuropeptide Y in hypothalamic neuropeptide Y-depleted rats (295) 27
Strigas, J. and Burcher, E.
Autoradiographic localization of tachykinin NK_2 and NK_1 receptors in the guinea-pig lung, using selective radioligands (311) 177
Stropova, D., see Li, X. (300) R1
Su, T.-P., see Tsao, L.-I. (311) R1
Suarez-Kurtz, G., see DeFarias, F.P. (314) 123
Sudakov, S.K., see Lyupina, Y.V. (304) 23
Sudjarwo, S.A. and Karaki, H.
Role of protein kinase C in the endothelin-induced contraction in the rabbit saphenous vein (294) 261
Südkamp, M., see Lenz, O. (294) 17
Suematsu, M., see Lai, L.-P. (309) 201
Sugano, S., see Kuwahara, M. (296) 55
Sugano, S., see Mito, K. (304) 93
Sugimoto, K., see Woo, J.-T. (300) 131
Sugimoto, T., see Hirasawa, Y. (303) 55
Sugimoto, Y., Yamada, J., Yoshikawa, T. and Horisaka, K.
Effects of the 5-$HT_{2C/2B}$ receptor agonist 1-(3-chlorophenyl)piperazine on plasma glucose levels of rats (307) 75
Sugimoto, Y., Yamada, J., Yoshikawa, T., Noma, T. and Horisaka, K.
Effects of peripheral 5-HT_2 and 5-HT_3 receptor agonists on food intake in food-deprived and 2-deoxy-D-glucose-treated rats (316) 15
Sugimoto, Y., see Yamada, J. (316) 23
Sugishita, Y., see Miyauchi, T. (303) 193
Sugita, K., see Asano, M. (311) 53
Sugiura, M., see Kamata, K. (303) 47
Suh, B.-C., Park, T.-J. and Kim, K.-T.
Synergistic activation of adenylyl cyclase is dependent upon phospholipase C-mediated processes in human neuroblastoma SK-N-BE(2)C cells (314) 235
Suh, H.-W., Kim, Y.-H., Choi, Y.-S., Choi, S.-R. and Song, D.-K.
Effects of GABA receptor antagonists injected spinally on antinociception induced by opioids administered supraspinally in mice (307) 141
Suh, H.-W., see Song, D.-K. (316) 165
Sumitani, K., see Woo, J.-T. (300) 131
Sun, M.-K. and Reis, D.J.
Intracisternally applied angiotensin II does not excite reticulospinal vasomotor neurons in anesthetized rats (304) 63
Sun, X.-Y., see Bergdahl, A. (316) 59
Sunami, A. and Hiraoka, M.
Blockade of cardiac Na^+ channels by a charged class I antiarrhythmic agent, bisaramil: possible interaction of the drug with a pre-open closed state (312) 245
Sundström, E., see Souverbie, F. (307) 347
Sussman, A.N., see Neisewander, J.L. (305) 13
Suzdak, P.D., see Jackson, H.C. (308) 21
Suzuki, F., see Muramatsu, I. (300) 155
Suzuki, H., see Xue, L. (294) 75
Suzuki, K., see Ishizuka, T. (312) 367
Suzuki, K., see Mita, Y. (297) 121
Suzuki, K.-i., see Hisamichi, N. (312) 69
Suzuki-Kusaba, M., see Adachi, Y. (308) 165
Suzuki, T., Ise, Y., Tsuda, M., Maeda, J. and Misawa, M.
Mecamylamine-precipitated nicotine-withdrawal aversion in rats (314) 281
Suzuki, T., Ito, T., Wellman, S.E. and Ho, I.K.
An autoradiographic study of [^{3}H]flunitrazepam binding sites in the brain of rat made tolerant to and dependent on pentobarbital (295) 169
Suzuki, T., Yamamoto, T., Hori, T., Baba, A., Shiraishi, H., Ito, T., Piletz, J.E. and Ho, I.K.
Autoradiographic study on the pharmacological characteristics of [^{3}H]3-OH-PCP binding sites in rat brain (310) 243
Suzuki, T., see Kamei, J. (300) 75
Suzuki, T., see Takahashi, T. (295) 229
Suzuki, T., see Tsuda, M. (307) 7
Suzuki, T., see Tsuji, M. (313) 169
Suzuki, Y., see Asano, M. (311) 53
Suzuki, Y., see Hayashi, K. (316) 297
Suzuki, Y., see Nagao, T. (316) 73
Suzuki, Y., see Tamura, K. (312) 195
Svensson, T.H., see Mathé, J.M. (309) 1
Swann, A.C., see Gaytan, O. (300) 1
Swedberg, M.D.B., see Jackson, H.C. (308) 21
Swerdlow, N.R., see Wan, F.-J. (314) 9
Święs, J., see Gryglewski, R.J. (308) 61
Swillens, S., see Motte, S. (307) 201
Syah, Y.M., see Pennacchio, M. (305) 169
Syrota, A., see Valette, H. (306) 133
Syvälahti, E., see Wong, G. (314) 319
Szabó, A., Bowman, M., Braun, C.J. and Alper, R.H.
Cardiovascular effects produced by *R*-(+)-8-hydroxy-2-(di-*n*-propylamino)tetralin in the preoptic area of conscious rats (315) 187
Szabó, C., Wong, H.R. and Salzman, A.L.
Pre-exposure to heat shock inhibits peroxynitrite-induced activation of poly(ADP) ribosyltransferase and protects against peroxynitrite cytotoxicity in J774 macrophages (315) 221
Szabo, C., see Jang, D. (312) 341
Szabó, G., Nunley, K.R. and Hoffman, P.L.
Antisense oligonucleotide to *c-fos* blocks the ability of arginine vasopressin to maintain ethanol tolerance (306) 67
Szallasi, A., Acs, G., Cravotto, G., Blumberg, P.M., Lundberg, J.M. and Appendino, G.
A novel agonist, phorbol 12-phenylacetate 13-acetate 20-homovanil-

late, abolishes positive cooperativity of binding by the vanilloid receptor (299) 221
Szallasi, A., Nilsson, S., Blumberg, P.M., Hökfelt, T. and Lundberg, J.M. Binding of neuroleptic drugs (trifluoperazine and rimcazole) to vanilloid receptors in porcine dorsal horn (298) 321
Szardenings, M., see Schiöth, H.B. (314) 381
Szczawinska, K., see Bernardi, M. (298) 51
Szeto, H.H., Wu, D., Cheng, P.Y., Soong, Y., Taylor, C.C. and Yee, J. Cardiovascular and respiratory actions of U50,488H in the unanaesthetized ovine foetus (297) 77
Szeto, H.H., Wu, D., Yee, J.S., Soong, Y., Fukuda, S. and Taylor, C.T. U50,488H-induced pressor effect in the ovine foetus is mediated by sympathetic activation and vasopressin (309) 183
Szilvassy, J., see Szilvassy, Z. (301) R17
Szilvassy, Z., Nagy, I., Szilvassy, J., Jakab, I., Csati, S. and Lonovics, J. Impaired nitrergic relaxation of the sphincter of Oddi of hyperlipidaemic rabbits (301) R17
Szolcsányi, J., see Abdel Salam, O.M.E. (305) 127
Szot, P., see Poulin, P. (294) 29
Szymanska, G., see Meissner, A. (316) 333

Tabo, M., Ohta, T., Ito, S. and Nakazato, Y. Effects of external K^+ on depletion-induced Ca^{2+} entry in rat ileal smooth muscle (313) 151
Tabrizchi, R., see Nekooeian, A.A. (307) 163
Tacconi, M.T., see Tsankova, V. (294) 601
Tacconi, M.T., see Tsankova, V. (299) 197
Taché, Y., see Martínez, V. (296) 153
Tack, I., see Praddaude, F. (294) 173
Tadano, T., see Tan-No, K. (314) 61
Tagami, K., see Woo, J.-T. (300) 131
Taglialatela, M., Ongini, E., Brown, A.M., Di Renzo, G. and Annunziato, L. Felbamate inhibits cloned voltage-dependent Na^+ channels from human and rat brain (316) 373
Taira, A., see Tan-No, K. (314) 61
Takaba, H., see Cai, H. (313) 103
Takada, Y., Takata, Y., Iwanishi, M., Imamura, T., Sawa, T., Morioka, H., Ishihara, H., Ishiki, M., Usui, I., Temaru, R., Urakaze, M., Satoh, Y., Inami, T., Tsuda, S. and Kobayashi, M. Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse (308) 205
Takagi, H., see Kawabata, A. (296) 23
Takahashi, H., see Kitamura, Y. (306) 297
Takahashi, K., see Noguchi, K. (308) 53
Takahashi, S., see Kai, T. (315) 313
Takahashi, T., Kanda, T., Imai, S., Suzuki, T., Kobayashi, I. and Murata, K. Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem (295) 229
Takahashi, Y., Ohno, H. and Misawa, M. Characteristics of vagal reflex-mediated tracheal response induced by bronchoconstriction in guinea pigs (302) 89
Takamatu, H., see Hirasawa, Y. (303) 55
Takao, K., Nagatani, T., Kitamura, Y., Kawasaki, K., Hayakawa, H. and Yamawaki, S. Chronic forced swim stress of rats increases frontal cortical 5-HT_2 receptors and the wet-dog shakes they mediate, but not frontal cortical β-adrenoceptors (294) 721
Takashima, T., see Tsuji, M. (313) 169
Takasugi, M., see Osajima, A. (315) 319
Takata, Y., see Takada, Y. (308) 205
Takaya, S., see Kawabata, A. (296) 23
Takayanagi, I., see Satoh, M. (308) 145
Takebayashi, M., Kagaya, A., Hayashi, T., Motohashi, N. and Yamawaki, S. γ-Aminobutyric acid increases intracellular Ca^{2+} concentration in cultured cortical neurons: role of Cl^- transport (297) 137
Takenaka, T., see Hisamichi, N. (312) 69
Takeo, S., see Ohoi, I. (306) 123
Takeshita, Y., see Iga, Y. (308) 13
Takeuchi, H., see Emaduddin, M. (302) 129
Takeuchi, H., see Salunga, T.L. (304) 163
Takeuchi, K., see Ito, K. (314) 143
Takeuchi, Y., see Ito, K. (307) 291
Takiguchi, Y. and Sogabe, K. The selective endothelin ET_A receptor antagonist FR139317 inhibits neointimal thickening in the rat (309) 59
Takita, M., see Muramatsu, I. (300) 155
Tamagawa, T., see Hiyoshi, Y. (294) 117
Tamargo, J., see Pérez-Vizcaíno, F. (314) 91
Tamminga, C.A., see Lahti, R.A. (301) R11
Tamura, K., Suzuki, Y., Koga, T., Akima, M., Kato, T. and Nabata, H. Actions of CP-060S on veratridine-induced Ca^{2+} overload in cardiomyocytes and mechanical activities in vascular strips (312) 195
Tamura, M., see Osajima, A. (315) 319
Tamura, T., Sano, I., Satoh, M., Mizumoto, A. and Itoh, Z. Pharmacological characterization of 5-hydroxytryptamine-induced motor activity (in vitro) in the guinea pig gastric antrum and corpus (308) 315
Tan-No, K., Taira, A., Sakurada, T., Inoue, M., Sakurada, S., Tadano, T., Sato, T., Sakurada, C., Nylander, I., Silberring, J., Terenius, L. and Kisara, K. Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test (314) 61
Tanabe, M. and Kaneko, T. Preferential enhancement of inhibitory synaptic transmission by CS-722 in the ventral horn neurons of neonatal rat spinal cord (313) 187
Tanabe, T., Otani, H., Bao, L.-h., Mikami, Y., Yasukura, T., Ninomiya, T., Ogawa, R. and Inagaki, C. Intracellular signaling pathway of substance P-induced superoxide production in human neutrophils (299) 187
Tanabe, T., Otani, H., Zeng, X.-T., Mishima, K., Ogawa, R. and Inagaki, C. Inhibitory effects of calcitonin gene-related peptide on substance-P-induced superoxide production in human neutrophils (314) 175
Tanaka, H., see Noguchi, K. (308) 53
Tanaka, K., see Ogino, Y. (316) 105
Tanaka, K., see Ohashi, H. (301) 129
Tanaka, M., see Tanaka, T. (297) 35
Tanaka, M.K., see Matsuno, K. (312) 267
Tanaka, T., Yoshida, M., Yokoo, H., Mizoguchi, K. and Tanaka, M. ATP-sensitive K^+ channel openers block sulpiride-induced dopamine release in the rat striatum (297) 35
Tanaka, T., see Nakatani, K. (315) 335
Tanaka, Y., see Yoshida, A. (312) 115
Tang, L. and Kongsamut, S. Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184 (300) 71
Tang, R., see Hatano, A. (313) 135
Tang, S.W., see Helmeste, D. (301) R1
Tang, S.W., see Helmeste, D.M. (314) R3
Tanganelli, S., see Ferraro, L. (306) 33
Taniguchi, H., Yazaki, N., Endo, T. and Nagasaki, M. Pharmacological profile of T-0632, a novel potent and selective CCK_A receptor antagonist, in vitro (304) 147
Taniguchi, H., Yazaki, N., Yomota, E., Shikano, T., Endo, T. and Nagasaki, M. Pharmacological profile of T-0632, a novel potent and selective CCK_A receptor antagonist, in vivo (312) 227
Taniguchi, S.-i., see Yoshida, A. (312) 115
Taniguchi, T., see Kitamura, Y. (306) 297
Taniuchi, Y., see Hisamichi, N. (312) 69
Tapia, R., see Morales-Villagrán, A. (305) 87
Taskila, K., see Riekkinen, M. (308) 243

Taskinen, P. and Ruskoaho, H.
Stretch-induced increase in atrial natriuretic peptide secretion is blocked by thapsigargin (308) 295
Tassini, M., see Federico, A. (304) 237
Tayag, E.C., Jeng, A.Y., Savage, P. and Lehmann, J.C.
Rat striatum contains pure population of ET_B receptors (300) 261
Taylor, C.C., see Szeto, H.H. (297) 77
Taylor, C.T., see Szeto, H.H. (309) 183
Taylor, J.E., see Ryan, R.R. (306) 307
Taylor, L., see Meng, F. (311) 285
Teheranian, R., see Lundkvist, J. (309) 195
Teixeira, R.M., Santos, A.R.S., Ribeiro, S.J., Calixto, J.B., Rae, G.A. and De Lima, T.C.M.
Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice (311) 7
Tel, B.C., see Gumusel, B. (306) 107
Telang, A.G., see Jagadish, M. (309) 63
Tella, S.R., see Ambrosio, E. (315) 43
Temaru, R., see Takada, Y. (308) 205
Teng, C.-M., Hsiao, G., Ko, F.-N., Lin, D.-T. and Lee, S.-S.
N-Allylsecoboldine as a novel antioxidant against peroxidative damage (303) 129
Teng, C.-M., see Chueh, S.-C. (305) 177
Teng, C.-M., see Guh, J.-H. (298) 191
Teoh, H., Malcangio, M., Fowler, L.J. and Bowery, N.G.
Evidence for release of glutamic acid, aspartic acid and substance P but not γ-aminobutyric acid from primary afferent fibres in rat spinal cord (302) 27
Tepper, P.G., see Lahti, R.A. (301) R11
Terencio, M.C., see Payá, M. (312) 97
Terenius, L., see Hou, Y.-N. (309) 307
Terenius, L., see Tan-No, K. (314) 61
Terrón, J.A.
GR127935 is a potent antagonist of the 5-HT_1-like receptor mediating contraction in the canine coronary artery (300) 109
Terry Jr., A.V., see Feldman, D.S. (313) 211
Terzic, A., see Brady, P.A. (308) 343
Terzic, A., see Jovanovic, A. (298) 63
Tessmer, J.P., see Hettrick, D.A. (316) 237
Thekkumkara, T.J., see Thomas, W.G. (295) 119
Theobald Jr., R.J.
The effect of N^G-monomethyl-L-arginine on bladder function (311) 73
Thiemermann, C., see Wu, C.-C. (300) 99
Thomas, H.A., see Wei, E.T. (306) 161
Thomas, P.T., see Bhargava, H.N. (311) 127
Thomas, W.G., Baker, K.M., Booz, G.W. and Thekkumkara, T.J.
Evidence against a role for protein kinase C in the regulation of the angiotensin II (AT_{1A}) receptor (295) 119
Thompson, A.J., see Mayers, R.M. (295) 199
Thompson, R.C., see Meng, F. (311) 285
Thorne, J.R., Danahay, H. and Broadley, K.J.
Analysis of the bronchoconstrictor responses to adenosine receptor agonists in sensitized guinea-pig lungs and trachea (316) 263
Thoss, V.S., Duc, D. and Hoyer, D.
Somatostatin receptors in the developing rat brain (297) 145
Thüring, H., see Stenger, S. (294) 703
Tibiriça, E., see Monassier, L. (305) 109
Tibiriçá, E., see Lopes-Martins, R. (308) 287
Tiemessen, R.C., see Paulussen, J.J.C. (312) 121
Tilakaratne, N. and Friedman, E.
Genomic responses to 5-HT_{1A} or 5-$HT_{2A/2C}$ receptor activation is differentially regulated in four regions of rat brain (307) 211
Tillement, J.-P., see Deprés-Brummer, P. (312) 171
Tillement, J.-P., see Sapena, R. (300) 159
Timmerman, H., see Waelbroeck, M. (303) 221
Tjon, G.H.K., see De Vries, T.J. (307) R3
Tjon, G.H.K., see Nestby, P. (294) 771
Tober, C., Rostock, A., Rundfeldt, C. and Bartsch, R.
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures (303) 163
Tobler, I., see Schwierin, B. (300) 163
Toda, N., see Zhang, J.-X. (311) 169
Todd, M.J., see Smith, I.D. (301) 7
Todo, N., see Momiyama, T. (310) 1
Toews, M.L., see Zhu, S.-J. (299) 205
Togashi, H., see Yoshioka, M. (294) 565
Toide, K., see Shinoda, M. (305) 31
Tojima, R., see Ishibashi, T. (303) 247
Tokarski, K., see Bijak, M. (305) 79
Tokutomi, N., see Frank, C. (295) 87
Tokuyama, S., Wakabayashi, H. and Ho, I.K.
Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome (295) 123
Tolboom, J.T.B.M., see Zethof, T.J.J. (294) 125
Toll, L., see Berzetei-Gurske, I.P. (302) R1
Tominaga, M., see Fujiki, H. (313) 191
Tomioka, K., see Hisamichi, N. (312) 69
Tomitaka, S.-i., see Narita, N. (307) 117
Tomiyama, K., see Nishio, E. (301) 203
Tomobe, Y., see Miyauchi, T. (303) 193
Tömösközi, Z., see Erdõ, S.L. (314) 69
Toms, N.J., see Bedingfield, J.S. (309) 71
Torii, S., see Ito, K. (307) 291
Torii, S., see Morishita, M. (298) 149
Torii, Y., see Andrews, P. (307) 305
Torrence-Campbell, C. and Bowen, W.D.
Differential solubilization of rat liver σ_1 and σ_2 receptors: retention of σ_2 sites in particulate fractions (304) 201
Torres, C., Morales, A., Cándido, A. and Maldonado, A.
Successive negative contrast in one-way avoidance: effect of thiopental sodium and chlorpromazine (314) 269
Totsuka, T., see Bandoh, T. (315) 37
Tough, I.R. and Cox, H.M.
Selective inhibition of neuropeptide Y Y_1 receptors by BIBP3226 in rat and human epithelial preparations (310) 55
Touitou, Y., see Deprés-Brummer, P. (312) 171
Towers, P., see Ge, J. (300) 113
Toyoshi, T., Ukai, M. and Kameyama, T.
Intrastriatal injection of opioid receptor agonists inhibits apomorphine-induced behavior in 6-hydroxydopamine-treated mice (294) 637
Tozzi, S., see Rizzo, C.A. (294) 329
Traiffort, E., see Morisset, S. (315) R1
Tran, M., see Ilyin, V.I. (310) 107
Tran-Van, T., see Praddaude, F. (294) 173
Traquandi, C., see Riva, E. (312) 293
Travis, M.D., see Lewis, S.J. (312) R3
Trazzi, R., see Paroni, R. (294) 737
Tricoire, A., see Messaoudi, M. (299) 17
Tritthart, H.A., see Stark, G. (310) 29
Trkulja, V. and Lacković, Z.
Involvement of muscarinic receptors in the control of female puberty in the rat (297) 93
Trongvanichnam, K., Mitsui-Saito, M., Ozaki, H. and Karaki, H.
Effects of chronic oral administration of a high dose of nicorandil on in vitro contractility of rat arterial smooth muscle (314) 83
Trongvanichnam, K., Mitsui-Saito, M., Ozaki, H. and Karaki, H.
Effects of chronic oral administration of levcromakalim on in vitro contractile responses of arterial smooth muscle (303) 39
Trouvin, J.-H., see Shen, S. (307) 133
Truong, D.D., see Kanthasamy, A.G. (297) 219
Truong, D.D., see Matsumoto, R.R. (301) 31
Tsankova, V., Magistrelli, A., Cantoni, L. and Tacconi, M.T.
Peripheral benzodiazepine receptor ligands in rat liver mitochondria: effect on cholesterol translocation (294) 601
Tsankova, V., Visentin, M., Cantoni, L., Carelli, M. and Tacconi, M.T.

Peripheral benzodiazepine receptor ligands in rat liver mitochondria: effect on 27-hydroxylation of cholesterol (299) 197
Tsao, L.-I. and Su, T.-P.
IP_3 receptor antagonist heparin uncompetitively inhibits [^{3}H](+)-SKF-10047 binding to σ receptors (311) R1
Tse, H.-W., see Kemp, M.C. (309) 79
Tseng, L.F. and Collins, K.A.
Pretreatment with pertussis toxin blocks morphine- but not β-endorphin-induced antinociception in the mouse (294) 345
Tseng, L.F., see Mizoguchi, H. (309) 37
Tseng, L.F., see Narita, M. (310) R1
Tseng, L.F., see Narita, M. (311) 121
Tsubone, H., see Kuwahara, M. (296) 55
Tsuchiya, K., see Inoue, T. (311) 1
Tsuchiya, K., see Izumi, T. (300) 25
Tsuda, M., Suzuki, T., Misawa, M. and Nagase, H.
Involvement of the opioid system in the anxiolytic effect of diazepam in mice (307) 7
Tsuda, M., see Suzuki, T. (314) 281
Tsuda, S., see Takada, Y. (308) 205
Tsuji, M., Nakagawa, Y., Ishibashi, Y., Yoshii, T., Takashima, T., Shimada, M. and Suzuki, T.
Activation of ventral tegmental $GABA_B$ receptors inhibits morphine-induced place preference in rats (313) 169
Tsuji, T., see Woo, J.-T. (300) 131
Tsukahara, F., see Fujii, E. (313) 129
Tsukii, K., Nakahata, N., Watanabe, K., Tsurufuji, S. and Ohizumi, Y.
Comparison of tBuBHQ with chemotactic peptide and phorbol ester in O_2^- production in HL-60 cells (298) 87
Tsunobuchi-Ushijima, H. and Gomi, Y.
The specific effect of Mn^{2+} on the tonic components of receptor-mediated contractions in isolated vas deferens of the guinea pig (295) 235
Tsurufuji, S., see Tsukii, K. (298) 87
Tubaro, E., Borelli, G.P., Belogi, L., Cavallo, G., Santoni, A. and Mainiero, F.
Effect of a new de-*N*-acetyl-lysoglycosphingolipid on some tumour models (294) 555
Tuček, S., see Proška, J. (305) 201
Tulkens, P.M., see Montenez, J.-P. (314) 215
Tulkens, P.M., see Van Bambeke, F. (314) 203
Tulloch, I., see Lightowler, S. (296) 137
Tümmler, B., see Demmer, A. (315) 339
Tung, C.-S., see Wong, C.-S. (297) 27
Turnbull, A.V., Vale, W. and Rivier, C.
Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats (303) 213
Turski, L., see Eblen, F. (299) 9
Turski, L., see Klockgether, T. (301) 67
Twort, C.H.C., see Mak, J.C.W. (302) 215
Tyce, G.M., see Hunter, L.W. (313) 79
Tygesen, C.K., see Andersen, P.H. (311) 95
Tytgat, J., Vereecke, J. and Carmeliet, E.
Mechanism of L- and T-type Ca^{2+} channel blockade by flunarizine in ventricular myocytes of the guinea-pig (296) 189
Tzschentke, T.M. and Schmidt, W.J.
Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist (295) 137

Uchida, I., Cestari, I.N. and Yang, J.
The differential antagonism by bicuculline and SR95531 of pentobarbitone-induced currents in cultured hippocampal neurons (307) 89
Uchida, Y., see Fujii, E. (313) 129
Ueda, Y., see Meng, F. (311) 285
Uemura, K., see Hiyoshi, Y. (294) 117
Ueno, A., see Naraba, H. (302) 117
Ueta, Y., see Osajima, A. (315) 319
Ueta, Y., see Yoshida, A. (312) 115
Uezono, Y., see Osajima, A. (315) 319
Ugolini, A. and Bordi, F.
Metabotropic glutamate group II receptors are responsible for the depression of synaptic transmission induced by ACPD in the dentate gyrus (294) 403
Uhlig, S., see Gantner, F. (294) 353
Ujiie, A., see Yamagishi, R. (315) 73
Ujike, H., Kuroda, S. and Otsuki, S.
σ Receptor antagonists block the development of sensitization to cocaine (296) 123
Ukai, M., Shan-Wu, X., Kobayashi, T. and Kameyama, T.
Systemic administration of dynorphin A-(1–13) markedly improves cycloheximide-induced amnesia in mice (313) 11
Ukai, M., see Toyoshi, T. (294) 637
Ullrich, B., see Eltze, M. (306) 139
Ulrich, W.-R., see Boer, R. (295) 253
Ulugöl, A., Karadağ, H.Ç., Dökmeci, D., Baldık, Y. and Dökmeci, İ.
The role of histamine H_1 receptors in the thermoregulatory effect of morphine in mice (308) 49
Ulus, I.H., see Savci, V. (309) 275
Ulus, I.H., see Savci, V. (311) 153
Umemura, K., see Kikuchi, S. (295) 221
Unger, T., see Höhle, S. (300) 119
Unno, T., see Ohashi, H. (301) 129
Upton, C., see Salunga, T.L. (304) 163
Upton, N., see Herdon, H. (314) R7
Urakaze, M., see Takada, Y. (308) 205
Urazaev, A.Kh., Naumenko, N.V., Poletayev, G.I., Nikolsky, E.E. and Vyskočil, F.
Nitroprusside decreases the early post-denervation depolarization of diaphragm muscle fibres of the rat (316) 219
Ureña-Guerrero, M.E., see Morales-Villagrán, A. (305) 87
Urien, S., see Deprés-Brummer, P. (312) 171
Urushidani, T., see Shimasue, K. (296) 347
Usui, I., see Takada, Y. (308) 205
Utsunomiya, I., see Oh-ishi, S. (300) 255

Vaal, M.J., see Siegel, B.W. (296) 307
Vaccher, C., see Kerr, D.I.B. (308) R1
Vaccher, M.-P., see Kerr, D.I.B. (308) R1
Valdemarson, S., see Bergdahl, A. (316) 59
Vale, W., see Turnbull, A.V. (303) 213
Valensin, G., see Federico, A. (304) 237
Valette, H., Syrota, A., Fuseau, C. and Brutesco, C.
In vivo effect of methyl-quinuclidinyl-benzylate on myocardial β-adrenoceptor density (306) 133
Vallejo, A.I., Bo, X. and Burnstock, G.
P2Y purinoceptors in gastric gland plasma membranes (312) 209
Vallett, M., see Gauvin, D.V. (294) 281
Valverde, O., Fournié-Zaluski, M.-C., Roques, B.P. and Maldonado, R.
Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids (312) 15
Van Ammel, K., see Van de Water, A. (299) 127
Van Bambeke, F., Montenez, J.-P., Piret, J., Tulkens, P.M., Courtoy, P.J. and Mingeot-Leclercq, M.-P.
Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A_1 activity (314) 203
Van Bambeke, F., see Montenez, J.-P. (314) 215
Van Bergen, P., Janssen, P.M.L., Hoogerhout, P., De Wildt, D.J. and Versteeg, D.H.G.
Cardiovascular effects of γ-MSH/ACTH-like peptides: structure-activity relationship (294) 795
Van Buren, T., Kasbergen, C.M., Gispen, W.H. and De Wildt, D.J.
Presynaptic deficit of sympathetic nerves: a cause for disturbed sciatic nerve blood flow responsiveness in diabetic rats (296) 277

Van de Loo, P.G.F., see Sadeghi-Hashjin, G. (302) 109
Van den Berg, R.J., Wang, Z., Grouls, R.J.E. and Korsten, H.H.M.
The local anesthetic, *n*-butyl-*p*-aminobenzoate, reduces rat sensory neuron excitability by differential actions on fast and slow Na^+ current components (316) 87
Van den Bosch, H., see Walker, G. (306) 265
Van den Burg, E.H., see Mensink, A. (310) 73
Vander Borght, T., Kilbourn, M., Desmond, T., Kuhl, D. and Frey, K.
The vesicular monoamine transporter is not regulated by dopaminergic drug treatments (294) 577
Van der Graaf, P.H., Stam, W.B. and Saxena, P.R.
Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery (300) 211
Van der Heyden, J.A.M., see Zethof, T.J.J. (294) 125
Vanderheyden, P.M.L., see Czerwiec, E. (315) 355
Van der Linde, H.J., see Sadeghi-Hashjin, G. (302) 109
Vandermeers, A., see Waelbroeck, M. (305) 187
Vandermeers-Piret, M.-C., see Waelbroeck, M. (305) 187
Vanderschuren, L.J.M.J., see De Vries, T.J. (307) R3
Van der Staay, F.J., Antonicek, H., Helpap, B. and Freund, W.-D.
Effects of the selective metabotropic glutamate receptor agonist, L-CCG-I, on acquisition of a Morris task by rats (294) 361
Van der Wijk, T., see Mensink, A. (310) 73
Van der Zee, L., see Sipma, H. (305) 207
Van de Water, A., D'Aubioul, J., Van Gerven, W., Van Ammel, K. and De Clerck, F.
Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs (299) 127
Vandier, C. and Bonnet, P.
Synergistic action of NS-004 and internal Ca^{2+} concentration in modulating pulmonary artery K^+ channels (295) 53
Van Gerven, W., see Van de Water, A. (299) 127
Van Hartesveldt, C., see Frantz, K. (302) 1
Van Heerikhuizen, H., see Gerhardt, C.C. (311) 249
Van Hove, C.E., see Matthys, K.E. (298) 97
Van Hove, C.E., see Van Put, D.J.M. (294) 753
Van Kampen, J., Frydryszak, H. and Stoessl, A.J.
Behavioural evidence for cholecystokinin-dopamine D_1 receptor interactions in the rat (298) 7
Van Put, D.J.M., Van Hove, C.E., De Meyer, G.R.Y., Wuyts, F., Herman, A.G. and Bult, H.
Dexamethasone influences intimal thickening and vascular reactivity in the rabbit collared carotid artery (294) 753
Van Ree, J.M., see Kuzmin, A. (295) 19
Van Ree, J.M., see Popik, P. (308) 113
Van Rijn, C.M., see Maes, J.H.R. (309) 131
Van Schaick, E.A., Jacobson, K.A., Kim, H.O., IJzerman, A.P. and Danhof, M.
Hemodynamic effects and histamine release elicited by the selective adenosine A_3 receptor agonist 2-Cl-IB-MECA in conscious rats (308) 311
Van Tilburg, E., see Waelbroeck, M. (303) 221
Van Wilgenburg, H., see Leeuwin, R.S. (299) 149
Van Wilgenburg, H., see Leeuwin, R.S. (315) 153
Van Zwieten, P.A., see Zwaveling, J. (300) 91
Varasi, M., see Speciale, C. (315) 263
Vardi, Y., see Ari, G. (307) 69
Varga, E.V., see Li, X. (300) R1
Varga, G. and Scarpignato, C.
Camostate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists (306) 153
Varga, G., see Kortezova, N. (304) 109
Varga, K., Lovas, G., Palkovits, M. and Kunos, G.
Ethanol inhibition of stress-related tachycardia involves medullary NMDA receptors (310) 145
Vargaftig, B.B., see De Castro, C.M.M.B. (294) 669
Vargas, H.M., see Zhou, L. (305) 173
Vaudry, H., see Esneu, M. (308) 187
Vaugeois, J.-M., Odièvre, C., Loisel, L. and Costentin, J.
A genetic mouse model of helplessness sensitive to imipramine (316) R1
Vauquelin, G., see Czerwiec, E. (315) 355
Vauquelin, G., see Czerwiec, E. (315) 99
Vaysse, N., see Dufresne, M. (297) 165
Vaysse, P., see Adham, N. (304) 231
Veenstra, E., see Zuiderwijk, M. (307) 275
Vegh, A., Györgyi, K., Gy Papp, J., Sakai, K. and Parratt, J.R.
Nicorandil suppressed ventricular arrhythmias in a canine model of myocardial ischaemia (305) 163
Veglio, F., see Ricci, A. (301) 189
Velíšek, L., see Velíšková, J. (309) 167
Velíšková, J., Velíšek, L., Nunes, M.L. and Moshé, S.L.
Developmental regulation of regional functionality of substantia nigra $GABA_A$ receptors involved in seizures (309) 167
Venter, D.P.
New methods for determining dissociation constants of agonist-receptor complexes (303) 235
Ventura, S. and Ludbrook, J.
L-Arginine reverses the abolition of hypovolaemic decompensation by *N*-nitro-L-arginine methyl ester and naloxone in conscious rabbits (294) 369
Vereecke, J., see Tytgat, J. (296) 189
Vergani, L., see Gorio, A. (303) 21
Verne-Mismer, J., see Bolkenius, F.N. (298) 37
Verrecchia, F., see Hervé, J.-C. (313) 243
Verrièle, L., see Newman-Tancredi, A. (307) 107
Versteeg, D.H.G., see Herz, R.C.G. (306) 113
Versteeg, D.H.G., see Van Bergen, P. (294) 795
Vestal, R.E., see Musser, B. (308) 357
Vetter, H., see Nickenig, G. (297) 307
Vetter, H., see Sachinidis, A. (307) 121
Vetter, H., see Sachinidis, A. (309) 95
Vetter, H., see Weber, A.-A. (309) 209
Vetulani, J., see Antkiewicz-Michaluk, L. (294) 459
Vetulani, J., see Karolewicz, B. (313) 181
Vetulani, J., see Popik, P. (308) 113
Vietor, I., Rusnak, M., Viskupic, E., Blazicek, P., Sabban, E.L. and Kvetnansky, R.
Glucoprivation by insulin leads to trans-synaptic increase in rat adrenal tyrosine hydroxylase mRNA levels (313) 119
Vikland, M.-L., see Jagerschmidt, A. (296) 97
Vila, J.M., see Medina, P. (300) 221
Vilamo, L., see Honkanen, A. (304) 7
Villalobos-Molina, R. and Ibarra, M.
α_1-Adrenoceptors mediating contraction in arteries of normotensive and spontaneously hypertensive rats are of the α_{1D} or α_{1A} subtypes (298) 257
Villamor, E., see Pérez-Vizcaíno, F. (314) 91
Villarroya, M., see Gandía, L. (298) 199
Vine, W., Beaumont, K., Gedulin, B., Pittner, R., Moore, C.X., Rink, T.J. and Young, A.A.
Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats (314) 115
Vinson, E.N., see MacLennan, A.J. (295) 103
Vinšová, J., see Hliňák, Z. (314) 1
Visentin, M., see Tsankova, V. (299) 197
Viskupic, E., see Vietor, I. (313) 119
Visser, D.T.M., see Nestby, P. (294) 771
Vital, M.A.B.F., see Bellot, R.G. (313) 175
Vitale, G., see Pini, L.A. (308) 31
Vitezić, D., see Župan, G. (310) 103
Vivi, A., see Federico, A. (304) 237

Vizi, E.S., see Kortezova, N. (304) 109
Vo, V.N., see Matsumoto, R.R. (301) 31
Vogel, Z., see Heldman, E. (297) 283
Volberg, M.L., see De Garavilla, L. (313) 89
Volicer, L., see Chen, J.-C. (303) 109
Volkow, N.D., see Gatley, S.J. (296) 145
Volkow, N.D., see Gatley, S.J. (307) 331
Von Euler, G., see Souverbie, F. (307) 347
Von Frijtag Drabbe Künzel, J.K., see IJzerman, A.P. (310) 269
Von Lubitz, D.K.J.E., Beenhakker, M., Lin, R.C.-S., Carter, M.F., Paul, I.A., Bischofberger, N. and Jacobson, K.A.
Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A_1 receptor agonist (302) 43
Von Lubitz, D.K.J.E., Lin, R.C.-S., Paul, I.A., Beenhakker, M., Boyd, M., Bischofberger, N. and Jacobson, K.A.
Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils (316) 171
Vonthron, C., see Bennai, F. (306) 211
Von Wichert, P., see Wagner, U. (298) 265
Vossen, J.M.H., see Maes, J.H.R. (309) 131
Vreugdenhil, E., see Gerhardt, C.C. (311) 249
Vrints, C.J., see Bosmans, J.M. (310) 163
Vu, T.Q., see Kanthasamy, A.G. (297) 219
Vuolteenaho, O., see Pelkonen, M. (304) 55
Vyskočil, F., see Urazaev, A.Kh. (316) 219

Wada, K., Kamisaki, Y., Kitano, M., Nakamoto, K. and Itoh, T.
Protective effect of cystathionine on acute gastric mucosal injury induced by ischemia-reperfusion in rats (294) 377
Wada, K., Kamisaki, Y., Nakamoto, K. and Itoh, T.
Effect of cystathionine as a scavenger of superoxide generated from human leukocytes or derived from xanthine oxidase in vitro (296) 335
Wada, T., Otsu, T., Hasegawa, Y., Mizuchi, A. and Ono, H.
Characterization of α_1-adrenoceptor subtypes in rat spinal cord (312) 263
Wadenberg, M.-L. and Ahlenius, S.
Antagonism by the 5-$HT_{2A/C}$ receptor agonist DOI of raclopride-induced catalepsy in the rat (294) 247
Waelbroeck, M., De Neef, P., Domenach, V., Vandermeers-Piret, M.-C. and Vandermeers, A.
Binding of the labelled muscarinic toxin ^{125}I-MT1 to rat brain muscarinic M_1 receptors (305) 187
Waelbroeck, M., Hou, X., Wehrle, J., Mutschler, E., Van Tilburg, E., Menge, W., Timmerman, H. and Lambrecht, G.
Stereoselective interaction of uncharged esters at four muscarinic receptor subtypes (303) 221
Wagner, J., see Bolkenius, F.N. (298) 37
Wagner, J., see Petty, M.A. (307) 149
Wagner, U., Bredenbröker, D., Fehmann, H.-C., Schwarz, F., Schudt, C. and Von Wichert, P.
Effects of selective and non-selective phosphodiesterase inhibitors on tracheal mucus secretion in the rat (298) 265
Wahl, P., Madsen, U., Banke, T., Krogsgaard-Larsen, P. and Schousboe, A.
Different characteristics of AMPA receptor agonists acting at AMPA receptors expressed in *Xenopus* oocytes (308) 211
Wakabayashi, H., see Tokuyama, S. (295) 123
Wakabayashi, I., Kukovetz, W.R. and Groschner, K.
NH_4Cl-induced contraction of porcine coronary artery involves activation of dihydropyridine-sensitive Ca^{2+} entry (299) 139
Wakao, T., see Nakamura, J. (294) 207
Walden, P.D., see Hatano, A. (313) 135
Walker, G., Kunz, D., Pignat, W., Wiesenberg, I., Van den Bosch, H. and Pfeilschifter, J.
Tetranactin inhibits interleukin 1β and cAMP induction of group II phospholipase A_2 in rat renal mesangial cells (306) 265
Walker, J.M., see Matsumoto, R.R. (301) 31
Walker, J.M., see Miller, A.S. (304) 29
Walker, M.J.A., see Pugsley, M.K. (294) 319
Wall, T.M., Linseman, D.A. and Hartman, J.C.
Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism (306) 165
Wallace, D.R. and Booze, R.M.
Dopamine D_3 receptor density elevation in aged Fischer-344 × Brown-Norway (F1) rats (308) 283
Wallis, R.A. and Panizzon, K.L.
Felbamate neuroprotection against CA1 traumatic neuronal injury (294) 475
Wallis, R.A., see Girard, J. (300) 43
Walsh, R.E., see Namovic, M.T. (315) 81
Walters, D.E., see Shieh, G.-J. (311) 103
Wan, F.-J., Caine, S.B. and Swerdlow, N.R.
The ventral subiculum modulation of prepulse inhibition is not mediated via dopamine D_2 or nucleus accumbens non-NMDA glutamate receptor activity (314) 9
Wang, H.-L., see Wu, T. (307) 125
Wang, S.Z., Edmundson, R., Zhu, S.Z. and El-Fakahany, E.E.
Selective enhancement of antagonist ligand binding at muscarinic M_2 receptors by heparin due to receptor uncoupling (296) 113
Wang, X., see Yue, T.-L. (294) 585
Wang, Y.-X., Zheng, Y.-M. and Zhou, X.-B.
Inhibitory effects of berberine on ATP-sensitive K^+ channels in cardiac myocytes (316) 307
Wang, Y.-X., see Zagvazdin, Y. (303) 61
Wang, Z., see Van den Berg, R.J. (316) 87
Wang, Z.-Q., see Salvemini, D. (303) 217
Wang, Z.-Y., Monstein, H.-J. and Håkanson, R.
Release of preprotachykinin-A mRNA from rabbit iris upon C-fibre stimulation (297) 157
Wanstall, J.C. and O'Brien, E.
In vitro hypoxia on rat pulmonary artery: effects on contractions to spasmogens and role of K_{ATP} channels (303) 71
Ward, C.A., see Sato, N. (314) 373
Ward, M., see O'Neill, M.J. (310) 115
Ward, M.A., see Bath, C.P. (299) 103
Warltier, D.C., see Hettrick, D.A. (316) 237
Warltier, D.C., see Lowe, D. (304) 81
Warner, T.D., see D'Amico, M. (316) 245
Wascher, T.C., see Graier, W.F. (294) 221
Wasserman, M.A., see Gater, P.R. (304) 123
Watanabe, A., see Yakushi, Y. (314) 243
Watanabe, K., see Kimura, T. (311) 265
Watanabe, K., see Tsukii, K. (298) 87
Watanabe, M., see Henmi, S. (306) 227
Watanabe, M., see Yoshida, A. (312) 115
Watanabe, S., see Ohno, M. (307) 21
Watanabe, S., see Ohno, M. (312) 145
Watanabe, T., see Kitayoshi, T. (305) 137
Watanabe, T., see Kusumoto, K. (296) 65
Watanabe, Y., see Abe, K. (297) 43
Watanabe, Y., see Nishio, E. (301) 203
Watanabe, Y., see Win, N.H.H. (299) 119
Waters, S.M., see Konkoy, C.S. (297) 47
Watson, J., see Gonsalves, S. (305) 181
Watson, J.M., Burton, M.J., Price, G.W., Jones, B.J. and Middlemiss, D.N.
GR127935 acts as a partial agonist at recombinant human 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors (314) 365
Watson, N., Reddy, H. and Eglen, R.M.
Characterization of muscarinic receptor and β-adrenoceptor interactions in guinea-pig oesophageal muscularis mucosae (294) 779
Watson, S.J., see Meng, F. (311) 285
Wattanathorn, J., Kotchabhakdi, N., Casalotti, S.O., Baldwin, B.A. and

Govitrapong, P.
Ethanol alone or with dexamethasone alters the kinetics of choline acetyltransferase (313) 69
Webb, M.L., see Bird, J.E. (294) 183
Weber, A.-A., Neuhaus, T., Seul, C., Düsing, R., Schrör, K., Sachinidis, A. and Vetter, H.
Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells (309) 209
Weber, E., see Ilyin, V.I. (310) 107
Wędzony, K., Maćkowiak, M., Fijał, K. and Gołembiowska, K.
Ipsapirone enhances the dopamine outflow via 5-HT_{1A} receptors in the rat prefrontal cortex (305) 73
Wędzony, K., see Bijak, M. (305) 79
Wegelius, K., see Honkanen, A. (304) 7
Wehrle, J., see Waelbroeck, M. (303) 221
Wei, E.T., Thomas, H.A., Price, J.S. and Kishimoto, T.
[D-Pro^5]Corticotropin-releasing factor analogs as selective agonists at corticotropin-releasing factor receptors (306) 161
Weigert, N., see Willis, S. (315) 59
Weinshank, R., see Adham, N. (304) 231
Weiss, R.M., see Saito, M. (310) 197
Weizman, R., see Gordon, I. (298) 27
Wellman, S.E., see Suzuki, T. (295) 169
Wenberg, K., see Gruen, R.J. (309) 115
Wendel, A., see Gantner, F. (294) 353
Werling, L.L., see Gonzalez-Alvear, G.M. (294) 713
West, A.R. and Galloway, M.P.
Desensitization of 5-hydroxytryptamine-facilitated dopamine release in vivo (298) 241
Westerink, B.H.C., see Drijfhout, W.J. (308) 117
Westerink, B.H.C., see Moor, E. (294) 155
White, D.L., see Fox, N. (308) 195
White, P.J., Rose'Meyer, R.B. and Hope, W.
Changes in adenosine receptors mediating hypotension in morphine-dependent rats (294) 215
White, T.D.
Potentiation of excitatory amino acid-evoked adenosine release from rat cortex by inhibitors of adenosine kinase and adenosine deaminase and by acadesine (303) 27
White, T.D., see Cahill, C.M. (298) 45
White, T.D., see Golembiowska, K. (307) 157
Whittemore, E.R., see Ilyin, V.I. (310) 107
Whittle, B.J.R., see Lamarque, D. (313) R5
Whitton, P.S., see Biggs, C.S. (299) 83
Whorlow, S.L., Loiacono, R.E., Angus, J.A. and Wright, C.E.
Distribution of N-type Ca^{2+} channel binding sites in rabbit brain following central administration of ω-conotoxin GVIA (315) 11
Wickenden, A.D., Prior, H., Kelly, E., Russell, K., Poucher, S.M. and Kumar, P.
The effects of pharmacological modulation of K_{ATP} on the guinea-pig isolated diaphragm (302) 79
Widdop, R.E., see Farina, N.K. (310) 185
Widmer, U., see Lundkvist, J. (309) 195
Wie, M.-B., see Song, D.-K. (316) 165
Wiedermann, C.J., Auer, B., Sitte, B., Reinisch, N., Schratzberger, P. and Kähler, C.M.
Induction of endothelial cell differentiation into capillary-like structures by substance P (298) 335
Wiedermann, C.J., see Kähler, C.M. (304) 135
Wieland, T., see Michel, M.C. (309) 87
Wiesenberg, I., see Walker, G. (306) 265
Wikberg, J.E.S., see Schiöth, H.B. (314) 381
Wikström, H., see Barf, T. (297) 205
Wikström, H., see Lahti, R.A. (301) R11
Wikström, H., see Saxena, P.R. (312) 53
Wilderman, M.J. and Armstead, W.M.
Influence of cAMP on cerebrospinal fluid opioid concentration: role in cAMP-induced pial artery dilation (309) 243
Wiley, J.L., Cristello, A.F. and Balster, R.L.
Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice (294) 101
Wiley, J.L., see Bowen, S.E. (312) 131
Wilffert, B., see Schneider, J. (302) 69
Willer, J.-C., see Gozariu, M. (313) 51
Willer, J.-C., see Guirimand, F. (294) 651
Williamson, A.P., Seifen, E., Lindemann, J.P. and Kennedy, R.H.
The positive inotropic effect of α_{1A}-adrenoceptor stimulation is inhibited by 4-aminopyridine (304) 73
Willis, R.J., see Harden, F.A. (307) 49
Willis, S., Allescher, H.-D., Weigert, N., Schusdziarra, V. and Schumpelick, V.
Influence of the L-arginine-nitric oxide pathway on vasoactive intestinal polypeptide release and motility in the rat stomach in vitro (315) 59
Willner, P., see Papp, M. (296) 129
Willner, P., see Papp, M. (310) 99
Wilsch, V.W., see Pidoplichko, V.I. (303) 145
Wilson, C.A., see Gonzalez, M.I. (312) 1
Wilson, R., see Kolesnikov, Y. (310) 141
Win, N.H.H., Ishikawa, T., Saito, N., Kato, M., Yokokura, H., Watanabe, Y., Iida, Y. and Hidaka, H.
A new and potent calmodulin antagonist, HF-2035, which inhibits vascular relaxation induced by nitric oxide synthase (299) 119
Winaver, J., see Gurbanov, K. (310) 193
Winkler Prins, E.A., see Zwaveling, J. (300) 91
Winter, J.C., see Rabin, R.A. (316) 343
Wise, R.A., Gingras, M.A. and Amit, Z.
Influence of novel and habituated testing conditions on cocaine sensitization (307) 15
Witzemann, V., see Cooper, J.C. (309) 287
Wnendt, S., see Schneider, J. (302) 69
Woda, A., see Dallel, R. (314) 19
Wolz, P., see Semkova, I. (315) 19
Wong, C.-S., Cherng, C.-H., Luk, H.-N., Ho, S.-T. and Tung, C.-S.
Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at μ-opioid receptors (297) 27
Wong, G., Kuoppamäki, M., Hietala, J., Lüddens, H., Syvälahti, E. and Korpi, E.R.
Effects of clozapine metabolites and chronic clozapine treatment on rat brain $GABA_A$ receptors (314) 319
Wong, H.R., see Szabó, C. (315) 221
Wong, M.G., see Cheung, N.S. (313) 159
Wong, S.M., see Salunga, T.L. (304) 163
Wong, T.-M., see Sheng, J.-Z. (307) 323
Woo, J.-T., Yamaguchi, K., Hayama, T., Kobori, T., Sigeizumi, S., Sugimoto, K., Kondo, K., Tsuji, T., Ohba, Y., Tagami, K. and Sumitani, K.
Suppressive effect of *N*-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo (300) 131
Wood, D., see Davies, M.P. (297) 249
Wood, J.D., see Xia, Y. (316) 81
Wood, J.D., see Zafirov, D. (311) 61
Wood, M., see Lightowler, S. (296) 137
Wood, P.L., see Hawkinson, J.E. (304) 141
Wood, P.L., see Hawkinson, J.E. (307) 219
Woodruff, G.N., see Singh, L. (307) 283
Woods, C.M., see Young, L.T. (309) 215
Woods, S.W., see Rosen, M.I. (307) 251
Woodward, J.J., see Moore, K.A. (311) 133
Woodward, R.M., see Ilyin, V.I. (310) 107
Wright, C.E., see Whorlow, S.L. (315) 11
Wright, R.A. and Schoepp, D.D.
Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus (297) 275
Wu, C.-C., Ruetten, H. and Thiemermann, C.
Comparison of the effects of aminoguanidine and N^{ω}-nitro-L-arginine

methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat (300) 99
Wu, D., see Szeto, H.H. (297) 77
Wu, D., see Szeto, H.H. (309) 183
Wu, H.-Q., see Speciale, C. (315) 263
Wu, T. and Wang, H.-L.
The excitatory effect of cholecystokinin on rat neostriatal neurons: ionic and molecular mechanisms (307) 125
Wu, T.-S., see Guh, J.-H. (298) 191
Wülfert, E., see Kim, S.Y. (316) 249
Wüllner, U., see Eblen, F. (299) 9
Wüllner, U., see Klockgether, T. (301) 67
Wuyts, F., see Van Put, D.J.M. (294) 753
Wyllie, M.G., see Ramage, A.G. (294) 645
Wynne, D.G., Del Monte, F. and Harding, S.E.
Cyclic AMP levels in ventricular myocytes from noradrenaline-treated guinea-pigs (310) 235

Xia, Y., Fertel, R.H. and Wood, J.D.
Stimulation of formation of adenosine 3′,5′-phosphate by histamine in myenteric ganglia isolated from guinea-pig small intestine (316) 81
Xia, Y., see Zafirov, D. (311) 61
Xiao, R., see Sim, L.J. (307) 97
Xiao, Z.-S., see Li, Y.-J. (311) 163
Xu, K., see Han, C. (294) 593
Xue, B.G., Friend, J.M. and Gee, K.W.
Loreclezole modulates [^{35}S]*t*-butylbicyclophosphorothionate and [^{3}H]flunitrazepam binding via a distinct site on the $GABA_A$ receptor complex (300) 125
Xue, L., Fukuta, H., Yamamoto, Y. and Suzuki, H.
Dual effects of trimebutine on electrical responses of gastric smooth muscles in the rat (294) 75
Xue, Y.-x., see Furukawa, Y. (300) 203
Xue, Y.-x., see Eto, K. (298) 247

Yabuuchi, K., Nishiyori, A., Minami, M. and Satoh, M.
Biphasic effects of intracerebroventricular interleukin-1β on mechanical nociception in the rat (300) 59
Yagi, N., see Naito, Y. (294) 47
Yakushi, Y., Watanabe, A., Murayama, T. and Nomura, Y.
P_2 purinoceptor-mediated stimulation of adenylyl cyclase in PC12 cells (314) 243
Yamada, J., Sugimoto, Y., Yoshikawa, T. and Horisaka, K.
Effects of a nitric oxide synthase inhibitor on 5-HT_{1A} receptor agonist 8-OH-DPAT-induced hyperphagia in rats (316) 23
Yamada, J., see Sugimoto, Y. (307) 75
Yamada, J., see Sugimoto, Y. (316) 15
Yamada, Y., see Hattori, Y. (301) 99
Yamagishi, R., Akiyama, K., Nakamura, S., Hora, M., Masuda, N., Matsuzawa, A., Murata, S., Ujiie, A., Kurashina, Y., Iizuka, K. and Kitazawa, M.
Effect of KMD-3213, an α_{1a}-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta (315) 73
Yamaguchi, K., see Woo, J.-T. (300) 131
Yamaguchi, T., see Okada, M. (309) 299
Yamaguchi, Y., Higashi, M. and Kobayashi, H.
Effects of ginsenosides on impaired performance caused by scopolamine in rats (312) 149
Yamaguchi, Y., see Kitagawa, S. (297) 71
Yamamoto, H., see Kishioka, S. (316) 7
Yamamoto, H., see Sagi, N. (304) 185
Yamamoto, I., see Kimura, T. (311) 265
Yamamoto, N., Sakai, F., Yamazaki, H., Nakahara, K. and Okuhara, M.
Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation (314) 137
Yamamoto, N., Yokota, K., Yamashita, A. and Oda, M.
Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo (297) 225
Yamamoto, T., Horikawa, N., Komuro, Y. and Hara, Y.
Effect of topical application of a stable prostacyclin analogue, SM-10902 on wound healing in diabetic mice (302) 53
Yamamoto, T., see Oh-ishi, S. (300) 255
Yamamoto, T., see Sagi, N. (304) 185
Yamamoto, T., see Suzuki, T. (310) 243
Yamamoto, Y., see Xue, L. (294) 75
Yamamura, H.I., see Li, X. (300) R1
Yamano, M., see Nagakura, Y. (311) 67
Yamashita, A., see Yamamoto, N. (297) 225
Yamashita, H., see Osajima, A. (315) 319
Yamaura, T., see Ichikawa, T. (297) 87
Yamawaki, S., see Takao, K. (294) 721
Yamawaki, S., see Takebayashi, M. (297) 137
Yamazaki, H., see Yamamoto, N. (314) 137
Yamazaki, J., see Kusayama, T. (312) 301
Yamazaki, K., Furukawa, Y., Kasama, M., Imamura, H. and Chiba, S.
Negative chronotropic and dromotropic effects of E-4031, an I_{Kr} blocker, on the atrioventricular node in anesthetized dog hearts (297) 233
Yan, Q.-S., Reith, M.E.A., Jobe, P.C. and Dailey, J.W.
Focal ethanol elevates extracellular dopamine and serotonin concentrations in the rat ventral tegmental area (301) 49
Yanagi, K., see Hisamichi, N. (312) 69
Yanagisawa, I., see Hisamichi, N. (312) 69
Yang, H.-T. and Endoh, M.
(±)-Tamsulosin, an α_{1A}-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart (312) 281
Yang, H.-T., Norota, I., Zhu, Y. and Endoh, M.
Methoxamine-induced inhibition of the positive inotropic effect of endothelin via α_1-adrenoceptors in the rabbit heart (296) 47
Yang, J., see Uchida, I. (307) 89
Yang, K.X.F. and Black, J.L.
Protein kinase C induced changes in human airway smooth muscle tone: the effects of Ca^{2+} and Na^+ transport (315) 65
Yang, R.S., see Chang, M.C. (297) 129
Yao, H., see Cai, H. (313) 103
Yarygin, V.N., see Lyupina, Y.V. (304) 23
Yashpal, K., Hui-Chan, C.W.Y. and Henry, J.L.
SR 48968 specifically depresses neurokinin A- vs. substance P-induced hyperalgesia in a nociceptive withdrawal reflex (308) 41
Yasuda, H., see Iga, Y. (308) 13
Yasui, J., see Ishibashi, T. (303) 247
Yasui, K., Niki, I. and Hidaka, H.
90-kDa S6 kinase is insufficient or not involved in the activation of glycogen synthase induced by insulin (316) 317
Yasukura, T., see Tanabe, T. (299) 187
Yasumitsu, R., Hirayama, Y., Imai, T., Miyayasu, K. and Hiroi, J.
Effects of specific tachykinin receptor antagonists on citric acid-induced cough and bronchoconstriction in unanesthetized guinea pigs (300) 215
Yasumoto, T., see Nishio, M. (297) 293
Yatani, A., see Lai, L.-P. (309) 235
Yazaki, N., see Taniguchi, H. (304) 147
Yazaki, N., see Taniguchi, H. (312) 227
Yee, J., see Szeto, H.H. (297) 77
Yee, J.S., see Szeto, H.H. (309) 183
Yen, M.-H., see Sheu, J.-R. (294) 231
Ying, S.-W., Rusak, B., Delagrange, P., Mocaër, E., Renard, P. and Guardiola-Lemaître, B.
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas (296) 33
Yiu, M.-k., Kwan, Y.W. and Ngan, M.-p.
Hormonal modulation of benzodiazepines' actions on rat isolated uterus (302) 99
Ylinen, A., see Lahtinen, H. (297) 213
Yokokura, H., see Win, N.H.H. (299) 119

Yokoo, H., see Tanaka, T. (297) 35
Yokota, K., see Yamamoto, N. (297) 225
Yomota, E., see Taniguchi, H. (312) 227
Yonezawa, T., Furukawa, Y., Kasama, M., Hoyano, Y., Imamura, H. and Chiba, S.
Inhibition by bertosamil of cardiac responses to pinacidil or Bay k 8644 in isolated dog atria and ventricles (309) 51
Yonezawa, T., Furukawa, Y., Lakhe, M., Nagashima, Y., Hirose, M. and Chiba, S.
PACAP-38 activates parasympathetic nerves in isolated, blood-perfused dog atria (315) 289
Yoshida, A., Hisatome, I., Nawada, T., Sasaki, N., Taniguchi, S.-i., Tanaka, Y., Manabe, I., Ahmmed, G.U., Sato, R., Mori, A., Hattori, K., Ueta, Y., Mitani, Y., Watanabe, M., Igawa, O., Fujimoto, Y. and Shigemasa, C.
Amitriptyline inhibits the G protein and K^+ channel in the cloned thyroid cell line (312) 115
Yoshida, K., see Fujiki, H. (313) 191
Yoshida, M., see Adachi, Y. (308) 165
Yoshida, M., see Tanaka, T. (297) 35
Yoshida, N., see Naito, Y. (294) 47
Yoshida, N., see Yoshikawa, T. (301) 143
Yoshida, Y., see Koshikawa, N. (303) 13
Yoshihara, S., Geppetti, P., Hara, M., Lindén, A., Ricciardolo, F.L.M., Chan, B. and Nadel, J.A.
Cold air-induced bronchoconstriction is mediated by tachykinin and kinin release in guinea pigs (296) 291
Yoshii, T., see Tsuji, M. (313) 169
Yoshikawa, T., Yoshida, N. and Hosoki, K.
Involvement of dopamine D_3 receptors in the area postrema in *R*(+)-7-OH-DPAT-induced emesis in the ferret (301) 143
Yoshikawa, T., see Naito, Y. (294) 47
Yoshikawa, T., see Sugimoto, Y. (307) 75
Yoshikawa, T., see Sugimoto, Y. (316) 15
Yoshikawa, T., see Yamada, J. (316) 23
Yoshimatsu, A., see Ohno, M. (307) 21
Yoshioka, M., Matsumoto, M., Numazawa, R., Togashi, H., Smith, C.B. and Saito, H.
Changes in the regulation of 5-hydroxytryptamine release by α_2-adrenoceptors in the rat hippocampus after long-term desipramine treatment (294) 565
Youdim, M.B.H., see Gassen, M. (308) 219
Young, A.A., see Vine, W. (314) 115
Young, L.T. and Woods, C.M.
Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells (309) 215
Yu, G., see Han, C. (294) 593
Yu, H., Liu, Y., Malmberg, Å., Mohell, N., Hacksell, U. and Lewander, T.
Differential serotoninergic and dopaminergic activities of the (*R*)- and the (*S*)-enantiomers of 2-(di-*n*-propylamino)tetralin (303) 151
Yu, S.-M., see Guh, J.-H. (298) 191
Yuan, C.-S.
Gastric effects of μ-, δ- and κ-opioid receptor agonists on brainstem unitary responses in the neonatal rat (314) 27
Yue, J.-L., see Miyamae, T. (300) 105
Yue, T.-L., Wang, X., Gu, J.-L., Ruffolo, Jr., R.R. and Feuerstein, G.Z.
Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation (294) 585
Yun, R.J., see Kanthasamy, A.G. (297) 219

Zaccheo, D., see Barili, P. (310) 129
Zadina, J.E., see Gergen, K.A. (298) 235
Zadina, J.E., see Gergen, K.A. (316) 33
Zafirov, D., Xia, Y., Furuhama, K. and Wood, J.D.
Actions of Daiichi DQ-2511 on electrical and synaptic behavior of enteric neurons in the guinea-pig small intestine (311) 61
Zagvazdin, Y., Sancesario, G., Wang, Y.-X., Share, L., Fitzgerald, M.E.C. and Reiner, A.
Evidence from its cardiovascular effects that 7-nitroindazole may inhibit endothelial nitric oxide synthase in vivo (303) 61
Zajac, J.-M., see Dossin, O. (308) 271
Zajac, J.-M., see Roumy, M. (306) 291
Zajaczkowski, W., Quack, G. and Danysz, W.
Infusion of (+)-MK-801 and memantine – contrasting effects on radial maze learning in rats with entorhinal cortex lesion (296) 239
Zakrzewska, K., see Chow, L. (294) 309
Zalewska, T., see Li, X. (300) R1
Zambon, A.C., see Matsumoto, R.R. (301) 31
Zanni, M., see Giardino, L. (312) 183
Zarifian, E., see Abadie, P. (295) 35
Zarrindast, M.-R. and Farzin, D.
Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice (298) 1
Zarrindast, M.-R., Sadegh, M. and Shafaghi, B.
Effects of nicotine on memory retrieval in mice (295) 1
Zarrindast, M.-R., Sharifzadeh, M. and Sadeghi, A.-I.
Theophylline-induced grooming: possible indirect dopaminergic mechanism (306) 1
Zeegers, A., see Leeuwin, R.S. (299) 149
Zeegers, A., see Leeuwin, R.S. (315) 153
Zeng, X.-T., see Tanabe, T. (314) 175
Zerr, P., Becherer, U., Rodeau, J.-L. and Feltz, A.
Forskolin's structural analogue 1,9-dideoxyforskolin has Ca^{2+} channel blocker-like action in rat cerebellar granule cells (303) 101
Zethof, T.J.J., Van der Heyden, J.A.M., Tolboom, J.T.B.M. and Olivier, B.
Stress-induced hyperthermia as a putative anxiety model (294) 125
Zetterström, T.S.C., see Mirza, N.R. (295) 207
Zezula, J., Slany, A. and Sieghart, W.
Interaction of allosteric ligands with $GABA_A$ receptors containing one, two, or three different subunits (301) 207
Zhang, A., see Altura, B.M. (314) R9
Zhang, C., Pfaff, D.W. and Kow, L.-M.
Functional analysis of opioid receptor subtypes in the ventromedial hypothalamic nucleus of the rat (308) 153
Zhang, J.-X., Okamura, T. and Toda, N.
Pre- and postjunctional modulation by endothelin-1 of the adrenergic neurogenic response in canine mesenteric arteries (311) 169
Zhang, J.M., see Abu-Dalu, R. (309) 189
Zhang, L. and Reith, M.E.A.
Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway (315) 345
Zhang, L.
Muscarinic receptors in developing rat colon (304) 211
Zhang, S., see Brady, P.A. (308) 343
Zhang, Y., Raud, J., Hedqvist, P. and Fredholm, B.B.
Propentofylline inhibits polymorphonuclear leukocyte recruitment in vivo by a mechanism involving adenosine A_{2A} receptors (313) 237
Zhang, Y., see Han, C. (294) 593
Zhao, G.-M., see Bhargava, H.N. (311) 127
Zhao, T.-j., Rosenberg, H.C. and Chiu, T.H.
Treatment with an antisense oligodeoxynucleotide to the $GABA_A$ receptor γ_2 subunit increases convulsive threshold for β-CCM, a benzodiazepine 'inverse agonist', in rats (306) 61
Zheng, Y.-M., see Wang, Y.-X. (316) 307
Zhou, L. and Vargas, H.M.
Vascular α_{1D}-adrenoceptors have a role in the pressor response to phenylephrine in the pithed rat (305) 173
Zhou, X.-B., see Wang, Y.-X. (316) 307
Zhou, Y., Spangler, R., Maggos, C.E., LaForge, K.S., Ho, A. and Kreek, M.J.
Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin (315) 31

Zhu, S.-J., Cerutis, D.R., Anderson, J.L. and Toews, M.L.
Regulation of hamster α_{1B}-adrenoceptors expressed in Chinese hamster ovary cells (299) 205
Zhu, S.Z., see Wang, S.Z. (296) 113
Zhu, Y., see Yang, H.-T. (296) 47
Zieglgänsberger, W., see Spanagel, R. (305) 39
Zieglgänsberger, W., see Spanagel, R. (305) 45
Zieglgänsberger, W., see Spanagel, R. (305) 51
Zimlichman, R., see Heldman, E. (297) 283
Zinetti, M., see Di Santo, E. (299) 179
Zingaro, G.J., see Kivlighn, S.D. (294) 439
Zini, R., see Sapena, R. (300) 159
Zuiderwijk, M., Veenstra, E., Lopes da Silva, F.H. and Ghijsen, W.E.J.M.
Effects of uptake carrier blockers SK&F 89976-A and L-*trans*-PDC on in vivo release of amino acids in rat hippocampus (307) 275
Zumbihl, R., see Cuq, P. (315) 213
Župan, G., Vitezić, D., Mršić, J., Matešić, D. and Simonić, A.
Effects of nimodipine, felodipine and amlodipine on electroconvulsive shock-induced amnesia in the rat (310) 103
Zurita, A., Murúa, S. and Molina, V.
An endogenous opiate mechanism seems to be involved in stress-induced anhedonia (299) 1
Zvartau, E.E., see Kuzmin, A. (295) 19
Zwaveling, J., Winkler Prins, E.A., Maas, M.A.W., Pfaffendorf, M. and Van Zwieten, P.A.
The influence of hyperthyroidism on pharmacologically induced contractions of isolated resistance arteries (300) 91

ELSEVIER

European Journal of Pharmacology

ejp

Master keyword index to volumes 294–316 (1996)

A-61603
BMY 7378; 5-Methylurapidil; α_1-Adrenoceptor; Arterial pressure (Zhou, L. (305) 173)

Aaminoglycoside
Azithromycin; Macrolide; Gentamicin; Lysosomal phospholipase; Phospholipidosis; Membrane aggregation (Van Bambeke, F. (314) 203)

[^{14}C]Aminopyrine accumulation
CCK-8; [Leu^{11}]Gastrin-(5–17); CCK receptor antagonist; Gastric gland (Oiry, C. (294) 511)

Acamprosate
Alcohol; Alcohol-deprivation effect; Craving; Relapse; (Rat) (Spanagel, R. (305) 39)

Alcohol; Withdrawal; Radiotelemetry; (Rat) (Spanagel, R. (305) 45)

Ethanol; Drug discrimination; NMDA receptor antagonist; (Rat) (Spanagel, R. (305) 51)

Accumbal core
Accumbal shell; Jaw movement; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 227)

Accumbal shell; Turning behavior; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 235)

Accumbal shell
Accumbal core; Jaw movement; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 227)

Accumbal core; Turning behavior; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 235)

ACEA 1021
NMDA receptor antagonist; NPC 17742; *N*-Nitro-L-arginine methyl ester; Phencyclidine; Anxiolytic (Wiley, J.L. (294) 101)

NMDA receptor; Glycine coagonist site; Desensitization; 5,7-Dichlorokynurenic acid; L-695,902; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Acetylcholine
Hippocampus; Microdialysis; Medial septum; Muscarinic autoreceptor (Moor, E. (294) 155)

Hippocampus; Striatum; Microdialysis; NMDA receptor; NMDA receptor antagonist (Hutson, P.H. (295) 45)

Vas deferens, guinea pig; Mn^{2+}; Contraction; Norepinephrine (Tsunobuchi-Ushijima, H. (295) 235)

Neutral endopeptidase; Epithelium; Trachea; Cholinergic neurotransmission; (Rabbit) (Loenders, B. (296) 89)

Muscarinic receptor; Spare receptor; Adenylate cyclase; Selectivity (Heldman, E. (297) 283)

PAF (platelet-activating factor); Nitric oxide (NO); EDHF (endothelium-derived hyperpolarizing factor) (Kamata, K. (298) 129)

Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Nitric oxide (NO) synthase; Arterial pressure, systemic; Sodium nitroprusside; 7-Nitroindazole (Zagvazdin, Y. (303) 61)

Endothelium; Nitric oxide (NO); Hind limb, rat; EDHF (endothelium-derived hyperpolarizing factor) (Brouwers-Ceiler, D.L. (307) 65)

Choline; Blood pressure; Hypotension; Vasopressin; Nicotinic receptor (Savci, V. (311) 153)

Glutamate; NMDA receptor; Learning; Memory; Inhibitory avoidance task (Ohno, M. (312) 145)

Pulmonary artery; Prostaglandin E_1; ATP; Tolazoline; Nifedipine; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

Parasympathetic nervous system; Chronotropism; Inotropism; Heart; PACAP-38 (pituitary adenylate cyclase-activating polypeptide-38); PACAP-(6–38) (pituitary adenylate cyclase-activating polypeptide-(6–38)); (Dog) (Yonezawa, T. (315) 289)

Acetylcholine receptor
Nucleus accumbens stimulation; Dopamine receptor; Ventrolateral striatum; Dopamine release; Turning behavior (Koshikawa, N. (303) 13)

Acetylcholine receptor antagonist
Nicotine; Morphine; Naloxone; Jumping; (Mouse) (Zarrindast, M.-R. (298) 1)

Acetylcholine release
Morphine; Dopamine release; Striatum; Dopamine D_2 receptor (Nestby, P. (294) 771)

Cholinergic synaptosome; Cetiedil; Cyclosporin A (Morot Gaudry-Talarmain, Y. (296) 341)

Hippocampus; Working memory (Fadda, F. (307) R1)

Acetylcholine release, hippocampus
Morphine administration, acute and chronic; Dopamine receptor, sensitization (Imperato, A. (302) 21)

Acetylcholinesterase
Histamine-*N*-methyl transferase; Histamine H_3 receptor antagonist (Morisset, S. (315) R1)

Acetyl coenzyme A
Choline acetyltransferase; Ethanol; Dexamethasone; Enzyme affinity; Stress (Wattanathorn, J. (313) 69)

Achatin-I (Gly-D-Phe-Ala-Asp)
Peptide neurotransmitter; Intracellular signal transduction system; H-89; KT5823; W-7; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

Excitatory neuropeptide; Promethazine; Triprolidine; Histamine H_1 receptor antagonist; Blocking effect; Neuron; (Snail) (Salunga, T.L. (304) 163)

Aconitase
Nitric oxide (NO); Glyceraldehyde-3-phosphate dehydrogenase; Cell death (Meßmer, U.K. (302) 171)

ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid)
Arachidonic acid; Long-term potentiation; NMDA (*N*-methyl-D-aspartate); Melittin; Phospholipase A_2 (Collins, D.R. (294) 147)

***t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid)**
Phospholipase C; Norepinephrine; Bombesin; LA-N-2 cell; β-Adrenoceptor; Metabotropic (Sorrentino, G. (308) 81)

ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate)
Aging; Arachidonic acid; Glutamate release; Protein kinase C; Inositol trisphosphate (McGahon, B. (309) 323)

ACTH (adrenocorticotrophin)
Choline; β-Endorphin; Atropine; Mecamylamine; Hemicholinium-3 (Savci, V. (309) 275)

5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Adrenaline; Pituitary (Korte, S.M. (309) 281)

ACTH-(4–10) (adrenocorticotropic hormone-(4–10))
γ_2-MSH (γ_2-melanocyte-stimulating hormone); Blood pressure; Heart rate; Structure-activity; Melanocortin receptor; (Rat) (Van Bergen, P. (294) 795)

ACTH (adrenocorticotropin)
Sauvagine; Urotensin I; CRF (corticotropin-releasing factor) receptor; Extravasation; Inflammation (Turnbull, A.V. (303) 213)

CRF (corticotropin-releasing factor); CRF receptor; Anti-edema; Structure-activity relationship (Wei, E.T. (306) 161)

ACTH-(4–9) analog, Org 2766
Diabetic rat; Nerve blood flow; Vasa nervorum; Adrenergic responsiveness (Van Buren, T. (296) 277)

Action potential
Forskolin; 1,9-Dideoxyforskolin; Ca^{2+} current; Ryanodine store; Cerebellar granule cell (Zerr, P. (303) 101)

Acylcarnitine
Lysophosphatidylcholine; Fibrillation; Fatty acid; Excitability; Antiarrhythmic (Kang, J.X. (297) 97)

***N*-Acylethanolamide**
Palmitoylethanolamide; Autacoid local inflammatory antagonism; Cannabinoid receptor, peripheral; Neurogenic inflammation; Passive cutaneous anaphylaxis (Mazzari, S. (300) 227)

Acyltransferase
PAF (platelet-activating factor); Arachidonic acid; Triacsin C; Zymosan (Naraba, H. (302) 117)

Adaptation
Chronic citalopram; NMDA receptor; Excitatory amino acid; Cortex; Hippocampus (Nowak, G. (295) 75)

Haloperidol; Pimozide; Dopamine metabolism; Catalepsy; (Chronic treatment) (Karolewicz, B. (313) 181)

Adenine nucleotide
Endotoxin; Platelet aggregation; PAF (platelet-activating factor) (Jarvis, G.E. (315) 203)

Adenosine
Morphine dependence; Blood pressure (White, P.J. (294) 215)

Opioid; Spinal cord; Synergy (Cahill, C.M. (298) 45)

Ca^{2+}, cytosolic; Ca^{2+} domain; Cardioprotection; Fluo-3; Heart (Jovanovic, A. (298) 63)

Caffeine; Sleep regulation; Sleep EEG (electroencephalogram); (Rat) (Schwierin, B. (300) 163)

Adenosine A_{2A} receptor; ZM 241385; Pharmacology, in vivo (Keddie, J.R. (301) 107)

K^+ channel opener; K^+ channel inhibitor; K^+ channel, ATP-sensitive; Skeletal muscle; Diaphragm, guinea-pig (Wickenden, A.D. (302) 79)

Taurine; Adenosine transport inhibitor; Spreading depression; NMDA receptor; Hippocampus (Hada, J. (305) 101)

Spinal cord; Adenosine kinase; Adenosine deaminase (Golembiowska, K. (307) 157)

Nitrobenzylthioinosine; Nucleoside transport; Propentofylline (Parkinson, F.E. (308) 97)

Adenosine A_1 receptor; Binding study (Cohen, F.R. (309) 111)

Ca^{2+} uptake; Ca^{2+} channel; Brain synaptosome (Gonçalves, M.L. (310) 257)

Ischemia, treatment; Memory; MAP2 (microtubule-associated protein 2); (Gerbil) (Von Lubitz, D.K.J.E. (316) 171)

Nitric oxide (NO) synthase; mRNA expression; Anti-inflammatory; Nitric oxide (NO) (Moochhala, S.M. (316) 287)

Dopamine; Adenylyl cyclase; Fibroblast; Receptor-receptor interaction (Dasgupta, S. (316) 325)

Adenosine A_1 receptor
CCK_A receptor; 5-HT_{1B} receptor; P_{2U} purinoceptor; Inositol phosphate; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (302) 141)

Dopamine D_1 receptor; EEG (electroencephalographic) arousal; (Rabbit) (Popoli, P. (305) 123)

Ca^{2+}; Ca^{2+} pumping; DDT_1 MF-2 cell; (Temperature) (Sipma, H. (306) 187)

Binding study; Adenosine (Cohen, F.R. (309) 111)

Adenosine A_{2A} receptor
Adenosine; ZM 241385; Pharmacology, in vivo (Keddie, J.R. (301) 107)

Adenosine A_{2B} receptor; Adenosine A_3 receptor; P_3 purinoceptor; Coronary vasculature; Heart, perfused, rat (Harden, F.A. (307) 49)

CGS 21680; Vascular conductance; Radioactive microsphere technique (Nekooeian, A.A. (307) 163)

Adenosine A_{2B} receptor
Adenosine A_{2A} receptor; Adenosine A_3 receptor; P_3 purinoceptor; Coronary vasculature; Heart, perfused, rat (Harden, F.A. (307) 49)

Adenosine A_3 receptor
Hypotension; Mast cell; Histamine; APNEA (N^6-2-(4-aminophenyl)ethyladenosine); Compound 48/80 (Fozard, J.R. (298) 293)

Adenosine A_{2A} receptor; Adenosine A_{2B} receptor; P_3 purinoceptor; Coronary vasculature; Heart, perfused, rat (Harden, F.A. (307) 49)

Hemodynamics; Histamine release; Tachyphylaxis; 2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA); Rat, conscious (Van Schaick, E.A. (308) 311)

TNF-α (tumor necrosis factor α) inhibition; Macrophage; Receptor; Cross-talk (McWhinney, C.D. (310) 209)

Adenosine A_1 receptor agonist
Adenosine receptor; Adenosine A_{2A} receptor agonist; Seizure; Pentylenetetrazole; (Rat) (Adami, M. (294) 383)

Adenosine A_{2A} receptor agonist
Adenosine receptor; Adenosine A_1 receptor agonist; Seizure; Pentylenetetrazole; (Rat) (Adami, M. (294) 383)

Adenosine A_{2A} receptor, human
Mutation; Glutamic acid; CGS21680; XAC; Amiloride (Uzerman, A.P. (310) 269)

Adenosine deaminase
Glutamate receptor, metabotropic; cAMP; Forskolin; VIP (vasoactive intestinal peptide); NECA (5'-*N*-ethylcarboxamidoadenosine); Hippocampus (Wright, R.A. (297) 275)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid); Kainate; Adenosine kinase; AICAR (AICA riboside, acadesine) (White, T.D. (303) 27)

Adenosine; Spinal cord; Adenosine kinase (Golembiowska, K. (307) 157)

Adenosine kinase
NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid); Kainate; Adenosine deaminase; AICAR (AICA riboside, acadesine) (White, T.D. (303) 27)

Adenosine; Spinal cord; Adenosine deaminase (Golembiowska, K. (307) 157)

Adenosine, pharmacology
Antinociception; Allodynia; Spinal cord; (Mouse) (Keil II, G.J. (312) 7)

Adenosine receptor
Adenosine A_1 receptor agonist; Adenosine A_{2A} receptor agonist; Seizure; Pentylenetetrazole; (Rat) (Adami, M. (294) 383)

Cerebral ischemia; Spatial memory; Water maze; (Gerbil) (Von Lubitz, D.K.J.E. (302) 43)

Vas deferens, rat; Receptor distribution (Brownhill, V.R. (303) 87)

Astrocyte, rat; cAMP accumulation (Peakman, M.-C. (306) 281)

Heart; β-Adrenoceptor; Species difference; (Guinea pig); (Pig); (Rabbit); (Rat) (Musser, B. (308) 357)

Propentofylline; Xanthine; Myeloperoxidase; Polymorphonuclear leukocyte influx (Zhang, Y. (313) 237)

Adenosine receptor agonist
Dopamine receptor antagonist; Behavioral interaction; Catalepsy; Schizophrenia (Kafka, S.H. (295) 147)

Adenosine receptor blocking drug
Benzodiazepine; Diazepam; Langendorff heart; Inotropy; Ca^{2+}-entry blocking drug (Leeuwin, R.S. (315) 153)

Adenosine transport inhibitor
Taurine; Adenosine; Spreading depression; NMDA receptor; Hippocampus (Hada, J. (305) 101)

Adenosine 5'-triphosphate
P_1 purinoceptor; P_2 purinoceptor; Trachealis muscle, guinea-pig, isolated; Suramin; 8-Sulphophenyltheophylline (Piper, A.S. (307) 183)

Adenylate cyclase
Cannabinoid receptor; Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; cAMP (Pertwee, R.G. (296) 169)

Muscarinic receptor; Acetylcholine; Spare receptor; Selectivity (Heldman, E. (297) 283)

α_{2B}-Adrenoceptor; Muscarinic M_4 receptor; δ-Opioid receptor; Prostaglandin E_1 receptor; Receptor cross-talk (Ammer, H. (302) 199)

CRF receptor; IMR-32 human neuroblastoma cell line; Differentiation; Radioligand binding (Hogg, J.E. (312) 257)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP (Xia, Y. (316) 81)

Adenylyl cyclase
Excitatory amino acid; Metabotropic glutamate receptor; GTP hydrolysis; G-protein; Cerebral cortex (Odagaki, Y. (300) 151)

β_2-Adrenoceptor; Receptor sequestration; CHO (Chinese hamster ovary) cell (Gabilondo, A.M. (307) 243)

Desensitization; Phospholipase C; G-protein (Galas, M.-C. (314) 157)

T-0509; β_1-Adrenoceptor agonist; β_3-Adrenoceptor; Intrinsic activity (Sato, Y. (315) 363)

Adenosine; Dopamine; Fibroblast; Receptor-receptor interaction (Dasgupta, S. (316) 325)

Ibogaine; Noribogaine; 5-HT receptors; Opioid receptors; Muscarinic acetylcholine receptors (Rabin, R.A. (316) 343)

Adenylyl cyclase activity
Steroidogenesis; CGRP (calcitonin gene-related peptide); Amylin; Adrenomedullin; CGRP receptor, type 2; Corticosteroid secretion (Esneu, M. (308) 187)

Adhesion
Glycosphingolipid; Tumor; Recombinant interleukin-2; Peritumoral (Tubaro, E. (294) 555)

Carvedilol; Low-density lipoprotein (LDL); Antioxidant; Monocyte (Yue, T.-L. (294) 585)

Adipocyte, rat, white
Lipolysis; β_3-Adrenoceptor; ZD7114, partial agonist effect (Mayers, R.M. (295) 199)

Adipose differentiation
β-Adrenoceptor; cAMP; Lipolysis (El Hadri, K. (297) 107)

A10 dopamine neuron
JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine); Antidepressant; Dorsal raphe; Locus coeruleus; Electrophysiology (Liégeois, J.-F. (310) 9)

ADP ribosylation
Lithium chloride; Valproic acid; G-protein; Bipolar disorder (Young, L.T. (309) 215)

Adrenal denervation
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Plasma catecholamine (Vietor, I. (313) 119)

Adrenalectomy
L-*N*-Arginine methyl ester (L-NAME); Nitric oxide (NO); Forced swimming test; Glucocorticoid (Jefferys, D. (295) 131)

Lipopolysaccharide; Endotoxin tolerance; Vascular permeability; Cytokine; Nitric oxide (NO) (Fujii, E. (313) 129)

Adrenal gland
Otilonium; Chromaffin cell; Ca^{2+} channel; Catecholamine release (Gandía, L. (298) 199)

Adrenaline
Imidazoline; α_2-Adrenoceptor; Insulin release; (In vivo); (Rat) (Hiyoshi, Y. (294) 117)

5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Pituitary; ACTH (adrenocorticotrophin) (Korte, S.M. (309) 281)

Adrenaline release
Chromaffin cell; Cell separation; Noradrenaline release; Nicotinic acetylcholine receptor (Krause, W. (302) 223)

Adrenal medulla
Dopamine receptor; Radioligand binding; Autoradiography; Chromaffin cell; (Rat) (Barili, P. (310) 129)

Adrenergic component
δ-Opioid receptor; Vas deferens, mouse; Cysteine sulfonamide enkephalin analog; Dalargin; Purinergic component; Electrical field stimulation (Pencheva, N. (304) 99)

Adrenergic nerve stimulation
Endothelin-1; Endothelin ET_A receptor; Prejunctional inhibition; Postjunctional potentiation; Mesenteric artery (Zhang, J.-X. (311) 169)

Tail artery, rat; Noradrenaline release; Gonadectomy (García-Villalón, A.L. (314) 339)

Adrenergic responsiveness
Diabetic rat; Nerve blood flow; Vasa nervorum; ACTH-(4–9) analog, Org 2766 (Van Buren, T. (296) 277)

Adrenoceptor
Desensitization; Internalization; Up-regulation; Intact cell binding (Zhu, S.-J. (299) 205)

Vas deferens; Noradrenaline; Agmatine; Neurotransmission; Imidazoline receptor (Jurkiewicz, N.H. (307) 299)

n−3 fatty acid; cAMP; Norepinephrine; Pinealocyte; (Rat) (Delton-Vandenbroucke, I. (312) 379)

α-Adrenoceptor
Prostate; cDNA; Fibroblast, rat-1; Doxazosin; (Enantiomer) (Hatano, A. (313) 135)

α_1-Adrenoceptor
Methoxamine; Positive inotropic effect; Endothelin; Ventricular myocardium, rabbit (Yang, H.-T. (296) 47)

Blood vessel; (±)-SDZ NVI 085; 5-HT_{2A} receptor (Lachnit, W.G. (297) 83)

NMDA receptor; Water maze; Passive avoidance; Prazosin; CPP ((±))-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Riekkinen, M. (300) 9)

BMY 7378; 5-Methylurapidil; A-61603; Arterial pressure (Zhou, L. (305) 173)

Liver; Hepatocyte; (Rhesus monkey) (García-Sáinz, J.A. (311) 277)

Uterine artery; Estrous cycle; Pregnancy (Nair, R. (312) 45)

Positive inotropic effect; Phosphoinositide hydrolysis; Oxymetazoline; Ventricular myocardium, rabbit; (±)-Tamsulosin [(±)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]-amino]propyl]-2-methoxybenzenesulfonamide-HCl] (Yang, H.-T. (312) 281)

α_{1a}-Adrenoceptor
KMD-3213; α_1-Adrenoceptor subtype; Prostate; Thoracic aorta (Yamagishi, R. (315) 73)

α_{1A}-Adrenoceptor
α_{1D}-Adrenoceptor; BMY 7378; Spontaneously hypertensive rat (SHR); Artery; Wistar Kyoto rat (WKY) (Villalobos-Molina, R. (298) 257)

α_{1D}-Adrenoceptor
Radioligand binding; Contractility; Aorta, rat (Buckner, S.A. (297) 241)

α_{1A}-Adrenoceptor; BMY 7378; Spontaneously hypertensive rat (SHR); Artery; Wistar Kyoto rat (WKY) (Villalobos-Molina, R. (298) 257)

α_{1L}-Adrenoceptor
α_1-Adrenoceptor subtype; JTH-601; Prazosin (Muramatsu, I. (300) 155)

α_2-Adrenoceptor
Imidazoline; Adrenaline; Insulin release; (In vivo); (Rat) (Hiyoshi, Y. (294) 117)

5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Desipramine (Yoshioka, M. (294) 565)

Purinergic transmission; P_{2X} purinoceptor; Autoinhibition; Electrical stimulation; Splenic artery; (Dog) (Ren, L.-M. (295) 61)

Central hyperalgesia; Atipamezole; Medetomidine; Neurogenic pain; Lateral reticular nucleus of the medulla; Spinal cord (Mansikka, H. (297) 19)

Analgesia; μ-Opioid receptor; Spinal cord; Desipramine; Neuropeptide (Gergen, K.A. (298) 235)

Phospholipase D; Smooth muscle, vascular; Tyrosine kinase; $pp60^{src}$; Hypertension; Protein kinase C (Jinsi, A. (302) 183)

Dexmedetomidine; DOI (1-(2.5-dimethoxy-4-iodophenyl)-2-aminopropane); Ritanserin; Monoamine; Locus ceruleus; (Rat) (Rabin, B.C. (306) 51)

Spinal cord, neonatal; Spinal cord, adult; Cerebral cortex; Imidazole receptor; Imidazole-preferring binding site (Savola, M.K.T. (306) 315)

Delequamine; RS15385; Lordosis; Sexual behavior, female; (Rat) (Gonzalez, M.I. (312) 1)

Analgesia; Pain; (Amphibian) (Stevens, C.W. (316) 205)

α_{2A}-Adrenoceptor
G_i-protein; Neuropeptide Y receptor; Ca^{2+}; Microtubule; Microfilament (Michel, M.C. (309) 87)

α_{2B}-Adrenoceptor
Adenylate cyclase; Muscarinic M_4 receptor; δ-Opioid receptor; Prostaglandin E_1 receptor; Receptor cross-talk (Ammer, H. (302) 199)

β-Adrenoceptor
Forced swim test; Stress; 5-HT_2 receptor; Wet-dog shake (Takao, K. (294) 721)

Adipose differentiation; cAMP; Lipolysis (El Hadri, K. (297) 107)

Glucose; Insulin; Pancreatic islet, blood flow; Blood pressure (Atef, N. (298) 287)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Dorsal hippocampus; Microdialysis (Petersen, B. (300) 67)

mRNA; Hybridisation, in situ; Northern blot analysis (Mak, J.C.W. (302) 215)

β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

Atropine; Methyl-quinuclidinyl-benzylate; CGP-12177; PET (positron emission tomography); Heart; Muscarinic receptor (Valette, H. (306) 133)

Noradrenaline; Propranolol; NMDA receptor; Hippocampus; Working memory (Ohno, M. (307) 21)

Phospholipase C; Norepinephrine; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); Bombesin; LA-N-2 cell; Metabotropic (Sorrentino, G. (308) 81)

Heart; Adenosine receptor; Species difference; (Guinea pig); (Pig); (Rabbit); (Rat) (Musser, B. (308) 357)

Microdialysis, in vivo; Citalopram; WAY-100635; Penbutolol enantiomer; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; Antidepressant augmentation (Hjorth, S. (316) 43)

β_1-Adrenoceptor
β_2-Adrenoceptor; Antibody; Fusion protein (Jahns, R. (316) 111)

β_2-Adrenoceptor
Adenylyl cyclase; Receptor sequestration; CHO (Chinese hamster ovary) cell (Gabilondo, A.M. (307) 243)

β_1-Adrenoceptor; Antibody; Fusion protein (Jahns, R. (316) 111)

β_3-Adrenoceptor
Adipocyte, rat, white; Lipolysis; ZD7114, partial agonist effect (Mayers, R.M. (295) 199)

β-Adrenoceptor; β-Adrenoceptor, atypical; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

β/β_3-Adrenoceptor, atypical; Smooth muscle, esophageal, rat; Trimetoquinol; Isomeric activity ratio; BRL 37344 (Lezama, E.J. (308) 69)

T-0509; β_1-Adrenoceptor agonist; Intrinsic activity; Adenylyl cyclase (Sato, Y. (315) 363)

Adrenoceptor agonist
Pain; Inflammation; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)

α_2-Adrenoceptor agonist
Mivazerol; Heart rate; NMDA receptor; Spinal cord (Kim, S.Y. (316) 249)

β_1-Adrenoceptor agonist
T-0509; β_3-Adrenoceptor; Intrinsic activity; Adenylyl cyclase (Sato, Y. (315) 363)

β_2-Adrenoceptor agonist
Uterus, rat; β_2-Adrenoceptor subtype; Pregnancy (Ohashi, T. (307) 315)

***β_2*-Adrenoceptor agonist**
Peritoneal eosinophil; Migration, in vitro; Phosphodiesterase inhibition (Alves, A.C. (312) 89)

Adrenoceptor antagonist
Pain; Inflammation; Adrenoceptor agonist; Formalin test (Hong, Y. (301) 41)

α_1-Adrenoceptor antagonist
Doxazosin; Terazosin; Sympathetic nerve activity; Bladder; (Anesthetized cat) (Ramage, A.G. (294) 645)

Microdialysis; NMDA receptor; Dizocilpine maleate; Locomotion (Mathé, J.M. (309) 1)

β-Adrenoceptor antagonist
Propranolol; S100 protein; Cardiac muscle; Mg^{2+} (Nakatani, K. (315) 335)

β-Adrenoceptor, atypical
β-Adrenoceptor; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

β/β_3-Adrenoceptor, atypical
β_3-Adrenoceptor; Smooth muscle, esophageal, rat; Trimetoquinol; Isomeric activity ratio; BRL 37344 (Lezama, E.J. (308) 69)

β-Adrenoceptor, β_1 and β_2 subtype
Desipramine; Binding site, high and low affinity; Astrocyte, isolated; Neuron, isolated (Sapena, R. (300) 159)

β-Adrenoceptor density
G-protein; Congestive heart failure; Norepinephrine (Lai, L.-P. (309) 201)

β-Adrenoceptor desensitization
Cardiac myocyte; cAMP; Contractility (Wynne, D.G. (310) 235)

β-Adrenoceptor, interaction
Aggression, isolation-induced; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Sánchez, C. (297) 1)

α_2-Adrenoceptors
RX821002; Imidazoline binding sites; Kidney, rat (Callado, L.F. (316) 359)

α_1-Adrenoceptor stimulation
Tamsulosin; Electrical field stimulation; Prostate, human (Chueh, S.-C. (305) 177)

α_1-Adrenoceptor subtype
mRNA; Heart; Thyroxine treatment (Han, C. (294) 593)

Na^+ excretion; Hypertension; Kidney function (Sattar, M.A. (294) 727)

JTH-601; Prazosin; α_{1L}-Adrenoceptor (Muramatsu, I. (300) 155)

4-Aminopyridine; Chloroethylclonidine; Cardiac muscle, isolated; Staurosporine; WB4101 (Williamson, A.P. (304) 73)

KMD-3213; α_{1a}-Adrenoceptor; Prostate; Thoracic aorta (Yamagishi, R. (315) 73)

Spinal cord; BMY 7378; 5-Methyl-urapidil; [^{3}H]Prazosin; (Rat) (Wada, T. (312) 263)

α_2-Adrenoceptor subtype
Brain, human; RX 821002; Autoradiography; Frontal cortex; Hippocampus (Grijalba, B. (310) 83)

5-HT_{1A} receptor; BRL 44408; ARC 239; Brain, rat (Meana, J.J. (312) 385)

β_2-Adrenoceptor subtype
Uterus, rat; β_2-Adrenoceptor agonist; Pregnancy (Ohashi, T. (307) 315)

α_1-Adrenoceptor, subtypes A and B
Risperidone; Functional experiment (Eltze, M. (295) 69)

α_1-Adrenoceptor, subtypes A, B and D
Spleen, mouse (Eltze, M. (311) 187)

α-Adrenoceptor subtype-selective blocker
Myocardial ischemia; Ventricular arrhythmia; Coronary occlusion; Heart rate; Arrhythmia (Geller, J.C. (294) 423)

Adrenomedullin
Steroidogenesis; CGRP (calcitonin gene-related peptide); Amylin; CGRP receptor, type 2; Corticosteroid secretion; Adenylyl cyclase activity (Esneu, M. (308) 187)

Amylin; Lactate; Calcium; Gastric emptying; CGRP (calcitonin gene-related peptide); (Rat) (Vine, W. (314) 115)

Amylin; cAMP; Mesangial cell, cultured, rat; Immunohistochemistry; CGRP (calcitonin gene-related peptide) (Osajima, A. (315) 319)

Aequorin
Ca^{2+}; Myocardium; Dantrolene; Sarcoplasmic reticulum; Ca^{2+} indicators (Meissner, A. (316) 333)

Aescine
Cell activation; Hypoxia; Endothelium; Neutrophil adherence; Reparil (Arnould, T. (315) 227)

AF102B
Learning; Memory; Synaptic plasticity; Cholinergic system; Muscarinic receptor agonist; Oxotremorine (Iga, Y. (308) 13)

Affinity state
5-HT_4 receptor; Splice variant; Radioligand binding (Adham, N. (304) 231)

Afterdischarge threshold
D-23129; Amygdala kindling; Anti-epileptic drug; Valproic acid (Tober, C. (303) 163)

Afterhyperpolarization
Sulfonylurea; K^+ channel, Ca^{2+}-dependent (Erdemli, G. (304) 37)

Ag^+
Au^{3+}; Skeletal muscle contraction; Ca^{2+} release channel; Single channel current (Nihonyanagi, K. (311) 271)

ω-Agatoxin
Ca^{2+} channel; Dihydropyridine; ω-Conotoxin; Melanotrope; Pituitary; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

ω-Agatoxin-IVA
Hippocampus; Ca^{2+} channel; Conotoxin (Nooney, J.M. (306) 41)

Aggression, isolation-induced
5-HT (5-hydroxytryptamine, serotonin); β-Adrenoceptor, interaction; (Mouse) (Sánchez, C. (297) 1)

Aging
Nitric oxide (NO); ATP; Non-adrenergic non-cholinergic (NANC); Ileum, rat (Smits, G.J.M. (303) 79)

Alzheimer's disease; Spatial navigation; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Tetrahydroaminoacridine (Riekkinen, M. (308) 243)

Scopolamine; Medial septum lesion; Metrifonate; Spatial navigation; Passive avoidance (Riekkinen Jr., P. (309) 121)

ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate); Arachidonic acid; Glutamate release; Protein kinase C; Inositol trisphosphate (McGahon, B. (309) 323)

Glutamate release; Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synaptophysin; Synapsin; Hippocampus (Mullany, P. (309) 311)

Anorexia; Food intake; Hypothalamus; Nitric oxide (NO) synthase; Nitric oxide (NO) (Morley, J.E. (311) 15)

5-HT_3 receptor; Avoidance, multiple choice; Memory; Itasetron (DAU 6215) (Pitsikas, N. (311) 115)

Agmatine
Morphine; Analgesia; Tolerance (Kolesnikov, Y. (296) 17)

Vas deferens; Noradrenaline; Neurotransmission; Imidazoline receptor; Adrenoceptor (Jurkiewicz, N.H. (307) 299)

Efaroxan; Imidazoline receptor; Insulin secretion; Vessel; Pancreas, rat (Berdeu, D. (308) 301)

Agonist
Muscarinic receptor; Allosteric modulation; Alcuronium; Heart (Maaß, A. (305) 231)

Agonist affinity
Agonist-antagonist combination, fixed; Carbachol; Tripitramine; Spare receptor; (New methods) (Venter, D.P. (303) 235)

Agonist and antagonist discrimination
5-HT_3 receptor; Binding thermodynamics; Thermodynamic compensation (Borea, P.A. (298) 329)

Agonist-antagonist combination, fixed
Agonist affinity; Carbachol; Tripitramine; Spare receptor; (New methods) (Venter, D.P. (303) 235)

Agonistic property
SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride); σ_1 Receptor subtype; Competitive inhibition (Matsuno, K. (306) 271)

AHPNs ((*R,S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide)
$GABA_B$ receptor; Baclofen; $GABA_B$ receptor antagonist; Ileum, guinea-pig; Neocortex, rat (Kerr, D.I.B. (294) 349)

AICAR (AICA riboside, acadesine)
NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid); Kainate; Adenosine kinase; Adenosine deaminase (White, T.D. (303) 27)

Air-pouch inflammation
Seminal vesicle protein; Transglutaminase; Polymorphonuclear leukocyte migration (Mancuso, F. (312) 327)

Airway
Autoradiography; NK_2 receptor; Substance P; [^{125}I][Lys^5,Tyr(I$_2$)^7, MeLeu^9,Nle^{10}]Neurokinin A-(4–10) (Strigas, J. (311) 177)

Airway epithelium
Airway responsiveness; Nitric oxide (NO); Methylene blue; Guanylate cyclase; Zaprinast (Sadeghi-Hashjin, G. (302) 109)

Airway neurogenic inflammation
Bronchoconstriction; Substance P; Neurokinin A; Capsaicin (Robineau, P. (294) 677)

Airway responsiveness
Nitric oxide (NO); Airway epithelium; Methylene blue; Guanylate cyclase; Zaprinast (Sadeghi-Hashjin, G. (302) 109)

AJ-3941
Subarachnoid hemorrhage; Endothelium-dependent relaxation; Lipid peroxidation; Nimodipine; Ca^{2+} channel antagonist (Minato, H. (315) 297)

Ajmaline
AV-node; Propafenone; Rate dependence; Time constant (Stark, G. (310) 29)

Alaptide
Cyclodipeptide; 2,5-Piperazinedione; Elevated plus-maze test; Memory; Oxiracetam; (Mouse) (Hliňák, Z. (314) 1)

Albumin transfer
Endothelium; Hydrogen peroxide; Sodium nitroprusside; Glyceryl trinitrate (McQuaid, K.E. (307) 233)

Alcohol
Acamprosate; Alcohol-deprivation effect; Craving; Relapse; (Rat) (Spanagel, R. (305) 39)

Acamprosate; Withdrawal; Radiotelemetry; (Rat) (Spanagel, R. (305) 45)

Craving; Memantine (Hölter, S.M. (314) R1)

Alcohol-deprivation effect
Acamprosate; Alcohol; Craving; Relapse; (Rat) (Spanagel, R. (305) 39)

Alcohol drinking
Food intake; δ-Opioid receptor; μ-Opioid receptor; Reinforcement; (Selected rat line) (Honkanen, A. (304) 7)

Alcuronium
Muscarinic receptor, heart; Muscarinic receptor, allosteric control; Allosteric interaction; Eburnamonine; Vincamine; Strychnine (Proška, J. (305) 201)

Muscarinic receptor; Allosteric modulation; Agonist; Heart (Maaß, A. (305) 231)

Aldose-reductase
Endothelial cell; Smooth muscle cell; Diabetes mellitus; Atherosclerosis; Aminoguanidine; Glutathione (Graier, W.F. (294) 221)

Aldose reductase inhibitor
Diabetic neuropathy; 2,3-Diphosphoglycerate; Hypoxia; Polyol pathway (Nakamura, J. (294) 207)

Alinidine
Falipamil; Sinoatrial node; His bundle; Atrial myocardium; AV node; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Allergic pleurisy
Salbutamol; Bt_2 cAMP (N^6,2′-*O*-dibutyryl adenosine 3′:5′-cyclic monophosphate) (Diaz, B.L. (296) 173)

Allodynia
Adenosine, pharmacology; Antinociception; Spinal cord; (Mouse) (Keil II, G.J. (312) 7)

Allosteric binding site
$GABA_A$ receptor, recombinant; [^{3}H]Flunitrazepam; [^{3}H]Muscimol; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) (Zezula, J. (301) 207)

Allosteric interaction
Muscarinic receptor; Heparin; Receptor subtype; Transfected cell; Receptor coupling (Wang, S.Z. (296) 113)

Muscarinic receptor, heart; Muscarinic receptor, allosteric control; Eburnamonine; Vincamine; Alcuronium; Strychnine (Proška, J. (305) 201)

Allosteric modulation
Muscarinic receptor; Alcuronium; Agonist; Heart (Maaß, A. (305) 231)

Muscarinic receptor; Structure-activity relationship; Heart porcine (Kostenis, E. (314) 385)

Allosteric regulation
Cyclothiazide; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline); GYKI 52466 (Okada, M. (309) 299)

Allosteric site
Muscarinic receptor subtype; Muscarinic toxin (Waelbroeck, M. (305) 187)

***N*-Allylsecoboldine**
Antioxidant; Lipid peroxidation; Peroxyl radical; Hydroxyl radical; Hypercoagulability; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

Alniditan
Sumatriptan; Ergotamine; Carotid arterial resistance (Van de Water, A. (299) 127)

Alveolar macrophage, guinea-pig
Fenspiride; Lipopolysaccharide; TNF (tumor necrosis factor); Phospholipase A_2 (De Castro, C.M.M.B. (294) 669)

Alzheimer's disease
5-HT (5-hydroxytryptamine, serotonin); *p*-Chloroamphetamine; Memory; (Rat) (Santucci, A.C. (295) 7)

Parkinson's disease; Huntington's disease; Losartan; PD123177; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II; Brain, human (Ge, J. (297) 299)

Aging; Spatial navigation; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Tetrahydroaminoacridine (Riekkinen, M. (308) 243)

Amantadine
Dopamine transporter; [^{3}H]GBR 12935 binding; L-DOPA; Reserpine; Benztropine (Gordon, I. (298) 27)

Ambulation
N-Cyanomethylmethamphetamine; Methamphetamine; Haloperidol; Behavioral sensitization; (Mouse) (Kuribara, H. (305) 1)

Ambulatory sensitization
Methamphetamine; Cocaine; Morphine; Interdose interval; (Mouse) (Kuribara, H. (316) 1)

Amiloride
Adenosine A_{2A} receptor, human; Mutation; Glutamic acid; CGS21680; XAC (IJzerman, A.P. (310) 269)

Amiloride analog
Prolactin; Na^+-Ca^{2+} exchanger; Na^+-H^+ antiporter (Di Renzo, G. (294) 11)

Amino acid
Anticonvulsant; Generalised seizure; Microdialysis (Rowley, H.L. (294) 541)

Microdialysis; Hippocampus; Uptake carrier; Vesicular release; Ca^{2+} dependency (Zuiderwijk, M. (307) 275)

Aminoalkylindole
Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Anandamide (Miller, A.S. (304) 29)

Aminoguanidine
Endothelial cell; Smooth muscle cell; Diabetes mellitus; Atherosclerosis; Glutathione; Aldose-reductase (Graier, W.F. (294) 221)

Nitric oxide (NO) synthase, inducible; Leishmaniasis; L-N^6-(1-Iminoethyl)-lysine; Nitric oxide (NO); N^G-Monomethyl-L-arginine (Stenger, S. (294) 703)

Aminopeptidase N
Haloperidol; Enkephalin; Neuroleptic; Neuropeptide (Konkoy, C.S. (297) 47)

***p*-Aminophenylalanine^6-angiotensin II**
Intestinal vascular bed; Angiotensin peptide; DuP532; PD123,319; Enalaprilat; Angiotensin II; Angiotensin IV (Champion, H.C. (309) 251)

3-Amino-propylphosphinic acid
$GABA_B$ receptor; (−)-Baclofen; Phaclofen; CGP 35348; 2-Hydroxysaclofen; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

4-Aminopyridine
α_1-Adrenoceptor subtype; Chloroethylclonidine; Cardiac muscle, isolated; Staurosporine; WB4101 (Williamson, A.P. (304) 73)

NMDA receptor antagonist; Seizure; Excitatory amino acid neurotransmission (Morales-Villagrán, A. (305) 87)

21-Aminosteroid
Glutathione; Lipid peroxidation; Oxidative stress; Ischemia-reperfusion injury; Kidney, rat (Paroni, R. (294) 737)

5-Aminovaleric acid
β-Endorphin; Morphine; SR 95531; Tail-flick inhibition (Suh, H.-W. (307) 141)

Amiodarone
Water exchange; NMR (nuclear magnetic resonance); Membrane (Federico, A. (304) 237)

Amitriptyline
Thyroid-stimulating antibody; Antidepressant; TSH (thyroid-stimulating hormone) (Yoshida, A. (312) 115)

Amlodipine
Electroconvulsive shock; Amnesia; Nimodipine; Felodipine; (Rat) (Župan, G. (310) 103)

Cerebral blood flow autoregulation; Ca^{2+} channel antagonist; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (313) 103)

Amnesia
Electroconvulsive shock; Nimodipine; Felodipine; Amlodipine; (Rat) (Župan, G. (310) 103)

U-50,488H; Cycloheximide; Naltrexone methobromide; Dynorphin A-(1–13); (Mouse) (Ukai, M. (313) 11)

Amnesia, delayed
Nor-binaltorphimine dihydrochloride; κ-Opioid receptor; Cholinergic neuronal system; Carbon monoxide (CO); U-50488H, (trans-(±)-3,4-dichloro-*N*-methyl-*N*-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate salt) (Hiramatsu, M. (315) 119)

cAMP
CNTF (ciliary neurotrophic factor receptor α); NB41A3 cell; PC12 cell; mRNA (MacLennan, A.J. (295) 103)

Cannabinoid receptor; Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; Adenylate cyclase (Pertwee, R.G. (296) 169)

β-Adrenoceptor; Adipose differentiation; Lipolysis (El Hadri, K. (297) 107)

Glutamate receptor, metabotropic; Adenosine deaminase; Forskolin; VIP (vasoactive intestinal peptide); NECA (5′-*N*-ethylcarboxamidoadenosine); Hippocampus (Wright, R.A. (297) 275)

Intestinal; Secretion; 5-HT receptor; Short-circuit current (Budhoo, M.R. (298) 137)

CINC (cytokine-induced neutrophil chemoattractant); Interleukin-1; Interleukin-6; Prostaglandin E_2; Prostaglandin I_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Phospholipase A_2; Interleukin 1β; Tetranactin; Renal mesangial cell (Walker, G. (306) 265)

Metabotropic glutamate receptor; Phosphoinositide hydrolysis; Cortex; Cerebellar granule cell; Phenylglycine (Bedingfield, J.S. (309) 71)

Metabotropic glutamate receptor; Cerebral cortex slice; (Agonist) (Kemp, M.C. (309) 79)

Cardiac myocyte; β-Adrenoceptor desensitization; Contractility (Wynne, D.G. (310) 235)

Behavioral sensitization; Rolipram; Methamphetamine; Microdialysis, in vivo (Iyo, M. (312) 163)

Opioid receptor; Binding characteristics; Partial agonist; KT-90 ((−)-3-acetyl-6β-acetylthio-*N*-cyclopropylmethyl-normorphine) (Katsumata, S. (312) 349)

n–3 fatty acid; Adrenoceptor; Norepinephrine; Pinealocyte; (Rat) (Delton-Vandenbroucke, I. (312) 379)

Rhythmic constriction; Norepinephrine; Pial vein; 5-HT (5-hydroxytryptamine, serotonin); (Porcine) (Ishine, T. (313) 97)

Synaptosome; Secretin; Isoproterenol; VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Kurjak, M. (314) 165)

PC12 cell; ATP receptor; Reactive blue 2 (Yakushi, Y. (314) 243)

Adrenomedullin; Amylin; Mesangial cell, cultured, rat; Immunohistochemistry; CGRP (calcitonin gene-related peptide) (Osajima, A. (315) 319)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Histamine; Adenylate cyclase (Xia, Y. (316) 81)

cAMP accumulation
Astrocyte, rat; Adenosine receptor (Peakman, M.-C. (306) 281)

GR127935; 5-$HT_{1D\alpha}$ receptor; 5-$HT_{1D\beta}$ receptor; [^{35}S]GTPγS binding; Receptor reserve (Watson, J.M. (314) 365)

cAMP formation
5-HT_{1D} receptor antagonist; Ketanserin; 5-HT_{1B} receptor antagonist; GR 127,935; 5-HT_{1D} receptor, human, cloned; 5-HT_{1B} receptor, human, cloned; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

cAMP production
SK-N-BE(2)C human neuroblastoma; Phospholipase C; U-73122; Ca^{2+} mobilization; Inositol 1,4,5-triphosphate; Neomycin (Suh, B.-C. (314) 235)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
2,3-Benzodiazepine; GYKI 52466; Aniracetam; Anticonvulsant drug; Epilepsy; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

NMDA (*N*-methyl-D-aspartate); Kainate; Adenosine kinase; Adenosine deaminase; AICAR (AICA riboside, acadesine) (White, T.D. (303) 27)

Ethanol; NMDA (*N*-methyl-D-aspartate); AP-1 (activator protein-1) DNA binding; Transcription factor; Granule cell, cerebellar (Hou, Y.-N. (309) 307)

AMPA / kainate receptor
Concentration jump; Hippocampal neuron; Glutamate receptor, ionotropic; Kainate-gated desensitization (Pidoplichko, V.I. (303) 145)

AMPA receptor
Catalepsy; Catatonia; Morphine; NMDA receptor; MK-801; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

NMDA receptor; Spinal cord; Hyperalgesia; (Mouse) (Brambilla, A. (305) 115)

AMPA receptor agonist
Glu_1-flop receptor; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*f*)quinoxaline); (Pharmacology) (Wahl, P. (308) 211)

AMPA receptor antagonist
Anticonvulsant; Neuroprotection; NMDA receptor glycine site antagonist (Ilyin, V.I. (310) 107)

Amphetamine
Microdialysis; Dopamine; Individual difference; Nucleus accumbens; (Rat) (Sills, T.L. (303) 177)

Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Behavioral sensitization; Glucocorticoid (De Vries, T.J. (307) R3)

Occasion setting; Pavlovian conditioning; Conditioned immobility; Midazolam; Flesinoxan (Maes, J.H.R. (309) 131)

***d*-Amphetamine**
Dose response; Psychomotor stimulant; Motor activity; Behavior (Gaytan, O. (300) 1)

DL-Amphetamine
Metabotropic glutamate receptors; MK-801; Basal ganglia; Open-field; Catalepsy (Kronthaler, U.O. (316) 129)

Amygdala
Enkephalin; Methylnaloxonium; RB 101; Antinociception; Thalamus, ventro-basal; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

Amygdala kindling
D-23129; Anti-epileptic drug; Valproic acid; Afterdischarge threshold (Tober, C. (303) 163)

Amygdala, lateral
Nitric oxide (NO); Long-term potentiation; Amygdala, medial (Abe, K. (297) 43)

Amygdala, medial
Nitric oxide (NO); Long-term potentiation; Amygdala, lateral (Abe, K. (297) 43)

Amylase release
CCK_A receptor; Pancreas; Gallbladder; Gallbladder contraction; T-0632 (Taniguchi, H. (304) 147)

Amylin
Steroidogenesis; CGRP (calcitonin gene-related peptide); Adrenomedullin; CGRP receptor, type 2; Corticosteroid secretion; Adenylyl cyclase activity (Esneu, M. (308) 187)

Adrenomedullin; Lactate; Calcium; Gastric emptying; CGRP (calcitonin gene-related peptide); (Rat) (Vine, W. (314) 115)

Adrenomedullin; cAMP; Mesangial cell, cultured, rat; Immunohistochemistry; CGRP (calcitonin gene-related peptide) (Osajima, A. (315) 319)

Analgesia
Morphine derivative; Metopon; Cinnamoylamino group; β-Endorphin receptor; (Mouse) (McLaughlin, J.P. (294) 201)

Agmatine; Morphine; Tolerance (Kolesnikov, Y. (296) 17)

Pain; Polyamine; NMDA receptor; Ifenprodil; Morphine; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

μ-Opioid receptor; Spinal cord; Desipramine; α_2-Adrenoceptor; Neuropeptide (Gergen, K.A. (298) 235)

Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)

Substance P; Neurokinin A; Tachykinin NK_1 receptor; Nociception; Hyperalgesia (Yashpal, K. (308) 41)

Pertussis toxin; Morphine; Diphenhydramine; Baclofen; Clomipramine; Physostigmine (Galeotti, N. (308) 125)

Neuro-immune interaction; Nociception; Opioid; Neuropeptide; Cytokine (Mousa, S.A. (311) 221)

Orphanin FQ; Nociceptin (Rossi, G.C. (311) R7)

Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (312) 391)

μ-Opioid receptor; Tyr-W-MIF-1; Antinociception (Gergen, K.A. (316) 33)

α_2-Adrenoceptor; Pain; (Amphibian) (Stevens, C.W. (316) 205)

Tramadol; Cloned human receptor; Opioid receptor type (Lai, J. (316) 369)

Analgesia, peripheral
κ-Opioid receptor; Tail-flick assay (Kolesnikov, Y. (310) 141)

Anandamide
Ca^{2+} channel; Arachidonic acid; [^{3}H](+)-PN200-110; [^{3}H]Diltiazem; [^{3}H](−)-Desmethoxyverapamil (Shimasue, K. (296) 347)

Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (304) 29)

Anaphylaxis, lung
Tachykinin receptor antagonist; Eicosanoid (Montuschi, P. (313) R1)

Ancrod-generated fibrin
Integrin $\alpha_v\beta_3$; Prostacyclin; Pertussis toxin; Phospholipase C (Chang, M.C. (297) 129)

Anesthesia
Propofol; Benzodiazepine; $GABA_A$ receptor; Flurazepam; *Xenopus* oocyte (Reynolds, J.N. (314) 151)

Anesthetic
2-Chloroethylethyl sulfide; Skin lesion, burn; Calmodulin antagonist (Kim, Y.-B. (313) 107)

Angina
FR144420; FK409; Nitric oxide (NO) (Hirasawa, Y. (303) 55)

Angiogenesis
Basement membrane; Neurogenic inflammation; Tachykinin; Wound healing (Wiedermann, C.J. (298) 335)

SM-10902 ointment; Wound healing; Prostacyclin analog; Blood flow, skin; Diabetic mouse (*db/db* mouse), genitically (Yamamoto, T. (302) 53)

Angiotensin
Cardiac hypertrophy; Myocyte; Stretch (Miyata, S. (307) 81)

Diabetes; Hypertension; Blood perfused; Nephropathy; Kidney; (Rat) (Farina, N.K. (310) 185)

Angiotensin analog, D-amino acid substituted
Des-Asp-angiotensin I; Angiotensin III; Blood pressure (Radhakrishnan, R. (294) 337)

Angiotensin AT_1 receptor
Stomach; Angiotensin II; Gastric hemodynamics; Pentagastrin; Renin-angiotensin system (Chow, L. (294) 309)

Parkinson's disease; Huntington's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II; Brain, human (Ge, J. (297) 299)

Smooth muscle cell, vascular; Cell growth; Arteriosclerosis (Nickenig, G. (297) 307)

Angiotensin AT_2 receptor; Atropine; Osmoregulation, central; PD 123177; Vasopressin (Höhle, S. (300) 119)

Angiotensin AT_{1A} receptor
Protein kinase C; Receptor phosphorylation; Ca^{2+}, intracellular free; Angiotensin II (Thomas, W.G. (295) 119)

Angiotensin AT_2 receptor
Parkinson's disease; Huntington's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT_1 receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II; Brain, human (Ge, J. (297) 299)

Angiotensin AT_1 receptor; Atropine; Osmoregulation, central; PD 123177; Vasopressin (Höhle, S. (300) 119)

Angiotensin AT_1 receptor antagonist
Angiotensin II-induced drinking; Blood-brain barrier; Losartan; EXP3174; GR117289; LR-B/081 (Polidori, C. (307) 259)

Angiotensin-converting enzyme
Ischemia; Reperfusion; Idrapril; Captopril; Heart; (Rat) (Riva, E. (312) 293)

Angiotensin-converting enzyme inhibitor
Heart failure; Renin-angiotensin-aldosterone system; Angiotensin II; Angiotensin II receptor (Lenz, O. (294) 17)

Bradykinin; Neutral endopeptidase inhibitor; DOCA-salt rat (Pham, I. (296) 267)

Ramiprilat; Bradykinin; Bradykinin B_2 receptor antagonism; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Cardiac myocyte; Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

Cough reflex; Enalapril; Moguisteine; Non-narcotic antitussive drug (Kamei, J. (312) 235)

Angiotensin converting enzyme inhibitor
Angiotensin II; Angiotensin receptor antagonist; Antihypertensive; L-163,017 (Kivlighn, S.D. (294) 439)

Angiotensin I-converting enzyme inhibitor
Angiotensin I-converting enzyme; Peptide; Hemoglobin; (Swine) (Mito, K. (304) 93)

Angiotensin I-converting enzyme
Angiotensin I-converting enzyme inhibitor; Peptide; Hemoglobin; (Swine) (Mito, K. (304) 93)

Angiotensin II
Heart failure; Renin-angiotensin-aldosterone system; Angiotensin II receptor; Angiotensin-converting enzyme inhibitor (Lenz, O. (294) 17)

Stomach; Gastric hemodynamics; Pentagastrin; Angiotensin AT_1 receptor; Renin-angiotensin system (Chow, L. (294) 309)

Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitor; Antihypertensive; L-163,017 (Kivlighn, S.D. (294) 439)

Angiotensin AT_{1A} receptor; Protein kinase C; Receptor phosphorylation; Ca^{2+}, intracellular free (Thomas, W.G. (295) 119)

Endothelin-1; Atherosclerosis; Cell cycle progression; Ca^{2+}, cytosolic; Primary culture (Jahan, H. (295) 261)

Pressor response; Medullary vasomotor neuron; Rostral ventrolateral medulla; Vasopressin (Sun, M.-K. (304) 63)

Thromboxane A_2; c-fos; Smooth muscle cell (Sachinidis, A. (307) 121)

Nitric oxide (NO); Losartan; L-NAME (N^{ω}-nitro-L-arginine methyl ester); Kidney; (Rabbit) (Adachi, Y. (308) 165)

Intestinal vascular bed; Angiotensin peptide; DuP532; PD123,319; Enalaprilat; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Peroxynitrite; Nitrotyrosine; Nitric oxide; Superoxide; Hemodynamics, in vivo (Kooy, N.W. (315) 165)

[^{125}I][Sar^1,Ile^8]Angiotensin II
Parkinson's disease; Huntington's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Brain, human (Ge, J. (297) 299)

Angiotensin II-induced drinking
Angiotensin AT_1 receptor antagonist; Blood-brain barrier; Losartan; EXP3174; GR117289; LR-B/081 (Polidori, C. (307) 259)

Angiotensin II receptor
Heart failure; Renin-angiotensin-aldosterone system; Angiotensin II; Angiotensin-converting enzyme inhibitor (Lenz, O. (294) 17)

Angiotensin II receptor subtype
Hypertension; L-163,017; Renin-angiotensin system (Chang, R.S.L. (294) 429)

Angiotensin III
Des-Asp-angiotensin I; Angiotensin analog, D-amino acid substituted; Blood pressure (Radhakrishnan, R. (294) 337)

Angiotensin IV
Intestinal vascular bed; Angiotensin peptide; DuP532; PD123,319; Enalaprilat; Angiotensin II; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Angiotensin IV binding
Aortic endothelial cell; (Porcine) (Riva, L. (305) 193)

Angiotensin peptide
Intestinal vascular bed; DuP532; PD123,319; Enalaprilat; Angiotensin II; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Angiotensin receptor antagonist
Angiotensin II; Angiotensin converting enzyme inhibitor; Antihypertensive; L-163,017 (Kivlighn, S.D. (294) 439)

Anhedonia
Stress, uncontrollable; Naloxone (Zurita, A. (299) 1)

D-cycloserine; Imipramine; Stress; Chronic; Antidepressant action; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

Animal model
Anxiety; Chlorpromazine; Diazepam; One-way avoidance; Successive negative contrast; Thiopental sodium (Torres, C. (314) 269)

Nucleus accumbens; Dopamine; Ethanol; Microdialysis; Tolerance (Nurmi, M. (315) 277)

Aniracetam
2,3-Benzodiazepine; GYKI 52466; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anticonvulsant drug; Epilepsy; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

Anorexia
Food intake; Aging; Hypothalamus; Nitric oxide (NO) synthase; Nitric oxide (NO) (Morley, J.E. (311) 15)

ANP (atrial natriuretic peptide)
Vas deferens, guinea-pig; Noradrenaline release; ATP release; Cotransmission; 8-Bromoguanosine 3′:5′-cyclic monophosphate (Driessen, B. (296) 261)

Cocaine; ANP, N-terminal; Mean arterial pressure; Heart rate; Right atrial pressure (Pelkonen, M. (304) 55)

ANP (atrial natriuretic peptide), chicken
Cardiac myocyte, cultured; Cardiac contractility; Endothelin-1; ChNP (chicken natriuretic peptide) mRNA (Bézie, Y. (311) 241)

ANP, N-terminal
Cocaine; ANP (atrial natriuretic peptide); Mean arterial pressure; Heart rate; Right atrial pressure (Pelkonen, M. (304) 55)

Antagonist
Water intake; Lipopolysaccharide; Interleukin-1; Interleukin-1 receptor; (Human) (Nava, F. (309) 223)

Antagonist affinity
BW A868C; Prostaglandin D_2; BW245C; DP receptor (Liu, Y.J. (303) 187)

Anthraquinone
Nitric oxide (NO); Senna; Cascara; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

Anti-allergic drug
α-Chymotrypsin; Histamine; Mast cell; Serine esterase (Emadi-Khiav, B. (295) 243)

Antiarrhythmic
Lysophosphatidylcholine; Acylcarnitine; Fibrillation; Fatty acid; Excitability (Kang, J.X. (297) 97)

Antiarrhythmic activity
Ischemic arrhythmia; Sparteine; BRB-I-28; Patch-clamp (Pugsley, M.K. (294) 319)

Antiarrhythmic agent, class I
Cardiac Na^+ channel; Na^+ channel block; Bisaramil (Sunami, A. (312) 245)

Antibody
Smooth muscle; Contraction; Phospholipase C; Muscarinic; G-protein (Cuq, P. (315) 213)

β_1-Adrenoceptor; β_2-Adrenoceptor; Fusion protein (Jahns, R. (316) 111)

Anticholinesterase
Muscarinic acetylcholine receptor; 5-HT_2 receptor; Neocortical high-voltage spindle; Thalamocortical oscillation; (Rat) (Jäkälä, P. (316) 181)

Anticonflict effect
κ-Opioid receptor agonist; Diazepam; Vogel-type conflict test; (Mouse) (Tsuda, M. (307) 7)

Anticonvulsant
Generalised seizure; Amino acid; Microdialysis (Rowley, H.L. (294) 541)

Epilepsy; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; GABA (γ-aminobutyric acid) (Löscher, W. (299) 61)

Na^+ channel, voltage-dependent (Tang, L. (300) 71)

AMPA receptor antagonist; Neuroprotection; NMDA receptor glycine site antagonist (Ilyin, V.I. (310) 107)

Vincamine; Vincanol; Vinpocetine; Na^+ channel; Voltage-gated; Batrachotoxin; Neuroprotection (Erdő, S.L. (314) 69)

Brain binding site; SB 204269 (Herdon, H. (314) R7)

Kynurenine; Microdialysis; Neurodegenerative disorder; Neuroprotection (Speciale, C. (315) 263)

Anticonvulsant drug
2,3-Benzodiazepine; GYKI 52466; Aniracetam; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Epilepsy; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

Antidepressant
Stress; Hyperthermia; Temperature; Anxiety; Benzodiazepine; 5-HT_{1A} receptor agonist; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor; Microdialysis; Hypothalamus, rat (Moret, C. (295) 189)

Repeated treatment; Dopamine D_2 receptor binding; [^{3}H]N-0437 (Maj, J. (304) 49)

Imipramine; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Baclofen; Hippocampal slice (Bijak, M. (305) 79)

JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine); Dorsal raphe; Locus coeruleus; A10 dopamine neuron; Electrophysiology (Liégeois, J.-F. (310) 9)

Thyroid-stimulating antibody; Amitriptyline; TSH (thyroid-stimulating hormone) (Yoshida, A. (312) 115)

Selective breeding; Depression, animal model (Vaugeois, J.-M. (316) R1)

Antidepressant action
D-cycloserine; Imipramine; Stress; Chronic; Anhedonia; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

Antidepressant augmentation
Microdialysis, in vivo; Citalopram; WAY-100635; Penbutolol enantiomer; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor (Hjorth, S. (316) 43)

Antidepressive effect
σ_1 Receptor agonist; Forced swimming test; SA4503; (Mouse) (Matsuno, K. (312) 267)

Anti-edema
CRF (corticotropin-releasing factor); CRF receptor; ACTH (adrenocorticotropin); Structure-activity relationship (Wei, E.T. (306) 161)

Anti-epileptic
GABA (γ-aminobutyric acid); Excitatory amino acid; Seizure; Ischemia; Neurological disorder; Drug screening (Kanthasamy, A.G. (297) 219)

Felbamate; Na^+ channel, voltage-dependent (Taglialatela, M. (316) 373)

Anti-epileptic drug
D-23129; Amygdala kindling; Valproic acid; Afterdischarge threshold (Tober, C. (303) 163)

Cortex; Ca^{2+} current; Neuroprotective agent (Stefani, A. (307) 113)

Anti-epileptic drugs
Epilepsy; Midbrain; GABA (γ-aminobutyric acid) (Bloms-Funke, P. (316) 211)

Antiflammin
Arachidonic acid; Phospholipase A_2; Chemotaxis; Inflammation; Anti-inflammatory drug (Moreno, J.J. (314) 129)

Anti-GBM nephritis
Butein; Intercellular adhesion molecules; Endothelial cells; Leukocyte, polymorphonuclear (Hayashi, K. (316) 297)

Antihyperglycemic effect
M16209; Insulin resistance; Genetically obese rodent; Hyperinsulinemic euglycemic clamp (Murakami, N. (304) 129)

Antihypertensive
Angiotensin II; Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitor; L-163,017 (Kivlighn, S.D. (294) 439)

Anti-idiotypic antibody
Idazoxan; Imidazoline receptor; Brain, human (Bennai, F. (306) 211)

Anti-inflammatory
Dolabrane; Neutrophil, human; Myeloperoxidase; Elastase; Prostaglandin; Leukotriene (Payá, M. (312) 97)

Nitric oxide (NO) synthase; mRNA expression; Adenosine; Nitric oxide (NO) (Moochhala, S.M. (316) 287)

Anti-inflammatory drug
Antiflammin; Arachidonic acid; Phospholipase A_2; Chemotaxis; Inflammation (Moreno, J.J. (314) 129)

Synovial cell; Human; Glucose uptake; Osteoarthritis; Rheumatoid arthritis (Hernvann, A. (314) 193)

Antimigraine drug
Arteriovenous anastomosis; Carotid artery; GMC2021; Coronary artery, human; Migraine; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

Antinociception
Morphine; β-Endorphin; Pertussis toxin; G-protein (Tseng, L.F. (294) 345)

α-Trinositol; Intrathecal; Formalin test; Behavior; (Rat) (Malmberg, A.B. (294) 609)

5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Sulfonylurea; Gliquidone; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Deltorphin analog; Catalepsy; Locomotion (Negri, L. (296) 9)

L-Ornithine; L-Arginine; Kyotorphin; Enkephalin; Pain (Kawabata, A. (296) 23)

Respiratory depression; Opioid receptor; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

Nicotine; Epibatidine; Tolerance; (Mouse) (Damaj, M.I. (300) 51)

Bioassay; Deltorphin; Opioid receptor; Peptide synthesis (Guerrini, R. (302) 37)

Paracetamol; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor, brain (Pini, L.A. (308) 31)

Ketorolac; Caffeine; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME); Potentiation (López-Muñoz, F.J. (308) 275)

Cold water swimming; Pertussis toxin; Gi/Go protein; Opioid receptor; (Mouse) (Mizoguchi, H. (309) 37)

Bradykinin; Nitric oxide (NO); N^G-Nitro-L-arginine (Germany, A. (310) 123)

δ-Opioid receptor, agonist, antagonist; δ_1-Opioid receptor; δ_2-Opioid receptor; [^{3}H][D-Pen^2,D-Pen^5]Enkephalin (Bhargava, H.N. (311) 127)

Adenosine, pharmacology; Allodynia; Spinal cord; (Mouse) (Keil II, G.J. (312) 7)

Enkephalin; Methylnaloxonium; RB 101; Amygdala; Thalamus, ventrobasal; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

Respiratory depression; Opioid receptor; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Analgesia; μ-Opioid receptor; Tyr-W-MIF-1 (Gergen, K.A. (316) 33)

Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Formalin; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Antinociception, spinal
Ca^{2+} channel, P-type; Morphine; Clonidine; Tolerance; G-protein (Roerig, S.C. (314) 293)

Antinociceptive effect
Colonic inflammation; Visceral nociception; Clonidine; S12813-4; Noradrenergic mechanism (Miampamba, M. (308) 251)

Antioxidant
Carvedilol; Low-density lipoprotein (LDL); Monocyte; Adhesion (Yue, T.-L. (294) 585)

α-Tocopherol analog (water-soluble); Neuroprotection; Lipid peroxidation; Vitamin E; Malondialdehyde; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

Cerebral ischemia/reperfusion; Spin trapping; ESR (electron spin resonance); Free radical scavenger (Cowley, D.J. (298) 227)

N-Allylsecoboldine; Lipid peroxidation; Peroxyl radical; Hydroxyl radical; Hypercoagulability; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

Polyol pathway; Diabetes; Galactosemia; Nerve conduction; Nerve regeneration; Oxygen free radical; Metal chelator (Love, A. (314) 33)

Antioxidant free radical scavenger
Head injury; Edema; Magnetic resonance imaging (Petty, M.A. (307) 149)

Antipain
Morphine analgesia; Reinforcing property; Morphine dependence; Withdrawal; Leupeptin (Lyupina, Y.V. (304) 23)

Anti-platelet potency
Ticlopidine; Thrombolysis; Prostacyclin; Nitric oxide (NO); Tissue plasminogen activator (Gryglewski, R.J. (308) 61)

Antiporter
Ca^{2+} paradox; Oxygen paradox; Caffeine; Extracellular K^+ (Harding, R.J. (316) 223)

Antipsychotic
Marijuana; SR 141716A; CP 55,940; Basal ganglion (Anderson, J.J. (295) 163)

SM-9018; Haloperidol; c-*fos* mRNA; 5-HT_2 receptor; Striatum (Ishibashi, T. (303) 247)

Antipsychotic drug
Norepinephrine; Risperidone; Primary olfactory cortex; Electrophysiology (Marek, G.J. (305) 95)

Ca^{2+} channel; Dopamine receptor antagonist; Calmodulin antagonist; Membrane current (Ito, K. (314) 143)

Antisense
κ-Opioid analgesia; Opioid receptor; σ Receptor; Haloperidol; KOR-1; κ-Opioid receptor (Chien, C.-C. (294) 303)

Immobility behaviour; Forced swim test; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Antisense oligodeoxynucleotide
$GABA_A$ receptor; γ_2 Subunit; Methyl-β-carboline-3-carboxylate; Strychnine; Picrotoxin; Convulsion (Zhao, T.-j. (306) 61)

Artery, human; Noradrenaline; Neuropeptide Y; BIBP3226; Reverse transcriptase-polymerase chain reaction (Bergdahl, A. (316) 59)

Antitussive effect
Morphine; μ-Opioid receptor, subtype; Cough reflex; (Beige rat) (Kamei, J. (300) 75)

Anxiety
Stress; Hyperthermia; Temperature; Benzodiazepine; 5-HT_{1A} receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

Myocardial infarction; Quality of life; Exploration; Social behavior; (Rat) (Schoemaker, R.G. (298) 17)

CCK (cholecystokinin); CCK receptor antagonist; CCK_B receptor; Conditioned fear stress; LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide) (Izumi, T. (300) 25)

CRF (corticotropin-releasing factor); Interleukin-1β; Fever; CRF receptor antagonist (Lundkvist, J. (309) 195)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptor antagonist; Elevated plus-maze (Silvestre, J.S. (309) 219)

Conditioned fear stress; Freezing behavior; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Citalopram (Inoue, T. (311) 1)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Substance P; Neurokinin A; FK 888; SR 48968; Plus-maze; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Immediate early gene; Elevated X-maze; CI-988; Benzodiazepine; CCK (cholecystokinin) (Hinks, G.L. (312) 153)

Cannabinoid; Cannabis; Ultrasonic vocalization; SR 141716A; CP 55,940 (McGregor, I.S. (313) 43)

Animal model; Chlorpromazine; Diazepam; One-way avoidance; Successive negative contrast; Thiopental sodium (Torres, C. (314) 269)

Anxiolytic
NMDA receptor antagonist; NPC 17742; ACEA 1021; *N*-Nitro-L-arginine methyl ester; Phencyclidine (Wiley, J.L. (294) 101)

Toluene; 1,1,1-Trichloroethane; Methoxyflurane; Flurothyl; Plus-maze; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

Aorta
Staurosporine; Calphostin C; Wortmannin; Protein kinase C; Myosin light chain kinase; (Rabbit) (Asano, M. (294) 693)

Reactive oxygen species; Endothelium-dependent relaxation; Electrolysis; L-Arginine (Gumusel, B. (306) 107)

Carotid artery; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Potassium chloride; Ca^{2+}; Cholesterol (Moreland, R.S. (307) 55)

Aorta, rabbit
α-Mangostin; Trachea, guinea-pig; Histamine; Histamine H_1 receptor antagonist (Chairungsrilerd, N. (314) 351)

Aorta, rat
Nucleotide receptor; ATP receptor; UTP receptor; Endothelium; Smooth muscle, vascular (García-Velasco, G. (294) 521)

α_{1D}-Adrenoceptor; Radioligand binding; Contractility (Buckner, S.A. (297) 241)

Levcromakalim; Sodium nitroprusside; Chronic treatment; Tolerance (Trongvanichnam, K. (303) 39)

N^G-Nitro-L-arginine; Methylene blue; Endothelium; Nitric oxide (NO); Hypertension; Arterial pressure (Gil-Longo, J. (310) 175)

Nicorandil; Relaxation; cGMP; Tolerance; Levcromakalim (Trongvanichnam, K. (314) 83)

Diphenyleneiodonium; Glyceryl trinitrate; Artery, bovine coronary (De la Lande, I.S. (314) 347)

Aortic endothelial cell
Angiotensin IV binding; (Porcine) (Riva, L. (305) 193)

Aorto-caval fistula
Bosentan; Renal hemodynamics; Congestive heart failure (Gurbanov, K. (310) 193)

AP-1 (activator protein-1) DNA binding
Ethanol; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) propionic acid); Transcription factor; Granule cell, cerebellar (Hou, Y.-N. (309) 307)

Apamin
Neurotensin; Peristalsis; Small intestine, guinea-pig (Ohashi, H. (301) 129)

D-AP3 (D-2-amino-3-phosphonopropionic acid)
Phosphoserine phosphatase; L-AP3 (L-2-amino-3-phosphonopropionic acid); Serine; Glycine (Hawkinson, J.E. (307) 219)

L-AP3 (L-2-amino-3-phosphonopropionic acid)
Phosphoserine phosphatase; D-AP3 (D-2-amino-3-phosphonopropionic acid); Serine; Glycine (Hawkinson, J.E. (307) 219)

AP-5 (DL-2-amino-5-phosphonovaleric acid)
Excitatory amino acid; NMDA receptor antagonist; MK-801 ((+)-5-methyl-10,11-dihydro(*a*,*d*)-cyclohepten-5,10-imine hydrogen maleate salt); Dopamine; Locomotor activity (Ouagazzal, A. (294) 137)

Apigenin
Flavonoid; Monoamine oxidase; Noradrenaline uptake (Lorenzo, P.S. (312) 203)

APNEA (*N*^{6}-2-(4-aminophenyl)ethyladenosine)
Adenosine A_3 receptor; Hypotension; Mast cell; Histamine; Compound 48/80 (Fozard, J.R. (298) 293)

Apomorphine
Neuroleptic withdrawal; Ca^{2+} channel blockade; Haloperidol; Pimozide; Nifedipine (Antkiewicz-Michaluk, L. (294) 459)

DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); Dynorphin A-(1–13); 6-Hydroxydopamine; (Mouse) (Toyoshi, T. (294) 637)

Free radical; Lipid peroxidation; Protein carbonyl; Iron; Ascorbate; Thiobarbituric acid (Gassen, M. (308) 219)

Apoptotic body
Cerebral ischemia; Nitric oxide (NO); Reperfusion; DNA fragmentation; Chromatin condensation; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

Appetite
Drinking; Food intake; Isatin; Motivation; 5-HT (5-hydroxytryptamine, serotonin); Tubulin; (Mouse) (Morley, J.E. (305) 23)

Arachidonic acid
Diabetes; Hindquarters; Endothelin; 5-HT (5-hydroxytryptamine, serotonin); Thromboxane (James, G.M. (294) 109)

Long-term potentiation; NMDA (*N*-methyl-D-aspartate); ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid); Melittin; Phospholipase A_2 (Collins, D.R. (294) 147)

Anandamide; Ca^{2+} channel; [^{3}H](+)-PN200-110; [^{3}H]Diltiazem; [^{3}H](−)-Desmethoxyverapamil (Shimasue, K. (296) 347)

Cyclooxygenase inhibitor; KBT-3022; Ischemic brain edema (Yamamoto, N. (297) 225)

PAF (platelet-activating factor); Acyltransferase; Triacsin C; Zymosan (Naraba, H. (302) 117)

Neuromedin B; Bombesin receptor antagonist; Ca^{2+}, intracellular (Ryan, R.R. (306) 307)

Aging; ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate); Glutamate release; Protein kinase C; Inositol trisphosphate (McGahon, B. (309) 323)

Antiflammin; Phospholipase A_2; Chemotaxis; Inflammation; Anti-inflammatory drug (Moreno, J.J. (314) 129)

Dopamine transporter; Dopamine uptake; WIN 35,428 binding; Protein kinase C; Second messenger (Zhang, L. (315) 345)

Epithelial cells; Cell cycle; Cell proliferation; TGF-β1 (transforming growth factor β1) (Kozubík, A. (316) 349)

ARC 239
5-HT_{1A} receptor; BRL 44408; α_2-Adrenoceptor subtype; Brain, rat (Meana, J.J. (312) 385)

Arcuate nucleus
Monosodium glutamate; Neurotoxicity; Meal size and duration; Hypophagia; Hypersensitivity to neuropeptide Y (Stricker-Krongrad, A. (295) 27)

Area postrema
Dopamine D_3 receptor; *R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Emesis; (Ferret) (Yoshikawa, T. (301) 143)

L-Arginine
Hypovolemia; *N*-Nitro-L-arginine methyl ester; Naloxone; Hemorrhagic shock; Nitric oxide (NO); (Conscious rabbit) (Ventura, S. (294) 369)

L-Ornithine; Kyotorphin; Enkephalin; Pain; Antinociception (Kawabata, A. (296) 23)

Reactive oxygen species; Endothelium-dependent relaxation; Electrolysis; Aorta (Gumusel, B. (306) 107)

Nitric oxide (NO); Nitric oxide (NO) synthase; Lipopolysaccharide; Septic shock; Mesenteric vascular bed; (Rat) (Mitolo-Chieppa, D. (309) 175)

Na^+ transport; K^+ transport; Opiate; Cholinergic responses; Nitric oxide (NO) (Neumann, V. (316) 123)

Arginine-aspartate
Catalepsy; Haloperidol; Locomotor activity; Dopamine (Patacchioli, F.R. (299) 29)

L-*N*-Arginine methyl ester (L-NAME)
Nitric oxide (NO); Forced swimming test; Adrenalectomy; Glucocorticoid (Jefferys, D. (295) 131)

Arginine vasopressin
Ethanol tolerance; c-*fos*; Immediate early gene (Szabó, G. (306) 67)

8-Arm radial maze
MF201; Tacrine; E2020; Physostigmine; (Rat) (Braida, D. (302) 13)

Aromatic L-amino acid decarboxylase
Dopamine; Tyrosine hydroxylase; Monoamine oxidase; Striatum; (Modulation) (Cho, S. (314) 51)

Arrhythmia
Myocardial ischemia; Ventricular arrhythmia; α-Adrenoceptor subtype-selective blocker; Coronary occlusion; Heart rate (Geller, J.C. (294) 423)

Dietary fat; *n*−3 fatty acid; Blood pressure; Proteinuria; Thromboxane (McLennan, P. (300) 83)

Arterial myogenic tone
Ryanodine; Sarcoplasmic reticulum; Ca^{2+}-buffering function; Ca^{2+} channel, voltage-dependent; Cerebral artery; (Dog) (Asano, M. (311) 53)

Arterial pressure
BMY 7378; 5-Methylurapidil; A-61603; α_1-Adrenoceptor (Zhou, L. (305) 173)

PAF (platelet-activating factor); Vasomotor tone; Endothelium; Blood flow; Noradrenaline; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

N^G-Nitro-L-arginine; Methylene blue; Endothelium; Nitric oxide (NO); Hypertension; Aorta, rat (Gil-Longo, J. (310) 175)

Arterial pressure, systemic
Nitric oxide (NO) synthase; Acetylcholine; Sodium nitroprusside; 7-Nitroindazole (Zagvazdin, Y. (303) 61)

Arteriosclerosis
Angiotensin AT_1 receptor; Smooth muscle cell, vascular; Cell growth (Nickenig, G. (297) 307)

Arteriovenous anastomosis
Antimigraine drug; Carotid artery; GMC2021; Coronary artery, human; Migraine; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

Artery
α_{1D}-Adrenoceptor; α_{1A}-Adrenoceptor; BMY 7378; Spontaneously hypertensive rat (SHR); Wistar Kyoto rat (WKY) (Villalobos-Molina, R. (298) 257)

Artery, bovine coronary
Diphenyleneiodonium; Glyceryl trinitrate; Aorta, rat (De la Lande, I.S. (314) 347)

Artery, human
Noradrenaline; Neuropeptide Y; Antisense oligodeoxynucleotide; BIBP3226; Reverse transcriptase-polymerase chain reaction (Bergdahl, A. (316) 59)

Arthritis
Cartilage; Chondrocyte; Nitric oxide (NO) synthase, inducible; Free radical (Jang, D. (312) 341)

Aryloxyalkylimidazoline
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{2A} receptor; 5-HT_{2C} receptor; Phosphoinositide hydrolysis; 5-HT receptor antagonist (Siegel, B.W. (296) 307)

Ascorbate
Apomorphine; Free radical; Lipid peroxidation; Protein carbonyl; Iron; Thiobarbituric acid (Gassen, M. (308) 219)

Astrocyte
Muscarinic receptor; Cell proliferation; Astrocytoma (Guizzetti, M. (297) 265)

Selegiline; MPP^+ (1-methyl-4-phenylpyridinium); Neuronal culture (Koutsilieri, E. (306) 181)

Astrocyte, cultured
Selegiline; Hippocampal cell; Excitotoxicity; Protection; Cerebral ischemia; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Astrocyte, isolated
β-Adrenoceptor, β_1 and β_2 subtype; Desipramine; Binding site, high and low affinity; Neuron, isolated (Sapena, R. (300) 159)

Astrocyte, rat
cAMP accumulation; Adenosine receptor (Peakman, M.-C. (306) 281)

Astrocytoma
Muscarinic receptor; Cell proliferation; Astrocyte (Guizzetti, M. (297) 265)

Ataxia
Ethanol; IGF-I (insulin-like growth factor I); IGF binding protein 1; Hypothermia; Hypnosis; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

Atherosclerosis
Endothelial cell; Smooth muscle cell; Diabetes mellitus; Aminoguanidine; Glutathione; Aldose-reductase (Graier, W.F. (294) 221)

Endothelin-1; Angiotensin II; Cell cycle progression; Ca^{2+}, cytosolic; Primary culture (Jahan, H. (295) 261)

Low-density lipoprotein, oxidized; Nitric oxide (NO); Prostaglandin; Macrophage (Matthys, K.E. (298) 97)

Cell proliferation; Cytokine; Gap junctional intercellular communication; Growth factor; Smooth muscle cell (Mensink, A. (310) 73)

Atipamezole
Central hyperalgesia; Medetomidine; α_2-Adrenoceptor; Neurogenic pain; Lateral reticular nucleus of the medulla; Spinal cord (Mansikka, H. (297) 19)

ATP
Aging; Nitric oxide (NO); Non-adrenergic non-cholinergic (NANC); Ileum, rat (Smits, G.J.M. (303) 79)

Ca^{2+} channel antagonist; Cardiomyocyte; CN^-; Hypoxia; Ca^{2+} channel, L-type (Stokke, M. (303) 115)

Purinergic; Nucleotide; Purinoceptor; Endothelial cell (Motte, S. (307) 201)

P_{2Y} purinoceptor; Gastric mucosa; Plasma membrane (Vallejo, A.I. (312) 209)

Calmodulin antagonist; Glycolysis; Melanoma; Glucose 1,6-bisphosphate (glucose-1,6-P_2, Glc-1,6-P_2); Fructose 1,6-bisphosphate (fructose-1,6-P_2, Fru-1,6-P_2) (Glass-Marmor, L. (313) 265)

Pulmonary artery; Prostaglandin E_1; Acetylcholine; Tolazoline; Nifedipine; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

P_{2x} purinoceptor; Suramin; Portal vein, guinea-pig (Orre, M. (316) 229)

ATPase
Thiamine deficiency; Thalamus; Pyrithiamine; [^{3}H]Ouabain; (Rat) (Mousseau, D.D. (300) 191)

ATPase inhibitor
Ptilomycalin A; Na^+,K^+-ATPase; Ca^{2+}-ATPase (Ohizumi, Y. (310) 95)

ATP-dependent K^+ channel blocker
Cardiac arrhythmia; Ventricular fibrillation (Friedrichs, G.S. (306) 99)

ATP receptor
Nucleotide receptor; UTP receptor; Aorta, rat; Endothelium; Smooth muscle, vascular (García-Velasco, G. (294) 521)

PC12 cell; cAMP; Reactive blue 2 (Yakushi, Y. (314) 243)

ATP receptor channel
Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Recombinant channel; *Xenopus* oocyte (Nakazawa, K. (296) 119)

ATP release
Vas deferens, guinea-pig; Noradrenaline release; Cotransmission; ANP (atrial natriuretic peptide); 8-Bromoguanosine 3′:5′-cyclic monophosphate (Driessen, B. (296) 261)

ATP-sensitive K^+ channel
Vasorelaxation; Heart; His bundle; Conduction; Refractory period; Electrophysiology (D'Alonzo, A.J. (294) 271)

Antinociception; 5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); Sulfonylurea; Gliquidone; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Nicorandil; Cromakalim; Dopamine autoreceptor; Microdialysis; Sulpiride (Tanaka, T. (297) 35)

Ca^{2+}, intracellular; Chemical hypoxia; Dinitrophenol; Cardiac cell; Glyburide; Fluo-3 (Brady, P.A. (308) 343)

Atrial myocardium
Falipamil; Alinidine; Sinoatrial node; His bundle; AV node; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Atrial myocardium refractoriness
Propafenone; 5-Hydroxypropafenone; Sinoatrial node automaticity; His bundle automaticity; AV node refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

Atrial natriuretic peptide
Thapsigargin; Hormone secretion; Mechanical stretch (Taskinen, P. (308) 295)

Atrium, rat
β-Adrenoceptor; β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

Atropine
Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Osmoregulation, central; PD 123177; Vasopressin (Höhle, S. (300) 119)

Methyl-quinuclidinyl-benzylate; CGP-12177; PET (positron emission tomography); Heart; β-Adrenoceptor; Muscarinic receptor (Valette, H. (306) 133)

Choline; ACTH (adrenocorticotrophin); β-Endorphin; Mecamylamine; Hemicholinium-3 (Savci, V. (309) 275)

Au^{3+}
Ag^+; Skeletal muscle contraction; Ca^{2+} release channel; Single channel current (Nihonyanagi, K. (311) 271)

Audiogenic seizure
2,3-Benzodiazepine; GYKI 52466; Aniracetam; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anticonvulsant drug; Epilepsy; (DBA/2 mouse) (De Sarro, G. (294) 411)

Aurintricarboxylic acid
Triflavin; Von Willebrand factor; Glycoprotein IIb/IIIa; Photochemically induced thrombosis (Hisamichi, N. (312) 69)

Austin model 1
Melatonin receptor; Comparative molecular field analysis; Quantitative structure-activity relationship model; Binding site; G protein-coupled receptor (Navajas, C. (304) 173)

Autacoid local inflammatory antagonism
N-Acylethanolamide; Palmitoylethanolamide; Cannabinoid receptor, peripheral; Neurogenic inflammation; Passive cutaneous anaphylaxis (Mazzari, S. (300) 227)

Autoinhibition
Purinergic transmission; P_{2X} purinoceptor; α_2-Adrenoceptor; Electrical stimulation; Splenic artery; (Dog) (Ren, L.-M. (295) 61)

Automaticity
Hyperpolarization-activated current (I_f); Ventricular arrhythmia; Zatebradine; Heart, dog (Furukawa, Y. (300) 203)

Autoradiography
Somatostatin receptor subtype; Brain, rat; Ontogeny (Thoss, V.S. (297) 145)

5-HT recognition site; Duodenum, rat; Ileum, rat; [^{125}I]S-(−)-Zacopride (Ge, J. (300) 113)

Endothelin; Endothelin receptor; BQ123; BQ788 (Tayag, E.C. (300) 261)

Capsaicin treatment, neonatal; Superfusion; Substance P; Glutamate receptor; $GABA_B$ receptor (Teoh, H. (302) 27)

Bradykinin B_2 receptor; HOE140 (Murone, C. (306) 237)

Morphine; Dyspnoea; Quenching; Opioid (Cabot, P.J. (310) 47)

α_2-Adrenoceptor subtype; Brain, human; RX 821002; Frontal cortex; Hippocampus (Grijalba, B. (310) 83)

Dopamine receptor; Adrenal medulla; Radioligand binding; Chromaffin cell; (Rat) (Barili, P. (310) 129)

3-OH-PCP (1-[1(3-hydroxyphenyl)-cyclohexyl]piperidine); Phencyclidine; NMDA receptor; Brain, rat (Suzuki, T. (310) 243)

NK_2 receptor; Airway; Substance P; [^{125}I][Lys^5,Tyr(I$_2$)^7,MeLeu^9, Nle^{10}]Neurokinin A-(4–10) (Strigas, J. (311) 177)

Piribedil; Dopamine receptor (Cagnotto, A. (313) 63)

Brain; ω-Conotoxin GVIA; Ca^{2+} channel, N-type; (Rabbit) (Whorlow, S.L. (315) 11)

Autoreceptor
Dopamine neuron; *l*-Sulpiride; Desipramine; Depression (Diana, M. (312) 179)

AV node
E-4031; K^+ current, delayed rectifier; Zatebradine; Heart, dog (Yamazaki, K. (297) 233)

Falipamil; Alinidine; Sinoatrial node; His bundle; Atrial myocardium; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Ajmaline; Propafenone; Rate dependence; Time constant (Stark, G. (310) 29)

AV node refractoriness
Propafenone; 5-Hydroxypropafenone; Sinoatrial node automaticity; His bundle automaticity; Atrial myocardium refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

Avoidance, multiple choice
Ageing; $5\text{-}HT_3$ receptor; Memory; Itasetron (DAU 6215) (Pitsikas, N. (311) 115)

Azapirone
5-HT (5-hydroxytryptamine, serotonin); 1-(2-Pyrimidinyl)piperazine; Hippocampus; Excitatory synaptic transmission; Electrophysiology; $5\text{-}HT_{1A}$ receptor (Manahan-Vaughan, D. (294) 617)

Azelastine
Traumatic brain injury; Leukotriene; NMDA (*N*-methyl-D-aspartate); Hippocampus; (In vitro) (Girard, J. (300) 43)

Azithromycin
Macrolide; Gentamicin; Aaminoglycoside; Lysosomal phospholipase; Phospholipidosis; Membrane aggregation (Van Bambeke, F. (314) 203)

Phospholipid; Fluorescence polarization; NMR spectroscopy, ^{31}P; Conformational analysis; Gentamicin (Montenez, J.-P. (314) 215)

Baclofen
$GABA_B$ receptor; AHPNs ((*R,S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide); $GABA_B$ receptor antagonist; Ileum, guinea-pig; Neocortex, rat (Kerr, D.I.B. (294) 349)

Ca^{2+} current; GTPγS; Photolysis, ultraviolet; G-protein; Hippocampus, rat (Frank, C. (295) 87)

Antidepressant; Imipramine; $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Hippocampal slice (Bijak, M. (305) 79)

Pertussis toxin; Analgesia; Morphine; Diphenhydramine; Clomipramine; Physostigmine (Galeotti, N. (308) 125)

(−)-Baclofen
$GABA_B$ receptor; 3-Amino-propylphosphinic acid; Phaclofen; CGP 35348; 2-Hydroxy-saclofen; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

(*R,S*)-Baclofen
$GABA_B$ receptor; (*R*)-Saclofen (Kerr, D.I.B. (308) R1)

Balloon angioplasty
Neointima; Restenosis; Endothelium; Nitric oxide (NO); Nitric oxide (NO) synthase; Von Willebrand factor (Bosmans, J.M. (310) 163)

Balloon catheterization
Hyperplasia; HMG-CoA reductase inhibitor (Bandoh, T. (315) 37)

BAPTA / AM (*O,O'*-bis(2-aminophenyl)ethyleneglycol-*N,N,N',N'*-tetraacetic acid, tetraacetoxymethyl ester)
tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone); *N*-Formyl-Met-Leu-Phe; Phorbol ester; Superoxide anion; Ca^{2+} (Tsukii, K. (298) 87)

Basal forebrain
Striatum; Nucleus accumbens (Wallace, D.R. (308) 283)

Basal forebrain lesion
σ_1 Receptor agonist; Cognitive enhancer; Scopolamine; Passive avoidance task; SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride); (Rat) (Senda, T. (315) 1)

Basal ganglia
Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

Individual difference; Novelty; $GABA_A$; Psychostimulant; Cortex; Locomotion (Gruen, R.J. (309) 115)

Metabotropic glutamate receptors; D,L-Amphetamine; MK-801; Openfield; Catalepsy (Kronthaler, U.O. (316) 129)

Basal ganglion
Marijuana; SR 141716A; CP 55,940; Antipsychotic (Anderson, J.J. (295) 163)

Baseline vascular tone
Portal hypertension; EDRF (endothelium-derived relaxing factor) (Pilette, C. (312) 63)

Basement membrane
Angiogenesis; Neurogenic inflammation; Tachykinin; Wound healing (Wiedermann, C.J. (298) 335)

Batrachotoxin
Vincamine; Vincanol; Vinpocetine; Na^+ channel; Voltage-gated; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

BayK 8644
Cocaine; Nimodipine; Self-administration, i.v.; (Rat); (Mouse) (Kuzmin, A. (295) 19)

B cell
15-Deoxyspergualin; T cell; Monocyte; Cytokine (Nicoletti, F. (311) 213)

BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl)cyclohexylamine)
σ Receptor; Dopamine release; (+)-Pentazocine; BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine); DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl) piperidine HBr) (Gonzalez-Alvear, G.M. (294) 713)

BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine)
σ Receptor; Dopamine release; (+)-Pentazocine; DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl)piperidine HBr); BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl)cyclohexylamine) (Gonzalez-Alvear, G.M. (294) 713)

Behavior
α-Trinositol; Antinociception; Intrathecal; Formalin test; (Rat) (Malmberg, A.B. (294) 609)

d-Amphetamine; Dose response; Psychomotor stimulant; Motor activity (Gaytan, O. (300) 1)

Cocaine analog; Dopamine transporter (Fleckenstein, A.E. (311) 109)

Behavioral interaction
Adenosine receptor agonist; Dopamine receptor antagonist; Catalepsy; Schizophrenia (Kafka, S.H. (295) 147)

Behavioral model
σ Receptor ligand; EMD 57445; Rimcazole; Central effect (Maj, J. (315) 235)

Behavioral sensitization
σ Receptor; Cocaine; BMY-14802; SR-31742A; Schizophrenia (Ujike, H. (296) 123)

N-Cyanomethylmethamphetamine; Methamphetamine; Haloperidol; Ambulation; (Mouse) (Kuribara, H. (305) 1)

Amphetamine; Glucocorticoid (De Vries, T.J. (307) R3)

cAMP; Rolipram; Methamphetamine; Microdialysis, in vivo (Iyo, M. (312) 163)

Benextramine
Prostanoid TP receptor; Mesenteric artery, small; SQ 30,741; U46619; (Rat) (Van der Graaf, P.H. (300) 211)

Benzamide, substituted
Gastrointestinal tract; Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug (Zafirov, D. (311) 61)

Benzodiazepine
Stress; Hyperthermia; Temperature; Anxiety; $5\text{-}HT_{1A}$ receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

Gastric lesion, ethanol-induced; Unilateral vagotomy; (Rat) (Khadour, F. (298) 271)

$GABA_A$ receptor; Flunitrazepam; Ro 15-4513; Hydroxylamine (Duncalfe, L.L. (298) 313)

Diazepam; Heart preparation, isolated; Inotropy; Peripheral-type benzodiazepine receptor antagonist (Leeuwin, R.S. (299) 149)

Drug discrimination; Time course; Bretazenil; Chlordiazepoxide; (Rat) (Bronson, M. (305) 7)

Anxiety; Immediate early gene; Elevated X-maze; CI-988; CCK (cholecystokinin) (Hinks, G.L. (312) 153)

Hyperphagia; Brain stem; Parabrachial nucleus; Palatability; (Rat) (Higgs, S. (313) 1)

Morphine withdrawal; Microdialysis (Gray, A.M. (313) 73)

Propofol; $GABA_A$ receptor; Flurazepam; Anesthesia; *Xenopus* oocyte (Reynolds, J.N. (314) 151)

Diazepam; Langendorff heart; Inotropy; Ca^{2+}-entry blocking drug; Adenosine receptor blocking drug (Leeuwin, R.S. (315) 153)

Benzodiazepine binding
Pentobarbital; $GABA_A$ receptor; Drug tolerance; Substance dependence (Suzuki, T. (295) 169)

Benzodiazepine binding site property
$GABA_A$ receptor subtype, recombinant, α4β3γ2S, α4γ2S, α1β3γ2S (Scholze, P. (304) 155)

Benzodiazepine receptor
β-CCE (ethyl β-carboline-3-carboxylate); Down-regulation; Inverse agonist; Primary cultured neuron (Katsura, M. (298) 71)

Loreclezole; $GABA_A$ receptor; Neuroactive steroid (Xue, B.G. (300) 125)

NNC 14-0185; NNC 14-0189; Seizure threshold; Epilepsy (Jackson, H.C. (308) 21)

N^3-Phenacyluridine; Sedative; Hypnotic; Central nervous system (Kimura, T. (311) 265)

Benzodiazepine receptor, central
PET (positron emission tomography); [^{11}C]Flumazenil; Imidazopyridine (Abadie, P. (295) 35)

Benzodiazepine receptor, peripheral
Mitochondria, liver; Cholesterol; Porphyrin (Tsankova, V. (294) 601)

Porphyrin; PK11195; Cholesterol; Metabolism; Liver (Tsankova, V. (299) 197)

Benzodiazepine tolerance
Medial vestibular nucleus; GABA receptor; Isoguvacine (Hutchinson, M.A. (301) 83)

2,3-Benzodiazepine
GYKI 52466; Aniracetam; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anticonvulsant drug; Epilepsy; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

[^{3}H]2-(2-Benzofuranyl)-2-imidazoline
Imidazoline I_2 receptor; Idazoxan; Clonidine (Lione, L.A. (304) 221)

Benztropine
Dopamine transporter; [^{3}H]GBR 12935 binding; L-DOPA; Reserpine; Amantadine (Gordon, I. (298) 27)

Bepridil
Voltage clamp, whole cell; Na^+ current; Myocyte, single, ventricular (Sato, N. (314) 373)

Berberine
K^+ channel, ATP-sensitive; Patch clamp; Microelectrode recording; Cardiac cell (Wang, Y.-X. (316) 307)

Bertosamil
K^+ channel, ATP-sensitive; Ca^{2+} channel, L-type; Chronotropism; Inotropism; Heart, dog (Yonezawa, T. (309) 51)

Bezold-Jarisch reflex
5-HT_3 receptor; Substance P; Capsaicin; (+)-Tubocurarine (Malinowska, B. (315) 159)

Bezold–Jarisch reflex
5-HT_3 receptor; 5-HT_3 receptor agonist; N1E-115 cells; NG 108-15 cells; [^{14}C]guanidinium; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

BHK cell
Glutamate receptor; Subunit; cDNA; AMPA (α-amino-3-hydroxy-5-methyl-isoxalazole-4-propionate) (Andersen, P.H. (311) 95)

BIBP 3226
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; Vasoconstriction, sympathetic; Vena cava, guinea-pig (Malmström, R.E. (294) 661)

BIBP3226
Neuropeptide Y; Y_1 receptor antagonist; Gastrointestinal epithelia (Tough, I.R. (310) 55)

Artery, human; Noradrenaline; Neuropeptide Y; Antisense oligodeoxynucleotide; Reverse transcriptase-polymerase chain reaction (Bergdahl, A. (316) 59)

Bicuculline
GABA receptor antagonist; SR95531; Pentobarbitone; Etomidate; Hippocampal neuron (Uchida, I. (307) 89)

Big endothelin-1
Endothelin; Sarafotoxin; Inositol phosphate; Spinal cord; Endothelin ET_A receptor (Poulat, P. (315) 327)

Binding
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; σ Receptor, subtype; Brain, rat (Narita, N. (307) 117)

Binding assay
Pheochromocytoma (PC12) cell; Ca^{2+} uptake; Nicotine; NE-100 (*N,N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl); σ Receptor (Sagi, N. (304) 185)

Binding characteristics
Opioid receptor; Partial agonist; cAMP; KT-90 ((−)-3-acetyl-6β-acetylthio-*N*-cyclopropylmethyl-normorphine) (Katsumata, S. (312) 349)

Binding cooperativity
Vanilloid receptor; Resiniferatoxin; Capsaicin; PPAHV (phorbol 12-phenylacetate 13-acetate 20-homovanillate) (Szallasi, A. (299) 221)

Binding, in vitro
Dopamine carrier, neuronal; Ion dependence; K^+ gradient (Héron, C. (301) 195)

Binding protein
Pancreatic polypeptide; Neuropeptide Y (NPY); (*Conus* anemone); Neuropeptide Y-(18-36) (Czerwiec, E. (315) 355)

Binding site
Opioid receptor, human; Opiate (Li, X. (300) R1)

Melatonin receptor; Comparative molecular field analysis; Quantitative structure-activity relationship model; Austin model 1; G protein-coupled receptor (Navajas, C. (304) 173)

σ Binding site
Smooth muscle; Ileum; σ Receptor subtype; (Guinea pig); (Rat) (Kinney, G.G. (294) 547)

Trishomocubane; 1,3-Di-*o*-tolylguanidine; Brain membrane; (+)-Pentazocine (Nguyen, V.H. (311) 233)

Binding site, high and low affinity
β-Adrenoceptor, β_1 and β_2 subtype; Desipramine; Astrocyte, isolated; Neuron, isolated (Sapena, R. (300) 159)

Binding study
Adenosine A_1 receptor; Adenosine (Cohen, F.R. (309) 111)

Binding thermodynamics
5-HT_3 receptor; Agonist and antagonist discrimination; Thermodynamic compensation (Borea, P.A. (298) 329)

5-HT_{1A} receptor; Drug-receptor interaction (Dalpiaz, A. (312) 107)

Bioassay
Antinociception; Deltorphin; Opioid receptor; Peptide synthesis (Guerrini, R. (302) 37)

Nociceptin receptor; Vas deferens, mouse (Calò, G. (311) R3)

Biotransformation
Cannabinoid; CP-55,940; Tolerance; Energetic metabolism (Costa, B. (313) 17)

Biperiden
Budipine; Muscarinic; NMDA (*N*-methyl-D-asparate); Parkinsonism (Klockgether, T. (301) 67)

Biphasic effect
Interleukin-1β; Mechanical nociception; (Rat) (Yabuuchi, K. (300) 59)

Bipolar disorder
Lithium chloride; Valproic acid; G-protein; ADP ribosylation (Young, L.T. (309) 215)

Bisaramil
Cardiac Na^+ channel; Na^+ channel block; Antiarrhythmic agent, class I (Sunami, A. (312) 245)

Bisquaternary allosteric antagonist
Muscarinic acetylcholine receptor agonist (Lanzafame, A. (316) 27)

BK_{Ca} channel
Coronary arterial cell; Patch-clamp; (Whole-cell recording); (Holding potential) (Hu, S. (294) 357)

Bladder
α_1-Adrenoceptor antagonist; Doxazosin; Terazosin; Sympathetic nerve activity; (Anesthetized cat) (Ramage, A.G. (294) 645)

Bleeding time
Triflavin; RGD (Arg-Gly-Asp)-containing peptide; Fibrinogen receptor antagonist; Mesenteric artery; Thrombosis (Sheu, J.-R. (294) 231)

Blocking effect
Achatin-I (Gly-D-Phe-Ala-Asp); Excitatory neuropeptide; Promethazine; Triprolidine; Histamine H_1 receptor antagonist; Neuron; (Snail) (Salunga, T.L. (304) 163)

Blood alcohol concentration
Ethanol; IGF-I (insulin-like growth factor I); IGF binding protein 1; Ataxia; Hypothermia; Hypnosis; Tolerance; (Transgenic mouse) (Pucilowski, O. (305) 57)

Blood-brain barrier
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Losartan; EXP3174; GR117289; LR-B/081 (Polidori, C. (307) 259)

Nitric oxide (NO) synthase, inducible; Ethanol; RBE4 cell; Inflammation; Endotoxin; Nitric oxide (NO) (Naassila, M. (313) 273)

Blood flow
PAF (platelet-activating factor); Vasomotor tone; Endothelium; Arterial pressure; Noradrenaline; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

Capsaicin; Pancreatic islet; Insulin release; Pancreas; Peptidergic neuron (Carlsson, P.-O. (312) 75)

Blood flow distribution
Positive inotropic agent; Systemic hemodynamics; Mean circulatory filling pressure; OPC-18790 (Fujiki, H. (313) 191)

Blood flow, skin
SM-10902 ointment; Wound healing; Prostacyclin analog; Angiogenesis; Diabetic mouse (*db/db* mouse), genitically (Yamamoto, T. (302) 53)

Blood monocyte, human
Prostaglandin endoperoxide synthase; Platelet, human; Flurbiprofen; Flurbinitroxybutylester (Santini, G. (316) 65)

Blood perfused
Diabetes; Hypertension; Angiotensin; Nephropathy; Kidney; (Rat) (Farina, N.K. (310) 185)

Blood pressure
Adenosine; Morphine dependence (White, P.J. (294) 215)

Des-Asp-angiotensin I; Angiotensin analog, D-amino acid substituted; Angiotensin III (Radhakrishnan, R. (294) 337)

5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

γ_2-MSH (γ_2-melanocyte-stimulating hormone); ACTH-(4–10) (adrenocorticotropic hormone-(4–10)); Heart rate; Structure-activity; Melanocortin receptor; (Rat) (Van Bergen, P. (294) 795)

Opioid; κ-Opioid receptor agonist; Pregnancy; Heart rate (Szeto, H.H. (297) 77)

Glucose; Insulin; Pancreatic islet, blood flow; β-Adrenoceptor (Atef, N. (298) 287)

Dietary fat; *n*–3 fatty acid; Arrhythmia; Proteinuria; Thromboxane (McLennan, P. (300) 83)

Falipamil; Alinidine; Sinoatrial node; His bundle; Atrial myocardium; AV node; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Local anesthetic; Cocaine; Lidocaine; Pseudococaine; Hemodynamics; Heart rate; Desipramine (Bernards, C.M. (307) 33)

κ-Opioid receptor; Cardiovascular; Phentolamine; Pregnancy (Szeto, H.H. (309) 183)

Choline; Acetylcholine; Hypotension; Vasopressin; Nicotinic receptor (Savci, V. (311) 153)

C-fiber; Reflex; Pain; Clonidine; (Rat) (Gozariu, M. (313) 51)

Nitroglycerin; Tolerance; Phosphodiesterase inhibitor; cGMP monophosphate; Zaprinast; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Spinal cord; Hypertension; Muscarinic receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Feldman, D.S. (313) 211)

Cocaine; Heart rate; Self-administration (Ambrosio, E. (315) 43)

Propafenone; 5-Hydroxypropafenone; Sinoatrial node automaticity; His bundle automaticity; Atrial myocardium refractoriness; AV node refractoriness; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

5-HT_{1A} receptor; Heart rate; Preoptic area; Forebrain; 8-OH-DPAT (*R*-(+)-8-hydroxy-2-(di-*n*-propylamino) tetralin) (Szabó, A. (315) 187)

Endothelin-1; Superior colliculus; Renal blood flow (D'Amico, M. (316) 245)

Blood pressure, mean arterial
Intravital microscopy; Flow cytometry; Leukocyte rolling; Leukocyte adherence; Venular shear rate (Scalia, R. (296) 181)

Blood pressure variability
HOE 140; Losartan; Renal hypertension; Spectral analysis (Ponchon, P. (297) 61)

Blood vessel
(±)-SDZ NVI 085; 5-HT_{2A} receptor; α_1-Adrenoceptor (Lachnit, W.G. (297) 83)

Neuropeptide Y; Noradrenaline; Peptide; Vascular control; Hemorrhage (Hunter, L.W. (313) 79)

BMS-181100
Haloperidol; Clozapine; BMY 14802; Methylphenidate; Flesinoxan; Buspirone; S 14506; Gnawing; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

BMY 7378
α_{1D}-Adrenoceptor; α_{1A}-Adrenoceptor; Spontaneously hypertensive rat (SHR); Artery; Wistar Kyoto rat (WKY) (Villalobos-Molina, R. (298) 257)

5-Methylurapidil; A-61603; α_1-Adrenoceptor; Arterial pressure (Zhou, L. (305) 173)

Spinal cord; α_1-Adrenoceptor subtype; 5-Methyl-urapidil; [^{3}H]Prazosin; (Rat) (Wada, T. (312) 263)

BMY-14802
σ Receptor; Behavioral sensitization; Cocaine; SR-31742A; Schizophrenia (Ujike, H. (296) 123)

Haloperidol; Clozapine; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; S 14506; Gnawing; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

BN 52021
Heparin; Protamine; Platelet; PAF (platelet-activating factor); PAF-acether; Thromboxane (Aïssa, J. (302) 123)

Body weight loss
Diltiazem; Naloxone-precipitated withdrawal; Morphine withdrawal, spontaneous; Corticosterone, plasma; Diarrhea; (Rat) (Kishioka, S. (316) 7)

Bombesin
Gastrin-releasing peptide; Neuromedin B; Structure-function study (Lin, J.-T. (294) 55)

Phospholipase C; Norepinephrine; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); LA-N-2 cell; β-Adrenoceptor; Metabotropic (Sorrentino, G. (308) 81)

Bombesin receptor antagonist
Neuromedin B; Ca^{2+}, intracellular; Arachidonic acid (Ryan, R.R. (306) 307)

Bone resorption
Cathepsin L; Cysteine protease inhibitor; Dipeptidyl aldehyde (Woo, J.-T. (300) 131)

Bosentan
Endothelin; Intestinal inflammation; Inflammatory bowel disease (Hogaboam, C.M. (309) 261)

Renal hemodynamics; Congestive heart failure; Aorto-caval fistula (Gurbanov, K. (310) 193)

BQ123
Endothelin-1; Heart, perfused, rat; TAK-044; Endothelin ET_A receptor; Endothelin ET_B receptor (Kusumoto, K. (296) 65)

Endothelin; Endothelin receptor; BQ788; Autoradiography (Tayag, E.C. (300) 261)

Endothelin receptor antagonist; Endothelin receptor subtype; Bronchus, human; Trachea, guinea-pig; Ro 47-0203; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

Endothelin-1; BQ-3020; Endothelin receptor; Cerebral circulation; Resistance arteriole, cerebral (Patel, T.R. (307) 41)

Coronary circulation; Endothelin ET_A receptor; Endothelin ET_B receptor; IRL 1620; Nitric oxide (NO) (García, J.L. (315) 179)

BQ788
Endothelin; Endothelin receptor; BQ123; Autoradiography (Tayag, E.C. (300) 261)

BQ3020
Endothelin-1; BQ-123; Endothelin receptor; Cerebral circulation; Resistance arteriole, cerebral (Patel, T.R. (307) 41)

Bradycardic agents, specific
Isovolumic relaxation; Ventricular filling; Myocardial contractility; Preload recruitable stroke work; Inotropes; Dobutamine; Zatebradine (Hettrick, D.A. (316) 237)

Bradykinin
Glomerular hemodynamics; Glomerular prostaglandin; Kinin antagonist; Glomerular receptor; Receptor desensitization (Praddaude, F. (294) 173)

Prostaglandin E_2; Pain; Nociceptor; Vein (Kindgen-Milles, D. (294) 491)

Angiotensin-converting enzyme inhibitor; Neutral endopeptidase inhibitor; DOCA-salt rat (Pham, I. (296) 267)

Bradykinin receptor; Coronary artery; (Pig) (Pruneau, D. (297) 53)

HOE140; Ketotifen; Bradykinin receptor; Mast cell; Vascular permeability (Morishita, M. (298) 149)

Ramiprilat; Angiotensin-converting enzyme inhibitor; Bradykinin B_2 receptor antagonism; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Cardiac myocyte; Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

Hoe140; Pneumococcal meningitis; Cerebral blood flow; Brain edema; Intracranial pressure (Lorenzl, S. (308) 335)

Nitric oxide (NO); N^G-Nitro-L-arginine; Antinociception (Germany, A. (310) 123)

Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Bradykinin receptor
Bradykinin; Coronary artery; (Pig) (Pruneau, D. (297) 53)

Bradykinin; HOE140; Ketotifen; Mast cell; Vascular permeability (Morishita, M. (298) 149)

CP-99,994; Formaldehyde; Mast cell; Tachykinin receptor; Vascular permeability (Ito, K. (307) 291)

Bradykinin B_1 receptor
Bradykinin; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Bradykinin B_2 receptor
HOE140; Autoradiography (Murone, C. (306) 237)

Bradykinin; Bradykinin B_1 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Bradykinin B_2 receptor antagonism
Ramiprilat; Angiotensin-converting enzyme inhibitor; Bradykinin; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Cardiac myocyte; Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

Brain
Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; SMS 201-995; Somatostatin receptor subtype; Gastric acid secretion; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Linopirdine; DuP 996; Membrane binding; Species difference (Höfner, G. (298) 307)

Melatonin; Kainate; Lipid peroxidation; (Rat) (Melchiorri, D. (305) 239)

Sertraline; Glutamic acid decarboxylase mRNA; Hybridization, in situ (Giardino, L. (312) 183)

Autoradiography; ω-Conotoxin GVIA; Ca^{2+} channel, N-type; (Rabbit) (Whorlow, S.L. (315) 11)

Brain binding site
Anticonvulsant; SB 204269 (Herdon, H. (314) R7)

Brain edema
Bradykinin; Hoe140; Pneumococcal meningitis; Cerebral blood flow; Intracranial pressure (Lorenzl, S. (308) 335)

Brain, hamster
2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML_2 receptor; Melatonin; Kidney; Testes; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

Brain, human
Parkinson's disease; Huntington's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II (Ge, J. (297) 299)

Imidazoline I_2 receptor; Extrapyramidal disorder (Reynolds, G.P. (301) R19)

Idazoxan; Imidazoline receptor; Anti-idiotypic antibody (Bennai, F. (306) 211)

α_2-Adrenoceptor subtype; RX 821002; Autoradiography; Frontal cortex; Hippocampus (Grijalba, B. (310) 83)

Brain membrane
σ Binding site; Trishomocubane; 1,3-Di-*o*-tolylguanidine; (+)-Pentazocine (Nguyen, V.H. (311) 233)

Brain, rat
Somatostatin receptor subtype; Autoradiography; Ontogeny (Thoss, V.S. (297) 145)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; σ Receptor, subtype; Binding (Narita, N. (307) 117)

3-OH-PCP (1-[1(3-hydroxyphenyl)-cyclohexyl]piperidine); Phencyclidine; NMDA receptor; Autoradiography (Suzuki, T. (310) 243)

$5\text{-}HT_{1A}$ receptor; BRL 44408; ARC 239; α_2-Adrenoceptor subtype (Meana, J.J. (312) 385)

Brain stem
Benzodiazepine; Hyperphagia; Parabrachial nucleus; Palatability; (Rat) (Higgs, S. (313) 1)

Brain synaptosome
Adenosine; Ca^{2+} uptake; Ca^{2+} channel (Gonçalves, M.L. (310) 257)

BRB-I-28
Antiarrhythmic activity; Ischemic arrhythmia; Sparteine; Patch-clamp (Pugsley, M.K. (294) 319)

Breast cancer cell (T47D)
Cell proliferation; Opioid; Opioid receptor; Opioid receptor subtype (Hatzoglou, A. (296) 199)

α-Casomorphin; β-Casomorphin; Opioid receptor; Receptor subtype; Somatostastin receptor (Hatzoglou, A. (310) 217)

Bretazenil
Benzodiazepine; Drug discrimination; Time course; Chlordiazepoxide; (Rat) (Bronson, M. (305) 7)

BRL 37344
β/β_3-Adrenoceptor, atypical; β_3-Adrenoceptor; Smooth muscle, esophageal, rat; Trimetoquinol; Isomeric activity ratio (Lezama, E.J. (308) 69)

BRL 44408
$5\text{-}HT_{1A}$ receptor; ARC 239; α_2-Adrenoceptor subtype; Brain, rat (Meana, J.J. (312) 385)

8-Bromoguanosine 3′:5′-cyclic monophosphate
Vas deferens, guinea-pig; Noradrenaline release; ATP release; Cotransmission; ANP (atrial natriuretic peptide) (Driessen, B. (296) 261)

Bronchoalveolar lavage fluid
Pulmonary eosinophilia; Inflammation; Leukotriene B_4; Leukotriene C_4; Leukotriene D_4; Leukotriene E_4; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Bronchoconstriction
Airway neurogenic inflammation; Substance P; Neurokinin A; Capsaicin (Robineau, P. (294) 677)

K^+ channel opener; Levcromakalim; HOE 234; Plasma exudation (Kidney, J.C. (296) 81)

Cold air; Tachykinin; Kinin; SR 48968; HOE 140; Neurogenic inflammation (Yoshihara, S. (296) 291)

FK888; SR48968; Citric acid; Cough; Tachykinin (Yasumitsu, R. (300) 215)

Vagal reflex; Tracheal innervation; (Guinea-pig) (Takahashi, Y. (302) 89)

Neurokinin; NK_1 receptor antagonist; Pain; Plasma extravasation; Neuropeptide (Bonnet, J. (310) 37)

Bronchoconstriction, adenosine-induced
Tracheal spirals; Cross-tachyphylaxis; Xanthine antagonist resistance; Transport inhibitors; (Sensitized guinea pigs) (Thorne, J.R. (316) 263)

Bronchus, human
Endothelin receptor antagonist; Endothelin receptor subtype; Trachea, guinea-pig; Ro 47-0203; BQ123; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

Brown adipose tissue, rat
β-Adrenoceptor; β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Trachea, rat; Distal colon, rat (Konkar, A.A. (305) 63)

BS-6181
Muscarinic receptor subtype; Muscarinic receptor antagonist; Carbon analog, uncharged; Stereoselectivity, at muscarinic receptor; BS-7826, (*R*)- and (*S*)-enantiomer (Waelbroeck, M. (303) 221)

BS-7826, (*R*)- and (*S*)-enantiomer
Muscarinic receptor subtype; Muscarinic receptor antagonist; Carbon analog, uncharged; Stereoselectivity, at muscarinic receptor; BS-6181 (Waelbroeck, M. (303) 221)

Bt_2 cAMP (N^6,2′-*O*-dibutyryl adenosine 3′:5′-cyclic monophosphate)
Salbutamol; Allergic pleurisy (Diaz, B.L. (296) 173)

tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone)
N-Formyl-Met-Leu-Phe; Phorbol ester; Superoxide anion; Ca^{2+}; BAPTA/AM (*O*,*O*′-bis(2-aminophenyl)ethyleneglycol-*N*,*N*,*N*′,*N*′-tetraacetic acid, tetraacetoxymethyl ester) (Tsukii, K. (298) 87)

Budipine
Biperiden; Muscarinic; NMDA (*N*-methyl-D-asparate); Parkinsonism (Klockgether, T. (301) 67)

Buprenorphine
C-fiber reflex; Nociception; Diffuse noxious inhibitory control; Descending inhibitory control; Spinal cord; Morphine (Guirimand, F. (294) 651)

Morphine; Castor oil; Diarrhoea; Gastrointestinal transit; Ethanol lesion (Bhounsule, S.A. (316) 253)

Buspirone
$5\text{-}HT_{1A}$ autoreceptor antagonism; (−)-Pindolol; Selective serotonin reuptake inhibitor (SSRI); Citalopram; 5-HT (5-hydroxytryptamine, serotonin), extracellular; Microdialysis, in vivo (Hjorth, S. (303) 183)

Haloperidol; Clozapine; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; S 14506; Gnawing; $5\text{-}HT_{1A}$ receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Butanedione monoxime (BDM)
Ca^{2+} sensitivity; Cross-bridge; EMD 53998; Cardiac skinned fiber (Barth, Z. (296) 285)

Butein
Anti-GBM nephritis; Intercellular adhesion molecules; Endothelial cells; Leukocyte, polymorphonuclear (Hayashi, K. (316) 297)

Butorphanol
Opioid dependence; Central nervous system; Glutamate; MK-801 (dizocilpine); Morphine (Tokuyama, S. (295) 123)

Glutamate; κ-Opioid receptor agonist; Locus coeruleus; Microdialysis; U-69,593 (Hoshi, K. (314) 301)

BW A868C
Prostaglandin D_2; BW245C; DP receptor; Antagonist affinity (Liu, Y.J. (303) 187)

DP receptor; Partial agonist; Cl^- secretion (Liu, Y.J. (304) 117)

BW245C
BW A868C; Prostaglandin D_2; DP receptor; Antagonist affinity (Liu, Y.J. (303) 187)

BW373U86
δ-Opioid receptor; G-protein; Radioligand binding (Campa, M.J. (310) 263)

BZ (ω) receptor
Zolpidem; Zaleplon; Hypnotic (Sanger, D.J. (313) 35)

CA1
Traumatic brain injury; Felbamate; Long-term potentiation; Hippocampus (Wallis, R.A. (294) 475)

Ca^{2+}
Myofilament; Ca^{2+} sensitiser; EMD 57033; Skinned fiber; Rigor (Palmer, S. (294) 83)

Pregnenolone sulfate; Steroid; GH3 cell; Pituitary (Büküşoğlu, C. (298) 79)

tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone); *N*-Formyl-Met-Leu-Phe; Phorbol ester; Superoxide anion; BAPTA/AM (*O*,*O*′-bis(2-aminophenyl)ethyleneglycol-*N*,*N*,*N*′,*N*′-tetraacetic acid, tetraacetoxymethyl ester) (Tsukii, K. (298) 87)

W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine); Thromboxane A_2; G-protein; Phosphoinositide hydrolysis (Ohkubo, S. (298) 175)

Colon, rat; Cl^- channel; K^+ channel; Genistein; Protein tyrosine kinase (Diener, M. (299) 161)

Retinal cell; Glutamate receptor; Neurotoxicity; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Ferreira, I.L. (302) 153)

Adenosine A_1 receptor; Ca^{2+} pumping; DDT_1 MF-2 cell; (Temperature) (Sipma, H. (306) 187)

Cytosolic; Fura-2; Parietal cell, rabbit; Elutriation; CCK_B/gastrin receptor antagonist (Letari, O. (306) 325)

Aorta; Carotid artery; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Potassium chloride; Cholesterol (Moreland, R.S. (307) 55)

G_i-protein; Neuropeptide Y receptor; α_{2A}-Adrenoceptor; Microtubule; Microfilament (Michel, M.C. (309) 87)

Smooth muscle, vascular; Protein kinase C, cytosolic; Protein kinase C, particulate (Bazan, E. (311) 101)

Myocardium; Dantrolene; Sarcoplasmic reticulum; Ca^{2+} indicators; Aequorin (Meissner, A. (316) 333)

Ca^{2+}-activated K^+ channel
Tremorgenic indole alkaloid; Charybdotoxin; Iberiotoxin; Excitation-contraction coupling (DeFarias, F.P. (314) 123)

Ca^{2+} assay
Spinal neuron; Purinoceptor; K^+ channel; G-protein; Protein kinase C; Patch clamp (Ikeuchi, Y. (302) 163)

Ca^{2+}-ATPase
Ptilomycalin A; Na^+,K^+-ATPase; ATPase inhibitor (Ohizumi, Y. (310) 95)

Endothelial cell, aortic; Ca^{2+} concentration, intracellular, free; Na^+-Ca^{2+} exchange; Fura-2 (Goto, Y. (314) 185)

Ca^{2+}-buffering function
Ryanodine; Sarcoplasmic reticulum; Ca^{2+} channel, voltage-dependent; Arterial myogenic tone; Cerebral artery; (Dog) (Asano, M. (311) 53)

Ca^{2+}/calmodulin-dependent protein kinase II
Glutamate release; Protein tyrosine kinase; Phosphorylation; Synaptophysin; Synapsin; Hippocampus; Ageing (Mullany, P. (309) 311)

Ca^{2+} channel
Whole-cell voltage-clamp; Dissociated Purkinje neuron; Inactivation; Eliprodil (Biton, B. (294) 91)

Myocyte, ventricular; Flunarizine (Tytgat, J. (296) 189)

Anandamide; Arachidonic acid; [^{3}H](+)-PN200-110; [^{3}H]Diltiazem; [^{3}H](−)-Desmethoxyverapamil (Shimasue, K. (296) 347)

Otilonium; Chromaffin cell; Adrenal gland; Catecholamine release (Gandía, L. (298) 199)

Acetylcholine; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Neuromuscular transmission; Suramin; P_2 purinoceptor; Non-depolarizing neuromuscular relaxant (Henning, R.H. (301) 91)

Lymphocyte; PN 200-110; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)

Uterus, rat; Sex hormone, female; Diazepam; 4′-Chlorodiazepam; Clonazepam; PK 11195 (Yiu, M.-k. (302) 99)

Hippocampus; Conotoxin; ω-Agatoxin-IVA (Nooney, J.M. (306) 41)

Adenosine; Ca^{2+} uptake; Brain synaptosome (Gonçalves, M.L. (310) 257)

K^+ channel; Seizure; Hippocampus; Levcromakalim; Patch clamp (Katsumori, H. (311) 37)

Dihydropyridine; ω-Conotoxin; ω-Agatoxin; Melanotrope; Pituitary; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

Oxatomide; RBL-2H3 cell; Signal transduction; Exocytosis; Protein tyrosine phosphorylation; Ca^{2+} flux (Paulussen, J.J.C. (312) 121)

CP-060*S*; Ca^{2+} overload; Veratridine; Cardiomyocyte; Smooth muscle, vascular (Tamura, K. (312) 195)

Antipsychotic drug; Dopamine receptor antagonist; Calmodulin antagonist; Membrane current (Ito, K. (314) 143)

Contraction; Human bronchus; Protein kinase C; Na^+/K^+-ATPase (Yang, K.X.F. (315) 65)

Ca^{2+} channel activator
CGP 48506; Ca^{2+} channel, L-type; Mode 2 gating (Herzig, S. (295) 113)

Ca^{2+} channel antagonist
Dystonia; Dopamine; Movement disorder (Richter, A. (300) 197)

Vascular relaxation; Negative inotropic action; Negative chronotropic action; Ca^{2+} current, L-type; NB-818 (Hattori, Y. (301) 99)

ATP; Cardiomyocyte; CN^-; Hypoxia; Ca^{2+} channel, L-type (Stokke, M. (303) 115)

CD-832; Myocardium; Chronotropic effect, negative; Inotropic effect, negative; (Guinea-pig) (Noguchi, K. (308) 53)

Cerebral blood flow autoregulation; Amlodipine; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (313) 103)

Subarachnoid hemorrhage; Endothelium-dependent relaxation; Lipid peroxidation; AJ-3941; Nimodipine (Minato, H. (315) 297)

Ca^{2+} channel blockade
Neuroleptic withdrawal; Haloperidol; Pimozide; Nifedipine; Apomorphine (Antkiewicz-Michaluk, L. (294) 459)

Ca^{2+} channel blocker
Spider venom; K^+ channel blocker; Endothelin-1; Nitric oxide (NO); Hoe 140 (Costa, S.K.P. (298) 113)

Ca^{2+} channel inhibitor
NMDA receptor antagonist; CGP 40116; CGP 43487; Flunarizine; Nicardipine; Nifedipine; Seizure (Gasior, M. (312) 27)

Ca^{2+} channel, L-type
CGP 48506; Mode 2 gating; Ca^{2+} channel activator (Herzig, S. (295) 113)

Stretch-activated channel; Na^+ dependence; Ca^{2+} uptake; Membrane potential (Ruiz-Velasco, V. (296) 327)

ATP; Ca^{2+} channel antagonist; Cardiomyocyte; CN^-; Hypoxia (Stokke, M. (303) 115)

Nimodipine; Ethanol; Substitution; Drug discrimination; Conditioned taste aversion (De Beun, R. (306) 5)

Bertosamil; K^+ channel, ATP-sensitive; Chronotropism; Inotropism; Heart, dog (Yonezawa, T. (309) 51)

Ca^{2+} channel, N-type
Autoradiography; Brain; ω-Conotoxin GVIA; (Rabbit) (Whorlow, S.L. (315) 11)

Ca^{2+} channel, P-type
Antinociception, spinal; Morphine; Clonidine; Tolerance; G-protein (Roerig, S.C. (314) 293)

Ca^{2+} channel, voltage-dependent
HEK293 cell; NMDA receptor antagonist; Ischemia; Neuroprotection; (Gerbil) (Bath, C.P. (299) 103)

Ryanodine; Sarcoplasmic reticulum; Ca^{2+}-buffering function; Arterial myogenic tone; Cerebral artery; (Dog) (Asano, M. (311) 53)

Ca^{2+} concentration, intracellular, free
Endothelial cell, aortic; Na^+-Ca^{2+} exchange; Ca^{2+}-ATPase; Fura-2 (Goto, Y. (314) 185)

Ca^{2+} current
GTPγS; Baclofen; Photolysis, ultraviolet; G-protein; Hippocampus, rat (Frank, C. (295) 87)

MCI-154 (6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3-(2*H*)-pyridazinone); Ventricular arrhythmia; Heart failure (Eto, K. (298) 247)

Forskolin; 1,9-Dideoxyforskolin; Ryanodine store; Action potential; Cerebellar granule cell (Zerr, P. (303) 101)

Anti-epileptic drug; Cortex; Neuroprotective agent (Stefani, A. (307) 113)

Endothelin-1; Ventricular cardiomyocyte (Kelso, E. (308) 351)

Ca^{2+} current, L-type
Ca^{2+} channel antagonist; Vascular relaxation; Negative inotropic action; Negative chronotropic action; NB-818 (Hattori, Y. (301) 99)

Niguldipine; Whole-cell recording; Voltage dependence; Enantioselectivity (Handrock, R. (309) 317)

Ca^{2+} current, L-type, voltage-dependent
17β-Estradiol; Estrogen; Vascular smooth muscle; Endothelin-1; Vasopressin; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Ca^{2+}, cytoplasmic
Sulphonylurea; Tolbutamide; Glibenclamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Ca^{2+}, cytosolic
Flupirtine; Focal cerebral ischemia; Primary neuronal culture; Glutamate; Fura-2 (Rupalla, K. (294) 469)

Endothelin-1; Angiotensin II; Atherosclerosis; Cell cycle progression; Primary culture (Jahan, H. (295) 261)

Adenosine; Ca^{2+} domain; Cardioprotection; Fluo-3; Heart (Jovanovic, A. (298) 63)

Platelet; Endothelin-3; Sodium nitroprusside; cGMP; Phosphodiesterase inhibitor; Ca^{2+} pump (Gagnet, C. (310) 67)

Ca^{2+}, cytosolic, free
Fetal alcohol syndrome; Digital image analysis (Altura, B.M. (314) R9)

Ca^{2+} dependency
Microdialysis; Hippocampus; Amino acid; Uptake carrier; Vesicular release (Zuiderwijk, M. (307) 275)

Ca^{2+} domain
Adenosine; Ca^{2+}, cytosolic; Cardioprotection; Fluo-3; Heart (Jovanovic, A. (298) 63)

Ca^{2+} entry
Histamine H_1 receptor; Neomycin; Phospholipase C (Sipma, H. (305) 207)

Ca^{2+}-entry blocking drug
Benzodiazepine; Diazepam; Langendorff heart; Inotropy; Adenosine receptor blocking drug (Leeuwin, R.S. (315) 153)

Ca^{2+} fluorescence
Human $mGlu_{1d}$; Metabotropic glutamate receptor (Laurie, D.J. (296) R1)

Human $mGlu_{1b}$; Metabotropic glutamate receptor (Laurie, D.J. (302) 229)

Ca^{2+} flux
Oxatomide; RBL-2H3 cell; Signal transduction; Exocytosis; Protein tyrosine phosphorylation; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

$[Ca^{2+}]_i$, free
NS-004; K^+ channel, Ca^{2+}-activated; K^+ channel, delayed rectifier; Whole cell patch clamp; Membrane potential; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

Ca^{2+} handling mechanism
Taurine depletion; Skeletal muscle; Mechanical threshold; Excitation-contraction coupling; Cl^- conductance (De Luca, A. (296) 215)

Ca^{2+} indicators
Ca^{2+}; Myocardium; Dantrolene; Sarcoplasmic reticulum; Aequorin (Meissner, A. (316) 333)

Ca^{2+} influx
GABA (γ-aminobutyric acid); Cortical neuron; Cl^- transport system; Furosemide; Ethacrynic acid (Takebayashi, M. (297) 137)

Ca^{2+}, intracellular
Ryanodine receptor; Synaptosome; Hippocampus; Subcellular localization (Padua, R.A. (298) 185)

Substance P; Neutrophil; Superoxide production; Phosphoinositide (Tanabe, T. (299) 187)

Dorsal root ganglion neuron; Neuropeptide FF; (Mouse) (Roumy, M. (306) 291)

Neuromedin B; Bombesin receptor antagonist; Arachidonic acid (Ryan, R.R. (306) 307)

ATP-sensitive K^+ channel; Chemical hypoxia; Dinitrophenol; Cardiac cell; Glyburide; Fluo-3 (Brady, P.A. (308) 343)

Gap junction; Cell-to-cell conductance; Dye diffusion; Trophoblast differentiation, human; Patch clamp, dual (Hervé, J.-C. (313) 243)

Halothane; Smooth muscle, airway; Ca^{2+} sensitivity (Kai, T. (315) 313)

Ca^{2+}, intracellular free
Angiotensin AT_{1A} receptor; Protein kinase C; Receptor phosphorylation; Angiotensin II (Thomas, W.G. (295) 119)

κ-Opioid receptor, tolerance; Inositol 1,4,5-trisphosphate; Myocyte, ventricular; U50,488H (Sheng, J.-Z. (307) 323)

Ca^{2+} mobilization
Diabetic pancreas; 1,4,5-IP_3-sensitive Ca^{2+} store; Ca^{2+} refilling; Muscarinic receptor (Komabayashi, T. (298) 299)

Protein kinase inhibitor; Respiratory burst; Degranulation; Neutrophil, human (Ahn, S.K. (306) 175)

Iris dilator, rabbit; Phorbol 12,13-dibutyrate (PDB); Protein kinase C; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

SK-N-BE(2)C human neuroblastoma; Phospholipase C; U-73122; cAMP production; Inositol 1,4,5-triphosphate; Neomycin (Suh, B.-C. (314) 235)

Ca^{2+} overload
CP-060*S*; Veratridine; Cardiomyocyte; Ca^{2+} channel; Smooth muscle, vascular (Tamura, K. (312) 195)

Ca^{2+} paradox
Oxygen paradox; Caffeine; Extracellular K^+; Antiporter (Harding, R.J. (316) 223)

Ca^{2+}-permeable non-selective cation current
17β-Estradiol; Estrogen; Vascular smooth muscle; Ca^{2+} current, L-type, voltage-dependent; Endothelin-1; Vasopressin (Nakajima, T. (294) 625)

Ca^{2+} pump
Platelet; Endothelin-3; Sodium nitroprusside; cGMP; Phosphodiesterase inhibitor; Ca^{2+}, cytosolic (Gagnet, C. (310) 67)

Ca^{2+} pumping
Adenosine A_1 receptor; Ca^{2+}; DDT_1 MF-2 cell; (Temperature) (Sipma, H. (306) 187)

Ca^{2+} refilling
Diabetic pancreas; Ca^{2+} mobilization; 1,4,5-IP_3-sensitive Ca^{2+} store; Muscarinic receptor (Komabayashi, T. (298) 299)

Ca^{2+} release channel
Ag^+; Au^{3+}; Skeletal muscle contraction; Single channel current (Nihonyanagi, K. (311) 271)

Ca^{2+} release, cytosolic
P_{2Y} purinoceptor; G-protein; Protein kinase C; K^+ channel; Hippocampal neuron (Ikeuchi, Y. (304) 191)

Ca^{2+} sensitiser
Ca^{2+}; Myofilament; EMD 57033; Skinned fiber; Rigor (Palmer, S. (294) 83)

Ca^{2+} sensitivity
Butanedione monoxime (BDM); Cross-bridge; EMD 53998; Cardiac skinned fiber (Barth, Z. (296) 285)

Halothane; Smooth muscle, airway; Ca^{2+}, intracellular (Kai, T. (315) 313)

Ca^{2+} store
Ryanodine; Heparin; Thapsigargin; Ruthenium red; cGMP (Duridanova, D.B. (298) 159)

Mn^{2+} influx; Ileum, rat; Ryanodine; Thapsigargin (Tabo, M. (313) 151)

Ca^{2+} uptake
Stretch-activated channel; Na^+ dependence; Membrane potential; Ca^{2+} channel, L-type (Ruiz-Velasco, V. (296) 327)

Pheochromocytoma (PC12) cell; Nicotine; NE-100 (*N,N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl); Binding assay; σ Receptor (Sagi, N. (304) 185)

Adenosine; Ca^{2+} channel; Brain synaptosome (Gonçalves, M.L. (310) 257)

Ca^{2} sensitization
Endothelin; Endothelin receptor; Protein kinase C; Smooth muscle, vascular (Sudjarwo, S.A. (294) 261)

Caerulein
CCK (cholecystokinin); Camostate; CCK receptor antagonist; Gastric emptying (Varga, G. (306) 153)

Caffeine
Formalin test; Stimulus intensity; 8-Cyclopentyltheophylline; 3,7-Dimethyl-1-propargylxanthine (Sawynok, J. (298) 105)

Adenosine; Sleep regulation; Sleep EEG (electroencephalogram); (Rat) (Schwierin, B. (300) 163)

Ketorolac; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME); Potentiation; Antinociception (López-Muñoz, F.J. (308) 275)

Ca^{2+} paradox; Oxygen paradox; Extracellular K^+; Antiporter (Harding, R.J. (316) 223)

Calcium
Adrenomedullin; Amylin; Lactate; Gastric emptying; CGRP (calcitonin gene-related peptide); (Rat) (Vine, W. (314) 115)

Calmodulin antagonist
HF-2035; W-7; Vascular relaxation; Nitric oxide (NO) synthase inhibitor (Win, N.H.H. (299) 119)

2-Chloroethylethyl sulfide; Skin lesion, burn; Anesthetic (Kim, Y.-B. (313) 107)

Glycolysis; Melanoma; ATP; Glucose 1,6-bisphosphate (glucose-1,6-P_2, Glc-1,6-P_2); Fructose 1,6-bisphosphate (fructose-1,6-P_2, Fru-1,6-P_2) (Glass-Marmor, L. (313) 265)

Ca^{2+} channel; Antipsychotic drug; Dopamine receptor antagonist; Membrane current (Ito, K. (314) 143)

Calphostin C
Staurosporine; Wortmannin; Protein kinase C; Myosin light chain kinase; Aorta; (Rabbit) (Asano, M. (294) 693)

Camostate
CCK (cholecystokinin); Caerulein; CCK receptor antagonist; Gastric emptying (Varga, G. (306) 153)

Cannabinoid
Basal ganglia; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

CP-55,940; Tolerance; Biotransformation; Energetic metabolism (Costa, B. (313) 17)

Cannabis; Ultrasonic vocalization; Anxiety; SR 141716A; CP 55,940 (McGregor, I.S. (313) 43)

Cannabinoid receptor
Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; cAMP; Adenylate cyclase (Pertwee, R.G. (296) 169)

Basal ganglia; Cannabinoid; Globus pallidus; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

Cannabinoid receptor antagonist
Cannabinoid receptor; SR141716A; Vas deferens, mouse; cAMP; Adenylate cyclase (Pertwee, R.G. (296) 169)

SR141617A; Δ^9-Tetrahydrocannabinol (Gatley, S.J. (307) 331)

Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

Cannabinoid receptor partial agonist
Cannabinoid receptor antagonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

Cannabinoid receptor, peripheral
N-Acylethanolamide; Palmitoylethanolamide; Autacoid local inflammatory antagonism; Neurogenic inflammation; Passive cutaneous anaphylaxis (Mazzari, S. (300) 227)

Cannabis
Cannabinoid; Ultrasonic vocalization; Anxiety; SR 141716A; CP 55,940 (McGregor, I.S. (313) 43)

Capillary permeability
Neuropeptide Y; Pulmonary edema; Sympathetic nervous system (Hirabayashi, A. (296) 297)

Capsaicin
Bronchoconstriction; Airway neurogenic inflammation; Substance P; Neurokinin A (Robineau, P. (294) 677)

Vanilloid receptor; Binding cooperativity; Resiniferatoxin; PPAHV (phorbol 12-phenylacetate 13-acetate 20-homovanillate) (Szallasi, A. (299) 221)

Gastrointestinal microcirculation; Laser Doppler; Resiniferatoxin (Abdel Salam, O.M.E. (305) 127)

Heart, rat; Preconditioning; Ruthenium red; CGRP (calcitonin gene-related peptide); CGRP-(8–37) (Li, Y.-J. (311) 163)

Pancreatic islet; Insulin release; Blood flow; Pancreas; Peptidergic neuron (Carlsson, P.-O. (312) 75)

5-HT_3 receptor; Substance P; Bezold-Jarisch reflex; (+)-Tubocurarine (Malinowska, B. (315) 159)

Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Capsaicin treatment, neonatal
Superfusion; Autoradiography; Substance P; Glutamate receptor; $GABA_B$ receptor (Teoh, H. (302) 27)

Capsazepine
[^{3}H]Resiniferatoxin; Vanilloid receptor; Neuroleptic; Cooperative binding (Szallasi, A. (298) 321)

Captopril
Myocardial infarction; Remodeling; Ischemia; Metabolism (Kalkman, E.A.J. (298) 121)

Ischemia; Reperfusion; Angiotensin-converting enzyme; Idrapril; Heart; (Rat) (Riva, E. (312) 293)

Carbachol
Sodium fluoride; (−)-N^6-Phenylisopropyl-adenosine; Phosphatase; Inotropy (Neumann, J. (294) 451)

Agonist affinity; Agonist-antagonist combination, fixed; Tripitramine; Spare receptor; (New methods) (Venter, D.P. (303) 235)

Parasympathetic; Pineal; Melatonin; Microdialysis; Muscarinic receptor agonist; Noradrenaline release (Drijfhout, W.J. (308) 117)

Carbamazepine
Edema; Inflammatory hyperalgesia; Nociception; Prostaglandin; Substance P (Bianchi, M. (294) 71)

β-Carboline
Dopamine; Harman; Norharman; Microdialysis; Nucleus accumbens; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

Dopamine; Uptake; Striatum; Microdialysis; MPP^+ (*N*-methyl-4-phenylpyridinium) (Matsubara, K. (315) 145)

Carbon analog, uncharged
Muscarinic receptor subtype; Muscarinic receptor antagonist; Stereoselectivity, at muscarinic receptor; BS-6181; BS-7826, (*R*)- and (*S*)-enantiomer (Waelbroeck, M. (303) 221)

5-Carboxamidotryptamine
5-HT_{1D} receptor; 5-HT_{1F} receptor; Metergoline; Migraine; [^{3}H]Sumatriptan (Pascual, J. (295) 271)

Cardiac arrhythmia
ATP-dependent K^+ channel blocker; Ventricular fibrillation (Friedrichs, G.S. (306) 99)

Cardiac cell
ATP-sensitive K^+ channel; Ca^{2+}, intracellular; Chemical hypoxia; Dinitrophenol; Glyburide; Fluo-3 (Brady, P.A. (308) 343)

Berberine; K^+ channel, ATP-sensitive; Patch clamp; Microelectrode recording (Wang, Y.-X. (316) 307)

Cardiac contractility
Cardiac myocyte, cultured; Endothelin-1; ANP (atrial natriuretic peptide), chicken; ChNP (chicken natriuretic peptide) mRNA (Bézie, Y. (311) 241)

Cardiac hypertrophy
Myocyte; Stretch; Angiotensin (Miyata, S. (307) 81)

Cardiac muscle
Protein kinase C; Smooth muscle, uterine; Steroid; Estradiol; Progesterone (Ruzycky, A.L. (313) 257)

β-Adrenoceptor antagonist; Propranolol; S100 protein; Mg^{2+} (Nakatani, K. (315) 335)

Cardiac muscle, isolated
4-Aminopyridine; α_1-Adrenoceptor subtype; Chloroethylclonidine; Staurosporine; WB4101 (Williamson, A.P. (304) 73)

Cardiac myocyte
σ Receptor; Contractility (Ela, C. (295) 275)

Ramiprilat; Angiotensin-converting enzyme inhibitor; Bradykinin; Bradykinin B_2 receptor antagonism; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

cAMP; β-Adrenoceptor desensitization; Contractility (Wynne, D.G. (310) 235)

Cardiac myocyte, cultured
Cardiac contractility; Endothelin-1; ANP (atrial natriuretic peptide), chicken; ChNP (chicken natriuretic peptide) mRNA (Bézie, Y. (311) 241)

Cardiac Na^+ channel
Na^+ channel block; Antiarrhythmic agent, class I; Bisaramil (Sunami, A. (312) 245)

Cardiac skinned fiber
Butanedione monoxime (BDM); Ca^{2+} sensitivity; Cross-bridge; EMD 53998 (Barth, Z. (296) 285)

Cardiomyocyte
ATP; Ca^{2+} channel antagonist; CN^-; Hypoxia; Ca^{2+} channel, L-type (Stokke, M. (303) 115)

CP-060*S*; Ca^{2+} overload; Veratridine; Ca^{2+} channel; Smooth muscle, vascular (Tamura, K. (312) 195)

Cardioprotection
Adenosine; Ca^{2+}, cytosolic; Ca^{2+} domain; Fluo-3; Heart (Jovanovic, A. (298) 63)

Cardiovascular
κ-Opioid receptor; Blood pressure; Phentolamine; Pregnancy (Szeto, H.H. (309) 183)

Cardiovascular effects
Growth hormone (GH) deficiency; Heart, rat; Ischemia (De Gennaro Colonna, V. (314) 333)

Carnitine
Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Insulin; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Carotid arterial resistance
Alniditan; Sumatriptan; Ergotamine (Van de Water, A. (299) 127)

Carotid artery
Aorta; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Potassium chloride; Ca^{2+}; Cholesterol (Moreland, R.S. (307) 55)

Antimigraine drug; Arteriovenous anastomosis; GMC2021; Coronary artery, human; Migraine; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

Carotid artery, rabbit
Intimal thickening; Vascular reactivity; Glucocorticoid; Nitric oxide (NO); Endothelium (Van Put, D.J.M. (294) 753)

Carrageenan
c-Fos; Inflammatory pain; Niflumic acid; (+)-HA966; Spinal cord; (Rat) (Buritova, J. (303) 91)

Inflammation; Peroxynitrite (Salvemini, D. (303) 217)

Cartilage
Chondrocyte; Nitric oxide (NO) synthase, inducible; Free radical; Arthritis (Jang, D. (312) 341)

Carvedilol
Low-density lipoprotein (LDL); Antioxidant; Monocyte; Adhesion (Yue, T.-L. (294) 585)

Myocardial ischaemia; Reperfusion injury, lethal; (Cat) (Brunvand, H. (314) 99)

Cascara
Nitric oxide (NO); Senna; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

α-Casomorphin
β-Casomorphin; Opioid receptor; Receptor subtype; Somatostastin receptor; Breast cancer cell, T47D (Hatzoglou, A. (310) 217)

β-Casomorphin
α-Casomorphin; Opioid receptor; Receptor subtype; Somatostastin receptor; Breast cancer cell, T47D (Hatzoglou, A. (310) 217)

Castor oil
Morphine; Buprenorphine; Diarrhoea; Gastrointestinal transit; Ethanol lesion (Bhounsule, S.A. (316) 253)

Catalase
Reperfusion arrhythmia; Superoxide dismutase; Dimethylthiourea; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Ohoi, I. (306) 123)

Catalepsy
Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Receptor; (Rat) (Wadenberg, M.-L. (294) 247)

Catatonia; Morphine; NMDA receptor; AMPA receptor; MK-801; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

Adenosine receptor agonist; Dopamine receptor antagonist; Behavioral interaction; Schizophrenia (Kafka, S.H. (295) 147)

Deltorphin analog; Antinociception; Locomotion (Negri, L. (296) 9)

Arginine-aspartate; Haloperidol; Locomotor activity; Dopamine (Patacchioli, F.R. (299) 29)

Haloperidol; Pimozide; Dopamine metabolism; Adaptation; (Chronic treatment) (Karolewicz, B. (313) 181)

NMDA receptor antagonist; Haloperidol; Parkinson's disease; (Rat) (McAllister, K.H. (314) 307)

Metabotropic glutamate receptors; D,L-Amphetamine; MK-801; Basal ganglia; Open-field (Kronthaler, U.O. (316) 129)

Catatonia
Catalepsy; Morphine; NMDA receptor; AMPA receptor; MK-801; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

Catecholamine absorbing protein
Central nervous system; Free radical; Oxidation; Dopamine; Neurodegeneration; Parkinson's disease (Modi, P.I. (299) 213)

Catecholamine release
Otilonium; Chromaffin cell; Ca^{2+} channel; Adrenal gland (Gandía, L. (298) 199)

Catecholaminergic neuron
Δ^9-Tetrahydrocannabinol; Nucleus tractus solitarii; Nausea; Glucose; 5-HT_3 receptor (Himmi, T. (312) 273)

Catecholamine secretion
Protein kinase C; CGP 41251; Chromaffin cell; Tyrosine hydroxylase; Nicotinic receptor (Loneragan, K. (311) 87)

Cathepsin L
Cysteine protease inhibitor; Bone resorption; Dipeptidyl aldehyde (Woo, J.-T. (300) 131)

Cationic current
CCK_B receptor; Neostriatal neuron; G-protein; Inositol 1,4,5-trisphosphate; Whole-cell patch-clamp recording (Wu, T. (307) 125)

Caudate
Cocaine; Opioid; Nucleus accumbens (Izenwasser, S. (297) 187)

Caudate-putamen
Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; (Rat) (Neisewander, J.L. (305) 13)

Caudate putamen
Fluphenazine; Microdialysis; Nucleus accumbens; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (308) 279)

β-CCE (ethyl β-carboline-3-carboxylate)
Benzodiazepine receptor; Down-regulation; Inverse agonist; Primary cultured neuron (Katsura, M. (298) 71)

L-CCG-I ((2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine)
Metabotropic glutamate receptor; Metabotropic receptor agonist; Morris maze; (Rat) (Van der Staay, F.J. (294) 361)

CCK-8
[^{14}C]Aminopyrine accumulation; [Leu^{11}]Gastrin-(5–17); CCK receptor antagonist; Gastric gland (Oiry, C. (294) 511)

CCK (cholecystokinin)
Dopamine; Dopamine D_1 receptor; Grooming; Vacuous chewing movement; (Rat) (Van Kampen, J. (298) 7)

CCK receptor antagonist; CCK_B receptor; Conditioned fear stress; Anxiety; LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide) (Izumi, T. (300) 25)

Caerulein; Camostate; CCK receptor antagonist; Gastric emptying (Varga, G. (306) 153)

CCK_B/gastrin receptor
Pancreas; Cloning; Ontogeny; Pharmacology (Dufresne, M. (297) 165)

CCK_B/gastrin receptor antagonist
Ca^{2+}; Cytosolic; Fura-2; Parietal cell, rabbit; Elutriation (Letari, O. (306) 325)

CCK receptor
Mutation; Histidine (Jagerschmidt, A. (296) 97)

CCK receptor antagonist
[^{14}C]Aminopyrine accumulation; CCK-8; [Leu^{11}]Gastrin-(5–17); Gastric gland (Oiry, C. (294) 511)

CCK (cholecystokinin); CCK_B receptor; Conditioned fear stress; Anxiety; LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide) (Izumi, T. (300) 25)

CCK (cholecystokinin); Caerulein; Camostate; Gastric emptying (Varga, G. (306) 153)

CCK_A receptor
Adenosine A_1 receptor; 5-HT_{1B} receptor; P_{2U} purinoceptor; Inositol phosphate; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (302) 141)

Pancreas; Gallbladder; Amylase release; Gallbladder contraction; T-0632 (Taniguchi, H. (304) 147)

Pancreatic secretion; Gallbladder contraction; Gastric emptying; T-0632 (Taniguchi, H. (312) 227)

CCK_B receptor
CCK (cholecystokinin); CCK receptor antagonist; Conditioned fear stress; Anxiety; LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide) (Izumi, T. (300) 25)

Neostriatal neuron; Cationic current; G-protein; Inositol 1,4,5-trisphosphate; Whole-cell patch-clamp recording (Wu, T. (307) 125)

CD-832
Ca^{2+} channel antagonist; Myocardium; Chronotropic effect, negative; Inotropic effect, negative; (Guinea-pig) (Noguchi, K. (308) 53)

CD69
Jatrophone; Natural killer activity; Lymphocyte proliferation; Protein kinase C; 12-*O*-Tetradecanoylphorbol 13-acetate; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

β Cell
Troglitazone; K_{ATP} channel; Insulin secretion (Lee, K. (313) 163)

Cell activation
Hypoxia; Endothelium; Neutrophil adherence; Aescine; Reparil (Arnould, T. (315) 227)

Cell cycle
DNA synthesis; Smooth muscle cell, rat, vascular; Osthole; (*Angelica pubescens*) (Guh, J.-H. (298) 191)

Arachidonic acid; Epithelial cells; Cell proliferation; TGF-β1 (transforming growth factor β1) (Kozubík, A. (316) 349)

Cell cycle progression
Endothelin-1; Angiotensin II; Atherosclerosis; Ca^{2+}, cytosolic; Primary culture (Jahan, H. (295) 261)

Cell death
Hippocampus; Seizure; Learning disorder; (Rat) (Lahtinen, H. (297) 213)

Nitric oxide (NO); Glyceraldehyde-3-phosphate dehydrogenase; Aconitase (Meßmer, U.K. (302) 171)

Cerebellar granule cell; Tyrosine kinase; Li^+ (Grignon, S. (315) 111)

Cell growth
Angiotensin AT_1 receptor; Smooth muscle cell, vascular; Arteriosclerosis (Nickenig, G. (297) 307)

Cell proliferation
Breast cancer cell (T47D); Opioid; Opioid receptor; Opioid receptor subtype (Hatzoglou, A. (296) 199)

Muscarinic receptor; Astrocyte; Astrocytoma (Guizzetti, M. (297) 265)

Atherosclerosis; Cytokine; Gap junctional intercellular communication; Growth factor; Smooth muscle cell (Mensink, A. (310) 73)

Arachidonic acid; Epithelial cells; Cell cycle; TGF-β1 (transforming growth factor β1) (Kozubík, A. (316) 349)

Cell separation
Chromaffin cell; Noradrenaline release; Adrenaline release; Nicotinic acetylcholine receptor (Krause, W. (302) 223)

Cell-to-cell conductance
Gap junction; Dye diffusion; Trophoblast differentiation, human; Ca^{2+}, intracellular; Patch clamp, dual (Hervé, J.-C. (313) 243)

Central effect
σ Receptor ligand; EMD 57445; Rimcazole; Behavioral model (Maj, J. (315) 235)

Central gray matter
Enkephalin; Methylnaloxonium; RB 101; Antinociception; Amygdala; Thalamus, ventro-basal; Raphe magnum nucleus (Valverde, O. (312) 15)

Central hyperalgesia
Atipamezole; Medetomidine; α_2-Adrenoceptor; Neurogenic pain; Lateral reticular nucleus of the medulla; Spinal cord (Mansikka, H. (297) 19)

Central nervous system
Opioid dependence; Glutamate; MK-801 (dizocilpine); Morphine; Butorphanol (Tokuyama, S. (295) 123)

Catecholamine absorbing protein; Free radical; Oxidation; Dopamine; Neurodegeneration; Parkinson's disease (Modi, P.I. (299) 213)

Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486 (Korte, S.M. (301) 19)

N^3-Phenacyluridine; Sedative; Hypnotic; Benzodiazepine receptor (Kimura, T. (311) 265)

Cerebellar granule cell
Forskolin; 1,9-Dideoxyforskolin; Ca^{2+} current; Ryanodine store; Action potential (Zerr, P. (303) 101)

Metabotropic glutamate receptor; cAMP; Phosphoinositide hydrolysis; Cortex; Phenylglycine (Bedingfield, J.S. (309) 71)

Cell death; Tyrosine kinase; Li^+ (Grignon, S. (315) 111)

Cerebellum
$GABA_A$ receptor; $GABA_A$ receptor subunit; Heterogeneity; Thalamus; Diazepam-insensitive (Huh, K.-H. (310) 225)

cGMP; MK-801; Purkinje cell; TRH tartrate (thyrotropin-releasing hormone tartrate); GABA (γ-aminobutyric acid) (Nakayama, T. (316) 157)

Cerebral artery
Ryanodine; Sarcoplasmic reticulum; Ca^{2+}-buffering function; Ca^{2+} channel, voltage-dependent; Arterial myogenic tone; (Dog) (Asano, M. (311) 53)

Cerebral blood flow
Bradykinin; Hoe140; Pneumococcal meningitis; Brain edema; Intracranial pressure (Lorenzl, S. (308) 335)

Cerebral blood flow autoregulation
Amlodipine; Ca^{2+} channel antagonist; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (313) 103)

Cerebral circulation
Endothelin-1; BQ-123; BQ-3020; Endothelin receptor; Resistance arteriole, cerebral (Patel, T.R. (307) 41)

Cyclic nucleotide; Newborn (Wilderman, M.J. (309) 243)

Cerebral cortex
5-HT_3 receptor; [^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Ileum; Colon; 5-HT_3 receptor, cloned, rat (Akuzawa, S. (296) 227)

Excitatory amino acid; Metabotropic glutamate receptor; GTP hydrolysis; G-protein; Adenylyl cyclase (Odagaki, Y. (300) 151)

α_2-Adrenoceptor; Spinal cord, neonatal; Spinal cord, adult; Imidazole receptor; Imidazole-preferring binding site (Savola, M.K.T. (306) 315)

Cerebral cortex, guinea-pig
NMDA receptor; 5-HT autoreceptor; Presynaptic receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Serotoninergic axon terminal (Fink, K. (300) 79)

Cerebral cortex, rat
Histamine H_3 receptor; Radioligand binding; [^{3}H]GR168320; [^{3}H]N^α-Methylhistamine (Brown, J.D. (311) 305)

Cerebral cortex slice
Metabotropic glutamate receptor; cAMP; (Agonist) (Kemp, M.C. (309) 79)

Cerebral cortical neuron
Nitric oxide (NO); Peroxynitrite; GABA (γ-aminobutyric acid) release; Superoxide (Ohkuma, S. (301) 179)

Cerebral ischemia
Adenosine receptor; Spatial memory; Water maze; (Gerbil) (Von Lubitz, D.K.J.E. (302) 43)

Dopamine D_1 receptor; Dopamine D_2 receptor; Dopamine uptake site; Receptor autoradiography (Araki, T. (306) 73)

Laser-Doppler flowmetry; Middle cerebral artery occlusion; γ_2-MSH (γ_2-melanocyte-stimulating hormone); Nimodipine; (Rat) (Herz, R.C.G. (306) 113)

7-Nitroindazole; Nitric oxide (NO); Hippocampus; (Mongolian gerbil) (O'Neill, M.J. (310) 115)

Nitric oxide (NO); Reperfusion; DNA fragmentation; Chromatin condensation; Apoptotic body; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

Selegiline; Astrocyte, cultured; Hippocampal cell; Excitotoxicity; Protection; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Cerebral ischemia / reperfusion
Spin trapping; ESR (electron spin resonance); Antioxidant; Free radical scavenger (Cowley, D.J. (298) 227)

Cerebral malaria
Endotoxin; Septic shock; DNA fragmentation; K^+ channel; Systemic inflammatory response syndrome (Gantner, F. (294) 353)

Ceritizine
Chlorpheniramine; EEG (electroencephalogram), quantitative; Oral administration, acute; Plasma concentration, drug; Neuropsychological status; (Healthy volunteer) (Sannita, W.G. (300) 33)

Cetiedil
Acetylcholine release; Cholinergic synaptosome; Cyclosporin A (Morot Gaudry-Talarmain, Y. (296) 341)

C-fiber
Reflex; Pain; Clonidine; Blood pressure; (Rat) (Gozariu, M. (313) 51)

Nociception; Spinal trigeminal nucleus oralis; Morphine (Dallel, R. (314) 19)

C-fiber activation
Preprotachykinin; mRNA; Polymerase chain reaction; Release (Wang, Z.-Y. (297) 157)

C-fiber reflex
Buprenorphine; Nociception; Diffuse noxious inhibitory control; Descending inhibitory control; Spinal cord; Morphine (Guirimand, F. (294) 651)

c-*fos*
Carrageenan; Inflammatory pain; Niflumic acid; (+)-HA966; Spinal cord; (Rat) (Buritova, J. (303) 91)

Ethanol tolerance; Arginine vasopressin; Immediate early gene (Szabó, G. (306) 67)

Angiotensin II; Thromboxane A_2; Smooth muscle cell (Sachinidis, A. (307) 121)

5-HT_{1A} receptor; 5-$HT_{2A/C}$ receptor; *ngf1c*; *tis1* (Tilakaratne, N. (307) 211)

c-*fos* mRNA
Antipsychotic; SM-9018; Haloperidol; 5-HT_2 receptor; Striatum (Ishibashi, T. (303) 247)

C_6 glioma cell
Phosphoinositide turnover; Protein kinase A; Endothelin; (ATP) (Lin, W.W. (296) 231)

CGP 12177
Atropine; Methyl-quinuclidinyl-benzylate; PET (positron emission tomography); Heart; β-Adrenoceptor; Muscarinic receptor (Valette, H. (306) 133)

CGP 35348
$GABA_B$ receptor; (−)-Baclofen; 3-Amino-propylphosphinic acid; Phaclofen; 2-Hydroxy-saclofen; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

Transcallosal response; Pyramidal tract neuron; Motor cortex; Paired-pulse method; (−)-Baclofen (Chowdhury, S.A. (314) 313)

CGP 37849
Catalepsy; Catatonia; Morphine; NMDA receptor; AMPA receptor; MK-801; GYKI 52466 (Tzschentke, T.M. (295) 137)

CGP 40116
NMDA receptor antagonist; CGP 43487; Ca^{2+} channel inhibitor; Flunarizine; Nicardipine; Nifedipine; Seizure (Gasior, M. (312) 27)

CGP 41251
Protein kinase C; Chromaffin cell; Tyrosine hydroxylase; Catecholamine secretion; Nicotinic receptor (Loneragan, K. (311) 87)

CGP 43487
NMDA receptor antagonist; CGP 40116; Ca^{2+} channel inhibitor; Flunarizine; Nicardipine; Nifedipine; Seizure (Gasior, M. (312) 27)

CGP 48506
Ca^{2+} channel, L-type; Mode 2 gating; Ca^{2+} channel activator (Herzig, S. (295) 113)

CGRP (calcitonin gene-related peptide)
Indomethacin; Interleukin-1 receptor antagonist; Hyperalgesia (Malcangio, M. (299) 113)

Steroidogenesis; Amylin; Adrenomedullin; CGRP receptor, type 2; Corticosteroid secretion; Adenylyl cyclase activity (Esneu, M. (308) 187)

CGRP receptor, type 2
Steroidogenesis; CGRP (calcitonin gene-related peptide); Amylin; Adrenomedullin; Corticosteroid secretion; Adenylyl cyclase activity (Esneu, M. (308) 187)

CGS 21680
Adenosine A_{2A} receptor; Vascular conductance; Radioactive microsphere technique (Nekooeian, A.A. (307) 163)

Adenosine A_{2A} receptor, human; Mutation; Glutamic acid; XAC; Amiloride (IJzerman, A.P. (310) 269)

Channel kinetics
Charybdotoxin; Dendrotoxin; Voltage dependence; Inactivation; Deactivation (Sprunger, L.K. (314) 357)

CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)
σ Receptor; Liver, rat; Solubilization; (+)-Pentazocine; DTG (1,3-di-*o*-tolylguanidine) (Torrence-Campbell, C. (304) 201)

Charcoal meal
Conditioned place preference; Tail-flick test; Formalin paw test (Singh, L. (307) 283)

Charybdotoxin
Trachea; Smooth muscle relaxation; Endothelin; Nitric oxide (NO); (Guinea-pig) (Hadj-Kaddour, K. (298) 145)

Tremorgenic indole alkaloid; Ca^{2+}-activated K^+ channel; Iberiotoxin; Excitation-contraction coupling (DeFarias, F.P. (314) 123)

Dendrotoxin; Voltage dependence; Channel kinetics; Inactivation; Deactivation (Sprunger, L.K. (314) 357)

Cheek pouch, hamster
Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Chelerythrine
Opioid withdrawal; Metabotropic glutamate receptor; Protein kinase C; Inositol-1,4,5-trisphosphate; Thapsigargin (Fundytus, M.E. (300) 173)

Chemical hypoxia
ATP-sensitive K^+ channel; Ca^{2+}, intracellular; Dinitrophenol; Cardiac cell; Glyburide; Fluo-3 (Brady, P.A. (308) 343)

Chemosensitizer
P-Glycoprotein; Photoaffinity labeling; Multidrug resistance (Boer, R. (295) 253)

Chemotaxis
Antiflammin; Arachidonic acid; Phospholipase A_2; Inflammation; Anti-inflammatory drug (Moreno, J.J. (314) 129)

Chemotherapy
Modulator; Multidrug resistance; P-glycoprotein (Demmer, A. (315) 339)

Chimeric receptor
Opioid receptor; Mutagenesis; Structure-function relationship; δ-Opioid receptor ligand (Meng, F. (311) 285)

Chiral compound
2-(Di-*n*-propylamino)tetralin; 5-HT_{1A} receptor; Dopamine D_2 receptor; (Racemate); (Rat); (Stereoisomer) (Yu, H. (303) 151)

Chlordiazepoxide
Benzodiazepine; Drug discrimination; Time course; Bretazenil; (Rat) (Bronson, M. (305) 7)

***p*-Chloroamphetamine**
5-HT (5-hydroxytryptamine, serotonin); Memory; Alzheimer's disease; (Rat) (Santucci, A.C. (295) 7)

4'-Chlorodiazepam
Uterus, rat; Sex hormone, female; Diazepam; Clonazepam; PK 11195; Ca^{2+} channel (Yiu, M.-k. (302) 99)

Chloroethylclonidine
4-Aminopyridine; α_1-Adrenoceptor subtype; Cardiac muscle, isolated; Staurosporine; WB4101 (Williamson, A.P. (304) 73)

2-Chloroethylethyl sulfide
Skin lesion, burn; Calmodulin antagonist; Anesthetic (Kim, Y.-B. (313) 107)

2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA)
Adenosine A_3 receptor; Hemodynamics; Histamine release; Tachyphylaxis; Rat, conscious (Van Schaick, E.A. (308) 311)

Chlorpheniramine
Ceritizine; EEG (electroencephalogram), quantitative; Oral administration, acute; Plasma concentration, drug; Neuropsychological status; (Healthy volunteer) (Sannita, W.G. (300) 33)

Chlorpromazine
Animal model; Anxiety; Diazepam; One-way avoidance; Successive negative contrast; Thiopental sodium (Torres, C. (314) 269)

ChNP (chicken natriuretic peptide) mRNA
Cardiac myocyte, cultured; Cardiac contractility; Endothelin-1; ANP (atrial natriuretic peptide), chicken (Bézie, Y. (311) 241)

CHO (Chinese hamster ovary) cell
CCK_A receptor; Adenosine A_1 receptor; 5-HT_{1B} receptor; P_{2U} purinoceptor; Inositol phosphate (Dickenson, J.M. (302) 141)

β_2-Adrenoceptor; Adenylyl cyclase; Receptor sequestration (Gabilondo, A.M. (307) 243)

Cholesterol
Benzodiazepine receptor, peripheral; Mitochondria, liver; Porphyrin (Tsankova, V. (294) 601)

Benzodiazepine receptor, peripheral; Porphyrin; PK11195; Metabolism; Liver (Tsankova, V. (299) 197)

Taurine; Hypercholesterolemia; Diabetes; Endothelium; LDL (low-density lipoprotein) (Kamata, K. (303) 47)

Aorta; Carotid artery; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Potassium chloride; Ca^{2+} (Moreland, R.S. (307) 55)

Cholesterol-feeding
Endothelium; P_{2X} purinoceptor; Mesenteric arterial bed, rat; Sympathetic neurotransmission; Donryu rat (Ralevic, V. (313) 221)

Choline
ACTH (adrenocorticotrophin); β-Endorphin; Atropine; Mecamylamine; Hemicholinium-3 (Savci, V. (309) 275)

Acetylcholine; Blood pressure; Hypotension; Vasopressin; Nicotinic receptor (Savci, V. (311) 153)

Choline acetyltransferase
NGF (nerve growth factor); Propentofylline; Learning; Memory; Dementia model; (Rat) (Nitta, A. (307) 1)

Ethanol; Dexamethasone; Acetyl coenzyme A; Enzyme affinity; Stress (Wattanathorn, J. (313) 69)

Cholinergic neuronal system
Nor-binaltorphimine dihydrochloride; Amnesia, delayed; κ-Opioid receptor; Carbon monoxide (CO); U-50488H, (trans-(±)-3,4-dichloro-*N*-methyl-*N*-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate salt) (Hiramatsu, M. (315) 119)

Cholinergic neurotransmission
Neutral endopeptidase; Acetylcholine; Epithelium; Trachea; (Rabbit) (Loenders, B. (296) 89)

Cholinergic responses
L-Arginine; Na^+ transport; K^+ transport; Opiate; Nitric oxide (NO) (Neumann, V. (316) 123)

Cholinergic synaptosome
Acetylcholine release; Cetiedil; Cyclosporin A (Morot Gaudry-Talarmain, Y. (296) 341)

Cholinergic system
Ovary; Puberty, female; Muscarinic receptor (Trkulja, V. (297) 93)

Learning; Memory; Synaptic plasticity; Muscarinic receptor agonist; AF102B; Oxotremorine (Iga, Y. (308) 13)

Cholinergic transmission
Melatonin; Nicotinic channel; Synaptic modulation; Submucosal neuron; Enteric neuron; Nerve terminal (Barajas-López, C. (312) 319)

Chondrocyte
Cartilage; Nitric oxide (NO) synthase, inducible; Free radical; Arthritis (Jang, D. (312) 341)

Chromaffin cell
Otilonium; Ca^{2+} channel; Adrenal gland; Catecholamine release (Gandía, L. (298) 199)

Cell separation; Noradrenaline release; Adrenaline release; Nicotinic acetylcholine receptor (Krause, W. (302) 223)

Ouabain; Cytosolic Ca^{2+}; Lithium chloride; Veratridine (De la Fuente, M.T. (306) 219)

Dopamine receptor; Adrenal medulla; Radioligand binding; Autoradiography; (Rat) (Barili, P. (310) 129)

Protein kinase C; CGP 41251; Tyrosine hydroxylase; Catecholamine secretion; Nicotinic receptor (Loneragan, K. (311) 87)

Chromatin condensation
Cerebral ischemia; Nitric oxide (NO); Reperfusion; DNA fragmentation; Apoptotic body; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

Chronic
D-cycloserine; Imipramine; Stress; Anhedonia; Antidepressant action; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

Chronic citalopram
NMDA receptor; Excitatory amino acid; Adaptation; Cortex; Hippocampus (Nowak, G. (295) 75)

Chronic infusion
Radial maze learning; Entorhinal cortex lesion; NMDA receptor antagonist; Memantine; (+)-MK-801; (Rat) (Zajaczkowski, W. (296) 239)

Chronic treatment
Levcromakalim; Sodium nitroprusside; Aorta, rat; Tolerance (Trongvanichnam, K. (303) 39)

Chronotropic effect, negative
CD-832; Ca^{2+} channel antagonist; Myocardium; Inotropic effect, negative; (Guinea-pig) (Noguchi, K. (308) 53)

Chronotropism
Bertosamil; K^+ channel, ATP-sensitive; Ca^{2+} channel, L-type; Inotropism; Heart, dog (Yonezawa, T. (309) 51)

Parasympathetic nervous system; Acetylcholine; Inotropism; Heart; PACAP-38 (pituitary adenylate cyclase-activating polypeptide-38); PACAP-(6–38) (pituitary adenylate cyclase-activating polypeptide-(6–38)); (Dog) (Yonezawa, T. (315) 289)

α-Chymotrypsin
Anti-allergic drug; Histamine; Mast cell; Serine esterase (Emadi-Khiav, B. (295) 243)

CI-988
Anxiety; Immediate early gene; Elevated X-maze; Benzodiazepine; CCK (cholecystokinin) (Hinks, G.L. (312) 153)

Cicaprost
TNF (tumor necrosis factor-α); Rolipram; Prostaglandin E_2 (Greten, T.F. (299) 229)

Cilostazol
Otsuka Long-Evans Tokushima Fatty rat; Motor nerve conduction velocity; R-R interval, coefficient of variation; Sciatic nerve blood flow; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

CINC (cytokine-induced neutrophil chemoattractant)
cAMP; Interleukin-1; Interleukin-6; Prostaglandin E_2; Prostaglandin I_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Cinnamoylamino group
Morphine derivative; Metopon; β-Endorphin receptor; Analgesia; (Mouse) (McLaughlin, J.P. (294) 201)

Circadian rhythm
Melatonin; Suprachiasmatic nucleus; Intergeniculate leaflet; Electrophysiology; Light; Entrainment (Ying, S.-W. (296) 33)

Pharmacokinetics; Melatonin; Continuous light; 6-Sulfatoxymelatonin; (Intravenous) (Deprés-Brummer, P. (312) 171)

Cisapride
Electron probe X-ray microanalysis; Small intestine; (Mouse) (Spencer, A.J. (303) 205)

Cisplatin
cis-Platinum (II) phosphonate complex; Murine mast cell; Histamine release (Brzezińska-Błaszczyk, E. (298) 155)

DNA repair; Drug resistance; Multidrug resistance (Chao, C.C.-K. (305) 213)

Citalopram
5-HT_{1A} autoreceptor antagonism; (−)-Pindolol; Buspirone; Selective serotonin reuptake inhibitor (SSRI); 5-HT (5-hydroxytryptamine, serotonin), extracellular; Microdialysis, in vivo (Hjorth, S. (303) 183)

Anxiety; Conditioned fear stress; Freezing behavior; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective (Inoue, T. (311) 1)

Microdialysis, in vivo; WAY-100635; Penbutolol enantiomer; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

Citric acid
FK888; SR48968; Bronchoconstriction; Cough; Tachykinin (Yasumitsu, R. (300) 215)

Citrulline
Lithium chloride; Tacrine; Seizure; Nitric oxide (NO); L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (294) 341)

Cl^-
Cl^- secretion; 5-HT receptor; Short circuit current; Jejunum (Budhoo, M.R. (314) 109)

Cl^- channel
Colon, rat; K^+ channel; Ca^{2+}; Genistein; Protein tyrosine kinase (Diener, M. (299) 161)

Tachykinin NK_1 receptor; Niflumic acid; Colon, rabbit (Patacchini, R. (303) 197)

Cl^- channel, Ca^{2+}-dependent
K^+ channel, Ca^{2+}-dependent; Patch clamp; Smooth muscle cell; Trachea (Henmi, S. (306) 227)

Cl^- conductance
Taurine depletion; Skeletal muscle; Mechanical threshold; Excitation-contraction coupling; Ca^{2+} handling mechanism (De Luca, A. (296) 215)

Cl^- secretion
BW A868C; DP receptor; Partial agonist (Liu, Y.J. (304) 117)

Cl^-; 5-HT receptor; Short circuit current; Jejunum (Budhoo, M.R. (314) 109)

Cl^- transport system
GABA (γ-aminobutyric acid); Cortical neuron; Ca^{2+} influx; Furosemide; Ethacrynic acid (Takebayashi, M. (297) 137)

Clomipramine
Pertussis toxin; Analgesia; Morphine; Diphenhydramine; Baclofen; Physostigmine (Galeotti, N. (308) 125)

Clonazepam
Uterus, rat; Sex hormone, female; Diazepam; 4'-Chlorodiazepam; PK 11195; Ca^{2+} channel (Yiu, M.-k. (302) 99)

Cloned human receptor
Muscarinic acetylcholine receptor; Receptor selection and amplification technology; Functional partial agonism; Functional receptor selectivity (Bräuner-Osborne, H. (313) 145)

Tramadol; Analgesia; Opioid receptor type (Lai, J. (316) 369)

Clonidine
Imidazoline I_2 receptor; [^{3}H]2-(2-Benzofuranyl)-2-imidazoline; Idazoxan (Lione, L.A. (304) 221)

Colonic inflammation; Visceral nociception; S12813-4; Antinociceptive effect; Noradrenergic mechanism (Miampamba, M. (308) 251)

C-fiber; Reflex; Pain; Blood pressure; (Rat) (Gozariu, M. (313) 51)

Ca^{2+} channel, P-type; Antinociception, spinal; Morphine; Tolerance; G-protein (Roerig, S.C. (314) 293)

Cloning
CCK_B/gastrin receptor; Pancreas; Ontogeny; Pharmacology (Dufresne, M. (297) 165)

Clotrimazole
K^+ channel; Erythrocyte; Efaroxan; Imidazoline binding site (Coupry, I. (295) 109)

Clot specificity
Urokinase variant; Fibrinolysis; Thrombin inhibition; Platelet aggregation; (Rabbit) (Schneider, J. (302) 69)

Clozapine
Thermoregulation; Dopamine; Dopamine receptor; (Rat) (Salmi, P. (307) 27)

Haloperidol; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; S 14506; Gnawing; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Clozapine metabolite; $GABA_A$ receptor; GABA (γ-aminobutyric acid) (Wong, G. (314) 319)

Haloperidol; Fos-protein; Cross-tolerance; Nucleus accumbens; Septum, lateral (Sebens, J.B. (315) 269)

Clozapine metabolite
Clozapine; $GABA_A$ receptor; GABA (γ-aminobutyric acid) (Wong, G. (314) 319)

CN^-
ATP; Ca^{2+} channel antagonist; Cardiomyocyte; Hypoxia; Ca^{2+} channel, L-type (Stokke, M. (303) 115)

CNQX (6-cyano-7-nitroquinoxaline-2,3-dione)
Glutamate; Turning; Striatum; Tetrodotoxin; *cis*-Flupenthixol (Smith, I.D. (301) 7)

Retinal cell; Glutamate receptor; Neurotoxicity; Ca^{2+}; MK-801 (Ferreira, I.L. (302) 153)

CNTF (ciliary neurotrophic factor receptor α)
cAMP; NB41A3 cell; PC12 cell; mRNA (MacLennan, A.J. (295) 103)

Cocaine
Drug discrimination; Diphenhydramine; Doxylamine (Gauvin, D.V. (294) 281)

Nimodipine; BayK 8644; Self-administration, i.v.; (Rat); (Mouse) (Kuzmin, A. (295) 19)

σ Receptor; Behavioral sensitization; BMY-14802; SR-31742A; Schizophrenia (Ujike, H. (296) 123)

Dopamine transporter; Meperidine (Izenwasser, S. (297) 9)

Opioid; Caudate; Nucleus accumbens (Izenwasser, S. (297) 187)

Enkephalin; δ-Opioid receptor; Naltrindole; Sensitization (Heidbreder, C. (298) 207)

ANP (atrial natriuretic peptide); ANP, N-terminal; Mean arterial pressure; Heart rate; Right atrial pressure (Pelkonen, M. (304) 55)

Sensitization; Reverse tolerance (Wise, R.A. (307) 15)

Local anesthetic; Lidocaine; Pseudococaine; Hemodynamics; Blood pressure; Heart rate; Desipramine (Bernards, C.M. (307) 33)

Heart rate; Blood pressure; Self-administration (Ambrosio, E. (315) 43)

Methamphetamine; Morphine; Ambulatory sensitization; Interdose interval; (Mouse) (Kuribara, H. (316) 1)

Cocaine analog
[^{123}I]RTI-55; Psychostimulant abuse; (Mouse) (Gatley, S.J. (296) 145)

Behavior; Dopamine transporter (Fleckenstein, A.E. (311) 109)

Cognitive enhancer
σ_1 Receptor agonist; Scopolamine; Basal forebrain lesion; Passive avoidance task; SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride); (Rat) (Senda, T. (315) 1)

Cold air
Tachykinin; Kinin; Bronchoconstriction; SR 48968; HOE 140; Neurogenic inflammation (Yoshihara, S. (296) 291)

Cold water swimming
Antinociception; Pertussis toxin; Gi/Go protein; Opioid receptor; (Mouse) (Mizoguchi, H. (309) 37)

Collagen
Endothelin-1; Proteoglycan; Fibronectin (Gutierrez, S. (302) 191)

Colon
5-HT_3 receptor; [^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Cerebral cortex; Ileum; 5-HT_3 receptor, cloned, rat (Akuzawa, S. (296) 227)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; Secretion; Mucosa; (Human) (Borman, R.A. (309) 271)

Colon, guinea-pig
5-HT_3 receptor; 5-HT_4 receptor; Tachykinin; Tetrodotoxin; Enteric nerve (Briejer, M.R. (308) 173)

Colon, rabbit
Tachykinin NK_1 receptor; Niflumic acid; Cl^- channel (Patacchini, R. (303) 197)

Colon, rat
Cl^- channel; K^+ channel; Ca^{2+}; Genistein; Protein tyrosine kinase (Diener, M. (299) 161)

Colonic inflammation
Visceral nociception; Clonidine; S12813-4; Antinociceptive effect; Noradrenergic mechanism (Miampamba, M. (308) 251)

Colonic temperature
Morphine; Histamine; Histamine receptor antagonist (Ulugöl, A. (308) 49)

Development; Muscarinic receptor (Zhang, L. (304) 211)

Comparative molecular field analysis
Melatonin receptor; Quantitative structure-activity relationship model; Austin model 1; Binding site; G protein-coupled receptor (Navajas, C. (304) 173)

Competitive antagonist
NMDA receptor; Radioligand binding; Neuroprotection; Molecular modelling (Cheung, N.S. (313) 159)

Competitive inhibition
SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride); σ_1 Receptor subtype; Agonistic property (Matsuno, K. (306) 271)

Compound 48/80
Adenosine A_3 receptor; Hypotension; Mast cell; Histamine; APNEA (N^6-2-(4-aminophenyl)ethyladenosine) (Fozard, J.R. (298) 293)

Concentration jump
Hippocampal neuron; Glutamate receptor, ionotropic; AMPA/kainate receptor; Kainate-gated desensitization (Pidoplichko, V.I. (303) 145)

Conditioned fear stress
σ Receptor; Phenytoin; Phencyclidine receptor; Motor suppression (Kamei, H. (299) 21)

CCK (cholecystokinin); CCK receptor antagonist; CCK_B receptor; Anxiety; LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide) (Izumi, T. (300) 25)

σ Receptor; Phenytoin; Dopaminergic system; Motor suppression (Kamei, H. (309) 149)

Anxiety; Freezing behavior; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Citalopram (Inoue, T. (311) 1)

Conditioned immobility
Occasion setting; Pavlovian conditioning; Midazolam; Amphetamine; Flesinoxan (Maes, J.H.R. (309) 131)

Conditioned place preference
Tail-flick test; Formalin paw test; Charcoal meal (Singh, L. (307) 283)

Sulpiride; Raclopride; Dopamine; Dopamine D_2 receptor; Lordosis (Meisel, R.L. (309) 21)

Conditioned place preference paradigm
Nicotine; Mecamylamine; Place aversion; Physical dependence (Suzuki, T. (314) 281)

Conditioned reward
Sensitization; Morphine; Opioid; Psychostimulant; Place preference conditioning (Shippenberg, T.S. (299) 33)

Conditioned taste aversion
Ca^{2+} channel, L-type; Nimodipine; Ethanol; Substitution; Drug discrimination (De Beun, R. (306) 5)

Conduction
Vasorelaxation; Heart; ATP-sensitive K^+ channel; His bundle; Refractory period; Electrophysiology (D'Alonzo, A.J. (294) 271)

Conduit artery
Endothelin-1; Norepinephrine; Resistance artery; (Human) (Miyauchi, T. (303) 193)

Conformational analysis
Azithromycin; Phospholipid; Fluorescence polarization; NMR spectroscopy, ^{31}P; Gentamicin (Montenez, J.-P. (314) 215)

Congestive heart failure
G-protein; β-Adrenoceptor density; Norepinephrine (Lai, L.-P. (309) 201)

Bosentan; Renal hemodynamics; Aorto-caval fistula (Gurbanov, K. (310) 193)

Conotoxin
Hippocampus; Ca^{2+} channel; ω-Agatoxin-IVA (Nooney, J.M. (306) 41)

ω-Conotoxin
Ca^{2+} channel; Dihydropyridine; ω-Agatoxin; Melanotrope; Pituitary; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

ω-Conotoxin GVIA
Autoradiography; Brain; Ca^{2+} channel, N-type; (Rabbit) (Whorlow, S.L. (315) 11)

Continuous light
Pharmacokinetics; Melatonin; Circadian rhythm; 6-Sulfatoxymelatonin; (Intravenous) (Deprés-Brummer, P. (312) 171)

Contractility
σ Receptor; Cardiac myocyte (Ela, C. (295) 275)

α_{1D}-Adrenoceptor; Radioligand binding; Aorta, rat (Buckner, S.A. (297) 241)

Cardiac myocyte; cAMP; β-Adrenoceptor desensitization (Wynne, D.G. (310) 235)

Contraction
Vas deferens, guinea pig; Mn^{2+}; Norepinephrine; Acetylcholine (Tsunobuchi-Ushijima, H. (295) 235)

D-NNA (N^G-nitro-D-arginine); Diphenyleneiodonium; Di-2-thienyliodonium; Methylene blue; Nitric oxide (NO); Lipopolysaccharide (Palacios, B. (296) 75)

Coronary artery, canine; GR127935; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1D}$ receptor; Sumatriptan (Terrón, J.A. (300) 109)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; Stomach; Relaxation; (Guinea pig) (Tamura, T. (308) 315)

Human bronchus; Protein kinase C; Na^+/K^+-ATPase; Ca^{2+} channel (Yang, K.X.F. (315) 65)

Smooth muscle; Phospholipase C; Muscarinic; G-protein; Antibody (Cuq, P. (315) 213)

Contralateral turning
Haloperidol; NMDA receptor; Non-NMDA receptor; Subsensitivity; Striatum (Ossowska, K. (294) 685)

***Conus* venom**
Imidazoline-binding site; Striatum; Monoamine oxidase; (Calf) (Czerwiec, E. (315) 99)

Convulsion
$GABA_A$ receptor; γ_2 Subunit; Antisense oligodeoxynucleotide; Methyl-β-carboline-3-carboxylate; Strychnine; Picrotoxin (Zhao, T.-j. (306) 61)

Cooperative binding
[^{3}H]Resiniferatoxin; Vanilloid receptor; Capsazepine; Neuroleptic (Szallasi, A. (298) 321)

Coronary arterial cell
BK_{Ca} channel; Patch-clamp; (Whole-cell recording); (Holding potential) (Hu, S. (294) 357)

Coronary artery
Bradykinin; Bradykinin receptor; (Pig) (Pruneau, D. (297) 53)

NH_4Cl; Vasoconstriction; Intracellular pH (Wakabayashi, I. (299) 139)

Coronary artery, canine
Contraction; GR127935; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor; Sumatriptan (Terrón, J.A. (300) 109)

Coronary artery, human
Antimigraine drug; Arteriovenous anastomosis; Carotid artery; GMC2021; Migraine; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

Coronary circulation
Nitric oxide (NO); Vasodilation; Nitric oxide (NO) synthase (Abdul-Hussain, M.N. (305) 155)

Endothelin ET_A receptor; Endothelin ET_B receptor; IRL 1620; BQ-123; Nitric oxide (NO) (García, J.L. (315) 179)

Coronary occlusion
Myocardial ischemia; Ventricular arrhythmia; α-Adrenoceptor subtype-selective blocker; Heart rate; Arrhythmia (Geller, J.C. (294) 423)

Coronary vasculature
Adenosine A_{2A} receptor; Adenosine A_{2B} receptor; Adenosine A_3 receptor; P_1 purinoceptor; Heart, perfused, rat (Harden, F.A. (307) 49)

Corpus cavernosum
Penile erection; Endothelin; Nitric oxide (NO); (Rat) (Ari, G. (307) 69)

Cortex
Chronic citalopram; NMDA receptor; Excitatory amino acid; Adaptation; Hippocampus (Nowak, G. (295) 75)

Anti-epileptic drug; Ca^{2+} current; Neuroprotective agent (Stefani, A. (307) 113)

Metabotropic glutamate receptor; cAMP; Phosphoinositide hydrolysis; Cerebellar granule cell; Phenylglycine (Bedingfield, J.S. (309) 71)

Individual difference; Novelty; $GABA_A$; Psychostimulant; Locomotion; Basal ganglia (Gruen, R.J. (309) 115)

Cortex, prefrontal
Dopamine; 5-HT_{1A} receptor; Ipsapirone; WAY 100135; NAN-190; Microdialysis (Wędzony, K. (305) 73)

Cortical neuron
GABA (γ-aminobutyric acid); Ca^{2+} influx; Cl^- transport system; Furosemide; Ethacrynic acid (Takebayashi, M. (297) 137)

Metabotropic glutamate receptor; Excitotoxicity (Bruno, V. (310) 61)

Excitotoxicity; LY293558; NS-102; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionate); (*S*)-5-Fluorowillardiine (Larm, J.A. (314) 249)

Cortical slice
Felbamate; 5,7-Dichlorokynurenic acid; Glutamate; Epilepsy (Srinivasan, J. (315) 285)

Corticosteroid secretion
Steroidogenesis; CGRP (calcitonin gene-related peptide); Amylin; Adrenomedullin; CGRP receptor, type 2; Adenylyl cyclase activity (Esneu, M. (308) 187)

Corticosterone
5-HT receptor subtype; Lower lip retraction; Penile erection; Head shake; Open field behavior (Berendsen, H.H.G. (308) 103)

Protein mono-ADP-ribosylation; Diabetes; Nerve lesion (Gorio, A. (311) 21)

Methadone; CRF type 1 receptor; Solution hybridization; POMC (pro-opiomelanocortin); CRF (corticotropin-releasing factor) (Zhou, Y. (315) 31)

Corticosterone, plasma
Diltiazem; Naloxone-precipitated withdrawal; Morphine withdrawal, spontaneous; Body weight loss; Diarrhea; (Rat) (Kishioka, S. (316) 7)

Corticosterone, serum
5-HT_{2A} receptor; 5-HT_{2C} receptor; Quipazine; MK-212; MDL 100,907; SB 200646A; (Rat) (Hemrick-Luecke, S.K. (311) 207)

Cotransmission
Vas deferens, guinea-pig; Noradrenaline release; ATP release; ANP (atrial natriuretic peptide); 8-Bromoguanosine 3′:5′-cyclic monophosphate (Driessen, B. (296) 261)

Cough
FK888; SR48968; Citric acid; Bronchoconstriction; Tachykinin (Yasumitsu, R. (300) 215)

Cough reflex
Morphine; μ-Opioid receptor, subtype; Antitussive effect; (Beige rat) (Kamei, J. (300) 75)

Angiotensin-converting enzyme inhibitor; Enalapril; Moguisteine; Non-narcotic antitussive drug (Kamei, J. (312) 235)

CP-060*S*
Ca^{2+} overload; Veratridine; Cardiomyocyte; Ca^{2+} channel; Smooth muscle, vascular (Tamura, K. (312) 195)

CP-55,940
Marijuana; SR 141716A; Basal ganglion; Antipsychotic (Anderson, J.J. (295) 163)

Cannabinoid; Tolerance; Biotransformation; Energetic metabolism (Costa, B. (313) 17)

Cannabinoid; Cannabis; Ultrasonic vocalization; Anxiety; SR 141716A (McGregor, I.S. (313) 43)

CP-99,994
Bradykinin receptor; Formaldehyde; Mast cell; Tachykinin receptor; Vascular permeability (Ito, K. (307) 291)

CP-122,721
Emesis; Tachykinin NK_1 receptor antagonist; (Ferret) (Gonsalves, S. (305) 181)

CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid)
α_1-Adrenoceptor; NMDA receptor; Water maze; Passive avoidance; Prazosin (Riekkinen, M. (300) 9)

5,7-Dichlorokynurenic acid; HA-966 (3-amino-1-hydroxy-2-pyrrolidone); Dizocilpine; Phencyclidine; Ifenprodil; 5-HT_{2C} receptor (Mazzola-Pomietto, P. (308) 329)

mCPP (1-(3-chlorophenyl)piperazine)
Hyperglycemia; 5-$HT_{2C/2B}$ receptor; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT_{2A} receptor (Sugimoto, Y. (307) 75)

D-CPPene (SDZ EAA 494
Nicotine; Sensitization; Dopamine, mesoaccumbens; Locomotor activity; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid) (Balfour, D.J.K. (316) 153)

Craving
Acamprosate; Alcohol; Alcohol-deprivation effect; Relapse; (Rat) (Spanagel, R. (305) 39)

Alcohol; Memantine (Hölter, S.M. (314) R1)

CRF (corticotropin-releasing factor) receptor
Sauvagine; Urotensin I; Extravasation; Inflammation; ACTH (adrenocorticotropin) (Turnbull, A.V. (303) 213)

CRF (corticotropin-releasing factor)
CRF receptor; Anti-edema; ACTH (adrenocorticotropin); Structure-activity relationship (Wei, E.T. (306) 161)

Anxiety; Interleukin-1β; Fever; CRF receptor antagonist (Lundkvist, J. (309) 195)

CRF receptor
CRF (corticotropin-releasing factor); Anti-edema; ACTH (adrenocorticotropin); Structure-activity relationship (Wei, E.T. (306) 161)

IMR-32 human neuroblastoma cell line; Differentiation; Radioligand binding; Adenylate cyclase (Hogg, J.E. (312) 257)

CRF receptor antagonist
CRF (corticotropin-releasing factor); Anxiety; Interleukin-1β; Fever (Lundkvist, J. (309) 195)

CRF type 1 receptor
Methadone; Solution hybridization; Corticosterone; POMC (proopiomelanocortin); CRF (corticotropin-releasing factor) (Zhou, Y. (315) 31)

Cromakalim
Antinociception; 5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Sulfonylurea; Gliquidone; Receptor binding (Robles, L.-I. (295) 181)

ATP-sensitive K^+ channel; Nicorandil; Dopamine autoreceptor; Microdialysis; Sulpiride (Tanaka, T. (297) 35)

Hypothyroidism; K_{ATP} channel; Portal vein; Pinacidil; Glibenclamide (Jagadish, M. (309) 63)

Cross-bridge
Butanedione monoxime (BDM); Ca^{2+} sensitivity; EMD 53998; Cardiac skinned fiber (Barth, Z. (296) 285)

Cross-tachyphylaxis
Bronchoconstriction, adenosine-induced; Tracheal spirals; Xanthine antagonist resistance; Transport inhibitors; (Sensitized guinea pigs) (Thorne, J.R. (316) 263)

Cross-talk
TNF-α (tumor necrosis factor α) inhibition; Adenosine A_3 receptor; Macrophage; Receptor (McWhinney, C.D. (310) 209)

Cross-tolerance
Haloperidol; Clozapine; Fos-protein; Nucleus accumbens; Septum, lateral (Sebens, J.B. (315) 269)

6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol
Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; O-823; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

***N*-Cyanomethylmethamphetamine**
Methamphetamine; Haloperidol; Behavioral sensitization; Ambulation; (Mouse) (Kuribara, H. (305) 1)

Cyclic adenosine monophosphate
Verbascoside; Langendorff heart preparation; (*Eremophila alternifolia*) (Pennacchio, M. (305) 169)

Cyclic nucleotide
Dipyridamole; Nitric oxide (NO); Smooth muscle cells, vascular; Interleukin-1β (Iimura, O. (296) 319)

Cerebral circulation; Newborn (Wilderman, M.J. (309) 243)

Cyclic voltammetry
α-Tocopherol analog (water-soluble); Neuroprotection; Lipid peroxidation; Antioxidant; Vitamin E; Malondialdehyde; Free radical (Bolkenius, F.N. (298) 37)

Cyclobenzaprine
Monosynaptic reflex; 5-HT (5-hydroxytryptamine, serotonin) (Kobayashi, H. (311) 29)

Cyclodipeptide
Alaptide; 2,5-Piperazinedione; Elevated plus-maze test; Memory; Oxiracetam; (Mouse) (Hliňák, Z. (314) 1)

Cycloheximide
U-50,488H; Naltrexone methobromide; Amnesia; Dynorphin A-(1–13); (Mouse) (Ukai, M. (313) 11)

Cyclooxygenase
Learning; Memory; Prostaglandin; Neurotransmitter; Retrograde messenger; Synaptic plasticity (Hölscher, C. (294) 253)

PAF (platelet-activating factor); Vasomotor tone; Endothelium; Arterial pressure; Blood flow; Noradrenaline; Glutamate; (Rabbit) (Lopes-Martins, R. (308) 287)

Cyclooxygenase inhibitor
KBT-3022; Arachidonic acid; Ischemic brain edema (Yamamoto, N. (297) 225)

Indomethacin; Gram-negative sepsis; TMF (tumor necrosis factor); Sepsis (Campanile, F. (307) 191)

8-Cyclopentyltheophylline
Formalin test; Caffeine; Stimulus intensity; 3,7-Dimethyl-1-propargylxanthine (Sawynok, J. (298) 105)

Cyclosporin A
Endothelin; Nephrotoxicity; Renal failure (Brooks, D.P. (294) 571)

Acetylcholine release; Cholinergic synaptosome; Cetiedil (Morot Gaudry-Talarmain, Y. (296) 341)

Cyclothiazide
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline); GYKI 52466; Allosteric regulation (Okada, M. (309) 299)

Cystathionine
Ischemia-reperfusion; Superoxide radical; Gastric mucosal injury; (Rat) (Wada, K. (294) 377)

Superoxide radical; Leukocyte, human (Wada, K. (296) 335)

Cysteine protease inhibitor
Cathepsin L; Bone resorption; Dipeptidyl aldehyde (Woo, J.-T. (300) 131)

Cysteine sulfonamide enkephalin analog
δ-Opioid receptor; Vas deferens, mouse; Dalargin; Purinergic component; Adrenergic component; Electrical field stimulation (Pencheva, N. (304) 99)

Cytokine
Growth factor; Neuroprotection; Excitotoxicity (Prehn, J.H.M. (306) 81)

Atherosclerosis; Cell proliferation; Gap junctional intercellular communication; Growth factor; Smooth muscle cell (Mensink, A. (310) 73)

15-Deoxyspergualin; T cell; B cell; Monocyte (Nicoletti, F. (311) 213)

Neuro-immune interaction; Analgesia; Nociception; Opioid; Neuropeptide (Mousa, S.A. (311) 221)

Lipopolysaccharide; Endotoxin tolerance; Vascular permeability; Adrenalectomy; Nitric oxide (NO) (Fujii, E. (313) 129)

Cytosolic
Ca^{2+}; Fura-2; Parietal cell, rabbit; Elutriation; CCK_B/gastrin receptor antagonist (Letari, O. (306) 325)

Cytosolic Ca^{2+}
Ouabain; Chromaffin cell; Lithium chloride; Veratridine (De la Fuente, M.T. (306) 219)

D-23129
Amygdala kindling; Anti-epileptic drug; Valproic acid; Afterdischarge threshold (Tober, C. (303) 163)

Dahl salt-sensitive rat
Endothelium-dependent relaxation; High-cholesterol diet; Hypercholesterolemia; Hypertension (Kitagawa, S. (297) 71)

Dalargin
δ-Opioid receptor; Vas deferens, mouse; Cysteine sulfonamide enkephalin analog; Purinergic component; Adrenergic component; Electrical field stimulation (Pencheva, N. (304) 99)

DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin)
DPLPE ([D-Pen^2,L-Pen^5]enkephalin); Dynorphin A-(1–13); 6-Hydroxydopamine; Apomorphine; (Mouse) (Toyoshi, T. (294) 637)

Dantrolene
Ca^{2+}; Myocardium; Sarcoplasmic reticulum; Ca^{2+} indicators; Aequorin (Meissner, A. (316) 333)

D-cycloserine
Imipramine; Stress; Chronic; Anhedonia; Antidepressant action; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

DDT_1 MF-2 cell
Adenosine A_1 receptor; Ca^{2+}; Ca^{2+} pumping; (Temperature) (Sipma, H. (306) 187)

Deactivation
Charybdotoxin; Dendrotoxin; Voltage dependence; Channel kinetics; Inactivation (Sprunger, L.K. (314) 357)

Defecation
5-HTP (5-hydroxytryptophan); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; $5\text{-}HT_4$ receptor; SB 204070; (Mouse) (Banner, S.E. (308) 181)

Defense area
Perifornical area; GABA (γ-aminobutyric acid); Glutamate; Nucleus tractus solitarii (Varga, K. (310) 145)

Defensive burying
$5\text{-}HT_{1A}$ receptor; Inescapable footshock; Plus-maze; 5-HIAA/5-HT (5-hydroxy-indole acetic acid/5-hydroxytryptamine) ratio (Barf, T. (297) 205)

Deferential artery, human
Vas deferens; Vasopressin; Endothelium; Nitric oxide (NO) (Medina, P. (300) 221)

Degranulation
Protein kinase inhibitor; Respiratory burst; Ca^{2+} mobilization; Neutrophil, human (Ahn, S.K. (306) 175)

Dehydroepiandrosterone sulfate
Neurosteroid; TNF (tumor necrosis factor); Glucocorticoid; Pregnenolone (Di Santo, E. (299) 179)

Delequamine
RS15385; α_2-Adrenoceptor; Lordosis; Sexual behavior, female; (Rat) (Gonzalez, M.I. (312) 1)

Deltorphin
Antinociception; Bioassay; Opioid receptor; Peptide synthesis (Guerrini, R. (302) 37)

Deltorphin analog
Antinociception; Catalepsy; Locomotion (Negri, L. (296) 9)

Dementia model
NGF (nerve growth factor); Propentofylline; Learning; Memory; Choline acetyltransferase; (Rat) (Nitta, A. (307) 1)

Dendrotoxin
Charybdotoxin; Voltage dependence; Channel kinetics; Inactivation; Deactivation (Sprunger, L.K. (314) 357)

Dentate gyrus
Hippocampus; Glutamate metabotropic receptor; Synaptic transmission; Electrophysiology, in vitro; Extracellular recording (Ugolini, A. (294) 403)

Hippocampus; Long-term potentiation; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); Slow-onset potentiation; MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Metabotropic glutamate receptor; (In vivo) (Manahan-Vaughan, D. (294) 497)

Glutamate; Dizocilpine; In situ hybridization; Schizophrenia (Healy, D.J. (306) 257)

2-Deoxy-D-glucose
Insulin; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Food intake; 5-HT_{2A} receptor, peripheral; 5-HT_3 receptor, peripheral; α-Methyl-5-HT (α-methyl-5-hydroxytryptamine); 2-Methyl-5-HT (2-methyl-5-hydroxytryptamine) (Sugimoto, Y. (316) 15)

Deoxyglucose
Morphine; Nucleus accumbens; Shell; Drug abuse (Orzi, F. (302) 49)

15-Deoxyspergualin
T cell; B cell; Monocyte; Cytokine (Nicoletti, F. (311) 213)

Dependence
Ethanol; Dopamine receptor agonist; Partial receptor agonist (Bono, G. (296) 233)

Depression
Dopamine neuron; *l*-Sulpiride; Desipramine; Autoreceptor (Diana, M. (312) 179)

Depression, animal model
Stress, chronic, mild; Pharmacological validation (Papp, M. (296) 129)

Stress, chronic, mild; Pharmacological validation (Papp, M. (310) 99)

Selective breeding; Antidepressant (Vaugeois, J.-M. (316) R1)

Dermal fibroblast, human
EGF (epidermal growth factor); MAPK (mitogen-activated protein kinase); Isoforms ($p42^{mapk}$ and $p44^{mapk}$); Protein kinase C (Le Panse, R. (307) 339)

Des-Asp-angiotensin I
Angiotensin analog, D-amino acid substituted; Angiotensin III; Blood pressure (Radhakrishnan, R. (294) 337)

Descending inhibitory control
C-fiber reflex; Buprenorphine; Nociception; Diffuse noxious inhibitory control; Spinal cord; Morphine (Guirimand, F. (294) 651)

Desensitization
5-HT_4 receptor; [^{3}H]GR 113808; Radioligand binding (Ansanay, H. (298) 165)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Striatum; Protein kinase A; Protein kinase C; (Rat) (West, A.R. (298) 241)

Adrenoceptor; Internalization; Up-regulation; Intact cell binding (Zhu, S.-J. (299) 205)

PAF (platelet-activating factor); Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)

VIP receptor, human; VIP receptor antagonist; Internalization; Recombinant protein; Transfection (Gaudin, P. (302) 207)

Dopamine D_1 receptor agonist; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease (Blanchet, P.J. (309) 13)

NMDA receptor; Glycine coagonist site; 5,7-Dichlorokynurenic acid; ACEA-1021; L-695,902; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Phospholipase C; G-protein; Adenylyl cyclase (Galas, M.-C. (314) 157)

Desipramine
5-HT (5-hydroxytryptamine, serotonin); Microdialysis; α_2-Adrenoceptor (Yoshioka, M. (294) 565)

Analgesia; μ-Opioid receptor; Spinal cord; α_2-Adrenoceptor; Neuropeptide (Gergen, K.A. (298) 235)

β-Adrenoceptor, β_1 and β_2 subtype; Binding site, high and low affinity; Astrocyte, isolated; Neuron, isolated (Sapena, R. (300) 159)

Local anesthetic; Cocaine; Lidocaine; Pseudococaine; Hemodynamics; Blood pressure; Heart rate (Bernards, C.M. (307) 33)

Dopamine neuron; *l*-Sulpiride; Autoreceptor; Depression (Diana, M. (312) 179)

Maprotiline; Prefrontal cortex; Locus ceruleus; Extracellular recording; (Anesthetized rat) (Ceci, A. (312) 189)

[^{3}H](−)-Desmethoxyverapamil
Anandamide; Ca^{2+} channel; Arachidonic acid; [^{3}H](+)-PN200-110; [^{3}H]Diltiazem (Shimasue, K. (296) 347)

***O*-Desmethylibogaine**
NMDA receptor; Ibogaine; Morphine; Naloxone (Layer, R.T. (309) 159)

Development
Colon, rat; Muscarinic receptor (Zhang, L. (304) 211)

Substantia nigra; Seizure; GABA (γ-aminobutyric acid); $GABA_A$ receptor; (Rat) (Velíšková, J. (309) 167)

Dopamine D_1 receptor; Locomotor activity; SKF 38393; SCH 23390; (Rat) (Shieh, G.-J. (311) 103)

Dexamethasone
Choline acetyltransferase; Ethanol; Acetyl coenzyme A; Enzyme affinity; Stress (Wattanathorn, J. (313) 69)

Dexmedetomidine
α_2-Adrenoceptor; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Ritanserin; Monoamine; Locus ceruleus; (Rat) (Rabin, B.C. (306) 51)

Dextromethorphan
NMDA receptor; Spatial learning; Memory; Water maze (Bane, A. (302) 7)

Opiate; Withdrawal; Naloxone; Excitatory amino acid (Rosen, M.I. (307) 251)

Diabetes
Hindquarters; Endothelin; Arachidonic acid; 5-HT (5-hydroxytryptamine, serotonin); Thromboxane (James, G.M. (294) 109)

Taurine; Hypercholesterolemia; Endothelium; LDL (low-density lipoprotein); Cholesterol (Kamata, K. (303) 47)

Hypertension; Angiotensin; Blood perfused; Nephropathy; Kidney; (Rat) (Farina, N.K. (310) 185)

Endothelin receptor; Prostate; (Rat) (Saito, M. (310) 197)

Protein mono-ADP-ribosylation; Nerve lesion; Corticosterone (Gorio, A. (311) 21)

Smooth muscle cell, vascular; Interleukin-1β; Growth; Nitric oxide (NO) (Etienne, P. (311) 79)

Polyol pathway; Galactosemia; Nerve conduction; Nerve regeneration; Oxygen free radical; Antioxidant; Metal chelator (Love, A. (314) 33)

Diabetes mellitus
Endothelial cell; Smooth muscle cell; Atherosclerosis; Aminoguanidine; Glutathione; Aldose-reductase (Graier, W.F. (294) 221)

Diabetic mouse (*db / db* mouse), genitically
SM-10902 ointment; Wound healing; Prostacyclin analog; Blood flow, skin; Angiogenesis (Yamamoto, T. (302) 53)

Diabetic neuropathy
2,3-Diphosphoglycerate; Hypoxia; Polyol pathway; Aldose reductase inhibitor (Nakamura, J. (294) 207)

Diabetic pancreas
Ca^{2+} mobilization; 1,4,5-IP_3-sensitive Ca^{2+} store; Ca^{2+} refilling; Muscarinic receptor (Komabayashi, T. (298) 299)

Diabetic rat
Nerve blood flow; Vasa nervorum; Adrenergic responsiveness; ACTH-(4–9) analog, Org 2766 (Van Buren, T. (296) 277)

Diabetic retinopathy
Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Insulin; Carnitine; Sorbitol; Serum lipid (Hotta, N. (311) 199)

Diaphragm, guinea-pig
K^+ channel opener; K^+ channel inhibitor; K^+ channel, ATP-sensitive; Adenosine; Skeletal muscle (Wickenden, A.D. (302) 79)

Diarrhea
Diltiazem; Naloxone-precipitated withdrawal; Morphine withdrawal, spontaneous; Corticosterone, plasma; Body weight loss; (Rat) (Kishioka, S. (316) 7)

Morphine; Buprenorphine; Castor oil; Gastrointestinal transit; Ethanol lesion (Bhounsule, S.A. (316) 253)

Diastolic function
Ventricular function; Preload recruitable stroke work; Isovolumic relaxation; Superoxide dismutase; SC-55858; SC-54417 (Lowe, D. (304) 81)

Diazepam
Benzodiazepine; Heart preparation, isolated; Inotropy; Peripheral-type benzodiazepine receptor antagonist (Leeuwin, R.S. (299) 149)

Uterus, rat; Sex hormone, female; 4'-Chlorodiazepam; Clonazepam; PK 11195; Ca^{2+} channel (Yiu, M.-k. (302) 99)

κ-Opioid receptor agonist; Anticonflict effect; Vogel-type conflict test; (Mouse) (Tsuda, M. (307) 7)

Animal model; Anxiety; Chlorpromazine; One-way avoidance; Successive negative contrast; Thiopental sodium (Torres, C. (314) 269)

Benzodiazepine; Langendorff heart; Inotropy; Ca^{2+}-entry blocking drug; Adenosine receptor blocking drug (Leeuwin, R.S. (315) 153)

Diazepam-insensitive
$GABA_A$ receptor; $GABA_A$ receptor subunit; Heterogeneity; Cerebellum; Thalamus (Huh, K.-H. (310) 225)

5,7-Dichlorokynurenic acid
HA-966 (3-amino-1-hydroxy-2-pyrrolidone); Dizocilpine; Phencyclidine; Ifenprodil; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); 5-HT_{2C} receptor (Mazzola-Pomietto, P. (308) 329)

NMDA receptor; Glycine coagonist site; Desensitization; ACEA-1021; L-695,902; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Felbamate; Glutamate; Epilepsy; Cortical slice (Srinivasan, J. (315) 285)

1,9-Dideoxyforskolin
Forskolin; Ca^{2+} current; Ryanodine store; Action potential; Cerebellar granule cell (Zerr, P. (303) 101)

Dietary fat
n–3 fatty acid; Arrhythmia; Blood pressure; Proteinuria; Thromboxane (McLennan, P. (300) 83)

Differentiation
CRF receptor; IMR-32 human neuroblastoma cell line; Radioligand binding; Adenylate cyclase (Hogg, J.E. (312) 257)

Diffuse noxious inhibitory control
C-fiber reflex; Buprenorphine; Nociception; Descending inhibitory control; Spinal cord; Morphine (Guirimand, F. (294) 651)

Digital image analysis
Ca^{2+}, cytosolic, free; Fetal alcohol syndrome (Altura, B.M. (314) R9)

Digitalis
Na^+,K^+-ATPase; Heart failure; Norepinephrine (Lai, L.-P. (309) 235)

Digoxin
Inotropic drug; Heart failure; K^+ channel, ATP-sensitive; Papillary muscle; Milrinone (Kocić, I. (301) 115)

Dihydropyridine
Ca^{2+} channel; ω-Conotoxin; ω-Agatoxin; Melanotrope; Pituitary; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

Dihydrotetrabenazine
Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Methoxytetrabenazine (Kilbourn, M. (307) 227)

Diltiazem
Naloxone-precipitated withdrawal; Morphine withdrawal, spontaneous; Corticosterone, plasma; Body weight loss; Diarrhea; (Rat) (Kishioka, S. (316) 7)

[^{3}H]Diltiazem
Anandamide; Ca^{2+} channel; Arachidonic acid; [^{3}H](+)-PN200-110; [^{3}H](−)-Desmethoxyverapamil (Shimasue, K. (296) 347)

3,7-Dimethyl-1-propargylxanthine
Formalin test; Caffeine; Stimulus intensity; 8-Cyclopentyltheophylline (Sawynok, J. (298) 105)

Dimethylthiourea
Reperfusion arrhythmia; Superoxide dismutase; Catalase; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Ohoi, I. (306) 123)

Dinitrophenol
ATP-sensitive K^+ channel; Ca^{2+}, intracellular; Chemical hypoxia; Cardiac cell; Glyburide; Fluo-3 (Brady, P.A. (308) 343)

2-(Di-*n*-propylamino)tetralin
Chiral compound; 5-HT_{1A} receptor; Dopamine D_2 receptor; (Racemate); (Rat); (Stereoisomer) (Yu, H. (303) 151)

1,3-Di-*o*-tolylguanidine
σ Binding site; Trishomocubane; Brain membrane; (+)-Pentazocine (Nguyen, V.H. (311) 233)

Dipeptidyl aldehyde
Cathepsin L; Cysteine protease inhibitor; Bone resorption (Woo, J.-T. (300) 131)

Diphenhydramine
Drug discrimination; Cocaine; Doxylamine (Gauvin, D.V. (294) 281)

Pertussis toxin; Analgesia; Morphine; Baclofen; Clomipramine; Physostigmine (Galeotti, N. (308) 125)

Diphenyleneiodonium
D-NNA (N^G-nitro-D-arginine); Di-2-thienyliodonium; Methylene blue; Nitric oxide (NO); Lipopolysaccharide; Contraction (Palacios, B. (296) 75)

Glyceryl trinitrate; Artery, bovine coronary; Aorta, rat (De la Lande, I.S. (314) 347)

2,3-Diphosphoglycerate
Diabetic neuropathy; Hypoxia; Polyol pathway; Aldose reductase inhibitor (Nakamura, J. (294) 207)

Cilostazol; Otsuka Long-Evans Tokushima Fatty rat; Motor nerve conduction velocity; R-R interval, coefficient of variation; Sciatic nerve blood flow; Platelet aggregation (Hotta, N. (313) 201)

Dipyridamole
Nitric oxide (NO); Smooth muscle cells, vascular; Interleukin-1β; Cyclic nucleotide (Iimura, O. (296) 319)

Nitroglycerin; Tolerance; Phosphodiesterase inhibitor; cGMP monophosphate; Blood pressure; Zaprinast; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Discriminative stimulus
Ethanol; 5-HT_3 receptor agonist; 5-HT_3 receptor antagonist (Stefanski, R. (309) 141)

Disseminated intravascular coagulation
Lipopolysaccharide; Interleukin-1; TNF-α (tumor necrosis factor-α) (Yamamoto, N. (314) 137)

Dissociated Purkinje neuron
Ca^{2+} channel; Whole-cell voltage-clamp; Inactivation; Eliprodil (Biton, B. (294) 91)

Distal colon, rat
β-Adrenoceptor; β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Trachea, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

Di-2-thienyliodonium
D-NNA (N^G-nitro-D-arginine); Diphenyleneiodonium; Methylene blue; Nitric oxide (NO); Lipopolysaccharide; Contraction (Palacios, B. (296) 75)

Dizocilpine
Glutamate; Dentate gyrus; In situ hybridization; Schizophrenia (Healy, D.J. (306) 257)

5,7-Dichlorokynurenic acid; HA-966 (3-amino-1-hydroxy-2-pyrrolidone); Phencyclidine; Ifenprodil; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); 5-HT_{2C} receptor (Mazzola-Pomietto, P. (308) 329)

Dizocilpine (MK-801)
Lamotrigine; Nitric oxide (NO); Opiate abstinence (Lizasoain, I. (299) 41)

Dizocilpine maleate
α_1-Adrenoceptor antagonist; Microdialysis; NMDA receptor; Locomotion (Mathé, J.M. (309) 1)

cDNA
Glutamate receptor; Subunit; BHK cell; AMPA (α-amino-3-hydroxy-5-methyl-isoxalazole-4-propionate) (Andersen, P.H. (311) 95)

α-Adrenoceptor; Prostate; Fibroblast, rat-1; Doxazosin; (Enantiomer) (Hatano, A. (313) 135)

DNA fragmentation
Endotoxin; Septic shock; K^+ channel; Systemic inflammatory response syndrome; Cerebral malaria (Gantner, F. (294) 353)

Cerebral ischemia; Nitric oxide (NO); Reperfusion; Chromatin condensation; Apoptotic body; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

DNA repair
Cisplatin; Drug resistance; Multidrug resistance (Chao, C.C.-K. (305) 213)

DNA synthesis
Cell cycle; Smooth muscle cell, rat, vascular; Osthole; (*Angelica pubescens*) (Guh, J.-H. (298) 191)

Dobutamine
Isovolumic relaxation; Ventricular filling; Myocardial contractility; Preload recruitable stroke work; Inotropes; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

DOCA-salt rat
Bradykinin; Angiotensin-converting enzyme inhibitor; Neutral endopeptidase inhibitor (Pham, I. (296) 267)

Docosahexaenoic acid
Polyunsaturated fatty acid; K^+ channel, cloned; Patch clamp, whole-cell (Garratt, J.C. (314) 393)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
α_2-Adrenoceptor; Dexmedetomidine; Ritanserin; Monoamine; Locus ceruleus; (Rat) (Rabin, B.C. (306) 51)

mCPP (1-(3-chlorophenyl)piperazine); Hyperglycemia; 5-$HT_{2C/2B}$ receptor; 5-HT_{2A} receptor (Sugimoto, Y. (307) 75)

Dolabrane
Anti-inflammatory; Neutrophil, human; Myeloperoxidase; Elastase; Prostaglandin; Leukotriene (Payá, M. (312) 97)

Donryu rat
Cholesterol-feeding; Endothelium; P_{2X} purinoceptor; Mesenteric arterial bed, rat; Sympathetic neurotransmission (Ralevic, V. (313) 221)

L-DOPA
Dopamine transporter; [^{3}H]GBR 12935 binding; Reserpine; Amantadine; Benztropine (Gordon, I. (298) 27)

L-DOPA (L-dihydroxyphenylalanine)
L-*threo*-DOPS (L-*threo*-dihydroxyphenylserine); Nucleus tractus solitarii; L-DOPA methyl ester; Neurotransmitter; (Rat) (Miyamae, T. (300) 105)

L-DOPA methyl ester
L-*threo*-DOPS (L-*threo*-dihydroxyphenylserine); L-DOPA (L-dihydroxyphenylalanine); Nucleus tractus solitarii; Neurotransmitter; (Rat) (Miyamae, T. (300) 105)

L-DOPA (3,4-dihydroxyphenylalanine) release
Nicotine; Locomotor activity, rat; Nucleus accumbens; Ventral tegmental area; Microdialysis (Goshima, Y. (309) 229)

Dopamine
Stress; Hyperthermia; Temperature; Anxiety; Benzodiazepine; 5-HT_{1A} receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin) (Zethof, T.J.J. (294) 125)

Excitatory amino acid; NMDA receptor antagonist; AP-5 (DL-2-amino-5-phosphonovaleric acid); MK-801 ((+)-5-methyl-10,11-dihydro(*a,d*)-cyclohepten-5,10-imine hydrogen maleate salt); Locomotor activity (Ouagazzal, A. (294) 137)

Catalepsy; 5-HT (5-hydroxytryptamine, serotonin); Receptor; (Rat) (Wadenberg, M.-L. (294) 247)

Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); Dopamine D_2 receptor; Presynaptic dopamine re-uptake site, presynaptic; Methoxytetrabenazine (Vander Borght, T. (294) 577)

Nicotine; Isoarecolone; Microdialysis; Nucleus accumbens (Mirza, N.R. (295) 207)

ATP receptor channel; 5-HT (5-hydroxytryptamine, serotonin); Recombinant channel; *Xenopus* oocyte (Nakazawa, K. (296) 119)

Levodopa; Microdialysis; Parkinson's disease; Dopamine receptor agonist; Dopamine receptor antagonist (Sarre, S. (296) 247)

β-Phenylethylamine; Nigrostriatal system; Rotation (Barroso, N. (297) 195)

Cholecystokinin; Dopamine D_1 receptor; Grooming; Vacuous chewing movement; (Rat) (Van Kampen, J. (298) 7)

5-HT (5-hydroxytryptamine, serotonin); Desensitization; Striatum; Protein kinase A; Protein kinase C; (Rat) (West, A.R. (298) 241)

Light extinction test; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Striatum; Substantia nigra (Messaoudi, M. (299) 17)

Arginine-aspartate; Catalepsy; Haloperidol; Locomotor activity (Patacchioli, F.R. (299) 29)

Epilepsy; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; GABA (γ-aminobutyric acid); Anticonvulsant (Löscher, W. (299) 61)

Glutamate receptor antagonist; Reserpine; Parkinsonism; Microdialysis (Biggs, C.S. (299) 83)

Catecholamine absorbing protein; Central nervous system; Free radical; Oxidation; Neurodegeneration; Parkinson's disease (Modi, P.I. (299) 213)

Ca^{2+} channel antagonist; Dystonia; Movement disorder (Richter, A. (300) 197)

Ethanol; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N,N*-2-(di-*n*-propylamino)tetralin); Locomotion; (Rat) (Frantz, K. (302) 1)

Amphetamine; Microdialysis; Individual difference; Nucleus accumbens; (Rat) (Sills, T.L. (303) 177)

Locomotion; Reserpine; Lamotrigine; (Mouse) (Kaur, S. (304) 1)

Reserpine; Oral dyskinesia; Tongue protrusion; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Cortex, prefrontal; 5-HT_{1A} receptor; Ipsapirone; WAY 100135; NAN-190; Microdialysis (Wędzony, K. (305) 73)

Na^+,K^+ATPase, activity; Dopamine receptor; Dopamine signal transduction; Smooth muscle, vascular; Smooth muscle cell, aortic; (Rat) (Rashed, S.M.K. (305) 223)

Haloperidol; MK-801; SCH 23390; Self-stimulation (Olds, M.E. (306) 23)

Clozapine; Thermoregulation; Dopamine receptor; (Rat) (Salmi, P. (307) 27)

NMDA receptor antagonist; Neuroleptic, chronic; Locomotor activity; Memory; (Mouse) (Mele, A. (308) 1)

Conditioned place preference; Sulpiride; Raclopride; Dopamine D_2 receptor; Lordosis (Meisel, R.L. (309) 21)

Transporter; Dopamine efflux (Kitayama, S. (309) 107)

Enkephalin; Ethanol drinking; (Inbred mouse) (Ng, G.Y.K. (311) 45)

Aromatic L-amino acid decarboxylase; Tyrosine hydroxylase; Monoamine oxidase; Striatum; (Modulation) (Cho, S. (314) 51)

β-Carboline; Harman; Norharman; Microdialysis; Nucleus accumbens; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

RP 62203; Fananserin; Dopamine D_4 receptor; 5-HT_{2A} receptor; 5-HT (serotonin) (Heuillet, E. (314) 229)

Ethanol; Nicotine; Nicotinic acetylcholine receptor; Preference; Sensitization; (Rat) (Blomqvist, O. (314) 257)

Placenta; β-Endorphin; Dynorphin; Perfusion; (Rat) (Stratakis, C.A. (315) 53)

β-Carboline; Uptake; Striatum; Microdialysis; MPP^+ (*N*-methyl-4-phenylpyridinium) (Matsubara, K. (315) 145)

Nucleus accumbens; Ethanol; Microdialysis; Tolerance; Animal model (Nurmi, M. (315) 277)

Adenosine; Adenylyl cyclase; Fibroblast; Receptor-receptor interaction (Dasgupta, S. (316) 325)

Dopamine autoreceptor
ATP-sensitive K^+ channel; Nicorandil; Cromakalim; Microdialysis; Sulpiride (Tanaka, T. (297) 35)

Dopamine carrier, neuronal
Binding, in vitro; Ion dependence; K^+ gradient (Héron, C. (301) 195)

Dopamine D_1/D_2 receptor interaction
Accumbal shell; Accumbal core; Jaw movement; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 227)

Accumbal shell; Accumbal core; Turning behavior; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 235)

Dopamine D_1/D_3 receptor interaction
Accumbal shell; Accumbal core; Jaw movement; Dopamine D_1/D_2 receptor interaction; (Rat) (Koshikawa, N. (308) 227)

Accumbal shell; Accumbal core; Turning behavior; Dopamine D_1/D_2 receptor interaction; (Rat) (Koshikawa, N. (308) 235)

Dopamine D_1 receptor
Cholecystokinin; Dopamine; Grooming; Vacuous chewing movement; (Rat) (Van Kampen, J. (298) 7)

Adenosine A_1 receptor; EEG (electroencephalographic) arousal; (Rabbit) (Popoli, P. (305) 123)

Dopamine D_2 receptor; Dopamine uptake site; Cerebral ischemia; Receptor autoradiography (Araki, T. (306) 73)

Development; Locomotor activity; SKF 38393; SCH 23390; (Rat) (Shieh, G.-J. (311) 103)

5-HT_{1A} receptor; Noradrenaline; SCH 23390; Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin) (Hajós-Korcsok, É. (314) 285)

Dopamine D_2 receptor
Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); Presynaptic dopamine re-uptake site, presynaptic; Dopamine; Methoxytetrabenazine (Vander Borght, T. (294) 577)

Morphine; Dopamine release; Acetylcholine release; Striatum (Nestby, P. (294) 771)

[^{3}H]Spiperone; [^{3}H]Raclopride; [^{125}I]NCQ-298; [^{3}H]YM-09151-2; Nemonapride; Receptor binding, in vitro (Malmberg, A. (303) 123)

2-(Di-*n*-propylamino)tetralin; Chiral compound; 5-HT_{1A} receptor; (Racemate); (Rat); (Stereoisomer) (Yu, H. (303) 151)

Dopamine D_1 receptor; Dopamine uptake site; Cerebral ischemia; Receptor autoradiography (Araki, T. (306) 73)

Dopamine release; Dopamine synthesis; Dopamine D_3 receptor; Microdialysis; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Gainetdinov, R.R. (308) 261)

Conditioned place preference; Sulpiride; Raclopride; Dopamine; Lordosis (Meisel, R.L. (309) 21)

Ventral tegmental area; OPC-14597; Extracellular recording in vivo; Whole-cell recording; Thin-slice preparation (Momiyama, T. (310) 1)

Dopamine D_3 receptor
R-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Emesis; Area postrema; (Ferret) (Yoshikawa, T. (301) 143)

Dopamine; 7-OH-DPAT (7-hydroxy-*N*,*N*-2-(di-*n*-propylamino)tetralin); Locomotion; (Rat) (Frantz, K. (302) 1)

Receptor reserve; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin) (Aretha, C.W. (305) 119)

Dopamine release; Dopamine synthesis; Dopamine D_2 receptor; Microdialysis; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Gainetdinov, R.R. (308) 261)

Dopamine receptor agonist; Dopamine neuronal firing; Pramipexole (Piercey, M.F. (312) 35)

Dopamine D_4 receptor
Raclopride (Helmeste, D. (301) R1)

RP 62203; Fananserin; Dopamine; 5-HT_{2A} receptor; 5-HT (serotonin) (Heuillet, E. (314) 229)

σ Receptor; Schizophrenia (Helmeste, D.M. (314) R3)

Dopamine D_1 receptor agonist
Desensitization; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Parkinson's disease (Blanchet, P.J. (309) 13)

Dopamine D_2 receptor binding
Antidepressant; Repeated treatment; [^{3}H]N-0437 (Maj, J. (304) 49)

Dopamine efflux
Dopamine; Transporter (Kitayama, S. (309) 107)

Dopamine hD_{2l} receptor
Dopamine $hD_{4.4}$ receptor; Intrinsic activity (Lahti, R.A. (301) R11)

Dopamine $hD_{4.4}$ receptor
Dopamine hD_{2l} receptor; Intrinsic activity (Lahti, R.A. (301) R11)

Dopamine, mesoaccumbens
Nicotine; D-CPPene (SDZ EAA 494; Sensitization; Locomotor activity; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid) (Balfour, D.J.K. (316) 153)

Dopamine metabolism
Haloperidol; Pimozide; Catalepsy; Adaptation; (Chronic treatment) (Karolewicz, B. (313) 181)

Dopamine neuron
l-Sulpiride; Desipramine; Autoreceptor; Depression (Diana, M. (312) 179)

Dopamine neuronal firing
D_3 receptor; Dopamine receptor agonist; Pramipexole (Piercey, M.F. (312) 35)

Dopamine receptor
Nucleus accumbens stimulation; Acetylcholine receptor; Ventrolateral striatum; Dopamine release; Turning behavior (Koshikawa, N. (303) 13)

Na^+,K^+ATPase, activity; Dopamine; Dopamine signal transduction; Smooth muscle, vascular; Smooth muscle cell, aortic; (Rat) (Rashed, S.M.K. (305) 223)

Clozapine; Thermoregulation; Dopamine; (Rat) (Salmi, P. (307) 27)

Adrenal medulla; Radioligand binding; Autoradiography; Chromaffin cell; (Rat) (Barili, P. (310) 129)

Piribedil; Autoradiography (Cagnotto, A. (313) 63)

Dopamine receptor agonist
Ethanol; Dependence; Partial receptor agonist (Bono, G. (296) 233)

Dopamine; Levodopa; Microdialysis; Parkinson's disease; Dopamine receptor antagonist (Sarre, S. (296) 247)

D_3 receptor; Dopamine neuronal firing; Pramipexole (Piercey, M.F. (312) 35)

Dopamine receptor antagonist
Adenosine receptor agonist; Behavioral interaction; Catalepsy; Schizophrenia (Kafka, S.H. (295) 147)

Dopamine; Levodopa; Microdialysis; Parkinson's disease; Dopamine receptor agonist (Sarre, S. (296) 247)

Theophylline; Grooming; (Rat) (Zarrindast, M.-R. (306) 1)

Ca^{2+} channel; Antipsychotic drug; Calmodulin antagonist; Membrane current (Ito, K. (314) 143)

Dopamine receptor, sensitization
Acetylcholine release, hippocampus; Morphine administration, acute and chronic (Imperato, A. (302) 21)

Dopamine release
σ Receptor; (+)-Pentazocine; BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine); DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl)piperidine HBr); BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl)cyclohexylamine) (Gonzalez-Alvear, G.M. (294) 713)

Morphine; Acetylcholine release; Striatum; Dopamine D_2 receptor (Nestby, P. (294) 771)

Nucleus accumbens stimulation; Dopamine receptor; Acetylcholine receptor; Ventrolateral striatum; Turning behavior (Koshikawa, N. (303) 13)

GABA (γ-aminobutyric acid); Modafinil; Microdialysis; Nucleus accumbens (Ferraro, L. (306) 33)

Dopamine synthesis; Dopamine D_3 receptor; Dopamine D_2 receptor; Microdialysis; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Gainetdinov, R.R. (308) 261)

Dopamine signal transduction
Na^+,K^+ATPase, activity; Dopamine; Dopamine receptor; Smooth muscle, vascular; Smooth muscle cell, aortic; (Rat) (Rashed, S.M.K. (305) 223)

Dopamine synthesis
Dopamine release; Dopamine D_3 receptor; Dopamine D_2 receptor; Microdialysis; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Gainetdinov, R.R. (308) 261)

Dopamine transporter
Cocaine; Meperidine (Izenwasser, S. (297) 9)

[^{3}H]GBR 12935 binding; L-DOPA; Reserpine; Amantadine; Benztropine (Gordon, I. (298) 27)

Cocaine analog; Behavior (Fleckenstein, A.E. (311) 109)

Methamphetamine; Illicit synthesis; Synthetic impurity; NMDA receptor; BNMPA (α-benzyl-*N*-methylphenethylamine) (Moore, K.A. (311) 133)

Dopamine uptake; WIN 35,428 binding; Arachidonic acid; Protein kinase C; Second messenger (Zhang, L. (315) 345)

Dopamine uptake
Dopamine transporter; WIN 35,428 binding; Arachidonic acid; Protein kinase C; Second messenger (Zhang, L. (315) 345)

Dopamine uptake site
Dopamine D_1 receptor; Dopamine D_2 receptor; Cerebral ischemia; Receptor autoradiography (Araki, T. (306) 73)

Dopaminergic modulation
Mesolimbic system, rat; Nucleus accumbens; Ventral tegmental area; 5-HT_3 receptor; Locomotor activity (Gillies, D.M. (303) 1)

Dopaminergic system
Conditioned fear stress; σ Receptor; Phenytoin; Motor suppression (Kamei, H. (309) 149)

L-*threo*-DOPS (L-*threo*-dihydroxyphenylserine)
L-DOPA (L-dihydroxyphenylalanine); Nucleus tractus solitarii; L-DOPA methyl ester; Neurotransmitter; (Rat) (Miyamae, T. (300) 105)

Dorsal hippocampus
5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; β-Adrenoceptor; Microdialysis (Petersen, B. (300) 67)

Dorsal horn
Intermediolateral cell column; Immunohistochemistry; Hyperalgesia; Tail-flick; Spinal cord; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

Dorsal raphe
JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine); Antidepressant; Locus coeruleus; A10 dopamine neuron; Electrophysiology (Liégeois, J.-F. (310) 9)

Dorsal root ganglion
Local anesthetic; *N*-butyl-*p*-aminobenzoate; Patch clamp; Na^+ current inactivation (Van den Berg, R.J. (316) 87)

Dorsal root ganglion neuron
Ca^{2+}, intracellular; Neuropeptide FF; (Mouse) (Roumy, M. (306) 291)

Dorsal skin
Sympathetic nerve; 6-Hydroxydopamine; Mast cell (Cambridge, H. (301) 151)

Dose response
d-Amphetamine; Psychomotor stimulant; Motor activity; Behavior (Gaytan, O. (300) 1)

Down-regulation
β-CCE (ethyl β-carboline-3-carboxylate); Benzodiazepine receptor; Inverse agonist; Primary cultured neuron (Katsura, M. (298) 71)

Doxazosin
α_1-Adrenoceptor antagonist; Terazosin; Sympathetic nerve activity; Bladder; (Anesthetized cat) (Ramage, A.G. (294) 645)

α-Adrenoceptor; Prostate; cDNA; Fibroblast, rat-1; (Enantiomer) (Hatano, A. (313) 135)

Doxylamine
Drug discrimination; Cocaine; Diphenhydramine (Gauvin, D.V. (294) 281)

DP-1904
Thromboxane A_2 synthase inhibitor; Heymann nephritis; Proteinuria (Nagao, T. (316) 73)

DPLPE ([D-Pen^2,L-Pen^5]enkephalin)
DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin); Dynorphin A-(1–13); 6-Hydroxydopamine; Apomorphine; (Mouse) (Toyoshi, T. (294) 637)

DP receptor
BW A868C; Prostaglandin D_2; BW245C; Antagonist affinity (Liu, Y.J. (303) 187)

BW A868C; Partial agonist; Cl^- secretion (Liu, Y.J. (304) 117)

Drinking
Appetite; Food intake; Isatin; Motivation; 5-HT (5-hydroxytryptamine, serotonin); Tubulin; (Mouse) (Morley, J.E. (305) 23)

Drug abuse
Morphine; Deoxyglucose; Nucleus accumbens; Shell (Orzi, F. (302) 49)

Drug discrimination
Cocaine; Diphenhydramine; Doxylamine (Gauvin, D.V. (294) 281)

Nicotine; Mecamylamine; Methyllycaconitine (Brioni, J.D. (301) 1)

Benzodiazepine; Time course; Bretazenil; Chlordiazepoxide; (Rat) (Bronson, M. (305) 7)

Acamprosate; Ethanol; NMDA receptor antagonist; (Rat) (Spanagel, R. (305) 51)

Ca^{2+} channel, L-type; Nimodipine; Ethanol; Substitution; Conditioned taste aversion (De Beun, R. (306) 5)

Ethanol; NMDA receptor antagonist; (Rat) (Bienkowski, P. (314) 277)

5-HT_{1A} receptor; Efficacy; Ultrasonic vocalization; (Rat) (Sánchez, C. (315) 245)

Drug metabolism
Rebamipide; Hepatic secretion; Ischemia/reperfusion (Lee, S.-M. (294) 41)

Drug-receptor interaction
Binding thermodynamics; 5-HT_{1A} receptor (Dalpiaz, A. (312) 107)

Drug resistance
Cisplatin; DNA repair; Multidrug resistance (Chao, C.C.-K. (305) 213)

Drug screening
GABA (γ-aminobutyric acid); Excitatory amino acid; Seizure; Ischemia; Neurological disorder; Antiepileptic (Kanthasamy, A.G. (297) 219)

Drug tolerance
Pentobarbital; $GABA_A$ receptor; Benzodiazepine binding; Substance dependence (Suzuki, T. (295) 169)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine)
Opiate; Tolerance; Withdrawal; Locus ceruleus; (Mouse) (Dossin, O. (308) 271)

DTG (1,3-di-*o*-tolylguanidine)
σ Receptor; Liver, rat; Solubilization; CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate); (+)-Pentazocine (Torrence-Campbell, C. (304) 201)

DTG (1,3-di(2-tolyl)guanidine)
Spinal cord, mouse; Haloperidol (Hornfeldt, C.S. (306) 15)

Duodenum, rat
5-HT recognition site; Ileum, rat; [^{125}I]*S*-(−)-Zacopride; Autoradiography (Ge, J. (300) 113)

DuP 996
Linopirdine; Brain; Membrane binding; Species difference (Höfner, G. (298) 307)

DuP532
Intestinal vascular bed; Angiotensin peptide; PD123,319; Enalaprilat; Angiotensin II; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl) piperidine HBr)
σ Receptor; Dopamine release; (+)-Pentazocine; BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine); BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl)cyclohexylamine) (Gonzalez-Alvear, G.M. (294) 713)

Dye diffusion
Gap junction; Cell-to-cell conductance; Trophoblast differentiation, human; Ca^{2+}, intracellular; Patch clamp, dual (Hervé, J.-C. (313) 243)

Dynorphin
Analgesia; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)

Analgesia; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (312) 391)

Dopamine; Placenta; β-Endorphin; Perfusion; (Rat) (Stratakis, C.A. (315) 53)

Dynorphin A
Dynorphin B; Dynorphin-converting enzyme; Formalin test; Intrathecal administration; Peptidohydrolase; (Mouse) (Tan-No, K. (314) 61)

Dynorphin A-(1–13)
DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); 6-Hydroxydopamine; Apomorphine; (Mouse) (Toyoshi, T. (294) 637)

Dynorphin B
Dynorphin A; Dynorphin-converting enzyme; Formalin test; Intrathecal administration; Peptidohydrolase; (Mouse) (Tan-No, K. (314) 61)

Dynorphin-converting enzyme
Dynorphin A; Dynorphin B; Formalin test; Intrathecal administration; Peptidohydrolase; (Mouse) (Tan-No, K. (314) 61)

Dyspnoea
Morphine; Quenching; Autoradiography; Opioid (Cabot, P.J. (310) 47)

Dystonia
Ca^{2+} channel antagonist; Dopamine; Movement disorder (Richter, A. (300) 197)

E2020
MF201; Tacrine; Physostigmine; 8-Arm radial maze; (Rat) (Braida, D. (302) 13)

E-4031
AV node; K^+ current, delayed rectifier; Zatebradine; Heart, dog (Yamazaki, K. (297) 233)

Eburnamonine
Muscarinic receptor, heart; Muscarinic receptor, allosteric control; Allosteric interaction; Vincamine; Alcuronium; Strychnine (Proška, J. (305) 201)

Edema
Carbamazepine; Inflammatory hyperalgesia; Nociception; Prostaglandin; Substance P (Bianchi, M. (294) 71)

Head injury; Antioxidant free radical scavenger; Magnetic resonance imaging (Petty, M.A. (307) 149)

EDHF (endothelium-derived hyperpolarizing factor)
Acetylcholine; PAF (platelet-activating factor); Nitric oxide (NO) (Kamata, K. (298) 129)

Endothelium; Acetylcholine; Nitric oxide (NO); Hind limb, rat (Brouwers-Ceiler, D.L. (307) 65)

EEG (electroencephalogram), quantitative
Ceritizine; Chlorpheniramine; Oral administration, acute; Plasma concentration, drug; Neuropsychological status; (Healthy volunteer) (Sannita, W.G. (300) 33)

EEG (electroencephalographic) arousal
Dopamine D_1 receptor; Adenosine A_1 receptor; (Rabbit) (Popoli, P. (305) 123)

Efaroxan
K^+ channel; Erythrocyte; Clotrimazole; Imidazoline binding site (Coupry, I. (295) 109)

Agmatine; Imidazoline receptor; Insulin secretion; Vessel; Pancreas, rat (Berdeu, D. (308) 301)

Efficacy
5-HT_{1A} receptor; Ultrasonic vocalization; Drug discrimination; (Rat) (Sánchez, C. (315) 245)

EGF (epidermal growth factor)
Smooth muscle, airway; Leukotriene; Tyrosine kinase; Phospholipase A_2 (Nasuhara, Y. (296) 161)

Mucosal protection; Tissue resistance; Receptor; Epithelium (Rao, R. (303) 209)

MAPK (mitogen-activated protein kinase); Isoforms ($p42^{mapk}$ and $p44^{mapk}$); Protein kinase C; Dermal fibroblast, human (Le Panse, R. (307) 339)

Eicosanoid
Tachykinin receptor antagonist; Anaphylaxis, lung (Montuschi, P. (313) R1)

Elastase
Dolabrane; Anti-inflammatory; Neutrophil, human; Myeloperoxidase; Prostaglandin; Leukotriene (Payá, M. (312) 97)

Electrical field stimulation
δ-Opioid receptor; Vas deferens, mouse; Cysteine sulfonamide enkephalin analog; Dalargin; Purinergic component; Adrenergic component (Pencheva, N. (304) 99)

Lower esophageal sphincter; NANC (non-adrenergic non-cholinergic) neurotransmission; Nicotine; Nitric oxide (NO); VIP (vasoactive intestinal peptide) (Kortezova, N. (304) 109)

Tamsulosin; α_1-Adrenoceptor stimulation; Prostate, human (Chueh, S.-C. (305) 177)

Electrical stimulation
Purinergic transmission; P_{2X} purinoceptor; α_2-Adrenoceptor; Autoinhibition; Splenic artery; (Dog) (Ren, L.-M. (295) 61)

Electroconvulsive shock
Amnesia; Nimodipine; Felodipine; Amlodipine; (Rat) (Župan, G. (310) 103)

Electrolysis
Reactive oxygen species; Endothelium-dependent relaxation; L-Arginine; Aorta (Gumusel, B. (306) 107)

Electron probe X-ray microanalysis
Cisapride; Small intestine; (Mouse) (Spencer, A.J. (303) 205)

Electrophysiology
Vasorelaxation; Heart; ATP-sensitive K^+ channel; His bundle; Conduction; Refractory period (D'Alonzo, A.J. (294) 271)

5-HT (5-hydroxytryptamine, serotonin); 1-(2-Pyrimidinyl)piperazine; Hippocampus; Excitatory synaptic transmission; 5-HT_{1A} receptor; Azapirone (Manahan-Vaughan, D. (294) 617)

Melatonin; Suprachiasmatic nucleus; Intergeniculate leaflet; Light; Circadian rhythm; Entrainment (Ying, S.-W. (296) 33)

Norepinephrine; Risperidone; Primary olfactory cortex; Antipsychotic drug (Marek, G.J. (305) 95)

Opioid receptor; δ-Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Ventromedial nucleus; (Rat) (Zhang, C. (308) 153)

JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine); Antidepressant; Dorsal raphe; Locus coeruleus; A10 dopamine neuron (Liégeois, J.-F. (310) 9)

Nodose ganglion; Guanylate cyclase; Enzyme; mRNA; Nitric oxide (NO) (Lawrence, A.J. (315) 127)

Electrophysiology, in vitro
Hippocampus; Dentate gyrus; Glutamate metabotropic receptor; Synaptic transmission; Extracellular recording (Ugolini, A. (294) 403)

Electroretinogram
Streptozotocin-induced diabetes, rat; Oscillatory potential; Propionyl-L-carnitine; Insulin; Carnitine; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Electroshock
G-protein; GTP-binding protein; In situ hybridization; Messenger RNA (McGowan, S. (306) 249)

Elevated plus-maze
Anxiety; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_4 receptor antagonist (Silvestre, J.S. (309) 219)

Elevated plus-maze test
Alaptide; Cyclodipeptide; 2,5-Piperazinedione; Memory; Oxiracetam; (Mouse) (Hliňák, Z. (314) 1)

Elevated X-maze
Anxiety; Immediate early gene; CI-988; Benzodiazepine; CCK (cholecystokinin) (Hinks, G.L. (312) 153)

Eliprodil
Ca^{2+} channel; Whole-cell voltage-clamp; Dissociated Purkinje neuron; Inactivation (Biton, B. (294) 91)

Elutriation
Ca^{2+}; Cytosolic; Fura-2; Parietal cell, rabbit; CCK_B/gastrin receptor antagonist (Letari, O. (306) 325)

EMD 53998
Butanedione monoxime (BDM); Ca^{2+} sensitivity; Cross-bridge; Cardiac skinned fiber (Barth, Z. (296) 285)

EMD 57033
Ca^{2+}; Myofilament; Ca^{2+} sensitiser; Skinned fiber; Rigor (Palmer, S. (294) 83)

EMD 57445
σ Receptor ligand; Rimcazole; Central effect; Behavioral model (Maj, J. (315) 235)

Emesis
Dopamine D_3 receptor; *R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Area postrema; (Ferret) (Yoshikawa, T. (301) 143)

Tachykinin NK_1 receptor antagonist; CP-122,721; (Ferret) (Gonsalves, S. (305) 181)

Morphine; Nicotine; Tachykinin NK_1 receptor; 5-HT_3 receptor; 5-HT_{1A} receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

5-HT_3 receptor; 5-HT_3 receptor agonist; N1E-115 cells; NG 108-15 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Inward current; (Rat) (Delagrange, P. (316) 195)

Enalapril
Cough reflex; Angiotensin-converting enzyme inhibitor; Moguisteine; Non-narcotic antitussive drug (Kamei, J. (312) 235)

Enalaprilat
Intestinal vascular bed; Angiotensin peptide; DuP532; PD123,319; Angiotensin II; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Enantioselectivity
Ca^{2+} current, L-type; Niguldipine; Whole-cell recording; Voltage dependence (Handrock, R. (309) 317)

β-Endorphin
Antinociception; Morphine; Pertussis toxin; G-protein (Tseng, L.F. (294) 345)

Morphine; SR 95531; 5-Aminovaleric acid; Tail-flick inhibition (Suh, H.-W. (307) 141)

Choline; ACTH (adrenocorticotrophin); Atropine; Mecamylamine; Hemicholinium-3 (Savci, V. (309) 275)

Dopamine; Placenta; Dynorphin; Perfusion; (Rat) (Stratakis, C.A. (315) 53)

β-Endorphin receptor
Morphine derivative; Metopon; Cinnamoylamino group; Analgesia; (Mouse) (McLaughlin, J.P. (294) 201)

Endothelial cell
Smooth muscle cell; Diabetes mellitus; Atherosclerosis; Aminoguanidine; Glutathione; Aldose-reductase (Graier, W.F. (294) 221)

ATP; Purinergic; Nucleotide; Purinoceptor (Motte, S. (307) 201)

Endothelial cell, aortic
Ca^{2+} concentration, intracellular, free; Na^+-Ca^{2+} exchange; Ca^{2+}-ATPase; Fura-2 (Goto, Y. (314) 185)

Endothelial cells
Butein; Anti-GBM nephritis; Intercellular adhesion molecules; Leukocyte, polymorphonuclear (Hayashi, K. (316) 297)

Endothelial injury
Tranilast; Photochemically induced thrombosis; Smooth muscle cell proliferation; Intimal thickening (Kikuchi, S. (295) 221)

Endothelial modulation
Resistance artery, small; Hyperthyroidism; Thromboxane A_2 receptor agonist; 5-HT (5-hydroxytryptamine, serotonin) (Zwaveling, J. (300) 91)

Endothelin
Diabetes; Hindquarters; Arachidonic acid; 5-HT (5-hydroxytryptamine, serotonin); Thromboxane (James, G.M. (294) 109)

Endothelin receptor; Protein kinase C; Ca^{2+} sensitization; Smooth muscle, vascular (Sudjarwo, S.A. (294) 261)

Cyclosporine A; Nephrotoxicity; Renal failure (Brooks, D.P. (294) 571)

Methoxamine; α_1-Adrenoceptor; Positive inotropic effect; Ventricular myocardium, rabbit (Yang, H.-T. (296) 47)

Phosphoinositide turnover; Protein kinase A; C_6 glioma cell; (ATP) (Lin, W.W. (296) 231)

Trachea; Smooth muscle relaxation; Charybdotoxin; Nitric oxide (NO); (Guinea-pig) (Hadj-Kaddour, K. (298) 145)

Endothelin receptor; BQ123; BQ788; Autoradiography (Tayag, E.C. (300) 261)

Myocardium, stunned; TAK-044; (Dog) (Kitayoshi, T. (305) 137)

Penile erection; Corpus cavernosum; Nitric oxide (NO); (Rat) (Ari, G. (307) 69)

Middle cerebral artery occlusion; Focal ischemia (McAuley, M.A. (307) 171)

Endothelin ET_A receptor antagonist; FR139317; Neointimal thickening; (Rat) (Takiguchi, Y. (309) 59)

Intestinal inflammation; Inflammatory bowel disease; Bosentan (Hogaboam, C.M. (309) 261)

Sarafotoxin; Big endothelin-1; Inositol phosphate; Spinal cord; Endothelin ET_A receptor (Poulat, P. (315) 327)

Endothelin-1
17β-Estradiol; Estrogen; Vascular smooth muscle; Ca^{2+} current, L-type, voltage-dependent; Vasopressin; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Angiotensin II; Atherosclerosis; Cell cycle progression; Ca^{2+}, cytosolic; Primary culture (Jahan, H. (295) 261)

Heart, perfused, rat; TAK-044; BQ-123; Endothelin ET_A receptor; Endothelin ET_B receptor (Kusumoto, K. (296) 65)

Spider venom; Ca^{2+} channel blocker; K^+ channel blocker; Nitric oxide (NO); Hoe 140 (Costa, S.K.P. (298) 113)

Proteoglycan; Fibronectin; Collagen (Gutierrez, S. (302) 191)

Norepinephrine; Resistance artery; Conduit artery; (Human) (Miyauchi, T. (303) 193)

Endothelin receptor antagonist; Endothelin receptor subtype; Bronchus, human; Trachea, guinea-pig; Ro 47-0203; BQ123; Sarafotoxin S6c (Gater, P.R. (304) 123)

BQ-123; BQ-3020; Endothelin receptor; Cerebral circulation; Resistance arteriole, cerebral (Patel, T.R. (307) 41)

Ventricular cardiomyocyte; Ca^{2+} current (Kelso, E. (308) 351)

Endothelin ET_A receptor; Adrenergic nerve stimulation; Prejunctional inhibition; Postjunctional potentiation; Mesenteric artery (Zhang, J.-X. (311) 169)

Cardiac myocyte, cultured; Cardiac contractility; ANP (atrial natriuretic peptide), chicken; ChNP (chicken natriuretic peptide) mRNA (Bézie, Y. (311) 241)

Superior colliculus; Blood pressure; Renal blood flow (D'Amico, M. (316) 245)

Endothelin-3
Platelet; Sodium nitroprusside; cGMP; Phosphodiesterase inhibitor; Ca^{2+}, cytosolic; Ca^{2+} pump (Gagnet, C. (310) 67)

Endothelin receptor
Endothelin; Protein kinase C; Ca^{2+} sensitization; Smooth muscle, vascular (Sudjarwo, S.A. (294) 261)

Endothelin; BQ123; BQ788; Autoradiography (Tayag, E.C. (300) 261)

Endothelin-1; BQ-123; BQ-3020; Cerebral circulation; Resistance arteriole, cerebral (Patel, T.R. (307) 41)

Diabetes; Prostate; (Rat) (Saito, M. (310) 197)

Endothelin ET_A receptor
Pial vein; Endothelin ET_B receptor; IRL 1620; (Dog) (Fernández, N. (294) 483)

Endothelin-1; Heart, perfused, rat; TAK-044; BQ-123; Endothelin ET_B receptor (Kusumoto, K. (296) 65)

Endothelin-1; Adrenergic nerve stimulation; Prejunctional inhibition; Postjunctional potentiation; Mesenteric artery (Zhang, J.-X. (311) 169)

Coronary circulation; Endothelin ET_B receptor; IRL 1620; BQ-123; Nitric oxide (NO) (García, J.L. (315) 179)

Endothelin; Sarafotoxin; Big endothelin-1; Inositol phosphate; Spinal cord (Poulat, P. (315) 327)

Endothelin ET_A receptor antagonist
Endothelin; FR139317; Neointimal thickening; (Rat) (Takiguchi, Y. (309) 59)

Endothelin ET_B receptor
Pial vein; Endothelin ET_A receptor; IRL 1620; (Dog) (Fernández, N. (294) 483)

IRL 1720; Sarafotoxin S6c; FR139317; Hemodynamics (Kuwahara, M. (296) 55)

Endothelin-1; Heart, perfused, rat; TAK-044; BQ-123; Endothelin ET_A receptor (Kusumoto, K. (296) 65)

Coronary circulation; Endothelin ET_A receptor; IRL 1620; BQ-123; Nitric oxide (NO) (García, J.L. (315) 179)

Endothelin receptor antagonist
Renal blood flow; Hypertension (Bird, J.E. (294) 183)

Endothelin receptor subtype; Bronchus, human; Trachea, guinea-pig; Ro 47-0203; BQ123; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

Endothelin receptor subtype
Endothelin receptor antagonist; Bronchus, human; Trachea, guinea-pig; Ro 47-0203; BQ123; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

Endothelium
Nucleotide receptor; ATP receptor; UTP receptor; Aorta, rat; Smooth muscle, vascular (García-Velasco, G. (294) 521)

Intimal thickening; Vascular reactivity; Glucocorticoid; Nitric oxide (NO); Carotid artery, rabbit (Van Put, D.J.M. (294) 753)

Deferential artery, human; Vas deferens; Vasopressin; Nitric oxide (NO) (Medina, P. (300) 221)

Taurine; Hypercholesterolemia; Diabetes; LDL (low-density lipoprotein); Cholesterol (Kamata, K. (303) 47)

Acetylcholine; Nitric oxide (NO); Hind limb, rat; EDHF (endothelium-derived hyperpolarizing factor) (Brouwers-Ceiler, D.L. (307) 65)

Albumin transfer; Hydrogen peroxide; Sodium nitroprusside; Glyceryl trinitrate (McQuaid, K.E. (307) 233)

PAF (platelet-activating factor); Vasomotor tone; Arterial pressure; Blood flow; Noradrenaline; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

Balloon angioplasty; Neointima; Restenosis; Nitric oxide (NO); Nitric oxide (NO) synthase; Von Willebrand factor (Bosmans, J.M. (310) 163)

N^G-Nitro-L-arginine; Methylene blue; Nitric oxide (NO); Hypertension; Aorta, rat; Arterial pressure (Gil-Longo, J. (310) 175)

Cholesterol-feeding; P_{2X} purinoceptor; Mesenteric arterial bed, rat; Sympathetic neurotransmission; Donryu rat (Ralevic, V. (313) 221)

Cell activation; Hypoxia; Neutrophil adherence; Aescine; Reparil (Arnould, T. (315) 227)

Endothelium-dependent relaxation
Dahl salt-sensitive rat; High-cholesterol diet; Hypercholesterolemia; Hypertension (Kitagawa, S. (297) 71)

Reactive oxygen species; Electrolysis; L-Arginine; Aorta (Gumusel, B. (306) 107)

Subarachnoid hemorrhage; Lipid peroxidation; AJ-3941; Nimodipine; Ca^{2+} channel antagonist (Minato, H. (315) 297)

Endotoxin
Septic shock; DNA fragmentation; K^+ channel; Systemic inflammatory response syndrome; Cerebral malaria (Gantner, F. (294) 353)

Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Multiple organ dysfunction syndrome; Liver failure (Wu, C.-C. (300) 99)

Nitric oxide (NO) synthase; mRNA; Septic shock; Plasma nitrate; Heart, rat (Bateson, A.N. (303) 141)

Nitric oxide (NO) synthase, inducible; Ethanol; Blood-brain barrier; RBE4 cell; Inflammation; Nitric oxide (NO) (Naassila, M. (313) 273)

Platelet aggregation; Adenine nucleotide; PAF (platelet-activating factor) (Jarvis, G.E. (315) 203)

Superoxide; Mitochondrial respiration; Shock; Inflammation; Nitric oxide (NO) (Szabó, C. (315) 221)

Endotoxin tolerance
Lipopolysaccharide; Vascular permeability; Cytokine; Adrenalectomy; Nitric oxide (NO) (Fujii, E. (313) 129)

Energetic metabolism
Cannabinoid; CP-55,940; Tolerance; Biotransformation (Costa, B. (313) 17)

Enkephalin
L-Ornithine; L-Arginine; Kyotorphin; Pain; Antinociception (Kawabata, A. (296) 23)

Haloperidol; Aminopeptidase N; Neuroleptic; Neuropeptide (Konkoy, C.S. (297) 47)

Cocaine; δ-Opioid receptor; Naltrindole; Sensitization (Heidbreder, C. (298) 207)

Dopamine; Ethanol drinking; (Inbred mouse) (Ng, G.Y.K. (311) 45)

Methylnaloxonium; RB 101; Antinociception; Amygdala; Thalamus, ventro-basal; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

[^{3}H][D-Pen^2,D-Pen^5]Enkephalin
δ-Opioid receptor, agonist, antagonist; δ_1-Opioid receptor; δ_2-Opioid receptor; Antinociception (Bhargava, H.N. (311) 127)

[Met^5]Enkephalin
Opioid receptor; δ-Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; Hypothalamus; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Enprofylline
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; 3-Isobutyl-methylxanthine; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Enteric nerve
5-HT$_3$ receptor; 5-HT$_4$ receptor; Tachykinin; Colon, guinea-pig; Tetrodotoxin (Briejer, M.R. (308) 173)

Enteric nervous system
Gastrointestinal tract; Intestine; Ganglion; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Intestine; Ganglion; Myenteric plexus; Histamine; cAMP; Adenylate cyclase (Xia, Y. (316) 81)

Enteric neuron
Melatonin; Nicotinic channel; Cholinergic transmission; Synaptic modulation; Submucosal neuron; Nerve terminal (Barajas-López, C. (312) 319)

Enthalpy
Nicotinic receptor; Thermodynamics; *d*-Tubocurarine; Skeletal muscle; Entropy (Banerjee, B. (310) 13)

Entorhinal cortex lesion
Radial maze learning; NMDA receptor antagonist; Chronic infusion; Memantine; (+)-MK-801; (Rat) (Zajaczkowski, W. (296) 239)

Entrainment
Melatonin; Suprachiasmatic nucleus; Intergeniculate leaflet; Electrophysiology; Light; Circadian rhythm (Ying, S.-W. (296) 33)

Entropy
Nicotinic receptor; Thermodynamics; *d*-Tubocurarine; Skeletal muscle; Enthalpy (Banerjee, B. (310) 13)

Enzyme
Nodose ganglion; Guanylate cyclase; Electrophysiology; mRNA; Nitric oxide (NO) (Lawrence, A.J. (315) 127)

Enzyme affinity
Choline acetyltransferase; Ethanol; Dexamethasone; Acetyl coenzyme A; Stress (Wattanathorn, J. (313) 69)

Eosinophil chemotaxis
N^{ω}-Nitro-L-arginine methyl ester; Nitric oxide (NO); Pleurisy; cGMP (Ferreira, H.H.A. (310) 201)

Epibatidine
Nicotine; Antinociception; Tolerance; (Mouse) (Damaj, M.I. (300) 51)

Epilepsy
2,3-Benzodiazepine; GYKI 52466; Aniracetam; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anticonvulsant drug; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

Nitric oxide (NO); 7-Nitroindazole; Harmaline; NMDA (*N*-methyl-D-aspartate); Parkinsonism (Eblen, F. (299) 9)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; GABA (γ-aminobutyric acid); Anticonvulsant (Löscher, W. (299) 61)

GABA (γ-aminobutyric acid); Hippocampus; Neuroprotection; Perforant pathway stimulation (Halonen, T. (299) 69)

NNC 14-0185; NNC 14-0189; Benzodiazepine receptor; Seizure threshold (Jackson, H.C. (308) 21)

Kava pyrone; *Piper methysticum*; Na^+ channel; Synaptosome (Gleitz, J. (315) 83)

Felbamate; 5,7-Dichlorokynurenic acid; Glutamate; Cortical slice (Srinivasan, J. (315) 285)

Anti-epileptic drugs; Midbrain; GABA (γ-aminobutyric acid) (Bloms-Funke, P. (316) 211)

Epithelial cells
Arachidonic acid; Cell cycle; Cell proliferation; TGF-β1 (transforming growth factor β1) (Kozubík, A. (316) 349)

Epithelium
Neutral endopeptidase; Acetylcholine; Trachea; Cholinergic neurotransmission; (Rabbit) (Loenders, B. (296) 89)

EGF (epidermal growth factor); Mucosal protection; Tissue resistance; Receptor (Rao, R. (303) 209)

Ergot alkaloid
Trigeminal; Middle meningeal artery; Sumatriptan; Migraine (Lambert, G. (311) 141)

Ergotamine
Alniditan; Sumatriptan; Carotid arterial resistance (Van de Water, A. (299) 127)

Erythrocyte
K^+ channel; Clotrimazole; Efaroxan; Imidazoline binding site (Coupry, I. (295) 109)

***Escherichia coli* enterotoxin-induced secretion**
Intestinal fluid transport; K^+ channels; Prostaglandin E_2; Nitric oxide (NO); N^{ω}-nitro-L-arginine methyl ester (L-NAME) (Schirgi-Degen, A. (316) 257)

Esophageal muscularis mucosae
Muscarinic receptor; Receptor alkylation (Watson, N. (294) 779)

ESR (electron spin resonance)
Cerebral ischemia/reperfusion; Spin trapping; Antioxidant; Free radical scavenger (Cowley, D.J. (298) 227)

Estradiol
Mitogen-activated protein kinase; Smooth muscle, uterine; Steroid; Progesterone (Ruzycky, A.L. (300) 247)

Protein kinase C; Smooth muscle, uterine; Cardiac muscle; Steroid; Progesterone (Ruzycky, A.L. (313) 257)

17β-Estradiol
Estrogen; Vascular smooth muscle; Ca^{2+} current, L-type, voltage-dependent; Endothelin-1; Vasopressin; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Estrogen
17β-Estradiol; Vascular smooth muscle; Ca^{2+} current, L-type, voltage-dependent; Endothelin-1; Vasopressin; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Vascular endothelium; Norepinephrine (McNeill, A.M. (308) 305)

Male pheromone; Glutamic acid decarboxylase; Olfactory bulb; Ovariectomy; Progesterone; (Rat) (Navarro Becerra, N. (312) 83)

Estrous cycle
α_1-Adrenoceptor; Uterine artery; Pregnancy (Nair, R. (312) 45)

Ethacrynic acid
GABA (γ-aminobutyric acid); Cortical neuron; Ca^{2+} influx; Cl^- transport system; Furosemide (Takebayashi, M. (297) 137)

Ethanol
RO15-4513; $GABA_A$/benzodiazepine receptor complex; Ethanol dependence/withdrawal (Becker, H.C. (296) 43)

Dopamine receptor agonist; Dependence; Partial receptor agonist (Bono, G. (296) 233)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

Acamprosate; Drug discrimination; NMDA receptor antagonist; (Rat) (Spanagel, R. (305) 51)

IGF-I (insulin-like growth factor I); IGF binding protein 1; Ataxia; Hypothermia; Hypnosis; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

Ca^{2+} channel, L-type; Nimodipine; Substitution; Drug discrimination; Conditioned taste aversion (De Beun, R. (306) 5)

Discriminative stimulus; $5\text{-}HT_3$ receptor agonist; $5\text{-}HT_3$ receptor antagonist (Stefanski, R. (309) 141)

NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) propionic acid); AP-1 (activator protein-1) DNA binding; Transcription factor; Granule cell, cerebellar (Hou, Y.-N. (309) 307)

Choline acetyltransferase; Dexamethasone; Acetyl coenzyme A; Enzyme affinity; Stress (Wattanathorn, J. (313) 69)

Monosialoganglioside; Sensitization; Locomotor activity (Bellot, R.G. (313) 175)

Nitric oxide (NO) synthase, inducible; Blood-brain barrier; RBE4 cell; Inflammation; Endotoxin; Nitric oxide (NO) (Naassila, M. (313) 273)

Dopamine; Nicotine; Nicotinic acetylcholine receptor; Preference; Sensitization; (Rat) (Blomqvist, O. (314) 257)

NMDA receptor antagonist; Drug discrimination; (Rat) (Bienkowski, P. (314) 277)

Nucleus accumbens; Dopamine; Microdialysis; Tolerance; Animal model (Nurmi, M. (315) 277)

Hypertension; BNP (brain natriuretic peptide) (Guillaume, P. (316) 49)

Ethanol, chronic
Spontaneously hypertensive rat (SHR); Hypertension; Papillary muscle (Brown, R.A. (302) 61)

Ethanol dependence / withdrawal
Ethanol; RO15-4513; $GABA_A$/benzodiazepine receptor complex (Becker, H.C. (296) 43)

Ethanol drinking
Enkephalin; Dopamine; (Inbred mouse) (Ng, G.Y.K. (311) 45)

Ethanol lesion
Morphine; Buprenorphine; Castor oil; Diarrhoea; Gastrointestinal transit (Bhounsule, S.A. (316) 253)

Ethanol tolerance
Arginine vasopressin; c-*fos*; Immediate early gene (Szabó, G. (306) 67)

Etomidate
GABA receptor antagonist; Bicuculline; SR95531; Pentobarbitone; Hippocampal neuron (Uchida, I. (307) 89)

Excitability
Lysophosphatidylcholine; Acylcarnitine; Fibrillation; Fatty acid; Antiarrhythmic (Kang, J.X. (297) 97)

Excitation-contraction coupling
Taurine depletion; Skeletal muscle; Mechanical threshold; Cl^- conductance; Ca^{2+} handling mechanism (De Luca, A. (296) 215)

Tremorgenic indole alkaloid; Ca^{2+}-activated K^+ channel; Charybdotoxin; Iberiotoxin (DeFarias, F.P. (314) 123)

Excitatory amino acid
NMDA receptor antagonist; AP-5 (DL-2-amino-5-phosphonovaleric acid); MK-801 ((+)-5-methyl-10,11-dihydro(*a,d*)-cyclohepten-5,10-imine hydrogen maleate salt); Dopamine; Locomotor activity (Ouagazzal, A. (294) 137)

Chronic citalopram; NMDA receptor; Adaptation; Cortex; Hippocampus (Nowak, G. (295) 75)

GABA (γ-aminobutyric acid); Seizure; Ischemia; Neurological disorder; Drug screening; Antiepileptic (Kanthasamy, A.G. (297) 219)

Metabotropic glutamate receptor; GTP hydrolysis; G-protein; Adenylyl cyclase; Cerebral cortex (Odagaki, Y. (300) 151)

Dextromethorphan; Opiate; Withdrawal; Naloxone (Rosen, M.I. (307) 251)

NMDA (*N*-methyl-D-aspartate); MK-801 binding; Spinal cord (Souverbie, F. (307) 347)

Excitatory amino acid neurotransmission
4-Aminopyridine; NMDA receptor antagonist; Seizure (Morales-Villagrán, A. (305) 87)

Excitatory amino acid receptor
Purinoceptor; Pyrimidinoceptor; Locus coeruleus; Extracellular recording (Fröhlich, R. (315) 255)

Excitatory neuropeptide
Achatin-I (Gly-D-Phe-Ala-Asp); Promethazine; Triprolidine; Histamine H_1 receptor antagonist; Blocking effect; Neuron; (Snail) (Salunga, T.L. (304) 163)

Excitatory synaptic transmission
5-HT (5-hydroxytryptamine, serotonin); 1-(2-Pyrimidinyl)piperazine; Hippocampus; Electrophysiology; 5-HT_{1A} receptor; Azapirone (Manahan-Vaughan, D. (294) 617)

Excitotoxicity
Growth factor; Cytokine; Neuroprotection (Prehn, J.H.M. (306) 81)

Metabotropic glutamate receptor; Cortical neuron (Bruno, V. (310) 61)

Cortical neuron; LY293558; NS-102; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionate); (*S*)-5-Fluorowillardiine (Larm, J.A. (314) 249)

Selegiline; Astrocyte, cultured; Hippocampal cell; Protection; Cerebral ischemia; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Exocytosis
Oxatomide; RBL-2H3 cell; Signal transduction; Protein tyrosine phosphorylation; Ca^{2+} flux; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

EXP3174
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Blood-brain barrier; Losartan; GR117289; LR-B/081 (Polidori, C. (307) 259)

Exploration
Myocardial infarction; Quality of life; Anxiety; Social behavior; (Rat) (Schoemaker, R.G. (298) 17)

Extracellular recording
Hippocampus; Dentate gyrus; Glutamate metabotropic receptor; Synaptic transmission; Electrophysiology, in vitro (Ugolini, A. (294) 403)

Desipramine; Maprotiline; Prefrontal cortex; Locus ceruleus; (Anesthetized rat) (Ceci, A. (312) 189)

Purinoceptor; Pyrimidinoceptor; Excitatory amino acid receptor; Locus coeruleus (Fröhlich, R. (315) 255)

Extracellular recording in vivo
Ventral tegmental area; OPC-14597; Whole-cell recording; Thin-slice preparation; Dopamine D_2 receptor (Momiyama, T. (310) 1)

Extrapyramidal disorder
Imidazoline I_2 receptor; Brain, human (Reynolds, G.P. (301) R19)

Extravasation
Sauvagine; Urotensin I; CRF (corticotropin-releasing factor) receptor; Inflammation; ACTH (adrenocorticotropin) (Turnbull, A.V. (303) 213)

Falipamil
Alinidine; Sinoatrial node; His bundle; Atrial myocardium; AV node; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Fananserin
RP 62203; Dopamine; Dopamine D_4 receptor; 5-HT_{2A} receptor; 5-HT (serotonin) (Heuillet, E. (314) 229)

Fatty acid
Lysophosphatidylcholine; Acylcarnitine; Fibrillation; Excitability; Antiarrhythmic (Kang, J.X. (297) 97)

***n*–3 Fatty acid**
Dietary fat; Arrhythmia; Blood pressure; Proteinuria; Thromboxane (McLennan, P. (300) 83)

cAMP; Adrenoceptor; Norepinephrine; Pinealocyte; (Rat) (Delton-Vandenbroucke, I. (312) 379)

Felbamate
Traumatic brain injury; Long-term potentiation; CA1; Hippocampus (Wallis, R.A. (294) 475)

5,7-Dichlorokynurenic acid; Glutamate; Epilepsy; Cortical slice (Srinivasan, J. (315) 285)

Na^+ channel, voltage-dependent; Anti-epileptic (Taglialatela, M. (316) 373)

Felodipine
Electroconvulsive shock; Amnesia; Nimodipine; Amlodipine; (Rat) (Župan, G. (310) 103)

Fenspiride
Lipopolysaccharide; TNF (tumor necrosis factor); Alveolar macrophage, guinea-pig; Phospholipase A_2 (De Castro, C.M.M.B. (294) 669)

Fentanyl
μ_1-Opioid receptor; Respiratory depression; Morphine; Muscle rigidity (Chen, S.-W. (312) 241)

Fenton
Tryptamine-4,5-dione; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Free radical (Chen, J.-C. (303) 109)

Fetal alcohol syndrome
Ca^{2+}, cytosolic, free; Digital image analysis (Altura, B.M. (314) R9)

Fever
CRF (corticotropin-releasing factor); Anxiety; Interleukin-1β; CRF receptor antagonist (Lundkvist, J. (309) 195)

Fibrillation
Lysophosphatidylcholine; Acylcarnitine; Fatty acid; Excitability; Antiarrhythmic (Kang, J.X. (297) 97)

Fibrinogen receptor antagonist
Triflavin; RGD (Arg-Gly-Asp)-containing peptide; Bleeding time; Mesenteric artery; Thrombosis (Sheu, J.-R. (294) 231)

Fibrinolysis
Urokinase variant; Thrombin inhibition; Platelet aggregation; Clot specificity; (Rabbit) (Schneider, J. (302) 69)

Fibroblast
Secretoneurin; Migration; Proliferation (Kähler, C.M. (304) 135)

Adenosine; Dopamine; Adenylyl cyclase; Receptor-receptor interaction (Dasgupta, S. (316) 325)

Fibroblast, rat-1
α-Adrenoceptor; Prostate; cDNA; Doxazosin; (Enantiomer) (Hatano, A. (313) 135)

Fibronectin
Endothelin-1; Proteoglycan; Collagen (Gutierrez, S. (302) 191)

FK409
FR144420; Nitric oxide (NO); Angina (Hirasawa, Y. (303) 55)

FK888
SR48968; Citric acid; Bronchoconstriction; Cough; Tachykinin (Yasumitsu, R. (300) 215)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Substance P; Neurokinin A; SR 48968; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Flavonoid
Apigenin; Monoamine oxidase; Noradrenaline uptake (Lorenzo, P.S. (312) 203)

Flesinoxan
Occasion setting; Pavlovian conditioning; Conditioned immobility; Midazolam; Amphetamine (Maes, J.H.R. (309) 131)

Haloperidol; Clozapine; BMY 14802; BMS-181100; Methylphenidate; Buspirone; S 14506; Gnawing; $5\text{-}HT_{1A}$ receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Flow
Mesenteric vascular bed; Nitric oxide (NO); Spontaneously hypertensive rat (SHR) (Kusayama, T. (312) 301)

Flow cytometry
Intravital microscopy; Blood pressure, mean arterial; Leukocyte rolling; Leukocyte adherence; Venular shear rate (Scalia, R. (296) 181)

[^{11}C]Flumazenil
PET (positron emission tomography); Imidazopyridine; Benzodiazepine receptor, central (Abadie, P. (295) 35)

Flunarizine
Myocyte, ventricular; Ca^{2+} channel (Tytgat, J. (296) 189)

NMDA receptor antagonist; CGP 40116; CGP 43487; Ca^{2+} channel inhibitor; Nicardipine; Nifedipine; Seizure (Gasior, M. (312) 27)

Flunitrazepam
$GABA_A$ receptor; Benzodiazepine; Ro 15-4513; Hydroxylamine (Duncalfe, L.L. (298) 313)

[^{3}H]Flunitrazepam
$GABA_A$ receptor, recombinant; [^{3}H]Muscimol; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

Fluo-3
Adenosine; Ca^{2+}, cytosolic; Ca^{2+} domain; Cardioprotection; Heart (Jovanovic, A. (298) 63)

ATP-sensitive K^+ channel; Ca^{2+}, intracellular; Chemical hypoxia; Dinitrophenol; Cardiac cell; Glyburide (Brady, P.A. (308) 343)

Fluorescence polarization
Azithromycin; Phospholipid; NMR spectroscopy, ^{31}P; Conformational analysis; Gentamicin (Montenez, J.-P. (314) 215)

Fluoxetine
Hypophagia; $5\text{-}HT_{2C}$ receptor; (Rat); (Pig) (Lightowler, S. (296) 137)

Seizure; 5-HT (5-hydroxytryptamine, serotonin); Genetically epilepsy-prone rat; Substantia nigra (Statnick, M. (299) 93)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Imipramine; Motion sickness (Okada, F. (309) 33)

Neuroendocrine challenge; 5-HT (5-hydroxytryptamine, serotonin) (McCann, U.D. (312) R1)

***cis*-Flupenthixol**
Glutamate; Turning; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Smith, I.D. (301) 7)

Fluphenazine
Microdialysis; Caudate putamen; Nucleus accumbens; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (308) 279)

Flupirtine
Focal cerebral ischemia; Primary neuronal culture; Glutamate; Ca^{2+}, cytosolic; Fura-2 (Rupalla, K. (294) 469)

Flurazepam
Propofol; Benzodiazepine; $GABA_A$ receptor; Anesthesia; *Xenopus* oocyte (Reynolds, J.N. (314) 151)

Flurbinitroxybutylester
Prostaglandin endoperoxide synthase; Blood monocyte, human; Platelet, human; Flurbiprofen (Santini, G. (316) 65)

Flurbiprofen
Prostaglandin endoperoxide synthase; Blood monocyte, human; Platelet, human; Flurbinitroxybutylester (Santini, G. (316) 65)

Flurothyl
Toluene; 1,1,1-Trichloroethane; Methoxyflurane; Anxiolytic; Plus-maze; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

Focal cerebral ischemia
Flupirtine; Primary neuronal culture; Glutamate; Ca^{2+}, cytosolic; Fura-2 (Rupalla, K. (294) 469)

Focal ischemia
Endothelin; Middle cerebral artery occlusion (McAuley, M.A. (307) 171)

Food intake
Alcohol drinking; δ-Opioid receptor; μ-Opioid receptor; Reinforcement; (Selected rat line) (Honkanen, A. (304) 7)

Appetite; Drinking; Isatin; Motivation; 5-HT (5-hydroxytryptamine, serotonin); Tubulin; (Mouse) (Morley, J.E. (305) 23)

Anorexia; Aging; Hypothalamus; Nitric oxide (NO) synthase; Nitric oxide (NO) (Morley, J.E. (311) 15)

2-Deoxy-D-glucose; $5\text{-}HT_{2A}$ receptor, peripheral; $5\text{-}HT_3$ receptor, peripheral; α-Methyl-5-HT (α-methyl-5-hydroxytryptamine); 2-Methyl-5-HT (2-methyl-5-hydroxytryptamine) (Sugimoto, Y. (316) 15)

$5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME) (Yamada, J. (316) 23)

Forced swimming test
L-*N*-Arginine methyl ester (L-NAME); Nitric oxide (NO); Adrenalectomy; Glucocorticoid (Jefferys, D. (295) 131)

σ_1 Receptor agonist; Antidepressive effect; SA4503; (Mouse) (Matsuno, K. (312) 267)

Forced swim test
Stress; 5-HT_2 receptor; Wet-dog shake; β-Adrenoceptor (Takao, K. (294) 721)

Immobility behaviour; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Forebrain
5-HT_{1A} receptor; Blood pressure; Heart rate; Preoptic area; 8-OH-DPAT (*R*-(+)-8-hydroxy-2-(di-*n*-propylamino) tetralin) (Szabó, A. (315) 187)

Formaldehyde
Bradykinin receptor; CP-99,994; Mast cell; Tachykinin receptor; Vascular permeability (Ito, K. (307) 291)

Formalin
Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Formalin test
α-Trinositol; Antinociception; Intrathecal; Behavior; (Rat) (Malmberg, A.B. (294) 609)

Caffeine; Stimulus intensity; 8-Cyclopentyltheophylline; 3,7-Dimethyl-1-propargylxanthine (Sawynok, J. (298) 105)

Pain; Inflammation; Adrenoceptor agonist; Adrenoceptor antagonist (Hong, Y. (301) 41)

Dynorphin A; Dynorphin B; Dynorphin-converting enzyme; Intrathecal administration; Peptidohydrolase; (Mouse) (Tan-No, K. (314) 61)

Formalin paw test
Conditioned place preference; Tail-flick test; Charcoal meal (Singh, L. (307) 283)

***N*-Formyl-Met-Leu-Phe**
tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone); Phorbol ester; Superoxide anion; Ca^{2+}; BAPTA/AM (*O,O'*-bis(2-aminophenyl)ethylen-eglycol-*N,N,N',N'*-tetraacetic acid, tetraacetoxymethyl ester) (Tsukii, K. (298) 87)

Forskolin
Glutamate receptor, metabotropic; cAMP; Adenosine deaminase; VIP (vasoactive intestinal peptide); NECA (5'-*N*-ethylcarboxamidoadenosine); Hippocampus (Wright, R.A. (297) 275)

1,9-Dideoxyforskolin; Ca^{2+} current; Ryanodine store; Action potential; Cerebellar granule cell (Zerr, P. (303) 101)

Fos-protein
Haloperidol; Clozapine; Cross-tolerance; Nucleus accumbens; Septum, lateral (Sebens, J.B. (315) 269)

FR139317
IRL 1720; Sarafotoxin S6c; Endothelin ET_B receptor; Hemodynamics (Kuwahara, M. (296) 55)

Endothelin; Endothelin ET_A receptor antagonist; Neointimal thickening; (Rat) (Takiguchi, Y. (309) 59)

FR144420
FK409; Nitric oxide (NO); Angina (Hirasawa, Y. (303) 55)

Free radical
α-Tocopherol analog (water-soluble); Neuroprotection; Lipid peroxidation; Antioxidant; Vitamin E; Malondialdehyde; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

Catecholamine absorbing protein; Central nervous system; Oxidation; Dopamine; Neurodegeneration; Parkinson's disease (Modi, P.I. (299) 213)

Tryptamine-4,5-dione; 5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Fenton (Chen, J.-C. (303) 109)

Apomorphine; Lipid peroxidation; Protein carbonyl; Iron; Ascorbate; Thiobarbituric acid (Gassen, M. (308) 219)

Hydrogen peroxide; Non-steroidal anti-inflammatory drug; Horseradish peroxidase; Glutathione peroxidase; Scavenging (Parij, N. (311) 259)

Cartilage; Chondrocyte; Nitric oxide (NO) synthase, inducible; Arthritis (Jang, D. (312) 341)

Free radical scavenger
Cerebral ischemia/reperfusion; Spin trapping; ESR (electron spin resonance); Antioxidant (Cowley, D.J. (298) 227)

Freezing behavior
Anxiety; Conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; Citalopram (Inoue, T. (311) 1)

FRG-8813
Histamine H_2 receptor antagonist; Gastric mucin biosynthesis; Organ culture; (Rat) (Ichikawa, T. (297) 87)

Frontal cortex
α_2-Adrenoceptor subtype; Brain, human; RX 821002; Autoradiography; Hippocampus (Grijalba, B. (310) 83)

Functional experiment
α_1-Adrenoceptor, subtypes A and B; Risperidone (Eltze, M. (295) 69)

Functional partial agonism
Muscarinic acetylcholine receptor; Cloned human receptor; Receptor selection and amplification technology; Functional receptor selectivity (Bräuner-Osborne, H. (313) 145)

Functional receptor selectivity
Muscarinic acetylcholine receptor; Cloned human receptor; Receptor selection and amplification technology; Functional partial agonism (Bräuner-Osborne, H. (313) 145)

Fura-2
Flupirtine; Focal cerebral ischemia; Primary neuronal culture; Glutamate; Ca^{2+}, cytosolic (Rupalla, K. (294) 469)

Ca^{2+}; Cytosolic; Parietal cell, rabbit; Elutriation; CCK_B/gastrin receptor antagonist (Letari, O. (306) 325)

Endothelial cell, aortic; Ca^{2+} concentration, intracellular, free; Na^+-Ca^{2+} exchange; Ca^{2+}-ATPase (Goto, Y. (314) 185)

Furosemide
GABA (γ-aminobutyric acid); Cortical neuron; Ca^{2+} influx; Cl^- transport system; Ethacrynic acid (Takebayashi, M. (297) 137)

Fusion protein
β_1-Adrenoceptor; β_2-Adrenoceptor; Antibody (Jahns, R. (316) 111)

$GABA_A$/benzodiazepine receptor complex
Ethanol; RO15-4513; Ethanol dependence/withdrawal (Becker, H.C. (296) 43)

GABA (γ-aminobutyric acid)
Cortical neuron; Ca^{2+} influx; Cl^- transport system; Furosemide; Ethacrynic acid (Takebayashi, M. (297) 137)

Excitatory amino acid; Seizure; Ischemia; Neurological disorder; Drug screening; Antiepileptic (Kanthasamy, A.G. (297) 219)

Epilepsy; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline; Anticonvulsant (Löscher, W. (299) 61)

Epilepsy; Hippocampus; Neuroprotection; Perforant pathway stimulation (Halonen, T. (299) 69)

Dopamine release; Modafinil; Microdialysis; Nucleus accumbens (Ferraro, L. (306) 33)

Fluphenazine; Microdialysis; Caudate putamen; Nucleus accumbens; Glutamate (See, R.E. (308) 279)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{2A}$ receptor; Hallucinogen; Ketanserin (Cozzi, N.V. (309) 25)

Substantia nigra; Seizure; $GABA_A$ receptor; Development; (Rat) (Velíšková, J. (309) 167)

Defense area; Perifornical area; Glutamate; Nucleus tractus solitarii (Varga, K. (310) 145)

GABA (γ-aminobutyric acid) release
Nitric oxide (NO); Peroxynitrite; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)

GABA (γ-aminobutyric acid) transport
Tetrahydrocannabinol; Pallidal slice; SR 141716A (Maneuf, Y.P. (308) 161)

GABA receptor
Medial vestibular nucleus; Benzodiazepine tolerance; Isoguvacine (Hutchinson, M.A. (301) 83)

GABA receptor antagonist
Bicuculline; SR95531; Pentobarbitone; Etomidate; Hippocampal neuron (Uchida, I. (307) 89)

$GABA_A$ receptor
Pentobarbital; Benzodiazepine binding; Drug tolerance; Substance dependence (Suzuki, T. (295) 169)

Benzodiazepine; Flunitrazepam; Ro 15-4513; Hydroxylamine (Duncalfe, L.L. (298) 313)

Loreclezole; Neuroactive steroid; Benzodiazepine receptor (Xue, B.G. (300) 125)

SR 95531; Neuroactive steroid; Neurosteroid; RU 5135; Pregnenolone sulfate; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

γ_2 Subunit; Antisense oligodeoxynucleotide; Methyl-β-carboline-3-carboxylate; Strychnine; Picrotoxin; Convulsion (Zhao, T.-j. (306) 61)

Individual difference; Novelty; Psychostimulant; Cortex; Locomotion; Basal ganglia (Gruen, R.J. (309) 115)

Substantia nigra; Seizure; GABA (γ-aminobutyric acid); Development; (Rat) (Velíšková, J. (309) 167)

$GABA_A$ receptor subunit; Heterogeneity; Cerebellum; Thalamus; Diazepam-insensitive (Huh, K.-H. (310) 225)

Propofol; Benzodiazepine; Flurazepam; Anesthesia; *Xenopus* oocyte (Reynolds, J.N. (314) 151)

Clozapine; Clozapine metabolite; GABA (γ-aminobutyric acid) (Wong, G. (314) 319)

$GABA_A$ receptor, recombinant
[^{3}H]Flunitrazepam; [^{3}H]Muscimol; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

$GABA_A$ receptor subtype, recombinant, α4β3γ2S, α4γ2S, α1β3γ2S
Benzodiazepine binding site property (Scholze, P. (304) 155)

$GABA_A$ receptor subunit
$GABA_A$ receptor; Heterogeneity; Cerebellum; Thalamus; Diazepam-insensitive (Huh, K.-H. (310) 225)

$GABA_B$ receptor
(−)-Baclofen; 3-Amino-propylphosphinic acid; Phaclofen; CGP 35348; 2-Hydroxy-saclofen; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

Baclofen; AHPNs ((*R,S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide); $GABA_B$ receptor antagonist; Ileum, guinea-pig; Neocortex, rat (Kerr, D.I.B. (294) 349)

Capsaicin treatment, neonatal; Superfusion; Autoradiography; Substance P; Glutamate receptor (Teoh, H. (302) 27)

(*R,S*)-Baclofen; (*R*)-Saclofen (Kerr, D.I.B. (308) R1)

Morphine; Ventral tegmental area; Reward; Place conditioning (Tsuji, M. (313) 169)

$GABA_B$ receptor antagonist
$GABA_B$ receptor; Baclofen; AHPNs ((*R,S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide); Ileum, guinea-pig; Neocortex, rat (Kerr, D.I.B. (294) 349)

Galactosemia
Polyol pathway; Diabetes; Nerve conduction; Nerve regeneration; Oxygen free radical; Antioxidant; Metal chelator (Love, A. (314) 33)

Gallbladder
CCK_A receptor; Pancreas; Amylase release; Gallbladder contraction; T-0632 (Taniguchi, H. (304) 147)

Gallbladder contraction
CCK_A receptor; Pancreas; Gallbladder; Amylase release; T-0632 (Taniguchi, H. (304) 147)

CCK_A receptor; Pancreatic secretion; Gastric emptying; T-0632 (Taniguchi, H. (312) 227)

Ganglion
Gastrointestinal tract; Intestine; Enteric nervous system; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Intestine; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase (Xia, Y. (316) 81)

Gap junction
Cell-to-cell conductance; Dye diffusion; Trophoblast differentiation, human; Ca^{2+}, intracellular; Patch clamp, dual (Hervé, J.-C. (313) 243)

Gap junctional intercellular communication
Atherosclerosis; Cell proliferation; Cytokine; Growth factor; Smooth muscle cell (Mensink, A. (310) 73)

Gastric acid secretion
$GABA_B$ receptor; (−)-Baclofen; 3-Amino-propylphosphinic acid; Phaclofen; CGP 35348; 2-Hydroxy-saclofen; Gastric pepsinogen secretion (Blandizzi, C. (294) 191)

Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; SMS 201-995; Somatostatin receptor subtype; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Gastric emptying
CCK (cholecystokinin); Caerulein; Camostate; CCK receptor antagonist (Varga, G. (306) 153)

CCK_A receptor; Pancreatic secretion; Gallbladder contraction; T-0632 (Taniguchi, H. (312) 227)

Adrenomedullin; Amylin; Lactate; Calcium; CGRP (calcitonin gene-related peptide); (Rat) (Vine, W. (314) 115)

Gastric gland
[^{14}C]Aminopyrine accumulation; CCK-8; [Leu^{11}]Gastrin-(5–17); CCK receptor antagonist (Oiry, C. (294) 511)

Gastric hemodynamics
Stomach; Angiotensin II; Pentagastrin; Angiotensin AT_1 receptor; Renin-angiotensin system (Chow, L. (294) 309)

Gastric lesion, ethanol-induced
Benzodiazepine; Unilateral vagotomy; (Rat) (Khadour, F. (298) 271)

Gastric mucin biosynthesis
FRG-8813; Histamine H_2 receptor antagonist; Organ culture; (Rat) (Ichikawa, T. (297) 87)

Gastric mucosa
P_{2Y} purinoceptor; ATP; Plasma membrane (Vallejo, A.I. (312) 209)

Gastric mucosal acute injury
IT-066; Ischemia-reperfusion injury; Histamine H_2 receptor antagonist; Superoxide radical; Hydroxyl radical (Naito, Y. (294) 47)

Gastric mucosal injury
Cystathionine; Ischemia-reperfusion; Superoxide radical; (Rat) (Wada, K. (294) 377)

Gastric pepsinogen secretion
$GABA_B$ receptor; (−)-Baclofen; 3-Amino-propylphosphinic acid; Phaclofen; CGP 35348; 2-Hydroxy-saclofen; Gastric acid secretion (Blandizzi, C. (294) 191)

[Leu^{11}]Gastrin-(5–17)
[^{14}C]Aminopyrine accumulation; CCK-8; CCK receptor antagonist; Gastric gland (Oiry, C. (294) 511)

Gastrin-releasing peptide
Neuromedin B; Bombesin; Structure-function study (Lin, J.-T. (294) 55)

Gastrointestinal epithelia
Neuropeptide Y; BIBP3226; Y_1 receptor antagonist (Tough, I.R. (310) 55)

Gastrointestinal microcirculation
Laser Doppler; Capsaicin; Resiniferatoxin (Abdel Salam, O.M.E. (305) 127)

Gastrointestinal motility
Gastrointestinal tract; Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Submucous plexus; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Gastrointestinal tract
Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Gastrointestinal transit
Morphine; Buprenorphine; Castor oil; Diarrhoea; Ethanol lesion (Bhounsule, S.A. (316) 253)

[^{3}H]GBR 12935 binding
Dopamine transporter; L-DOPA; Reserpine; Amantadine; Benztropine (Gordon, I. (298) 27)

Gene expression
Neuroactive steroid; Neurosteroid; Progesterone receptor (Rupprecht, R. (303) 227)

Generalised seizure
Anticonvulsant; Amino acid; Microdialysis (Rowley, H.L. (294) 541)

Genetically epilepsy-prone rat
Seizure; 5-HT (5-hydroxytryptamine, serotonin); Fluoxetine; Substantia nigra (Statnick, M. (299) 93)

Genetically obese rodent
M16209; Insulin resistance; Hyperinsulinemic euglycemic clamp; Antihyperglycemic effect (Murakami, N. (304) 129)

Genistein
Colon, rat; Cl^- channel; K^+ channel; Ca^{2+}; Protein tyrosine kinase (Diener, M. (299) 161)

Hyperosmolarity; Protein kinase C; Staurosporine; Uterus, rat (Ausina, P. (312) 309)

Gentamicin
Azithromycin; Macrolide; Aaminoglycoside; Lysosomal phospholipase; Phospholipidosis; Membrane aggregation (Van Bambeke, F. (314) 203)

Azithromycin; Phospholipid; Fluorescence polarization; NMR spectroscopy, ^{31}P; Conformational analysis (Montenez, J.-P. (314) 215)

GF 109203X
(2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)maleimide)
Iris dilator, rabbit; Phorbol 12,13-dibutyrate (PDB); Ca^{2+} mobilization; Protein kinase C; H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

GH3 cell
Pregnenolone sulfate; Steroid; Ca^{2+}; Pituitary (Büküşoğlu, C. (298) 79)

Gi/Go protein
Cold water swimming; Antinociception; Pertussis toxin; Opioid receptor; (Mouse) (Mizoguchi, H. (309) 37)

Ginsenoside
Scopolamine; Maze; (Rat) (Yamaguchi, Y. (312) 149)

Glibenclamide
K^+ channel, drug effect; Intestine, small (Davies, M.P. (297) 249)

Sulphonylurea; Tolbutamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Hypothyroidism; K_{ATP} channel; Portal vein; Pinacidil; Cromakalim (Jagadish, M. (309) 63)

Glimepiride
KK-Ay mouse; Sulfonylurea (Takada, Y. (308) 205)

Gliquidone
Antinociception; 5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Sulfonylurea; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Globus pallidus
Basal ganglia; Cannabinoid; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

Glomerular hemodynamics
Bradykinin; Glomerular prostaglandin; Kinin antagonist; Glomerular receptor; Receptor desensitization (Praddaude, F. (294) 173)

Glomerular prostaglandin
Bradykinin; Glomerular hemodynamics; Kinin antagonist; Glomerular receptor; Receptor desensitization (Praddaude, F. (294) 173)

Glomerular receptor
Bradykinin; Glomerular hemodynamics; Glomerular prostaglandin; Kinin antagonist; Receptor desensitization (Praddaude, F. (294) 173)

Glucocorticoid
Intimal thickening; Vascular reactivity; Nitric oxide (NO); Endothelium; Carotid artery, rabbit (Van Put, D.J.M. (294) 753)

L-*N*-Arginine methyl ester (L-NAME); Nitric oxide (NO); Forced swimming test; Adrenalectomy (Jefferys, D. (295) 131)

Neurosteroid; TNF (tumor necrosis factor); Dehydroepiandrosterone sulfate; Pregnenolone (Di Santo, E. (299) 179)

Amphetamine; Behavioral sensitization (De Vries, T.J. (307) R3)

Glucocorticoid receptor
Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; RU38486; Central nervous system (Korte, S.M. (301) 19)

Glucoprivation
Insulin; 2-Deoxy-D-glucose; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Glucose
Insulin; Pancreatic islet, blood flow; Blood pressure; β-Adrenoceptor (Atef, N. (298) 287)

Δ^9-Tetrahydrocannabinol; Nucleus tractus solitarii; Nausea; Catecholaminergic neuron; 5-HT_3 receptor (Himmi, T. (312) 273)

Glucose uptake
Synovial cell; Human; Anti-inflammatory drug; Osteoarthritis; Rheumatoid arthritis (Hernvann, A. (314) 193)

Glu_1-flop receptor
AMPA receptor agonist; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(*f*)quinoxaline); (Pharmacology) (Wahl, P. (308) 211)

Glutamate
Flupirtine; Focal cerebral ischemia; Primary neuronal culture; Ca^{2+}, cytosolic; Fura-2 (Rupalla, K. (294) 469)

Opioid dependence; Central nervous system; MK-801 (dizocilpine); Morphine; Butorphanol (Tokuyama, S. (295) 123)

RPR 104632; Glycine receptor antagonist; NMDA receptor-channel complex; Neurotoxicity (Boireau, A. (300) 237)

Turning; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Dentate gyrus; Dizocilpine; In situ hybridization; Schizophrenia (Healy, D.J. (306) 257)

Fluphenazine; Microdialysis; Caudate putamen; Nucleus accumbens; GABA (γ-aminobutyric acid) (See, R.E. (308) 279)

PAF (platelet-activating factor); Vasomotor tone; Endothelium; Arterial pressure; Blood flow; Noradrenaline; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

Long-term depression; Long-term potentiation; Metabotropic receptor; NMDA receptor; Plasticity; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

Defense area; Perifornical area; GABA (γ-aminobutyric acid); Nucleus tractus solitarii (Varga, K. (310) 145)

Acetylcholine; NMDA receptor; Learning; Memory; Inhibitory avoidance task (Ohno, M. (312) 145)

Butorphanol; κ-Opioid receptor agonist; Locus coeruleus; Microdialysis; U-69,593 (Hoshi, K. (314) 301)

Felbamate; 5,7-Dichlorokynurenic acid; Epilepsy; Cortical slice (Srinivasan, J. (315) 285)

Glutamate metabotropic receptor
Hippocampus; Dentate gyrus; Synaptic transmission; Electrophysiology, in vitro; Extracellular recording (Ugolini, A. (294) 403)

Glutamate receptor
Capsaicin treatment, neonatal; Superfusion; Autoradiography; Substance P; $GABA_B$ receptor (Teoh, H. (302) 27)

Retinal cell; Neurotoxicity; Ca^{2+}; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Ferreira, I.L. (302) 153)

Subunit; BHK cell; cDNA; AMPA (α-amino-3-hydroxy-5-methyl-isoxalazole-4-propionate) (Andersen, P.H. (311) 95)

Glutamate receptor, ionotropic
Concentration jump; Hippocampal neuron; AMPA/kainate receptor; Kainate-gated desensitization (Pidoplichko, V.I. (303) 145)

Glutamate receptor, metabotropic
cAMP; Adenosine deaminase; Forskolin; VIP (vasoactive intestinal peptide); NECA (5′-*N*-ethylcarboxamidoadenosine); Hippocampus (Wright, R.A. (297) 275)

Long-term potentiation; Mutant mouse (Bordi, F. (301) R15)

Glutamate receptor antagonist
Dopamine; Reserpine; Parkinsonism; Microdialysis (Biggs, C.S. (299) 83)

Glutamate release
Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synaptophysin; Synapsin; Hippocampus; Ageing (Mullany, P. (309) 311)

Aging; ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate); Arachidonic acid; Protein kinase C; Inositol trisphosphate (McGahon, B. (309) 323)

Glutamic acid
Adenosine A_{2A} receptor, human; Mutation; CGS21680; XAC; Amiloride (IJzerman, A.P. (310) 269)

Glutamic acid decarboxylase
Male pheromone; Olfactory bulb; Ovariectomy; Estrogen; Progesterone; (Rat) (Navarro Becerra, N. (312) 83)

Glutamic acid decarboxylase mRNA
Sertraline; Hybridization, in situ; Brain (Giardino, L. (312) 183)

Glutathione
Endothelial cell; Smooth muscle cell; Diabetes mellitus; Atherosclerosis; Aminoguanidine; Aldose-reductase (Graier, W.F. (294) 221)

Lipid peroxidation; Oxidative stress; Ischemia-reperfusion injury; 21-Aminosteroid; Kidney, rat (Paroni, R. (294) 737)

Glutathione peroxidase
Free radical; Hydrogen peroxide; Non-steroidal anti-inflammatory drug; Horseradish peroxidase; Scavenging (Parij, N. (311) 259)

Glyburide
ATP-sensitive K^+ channel; Ca^{2+}, intracellular; Chemical hypoxia; Dinitrophenol; Cardiac cell; Fluo-3 (Brady, P.A. (308) 343)

Glyceraldehyde-3-phosphate dehydrogenase
Nitric oxide (NO); Aconitase; Cell death (Meßmer, U.K. (302) 171)

Glyceryl trinitrate
Endothelium; Albumin transfer; Hydrogen peroxide; Sodium nitroprusside (McQuaid, K.E. (307) 233)

Nitrite; Nitrate tolerance; Platelet; Smooth muscle cell; Vascular (Weber, A.-A. (309) 209)

Diphenyleneiodonium; Artery, bovine coronary; Aorta, rat (De la Lande, I.S. (314) 347)

Glycine
Phosphoserine phosphatase; L-AP3 (L-2-amino-3-phosphonopropionic acid); D-AP3 (D-2-amino-3-phosphonopropionic acid); Serine (Hawkinson, J.E. (307) 219)

NMDA receptor; [^{3}H]MDL 105,519; (Binding) (Siegel, B.W. (312) 357)

Glycine coagonist site
NMDA receptor; Desensitization; 5,7-Dichlorokynurenic acid; ACEA-1021; L-695,902; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Glycine receptor antagonist
RPR 104632; Glutamate; NMDA receptor-channel complex; Neurotoxicity (Boireau, A. (300) 237)

Glycogen synthesis
S6 kinase, 90 kDa; Insulin; Protein phosphatase 1G; EGF (epidermal growth factor) (Yasui, K. (316) 317)

Glycolysis
Calmodulin antagonist; Melanoma; ATP; Glucose 1,6-bisphosphate (glucose-1,6-P_2, Glc-1,6-P_2); Fructose 1,6-bisphosphate (fructose-1,6-P_2, Fru-1,6-P_2) (Glass-Marmor, L. (313) 265)

P-Glycoprotein
Photoaffinity labeling; Chemosensitizer; Multidrug resistance (Boer, R. (295) 253)

Glycoprotein IIb / IIIa
Aurintricarboxylic acid; Triflavin; Von Willebrand factor; Photochemically induced thrombosis (Hisamichi, N. (312) 69)

Glycosphingolipid
Tumor; Recombinant interleukin-2; Adhesion; Peritumoral (Tubaro, E. (294) 555)

GMC2021
Antimigraine drug; Arteriovenous anastomosis; Carotid artery; Coronary artery, human; Migraine; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

cGMP
Ca^{2+} store; Ryanodine; Heparin; Thapsigargin; Ruthenium red (Duridanova, D.B. (298) 159)

Vasoconstrictor sympathetic nerve; Nitric oxide (NO); Saphenous vein, human; L-N^{ω}-Nitro-L-arginine (L-NNA) (Fabi, F. (309) 41)

Platelet; Endothelin-3; Sodium nitroprusside; Phosphodiesterase inhibitor; Ca^{2+}, cytosolic; Ca^{2+} pump (Gagnet, C. (310) 67)

N^{ω}-Nitro-L-arginine methyl ester; Eosinophil chemotaxis; Nitric oxide (NO); Pleurisy (Ferreira, H.H.A. (310) 201)

Nicorandil; Aorta, rat; Relaxation; Tolerance; Levcromakalim (Trongvanichnam, K. (314) 83)

Cerebellum; MK-801; Purkinje cell; TRH tartrate (thyrotropin-releasing hormone tartrate); GABA (γ-aminobutyric acid) (Nakayama, T. (316) 157)

cGMP monophosphate
Nitroglycerin; Tolerance; Phosphodiesterase inhibitor; Blood pressure; Zaprinast; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Gnawing
Haloperidol; Clozapine; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; S 14506; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Gonadectomy
Tail artery, rat; Adrenergic nerve stimulation; Noradrenaline release (García-Villalón, A.L. (314) 339)

G-protein
Antinociception; Morphine; β-Endorphin; Pertussis toxin (Tseng, L.F. (294) 345)

Ca^{2+} current; GTPγS; Baclofen; Photolysis, ultraviolet; Hippocampus, rat (Frank, C. (295) 87)

Muscarinic receptor; High-throughput assay; Molecular biology (Bräuner-Osborne, H. (295) 93)

[^{35}S]GTPγ[S] binding; Histamine H_3 receptor; Pertussis toxin (Clark, E.A. (296) 223)

W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine); Thromboxane A_2; Phosphoinositide hydrolysis; Ca^{2+} (Ohkubo, S. (298) 175)

Excitatory amino acid; Metabotropic glutamate receptor; GTP hydrolysis; Adenylyl cyclase; Cerebral cortex (Odagaki, Y. (300) 151)

Spinal neuron; Purinoceptor; K^+ channel; Protein kinase C; Patch clamp; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

P_{2Y} purinoceptor; Protein kinase C; K^+ channel; Ca^{2+} release, cytosolic; Hippocampal neuron (Ikeuchi, Y. (304) 191)

Electroshock; GTP-binding protein; In situ hybridization; Messenger RNA (McGowan, S. (306) 249)

CCK_B receptor; Neostriatal neuron; Cationic current; Inositol 1,4,5-trisphosphate; Whole-cell patch-clamp recording (Wu, T. (307) 125)

β-Adrenoceptor density; Congestive heart failure; Norepinephrine (Lai, L.-P. (309) 201)

Lithium chloride; Valproic acid; Bipolar disorder; ADP ribosylation (Young, L.T. (309) 215)

BW373U86; δ-Opioid receptor; Radioligand binding (Campa, M.J. (310) 263)

Desensitization; Phospholipase C; Adenylyl cyclase (Galas, M.-C. (314) 157)

Ca^{2+} channel, P-type; Antinociception, spinal; Morphine; Clonidine; Tolerance (Roerig, S.C. (314) 293)

Smooth muscle; Contraction; Phospholipase C; Muscarinic; Antibody (Cuq, P. (315) 213)

Thrombin receptor; Phosphoinositide hydrolysis; GTPase (Ogino, Y. (316) 105)

G-protein-coupled receptor
Melatonin receptor; Comparative molecular field analysis; Quantitative structure-activity relationship model; Austin model 1; Binding site (Navajas, C. (304) 173)

[^{35}S]GTPγS autoradiography (Sim, L.J. (307) 97)

5-HT_2 receptor; 5-HT (5-hydroxtryptamine, serotonin); (*Lymnaea stagnalis*); (Mollusc) (Gerhardt, C.C. (311) 249)

G_i-protein
Neuropeptide Y receptor; $α_{2A}$-Adrenoceptor; Ca^{2+}; Microtubule; Microfilament (Michel, M.C. (309) 87)

GR117289
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Blood-brain barrier; Losartan; EXP3174; LR-B/081 (Polidori, C. (307) 259)

GR127935
Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; WAY 100635; 5-HT_{1D} receptor; 5-HT_{1A} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Coronary artery, canine; Contraction; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor; Sumatriptan (Terrón, J.A. (300) 109)

5-HT_{1D} receptor antagonist; Ketanserin; 5-HT_{1B} receptor antagonist; 5-HT_{1D} receptor, human, cloned; 5-HT_{1B} receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-$HT_{1D\alpha}$ receptor; 5-$HT_{1D\beta}$ receptor; [^{35}S]GTPγS binding; cAMP accumulation; Receptor reserve (Watson, J.M. (314) 365)

[^{3}H]GR 113808
5-HT_4 receptor; Radioligand binding; Desensitization (Ansanay, H. (298) 165)

[^{3}H]GR168320
Histamine H_3 receptor; Radioligand binding; Cerebral cortex, rat; [^{3}H]N^{α}-Methylhistamine (Brown, J.D. (311) 305)

Gram-negative sepsis
Indomethacin; TMF (tumor necrosis factor); Cyclooxygenase inhibitor; Sepsis (Campanile, F. (307) 191)

Granule cell, cerebellar
Ethanol; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) propionic acid); AP-1 (activator protein-1) DNA binding; Transcription factor (Hou, Y.-N. (309) 307)

Grooming
Cholecystokinin; Dopamine; Dopamine D_1 receptor; Vacuous chewing movement; (Rat) (Van Kampen, J. (298) 7)

Theophylline; Dopamine receptor antagonist; (Rat) (Zarrindast, M.-R. (306) 1)

Growth
Diabetes; Smooth muscle cell, vascular; Interleukin-1β; Nitric oxide (NO) (Etienne, P. (311) 79)

Growth factor
Cytokine; Neuroprotection; Excitotoxicity (Prehn, J.H.M. (306) 81)

Oligodeoxynucleotide; Immediate-early gene (Sachinidis, A. (309) 95)

Atherosclerosis; Cell proliferation; Cytokine; Gap junctional intercellular communication; Smooth muscle cell (Mensink, A. (310) 73)

Growth hormone (GH) deficiency
Cardiovascular effects; Heart, rat; Ischemia (De Gennaro Colonna, V. (314) 333)

GTPase
δ-Opioid receptor; Protein kinase C (Narita, M. (310) R1)

Thrombin receptor; Phosphoinositide hydrolysis; G-protein (Ogino, Y. (316) 105)

GTP-binding protein
PAF (platelet-activating factor); Desensitization; Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR) (Kamata, K. (301) 121)

Electroshock; G-protein; In situ hybridization; Messenger RNA (McGowan, S. (306) 249)

GTP cyclohydrolase I
Nuclear factor κB; Tetrahydrobiopterin; Nitric oxide (NO); Smooth muscle cell, vascular; (Rat) (Hattori, Y. (296) 107)

GTPγS
Ca^{2+} current; Baclofen; Photolysis, ultraviolet; G-protein; Hippocampus, rat (Frank, C. (295) 87)

[^{35}S]GTPγS autoradiography
G-protein-coupled receptor (Sim, L.J. (307) 97)

[^{35}S]GTPγS binding
S 15535; WAY 100,635; 5-HT_{1A}; (±)-8-OH-DPAT ((±)-hydroxy-2-(di-*n*-propylamino)tetralin) (Newman-Tancredi, A. (307) 107)

[^{35}S]GTPγ[S] binding
Histamine H_3 receptor; G-protein; Pertussis toxin (Clark, E.A. (296) 223)

GTP hydrolysis
Excitatory amino acid; Metabotropic glutamate receptor; G-protein; Adenylyl cyclase; Cerebral cortex (Odagaki, Y. (300) 151)

[^{14}C]Guanidinium
5-HT_3 receptor; 5-HT_3 receptor agonist; N1E-115 cells; NG 108-15 cells; Bezold–Jarisch reflex; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

Guanylate cyclase
Nitric oxide (NO) donor; Penile erection; Yawning; Paraventricular nucleus; (Rat) (Melis, M.R. (294) 1)

Airway responsiveness; Nitric oxide (NO); Airway epithelium; Methylene blue; Zaprinast (Sadeghi-Hashjin, G. (302) 109)

Nodose ganglion; Electrophysiology; Enzyme; mRNA; Nitric oxide (NO) (Lawrence, A.J. (315) 127)

GYKI 52466
2,3-Benzodiazepine; Aniracetam; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Anticonvulsant drug; Epilepsy; Audiogenic seizure; (DBA/2 mouse) (De Sarro, G. (294) 411)

Catalepsy; Catatonia; Morphine; NMDA receptor; AMPA receptor; MK-801; CGP 37849 (Tzschentke, T.M. (295) 137)

Cyclothiazide; NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline); Allosteric regulation (Okada, M. (309) 299)

H-89
Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; Intracellular signal transduction system; KT5823; W-7; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

U-50,488H
Cycloheximide; Naltrexone methobromide; Amnesia; Dynorphin A-(1–13); (Mouse) (Ukai, M. (313) 11)

(+)-HA966
Carrageenan; c-Fos; Inflammatory pain; Niflumic acid; Spinal cord; (Rat) (Buritova, J. (303) 91)

HA-966 (3-amino-1-hydroxy-2-pyrrolidone)
5,7-Dichlorokynurenic acid; Dizocilpine; Phencyclidine; Ifenprodil; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); 5-HT_{2C} receptor (Mazzola-Pomietto, P. (308) 329)

Hallucinogen
5-HT (5-hydroxytryptamine, serotonin); 5-HT_{2A} receptor; γ-Aminobutyric acid; Ketanserin (Cozzi, N.V. (309) 25)

Haloperidol
κ-Opioid analgesia; Opioid receptor; σ Receptor; Antisense; KOR-1; κ-Opioid receptor (Chien, C.-C. (294) 303)

Neuroleptic withdrawal; Ca^{2+} channel blockade; Pimozide; Nifedipine; Apomorphine (Antkiewicz-Michaluk, L. (294) 459)

NMDA receptor; Non-NMDA receptor; Subsensitivity; Striatum; Contralateral turning (Ossowska, K. (294) 685)

Enkephalin; Aminopeptidase N; Neuroleptic; Neuropeptide (Konkoy, C.S. (297) 47)

Arginine-aspartate; Catalepsy; Locomotor activity; Dopamine (Patacchioli, F.R. (299) 29)

Median eminence; Intermediate lobe; Pentazocine; Raclopride; Prolactin secretion; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

Antipsychotic; SM-9018; c-*fos* mRNA; 5-HT_2 receptor; Striatum (Ishibashi, T. (303) 247)

N-Cyanomethylmethamphetamine; Methamphetamine; Behavioral sensitization; Ambulation; (Mouse) (Kuribara, H. (305) 1)

Spinal cord, mouse; DTG (1,3-di(2-tolyl)guanidine) (Hornfeldt, C.S. (306) 15)

Dopamine; MK-801; SCH 23390; Self-stimulation (Olds, M.E. (306) 23)

Clozapine; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; S 14506; Gnawing; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Pimozide; Dopamine metabolism; Catalepsy; Adaptation; (Chronic treatment) (Karolewicz, B. (313) 181)

NMDA receptor antagonist; Catalepsy; Parkinson's disease; (Rat) (McAllister, K.H. (314) 307)

Clozapine; Fos-protein; Cross-tolerance; Nucleus accumbens; Septum, lateral (Sebens, J.B. (315) 269)

Halothane
Smooth muscle, airway; Ca^{2+}, intracellular; Ca^{2+} sensitivity (Kai, T. (315) 313)

Harmaline
Nitric oxide (NO); 7-Nitroindazole; NMDA (*N*-methyl-D-aspartate); Parkinsonism; Epilepsy (Eblen, F. (299) 9)

Harman
β-Carboline; Dopamine; Norharman; Microdialysis; Nucleus accumbens; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

Head injury
Edema; Antioxidant free radical scavenger; Magnetic resonance imaging (Petty, M.A. (307) 149)

Head shake
Corticosterone; 5-HT receptor subtype; Lower lip retraction; Penile erection; Open field behavior (Berendsen, H.H.G. (308) 103)

Heart
Vasorelaxation; ATP-sensitive K^+ channel; His bundle; Conduction; Refractory period; Electrophysiology (D'Alonzo, A.J. (294) 271)

α_1-Adrenoceptor, subtype; mRNA; Thyroxine treatment (Han, C. (294) 593)

Adenosine; Ca^{2+}, cytosolic; Ca^{2+} domain; Cardioprotection; Fluo-3 (Jovanovic, A. (298) 63)

Muscarinic receptor; Allosteric modulation; Alcuronium; Agonist (Maaß, A. (305) 231)

Atropine; Methyl-quinuclidinyl-benzylate; CGP-12177; PET (positron emission tomography); β-Adrenoceptor; Muscarinic receptor (Valette, H. (306) 133)

Adenosine receptor; β-Adrenoceptor; Species difference; (Guinea pig); (Pig); (Rabbit); (Rat) (Musser, B. (308) 357)

Ischemia; Reperfusion; Angiotensin-converting enzyme; Idrapril; Captopril; (Rat) (Riva, E. (312) 293)

Parasympathetic nervous system; Acetylcholine; Chronotropism; Inotropism; PACAP-38 (pituitary adenylate cyclase-activating polypeptide-38); PACAP-(6–38) (pituitary adenylate cyclase-activating polypeptide-(6–38)); (Dog) (Yonezawa, T. (315) 289)

Heart, dog
AV node; E-4031; K^+ current, delayed rectifier; Zatebradine (Yamazaki, K. (297) 233)

Automaticity; Hyperpolarization-activated current (I_f); Ventricular arrhythmia; Zatebradine (Furukawa, Y. (300) 203)

Bertosamil; K^+ channel, ATP-sensitive; Ca^{2+} channel, L-type; Chronotropism; Inotropism (Yonezawa, T. (309) 51)

Heart failure
Renin-angiotensin-aldosterone system; Angiotensin II; Angiotensin II receptor; Angiotensin-converting enzyme inhibitor (Lenz, O. (294) 17)

MCI-154 (6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3-(2*H*)-pyridazinone); Ventricular arrhythmia; Ca^{2+} current (Eto, K. (298) 247)

Inotropic drug; K^+ channel, ATP-sensitive; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

Na^+,K^+-ATPase; Digitalis; Norepinephrine (Lai, L.-P. (309) 235)

Heart, perfused, rat
Endothelin-1; TAK-044; BQ-123; Endothelin ET_A receptor; Endothelin ET_B receptor (Kusumoto, K. (296) 65)

Adenosine A_{2A} receptor; Adenosine A_{2B} receptor; Adenosine A_3 receptor; P_3 purinoceptor; Coronary vasculature (Harden, F.A. (307) 49)

Heart porcine
Muscarinic receptor; Allosteric modulation; Structure-activity relationship (Kostenis, E. (314) 385)

Heart preparation, isolated
Benzodiazepine; Diazepam; Inotropy; Peripheral-type benzodiazepine receptor antagonist (Leeuwin, R.S. (299) 149)

Heart, rat
Endotoxin; Nitric oxide (NO) synthase; mRNA; Septic shock; Plasma nitrate (Bateson, A.N. (303) 141)

Preconditioning; Capsaicin; Ruthenium red; CGRP (calcitonin gene-related peptide); CGRP-(8–37) (Li, Y.-J. (311) 163)

Growth hormone (GH) deficiency; Cardiovascular effects; Ischemia (De Gennaro Colonna, V. (314) 333)

Heart rate
Myocardial ischemia; Ventricular arrhythmia; α-Adrenoceptor subtype-selective blocker; Coronary occlusion; Arrhythmia (Geller, J.C. (294) 423)

γ_2-MSH (γ_2-melanocyte-stimulating hormone); ACTH-(4–10) (adrenocorticotropic hormone-(4–10)); Blood pressure; Structure-activity; Melanocortin receptor; (Rat) (Van Bergen, P. (294) 795)

Opioid; κ-Opioid receptor agonist; Pregnancy; Blood pressure (Szeto, H.H. (297) 77)

Cocaine; ANP (atrial natriuretic peptide); ANP, N-terminal; Mean arterial pressure; Right atrial pressure (Pelkonen, M. (304) 55)

Local anesthetic; Cocaine; Lidocaine; Pseudococaine; Hemodynamics; Blood pressure; Desipramine (Bernards, C.M. (307) 33)

Cocaine; Blood pressure; Self-administration (Ambrosio, E. (315) 43)

5-HT_{1A} receptor; Blood pressure; Preoptic area; Forebrain; 8-OH-DPAT (*R*-(+)-8-hydroxy-2-(di-*n*-propylamino) tetralin) (Szabó, A. (315) 187)

Mivazerol; α_2-Adrenoceptor agonist; NMDA receptor; Spinal cord (Kim, S.Y. (316) 249)

HEK293 cell
Ca^{2+} channel, voltage-dependent; NMDA receptor antagonist; Ischemia; Neuroprotection; (Gerbil) (Bath, C.P. (299) 103)

Hemicholinium-3
Choline; ACTH (adrenocorticotrophin); β-Endorphin; Atropine; Mecamylamine (Savci, V. (309) 275)

Hemodynamics
IRL 1720; Sarafotoxin S6c; Endothelin ET_B receptor; FR139317 (Kuwahara, M. (296) 55)

Local anesthetic; Cocaine; Lidocaine; Pseudococaine; Blood pressure; Heart rate; Desipramine (Bernards, C.M. (307) 33)

Adenosine A_3 receptor; Histamine release; Tachyphylaxis; 2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA); Rat, conscious (Van Schaick, E.A. (308) 311)

Hemodynamics, in vivo
Peroxynitrite; Tachyphylaxis (Kooy, N.W. (307) R5)

Peroxynitrite; Nitrotyrosine; Nitric oxide (NO); Superoxide (Kooy, N.W. (310) 155)

Peroxynitrite; Nitrotyrosine; Nitric oxide; Superoxide; Angiotensin II (Kooy, N.W. (315) 165)

Hemoglobin
Angiotensin I-converting enzyme; Angiotensin I-converting enzyme inhibitor; Peptide; (Swine) (Mito, K. (304) 93)

Muscle denervation; Nitroprusside; ODQ (1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one); Nitric oxide (NO) (Urazaev, A.Kh. (316) 219)

Hemorrhage
Neuropeptide Y; Noradrenaline; Peptide; Blood vessel; Vascular control (Hunter, L.W. (313) 79)

Hemorrhagic hypotension
Cerebral blood flow autoregulation; Amlodipine; Ca^{2+} channel antagonist; Spontaneously hypertensive rat (SHR) (Cai, H. (313) 103)

Hemorrhagic shock
Hypovolemia; *N*-Nitro-L-arginine methyl ester; L-Arginine; Naloxone; Nitric oxide (NO); (Conscious rabbit) (Ventura, S. (294) 369)

Heparin
Muscarinic receptor; Receptor subtype; Transfected cell; Allosteric interaction; Receptor coupling (Wang, S.Z. (296) 113)

Ca^{2+} store; Ryanodine; Thapsigargin; Ruthenium red; cGMP (Duridanova, D.B. (298) 159)

Protamine; Platelet; PAF (platelet-activating factor); PAF-acether; Thromboxane; BN 52021 (Aïssa, J. (302) 123)

Hepatic secretion
Rebamipide; Drug metabolism; Ischemia/reperfusion (Lee, S.-M. (294) 41)

Hepatocyte
α_1-Adrenoceptor; Liver; (Rhesus monkey) (García-Sáinz, J.A. (311) 277)

Herbimycin A
Nitric oxide (NO) synthase, inducible; Interferon-γ; Janus kinase; Signal transducer and activator of transcription-1 (STAT1); Microglia (Kitamura, Y. (306) 297)

Heterogeneity
$GABA_A$ receptor; $GABA_A$ receptor subunit; Cerebellum; Thalamus; Diazepam-insensitive (Huh, K.-H. (310) 225)

Heymann nephritis
DP-1904; Thromboxane A_2 synthase inhibitor; Proteinuria (Nagao, T. (316) 73)

HF-2035
W-7; Calmodulin antagonist; Vascular relaxation; Nitric oxide (NO) synthase inhibitor (Win, N.H.H. (299) 119)

HI-6
Acetylcholine; Ca^{2+} channel; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

5-HIAA (5-hydroxyindoleacetic acid)
5-HT (5-hydroxytryptamine, serotonin); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

5-HIAA / 5-HT (5-hydroxy-indole acetic acid / 5-hydroxytryptamine) ratio
$5\text{-}HT_{1A}$ receptor; Defensive burying; Inescapable footshock; Plus-maze (Barf, T. (297) 205)

High-cholesterol diet
Dahl salt-sensitive rat; Endothelium-dependent relaxation; Hypercholesterolemia; Hypertension (Kitagawa, S. (297) 71)

High-throughput assay
Muscarinic receptor; G-protein; Molecular biology (Bräuner-Osborne, H. (295) 93)

Hind limb, rat
Endothelium; Acetylcholine; Nitric oxide (NO); EDHF (endothelium-derived hyperpolarizing factor) (Brouwers-Ceiler, D.L. (307) 65)

Hindquarters
Diabetes; Endothelin; Arachidonic acid; 5-HT (5-hydroxytryptamine, serotonin); Thromboxane (James, G.M. (294) 109)

Hippocampal cell
Selegiline; Astrocyte, cultured; Excitotoxicity; Protection; Cerebral ischemia; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Hippocampal neuron
Concentration jump; Glutamate receptor, ionotropic; AMPA/kainate receptor; Kainate-gated desensitization (Pidoplichko, V.I. (303) 145)

P_{2Y} purinoceptor; G-protein; Protein kinase C; K^+ channel; Ca^{2+} release, cytosolic (Ikeuchi, Y. (304) 191)

GABA receptor antagonist; Bicuculline; SR95531; Pentobarbitone; Etomidate (Uchida, I. (307) 89)

Hippocampal slice
Antidepressant; Imipramine; $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Baclofen (Bijak, M. (305) 79)

Hippocampus
Acetylcholine; Microdialysis; Medial septum; Muscarinic autoreceptor (Moor, E. (294) 155)

Dentate gyrus; Glutamate metabotropic receptor; Synaptic transmission; Electrophysiology, in vitro; Extracellular recording (Ugolini, A. (294) 403)

Traumatic brain injury; Felbamate; Long-term potentiation; CA1 (Wallis, R.A. (294) 475)

Long-term potentiation; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); Slow-onset potentiation; MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Metabotropic glutamate receptor; Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

5-HT (5-hydroxytryptamine, serotonin); 1-(2-Pyrimidinyl)piperazine; Excitatory synaptic transmission; Electrophysiology; $5\text{-}HT_{1A}$ receptor; Azapirone (Manahan-Vaughan, D. (294) 617)

Striatum; Acetylcholine; Microdialysis; NMDA receptor; NMDA receptor antagonist (Hutson, P.H. (295) 45)

Chronic citalopram; NMDA receptor; Excitatory amino acid; Adaptation; Cortex (Nowak, G. (295) 75)

Seizure; Cell death; Learning disorder; (Rat) (Lahtinen, H. (297) 213)

Glutamate receptor, metabotropic; cAMP; Adenosine deaminase; Forskolin; VIP (vasoactive intestinal peptide); NECA (5′-*N*-ethylcarboxamidoadenosine) (Wright, R.A. (297) 275)

Ryanodine receptor; Synaptosome; Ca^{2+}, intracellular; Subcellular localization (Padua, R.A. (298) 185)

GABA (γ-aminobutyric acid); Epilepsy; Neuroprotection; Perforant pathway stimulation (Halonen, T. (299) 69)

Azelastine; Traumatic brain injury; Leukotriene; NMDA (*N*-methyl-D-aspartate); (In vitro) (Girard, J. (300) 43)

Taurine; Adenosine transport inhibitor; Adenosine; Spreading depression; NMDA receptor (Hada, J. (305) 101)

Ca^{2+} channel; Conotoxin; ω-Agatoxin-IVA (Nooney, J.M. (306) 41)

Noradrenaline; β-Adrenoceptor; Propranolol; NMDA receptor; Working memory (Ohno, M. (307) 21)

Microdialysis; Amino acid; Uptake carrier; Vesicular release; Ca^{2+} dependency (Zuiderwijk, M. (307) 275)

Working memory; Acetylcholine release (Fadda, F. (307) R1)

Glutamate release; Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synaptophysin; Synapsin; Ageing (Mullany, P. (309) 311)

α_2-Adrenoceptor subtype; Brain, human; RX 821002; Autoradiography; Frontal cortex (Grijalba, B. (310) 83)

Cerebral ischemia; 7-Nitroindazole; Nitric oxide (NO); (Mongolian gerbil) (O'Neill, M.J. (310) 115)

K^+ channel; Seizure; Ca^{2+} channel; Levcromakalim; Patch clamp (Katsumori, H. (311) 37)

Hippocampus, rat
Ca^{2+} current; GTPγS; Baclofen; Photolysis, ultraviolet; G-protein (Frank, C. (295) 87)

His bundle
Vasorelaxation; Heart; ATP-sensitive K^+ channel; Conduction; Refractory period; Electrophysiology (D'Alonzo, A.J. (294) 271)

Falipamil; Alinidine; Sinoatrial node; Atrial myocardium; AV node; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

His bundle automaticity
Propafenone; 5-Hydroxypropafenone; Sinoatrial node automaticity; Atrial myocardium refractoriness; AV node refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride)
Iris dilator, rabbit; Phorbol 12,13-dibutyrate (PDB); Ca^{2+} mobilization; Protein kinase C; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

Histamine
Anti-allergic drug; α-Chymotrypsin; Mast cell; Serine esterase (Emadi-Khiav, B. (295) 243)

Adenosine A_3 receptor; Hypotension; Mast cell; APNEA (N^6-2-(4-aminophenyl)ethyladenosine); Compound 48/80 (Fozard, J.R. (298) 293)

Morphine; Colonic temperature; Histamine receptor antagonist (Ulugöl, A. (308) 49)

α-Mangostin; Trachea, guinea-pig; Histamine H_1 receptor antagonist; Aorta, rabbit (Chairungsrilerd, N. (314) 351)

Intestine; Ganglion; Enteric nervous system; Myenteric plexus; cAMP; Adenylate cyclase (Xia, Y. (316) 81)

Histamine-*N*-methyl transferase
Acetylcholinesterase; Histamine H_3 receptor antagonist (Morisset, S. (315) R1)

Histamine receptor antagonist
Morphine; Histamine; Colonic temperature (Ulugöl, A. (308) 49)

Histamine release
cis-Platinum (II) phosphonate complex; Cisplatin; Murine mast cell (Brzezińska-Błaszczyk, E. (298) 155)

Adenosine A_3 receptor; Hemodynamics; Tachyphylaxis; 2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA); Rat, conscious (Van Schaick, E.A. (308) 311)

Histamine H_1 receptor
Neomycin; Ca^{2+} entry; Phospholipase C (Sipma, H. (305) 207)

Histamine H_1 receptor antagonist
Achatin-I (Gly-D-Phe-Ala-Asp); Excitatory neuropeptide; Promethazine; Triprolidine; Blocking effect; Neuron; (Snail) (Salunga, T.L. (304) 163)

α-Mangostin; Trachea, guinea-pig; Histamine; Aorta, rabbit (Chairungsrilerd, N. (314) 351)

Histamine H_2 receptor antagonist
IT-066; Ischemia-reperfusion injury; Gastric mucosal acute injury; Superoxide radical; Hydroxyl radical (Naito, Y. (294) 47)

FRG-8813; Gastric mucin biosynthesis; Organ culture; (Rat) (Ichikawa, T. (297) 87)

Histamine H_3 receptor
Radioligand binding; [^{3}H]GR168320; Cerebral cortex, rat; [^{3}H]N^α-Methylhistamine (Brown, J.D. (311) 305)

[^{35}S]GTPγ[S] binding; G-protein; Pertussis toxin (Clark, E.A. (296) 223)

Histamine H_3 receptor antagonist
Histamine-*N*-methyl transferase; Acetylcholinesterase (Morisset, S. (315) R1)

Histamine H_3 receptor subtype
Parasympathetic neuron; (*R*)-α-Methylhistamine; Sympathetic neuron (Rizzo, C.A. (294) 329)

Histidine
CCK receptor; Mutation (Jagerschmidt, A. (296) 97)

HLö-7
Acetylcholine; Ca^{2+} channel; HI-6; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

HMG-CoA reductase inhibitor
Balloon catheterization; Hyperplasia (Bandoh, T. (315) 37)

H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide)
Iris dilator, rabbit; Phorbol 12,13-dibutyrate (PDB); Ca^{2+} mobilization; Protein kinase C; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride) (Satoh, M. (308) 145)

Hoe 140
Cold air; Tachykinin; Kinin; Bronchoconstriction; SR 48968; Neurogenic inflammation (Yoshihara, S. (296) 291)

Blood pressure variability; Losartan; Renal hypertension; Spectral analysis (Ponchon, P. (297) 61)

Spider venom; Ca^{2+} channel blocker; K^+ channel blocker; Endothelin-1; Nitric oxide (NO) (Costa, S.K.P. (298) 113)

Bradykinin; Ketotifen; Bradykinin receptor; Mast cell; Vascular permeability (Morishita, M. (298) 149)

Bradykinin B_2 receptor; Autoradiography (Murone, C. (306) 237)

Bradykinin; Pneumococcal meningitis; Cerebral blood flow; Brain edema; Intracranial pressure (Lorenzl, S. (308) 335)

HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH)
Ramiprilat; Angiotensin-converting enzyme inhibitor; Bradykinin; Bradykinin B_2 receptor antagonism; Cardiac myocyte; Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

HOE 234
K^+ channel opener; Levcromakalim; Bronchoconstriction; Plasma exudation (Kidney, J.C. (296) 81)

Hormone secretion
Atrial natriuretic peptide; Thapsigargin; Mechanical stretch (Taskinen, P. (308) 295)

Horseradish peroxidase
Free radical; Hydrogen peroxide; Non-steroidal anti-inflammatory drug; Glutathione peroxidase; Scavenging (Parij, N. (311) 259)

5-HT_{1A}
S 15535; WAY 100,635; [^{35}S]GTPγS binding; (±)-8-OH-DPAT ((±)-hydroxy-2-(di-*n*-propylamino)tetralin) (Newman-Tancredi, A. (307) 107)

5-HT autoreceptor
NMDA receptor; Presynaptic receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Cerebral cortex, guinea-pig; Serotoninergic axon terminal (Fink, K. (300) 79)

5-HT_{1A} autoreceptor, raphe
Microdialysis, in vivo; Citalopram; WAY-100635; Penbutolol enantiomer; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

5-HT_{1A} autoreceptor antagonism
(−)-Pindolol; Buspirone; Selective serotonin reuptake inhibitor (SSRI); Citalopram; 5-HT (5-hydroxytryptamine, serotonin), extracellular; Microdialysis, in vivo (Hjorth, S. (303) 183)

5-HT (5-hydroxytryptamine, serotonin)
Diabetes; Hindquarters; Endothelin; Arachidonic acid; Thromboxane (James, G.M. (294) 109)

Stress; Hyperthermia; Temperature; Anxiety; Benzodiazepine; 5-HT_{1A} receptor agonist; Antidepressant; Dopamine (Zethof, T.J.J. (294) 125)

Catalepsy; Dopamine; Receptor; (Rat) (Wadenberg, M.-L. (294) 247)

Stress; 5-HT_{1B} receptor; 5-HT release (Bolaños-Jiménez, F. (294) 531)

Microdialysis; Desipramine; α_2-Adrenoceptor (Yoshioka, M. (294) 565)

1-(2-Pyrimidinyl)piperazine; Hippocampus; Excitatory synaptic transmission; Electrophysiology; 5-HT_{1A} receptor; Azapirone (Manahan-Vaughan, D. (294) 617)

5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

p-Chloroamphetamine; Memory; Alzheimer's disease; (Rat) (Santucci, A.C. (295) 7)

5-HT uptake inhibitor; Antidepressant; Microdialysis; Hypothalamus, rat (Moret, C. (295) 189)

ATP receptor channel; Dopamine; Recombinant channel; *Xenopus* oocyte (Nakazawa, K. (296) 119)

5-HT_{2A} receptor; 5-HT_{2C} receptor; Phosphoinositide hydrolysis; 5-HT receptor antagonist; Aryloxyalkylimidazoline (Siegel, B.W. (296) 307)

Aggression, isolation-induced; β-Adrenoceptor, interaction; (Mouse) (Sánchez, C. (297) 1)

Dopamine; Desensitization; Striatum; Protein kinase A; Protein kinase C; (Rat) (West, A.R. (298) 241)

Epilepsy; Dopamine; Noradrenaline; GABA (γ-aminobutyric acid); Anticonvulsant (Löscher, W. (299) 61)

Seizure; Fluoxetine; Genetically epilepsy-prone rat; Substantia nigra (Statnick, M. (299) 93)

Resistance artery, small; Hyperthyroidism; Thromboxane A_2 receptor agonist; Endothelial modulation (Zwaveling, J. (300) 91)

Coronary artery, canine; Contraction; GR127935; 5-HT_{1D} receptor; Sumatriptan (Terrón, J.A. (300) 109)

Ethanol; Dopamine; Microdialysis; Ventral tegmental area (Yan, Q.-S. (301) 49)

Tryptamine-4,5-dione; Neurotoxicity; Free radical; Fenton (Chen, J.-C. (303) 109)

Appetite; Drinking; Food intake; Isatin; Motivation; Tubulin; (Mouse) (Morley, J.E. (305) 23)

Antidepressant; Imipramine; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Baclofen; Hippocampal slice (Bijak, M. (305) 79)

Aorta; Carotid artery; Norepinephrine; Potassium chloride; Ca^{2+}; Cholesterol (Moreland, R.S. (307) 55)

Paracetamol; Antinociception; 5-HT receptor, brain (Pini, L.A. (308) 31)

5-HTP (5-hydroxytryptophan); 5-HT receptor antagonist; 5-HT_4 receptor; SB 204070; Defecation; (Mouse) (Banner, S.E. (308) 181)

Aging; Alzheimer's disease; Spatial navigation; Nicotine; Tetrahydroaminoacridine (Riekkinen, M. (308) 243)

5-HT receptor antagonist; Stomach; Contraction; Relaxation; (Guinea pig) (Tamura, T. (308) 315)

5-HT_{2A} receptor; γ-Aminobutyric acid; Hallucinogen; Ketanserin (Cozzi, N.V. (309) 25)

Anxiety; 5-HT_4 receptor antagonist; Elevated plus-maze (Silvestre, J.S. (309) 219)

5-HT receptor; Secretion; Colon; Mucosa; (Human) (Borman, R.A. (309) 271)

5-HT (5-hydroxytryptamine, serotonin), extracellular
5-HT_{1A} autoreceptor antagonism; (−)-Pindolol; Buspirone; Selective serotonin reuptake inhibitor (SSRI); Citalopram; Microdialysis, in vivo (Hjorth, S. (303) 183)

5-HT (5-hydroxytryptamine, serotonin) level, extracellular
5-HT_{1A} receptor antagonist; Microdialysis; (*S*)-WAY100135; WAY100635 (Assié, M.-B. (304) 15)

5-HT (5-hydroxytryptamine, serotonin) release
NMDA receptor; 5-HT autoreceptor; Presynaptic receptor; Cerebral cortex, guinea-pig; Serotoninergic axon terminal (Fink, K. (300) 79)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor
σ Receptor, subtype; Binding; Brain, rat (Narita, N. (307) 117)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective
β-Adrenoceptor; Dorsal hippocampus; Microdialysis (Petersen, B. (300) 67)

Anxiety; Conditioned fear stress; Freezing behavior; Citalopram (Inoue, T. (311) 1)

5-HT (hydroxytryptamine, serotonin)-*N*-acetyltransferase
Melatonin; Pineal gland, ovine; Tryptamine (Shen, S. (307) 133)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor
Imipramine; Fluoxetine; Motion sickness (Okada, F. (309) 33)

5-HT receptor
Locomotor activity; Stereotyped behavior; (Rat) (Hillegaart, V. (295) 155)

Intestinal; Secretion; Short-circuit current; cAMP (Budhoo, M.R. (298) 137)

5-HT (5-hydroxytryptamine, serotonin); Secretion; Colon; Mucosa; (Human) (Borman, R.A. (309) 271)

Cl^-; Cl^- secretion; Short circuit current; Jejunum (Budhoo, M.R. (314) 109)

5-HT_1-like receptor
Vasoconstriction; Sumatriptan; Vasoconstrictor synergy; Vascular tone; (Rabbit, anesthetised) (Choppin, A. (304) 87)

5-HT_{1A} receptor
5-HT (5-hydroxytryptamine, serotonin); 1-(2-Pyrimidinyl)piperazine; Hippocampus; Excitatory synaptic transmission; Electrophysiology; Azapirone (Manahan-Vaughan, D. (294) 617)

Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; GR 127935; WAY 100635; 5-HT_{1D} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Antinociception; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Sulfonylurea; Gliquidone; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Spinal reflex; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide); Motor function; Spinal cord (Hasegawa, Y. (295) 211)

Defensive burying; Inescapable footshock; Plus-maze; 5-HIAA/5-HT (5-hydroxy-indole acetic acid/5-hydroxytryptamine) ratio (Barf, T. (297) 205)

2-(Di-*n*-propylamino)tetralin; Chiral compound; Dopamine D_2 receptor; (Racemate); (Rat); (Stereoisomer) (Yu, H. (303) 151)

Dopamine; Cortex, prefrontal; Ipsapirone; WAY 100135; NAN-190; Microdialysis (Wędzony, K. (305) 73)

Antidepressant; Imipramine; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Baclofen; Hippocampal slice (Bijak, M. (305) 79)

5-$HT_{2A/C}$ receptor; *c-fos*; *ngf1c*; *tis1* (Tilakaratne, N. (307) 211)

Emesis; Morphine; Nicotine; Tachykinin NK_1 receptor; 5-HT_3 receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Adrenaline; Pituitary; ACTH (adrenocorticotrophin) (Korte, S.M. (309) 281)

Binding thermodynamics; Drug-receptor interaction (Dalpiaz, A. (312) 107)

5-HT syndrome; Hyperphagia; Hypothermia; Tail-flick; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (O'Connell, M.T. (312) 137)

BRL 44408; ARC 239; α_2-Adrenoceptor subtype; Brain, rat (Meana, J.J. (312) 385)

Noradrenaline; Dopamine D_1 receptor; SCH 23390; Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin) (Hajós-Korcsok, É. (314) 285)

Blood pressure; Heart rate; Preoptic area; Forebrain; 8-OH-DPAT (*R*-(+)-8-hydroxy-2-(di-*n*-propylamino) tetralin) (Szabó, A. (315) 187)

Efficacy; Ultrasonic vocalization; Drug discrimination; (Rat) (Sánchez, C. (315) 245)

Food intake; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME) (Yamada, J. (316) 23)

5-HT_{1B} receptor
Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HT release (Bolaños-Jiménez, F. (294) 531)

CCK_A receptor; Adenosine A_1 receptor; P_{2U} purinoceptor; Inositol phosphate; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (302) 141)

5-HT_{1D} receptor
5-Carboxamidotryptamine; 5-HT_{1F} receptor; Metergoline; Migraine; [^{3}H]Sumatriptan (Pascual, J. (295) 271)

Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; GR 127935; WAY 100635; 5-HT_{1A} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Coronary artery, canine; Contraction; GR127935; 5-HT (5-hydroxytryptamine, serotonin); Sumatriptan (Terrón, J.A. (300) 109)

8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); Stereoselectivity (Pauwels, P.J. (300) 137)

5-$HT_{1D\alpha}$ receptor
GR127935; 5-$HT_{1D\beta}$ receptor; [^{35}S]GTPγS binding; cAMP accumulation; Receptor reserve (Watson, J.M. (314) 365)

5-$HT_{1D\beta}$ receptor
GR127935; 5-$HT_{1D\alpha}$ receptor; [^{35}S]GTPγS binding; cAMP accumulation; Receptor reserve (Watson, J.M. (314) 365)

5-HT_{1F} receptor
5-Carboxamidotryptamine; 5-HT_{1D} receptor; Metergoline; Migraine; [^{3}H]Sumatriptan (Pascual, J. (295) 271)

5-HT$_2$ receptor
Forced swim test; Stress; Wet-dog shake; β-Adrenoceptor (Takao, K. (294) 721)

Nicotinic acetylcholine receptor; Neocortical high-voltage spindle; Thalamocortical oscillation; (Rat) (Jäkälä, P. (299) 47)

Antipsychotic; SM-9018; Haloperidol; c-*fos* mRNA; Striatum (Ishibashi, T. (303) 247)

G-protein-coupled receptor; 5-HT (5-hydroxtryptamine, serotonin); (*Lymnaea stagnalis*); (Mollusc) (Gerhardt, C.C. (311) 249)

Anticholinesterase; Muscarinic acetylcholine receptor; Neocortical high-voltage spindle; Thalamocortical oscillation; (Rat) (Jäkälä, P. (316) 181)

5-HT$_{2A}$ receptor
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{2C}$ receptor; Phosphoinositide hydrolysis; 5-HT receptor antagonist; Aryloxyalkylimidazoline (Siegel, B.W. (296) 307)

Blood vessel; (±)-SDZ NVI 085; α_1-Adrenoceptor (Lachnit, W.G. (297) 83)

mCPP (1-(3-chlorophenyl)piperazine); Hyperglycemia; 5-HT$_{2C/2B}$ receptor; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) (Sugimoto, Y. (307) 75)

5-HT (5-hydroxytryptamine, serotonin); γ-Aminobutyric acid; Hallucinogen; Ketanserin (Cozzi, N.V. (309) 25)

5-HT$_{2C}$ receptor; Quipazine; MK-212; MDL 100,907; SB 200646A; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

RP 62203; Fananserin; Dopamine; Dopamine D$_4$ receptor; 5-HT (serotonin) (Heuillet, E. (314) 229)

5-HT$_{2A/C}$ receptor
5-HT$_{1A}$ receptor; *c-fos*; *ngf1c*; *tis1* (Tilakaratne, N. (307) 211)

5-HT$_{2c}$ receptor
Quinpirole; Normethylclozapine; Parkinson's disease (Fox, S. (301) 27)

5-HT$_{2C}$ receptor
Fluoxetine; Hypophagia; (Rat); (Pig) (Lightowler, S. (296) 137)

5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{2A}$ receptor; Phosphoinositide hydrolysis; 5-HT receptor antagonist; Aryloxyalkylimidazoline (Siegel, B.W. (296) 307)

Molecular modeling; Three-dimensional structure; Receptor binding; Subtype selectivity (Kristiansen, K. (306) 195)

5,7-Dichlorokynurenic acid; HA-966 (3-amino-1-hydroxy-2-pyrrolidone); Dizocilpine; Phencyclidine; Ifenprodil; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Mazzola-Pomietto, P. (308) 329)

5-HT$_{2A}$ receptor; Quipazine; MK-212; MDL 100,907; SB 200646A; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

5-HT$_{2C/2B}$ receptor
mCPP (1-(3-chlorophenyl)piperazine); Hyperglycemia; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); 5-HT$_{2A}$ receptor (Sugimoto, Y. (307) 75)

5-HT$_3$ receptor
[^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Cerebral cortex; Ileum; Colon; 5-HT$_3$ receptor, cloned, rat (Akuzawa, S. (296) 227)

Binding thermodynamics; Agonist and antagonist discrimination; Thermodynamic compensation (Borea, P.A. (298) 329)

Mesolimbic system, rat; Nucleus accumbens; Ventral tegmental area; Dopaminergic modulation; Locomotor activity (Gillies, D.M. (303) 1)

Emesis; Morphine; Nicotine; Tachykinin NK$_1$ receptor; 5-HT$_{1A}$ receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

5-HT$_4$ receptor; Tachykinin; Colon, guinea-pig; Tetrodotoxin; Enteric nerve (Briejer, M.R. (308) 173)

Intestinal transit; Prokinetic benzamide; (Mouse) (Nagakura, Y. (311) 67)

Ageing; Avoidance, multiple choice; Memory; Itasetron (DAU 6215) (Pitsikas, N. (311) 115)

Jejunum, rat; Smooth muscle contraction; 5-ht$_7$ receptor; Neurokinin, tachykinin NK$_2$ receptor; 5-HT (5-hydroxytryptamine, serotonin) (McLean, P.G. (312) 215)

Δ^9-Tetrahydrocannabinol; Nucleus tractus solitarii; Nausea; Glucose; Catecholaminergic neuron (Himmi, T. (312) 273)

Substance P; Bezold-Jarisch reflex; Capsaicin; (+)-Tubocurarine (Malinowska, B. (315) 159)

5-HT$_3$ receptor agonist; N1E-115 cells; NG 108-15 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

5-HT$_4$ receptor
[^{3}H]GR 113808; Radioligand binding; Desensitization (Ansanay, H. (298) 165)

Splice variant; Affinity state; Radioligand binding (Adham, N. (304) 231)

5-HT$_3$ receptor; Tachykinin; Colon, guinea-pig; Tetrodotoxin; Enteric nerve (Briejer, M.R. (308) 173)

5-HTP (5-hydroxytryptophan); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; SB 204070; Defecation; (Mouse) (Banner, S.E. (308) 181)

5-ht$_7$ receptor
Jejunum, rat; Smooth muscle contraction; 5-HT$_3$ receptor; Neurokinin, tachykinin NK$_2$ receptor; 5-HT (5-hydroxytryptamine, serotonin) (McLean, P.G. (312) 215)

5-HT receptor antagonist
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{2A}$ receptor; 5-HT$_{2C}$ receptor; Phosphoinositide hydrolysis; Aryloxyalkylimidazoline (Siegel, B.W. (296) 307)

5-HTP (5-hydroxytryptophan); 5-HT (5-hydroxytryptamine, serotonin); 5-HT$_4$ receptor; SB 204070; Defecation; (Mouse) (Banner, S.E. (308) 181)

5-HT (5-hydroxytryptamine, serotonin); Stomach; Contraction; Relaxation; (Guinea pig) (Tamura, T. (308) 315)

5-HT$_{1A}$ receptor agonist
Stress; Hyperthermia; Temperature; Anxiety; Benzodiazepine; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

Haloperidol; Clozapine; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; S 14506; Gnawing; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

5-HT (5-hydroxytryptamine, serotonin) level, extracellular; Microdialysis; (*S*)-WAY100135; WAY100635 (Assié, M.-B. (304) 15)

5-HT$_{1B}$ receptor antagonist
5-HT$_{1D}$ receptor antagonist; Ketanserin; GR 127,935; 5-HT$_{1D}$ receptor, human, cloned; 5-HT$_{1B}$ receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-HT$_{1D}$ receptor antagonist
Ketanserin; 5-HT$_{1B}$ receptor antagonist; GR 127,935; 5-HT$_{1D}$ receptor, human, cloned; 5-HT$_{1B}$ receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-HT$_3$ receptor agonist
Discriminative stimulus; Ethanol; 5-HT$_3$ receptor antagonist (Stefanski, R. (309) 141)

5-HT$_3$ receptor; N1E-115 cells; NG 108-15 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

5-HT$_3$ receptor antagonist
Discriminative stimulus; Ethanol; 5-HT$_3$ receptor agonist (Stefanski, R. (309) 141)

5-HT$_4$ receptor antagonist
Anxiety; 5-HT (5-hydroxytryptamine, serotonin); Elevated plus-maze (Silvestre, J.S. (309) 219)

5-HT receptor, brain
Paracetamol; Antinociception; 5-HT (5-hydroxytryptamine, serotonin) (Pini, L.A. (308) 31)

5-HT$_3$ receptor, cloned, rat
5-HT$_3$ receptor; [^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Cerebral cortex; Ileum; Colon (Akuzawa, S. (296) 227)

5-HT$_{1A}$ receptor, human
PET (positron emission tomography); [*carbonyl*-^{11}C]WAY-100635 (Pike, V.W. (301) R5)

5-HT$_{1B}$ receptor, human, cloned
5-HT$_{1D}$ receptor antagonist; Ketanserin; 5-HT$_{1B}$ receptor antagonist; GR 127,935; 5-HT$_{1D}$ receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-HT$_{1D}$ receptor, human, cloned
5-HT$_{1D}$ receptor antagonist; Ketanserin; 5-HT$_{1B}$ receptor antagonist; GR 127,935; 5-HT$_{1B}$ receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-HT$_{2A}$ receptor, peripheral
Food intake; 2-Deoxy-D-glucose; 5-HT$_3$ receptor, peripheral; α-Methyl-5-HT (α-methyl-5-hydroxytryptamine); 2-Methyl-5-HT (2-methyl-5-hydroxytryptamine) (Sugimoto, Y. (316) 15)

5-HT$_3$ receptor, peripheral
Food intake; 2-Deoxy-D-glucose; 5-HT$_{2A}$ receptor, peripheral; α-Methyl-5-HT (α-methyl-5-hydroxytryptamine); 2-Methyl-5-HT (2-methyl-5-hydroxytryptamine) (Sugimoto, Y. (316) 15)

5-HT$_{1A}$ receptor, postsynaptic
Microdialysis, in vivo; Citalopram; WAY-100635; Penbutolol enantiomer; 5-HT$_{1A}$ autoreceptor, raphe; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

5-HT receptors
Ibogaine; Noribogaine; Adenylyl cyclase; Opioid receptors; Muscarinic acetylcholine receptors (Rabin, R.A. (316) 343)

5-HT receptor subtype
Corticosterone; Lower lip retraction; Penile erection; Head shake; Open field behavior (Berendsen, H.H.G. (308) 103)

5-HT recognition site
Duodenum, rat; Ileum, rat; [^{125}I]*S*-(−)-Zacopride; Autoradiography (Ge, J. (300) 113)

5-HT release
Stress; 5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{1B}$ receptor (Bolaños-Jiménez, F. (294) 531)

5-HT syndrome
5-HT$_{1A}$ receptor; Hyperphagia; Hypothermia; Tail-flick; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (O'Connell, M.T. (312) 137)

5-HT uptake inhibitor
5-HT (5-hydroxytryptamine, serotonin); Antidepressant; Microdialysis; Hypothalamus, rat (Moret, C. (295) 189)

5-HTP (5-hydroxytryptophan)
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; 5-HT$_4$ receptor; SB 204070; Defecation; (Mouse) (Banner, S.E. (308) 181)

Human
Synovial cell; Glucose uptake; Anti-inflammatory drug; Osteoarthritis; Rheumatoid arthritis (Hernvann, A. (314) 193)

Human bronchus
Contraction; Protein kinase C; Na^+/K^+-ATPase; Ca^{2+} channel (Yang, K.X.F. (315) 65)

Human mGlu$_{1d}$
Metabotropic glutamate receptor; Ca^{2+} fluorescence (Laurie, D.J. (296) R1)

Metabotropic glutamate receptor; Ca^{2+} fluorescence (Laurie, D.J. (302) 229)

Huntington's disease
Parkinson's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT$_1$ receptor; Angiotensin AT$_2$ receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II; Brain, human (Ge, J. (297) 299)

Hybridization, in situ
β-Adrenoceptor; mRNA; Northern blot analysis (Mak, J.C.W. (302) 215)

Sertraline; Glutamic acid decarboxylase mRNA; Brain (Giardino, L. (312) 183)

Hydrogen peroxide
Endothelium; Albumin transfer; Sodium nitroprusside; Glyceryl trinitrate (McQuaid, K.E. (307) 233)

Free radical; Non-steroidal anti-inflammatory drug; Horseradish peroxidase; Glutathione peroxidase; Scavenging (Parij, N. (311) 259)

3α-Hydroxy-5β-pregnan-20-one
SR 95531; Neuroactive steroid; Neurosteroid; $GABA_A$ receptor; RU 5135; Pregnenolone sulfate (Hawkinson, J.E. (304) 141)

6-Hydroxydopamine
DAMGO ([D-Ala^2,*N*-Me-Phe^4,Gly^5-ol]enkephalin); DPLPE ([D-Pen^2,L-Pen^5]enkephalin); Dynorphin A-(1–13); Apomorphine; (Mouse) (Toyoshi, T. (294) 637)

Sympathetic nerve; Mast cell; Dorsal skin (Cambridge, H. (301) 151)

Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Hydroxylamine
$GABA_A$ receptor; Benzodiazepine; Flunitrazepam; Ro 15-4513 (Duncalfe, L.L. (298) 313)

Pancreatic islet, rat; Insulin release; K^+ channel, ATP-sensitive; Nitric oxide (NO) (Antoine, M.-H. (313) 229)

Hydroxyl radical
IT-066; Ischemia-reperfusion injury; Gastric mucosal acute injury; Histamine H_2 receptor antagonist; Superoxide radical (Naito, Y. (294) 47)

N-Allylsecoboldine; Antioxidant; Lipid peroxidation; Peroxyl radical; Hypercoagulability; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

5-Hydroxypropafenone
Propafenone; Sinoatrial node automaticity; His bundle automaticity; Atrial myocardium refractoriness; AV node refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

2-Hydroxy-saclofen
$GABA_B$ receptor; (−)-Baclofen; 3-Amino-propylphosphinic acid; Phaclofen; CGP 35348; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

5-Hydroxytryptophan
Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; GR 127935; WAY 100635; $5\text{-}HT_{1D}$ receptor; $5\text{-}HT_{1A}$ receptor; (Guinea-pig) (Hagan, J.J. (294) 743)

Hyperalgesia
CGRP (calcitonin gene-related peptide); Indomethacin; Interleukin-1 receptor antagonist (Malcangio, M. (299) 113)

NMDA receptor; AMPA receptor; Spinal cord; (Mouse) (Brambilla, A. (305) 115)

Substance P; Neurokinin A; Tachykinin NK_1 receptor; Nociception; Analgesia (Yashpal, K. (308) 41)

Dorsal horn; Intermediolateral cell column; Immunohistochemistry; Tail-flick; Spinal cord; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

Hypercholesterolemia
Dahl salt-sensitive rat; Endothelium-dependent relaxation; High-cholesterol diet; Hypertension (Kitagawa, S. (297) 71)

Nitric oxide (NO); Sphincter of Oddi (Szilvassy, Z. (301) R17)

Taurine; Diabetes; Endothelium; LDL (low-density lipoprotein); Cholesterol (Kamata, K. (303) 47)

Hypercoagulability
N-Allylsecoboldine; Antioxidant; Lipid peroxidation; Peroxyl radical; Hydroxyl radical; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

Hyperemia
Cheek pouch, hamster; Microvascular flow; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Hyperglycemia
mCPP (1-(3-chlorophenyl)piperazine); $5\text{-}HT_{2C/2B}$ receptor; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); $5\text{-}HT_{2A}$ receptor (Sugimoto, Y. (307) 75)

Hyperinsulinemic euglycemic clamp
M16209; Insulin resistance; Genetically obese rodent; Antihyperglycemic effect (Murakami, N. (304) 129)

Hyperosmolarity
Protein kinase C; Genistein; Staurosporine; Uterus, rat (Ausina, P. (312) 309)

Hyperphagia
$5\text{-}HT_{1A}$ receptor; 5-HT syndrome; Hypothermia; Tail-flick; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (O'Connell, M.T. (312) 137)

Benzodiazepine; Brain stem; Parabrachial nucleus; Palatability; (Rat) (Higgs, S. (313) 1)

Hyperplasia
Balloon catheterization; HMG-CoA reductase inhibitor (Bandoh, T. (315) 37)

Hyperpolarization-activated current (I_f)
Automaticity; Ventricular arrhythmia; Zatebradine; Heart, dog (Furukawa, Y. (300) 203)

Hypersensitivity to neuropeptide Y
Monosodium glutamate; Neurotoxicity; Meal size and duration; Hypophagia; Arcuate nucleus (Stricker-Krongrad, A. (295) 27)

Hypertension
Endothelin receptor antagonist; Renal blood flow (Bird, J.E. (294) 183)

Angiotensin II receptor subtype; L-163,017; Renin-angiotensin system (Chang, R.S.L. (294) 429)

Na^+ excretion; α_1-Adrenoceptor subtype; Kidney function (Sattar, M.A. (294) 727)

Dahl salt-sensitive rat; Endothelium-dependent relaxation; High-cholesterol diet; Hypercholesterolemia (Kitagawa, S. (297) 71)

Ethanol, chronic; Spontaneously hypertensive rat (SHR); Papillary muscle (Brown, R.A. (302) 61)

α_2-Adrenoceptor; Phospholipase D; Smooth muscle, vascular; Tyrosine kinase; $pp60^{src}$; Protein kinase C (Jinsi, A. (302) 183)

N^G-Nitro-L-arginine; Methylene blue; Endothelium; Nitric oxide (NO); Aorta, rat; Arterial pressure (Gil-Longo, J. (310) 175)

Diabetes; Angiotensin; Blood perfused; Nephropathy; Kidney; (Rat) (Farina, N.K. (310) 185)

Blood pressure; Spinal cord; Muscarinic receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Feldman, D.S. (313) 211)

K^+ channel, ATP-sensitive; Myocardial hypertrophy; Trypsin; Single-channel recording (Sodder, V.H. (315) 115)

Ethanol; BNP (brain natriuretic peptide) (Guillaume, P. (316) 49)

Hyperthermia
Stress; Temperature; Anxiety; Benzodiazepine; 5-HT_{1A} receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

Hyperthyroidism
Resistance artery, small; Thromboxane A_2 receptor agonist; 5-HT (5-hydroxytryptamine, serotonin); Endothelial modulation (Zwaveling, J. (300) 91)

Hypervolemia
5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

Hypnosis
Ethanol; IGF-I (insulin-like growth factor I); IGF binding protein 1; Ataxia; Hypothermia; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

Hypnotic
N^3-Phenacyluridine; Sedative; Central nervous system; Benzodiazepine receptor (Kimura, T. (311) 265)

Zolpidem; Zaleplon; BZ (ω) receptor (Sanger, D.J. (313) 35)

Hypophagia
Monosodium glutamate; Neurotoxicity; Meal size and duration; Hypersensitivity to neuropeptide Y; Arcuate nucleus (Stricker-Krongrad, A. (295) 27)

Fluoxetine; 5-HT_{2C} receptor; (Rat); (Pig) (Lightowler, S. (296) 137)

Hypotension
Adenosine A_3 receptor; Mast cell; Histamine; APNEA (N^6-2-(4-aminophenyl)ethyladenosine); Compound 48/80 (Fozard, J.R. (298) 293)

Choline; Acetylcholine; Blood pressure; Vasopressin; Nicotinic receptor (Savci, V. (311) 153)

Hypothalamus
5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

Opioid receptor; δ-Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Anorexia; Food intake; Aging; Nitric oxide (NO) synthase; Nitric oxide (NO) (Morley, J.E. (311) 15)

Hypothalamus, rat
5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor; Antidepressant; Microdialysis (Moret, C. (295) 189)

Hypothermia
Ethanol; IGF-I (insulin-like growth factor I); IGF binding protein 1; Ataxia; Hypnosis; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

5-HT_{1A} receptor; 5-HT syndrome; Hyperphagia; Tail-flick; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (O'Connell, M.T. (312) 137)

Hypothyroidism
K_{ATP} channel; Portal vein; Pinacidil; Cromakalim; Glibenclamide (Jagadish, M. (309) 63)

Hypovolemia
N-Nitro-L-arginine methyl ester; L-Arginine; Naloxone; Hemorrhagic shock; Nitric oxide (NO); (Conscious rabbit) (Ventura, S. (294) 369)

5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Push-pull cannula (Singewald, N. (294) 787)

Hypoxia
Diabetic neuropathy; 2,3-Diphosphoglycerate; Polyol pathway; Aldose reductase inhibitor (Nakamura, J. (294) 207)

K_{ATP} channel; Pulmonary artery; Pulmonary vasoconstrictor; Hypoxic pulmonary vasoconstriction (Wanstall, J.C. (303) 71)

ATP; Ca^{2+} channel antagonist; Cardiomyocyte; CN^-; Ca^{2+} channel, L-type (Stokke, M. (303) 115)

Cell activation; Endothelium; Neutrophil adherence; Aescine; Reparil (Arnould, T. (315) 227)

Hypoxia / reoxygenation injury
Ramiprilat; Angiotensin-converting enzyme inhibitor; Bradykinin; Bradykinin B_2 receptor antagonism; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Cardiac myocyte (Wall, T.M. (306) 165)

Hypoxic pulmonary vasoconstriction
Hypoxia; K_{ATP} channel; Pulmonary artery; Pulmonary vasoconstrictor (Wanstall, J.C. (303) 71)

Iberiotoxin
Tremorgenic indole alkaloid; Ca^{2+}-activated K^+ channel; Charybdotoxin; Excitation-contraction coupling (DeFarias, F.P. (314) 123)

IBMX (3-isobutyl-1-methylxanthine)
Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; Intracellular signal transduction system; H-89; KT5823; W-7; Neurone; (Snail) (Emaduddin, M. (302) 129)

Ibogaine
NMDA receptor; *O*-Desmethylibogaine; Morphine; Naloxone (Layer, R.T. (309) 159)

Noribogaine; Adenylyl cyclase; 5-HT receptors; Opioid receptors; Muscarinic acetylcholine receptors (Rabin, R.A. (316) 343)

Idazoxan
Imidazoline I_2 receptor; [^{3}H]2-(2-Benzofuranyl)-2-imidazoline; Clonidine (Lione, L.A. (304) 221)

Imidazoline receptor; Anti-idiotypic antibody; Brain, human (Bennai, F. (306) 211)

Idrapril
Ischemia; Reperfusion; Angiotensin-converting enzyme; Captopril; Heart; (Rat) (Riva, E. (312) 293)

Ifenprodil
Pain; Analgesia; Polyamine; NMDA receptor; Morphine; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

5,7-Dichlorokynurenic acid; HA-966 (3-amino-1-hydroxy-2-pyrrolidone); Dizocilpine; Phencyclidine; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); 5-HT_{2C} receptor (Mazzola-Pomietto, P. (308) 329)

Ifenprodil stereoisomer
Recombinant NMDA receptor; *Xenopus* oocyte; Voltage clamp (Avenet, P. (296) 209)

IGF binding protein 1
Ethanol; IGF-I (insulin-like growth factor I); Ataxia; Hypothermia; Hypnosis; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

IGF-I (insulin-like growth factor I)
Ethanol; IGF binding protein 1; Ataxia; Hypothermia; Hypnosis; Tolerance; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

Ileum
σ Binding site; Smooth muscle; σ Receptor subtype; (Guinea pig); (Rat) (Kinney, G.G. (294) 547)

5-HT_3 receptor; [^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Cerebral cortex; Colon; 5-HT_3 receptor, cloned, rat (Akuzawa, S. (296) 227)

Ileum, guinea-pig
$GABA_B$ receptor; Baclofen; AHPNs ((*R,S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide); $GABA_B$ receptor antagonist; Neocortex, rat (Kerr, D.I.B. (294) 349)

Ileum, rat
5-HT recognition site; Duodenum, rat; [^{125}I]*S*-(−)-Zacopride; Autoradiography (Ge, J. (300) 113)

Aging; Nitric oxide (NO); ATP; Non-adrenergic non-cholinergic (NANC) (Smits, G.J.M. (303) 79)

Ca^{2+} store; Mn^{2+} influx; Ryanodine; Thapsigargin (Tabo, M. (313) 151)

Illicit synthesis
Methamphetamine; Synthetic impurity; NMDA receptor; Dopamine transporter; BNMPA (α-benzyl-*N*-methylphenethylamine) (Moore, K.A. (311) 133)

Imidazole-preferring binding site
α_2-Adrenoceptor; Spinal cord, neonatal; Spinal cord, adult; Cerebral cortex; Imidazole receptor (Savola, M.K.T. (306) 315)

Imidazole receptor
α_2-Adrenoceptor; Spinal cord, neonatal; Spinal cord, adult; Cerebral cortex; Imidazole-preferring binding site (Savola, M.K.T. (306) 315)

Imidazoline
α_2-Adrenoceptor; Adrenaline; Insulin release; (In vivo); (Rat) (Hiyoshi, Y. (294) 117)

Imidazoline binding site
K^+ channel; Erythrocyte; Clotrimazole; Efaroxan (Coupry, I. (295) 109)

Imidazoline-binding site
Striatum; Monoamine oxidase; *Conus* venom; (Calf) (Czerwiec, E. (315) 99)

Imidazoline binding sites
RX821002; α_2-Adrenoceptors; Kidney, rat (Callado, L.F. (316) 359)

Imidazoline drug
NMDA receptor; Phencyclidine site; [^{3}H](+)-MK-801; K^+ channel, ATP-sensitive (Olmos, G. (310) 273)

Imidazoline receptor
Idazoxan; Anti-idiotypic antibody; Brain, human (Bennai, F. (306) 211)

Vas deferens; Noradrenaline; Agmatine; Neurotransmission; Adrenoceptor (Jurkiewicz, N.H. (307) 299)

Agmatine; Efaroxan; Insulin secretion; Vessel; Pancreas, rat (Berdeu, D. (308) 301)

Imidazoline I_2 receptor
Brain, human; Extrapyramidal disorder (Reynolds, G.P. (301) R19)

[^{3}H]2-(2-Benzofuranyl)-2-imidazoline; Idazoxan; Clonidine (Lione, L.A. (304) 221)

Imidazopyridine
PET (positron emission tomography); [^{11}C]Flumazenil; Benzodiazepine receptor, central (Abadie, P. (295) 35)

L-N^6-(1-Iminoethyl)-lysine
Aminoguanidine; Nitric oxide (NO) synthase, inducible; Leishmaniasis; Nitric oxide (NO); N^G-Monomethyl-L-arginine (Stenger, S. (294) 703)

Imipramine
Antidepressant; 5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); 5-HT (5-hydroxytryptamine, serotonin); Baclofen; Hippocampal slice (Bijak, M. (305) 79)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Fluoxetine; Motion sickness (Okada, F. (309) 33)

D-cycloserine; Stress; Chronic; Anhedonia; Antidepressant action; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

Immediate early gene
Ethanol tolerance; Arginine vasopressin; c-*fos* (Szabó, G. (306) 67)

Anxiety; Elevated X-maze; CI-988; Benzodiazepine; CCK (cholecystokinin) (Hinks, G.L. (312) 153)

Oligodeoxynucleotide; Growth factor (Sachinidis, A. (309) 95)

Immobility behaviour
Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

Immobilization stress
Interleukin-6, plasma; MK-801; NMDA (*N*-methyl-D-aspartate); (Mouse) (Song, D.-K. (316) 165)

Immune function
Lymphocyte; Ca^{2+} channel; PN 200-110; Radioligand binding; (Human) (Ricci, A. (301) 189)

Immunohistochemistry
Dorsal horn; Intermediolateral cell column; Hyperalgesia; Tail-flick; Spinal cord; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

Adrenomedullin; Amylin; cAMP; Mesangial cell, cultured, rat; CGRP (calcitonin gene-related peptide) (Osajima, A. (315) 319)

IMR-32 human neuroblastoma cell line
CRF receptor; Differentiation; Radioligand binding; Adenylate cyclase (Hogg, J.E. (312) 257)

Inactivation
Ca^{2+} channel; Whole-cell voltage-clamp; Dissociated Purkinje neuron; Eliprodil (Biton, B. (294) 91)

Charybdotoxin; Dendrotoxin; Voltage dependence; Channel kinetics; Deactivation (Sprunger, L.K. (314) 357)

Individual difference
Amphetamine; Microdialysis; Dopamine; Nucleus accumbens; (Rat) (Sills, T.L. (303) 177)

Novelty; $GABA_A$; Psychostimulant; Cortex; Locomotion; Basal ganglia (Gruen, R.J. (309) 115)

Indomethacin
CGRP (calcitonin gene-related peptide); Interleukin-1 receptor antagonist; Hyperalgesia (Malcangio, M. (299) 113)

Gram-negative sepsis; TMF (tumor necrosis factor); Cyclooxygenase inhibitor; Sepsis (Campanile, F. (307) 191)

Inescapable footshock
$5\text{-}HT_{1A}$ receptor; Defensive burying; Plus-maze; 5-HIAA/5-HT (5-hydroxy-indole acetic acid/5-hydroxytryptamine) ratio (Barf, T. (297) 205)

Inflammation
Pain; Adrenoceptor agonist; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)

Sauvagine; Urotensin I; CRF (corticotropin-releasing factor) receptor; Extravasation; ACTH (adrenocorticotropin) (Turnbull, A.V. (303) 213)

Carrageenan; Peroxynitrite (Salvemini, D. (303) 217)

Phospholipase A_2; Transgenic mouse; Phospholipase inhibitor (Fox, N. (308) 195)

Nitric oxide (NO) synthase, inducible; Ethanol; Blood-brain barrier; RBE4 cell; Endotoxin; Nitric oxide (NO) (Naassila, M. (313) 273)

Antiflammin; Arachidonic acid; Phospholipase A_2; Chemotaxis; Anti-inflammatory drug (Moreno, J.J. (314) 129)

Pulmonary eosinophilia; Leukotriene B_4; Leukotriene C_4; Leukotriene D_4; Leukotriene E_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Superoxide; Mitochondrial respiration; Shock; Endotoxin; Nitric oxide (NO) (Szabó, C. (315) 221)

Inflammatory bowel disease
Endothelin; Intestinal inflammation; Bosentan (Hogaboam, C.M. (309) 261)

Inflammatory hyperalgesia
Carbamazepine; Edema; Nociception; Prostaglandin; Substance P (Bianchi, M. (294) 71)

Inflammatory pain
Carrageenan; c-Fos; Niflumic acid; (+)-HA966; Spinal cord; (Rat) (Buritova, J. (303) 91)

Inhalant abuse
Toluene; 1,1,1-Trichloroethane; Methoxyflurane; Flurothyl; Anxiolytic; Plus-maze; (Mouse) (Bowen, S.E. (312) 131)

Inhibition
Purinergic; Micturition volume threshold; Nitric oxide (NO) (Theobald Jr., R.J. (311) 73)

Inhibitory avoidance task
Glutamate; Acetylcholine; NMDA receptor; Learning; Memory (Ohno, M. (312) 145)

Inositol phosphate
CCK_A receptor; Adenosine A_1 receptor; $5\text{-}HT_{1B}$ receptor; P_{2U} purinoceptor; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (302) 141)

Endothelin; Sarafotoxin; Big endothelin-1; Spinal cord; Endothelin ET_A receptor (Poulat, P. (315) 327)

Inositol trisphosphate
Aging; ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate); Arachidonic acid; Glutamate release; Protein kinase C (McGahon, B. (309) 323)

Inositol-1,4,5-trisphosphate
Opioid withdrawal; Metabotropic glutamate receptor; Protein kinase C; Chelerythrine; Thapsigargin (Fundytus, M.E. (300) 173)

μ-Opioid receptor; SH-SY5Y cell; Phospholipase C; Tyr-D-Arg^2-Phe-sarcosine^4 (TAPS) (Smart, D. (305) 235)

CCK_B receptor; Neostriatal neuron; Cationic current; G-protein; Whole-cell patch-clamp recording (Wu, T. (307) 125)

κ-Opioid receptor, tolerance; Ca^{2+}, intracellular, free; Myocyte, ventricular; U50,488H (Sheng, J.-Z. (307) 323)

SK-N-BE(2)C human neuroblastoma; Phospholipase C; U-73122; cAMP production; Ca^{2+} mobilization; Neomycin (Suh, B.-C. (314) 235)

Inotropes
Isovolumic relaxation; Ventricular filling; Myocardial contractility; Preload recruitable stroke work; Dobutamine; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

Inotropic drug
Heart failure; K^+ channel, ATP-sensitive; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

Inotropic effect, negative
CD-832; Ca^{2+} channel antagonist; Myocardium; Chronotropic effect, negative; (Guinea-pig) (Noguchi, K. (308) 53)

Inotropism
Bertosamil; K^+ channel, ATP-sensitive; Ca^{2+} channel, L-type; Chronotropism; Heart, dog (Yonezawa, T. (309) 51)

Parasympathetic nervous system; Acetylcholine; Chronotropism; Heart; PACAP-38 (pituitary adenylate cyclase-activating polypeptide-38); PACAP-(6–38) (pituitary adenylate cyclase-activating polypeptide-(6–38)); (Dog) (Yonezawa, T. (315) 289)

Inotropy
Sodium fluoride; Carbachol; (−)-N^6-Phenylisopropyl-adenosine; Phosphatase (Neumann, J. (294) 451)

Benzodiazepine; Diazepam; Heart preparation, isolated; Peripheral-type benzodiazepine receptor antagonist (Leeuwin, R.S. (299) 149)

Benzodiazepine; Diazepam; Langendorff heart; Ca^{2+}-entry blocking drug; Adenosine receptor blocking drug (Leeuwin, R.S. (315) 153)

In situ hybridization
Electroshock; G-protein; GTP-binding protein; Messenger RNA (McGowan, S. (306) 249)

Glutamate; Dentate gyrus; Dizocilpine; Schizophrenia (Healy, D.J. (306) 257)

Insulin
Glucose; Pancreatic islet, blood flow; Blood pressure; β-Adrenoceptor (Atef, N. (298) 287)

Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Carnitine; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

S6 kinase, 90 kDa; Glycogen synthesis; Protein phosphatase 1G; EGF (epidermal growth factor) (Yasui, K. (316) 317)

Insulin receptor
(Takada, Y. (308) 205)

Insulin release
Imidazoline; α_2-Adrenoceptor; Adrenaline; (In vivo); (Rat) (Hiyoshi, Y. (294) 117)

Sulphonylurea; Tolbutamide; Glibenclamide; Pancreatic B-cell; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Capsaicin; Pancreatic islet; Blood flow; Pancreas; Peptidergic neuron (Carlsson, P.-O. (312) 75)

Pancreatic islet, rat; Hydroxylamine; K^+ channel, ATP-sensitive; Nitric oxide (NO) (Antoine, M.-H. (313) 229)

Insulin resistance
M16209; Genetically obese rodent; Hyperinsulinemic euglycemic clamp; Antihyperglycemic effect (Murakami, N. (304) 129)

Insulin secretion
Agmatine; Efaroxan; Imidazoline receptor; Vessel; Pancreas, rat (Berdeu, D. (308) 301)

Troglitazone; K_{ATP} channel; β Cell (Lee, K. (313) 163)

Intact cell binding
Adrenoceptor; Desensitization; Internalization; Up-regulation (Zhu, S.-J. (299) 205)

Integrin $\alpha_v\beta_3$
Ancrod-generated fibrin; Prostacyclin; Pertussis toxin; Phospholipase C (Chang, M.C. (297) 129)

Intercellular adhesion molecules
Butein; Anti-GBM nephritis; Endothelial cells; Leukocyte, polymorphonuclear (Hayashi, K. (316) 297)

Interdose interval
Methamphetamine; Cocaine; Morphine; Ambulatory sensitization; (Mouse) (Kuribara, H. (316) 1)

Interferon-γ
Muscarinic receptor (Mita, Y. (297) 121)

Nitric oxide (NO) synthase, inducible; Herbimycin A; Janus kinase; Signal transducer and activator of transcription-1 (STAT1); Microglia (Kitamura, Y. (306) 297)

Intergeniculate leaflet
Melatonin; Suprachiasmatic nucleus; Electrophysiology; Light; Circadian rhythm; Entrainment (Ying, S.-W. (296) 33)

Interleukin-1
CINC (cytokine-induced neutrophil chemoattractant); cAMP; Interleukin-6; Prostaglandin E_2; Prostaglandin I_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Water intake; Lipopolysaccharide; Interleukin-1 receptor; Antagonist; (Human) (Nava, F. (309) 223)

Lipopolysaccharide; Disseminated intravascular coagulation; TNF-α (tumor necrosis factor-α) (Yamamoto, N. (314) 137)

Nitrite; Nitric oxide (NO) synthase (Ikeda, U. (314) 197)

Interleukin-1β
Dipyridamole; Nitric oxide (NO); Smooth muscle cells, vascular; Cyclic nucleotide (Iimura, O. (296) 319)

Biphasic effect; Mechanical nociception; (Rat) (Yabuuchi, K. (300) 59)

Phospholipase A_2; cAMP; Tetranactin; Renal mesangial cell (Walker, G. (306) 265)

CRF (corticotropin-releasing factor); Anxiety; Fever; CRF receptor antagonist (Lundkvist, J. (309) 195)

Diabetes; Smooth muscle cell, vascular; Growth; Nitric oxide (NO) (Etienne, P. (311) 79)

Interleukin-2
Jatrophone; Natural killer activity; Lymphocyte proliferation; Protein kinase C; 12-*O*-Tetradecanoylphorbol 13-acetate; CD69 (Gonçalves de Moraes, V.L. (312) 333)

Interleukin-6
CINC (cytokine-induced neutrophil chemoattractant); cAMP; Interleukin-1; Prostaglandin E_2; Prostaglandin I_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Interleukin-6, plasma
MK-801; Immobilization stress; NMDA (*N*-methyl-D-aspartate); (Mouse) (Song, D.-K. (316) 165)

Interleukin-1 receptor
Water intake; Lipopolysaccharide; Interleukin-1; Antagonist; (Human) (Nava, F. (309) 223)

Interleukin-1 receptor antagonist
CGRP (calcitonin gene-related peptide); Indomethacin; Hyperalgesia (Malcangio, M. (299) 113)

Intermediate lobe
Median eminence; Pentazocine; Haloperidol; Raclopride; Prolactin secretion; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

Intermediolateral cell column
Dorsal horn; Immunohistochemistry; Hyperalgesia; Tail-flick; Spinal cord; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

Internalization
Adrenoceptor; Desensitization; Up-regulation; Intact cell binding (Zhu, S.-J. (299) 205)

VIP receptor, human; VIP receptor antagonist; Desensitization; Recombinant protein; Transfection (Gaudin, P. (302) 207)

Intestinal
Secretion; 5-HT receptor; Short-circuit current; cAMP (Budhoo, M.R. (298) 137)

Intestinal erythrocyte extravasation
Lipopolysaccharide; Phosphodiesterase inhibitor (Cardelús, I. (299) 153)

Intestinal fluid transport
K^+ channels; Prostaglandin E_2; *Escherichia coli* enterotoxin-induced secretion; Nitric oxide (NO); N^{ω}-nitro-L-arginine methyl ester (L-NAME) (Schirgi-Degen, A. (316) 257)

Intestinal inflammation
Endothelin; Inflammatory bowel disease; Bosentan (Hogaboam, C.M. (309) 261)

Intestinal prokinetic drug
Gastrointestinal tract; Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Benzamide, substituted (Zafirov, D. (311) 61)

Intestinal secretion
Nitric oxide (NO); Senna; Cascara; Anthraquinone; Laxative (Izzo, A.A. (301) 137)

Intestinal transit
5-HT_3 receptor; Prokinetic benzamide; (Mouse) (Nagakura, Y. (311) 67)

Intestinal vascular bed
Angiotensin peptide; DuP532; PD123,319; Enalaprilat; Angiotensin II; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Intestine
Ketotifen; Noradrenaline; Nitric oxide (NO); Smooth muscle (Abu-Dalu, R. (309) 189)

Gastrointestinal tract; Ganglion; Enteric nervous system; Myenteric plexus; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Ganglion; Enteric nervous system; Myenteric plexus; Histamine; cAMP; Adenylate cyclase (Xia, Y. (316) 81)

Intestine, small
K^+ channel, drug effect; Glibenclamide (Davies, M.P. (297) 249)

Intimal thickening
Vascular reactivity; Glucocorticoid; Nitric oxide (NO); Endothelium; Carotid artery, rabbit (Van Put, D.J.M. (294) 753)

Tranilast; Photochemically induced thrombosis; Endothelial injury; Smooth muscle cell proliferation (Kikuchi, S. (295) 221)

Intracellular pH
NH_4Cl; Vasoconstriction; Coronary artery (Wakabayashi, I. (299) 139)

Intracellular signal transduction system
Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; H-89; KT5823; W-7; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

Intracranial pressure
Bradykinin; Hoe140; Pneumococcal meningitis; Cerebral blood flow; Brain edema (Lorenzl, S. (308) 335)

Intrathecal
α-Trinositol; Antinociception; Formalin test; Behavior; (Rat) (Malmberg, A.B. (294) 609)

Intrathecal administration
Dynorphin A; Dynorphin B; Dynorphin-converting enzyme; Formalin test; Peptidohydrolase; (Mouse) (Tan-No, K. (314) 61)

Intravital microscopy
Flow cytometry; Blood pressure, mean arterial; Leukocyte rolling; Leukocyte adherence; Venular shear rate (Scalia, R. (296) 181)

Intrinsic activity
Dopamine hD_{2l} receptor; Dopamine $hD_{4.4}$ receptor (Lahti, R.A. (301) R11)

T-0509; β_1-Adrenoceptor agonist; β_3-Adrenoceptor; Adenylyl cyclase (Sato, Y. (315) 363)

Inverse agonist
β-CCE (ethyl β-carboline-3-carboxylate); Benzodiazepine receptor; Down-regulation; Primary cultured neuron (Katsura, M. (298) 71)

Inward current
5-HT_3 receptor; 5-HT_3 receptor agonist; N1E-115 cells; NG 108-15 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Emesis; (Rat) (Delagrange, P. (316) 195)

2-[^{125}I]Iodomelatonin
Melatonin; Receptor autoradiography; Visual system; (Reptile) (Larson-Prior, L.J. (297) 181)

2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML_2 receptor; Melatonin; Brain, hamster; Kidney; Testes (Molinari, E.J. (301) 159)

Ion dependence
Dopamine carrier, neuronal; Binding, in vitro; K^+ gradient (Héron, C. (301) 195)

Ion transport
Loop of Henle; [Arg^8]Vasopressin; Microperfusion, in vitro (Grider, J. (313) 115)

Ipsapirone
Dopamine; Cortex, prefrontal; 5-HT$_{1A}$ receptor; WAY 100135; NAN-190; Microdialysis (Wędzony, K. (305) 73)

1,4,5-IP$_3$-sensitive Ca^{2+} store
Diabetic pancreas; Ca^{2+} mobilization; Ca^{2+} refilling; Muscarinic receptor (Komabayashi, T. (298) 299)

Iris dilator, rabbit
Phorbol 12,13-dibutyrate (PDB); Ca^{2+} mobilization; Protein kinase C; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

IRL 1620
Pial vein; Endothelin ET$_A$ receptor; Endothelin ET$_B$ receptor; (Dog) (Fernández, N. (294) 483)

Coronary circulation; Endothelin ET$_A$ receptor; Endothelin ET$_B$ receptor; BQ-123; Nitric oxide (NO) (García, J.L. (315) 179)

IRL 1720
Sarafotoxin S6c; Endothelin ET$_B$ receptor; FR139317; Hemodynamics (Kuwahara, M. (296) 55)

Iron
Apomorphine; Free radical; Lipid peroxidation; Protein carbonyl; Ascorbate; Thiobarbituric acid (Gassen, M. (308) 219)

Isatin
Appetite; Drinking; Food intake; Motivation; 5-HT (5-hydroxytryptamine, serotonin); Tubulin; (Mouse) (Morley, J.E. (305) 23)

Ischemia
GABA (γ-aminobutyric acid); Excitatory amino acid; Seizure; Neurological disorder; Drug screening; Antiepileptic (Kanthasamy, A.G. (297) 219)

Myocardial infarction; Remodeling; Metabolism; Captopril (Kalkman, E.A.J. (298) 121)

HEK293 cell; Ca^{2+} channel, voltage-dependent; NMDA receptor antagonist; Neuroprotection; (Gerbil) (Bath, C.P. (299) 103)

Reperfusion; Angiotensin-converting enzyme; Idrapril; Captopril; Heart; (Rat) (Riva, E. (312) 293)

Growth hormone (GH) deficiency; Cardiovascular effects; Heart, rat (De Gennaro Colonna, V. (314) 333)

Ischemia-reperfusion
Rebamipide; Hepatic secretion; Drug metabolism (Lee, S.-M. (294) 41)

Cystathionine; Superoxide radical; Gastric mucosal injury; (Rat) (Wada, K. (294) 377)

Ischemia-reperfusion injury
IT-066; Gastric mucosal acute injury; Histamine H$_2$ receptor antagonist; Superoxide radical; Hydroxyl radical (Naito, Y. (294) 47)

Glutathione; Lipid peroxidation; Oxidative stress; 21-Aminosteroid; Kidney, rat (Paroni, R. (294) 737)

Ischemia, treatment
Adenosine; Memory; MAP2 (microtubule-associated protein 2); (Gerbil) (Von Lubitz, D.K.J.E. (316) 171)

Ischemic arrhythmia
Antiarrhythmic activity; Sparteine; BRB-I-28; Patch-clamp (Pugsley, M.K. (294) 319)

Ischemic brain edema
Cyclooxygenase inhibitor; KBT-3022; Arachidonic acid (Yamamoto, N. (297) 225)

Islet, mouse
Sulphonylurea; Tolbutamide; Glibenclamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive (Garcia-Barrado, M.-J. (298) 279)

Isoarecolone
Nicotine; Microdialysis; Dopamine; Nucleus accumbens (Mirza, N.R. (295) 207)

3-Isobutyl-methylxanthine
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Isoforms (p42^{mapk} and p44^{mapk})
EGF (epidermal growth factor); MAPK (mitogen-activated protein kinase); Protein kinase C; Dermal fibroblast, human (Le Panse, R. (307) 339)

Isoguvacine
Medial vestibular nucleus; Benzodiazepine tolerance; GABA receptor (Hutchinson, M.A. (301) 83)

Isomeric activity ratio
β-Adrenoceptor; β-Adrenoceptor, atypical; β$_3$-Adrenoceptor; Trimetoquinol; Atrium, rat; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

β/β$_3$-Adrenoceptor, atypical; β$_3$-Adrenoceptor; Smooth muscle, esophageal, rat; Trimetoquinol; BRL 37344 (Lezama, E.J. (308) 69)

Isoprenoid
3T3-L1 cell; Lovastatin (Nishio, E. (301) 203)

Isoproterenol
Synaptosome; Secretin; cAMP; VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Kurjak, M. (314) 165)

Isovolumic relaxation
Ventricular function; Preload recruitable stroke work; Diastolic function; Superoxide dismutase; SC-55858; SC-54417 (Lowe, D. (304) 81)

Ventricular filling; Myocardial contractility; Preload recruitable stroke work; Inotropes; Dobutamine; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

IT-066
Ischemia-reperfusion injury; Gastric mucosal acute injury; Histamine H$_2$ receptor antagonist; Superoxide radical; Hydroxyl radical (Naito, Y. (294) 47)

Janus kinase
Nitric oxide (NO) synthase, inducible; Herbimycin A; Interferon-γ; Signal transducer and activator of transcription-1 (STAT1); Microglia (Kitamura, Y. (306) 297)

Jatrophone
Natural killer activity; Lymphocyte proliferation; Protein kinase C; 12-*O*-Tetradecanoylphorbol 13-acetate; CD69; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

Jaw movement
Accumbal shell; Accumbal core; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 227)

Jaw opening reflex
NK433; Tonic vibration reflex; Tonic periodontal masseteric reflex (Ozawa, Y. (298) 57)

Jejunum
Cl^-; Cl^- secretion; 5-HT receptor; Short circuit current (Budhoo, M.R. (314) 109)

Jejunum, rat
Smooth muscle contraction; 5-ht_7 receptor; 5-HT_3 receptor; Neurokinin, tachykinin NK_2 receptor; 5-HT (5-hydroxytryptamine, serotonin) (McLean, P.G. (312) 215)

JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine)
Antidepressant; Dorsal raphe; Locus coeruleus; A10 dopamine neuron; Electrophysiology (Liégeois, J.-F. (310) 9)

J774 macrophage
Ursodeoxycholic acid; Nitric oxide (NO) synthase; Lipopolysaccharide (Hattori, Y. (300) 147)

JTH-601
α_1-Adrenoceptor subtype; Prazosin; α_{1L}-Adrenoceptor (Muramatsu, I. (300) 155)

JTP-4819
Prolyl endopeptidase; Morris water maze task; Passive avoidance task; TRH (thyrotropin-releasing hormone); Middle cerebral artery occlusion (Shinoda, M. (305) 31)

Jumping
Nicotine; Morphine; Naloxone; Acetylcholine receptor antagonist; (Mouse) (Zarrindast, M.-R. (298) 1)

Junction potential
Stomach; Smooth muscle, gastric; Membrane potential; Slow wave; Trimebutine (Xue, L. (294) 75)

K^+ channel
Endotoxin; Septic shock; DNA fragmentation; Systemic inflammatory response syndrome; Cerebral malaria (Gantner, F. (294) 353)

Erythrocyte; Clotrimazole; Efaroxan; Imidazoline binding site (Coupry, I. (295) 109)

Colon, rat; Cl^- channel; Ca^{2+}; Genistein; Protein tyrosine kinase (Diener, M. (299) 161)

Spinal neuron; Purinoceptor; G-protein; Protein kinase C; Patch clamp; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

P_{2Y} purinoceptor; G-protein; Protein kinase C; Ca^{2+} release, cytosolic; Hippocampal neuron (Ikeuchi, Y. (304) 191)

Seizure; Ca^{2+} channel; Hippocampus; Levcromakalim; Patch clamp (Katsumori, H. (311) 37)

Thyroid gland (Yoshida, A. (312) 115)

K^+ channel blocker
Spider venom; Ca^{2+} channel blocker; Endothelin-1; Nitric oxide (NO); Hoe 140 (Costa, S.K.P. (298) 113)

K^+ channel, ATP-sensitive
Sulphonylurea; Tolbutamide; Glibenclamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Inotropic drug; Heart failure; Papillary muscle; Digoxin; Milrinone (Kocić, I. (301) 115)

K^+ channel opener; K^+ channel inhibitor; Adenosine; Skeletal muscle; Diaphragm, guinea-pig (Wickenden, A.D. (302) 79)

Bertosamil; Ca^{2+} channel, L-type; Chronotropism; Inotropism; Heart, dog (Yonezawa, T. (309) 51)

NMDA receptor; Phencyclidine site; [^{3}H](+)-MK-801; Imidazoline drug (Olmos, G. (310) 273)

Pancreatic islet, rat; Insulin release; Hydroxylamine; Nitric oxide (NO) (Antoine, M.-H. (313) 229)

Hypertension; Myocardial hypertrophy; Trypsin; Single-channel recording (Sodder, V.H. (315) 115)

Berberine; Patch clamp; Microelectrode recording; Cardiac cell (Wang, Y.-X. (316) 307)

K^+ channel, Ca^{2+}-activated
NS-004; $[Ca^{2+}]_i$, free; K^+ channel, delayed rectifier; Whole cell patch clamp; Membrane potential; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

K^+ channel, Ca^{2+}-dependent
Sulfonylurea; Afterhyperpolarization (Erdemli, G. (304) 37)

Cl^- channel, Ca^{2+}-dependent; Patch clamp; Smooth muscle cell; Trachea (Henmi, S. (306) 227)

K^+ channel, cloned
Polyunsaturated fatty acid; Docosahexaenoic acid; Patch clamp, whole-cell (Garratt, J.C. (314) 393)

K^+ channel, delayed rectifier
NS-004; $[Ca^{2+}]_i$, free; K^+ channel, Ca^{2+}-activated; Whole cell patch clamp; Membrane potential; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

K^+ channel, drug effect
Intestine, small; Glibenclamide (Davies, M.P. (297) 249)

K^+ channel inhibitor
K^+ channel opener; K^+ channel, ATP-sensitive; Adenosine; Skeletal muscle; Diaphragm, guinea-pig (Wickenden, A.D. (302) 79)

K^+ channel opener
Levcromakalim; HOE 234; Bronchoconstriction; Plasma exudation (Kidney, J.C. (296) 81)

K^+ channel inhibitor; K^+ channel, ATP-sensitive; Adenosine; Skeletal muscle; Diaphragm, guinea-pig (Wickenden, A.D. (302) 79)

K^+ channels
Intestinal fluid transport; Prostaglandin E_2; *Escherichia coli* enterotoxin-induced secretion; Nitric oxide (NO); N^{ω}-nitro-L-arginine methyl ester (L-NAME) (Schirgi-Degen, A. (316) 257)

K^+ current, delayed rectifier
AV node; E-4031; Zatebradine; Heart, dog (Yamazaki, K. (297) 233)

K^+ transport
L-Arginine; Na^+ transport; Opiate; Cholinergic responses; Nitric oxide (NO) (Neumann, V. (316) 123)

K^+, extracellular
Ca^{2+} paradox; Oxygen paradox; Caffeine; Antiporter (Harding, R.J. (316) 223)

K^+ gradient
Dopamine carrier, neuronal; Binding, in vitro; Ion dependence (Héron, C. (301) 195)

K_{ATP} channel
Hypoxia; Pulmonary artery; Pulmonary vasoconstrictor; Hypoxic pulmonary vasoconstriction (Wanstall, J.C. (303) 71)

Nicorandil; Myocardial ischemia; Ventricular arrhythmia; Nitric oxide (NO); Reperfusion (Vegh, A. (305) 163)

Hypothyroidism; Portal vein; Pinacidil; Cromakalim; Glibenclamide (Jagadish, M. (309) 63)

Troglitazone; β Cell; Insulin secretion (Lee, K. (313) 163)

Kainate
NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid); Adenosine kinase; Adenosine deaminase; AICAR (AICA riboside, acadesine) (White, T.D. (303) 27)

Melatonin; Lipid peroxidation; Brain; (Rat) (Melchiorri, D. (305) 239)

Kainate-gated desensitization
Concentration jump; Hippocampal neuron; Glutamate receptor, ionotropic; AMPA/kainate receptor (Pidoplichko, V.I. (303) 145)

Kava pyrone
Epilepsy; *Piper methysticum*; Na^+ channel; Synaptosome (Gleitz, J. (315) 83)

KBT-3022
Cyclooxygenase inhibitor; Arachidonic acid; Ischemic brain edema (Yamamoto, N. (297) 225)

Ketamine hydrochloride
(+)-SKF10047; σ Receptor; (Guinea pig) (Jerram, A.H. (307) 269)

Ketanserin
5-HT_{1D} receptor antagonist; 5-HT_{1B} receptor antagonist; GR 127,935; 5-HT_{1D} receptor, human, cloned; 5-HT_{1B} receptor, human, cloned; cAMP formation; (Transfected rat C6-glial cell line) (Pauwels, P.J. (300) 141)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{2A} receptor; γ-Aminobutyric acid; Hallucinogen (Cozzi, N.V. (309) 25)

Ketorolac
Caffeine; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME); Potentiation; Antinociception (López-Muñoz, F.J. (308) 275)

Ketotifen
Bradykinin; HOE140; Bradykinin receptor; Mast cell; Vascular permeability (Morishita, M. (298) 149)

Intestine; Noradrenaline; Nitric oxide (NO); Smooth muscle (Abu-Dalu, R. (309) 189)

Kidney
2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML_2 receptor; Melatonin; Brain, hamster; Testes; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

Angiotensin II; Nitric oxide (NO); Losartan; L-NAME (N^{ω}-nitro-L-arginine methyl ester); (Rabbit) (Adachi, Y. (308) 165)

Diabetes; Hypertension; Angiotensin; Blood perfused; Nephropathy; (Rat) (Farina, N.K. (310) 185)

Kidney function
Na^+ excretion; α_1-Adrenoceptor subtype; Hypertension (Sattar, M.A. (294) 727)

Kidney, rat
Glutathione; Lipid peroxidation; Oxidative stress; Ischemia-reperfusion injury; 21-Aminosteroid (Paroni, R. (294) 737)

RX821002; α_2-Adrenoceptors; Imidazoline binding sites (Callado, L.F. (316) 359)

Kidney, perfused, rat
Purinoceptor P_{2X}; Purinoceptor P_{2Y}; Purinoceptor P_{2U}; Purinoceptor agonist; Purinoceptor antagonist (Eltze, M. (306) 139)

Kidney, isolated, perfused, rat
[Arg^8]Vasopressin; [Mpa^1,D-Arg^8]Vasopressin; SR 49059; Vasopressin V_{1A} receptor (Barthelmebs, M. (314) 325)

Kinin
Cold air; Tachykinin; Bronchoconstriction; SR 48968; HOE 140; Neurogenic inflammation (Yoshihara, S. (296) 291)

Kinin antagonist
Bradykinin; Glomerular hemodynamics; Glomerular prostaglandin; Glomerular receptor; Receptor desensitization (Praddaude, F. (294) 173)

KK-Ay mouse
Glimepiride; Sulfonylurea (Takada, Y. (308) 205)

KMD-3213
α_1-Adrenoceptor subtype; α_{1a}-Adrenoceptor; Prostate; Thoracic aorta (Yamagishi, R. (315) 73)

KOR-1
κ-Opioid analgesia; Opioid receptor; σ Receptor; Haloperidol; Antisense; κ-Opioid receptor (Chien, C.-C. (294) 303)

KT5823
Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; Intracellular signal transduction system; H-89; W-7; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

Kynurenine
Anticonvulsant; Microdialysis; Neurodegenerative disorder; Neuroprotection (Speciale, C. (315) 263)

Kyotorphin
L-Ornithine; L-Arginine; Enkephalin; Pain; Antinociception (Kawabata, A. (296) 23)

L-163,017
Angiotensin II receptor subtype; Hypertension; Renin-angiotensin system (Chang, R.S.L. (294) 429)

Angiotensin II; Angiotensin receptor antagonist; Angiotensin converting enzyme inhibitor; Antihypertensive (Kivlighn, S.D. (294) 439)

L-695,902
NMDA receptor; Glycine coagonist site; Desensitization; 5,7-Dichlorokynurenic acid; ACEA-1021; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Labor
Melatonin; Myometrium, human; Pregnancy; Noradrenaline (Mårtensson, L.G.E. (316) 273)

Lactate
Adrenomedullin; Amylin; Calcium; Gastric emptying; CGRP (calcitonin gene-related peptide); (Rat) (Vine, W. (314) 115)

Lamotrigine
Nitric oxide (NO); Dizocilpine (MK-801); Opiate abstinence (Lizasoain, I. (299) 41)

Locomotion; Reserpine; Dopamine; (Mouse) (Kaur, S. (304) 1)

LA-N-2 cell
Phospholipase C; Norepinephrine; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); Bombesin; β-Adrenoceptor; Metabotropic (Sorrentino, G. (308) 81)

Langendorff heart
Benzodiazepine; Diazepam; Inotropy; Ca^{2+}-entry blocking drug; Adenosine receptor blocking drug (Leeuwin, R.S. (315) 153)

Langendorff heart preparation
Verbascoside; Cyclic adenosine monophosphate; (*Eremophila alternifolia*) (Pennacchio, M. (305) 169)

Laser Doppler
Gastrointestinal microcirculation; Capsaicin; Resiniferatoxin (Abdel Salam, O.M.E. (305) 127)

Laser-Doppler flowmetry
Cerebral ischemia; Middle cerebral artery occlusion; γ_2-MSH (γ_2-melanocyte-stimulating hormone); Nimodipine; (Rat) (Herz, R.C.G. (306) 113)

Lateral reticular nucleus of the medulla
Central hyperalgesia; Atipamezole; Medetomidine; α_2-Adrenoceptor; Neurogenic pain; Spinal cord (Mansikka, H. (297) 19)

Laxative
Nitric oxide (NO); Senna; Cascara; Anthraquinone; Intestinal secretion (Izzo, A.A. (301) 137)

LDL (low-density lipoprotein)
Taurine; Hypercholesterolemia; Diabetes; Endothelium; Cholesterol (Kamata, K. (303) 47)

Learning
Memory; Prostaglandin; Cyclooxygenase; Neurotransmitter; Retrograde messenger; Synaptic plasticity (Hölscher, C. (294) 253)

Quinolinic acid, i.c.v. infusion; Long-term potentiation; Memantine; MK-801 (Misztal, M. (296) 1)

α-Linolenic acid deficiency, dietary; Morris water maze; Morphine effect; (Mouse) (Francès, H. (298) 217)

NGF (nerve growth factor); Propentofylline; Memory; Choline acetyltransferase; Dementia model; (Rat) (Nitta, A. (307) 1)

Memory; Synaptic plasticity; Cholinergic system; Muscarinic receptor agonist; AF102B; Oxotremorine (Iga, Y. (308) 13)

Glutamate; Acetylcholine; NMDA receptor; Memory; Inhibitory avoidance task (Ohno, M. (312) 145)

Learning disorder
Hippocampus; Seizure; Cell death; (Rat) (Lahtinen, H. (297) 213)

Leishmaniasis
Aminoguanidine; Nitric oxide (NO) synthase, inducible; L-N^6-(1-Iminoethyl)-lysine; Nitric oxide (NO); N^G-Monomethyl-L-arginine (Stenger, S. (294) 703)

Leukocyte adherence
Intravital microscopy; Flow cytometry; Blood pressure, mean arterial; Leukocyte rolling; Venular shear rate (Scalia, R. (296) 181)

Leukocyte, human
Superoxide radical; Cystathionine (Wada, K. (296) 335)

Leukocyte, polymorphonuclear
Butein; Anti-GBM nephritis; Intercellular adhesion molecules; Endothelial cells (Hayashi, K. (316) 297)

Leukocyte rolling
Intravital microscopy; Flow cytometry; Blood pressure, mean arterial; Leukocyte adherence; Venular shear rate (Scalia, R. (296) 181)

Leukotriene
EGF (epidermal growth factor); Smooth muscle, airway; Tyrosine kinase; Phospholipase A_2 (Nasuhara, Y. (296) 161)

Azelastine; Traumatic brain injury; NMDA (*N*-methyl-D-aspartate); Hippocampus; (In vitro) (Girard, J. (300) 43)

NGF (nerve growth factor); Thermal hyperalgesia (Amann, R. (306) 89)

Dolabrane; Anti-inflammatory; Neutrophil, human; Myeloperoxidase; Elastase; Prostaglandin (Payá, M. (312) 97)

Leukotriene B_4
Pulmonary eosinophilia; Inflammation; Leukotriene C_4; Leukotriene D_4; Leukotriene E_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Leukotriene C_4
Pulmonary eosinophilia; Inflammation; Leukotriene B_4; Leukotriene D_4; Leukotriene E_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Leukotriene D_4
Pulmonary eosinophilia; Inflammation; Leukotriene B_4; Leukotriene C_4; Leukotriene E_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Leukotriene E_4
Pulmonary eosinophilia; Inflammation; Leukotriene B_4; Leukotriene C_4; Leukotriene D_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Leupeptin
Morphine analgesia; Reinforcing property; Morphine dependence; Withdrawal; Antipain (Lyupina, Y.V. (304) 23)

Levcromakalim
K^+ channel opener; HOE 234; Bronchoconstriction; Plasma exudation (Kidney, J.C. (296) 81)

Sodium nitroprusside; Aorta, rat; Chronic treatment; Tolerance (Trongvanichnam, K. (303) 39)

K^+ channel; Seizure; Ca^{2+} channel; Hippocampus; Patch clamp (Katsumori, H. (311) 37)

Nicorandil; Aorta, rat; Relaxation; cGMP; Tolerance (Trongvanichnam, K. (314) 83)

Levodopa
Dopamine; Microdialysis; Parkinson's disease; Dopamine receptor agonist; Dopamine receptor antagonist (Sarre, S. (296) 247)

Levorphanol
Antinociception; Respiratory depression; Opioid receptor; Naloxonazine; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

Antinociception; Respiratory depression; Opioid receptor; Naloxonazine; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Li^+
Cerebellar granule cell; Cell death; Tyrosine kinase (Grignon, S. (315) 111)

Licking
Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Lidocaine
Local anesthetic; Cocaine; Pseudococaine; Hemodynamics; Blood pressure; Heart rate; Desipramine (Bernards, C.M. (307) 33)

Ligand binding
Melanocortin MC_3 receptor; Mutagenesis; MSH (melanocyte-stimulating hormone) (Schiöth, H.B. (314) 381)

Light
Melatonin; Suprachiasmatic nucleus; Intergeniculate leaflet; Electrophysiology; Circadian rhythm; Entrainment (Ying, S.-W. (296) 33)

Light extinction test
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopamine; Striatum; Substantia nigra (Messaoudi, M. (299) 17)

α-Linolenic acid deficiency, dietary
Morris water maze; Learning; Morphine effect; (Mouse) (Francès, H. (298) 217)

Linopirdine
DuP 996; Brain; Membrane binding; Species difference (Höfner, G. (298) 307)

Lipid peroxidation
Glutathione; Oxidative stress; Ischemia-reperfusion injury; 21-Aminosteroid; Kidney, rat (Paroni, R. (294) 737)

α-Tocopherol analog (water-soluble); Neuroprotection; Antioxidant; Vitamin E; Malondialdehyde; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

N-Allylsecoboldine; Antioxidant; Peroxyl radical; Hydroxyl radical; Hypercoagulability; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

Melatonin; Kainate; Brain; (Rat) (Melchiorri, D. (305) 239)

Apomorphine; Free radical; Protein carbonyl; Iron; Ascorbate; Thiobarbituric acid (Gassen, M. (308) 219)

Subarachnoid hemorrhage; Endothelium-dependent relaxation; AJ-3941; Nimodipine; Ca^{2+} channel antagonist (Minato, H. (315) 297)

Lipid peroxidation, stomach
Nitric oxide (NO) (Lamarque, D. (313) R5)

Lipolysis
Adipocyte, rat, white; β_3-Adrenoceptor; ZD7114, partial agonist effect (Mayers, R.M. (295) 199)

β-Adrenoceptor; Adipose differentiation; cAMP (El Hadri, K. (297) 107)

Lipopolysaccharide
Fenspiride; TNF (tumor necrosis factor); Alveolar macrophage, guinea-pig; Phospholipase A_2 (De Castro, C.M.M.B. (294) 669)

Nitric oxide (NO) synthase; Nitrosyl-hemoglobin (NO-hemoglobin); Pressor response (Cai, M. (295) 215)

D-NNA (N^G-nitro-D-arginine); Diphenyleneiodonium; Di-2-thienyliodonium; Methylene blue; Nitric oxide (NO); Contraction (Palacios, B. (296) 75)

Vascular permeability; Nitric oxide (NO); Prostaglandin; Skin; (Mouse) (Fujii, E. (297) 257)

Intestinal erythrocyte extravasation; Phosphodiesterase inhibitor (Cardelús, I. (299) 153)

Nitric oxide (NO) synthase, inducible; Multiple organ dysfunction syndrome; Liver failure; Endotoxin (Wu, C.-C. (300) 99)

Ursodeoxycholic acid; Nitric oxide (NO) synthase; J774 macrophage (Hattori, Y. (300) 147)

L-Arginine; Nitric oxide (NO); Nitric oxide (NO) synthase; Septic shock; Mesenteric vascular bed; (Rat) (Mitolo-Chieppa, D. (309) 175)

Water intake; Interleukin-1; Interleukin-1 receptor; Antagonist; (Human) (Nava, F. (309) 223)

Endotoxin tolerance; Vascular permeability; Cytokine; Adrenalectomy; Nitric oxide (NO) (Fujii, E. (313) 129)

Disseminated intravascular coagulation; Interleukin-1; TNF-α (tumor necrosis factor-α) (Yamamoto, N. (314) 137)

Lithium chloride
Tacrine; Seizure; Nitric oxide (NO); Citrulline; L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (294) 341)

Ouabain; Cytosolic Ca^{2+}; Chromaffin cell; Veratridine (De la Fuente, M.T. (306) 219)

Valproic acid; G-protein; Bipolar disorder; ADP ribosylation (Young, L.T. (309) 215)

Liver
Benzodiazepine receptor, peripheral; Porphyrin; PK11195; Cholesterol; Metabolism (Tsankova, V. (299) 197)

α_1-Adrenoceptor; Hepatocyte; (Rhesus monkey) (García-Sáinz, J.A. (311) 277)

Liver failure
Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Multiple organ dysfunction syndrome; Endotoxin (Wu, C.-C. (300) 99)

Liver, rat
σ Receptor; Solubilization; CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate); (+)-Pentazocine; DTG (1,3-di-*o*-tolylguanidine) (Torrence-Campbell, C. (304) 201)

Local anesthetic
Cocaine; Lidocaine; Pseudococaine; Hemodynamics; Blood pressure; Heart rate; Desipramine (Bernards, C.M. (307) 33)

Pentacaine; Pentacaine derivative; Smooth muscle, gastric; (Guinea-pig) (Mai, M.P. (315) 305)

N-butyl-*p*-aminobenzoate; Patch clamp; Na^+ current inactivation; Dorsal root ganglion (Van den Berg, R.J. (316) 87)

Locomotion
Deltorphin analog; Antinociception; Catalepsy (Negri, L. (296) 9)

Dopamine; Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-2-(di-*n*-propylamino)tetralin); (Rat) (Frantz, K. (302) 1)

Reserpine; Lamotrigine; Dopamine; (Mouse) (Kaur, S. (304) 1)

α_1-Adrenoceptor antagonist; Microdialysis; NMDA receptor; Dizocilpine maleate (Mathé, J.M. (309) 1)

Individual difference; Novelty; $GABA_A$; Psychostimulant; Cortex; Basal ganglia (Gruen, R.J. (309) 115)

Locomotor activity
Excitatory amino acid; NMDA receptor antagonist; AP-5 (DL-2-amino-5-phosphonovaleric acid); MK-801 ((+)-5-methyl-10,11-dihydro(*a*,*d*)-cyclohepten-5,10-imine hydrogen maleate salt); Dopamine (Ouagazzal, A. (294) 137)

[Arg^8]Vasopressin; Vasopressin V_1 receptor antagonist; Ventral hippocampus; Retrieval; Relearning (Alescio-Lautier, B. (294) 763)

5-HT receptor; Stereotyped behavior; (Rat) (Hillegaart, V. (295) 155)

Arginine-aspartate; Catalepsy; Haloperidol; Dopamine (Patacchioli, F.R. (299) 29)

Mesolimbic system, rat; Nucleus accumbens; Ventral tegmental area; $5\text{-}HT_3$ receptor; Dopaminergic modulation (Gillies, D.M. (303) 1)

NMDA receptor antagonist; Dopamine; Neuroleptic, chronic; Memory; (Mouse) (Mele, A. (308) 1)

Dopamine D_1 receptor; Development; SKF 38393; SCH 23390; (Rat) (Shieh, G.-J. (311) 103)

Monosialoganglioside; Ethanol; Sensitization (Bellot, R.G. (313) 175)

Nicotine; D-CPPene (SDZ EAA 494; Sensitization; Dopamine, mesoaccumbens; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid) (Balfour, D.J.K. (316) 153)

Locomotor activity, rat
Nicotine; L-DOPA (3,4-dihydroxyphenylalanine) release; Nucleus accumbens; Ventral tegmental area; Microdialysis (Goshima, Y. (309) 229)

Locus ceruleus
α_2-Adrenoceptor; Dexmedetomidine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Ritanserin; Monoamine; (Rat) (Rabin, B.C. (306) 51)

Opiate; Tolerance; Withdrawal; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); (Mouse) (Dossin, O. (308) 271)

Desipramine; Maprotiline; Prefrontal cortex; Extracellular recording; (Anesthetized rat) (Ceci, A. (312) 189)

JL3 (10-(4-methylpiperazin-1-yl)pyrido[4,3-*b*][1,4]benzothiazepine); Antidepressant; Dorsal raphe; A10 dopamine neuron; Electrophysiology (Liégeois, J.-F. (310) 9)

Butorphanol; Glutamate; κ-Opioid receptor agonist; Microdialysis; U-69,593 (Hoshi, K. (314) 301)

Purinoceptor; Pyrimidinoceptor; Excitatory amino acid receptor; Extracellular recording (Fröhlich, R. (315) 255)

Long-term depression
Glutamate; Long-term potentiation; Metabotropic receptor; NMDA receptor; Plasticity; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

Long-term potentiation
Arachidonic acid; NMDA (*N*-methyl-D-aspartate); ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid); Melittin; Phospholipase A_2 (Collins, D.R. (294) 147)

Traumatic brain injury; Felbamate; CA1; Hippocampus (Wallis, R.A. (294) 475)

Hippocampus; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); Slow-onset potentiation; MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Metabotropic glutamate receptor; Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

Quinolinic acid, i.c.v. infusion; Learning; Memantine; MK-801 (Misztal, M. (296) 1)

Nitric oxide (NO); Amygdala, medial; Amygdala, lateral (Abe, K. (297) 43)

Mutant mouse; Glutamate receptor, metabotropic (Bordi, F. (301) R15)

Glutamate; Long-term depression; Metabotropic receptor; NMDA receptor; Plasticity; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

Loop of Henle
[Arg^8]Vasopressin; Microperfusion, in vitro; Ion transport (Grider, J. (313) 115)

Lordosis
Conditioned place preference; Sulpiride; Raclopride; Dopamine; Dopamine D_2 receptor (Meisel, R.L. (309) 21)

Delequamine; RS15385; α_2-Adrenoceptor; Sexual behavior, female; (Rat) (Gonzalez, M.I. (312) 1)

Loreclezole
$GABA_A$ receptor; Neuroactive steroid; Benzodiazepine receptor (Xue, B.G. (300) 125)

Losartan
Blood pressure variability; HOE 140; Renal hypertension; Spectral analysis (Ponchon, P. (297) 61)

Parkinson's disease; Huntington's disease; Alzheimer's disease; PD123177; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8]Angiotensin II; Brain, human (Ge, J. (297) 299)

Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Blood-brain barrier; EXP3174; GR117289; LR-B/081 (Polidori, C. (307) 259)

Angiotensin II; Nitric oxide (NO); L-NAME (N^{ω}-nitro-L-arginine methyl ester); Kidney; (Rabbit) (Adachi, Y. (308) 165)

Lovastatin
3T3-L1 cell; Isoprenoid (Nishio, E. (301) 203)

Low-density lipoprotein (LDL)
Carvedilol; Antioxidant; Monocyte; Adhesion (Yue, T.-L. (294) 585)

Low-density lipoprotein, oxidized
Nitric oxide (NO); Prostaglandin; Macrophage; Atherosclerosis (Matthys, K.E. (298) 97)

Lower esophageal sphincter
NANC (non-adrenergic non-cholinergic) neurotransmission; Electrical field stimulation; Nicotine; Nitric oxide (NO); VIP (vasoactive intestinal peptide) (Kortezova, N. (304) 109)

Lower lip retraction
Corticosterone; 5-HT receptor subtype; Penile erection; Head shake; Open field behavior (Berendsen, H.H.G. (308) 103)

LR-B/081
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Blood-brain barrier; Losartan; EXP3174; GR117289 (Polidori, C. (307) 259)

LY293558
Cortical neuron; Excitotoxicity; NS-102; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionate); (*S*)-5-Fluorowillardiine (Larm, J.A. (314) 249)

LY-294,619
NMDA receptor; Glycine coagonist site; Desensitization; 5,7-Dichlorokynurenic acid; ACEA-1021; L-695,902; RPR-104,632 (Molnár, P. (311) 311)

Lymphocyte
Ca^{2+} channel; PN 200-110; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)

Lymphocyte proliferation
Jatrophone; Natural killer activity; Protein kinase C; 12-*O*-Tetradecanoylphorbol 13-acetate; CD69; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

Lysophosphatidylcholine
Acylcarnitine; Fibrillation; Fatty acid; Excitability; Antiarrhythmic (Kang, J.X. (297) 97)

Lysosomal phospholipase
Azithromycin; Macrolide; Gentamicin; Aaminoglycoside; Phospholipidosis; Membrane aggregation (Van Bambeke, F. (314) 203)

LY288513 ((4*S*,5*R*)-*N*-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide)
CCK (cholecystokinin); CCK receptor antagonist; CCK_B receptor; Conditioned fear stress; Anxiety (Izumi, T. (300) 25)

M16209
Insulin resistance; Genetically obese rodent; Hyperinsulinemic euglycemic clamp; Antihyperglycemic effect (Murakami, N. (304) 129)

Macrolide
Azithromycin; Gentamicin; Aaminoglycoside; Lysosomal phospholipase; Phospholipidosis; Membrane aggregation (Van Bambeke, F. (314) 203)

Macrophage
Low-density lipoprotein, oxidized; Nitric oxide (NO); Prostaglandin; Atherosclerosis (Matthys, K.E. (298) 97)

TNF-α (tumor necrosis factor α) inhibition; Adenosine A_3 receptor; Receptor; Cross-talk (McWhinney, C.D. (310) 209)

Magnetic resonance imaging
Head injury; Edema; Antioxidant free radical scavenger (Petty, M.A. (307) 149)

Maitotoxin
Na^+-permeable channel; Patch clamp; Ventricular cell, guinea-pig (Nishio, M. (297) 293)

Male pheromone
Glutamic acid decarboxylase; Olfactory bulb; Ovariectomy; Estrogen; Progesterone; (Rat) (Navarro Becerra, N. (312) 83)

Malondialdehyde
α-Tocopherol analog (water-soluble); Neuroprotection; Lipid peroxidation; Antioxidant; Vitamin E; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

α-Mangostin
Trachea, guinea-pig; Histamine; Histamine H_1 receptor antagonist; Aorta, rabbit (Chairungsrilerd, N. (314) 351)

MAPK (mitogen-activated protein kinase)
EGF (epidermal growth factor); Isoforms ($p42^{mapk}$ and $p44^{mapk}$); Protein kinase C; Dermal fibroblast, human (Le Panse, R. (307) 339)

Maprotiline
Desipramine; Prefrontal cortex; Locus ceruleus; Extracellular recording; (Anesthetized rat) (Ceci, A. (312) 189)

Marijuana
SR 141716A; CP 55,940; Basal ganglion; Antipsychotic (Anderson, J.J. (295) 163)

Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

Mast cell
Anti-allergic drug; α-Chymotrypsin; Histamine; Serine esterase (Emadi-Khiav, B. (295) 243)

Bradykinin; HOE140; Ketotifen; Bradykinin receptor; Vascular permeability (Morishita, M. (298) 149)

Adenosine A_3 receptor; Hypotension; Histamine; APNEA (N^6-2-(4-aminophenyl)ethyladenosine); Compound 48/80 (Fozard, J.R. (298) 293)

Sympathetic nerve; 6-Hydroxydopamine; Dorsal skin (Cambridge, H. (301) 151)

Bradykinin receptor; CP-99,994; Formaldehyde; Tachykinin receptor; Vascular permeability (Ito, K. (307) 291)

Maze
Ginsenoside; Scopolamine; (Rat) (Yamaguchi, Y. (312) 149)

2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine)
Melatonin ML_2 receptor; Melatonin; Brain, hamster; Kidney; Testes; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

MCI-154 (6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3-(2*H*)-pyridazinone)
Ventricular arrhythmia; Heart failure; Ca^{2+} current (Eto, K. (298) 247)

MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine)
Hippocampus; Long-term potentiation; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); Slow-onset potentiation; Metabotropic glutamate receptor; Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

MDL 100,907
$5\text{-}HT_{2A}$ receptor; $5\text{-}HT_{2C}$ receptor; Quipazine; MK-212; SB 200646A; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

[^{3}H]MDL 105,519
NMDA receptor; Glycine; (Binding) (Siegel, B.W. (312) 357)

Meal size and duration
Monosodium glutamate; Neurotoxicity; Hypophagia; Hypersensitivity to neuropeptide Y; Arcuate nucleus (Stricker-Krongrad, A. (295) 27)

Mean arterial pressure
Cocaine; ANP (atrial natriuretic peptide); ANP, N-terminal; Heart rate; Right atrial pressure (Pelkonen, M. (304) 55)

Mean circulatory filling pressure
Positive inotropic agent; Systemic hemodynamics; Blood flow distribution; OPC-18790 (Fujiki, H. (313) 191)

Mecamylamine
Nicotine; Drug discrimination; Methyllycaconitine (Brioni, J.D. (301) 1)

Choline; ACTH (adrenocorticotrophin); β-Endorphin; Atropine; Hemicholinium-3 (Savci, V. (309) 275)

Nicotine; Conditioned place preference paradigm; Place aversion; Physical dependence (Suzuki, T. (314) 281)

Mechanical nociception
Interleukin-1β; Biphasic effect; (Rat) (Yabuuchi, K. (300) 59)

Mechanical stretch
Atrial natriuretic peptide; Thapsigargin; Hormone secretion (Taskinen, P. (308) 295)

Mechanical threshold
Taurine depletion; Skeletal muscle; Excitation-contraction coupling; Cl^- conductance; Ca^{2+} handling mechanism (De Luca, A. (296) 215)

Medetomidine
Central hyperalgesia; Atipamezole; α_2-Adrenoceptor; Neurogenic pain; Lateral reticular nucleus of the medulla; Spinal cord (Mansikka, H. (297) 19)

Medial septum
Acetylcholine; Hippocampus; Microdialysis; Muscarinic autoreceptor (Moor, E. (294) 155)

Medial septum lesion
Scopolamine; Aging; Metrifonate; Spatial navigation; Passive avoidance (Riekkinen Jr., P. (309) 121)

Medial vestibular nucleus
Benzodiazepine tolerance; GABA receptor; Isoguvacine (Hutchinson, M.A. (301) 83)

Median eminence
Intermediate lobe; Pentazocine; Haloperidol; Raclopride; Prolactin secretion; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

Media thickening
Semotiadil; Ventricular hypertrophy, right; Pulmonary hypertension (Takahashi, T. (295) 229)

Medullary vasomotor neuron
Angiotensin II; Pressor response; Rostral ventrolateral medulla; Vasopressin (Sun, M.-K. (304) 63)

Melanocortin receptor
γ_2-MSH (γ_2-melanocyte-stimulating hormone); ACTH-(4–10) (adrenocorticotropic hormone-(4–10)); Blood pressure; Heart rate; Structure-activity; (Rat) (Van Bergen, P. (294) 795)

Melanocortin MC_3 receptor
Ligand binding; Mutagenesis; MSH (melanocyte-stimulating hormone) (Schiöth, H.B. (314) 381)

Melanoma
Calmodulin antagonist; Glycolysis; ATP; Glucose 1,6-bisphosphate (glucose-1,6-P_2, Glc-1,6-P_2); Fructose 1,6-bisphosphate (fructose-1,6-P_2, Fru-1,6-P_2) (Glass-Marmor, L. (313) 265)

Melanotrope
Ca^{2+} channel; Dihydropyridine; ω-Conotoxin; ω-Agatoxin; Pituitary; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

Melatonin
Suprachiasmatic nucleus; Intergeniculate leaflet; Electrophysiology; Light; Circadian rhythm; Entrainment (Ying, S.-W. (296) 33)

Receptor autoradiography; 2-[^{125}I]Iodomelatonin; Visual system; (Reptile) (Larson-Prior, L.J. (297) 181)

2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML_2 receptor; Brain, hamster; Kidney; Testes; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

Kainate; Lipid peroxidation; Brain; (Rat) (Melchiorri, D. (305) 239)

Pineal gland, ovine; 5-HT (hydroxytryptamine, serotonin)-*N*-acetyltransferase; Tryptamine (Shen, S. (307) 133)

Parasympathetic; Pineal; Microdialysis; Muscarinic receptor agonist; Carbachol; Noradrenaline release (Drijfhout, W.J. (308) 117)

Pharmacokinetics; Continuous light; Circadian rhythm; 6-Sulfatoxymelatonin; (Intravenous) (Deprés-Brummer, P. (312) 171)

Nicotinic channel; Cholinergic transmission; Synaptic modulation; Submucosal neuron; Enteric neuron; Nerve terminal (Barajas-López, C. (312) 319)

Myometrium, human; Pregnancy; Labor; Noradrenaline (Mårtensson, L.G.E. (316) 273)

Melatonin receptor
Comparative molecular field analysis; Quantitative structure-activity relationship model; Austin model 1; Binding site; G protein-coupled receptor (Navajas, C. (304) 173)

Melatonin ML_2 receptor
2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin; Brain, hamster; Kidney; Testes; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

Melittin
Arachidonic acid; Long-term potentiation; NMDA (*N*-methyl-D-aspartate); ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid); Phospholipase A_2 (Collins, D.R. (294) 147)

Memantine
Quinolinic acid, i.c.v. infusion; Learning; Long-term potentiation; MK-801 (Misztal, M. (296) 1)

Radial maze learning; Entorhinal cortex lesion; NMDA receptor antagonist; Chronic infusion; (+)-MK-801; (Rat) (Zajaczkowski, W. (296) 239)

Paraventricular nucleus of the hypothalamus; Myocardial oxygen demand; MK-801; (Rabbit) (Monassier, L. (305) 109)

Alcohol; Craving (Hölter, S.M. (314) R1)

Membrane
Amiodarone; Water exchange; NMR (nuclear magnetic resonance) (Federico, A. (304) 237)

Membrane aggregation
Azithromycin; Macrolide; Gentamicin; Aaminoglycoside; Lysosomal phospholipase; Phospholipidosis (Van Bambeke, F. (314) 203)

Membrane binding
Linopirdine; DuP 996; Brain; Species difference (Höfner, G. (298) 307)

Membrane current
Ca^{2+} channel; Antipsychotic drug; Dopamine receptor antagonist; Calmodulin antagonist (Ito, K. (314) 143)

Membrane potential
Stomach; Smooth muscle, gastric; Junction potential; Slow wave; Trimebutine (Xue, L. (294) 75)

NS-004; $[Ca^{2+}]_i$, free; K^+ channel, Ca^{2+}-activated; K^+ channel, delayed rectifier; Whole cell patch clamp; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

Stretch-activated channel; Na^+ dependence; Ca^{2+} uptake; Ca^{2+} channel, L-type (Ruiz-Velasco, V. (296) 327)

Memory
Learning; Prostaglandin; Cyclooxygenase; Neurotransmitter; Retrograde messenger; Synaptic plasticity (Hölscher, C. (294) 253)

5-HT (5-hydroxytryptamine, serotonin); *p*-Chloroamphetamine; Alzheimer's disease; (Rat) (Santucci, A.C. (295) 7)

Dextromethorphan; NMDA receptor; Spatial learning; Water maze (Bane, A. (302) 7)

NGF (nerve growth factor); Propentofylline; Learning; Choline acetyltransferase; Dementia model; (Rat) (Nitta, A. (307) 1)

NMDA receptor antagonist; Dopamine; Neuroleptic, chronic; Locomotor activity; (Mouse) (Mele, A. (308) 1)

Learning; Synaptic plasticity; Cholinergic system; Muscarinic receptor agonist; AF102B; Oxotremorine (Iga, Y. (308) 13)

Ageing; $5\text{-}HT_3$ receptor; Avoidance, multiple choice; Itasetron (DAU 6215) (Pitsikas, N. (311) 115)

Glutamate; Acetylcholine; NMDA receptor; Learning; Inhibitory avoidance task (Ohno, M. (312) 145)

Alaptide; Cyclodipeptide; 2,5-Piperazinedione; Elevated plus-maze test; Oxiracetam; (Mouse) (Hliňák, Z. (314) 1)

Ischemia, treatment; Adenosine; MAP2 (microtubule-associated protein 2); (Gerbil) (Von Lubitz, D.K.J.E. (316) 171)

Meperidine
Dopamine transporter; Cocaine (Izenwasser, S. (297) 9)

Mesangial cell, cultured, rat
Adrenomedullin; Amylin; cAMP; Immunohistochemistry; CGRP (calcitonin gene-related peptide) (Osajima, A. (315) 319)

Mesenteric arterial bed, rat
Cholesterol-feeding; Endothelium; P_{2X} purinoceptor; Sympathetic neurotransmission; Donryu rat (Ralevic, V. (313) 221)

Mesenteric artery
Triflavin; RGD (Arg-Gly-Asp)-containing peptide; Fibrinogen receptor antagonist; Bleeding time; Thrombosis (Sheu, J.-R. (294) 231)

Endothelin-1; Endothelin ET_A receptor; Adrenergic nerve stimulation; Prejunctional inhibition; Postjunctional potentiation (Zhang, J.-X. (311) 169)

Mesenteric artery, small
Benextramine; Prostanoid TP receptor; SQ 30,741; U46619; (Rat) (Van der Graaf, P.H. (300) 211)

Mesenteric vascular bed
L-Arginine; Nitric oxide (NO); Nitric oxide (NO) synthase; Lipopolysaccharide; Septic shock; (Rat) (Mitolo-Chieppa, D. (309) 175)

Flow; Nitric oxide (NO); Spontaneously hypertensive rat (SHR) (Kusayama, T. (312) 301)

Mesolimbic system, rat
Nucleus accumbens; Ventral tegmental area; $5\text{-}HT_3$ receptor; Dopaminergic modulation; Locomotor activity (Gillies, D.M. (303) 1)

Messenger RNA
Electroshock; G-protein; GTP-binding protein; In situ hybridization (McGowan, S. (306) 249)

Metabolism
Myocardial infarction; Remodeling; Ischemia; Captopril (Kalkman, E.A.J. (298) 121)

Benzodiazepine receptor, peripheral; Porphyrin; PK11195; Cholesterol; Liver (Tsankova, V. (299) 197)

Metabotropic
Phospholipase C; Norepinephrine; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); Bombesin; LA-N-2 cell; β-Adrenoceptor (Sorrentino, G. (308) 81)

Metabotropic glutamate receptor
Metabotropic receptor agonist; L-CCG-I ((2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); Morris maze; (Rat) (Van der Staay, F.J. (294) 361)

Hippocampus; Long-term potentiation; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); Slow-onset potentiation; MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

Human $mGlu_{1d}$; Ca^{2+} fluorescence (Laurie, D.J. (296) R1)

Excitatory amino acid; GTP hydrolysis; G-protein; Adenylyl cyclase; Cerebral cortex (Odagaki, Y. (300) 151)

Opioid withdrawal; Protein kinase C; Inositol-1,4,5-trisphosphate; Chelerythrine; Thapsigargin (Fundytus, M.E. (300) 173)

Human $mGlu_{1d}$; Ca^{2+} fluorescence (Laurie, D.J. (302) 229)

cAMP; Phosphoinositide hydrolysis; Cortex; Cerebellar granule cell; Phenylglycine (Bedingfield, J.S. (309) 71)

Cerebral cortex slice; cAMP; (Agonist) (Kemp, M.C. (309) 79)

Excitotoxicity; Cortical neuron (Bruno, V. (310) 61)

Metabotropic glutamate receptors
D,L-Amphetamine; MK-801; Basal ganglia; Open-field; Catalepsy (Kronthaler, U.O. (316) 129)

Metabotropic receptor
Glutamate; Long-term depression; Long-term potentiation; NMDA receptor; Plasticity; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

Metabotropic receptor agonist
Metabotropic glutamate receptor; L-CCG-I ((2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); Morris maze; (Rat) (Van der Staay, F.J. (294) 361)

Metal chelator
Polyol pathway; Diabetes; Galactosemia; Nerve conduction; Nerve regeneration; Oxygen free radical; Antioxidant (Love, A. (314) 33)

Metergoline
5-Carboxamidotryptamine; $5\text{-}HT_{1D}$ receptor; $5\text{-}HT_{1F}$ receptor; Migraine; [^{3}H]Sumatriptan (Pascual, J. (295) 271)

Methadone
CRF type 1 receptor; Solution hybridization; Corticosterone; POMC (proopiomelanocortin); CRF (corticotropin-releasing factor) (Zhou, Y. (315) 31)

Methamphetamine
N-Cyanomethylmethamphetamine; Haloperidol; Behavioral sensitization; Ambulation; (Mouse) (Kuribara, H. (305) 1)

Illicit synthesis; Synthetic impurity; NMDA receptor; Dopamine transporter; BNMPA (α-benzyl-*N*-methylphenethylamine) (Moore, K.A. (311) 133)

cAMP; Behavioral sensitization; Rolipram; Microdialysis, in vivo (Iyo, M. (312) 163)

Cocaine; Morphine; Ambulatory sensitization; Interdose interval; (Mouse) (Kuribara, H. (316) 1)

Methoxamine
α_1-Adrenoceptor; Positive inotropic effect; Endothelin; Ventricular myocardium, rabbit (Yang, H.-T. (296) 47)

Methoxyflurane
Toluene; 1,1,1-Trichloroethane; Flurothyl; Anxiolytic; Plus-maze; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

Methoxytetrabenazine
Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); Dopamine D_2 receptor; Presynaptic dopamine re-uptake site, presynaptic; Dopamine (Vander Borght, T. (294) 577)

Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dihydrotetrabenazine (Kilbourn, M. (307) 227)

Methyl-β-carboline-3-carboxylate
$GABA_A$ receptor; γ_2 Subunit; Antisense oligodeoxynucleotide; Strychnine; Picrotoxin; Convulsion (Zhao, T.-j. (306) 61)

Methylene blue
D-NNA (N^G-nitro-D-arginine); Diphenyleneiodonium; Di-2-thienyliodonium; Nitric oxide (NO); Lipopolysaccharide; Contraction (Palacios, B. (296) 75)

Airway responsiveness; Nitric oxide (NO); Airway epithelium; Guanylate cyclase; Zaprinast (Sadeghi-Hashjin, G. (302) 109)

N^G-Nitro-L-arginine; Endothelium; Nitric oxide (NO); Hypertension; Aorta, rat; Arterial pressure (Gil-Longo, J. (310) 175)

(*R*)-α-Methylhistamine
Histamine H_3 receptor subtype; Parasympathetic neuron; Sympathetic neuron (Rizzo, C.A. (294) 329)

[^{3}H]N^α-Methylhistamine
Histamine H_3 receptor; Radioligand binding; [^{3}H]GR168320; Cerebral cortex, rat (Brown, J.D. (311) 305)

Methyllycaconitine
Nicotine; Drug discrimination; Mecamylamine (Brioni, J.D. (301) 1)

Methylnaloxonium
Enkephalin; RB 101; Antinociception; Amygdala; Thalamus, ventro-basal; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

Methylphenidate
Haloperidol; Clozapine; BMY 14802; BMS-181100; Flesinoxan; Buspirone; S 14506; Gnawing; $5\text{-}HT_{1A}$ receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

Methyl-quinuclidinyl-benzylate
Atropine; CGP-12177; PET (positron emission tomography); Heart; β-Adrenoceptor; Muscarinic receptor (Valette, H. (306) 133)

5-Methylurapidil
BMY 7378; A-61603; α_1-Adrenoceptor; Arterial pressure (Zhou, L. (305) 173)

Spinal cord; α_1-Adrenoceptor subtype; BMY 7378; [^{3}H]Prazosin; (Rat) (Wada, T. (312) 263)

Metopon
Morphine derivative; Cinnamoylamino group; β-Endorphin receptor; Analgesia; (Mouse) (McLaughlin, J.P. (294) 201)

Metrifonate
Scopolamine; Medial septum lesion; Aging; Spatial navigation; Passive avoidance (Riekkinen Jr., P. (309) 121)

MF201
Tacrine; E2020; Physostigmine; 8-Arm radial maze; (Rat) (Braida, D. (302) 13)

Mg^{2+}
β-Adrenoceptor antagonist; Propranolol; S100 protein; Cardiac muscle (Nakatani, K. (315) 335)

Microdialysis
Acetylcholine; Hippocampus; Medial septum; Muscarinic autoreceptor (Moor, E. (294) 155)

Anticonvulsant; Generalised seizure; Amino acid (Rowley, H.L. (294) 541)

5-HT (5-hydroxytryptamine, serotonin); Desipramine; α_2-Adrenoceptor (Yoshioka, M. (294) 565)

Hippocampus; Striatum; Acetylcholine; NMDA receptor; NMDA receptor antagonist (Hutson, P.H. (295) 45)

5-HT (5-hydroxytryptamine, serotonin); 5-HT uptake inhibitor; Antidepressant; Hypothalamus, rat (Moret, C. (295) 189)

Nicotine; Isoarecolone; Dopamine; Nucleus accumbens (Mirza, N.R. (295) 207)

Dopamine; Levodopa; Parkinson's disease; Dopamine receptor agonist; Dopamine receptor antagonist (Sarre, S. (296) 247)

ATP-sensitive K^+ channel; Nicorandil; Cromakalim; Dopamine autoreceptor; Sulpiride (Tanaka, T. (297) 35)

Glutamate receptor antagonist; Dopamine; Reserpine; Parkinsonism (Biggs, C.S. (299) 83)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; β-Adrenoceptor; Dorsal hippocampus (Petersen, B. (300) 67)

Ethanol; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Ventral tegmental area (Yan, Q.-S. (301) 49)

Amphetamine; Dopamine; Individual difference; Nucleus accumbens; (Rat) (Sills, T.L. (303) 177)

5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) level, extracellular; (*S*)-WAY100135; WAY100635 (Assié, M.-B. (304) 15)

Dopamine; Cortex, prefrontal; 5-HT_{1A} receptor; Ipsapirone; WAY 100135; NAN-190 (Wędzony, K. (305) 73)

GABA (γ-aminobutyric acid); Dopamine release; Modafinil; Nucleus accumbens (Ferraro, L. (306) 33)

Hippocampus; Amino acid; Uptake carrier; Vesicular release; Ca^{2+} dependency (Zuiderwijk, M. (307) 275)

Parasympathetic; Pineal; Melatonin; Muscarinic receptor agonist; Carbachol; Noradrenaline release (Drijfhout, W.J. (308) 117)

Dopamine release; Dopamine synthesis; Dopamine D_3 receptor; Dopamine D_2 receptor; 7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin) (Gainetdinov, R.R. (308) 261)

Fluphenazine; Caudate putamen; Nucleus accumbens; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (308) 279)

α_1-Adrenoceptor antagonist; NMDA receptor; Dizocilpine maleate; Locomotion (Mathé, J.M. (309) 1)

Nicotine; L-DOPA (3,4-dihydroxyphenylalanine) release; Locomotor activity, rat; Nucleus accumbens; Ventral tegmental area (Goshima, Y. (309) 229)

Morphine withdrawal; Benzodiazepine (Gray, A.M. (313) 73)

β-Carboline; Dopamine; Harman; Norharman; Nucleus accumbens; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

5-HT_{1A} receptor; Noradrenaline; Dopamine D_1 receptor; SCH 23390; 8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin) (Hajós-Korcsok, É. (314) 285)

Butorphanol; Glutamate; κ-Opioid receptor agonist; Locus coeruleus; U-69,593 (Hoshi, K. (314) 301)

Dopamine; β-Carboline; Uptake; Striatum; MPP^+ (*N*-methyl-4-phenylpyridinium) (Matsubara, K. (315) 145)

Anticonvulsant; Kynurenine; Neurodegenerative disorder; Neuroprotection (Speciale, C. (315) 263)

Nucleus accumbens; Dopamine; Ethanol; Tolerance; Animal model (Nurmi, M. (315) 277)

Microdialysis, in vivo
5-HT_{1A} autoreceptor antagonism; (−)-Pindolol; Buspirone; Selective serotonin reuptake inhibitor (SSRI); Citalopram; 5-HT (5-hydroxytryptamine, serotonin), extracellular (Hjorth, S. (303) 183)

cAMP; Behavioral sensitization; Rolipram; Methamphetamine (Iyo, M. (312) 163)

Citalopram; WAY-100635; Penbutolol enantiomer; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

Microelectrode recording
Berberine; K^+ channel, ATP-sensitive; Patch clamp; Cardiac cell (Wang, Y.-X. (316) 307)

Microfilament
G_i-protein; Neuropeptide Y receptor; α_{2A}-Adrenoceptor; Ca^{2+}; Microtubule (Michel, M.C. (309) 87)

Microglia
Nitric oxide (NO) synthase, inducible; Herbimycin A; Interferon-γ; Janus kinase; Signal transducer and activator of transcription-1 (STAT1) (Kitamura, Y. (306) 297)

Microperfusion, in vitro
Loop of Henle; [Arg^8]Vasopressin; Ion transport (Grider, J. (313) 115)

Microtubule
G_i-protein; Neuropeptide Y receptor; α_{2A}-Adrenoceptor; Ca^{2+}; Microfilament (Michel, M.C. (309) 87)

Microvascular flow
Cheek pouch, hamster; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Microvascular leakage
Tachykinin receptor antagonist; (Guinea-pig) (Biyah, K. (308) 325)

Micturition volume threshold
Purinergic; Inhibition; Nitric oxide (NO) (Theobald Jr., R.J. (311) 73)

Midazolam
Occasion setting; Pavlovian conditioning; Conditioned immobility; Amphetamine; Flesinoxan (Maes, J.H.R. (309) 131)

Midbrain
Anti-epileptic drugs; Epilepsy; GABA (γ-aminobutyric acid) (Bloms-Funke, P. (316) 211)

Middle cerebral artery occlusion
JTP-4819; Prolyl endopeptidase; Morris water maze task; Passive avoidance task; TRH (thyrotropin-releasing hormone) (Shinoda, M. (305) 31)

Cerebral ischemia; Laser-Doppler flowmetry; γ_2-MSH (γ_2-melanocyte-stimulating hormone); Nimodipine; (Rat) (Herz, R.C.G. (306) 113)

Endothelin; Focal ischemia (McAuley, M.A. (307) 171)

Middle meningeal artery
Trigeminal; Ergot alkaloid; Sumatriptan; Migraine (Lambert, G. (311) 141)

Migraine
5-Carboxamidotryptamine; 5-HT_{1D} receptor; 5-HT_{1F} receptor; Metergoline; [^{3}H]Sumatriptan (Pascual, J. (295) 271)

Trigeminal; Middle meningeal artery; Ergot alkaloid; Sumatriptan (Lambert, G. (311) 141)

Antimigraine drug; Arteriovenous anastomosis; Carotid artery; GMC2021; Coronary artery, human; Sumatriptan; (Human); (Pig) (Saxena, P.R. (312) 53)

Migration
Secretoneurin; Fibroblast; Proliferation (Kähler, C.M. (304) 135)

Migration, in vitro
Peritoneal eosinophil; Phosphodiesterase inhibition; β_2-Adrenoceptor agonist (Alves, A.C. (312) 89)

Milrinone
Inotropic drug; Heart failure; K^+ channel, ATP-sensitive; Papillary muscle; Digoxin (Kocić, I. (301) 115)

Mitochondria, liver
Benzodiazepine receptor, peripheral; Cholesterol; Porphyrin (Tsankova, V. (294) 601)

Mitochondrial respiration
Superoxide; Shock; Inflammation; Endotoxin; Nitric oxide (NO) (Szabó, C. (315) 221)

Mitogen-activated protein kinase
Smooth muscle, uterine; Steroid; Estradiol; Progesterone (Ruzycky, A.L. (300) 247)

Mivazerol
α_2-Adrenoceptor agonist; Heart rate; NMDA receptor; Spinal cord (Kim, S.Y. (316) 249)

MK-212
5-HT_{2A} receptor; 5-HT_{2C} receptor; Quipazine; MDL 100,907; SB 200646A; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

MK-801
Spinal cord; Morphine tolerance; NMDA receptor antagonist; Ventral root potential (Bell, J.A. (294) 289)

Morphine withdrawal; Spinal cord; Naloxone; Morphine dependence (Bell, J.A. (294) 297)

Catalepsy; Catatonia; Morphine; NMDA receptor; AMPA receptor; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

Quinolinic acid, i.c.v. infusion; Learning; Long-term potentiation; Memantine (Misztal, M. (296) 1)

Retinal cell; Glutamate receptor; Neurotoxicity; Ca^{2+}; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Ferreira, I.L. (302) 153)

Paraventricular nucleus of the hypothalamus; Myocardial oxygen demand; Memantine; (Rabbit) (Monassier, L. (305) 109)

Dopamine; Haloperidol; SCH 23390; Self-stimulation (Olds, M.E. (306) 23)

Metabotropic glutamate receptors; D,L-Amphetamine; Basal ganglia; Open-field; Catalepsy (Kronthaler, U.O. (316) 129)

cGMP; Cerebellum; Purkinje cell; TRH tartrate (thyrotropin-releasing hormone tartrate); GABA (γ-aminobutyric acid) (Nakayama, T. (316) 157)

Interleukin-6, plasma; Immobilization stress; NMDA (*N*-methyl-D-aspartate); (Mouse) (Song, D.-K. (316) 165)

MK-801 (dizocilpine)
Opioid dependence; Central nervous system; Glutamate; Morphine; Butorphanol (Tokuyama, S. (295) 123)

Vas deferens, rat; Noradrenaline; Uptake (Pubill, D. (303) 171)

MK-801 ((+)-5-methyl-10,11-dihydro(*a*,*d*)-cyclohepten-5,10-imine hydrogen maleate salt)
Excitatory amino acid; NMDA receptor antagonist; AP-5 (DL-2-amino-5-phosphonovaleric acid); Dopamine; Locomotor activity (Ouagazzal, A. (294) 137)

(+)-MK-801
Radial maze learning; Entorhinal cortex lesion; NMDA receptor antagonist; Chronic infusion; Memantine; (Rat) (Zajaczkowski, W. (296) 239)

[^{3}H](+)-MK-801
NMDA receptor; Phencyclidine site; Imidazoline drug; K^+ channel, ATP-sensitive (Olmos, G. (310) 273)

MK-801 binding
Excitatory amino acid; NMDA (*N*-methyl-D-aspartate); Spinal cord (Souverbie, F. (307) 347)

ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine)
W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); Thromboxane A_2; G-protein; Phosphoinositide hydrolysis; Ca^{2+} (Ohkubo, S. (298) 175)

Mn^{2+}
Vas deferens, guinea pig; Contraction; Norepinephrine; Acetylcholine (Tsunobuchi-Ushijima, H. (295) 235)

Mn^{2+} influx
Ca^{2+} store; Ileum, rat; Ryanodine; Thapsigargin (Tabo, M. (313) 151)

Modafinil
GABA (γ-aminobutyric acid); Dopamine release; Microdialysis; Nucleus accumbens (Ferraro, L. (306) 33)

Mode 2 gating
CGP 48506; Ca^{2+} channel, L-type; Ca^{2+} channel activator (Herzig, S. (295) 113)

Modulator
Chemotherapy; Multidrug resistance; P-glycoprotein (Demmer, A. (315) 339)

Moguisteine
Cough reflex; Angiotensin-converting enzyme inhibitor; Enalapril; Non-narcotic antitussive drug (Kamei, J. (312) 235)

Molecular biology
Muscarinic receptor; G-protein; High-throughput assay (Bräuner-Osborne, H. (295) 93)

Molecular modeling
Three-dimensional structure; $5\text{-}HT_{2C}$ receptor; Receptor binding; Subtype selectivity (Kristiansen, K. (306) 195)

Nicotinic acetylcholine receptor; Muscle, fetal, rat; Patch-clamp; Voltage-clamp; Nicotinic agonist; Non-competitive agonist (Cooper, J.C. (309) 287)

NMDA receptor; Competitive antagonist; Radioligand binding; Neuroprotection (Cheung, N.S. (313) 159)

Monoamine
α_2-Adrenoceptor; Dexmedetomidine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Ritanserin; Locus ceruleus; (Rat) (Rabin, B.C. (306) 51)

Monoamine oxidase
Apigenin; Flavonoid; Noradrenaline uptake (Lorenzo, P.S. (312) 203)

Dopamine; Aromatic L-amino acid decarboxylase; Tyrosine hydroxylase; Striatum; (Modulation) (Cho, S. (314) 51)

Imidazoline-binding site; Striatum; *Conus* venom; (Calf) (Czerwiec, E. (315) 99)

Monocyte
Carvedilol; Low-density lipoprotein (LDL); Antioxidant; Adhesion (Yue, T.-L. (294) 585)

15-Deoxyspergualin; T cell; B cell; Cytokine (Nicoletti, F. (311) 213)

N^G-Monomethyl-L-arginine
Aminoguanidine; Nitric oxide (NO) synthase, inducible; Leishmaniasis; L-N^6-(1-Iminoethyl)-lysine; Nitric oxide (NO) (Stenger, S. (294) 703)

Mononeuropathic rat
Peripheral antinociception; Paw pressure; Systemic morphine; κ-Opioid receptor antagonist; δ-Opioid receptor antagonist (Catheline, G. (315) 135)

Monosialoganglioside
Ethanol; Sensitization; Locomotor activity (Bellot, R.G. (313) 175)

Monosodium glutamate
Neurotoxicity; Meal size and duration; Hypophagia; Hypersensitivity to neuropeptide Y; Arcuate nucleus (Stricker-Krongrad, A. (295) 27)

Monosynaptic reflex
Cyclobenzaprine; 5-HT (5-hydroxytryptamine, serotonin) (Kobayashi, H. (311) 29)

Morphine
Antinociception; β-Endorphin; Pertussis toxin; G-protein (Tseng, L.F. (294) 345)

C-fiber reflex; Buprenorphine; Nociception; Diffuse noxious inhibitory control; Descending inhibitory control; Spinal cord (Guirimand, F. (294) 651)

Dopamine release; Acetylcholine release; Striatum; Dopamine D_2 receptor (Nestby, P. (294) 771)

Opioid dependence; Central nervous system; Glutamate; MK-801 (dizocilpine); Butorphanol (Tokuyama, S. (295) 123)

Catalepsy; Catatonia; NMDA receptor; AMPA receptor; MK-801; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

Agmatine; Analgesia; Tolerance (Kolesnikov, Y. (296) 17)

Nicotine; Naloxone; Acetylcholine receptor antagonist; Jumping; (Mouse) (Zarrindast, M.-R. (298) 1)

Pain; Analgesia; Polyamine; NMDA receptor; Ifenprodil; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

Sensitization; Opioid; Psychostimulant; Conditioned reward; Place preference conditioning (Shippenberg, T.S. (299) 33)

μ-Opioid receptor, subtype; Antitussive effect; Cough reflex; (Beige rat) (Kamei, J. (300) 75)

Deoxyglucose; Nucleus accumbens; Shell; Drug abuse (Orzi, F. (302) 49)

β-Endorphin; SR 95531; 5-Aminovaleric acid; Tail-flick inhibition (Suh, H.-W. (307) 141)

Emesis; Nicotine; Tachykinin NK_1 receptor; $5\text{-}HT_3$ receptor; $5\text{-}HT_{1A}$ receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

Histamine; Colonic temperature; Histamine receptor antagonist (Ulugöl, A. (308) 49)

Pertussis toxin; Analgesia; Diphenhydramine; Baclofen; Clomipramine; Physostigmine (Galeotti, N. (308) 125)

NMDA receptor; Ibogaine; *O*-Desmethylibogaine; Naloxone (Layer, R.T. (309) 159)

Dyspnoea; Quenching; Autoradiography; Opioid (Cabot, P.J. (310) 47)

μ_1-Opioid receptor; Respiratory depression; Fentanyl; Muscle rigidity (Chen, S.-W. (312) 241)

$GABA_B$ receptor; Ventral tegmental area; Reward; Place conditioning (Tsuji, M. (313) 169)

Nociception; Spinal trigeminal nucleus oralis; C-fiber (Dallel, R. (314) 19)

Ca^{2+} channel, P-type; Antinociception, spinal; Clonidine; Tolerance; G-protein (Roerig, S.C. (314) 293)

Methamphetamine; Cocaine; Ambulatory sensitization; Interdose interval; (Mouse) (Kuribara, H. (316) 1)

Buprenorphine; Castor oil; Diarrhoea; Gastrointestinal transit; Ethanol lesion (Bhounsule, S.A. (316) 253)

Morphine administration, acute and chronic
Acetylcholine release, hippocampus; Dopamine receptor, sensitization (Imperato, A. (302) 21)

Morphine analgesia
Reinforcing property; Morphine dependence; Withdrawal; Antipain; Leupeptin (Lyupina, Y.V. (304) 23)

Morphine dependence
Adenosine; Blood pressure (White, P.J. (294) 215)

MK-801; Morphine withdrawal; Spinal cord; Naloxone (Bell, J.A. (294) 297)

Morphine analgesia; Reinforcing property; Withdrawal; Antipain; Leupeptin (Lyupina, Y.V. (304) 23)

Morphine derivative
Metopon; Cinnamoylamino group; β-Endorphin receptor; Analgesia; (Mouse) (McLaughlin, J.P. (294) 201)

Morphine effect
α-Linolenic acid deficiency, dietary; Morris water maze; Learning; (Mouse) (Francès, H. (298) 217)

Morphine tolerance
MK-801; Spinal cord; NMDA receptor antagonist; Ventral root potential (Bell, J.A. (294) 289)

NMDA receptor; Opioid receptor; (Intrathecal administration) (Wong, C.-S. (297) 27)

Morphine withdrawal
MK-801; Spinal cord; Naloxone; Morphine dependence (Bell, J.A. (294) 297)

Benzodiazepine; Microdialysis (Gray, A.M. (313) 73)

Morphine withdrawal, spontaneous
Diltiazem; Naloxone-precipitated withdrawal; Corticosterone, plasma; Body weight loss; Diarrhea; (Rat) (Kishioka, S. (316) 7)

Morris maze
Metabotropic glutamate receptor; Metabotropic receptor agonist; L-CCG-I ((2*S*,3*S*,4*S*)-α-(carboxycyclopropyl)glycine); (Rat) (Van der Staay, F.J. (294) 361)

Morris water maze
α-Linolenic acid deficiency, dietary; Learning; Morphine effect; (Mouse) (Francès, H. (298) 217)

Morris water maze task
JTP-4819; Prolyl endopeptidase; Passive avoidance task; TRH (thyrotropin-releasing hormone); Middle cerebral artery occlusion (Shinoda, M. (305) 31)

Motapizone
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Motility
Pylorus, rat; Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); NANC (non-adrenergic non-cholinergic) (Willis, S. (315) 59)

Motion sickness
5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Imipramine; Fluoxetine (Okada, F. (309) 33)

Motivation
Appetite; Drinking; Food intake; Isatin; 5-HT (5-hydroxytryptamine, serotonin); Tubulin; (Mouse) (Morley, J.E. (305) 23)

Motor activity
d-Amphetamine; Dose response; Psychomotor stimulant; Behavior (Gaytan, O. (300) 1)

Motor cortex
CGP 35348; Transcallosal response; Pyramidal tract neuron; Paired-pulse method; (−)-Baclofen (Chowdhury, S.A. (314) 313)

Motor function
Spinal reflex; $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide); Spinal cord (Hasegawa, Y. (295) 211)

Motor nerve conduction velocity
Cilostazol; Otsuka Long-Evans Tokushima Fatty rat; R-R interval, coefficient of variation; Sciatic nerve blood flow; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

Motor suppression
Conditioned fear stress; σ Receptor; Phenytoin; Phencyclidine receptor (Kamei, H. (299) 21)

Conditioned fear stress; σ Receptor; Phenytoin; Dopaminergic system (Kamei, H. (309) 149)

Motor system
Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

Movement disorder
Ca^{2+} channel antagonist; Dystonia; Dopamine (Richter, A. (300) 197)

MPP^+ (1-methyl-4-phenylpyridinium)
Selegiline; Astrocyte; Neuronal culture (Koutsilieri, E. (306) 181)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Light extinction test; Dopamine; Striatum; Substantia nigra (Messaoudi, M. (299) 17)

Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); Methoxytetrabenazine; Dihydrotetrabenazine (Kilbourn, M. (307) 227)

Dopamine D_1 receptor agonist; Desensitization; Parkinson's disease (Blanchet, P.J. (309) 13)

α-MSH (α-melanocyte-stimulating hormone)
Pain; Analgesia; Polyamine; NMDA receptor; Ifenprodil; Morphine; Naloxone (Bernardi, M. (298) 51)

α-MSH (α-melanocyte stimulating hormone) secretion
Median eminence; Intermediate lobe; Pentazocine; Haloperidol; Raclopride; Prolactin secretion (Eaton, M.J. (299) 171)

γ_2-MSH (γ_2-melanocyte-stimulating hormone)
ACTH-(4–10) (adrenocorticotropic hormone-(4–10)); Blood pressure; Heart rate; Structure-activity; Melanocortin receptor; (Rat) (Van Bergen, P. (294) 795)

Cerebral ischemia; Laser-Doppler flowmetry; Middle cerebral artery occlusion; Nimodipine; (Rat) (Herz, R.C.G. (306) 113)

Mucosa
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; Secretion; Colon; (Human) (Borman, R.A. (309) 271)

Mucosal protection
EGF (epidermal growth factor); Tissue resistance; Receptor; Epithelium (Rao, R. (303) 209)

Mucus secretion
Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutylmethylxanthine; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Multidrug resistance
P-Glycoprotein; Photoaffinity labeling; Chemosensitizer (Boer, R. (295) 253)

Cisplatin; DNA repair; Drug resistance (Chao, C.C.-K. (305) 213)

Chemotherapy; Modulator; P-glycoprotein (Demmer, A. (315) 339)

Multiple organ dysfunction syndrome
Nitric oxide (NO) synthase, inducible; Lipopolysaccharide; Liver failure; Endotoxin (Wu, C.-C. (300) 99)

Murine mast cell
cis-Platinum (II) phosphonate complex; Cisplatin; Histamine release (Brzezińska-Błaszczyk, E. (298) 155)

Muscarinic
Biperiden; Budipine; NMDA (*N*-methyl-D-asparate); Parkinsonism (Klockgether, T. (301) 67)

Smooth muscle; Contraction; Phospholipase C; G-protein; Antibody (Cuq, P. (315) 213)

Muscarinic acetylcholine receptor
Cloned human receptor; Receptor selection and amplification technology; Functional partial agonism; Functional receptor selectivity (Bräuner-Osborne, H. (313) 145)

Anticholinesterase; 5-HT_2 receptor; Neocortical high-voltage spindle; Thalamocortical oscillation; (Rat) (Jäkälä, P. (316) 181)

Muscarinic acetylcholine receptor agonist
Bisquaternary allosteric antagonist (Lanzafame, A. (316) 27)

Muscarinic acetylcholine receptors
Ibogaine; Noribogaine; Adenylyl cyclase; 5-HT receptors; Opioid receptors (Rabin, R.A. (316) 343)

Muscarinic autoreceptor
Acetylcholine; Hippocampus; Microdialysis; Medial septum (Moor, E. (294) 155)

Muscarinic receptor
Esophageal muscularis mucosae; Receptor alkylation (Watson, N. (294) 779)

G-protein; High-throughput assay; Molecular biology (Bräuner-Osborne, H. (295) 93)

Heparin; Receptor subtype; Transfected cell; Allosteric interaction; Receptor coupling (Wang, S.Z. (296) 113)

Ovary; Puberty, female; Cholinergic system (Trkulja, V. (297) 93)

Interferon-γ (Mita, Y. (297) 121)

Cell proliferation; Astrocyte; Astrocytoma (Guizzetti, M. (297) 265)

Acetylcholine; Spare receptor; Adenylate cyclase; Selectivity (Heldman, E. (297) 283)

Diabetic pancreas; Ca^{2+} mobilization; 1,4,5-IP_3-sensitive Ca^{2+} store; Ca^{2+} refilling (Komabayashi, T. (298) 299)

Colon, rat; Development (Zhang, L. (304) 211)

Allosteric modulation; Alcuronium; Agonist; Heart (Maaß, A. (305) 231)

Atropine; Methyl-quinuclidinyl-benzylate; CGP-12177; PET (positron emission tomography); Heart; β-Adrenoceptor (Valette, H. (306) 133)

Blood pressure; Spinal cord; Hypertension; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Feldman, D.S. (313) 211)

Allosteric modulation; Structure-activity relationship; Heart porcine (Kostenis, E. (314) 385)

Muscarinic receptor agonist
Learning; Memory; Synaptic plasticity; Cholinergic system; AF102B; Oxotremorine (Iga, Y. (308) 13)

Parasympathetic; Pineal; Melatonin; Microdialysis; Carbachol; Noradrenaline release (Drijfhout, W.J. (308) 117)

Muscarinic receptor, allosteric control
Muscarinic receptor, heart; Allosteric interaction; Eburnamonine; Vincamine; Alcuronium; Strychnine (Proška, J. (305) 201)

Muscarinic receptor antagonist
Muscarinic receptor subtype; Carbon analog, uncharged; Stereoselectivity, at muscarinic receptor; BS-6181; BS-7826, (*R*)- and (*S*)-enantiomer (Waelbroeck, M. (303) 221)

Muscarinic receptor, heart
Muscarinic receptor, allosteric control; Allosteric interaction; Eburnamonine; Vincamine; Alcuronium; Strychnine (Proška, J. (305) 201)

Muscarinic receptor subtype
Muscarinic receptor antagonist; Carbon analog, uncharged; Stereoselectivity, at muscarinic receptor; BS-6181; BS-7826, (*R*)- and (*S*)-enantiomer (Waelbroeck, M. (303) 221)

Muscarinic toxin; Allosteric site (Waelbroeck, M. (305) 187)

Muscarinic M_4 receptor
Adenylate cyclase; α_{2B}-Adrenoceptor; δ-Opioid receptor; Prostaglandin E_1 receptor; Receptor cross-talk (Ammer, H. (302) 199)

Muscarinic toxin
Muscarinic receptor subtype; Allosteric site (Waelbroeck, M. (305) 187)

[^{3}H]Muscimol
$GABA_A$ receptor, recombinant; [^{3}H]Flunitrazepam; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate); Allosteric binding site (Zezula, J. (301) 207)

Muscle denervation
Nitroprusside; Hemoglobin; ODQ (1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one); Nitric oxide (NO) (Urazaev, A.Kh. (316) 219)

Muscle, fetal, rat
Nicotinic acetylcholine receptor; Patch-clamp; Voltage-clamp; Molecular modelling; Nicotinic agonist; Non-competitive agonist (Cooper, J.C. (309) 287)

Muscle relaxant
Paired pulse facilitation; Spinal cord; EPSC (excitatory postsynaptic current); IPSC (inhibitory postsynaptic current); (Slice) (Tanabe, M. (313) 187)

Muscle rigidity
μ_1-Opioid receptor; Respiratory depression; Fentanyl; Morphine (Chen, S.-W. (312) 241)

Mutagenesis
Opioid receptor; Chimeric receptor; Structure-function relationship; δ-Opioid receptor ligand (Meng, F. (311) 285)

Melanocortin MC_3 receptor; Ligand binding; MSH (melanocyte-stimulating hormone) (Schiöth, H.B. (314) 381)

Mutant mouse
Long-term potentiation; Glutamate receptor, metabotropic (Bordi, F. (301) R15)

Mutation
CCK receptor; Histidine (Jagerschmidt, A. (296) 97)

Adenosine A_{2A} receptor, human; Glutamic acid; CGS21680; XAC; Amiloride (IJzerman, A.P. (310) 269)

Myeloperoxidase
Dolabrane; Anti-inflammatory; Neutrophil, human; Elastase; Prostaglandin; Leukotriene (Payá, M. (312) 97)

Propentofylline; Adenosine receptor; Xanthine; Polymorphonuclear leukocyte influx (Zhang, Y. (313) 237)

Myenteric plexus
Gastrointestinal tract; Intestine; Ganglion; Enteric nervous system; Submucous plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Intestine; Ganglion; Enteric nervous system; Histamine; cAMP; Adenylate cyclase (Xia, Y. (316) 81)

Myenteric plexus-longitudinal muscle preparation
Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; SR141716A; Vas deferens, mouse; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

Myocardial contractility
Isovolumic relaxation; Ventricular filling; Preload recruitable stroke work; Inotropes; Dobutamine; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

Myocardial hypertrophy
K^+ channel, ATP-sensitive; Hypertension; Trypsin; Single-channel recording (Sodder, V.H. (315) 115)

Myocardial infarction
Quality of life; Anxiety; Exploration; Social behavior; (Rat) (Schoemaker, R.G. (298) 17)

Remodeling; Ischemia; Metabolism; Captopril (Kalkman, E.A.J. (298) 121)

Myocardial ischemia
Ventricular arrhythmia; α-Adrenoceptor subtype-selective blocker; Coronary occlusion; Heart rate; Arrhythmia (Geller, J.C. (294) 423)

Nicorandil; Ventricular arrhythmia; K_{ATP} channel; Nitric oxide (NO); Reperfusion (Vegh, A. (305) 163)

Myocardial oxygen demand
Paraventricular nucleus of the hypothalamus; MK-801; Memantine; (Rabbit) (Monassier, L. (305) 109)

Carvedilol; Reperfusion injury, lethal; (Cat) (Brunvand, H. (314) 99)

Myocardium
CD-832; Ca^{2+} channel antagonist; Chronotropic effect, negative; Inotropic effect, negative; (Guinea-pig) (Noguchi, K. (308) 53)

Ca^{2+}; Dantrolene; Sarcoplasmic reticulum; Ca^{2+} indicators; Aequorin (Meissner, A. (316) 333)

Myocardium, stunned
Endothelin; TAK-044; (Dog) (Kitayoshi, T. (305) 137)

Myoclonic jerk
8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; GR 127935; WAY 100635; $5\text{-}HT_{1D}$ receptor; $5\text{-}HT_{1A}$ receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Myocyte
Cardiac hypertrophy; Stretch; Angiotensin (Miyata, S. (307) 81)

Myocyte, single, ventricular
Bepridil; Voltage clamp, whole cell; Na^+ current (Sato, N. (314) 373)

Myocyte, ventricular
Ca^{2+} channel; Flunarizine (Tytgat, J. (296) 189)

κ-Opioid receptor, tolerance; Ca^{2+}, intracellular, free; Inositol 1,4,5-trisphosphate; U50,488H (Sheng, J.-Z. (307) 323)

Myofilament
Ca^{2+}; Ca^{2+} sensitiser; EMD 57033; Skinned fiber; Rigor (Palmer, S. (294) 83)

Myometrium, human
Melatonin; Pregnancy; Labor; Noradrenaline (Mårtensson, L.G.E. (316) 273)

Myosin light chain kinase
Staurosporine; Calphostin C; Wortmannin; Protein kinase C; Aorta; (Rabbit) (Asano, M. (294) 693)

[^{3}H]N-0437
Antidepressant; Repeated treatment; Dopamine D_2 receptor binding (Maj, J. (304) 49)

Na^+-Ca^{2+} exchange
Endothelial cell, aortic; Ca^{2+} concentration, intracellular, free; Ca^{2+}-ATPase; Fura-2 (Goto, Y. (314) 185)

Taurine; Ventricular myocyte, rat; Patch-clamp (Katsube, Y. (316) 97)

Na^+-Ca^{2+} exchanger
Prolactin; Na^+-H^+ antiporter; Amiloride analog (Di Renzo, G. (294) 11)

Na^+ channel
Vincamine; Vincanol; Vinpocetine; Voltage-gated; Batrachotoxin; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

Epilepsy; Kava pyrone; *Piper methysticum*; Synaptosome (Gleitz, J. (315) 83)

Na^+ channel block
Cardiac Na^+ channel; Antiarrhythmic agent, class I; Bisaramil (Sunami, A. (312) 245)

Na^+ channel, voltage-dependent
Anticonvulsant (Tang, L. (300) 71)

Felbamate; Anti-epileptic (Taglialatela, M. (316) 373)

Na^+ current
Bepridil; Voltage clamp, whole cell; Myocyte, single, ventricular (Sato, N. (314) 373)

Na^+ current inactivation
Local anesthetic; *N*-butyl-*p*-aminobenzoate; Patch clamp; Dorsal root ganglion (Van den Berg, R.J. (316) 87)

Na^+ dependence
Stretch-activated channel; Ca^{2+} uptake; Membrane potential; Ca^{2+} channel, L-type (Ruiz-Velasco, V. (296) 327)

Na^+ excretion
α_1-Adrenoceptor subtype; Hypertension; Kidney function (Sattar, M.A. (294) 727)

Na^+-H^+ antiporter
Prolactin; Na^+-Ca^{2+} exchanger; Amiloride analog (Di Renzo, G. (294) 11)

Na^+,K^+-ATPase
Digitalis; Heart failure; Norepinephrine (Lai, L.-P. (309) 235)

Ptilomycalin A; Ca^{2+}-ATPase; ATPase inhibitor (Ohizumi, Y. (310) 95)

Contraction; Human bronchus; Protein kinase C; Ca^{2+} channel (Yang, K.X.F. (315) 65)

Na^+,K^+ATPase, activity
Dopamine; Dopamine receptor; Dopamine signal transduction; Smooth muscle, vascular; Smooth muscle cell, aortic; (Rat) (Rashed, S.M.K. (305) 223)

Na^+-permeable channel
Maitotoxin; Patch clamp; Ventricular cell, guinea-pig (Nishio, M. (297) 293)

Na^+ transport
L-Arginine; K^+ transport; Opiate; Cholinergic responses; Nitric oxide (NO) (Neumann, V. (316) 123)

Naloxonazine
Antinociception; Respiratory depression; Opioid receptor; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

Antinociception; Respiratory depression; Opioid receptor; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Naloxone
MK-801; Morphine withdrawal; Spinal cord; Morphine dependence (Bell, J.A. (294) 297)

Hypovolemia; *N*-Nitro-L-arginine methyl ester; L-Arginine; Hemorrhagic shock; Nitric oxide (NO); (Conscious rabbit) (Ventura, S. (294) 369)

Nicotine; Morphine; Acetylcholine receptor antagonist; Jumping; (Mouse) (Zarrindast, M.-R. (298) 1)

Pain; Analgesia; Polyamine; NMDA receptor; Ifenprodil; Morphine; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

Stress, uncontrollable; Anhedonia (Zurita, A. (299) 1)

Dextromethorphan; Opiate; Withdrawal; Excitatory amino acid (Rosen, M.I. (307) 251)

NMDA receptor; Ibogaine; *O*-Desmethylibogaine; Morphine (Layer, R.T. (309) 159)

Naloxone-precipitated withdrawal
Diltiazem; Morphine withdrawal, spontaneous; Corticosterone, plasma; Body weight loss; Diarrhea; (Rat) (Kishioka, S. (316) 7)

Naltrexone
Opiate detoxification; Withdrawal syndrome (Muntoni, A.L. (301) R9)

Naltrexone methobromide
U-50,488H; Cycloheximide; Amnesia; Dynorphin A-(1–13); (Mouse) (Ukai, M. (313) 11)

Naltriben
Naltrindole; δ-Opioid receptor; Opioid withdrawal (Funada, M. (300) 17)

Naltrindole
Cocaine; Enkephalin; δ-Opioid receptor; Sensitization (Heidbreder, C. (298) 207)

Naltriben; δ-Opioid receptor; Opioid withdrawal (Funada, M. (300) 17)

Opioids; Opioid receptor antagonist; DAMGO ([D-Ala^2–MePhe^4–Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2, D-Pen^5]enkephalin) (Duvauchelle, C.L. (316) 137)

L-NAME (*N*$^{\omega}$-nitro-L-arginine methyl ester)
Lithium chloride; Tacrine; Seizure; Nitric oxide (NO); Citrulline (Bagetta, G. (294) 341)

Angiotensin II; Nitric oxide (NO); Losartan; Kidney; (Rabbit) (Adachi, Y. (308) 165)

NAN-190
Dopamine; Cortex, prefrontal; 5-HT_{1A} receptor; Ipsapirone; WAY 100135; Microdialysis (Wędzony, K. (305) 73)

NANC (non-adrenergic non-cholinergic) neurotransmission
Lower esophageal sphincter; Electrical field stimulation; Nicotine; Nitric oxide (NO); VIP (vasoactive intestinal peptide) (Kortezova, N. (304) 109)

Natural killer activity
Jatrophone; Lymphocyte proliferation; Protein kinase C; 12-*O*-Tetradecanoylphorbol 13-acetate; CD69; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

Nausea
Δ^9-Tetrahydrocannabinol; Nucleus tractus solitarii; Glucose; Catecholaminergic neuron; 5-HT_3 receptor (Himmi, T. (312) 273)

NB-818
Ca^{2+} channel antagonist; Vascular relaxation; Negative inotropic action; Negative chronotropic action; Ca^{2+} current, L-type (Hattori, Y. (301) 99)

NB41A3 cell
CNTF (ciliary neurotrophic factor receptor α); cAMP; PC12 cell; mRNA (MacLennan, A.J. (295) 103)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(*f*)quinoxaline)
Glu_1-flop receptor; AMPA receptor agonist; (Pharmacology) (Wahl, P. (308) 211)

NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(*F*)quinoxaline)
Cyclothiazide; GYKI 52466; Allosteric regulation (Okada, M. (309) 299)

***N*-butyl-*p*-aminobenzoate**
Local anesthetic; Patch clamp; Na^+ current inactivation; Dorsal root ganglion (Van den Berg, R.J. (316) 87)

[^{125}I]NCQ-298
Dopamine D_2 receptor; [^{3}H]Spiperone; [^{3}H]Raclopride; [^{3}H]YM-09151-2; Nemonapride; Receptor binding, in vitro (Malmberg, Å. (303) 123)

NECA (5′-*N*-ethylcarboxamidoadenosine)
Glutamate receptor, metabotropic; cAMP; Adenosine deaminase; Forskolin; VIP (vasoactive intestinal peptide); Hippocampus (Wright, R.A. (297) 275)

N1E-115 cells
5-HT_3 receptor; 5-HT_3 receptor agonist; NG 108-15 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

Negative chronotropic action
Ca^{2+} channel antagonist; Vascular relaxation; Negative inotropic action; Ca^{2+} current, L-type; NB-818 (Hattori, Y. (301) 99)

Negative inotropic action
Ca^{2+} channel antagonist; Vascular relaxation; Negative chronotropic action; Ca^{2+} current, L-type; NB-818 (Hattori, Y. (301) 99)

Nemonapride
Dopamine D_2 receptor; [^{3}H]Spiperone; [^{3}H]Raclopride; [^{125}I]NCQ-298; [^{3}H]YM-09151-2; Receptor binding, in vitro (Malmberg, Å. (303) 123)

NE-100 (*N*,*N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl)
Pheochromocytoma (PC12) cell; Ca^{2+} uptake; Nicotine; Binding assay; σ Receptor (Sagi, N. (304) 185)

Neocortex, rat
$GABA_B$ receptor; Baclofen; AHPNs ((*R*,*S*)-3-amino-2-hydroxy-*N*-(4-nitrophenyl)-propanesulphonamide); $GABA_B$ receptor antagonist; Ileum, guinea-pig (Kerr, D.I.B. (294) 349)

Neocortical high-voltage spindle
Nicotinic acetylcholine receptor; 5-HT_2 receptor; Thalamocortical oscillation; (Rat) (Jäkälä, P. (299) 47)

Anticholinesterase; Muscarinic acetylcholine receptor; 5-HT_2 receptor; Thalamocortical oscillation; (Rat) (Jäkälä, P. (316) 181)

Neointima
Balloon angioplasty; Restenosis; Endothelium; Nitric oxide (NO); Nitric oxide (NO) synthase; Von Willebrand factor (Bosmans, J.M. (310) 163)

Neointimal thickening
Endothelin; Endothelin ET_A receptor antagonist; FR139317; (Rat) (Takiguchi, Y. (309) 59)

Neomycin
Histamine H_1 receptor; Ca^{2+} entry; Phospholipase C (Sipma, H. (305) 207)

SK-N-BE(2)C human neuroblastoma; Phospholipase C; U-73122; cAMP production; Ca^{2+} mobilization; Inositol 1,4,5-triphosphate (Suh, B.-C. (314) 235)

Neostriatal neuron
CCK_B receptor; Cationic current; G-protein; Inositol 1,4,5-trisphosphate; Whole-cell patch-clamp recording (Wu, T. (307) 125)

Nephropathy
Diabetes; Hypertension; Angiotensin; Blood perfused; Kidney; (Rat) (Farina, N.K. (310) 185)

Nephrotoxicity
Cyclosporine A; Endothelin; Renal failure (Brooks, D.P. (294) 571)

Nerve blood flow
Diabetic rat; Vasa nervorum; Adrenergic responsiveness; ACTH-(4–9) analog, Org 2766 (Van Buren, T. (296) 277)

Nerve conduction
Polyol pathway; Diabetes; Galactosemia; Nerve regeneration; Oxygen free radical; Antioxidant; Metal chelator (Love, A. (314) 33)

Nerve lesion
Protein mono-ADP-ribosylation; Diabetes; Corticosterone (Gorio, A. (311) 21)

Nerve regeneration
Polyol pathway; Diabetes; Galactosemia; Nerve conduction; Oxygen free radical; Antioxidant; Metal chelator (Love, A. (314) 33)

Nerve terminal
Melatonin; Nicotinic channel; Cholinergic transmission; Synaptic modulation; Submucosal neuron; Enteric neuron (Barajas-López, C. (312) 319)

Nervous system
Opioid receptor; Steroid; Neuroblastoma (Maggi, R. (301) 169)

Neuroactive steroid
Loreclezole; $GABA_A$ receptor; Benzodiazepine receptor (Xue, B.G. (300) 125)

Neurosteroid; Progesterone receptor; Gene expression (Rupprecht, R. (303) 227)

SR 95531; Neurosteroid; $GABA_A$ receptor; RU 5135; Pregnenolone sulfate; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

Neuroblastoma
Opioid receptor; Steroid; Nervous system (Maggi, R. (301) 169)

Neurodegeneration
Catecholamine absorbing protein; Central nervous system; Free radical; Oxidation; Dopamine; Parkinson's disease (Modi, P.I. (299) 213)

Neurodegenerative disorder
Anticonvulsant; Kynurenine; Microdialysis; Neuroprotection (Speciale, C. (315) 263)

Neuroendocrine challenge
Fluoxetine; 5-HT (5-hydroxytryptamine, serotonin) (McCann, U.D. (312) R1)

Neurogenic inflammation
Cold air; Tachykinin; Kinin; Bronchoconstriction; SR 48968; HOE 140 (Yoshihara, S. (296) 291)

Angiogenesis; Basement membrane; Tachykinin; Wound healing (Wiedermann, C.J. (298) 335)

N-Acylethanolamide; Palmitoylethanolamide; Autacoid local inflammatory antagonism; Cannabinoid receptor, peripheral; Passive cutaneous anaphylaxis (Mazzari, S. (300) 227)

Neurogenic pain
Central hyperalgesia; Atipamezole; Medetomidine; α_2-Adrenoceptor; Lateral reticular nucleus of the medulla; Spinal cord (Mansikka, H. (297) 19)

Neurohypophyseal hormone
Social recognition; Social memory, rat; Oxytocin; PLG (prolyl-leucyl-glycinamide); Structure activity (Popik, P. (308) 113)

Neuro-immune interaction
Analgesia; Nociception; Opioid; Neuropeptide; Cytokine (Mousa, S.A. (311) 221)

Neurokinin
NK_1 receptor antagonist; Bronchoconstriction; Pain; Plasma extravasation; Neuropeptide (Bonnet, J. (310) 37)

Neurokinin A
Bronchoconstriction; Airway neurogenic inflammation; Substance P; Capsaicin (Robineau, P. (294) 677)

Substance P; Tachykinin NK_1 receptor; Nociception; Analgesia; Hyperalgesia (Yashpal, K. (308) 41)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Substance P; FK 888; SR 48968; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

[^{3}H][β-Ala^8]Neurokinin A-(4–10)
Urinary bladder, hamster; Tachykinin, NK_2 receptor; Tachykinin; (Binding) (Goso, C. (294) 239)

Neurokinin, tachykinin NK_2 receptor
Jejunum, rat; Smooth muscle contraction; 5-ht$_7$ receptor; 5-HT_3 receptor; 5-HT (5-hydroxytryptamine, serotonin) (McLean, P.G. (312) 215)

Neuroleptic
Haloperidol; Enkephalin; Aminopeptidase N; Neuropeptide (Konkoy, C.S. (297) 47)

[^{3}H]Resiniferatoxin; Vanilloid receptor; Capsazepine; Cooperative binding (Szallasi, A. (298) 321)

Neuroleptic, chronic
NMDA receptor antagonist; Dopamine; Locomotor activity; Memory; (Mouse) (Mele, A. (308) 1)

Neuroleptic withdrawal
Ca^{2+} channel blockade; Haloperidol; Pimozide; Nifedipine; Apomorphine (Antkiewicz-Michaluk, L. (294) 459)

Neurological disorder
GABA (γ-aminobutyric acid); Excitatory amino acid; Seizure; Ischemia; Drug screening; Antiepileptic (Kanthasamy, A.G. (297) 219)

Neuromedin B
Gastrin-releasing peptide; Bombesin; Structure-function study (Lin, J.-T. (294) 55)

Bombesin receptor antagonist; Ca^{2+}, intracellular; Arachidonic acid (Ryan, R.R. (306) 307)

Neuromodulation
Oxytocin; Structure-activity (Poulin, P. (294) 29)

Neuromuscular transmission
Suramin; P_2 purinoceptor; Non-depolarizing neuromuscular relaxant; Ca^{2+} channel (Henning, R.H. (301) 91)

Neuron
Achatin-I (Gly-D-Phe-Ala-Asp); Excitatory neuropeptide; Promethazine; Triprolidine; Histamine H_1 receptor antagonist; Blocking effect; (Snail) (Salunga, T.L. (304) 163)

Neuronal culture
Selegiline; MPP^+ (1-methyl-4-phenylpyridinium); Astrocyte (Koutsilieri, E. (306) 181)

Neuronal plasticity
Opiate receptor; Synapsin I; Pruning effect (Gorio, A. (303) 21)

Neurone
Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; Intracellular signal transduction system; H-89; KT5823; W-7; IBMX (3-isobutyl-1-methylxanthine); (Snail) (Emaduddin, M. (302) 129)

Neuron, isolated
β-Adrenoceptor, β_1 and β_2 subtype; Desipramine; Binding site, high and low affinity; Astrocyte, isolated (Sapena, R. (300) 159)

Neuropeptide
Haloperidol; Enkephalin; Aminopeptidase N; Neuroleptic (Konkoy, C.S. (297) 47)

Analgesia; μ-Opioid receptor; Spinal cord; Desipramine; α_2-Adrenoceptor (Gergen, K.A. (298) 235)

Neurokinin; NK_1 receptor antagonist; Bronchoconstriction; Pain; Plasma extravasation (Bonnet, J. (310) 37)

Neuro-immune interaction; Analgesia; Nociception; Opioid; Cytokine (Mousa, S.A. (311) 221)

Neuropeptide FF
Ca^{2+}, intracellular; Dorsal root ganglion neuron; (Mouse) (Roumy, M. (306) 291)

Neuropeptide Y
Cheek pouch, hamster; Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}] Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Neuropeptide Y Y_1 receptor antagonist; BIBP 3226; Vasoconstriction, sympathetic; Vena cava, guinea-pig (Malmström, R.E. (294) 661)

Pulmonary edema; Sympathetic nervous system; Capillary permeability (Hirabayashi, A. (296) 297)

BIBP3226; Y_1 receptor antagonist; Gastrointestinal epithelia (Tough, I.R. (310) 55)

Noradrenaline; Peptide; Blood vessel; Vascular control; Hemorrhage (Hunter, L.W. (313) 79)

Artery, human; Noradrenaline; Antisense oligodeoxynucleotide; BIBP3226; Reverse transcriptase-polymerase chain reaction (Bergdahl, A. (316) 59)

[Leu^{31},Pro^{34}]Neuropeptide Y
Cheek pouch, hamster; Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Neuropeptide Y-(13–36)
Cheek pouch, hamster; Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y (Boric, M.P. (294) 391)

Neuropeptide Y receptor
G_i-protein; α_{2A}-Adrenoceptor; Ca^{2+}; Microtubule; Microfilament (Michel, M.C. (309) 87)

Neuropeptide Y Y_1 receptor
Cheek pouch, hamster; Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Neuropeptide Y Y_1 receptor antagonist
Neuropeptide Y; BIBP 3226; Vasoconstriction, sympathetic; Vena cava, guinea-pig (Malmström, R.E. (294) 661)

SR 120107A; Sympathetic vasoconstriction; (Pig) (Malmström, R.E. (305) 145)

Neuropeptide Y Y_2 receptor
Cheek pouch, hamster; Microvascular flow; Hyperemia; Noradrenaline; Neuropeptide Y; Neuropeptide Y Y_1 receptor; [Leu^{31},Pro^{34}]Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

Neuroprotection
α-Tocopherol analog (water-soluble); Lipid peroxidation; Antioxidant; Vitamin E; Malondialdehyde; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

GABA (γ-aminobutyric acid); Epilepsy; Hippocampus; Perforant pathway stimulation (Halonen, T. (299) 69)

HEK293 cell; Ca^{2+} channel, voltage-dependent; NMDA receptor antagonist; Ischemia; (Gerbil) (Bath, C.P. (299) 103)

Growth factor; Cytokine; Excitotoxicity (Prehn, J.H.M. (306) 81)

Anticonvulsant; AMPA receptor antagonist; NMDA receptor glycine site antagonist (Ilyin, V.I. (310) 107)

NMDA receptor; Competitive antagonist; Radioligand binding; Molecular modelling (Cheung, N.S. (313) 159)

Vincamine; Vincanol; Vinpocetine; Na^+ channel; Voltage-gated; Batrachotoxin; Anticonvulsant (Erdő, S.L. (314) 69)

Anticonvulsant; Kynurenine; Microdialysis; Neurodegenerative disorder (Speciale, C. (315) 263)

Neuroprotective agent
Anti-epileptic drug; Cortex; Ca^{2+} current (Stefani, A. (307) 113)

Neuropsychological status
Ceritizine; Chlorpheniramine; EEG (electroencephalogram), quantitative; Oral administration, acute; Plasma concentration, drug; (Healthy volunteer) (Sannita, W.G. (300) 33)

Neurosteroid
TNF (tumor necrosis factor); Glucocorticoid; Dehydroepiandrosterone sulfate; Pregnenolone (Di Santo, E. (299) 179)

Neuroactive steroid; Progesterone receptor; Gene expression (Rupprecht, R. (303) 227)

SR 95531; Neuroactive steroid; $GABA_A$ receptor; RU 5135; Pregnenolone sulfate; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

Neurotensin
Peristalsis; Small intestine, guinea-pig; Apamin (Ohashi, H. (301) 129)

Neurotoxicity
Monosodium glutamate; Meal size and duration; Hypophagia; Hypersensitivity to neuropeptide Y; Arcuate nucleus (Stricker-Krongrad, A. (295) 27)

RPR 104632; Glycine receptor antagonist; Glutamate; NMDA receptor-channel complex (Boireau, A. (300) 237)

Retinal cell; Glutamate receptor; Ca^{2+}; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Ferreira, I.L. (302) 153)

Tryptamine-4,5-dione; 5-HT (5-hydroxytryptamine, serotonin); Free radical; Fenton (Chen, J.-C. (303) 109)

Neurotransmission
Vas deferens; Noradrenaline; Agmatine; Imidazoline receptor; Adrenoceptor (Jurkiewicz, N.H. (307) 299)

Neurotransmitter
Learning; Memory; Prostaglandin; Cyclooxygenase; Retrograde messenger; Synaptic plasticity (Hölscher, C. (294) 253)

L-*threo*-DOPS (L-*threo*-dihydroxyphenylserine); L-DOPA (L-dihydroxyphenylalanine); Nucleus tractus solitarii; L-DOPA methyl ester; (Rat) (Miyamae, T. (300) 105)

Neutral endopeptidase
Acetylcholine; Epithelium; Trachea; Cholinergic neurotransmission; (Rabbit) (Loenders, B. (296) 89)

Neutral endopeptidase inhibitor
Bradykinin; Angiotensin-converting enzyme inhibitor; DOCA-salt rat (Pham, I. (296) 267)

Neutrophil
Substance P; Superoxide production; Ca^{2+}, intracellular; Phosphoinositide (Tanabe, T. (299) 187)

Substance P; Superoxide; CGRP (calcitonin gene-related peptide) (Tanabe, T. (314) 175)

Neutrophil adherence
Cell activation; Hypoxia; Endothelium; Aescine; Reparil (Arnould, T. (315) 227)

Neutrophil, human
Protein kinase inhibitor; Respiratory burst; Degranulation; Ca^{2+} mobilization (Ahn, S.K. (306) 175)

Dolabrane; Anti-inflammatory; Myeloperoxidase; Elastase; Prostaglandin; Leukotriene (Payá, M. (312) 97)

Newborn
Cyclic nucleotide; Cerebral circulation (Wilderman, M.J. (309) 243)

NG 108-15 cells
5-HT_3 receptor; 5-HT_3 receptor agonist; N1E-115 cells; Bezold–Jarisch reflex; [^{14}C]guanidinium; Emesis; Inward current; (Rat) (Delagrange, P. (316) 195)

ngf1c
5-HT_{1A} receptor; 5-$HT_{2A/C}$ receptor; *c-fos*; *tis1* (Tilakaratne, N. (307) 211)

NGF (nerve growth factor)
Leukotriene; Thermal hyperalgesia (Amann, R. (306) 89)

Propentofylline; Learning; Memory; Choline acetyltransferase; Dementia model; (Rat) (Nitta, A. (307) 1)

NH_4Cl
Vasoconstriction; Coronary artery; Intracellular pH (Wakabayashi, I. (299) 139)

Nicardipine
NMDA receptor antagonist; CGP 40116; CGP 43487; Ca^{2+} channel inhibitor; Flunarizine; Nifedipine; Seizure (Gasior, M. (312) 27)

Nicorandil
ATP-sensitive K^+ channel; Cromakalim; Dopamine autoreceptor; Microdialysis; Sulpiride (Tanaka, T. (297) 35)

Myocardial ischemia; Ventricular arrhythmia; K_{ATP} channel; Nitric oxide (NO); Reperfusion (Vegh, A. (305) 163)

Aorta, rat; Relaxation; cGMP; Tolerance; Levcromakalim (Trongvanichnam, K. (314) 83)

Nicotine
Retrieval; Passive avoidance; (Mouse) (Zarrindast, M.-R. (295) 1)

Isoarecolone; Microdialysis; Dopamine; Nucleus accumbens (Mirza, N.R. (295) 207)

Morphine; Naloxone; Acetylcholine receptor antagonist; Jumping; (Mouse) (Zarrindast, M.-R. (298) 1)

Epibatidine; Antinociception; Tolerance; (Mouse) (Damaj, M.I. (300) 51)

Drug discrimination; Mecamylamine; Methyllycaconitine (Brioni, J.D. (301) 1)

Lower esophageal sphincter; NANC (non-adrenergic non-cholinergic) neurotransmission; Electrical field stimulation; Nitric oxide (NO); VIP (vasoactive intestinal peptide) (Kortezova, N. (304) 109)

Pheochromocytoma (PC12) cell; Ca^{2+} uptake; NE-100 (*N,N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl); Binding assay; σ Receptor (Sagi, N. (304) 185)

Emesis; Morphine; Tachykinin NK_1 receptor; 5-HT_3 receptor; 5-HT_{1A} receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

Aging; Alzheimer's disease; Spatial navigation; 5-HT (5-hydroxytryptamine, serotonin); Tetrahydroaminoacridine (Riekkinen, M. (308) 243)

L-DOPA (3,4-dihydroxyphenylalanine) release; Locomotor activity, rat; Nucleus accumbens; Ventral tegmental area; Microdialysis (Goshima, Y. (309) 229)

Dopamine; Ethanol; Nicotinic acetylcholine receptor; Preference; Sensitization; (Rat) (Blomqvist, O. (314) 257)

Mecamylamine; Conditioned place preference paradigm; Place aversion; Physical dependence (Suzuki, T. (314) 281)

D-CPPene (SDZ EAA 494; Sensitization; Dopamine, mesoaccumbens; Locomotor activity; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid) (Balfour, D.J.K. (316) 153)

Nicotinic acetylcholine receptor
5-HT_2 receptor; Neocortical high-voltage spindle; Thalamocortical oscillation; (Rat) (Jäkälä, P. (299) 47)

Chromaffin cell; Cell separation; Noradrenaline release; Adrenaline release (Krause, W. (302) 223)

Muscle, fetal, rat; Patch-clamp; Voltage-clamp; Molecular modelling; Nicotinic agonist; Non-competitive agonist (Cooper, J.C. (309) 287)

Dopamine; Ethanol; Nicotine; Preference; Sensitization; (Rat) (Blomqvist, O. (314) 257)

Nicotinic agonist
Nicotinic acetylcholine receptor; Muscle, fetal, rat; Patch-clamp; Voltage-clamp; Molecular modelling; Non-competitive agonist (Cooper, J.C. (309) 287)

Nicotinic channel
Melatonin; Cholinergic transmission; Synaptic modulation; Submucosal neuron; Enteric neuron; Nerve terminal (Barajas-López, C. (312) 319)

Nicotinic receptor
Thermodynamics; *d*-Tubocurarine; Skeletal muscle; Entropy; Enthalpy (Banerjee, B. (310) 13)

Protein kinase C; CGP 41251; Chromaffin cell; Tyrosine hydroxylase; Catecholamine secretion (Loneragan, K. (311) 87)

Choline; Acetylcholine; Blood pressure; Hypotension; Vasopressin (Savci, V. (311) 153)

Nifedipine
Neuroleptic withdrawal; Ca^{2+} channel blockade; Haloperidol; Pimozide; Apomorphine (Antkiewicz-Michaluk, L. (294) 459)

NMDA receptor antagonist; CGP 40116; CGP 43487; Ca^{2+} channel inhibitor; Flunarizine; Nicardipine; Seizure (Gasior, M. (312) 27)

Pulmonary artery; Prostaglandin E_1; ATP; Acetylcholine; Tolazoline; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

Niflumic acid
Carrageenan; c-Fos; Inflammatory pain; (+)-HA966; Spinal cord; (Rat) (Buritova, J. (303) 91)

Tachykinin NK_1 receptor; Cl^- channel; Colon, rabbit (Patacchini, R. (303) 197)

Nigrostriatal
Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Nigrostriatal system
β-Phenylethylamine; Dopamine; Rotation (Barroso, N. (297) 195)

Niguldipine
Ca^{2+} current, L-type; Whole-cell recording; Voltage dependence; Enantioselectivity (Handrock, R. (309) 317)

Nimodipine
Cocaine; BayK 8644; Self-administration, i.v.; (Rat); (Mouse) (Kuzmin, A. (295) 19)

Ca^{2+} channel, L-type; Ethanol; Substitution; Drug discrimination; Conditioned taste aversion (De Beun, R. (306) 5)

Cerebral ischemia; Laser-Doppler flowmetry; Middle cerebral artery occlusion; γ_2-MSH (γ_2-melanocyte-stimulating hormone); (Rat) (Herz, R.C.G. (306) 113)

Electroconvulsive shock; Amnesia; Felodipine; Amlodipine; (Rat) (Župan, G. (310) 103)

Subarachnoid hemorrhage; Endothelium-dependent relaxation; Lipid peroxidation; AJ-3941; Ca^{2+} channel antagonist (Minato, H. (315) 297)

Nitrate tolerance
Glyceryl trinitrate; Nitrite; Platelet; Smooth muscle cell; Vascular (Weber, A.-A. (309) 209)

Nitric oxide
Peroxynitrite; Nitrotyrosine; Superoxide; Angiotensin II; Hemodynamics, in vivo (Kooy, N.W. (315) 165)

Nitric oxide (NO)
Lithium chloride; Tacrine; Seizure; Citrulline; L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (294) 341)

Hypovolemia; *N*-Nitro-L-arginine methyl ester; L-Arginine; Naloxone; Hemorrhagic shock; (Conscious rabbit) (Ventura, S. (294) 369)

Sexual behavior; Nitric oxide (NO) synthase; Paraventricular nucleus; (Rat) (Benelli, A. (294) 505)

Aminoguanidine; Nitric oxide (NO) synthase, inducible; Leishmaniasis; L-N^6-(1-Iminoethyl)-lysine; N^G-Monomethyl-L-arginine (Stenger, S. (294) 703)

Intimal thickening; Vascular reactivity; Glucocorticoid; Endothelium; Carotid artery, rabbit (Van Put, D.J.M. (294) 753)

L-*N*-Arginine methyl ester (L-NAME); Forced swimming test; Adrenalectomy; Glucocorticoid (Jefferys, D. (295) 131)

D-NNA (N^G-nitro-D-arginine); Diphenyleneiodonium; Di-2-thienyliodonium; Methylene blue; Lipopolysaccharide; Contraction (Palacios, B. (296) 75)

Nuclear factor κB; Tetrahydrobiopterin; GTP cyclohydrolase I; Smooth muscle cell, vascular; (Rat) (Hattori, Y. (296) 107)

Dipyridamole; Smooth muscle cells, vascular; Interleukin-1β; Cyclic nucleotide (Iimura, O. (296) 319)

Long-term potentiation; Amygdala, medial; Amygdala, lateral (Abe, K. (297) 43)

Vascular permeability; Lipopolysaccharide; Prostaglandin; Skin; (Mouse) (Fujii, E. (297) 257)

Low-density lipoprotein, oxidized; Prostaglandin; Macrophage; Atherosclerosis (Matthys, K.E. (298) 97)

Spider venom; Ca^{2+} channel blocker; K^+ channel blocker; Endothelin-1; Hoe 140 (Costa, S.K.P. (298) 113)

Acetylcholine; PAF (platelet-activating factor); EDHF (endothelium-derived hyperpolarizing factor) (Kamata, K. (298) 129)

Trachea; Smooth muscle relaxation; Endothelin; Charybdotoxin; (Guinea-pig) (Hadj-Kaddour, K. (298) 145)

7-Nitroindazole; Harmaline; NMDA (*N*-methyl-D-aspartate); Parkinsonism; Epilepsy (Eblen, F. (299) 9)

Lamotrigine; Dizocilpine (MK-801); Opiate abstinence (Lizasoain, I. (299) 41)

Deferential artery, human; Vas deferens; Vasopressin; Endothelium (Medina, P. (300) 221)

Senna; Cascara; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

Peroxynitrite; GABA (γ-aminobutyric acid) release; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)

Hypercholesterolemia; Sphincter of Oddi (Szilvassy, Z. (301) R17)

Airway responsiveness; Airway epithelium; Methylene blue; Guanylate cyclase; Zaprinast (Sadeghi-Hashjin, G. (302) 109)

Glyceraldehyde-3-phosphate dehydrogenase; Aconitase; Cell death (Meßmer, U.K. (302) 171)

FR144420; FK409; Angina (Hirasawa, Y. (303) 55)

Aging; ATP; Non-adrenergic non-cholinergic (NANC); Ileum, rat (Smits, G.J.M. (303) 79)

Lower esophageal sphincter; NANC (non-adrenergic non-cholinergic) neurotransmission; Electrical field stimulation; Nicotine; VIP (vasoactive intestinal peptide) (Kortezova, N. (304) 109)

Vasodilation; Coronary circulation; Nitric oxide (NO) synthase (Abdul-Hussain, M.N. (305) 155)

Nicorandil; Myocardial ischemia; Ventricular arrhythmia; K_{ATP} channel; Reperfusion (Vegh, A. (305) 163)

Endothelium; Acetylcholine; Hind limb, rat; EDHF (endothelium-derived hyperpolarizing factor) (Brouwers-Ceiler, D.L. (307) 65)

Penile erection; Corpus cavernosum; Endothelin; (Rat) (Ari, G. (307) 69)

Ticlopidine; Thrombolysis; Anti-platelet potency; Prostacyclin; Tissue plasminogen activator (Gryglewski, R.J. (308) 61)

Angiotensin II; Losartan; L-NAME (N^{ω}-nitro-L-arginine methyl ester); Kidney; (Rabbit) (Adachi, Y. (308) 165)

Ketorolac; Caffeine; N^{G}-Nitro-L-arginine methyl ester (L-NAME); Potentiation; Antinociception (López-Muñoz, F.J. (308) 275)

Vasoconstrictor sympathetic nerve; Saphenous vein, human; L-N^{ω}-Nitro-L-arginine (L-NNA); cGMP (Fabi, F. (309) 41)

L-Arginine; Nitric oxide (NO) synthase; Lipopolysaccharide; Septic shock; Mesenteric vascular bed; (Rat) (Mitolo-Chieppa, D. (309) 175)

Ketotifen; Intestine; Noradrenaline; Smooth muscle (Abu-Dalu, R. (309) 189)

Cerebral ischemia; 7-Nitroindazole; Hippocampus; (Mongolian gerbil) (O'Neill, M.J. (310) 115)

Bradykinin; N^{G}-Nitro-L-arginine; Antinociception (Germany, A. (310) 123)

Cerebral ischemia; Reperfusion; DNA fragmentation; Chromatin condensation; Apoptotic body; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

Peroxynitrite; Nitrotyrosine; Superoxide; Hemodynamics, in vivo (Kooy, N.W. (310) 155)

Balloon angioplasty; Neointima; Restenosis; Endothelium; Nitric oxide (NO) synthase; Von Willebrand factor (Bosmans, J.M. (310) 163)

N^{G}-Nitro-L-arginine; Methylene blue; Endothelium; Hypertension; Aorta, rat; Arterial pressure (Gil-Longo, J. (310) 175)

N^{ω}-Nitro-L-arginine methyl ester; Eosinophil chemotaxis; Pleurisy; cGMP (Ferreira, H.H.A. (310) 201)

Nitric oxide (NO) donor
Penile erection; Yawning; Guanylate cyclase; Paraventricular nucleus; (Rat) (Melis, M.R. (294) 1)

Nitric oxide (NO) synthase
Sexual behavior; Nitric oxide (NO); Paraventricular nucleus; (Rat) (Benelli, A. (294) 505)

Lipopolysaccharide; Nitrosyl-hemoglobin (NO-hemoglobin); Pressor response (Cai, M. (295) 215)

Ursodeoxycholic acid; Lipopolysaccharide; J774 macrophage (Hattori, Y. (300) 147)

Arterial pressure, systemic; Acetylcholine; Sodium nitroprusside; 7-Nitroindazole (Zagvazdin, Y. (303) 61)

Endotoxin; mRNA; Septic shock; Plasma nitrate; Heart, rat (Bateson, A.N. (303) 141)

Nitric oxide (NO); Vasodilation; Coronary circulation (Abdul-Hussain, M.N. (305) 155)

L-Arginine; Nitric oxide (NO); Lipopolysaccharide; Septic shock; Mesenteric vascular bed; (Rat) (Mitolo-Chieppa, D. (309) 175)

Balloon angioplasty; Neointima; Restenosis; Endothelium; Nitric oxide (NO); Von Willebrand factor (Bosmans, J.M. (310) 163)

Anorexia; Food intake; Aging; Hypothalamus; Nitric oxide (NO) (Morley, J.E. (311) 15)

Interleukin-1; Nitrite (Ikeda, U. (314) 197)

mRNA expression; Adenosine; Anti-inflammatory; Nitric oxide (NO) (Moochhala, S.M. (316) 287)

Nitric oxide (NO) synthase, inducible
Aminoguanidine; Leishmaniasis; L-N^{6}-(1-Iminoethyl)-lysine; Nitric oxide (NO); N^{G}-Monomethyl-L-arginine (Stenger, S. (294) 703)

Lipopolysaccharide; Multiple organ dysfunction syndrome; Liver failure; Endotoxin (Wu, C.-C. (300) 99)

Herbimycin A; Interferon-γ; Janus kinase; Signal transducer and activator of transcription-1 (STAT1); Microglia (Kitamura, Y. (306) 297)

Cartilage; Chondrocyte; Free radical; Arthritis (Jang, D. (312) 341)

Ethanol; Blood-brain barrier; RBE4 cell; Inflammation; Endotoxin; Nitric oxide (NO) (Naassila, M. (313) 273)

Nitric oxide (NO) synthase inhibitor
HF-2035; W-7; Calmodulin antagonist; Vascular relaxation (Win, N.H.H. (299) 119)

Nitrite
Glyceryl trinitrate; Nitrate tolerance; Platelet; Smooth muscle cell; Vascular (Weber, A.-A. (309) 209)

Interleukin-1; Nitric oxide (NO) synthase (Ikeda, U. (314) 197)

Nitrobenzylthioinosine
Adenosine; Nucleoside transport; Propentofylline (Parkinson, F.E. (308) 97)

Nitroglycerin
Tolerance; Phosphodiesterase inhibitor; cGMP monophosphate; Blood pressure; Zaprinast; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

7-Nitroindazole
Nitric oxide (NO); Harmaline; NMDA (*N*-methyl-D-aspartate); Parkinsonism; Epilepsy (Eblen, F. (299) 9)

Nitric oxide (NO) synthase; Arterial pressure, systemic; Acetylcholine; Sodium nitroprusside (Zagvazdin, Y. (303) 61)

Cerebral ischemia; Nitric oxide (NO); Hippocampus; (Mongolian gerbil) (O'Neill, M.J. (310) 115)

N^{G}-Nitro-L-arginine
Reperfusion arrhythmia; Superoxide dismutase; Catalase; Dimethylthiourea; N^{G}-Nitro-L-arginine methyl ester (Ohoi, I. (306) 123)

Bradykinin; Nitric oxide (NO); Antinociception (Germany, A. (310) 123)

Methylene blue; Endothelium; Nitric oxide (NO); Hypertension; Aorta, rat; Arterial pressure (Gil-Longo, J. (310) 175)

***N*-Nitro-L-arginine methyl ester**
NMDA receptor antagonist; NPC 17742; ACEA 1021; Phencyclidine; Anxiolytic (Wiley, J.L. (294) 101)

Hypovolemia; L-Arginine; Naloxone; Hemorrhagic shock; Nitric oxide (NO); (Conscious rabbit) (Ventura, S. (294) 369)

***N*^{G}-Nitro-L-arginine methyl ester**
Reperfusion arrhythmia; Superoxide dismutase; Catalase; Dimethylthiourea; N^{G}-Nitro-L-arginine (Ohoi, I. (306) 123)

N^G-Nitro-L-arginine methyl ester (L-NAME)
Ketorolac; Caffeine; Nitric oxide (NO); Potentiation; Antinociception (López-Muñoz, F.J. (308) 275)

L-N^{ω}-Nitro-L-arginine (L-NNA)
Vasoconstrictor sympathetic nerve; Nitric oxide (NO); Saphenous vein, human; cGMP (Fabi, F. (309) 41)

N^{ω}-Nitro-L-arginine methyl ester
Eosinophil chemotaxis; Nitric oxide (NO); Pleurisy; cGMP (Ferreira, H.H.A. (310) 201)

Nitroprusside
Muscle denervation; Hemoglobin; ODQ (1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one); Nitric oxide (NO) (Urazaev, A.Kh. (316) 219)

***S*-Nitrosocysteine**
Stereoisomer; Nitric oxide (NO) (Lewis, S.J. (312) R3)

Nitrosyl-hemoglobin (NO-hemoglobin)
Lipopolysaccharide; Nitric oxide (NO) synthase; Pressor response (Cai, M. (295) 215)

Nitrotyrosine
Peroxynitrite; Nitric oxide (NO); Superoxide; Hemodynamics, in vivo (Kooy, N.W. (310) 155)

Peroxynitrite; Nitric oxide; Superoxide; Angiotensin II; Hemodynamics, in vivo (Kooy, N.W. (315) 165)

NK433
Tonic vibration reflex; Tonic periodontal masseteric reflex; Jaw opening reflex (Ozawa, Y. (298) 57)

NK_1 receptor antagonist
Neurokinin; Bronchoconstriction; Pain; Plasma extravasation; Neuropeptide (Bonnet, J. (310) 37)

NK_2 receptor
Autoradiography; Airway; Substance P; [^{125}I][Lys^5,Tyr(I_2)^7,MeLeu^9, Nle^{10}]Neurokinin A-(4–10) (Strigas, J. (311) 177)

NMDA (*N*-methyl-D-aspartate)
Arachidonic acid; Long-term potentiation; ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid); Melittin; Phospholipase A_2 (Collins, D.R. (294) 147)

Nitric oxide (NO); 7-Nitroindazole; Harmaline; Parkinsonism; Epilepsy (Eblen, F. (299) 9)

Azelastine; Traumatic brain injury; Leukotriene; Hippocampus; (In vitro) (Girard, J. (300) 43)

Biperiden; Budipine; Muscarinic; Parkinsonism (Klockgether, T. (301) 67)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid); Kainate; Adenosine kinase; Adenosine deaminase; AICAR (AICA riboside, acadesine) (White, T.D. (303) 27)

Excitatory amino acid; MK-801 binding; Spinal cord (Souverbie, F. (307) 347)

Ethanol; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) propionic acid); AP-1 (activator protein-1) DNA binding; Transcription factor; Granule cell, cerebellar (Hou, Y.-N. (309) 307)

NMDA receptor
Haloperidol; Non-NMDA receptor; Subsensitivity; Striatum; Contralateral turning (Ossowska, K. (294) 685)

Hippocampus; Striatum; Acetylcholine; Microdialysis; NMDA receptor antagonist (Hutson, P.H. (295) 45)

Chronic citalopram; Excitatory amino acid; Adaptation; Cortex; Hippocampus (Nowak, G. (295) 75)

Catalepsy; Catatonia; Morphine; AMPA receptor; MK-801; CGP 37849; GYKI 52466 (Tzschentke, T.M. (295) 137)

Opioid receptor; Morphine tolerance; (Intrathecal administration) (Wong, C.-S. (297) 27)

Pain; Analgesia; Polyamine; Ifenprodil; Morphine; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

α_1-Adrenoceptor; Water maze; Passive avoidance; Prazosin; CPP ((±))-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Riekkinen, M. (300) 9)

5-HT autoreceptor; Presynaptic receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Cerebral cortex, guinea-pig; Serotoninergic axon terminal (Fink, K. (300) 79)

TRH (thyrotropin-releasing hormone); Spinal cord; Nociception; 'Wind-up' (Chizh, B.A. (300) 183)

Dextromethorphan; Spatial learning; Memory; Water maze (Bane, A. (302) 7)

Taurine; Adenosine transport inhibitor; Adenosine; Spreading depression; Hippocampus (Hada, J. (305) 101)

AMPA receptor; Spinal cord; Hyperalgesia; (Mouse) (Brambilla, A. (305) 115)

Noradrenaline; β-Adrenoceptor; Propranolol; Hippocampus; Working memory (Ohno, M. (307) 21)

α_1-Adrenoceptor antagonist; Microdialysis; Dizocilpine maleate; Locomotion (Mathé, J.M. (309) 1)

Ibogaine; *O*-Desmethylibogaine; Morphine; Naloxone (Layer, R.T. (309) 159)

Glutamate; Long-term depression; Long-term potentiation; Metabotropic receptor; Plasticity; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

3-OH-PCP (1-[1(3-hydroxyphenyl)-cyclohexyl]piperidine); Phencyclidine; Autoradiography; Brain, rat (Suzuki, T. (310) 243)

Phencyclidine site; [^{3}H](+)-MK-801; Imidazoline drug; K^+ channel, ATP-sensitive (Olmos, G. (310) 273)

Methamphetamine; Illicit synthesis; Synthetic impurity; Dopamine transporter; BNMPA (α-benzyl-*N*-methylphenethylamine) (Moore, K.A. (311) 133)

Glycine coagonist site; Desensitization; 5,7-Dichlorokynurenic acid; ACEA-1021; L-695,902; LY-294,619; RPR-104,632 (Molnár, P. (311) 311)

Glutamate; Acetylcholine; Learning; Memory; Inhibitory avoidance task (Ohno, M. (312) 145)

[^{3}H]MDL 105,519; Glycine; (Binding) (Siegel, B.W. (312) 357)

Competitive antagonist; Radioligand binding; Neuroprotection; Molecular modelling (Cheung, N.S. (313) 159)

Mivazerol; α_2-Adrenoceptor agonist; Heart rate; Spinal cord (Kim, S.Y. (316) 249)

NMDA receptor antagonist
NPC 17742; ACEA 1021; *N*-Nitro-L-arginine methyl ester; Phencyclidine; Anxiolytic (Wiley, J.L. (294) 101)

Excitatory amino acid; AP-5 (DL-2-amino-5-phosphonovaleric acid); MK-801 ((+)-5-methyl-10,11-dihydro(*a,d*)-cyclohepten-5,10-imine hydrogen maleate salt); Dopamine; Locomotor activity (Ouagazzal, A. (294) 137)

MK-801; Spinal cord; Morphine tolerance; Ventral root potential (Bell, J.A. (294) 289)

Hippocampus; Striatum; Acetylcholine; Microdialysis; NMDA receptor (Hutson, P.H. (295) 45)

Radial maze learning; Entorhinal cortex lesion; Chronic infusion; Memantine; (+)-MK-801; (Rat) (Zajaczkowski, W. (296) 239)

HEK293 cell; Ca^{2+} channel, voltage-dependent; Ischemia; Neuroprotection; (Gerbil) (Bath, C.P. (299) 103)

Acamprosate; Ethanol; Drug discrimination; (Rat) (Spanagel, R. (305) 51)

4-Aminopyridine; Seizure; Excitatory amino acid neurotransmission (Morales-Villagrán, A. (305) 87)

Dopamine; Neuroleptic, chronic; Locomotor activity; Memory; (Mouse) (Mele, A. (308) 1)

CGP 40116; CGP 43487; Ca^{2+} channel inhibitor; Flunarizine; Nicardipine; Nifedipine; Seizure (Gasior, M. (312) 27)

Ethanol; Drug discrimination; (Rat) (Bienkowski, P. (314) 277)

Haloperidol; Catalepsy; Parkinson's disease; (Rat) (McAllister, K.H. (314) 307)

NMDA receptor-channel complex
RPR 104632; Glycine receptor antagonist; Glutamate; Neurotoxicity (Boireau, A. (300) 237)

NMDA receptor glycine site antagonist
Anticonvulsant; AMPA receptor antagonist; Neuroprotection (Ilyin, V.I. (310) 107)

NMDA receptor subtype
Spinal cord; [^{3}H]Noradrenaline release (Klarica, M. (308) 135)

NMR (nuclear magnetic resonance)
Amiodarone; Water exchange; Membrane (Federico, A. (304) 237)

NMR spectroscopy, ^{31}P
Azithromycin; Phospholipid; Fluorescence polarization; Conformational analysis; Gentamicin (Montenez, J.-P. (314) 215)

D-NNA (N^G-nitro-D-arginine)
Diphenyleneiodonium; Di-2-thienyliodonium; Methylene blue; Nitric oxide (NO); Lipopolysaccharide; Contraction (Palacios, B. (296) 75)

NNC 14-0185
NNC 14-0189; Benzodiazepine receptor; Seizure threshold; Epilepsy (Jackson, H.C. (308) 21)

NNC 14-0189
NNC 14-0185; Benzodiazepine receptor; Seizure threshold; Epilepsy (Jackson, H.C. (308) 21)

Nociceptin
ORL_1; Vas deferens, mouse (Berzetei-Gurske, I.P. (302) R1)

Orphanin FQ; Analgesia (Rossi, G.C. (311) R7)

Nociceptin receptor
Bioassay; Vas deferens, mouse (Calò, G. (311) R3)

Nociception
Carbamazepine; Edema; Inflammatory hyperalgesia; Prostaglandin; Substance P (Bianchi, M. (294) 71)

C-fiber reflex; Buprenorphine; Diffuse noxious inhibitory control; Descending inhibitory control; Spinal cord; Morphine (Guirimand, F. (294) 651)

TRH (thyrotropin-releasing hormone); NMDA receptor; Spinal cord; 'Wind-up' (Chizh, B.A. (300) 183)

Substance P; Neurokinin A; Tachykinin NK_1 receptor; Analgesia; Hyperalgesia (Yashpal, K. (308) 41)

Neuro-immune interaction; Analgesia; Opioid; Neuropeptide; Cytokine (Mousa, S.A. (311) 221)

Spinal trigeminal nucleus oralis; C-fiber; Morphine (Dallel, R. (314) 19)

Nociceptor
Prostaglandin E_2; Bradykinin; Pain; Vein (Kindgen-Milles, D. (294) 491)

Nodose ganglion
Guanylate cyclase; Electrophysiology; Enzyme; mRNA; Nitric oxide (NO) (Lawrence, A.J. (315) 127)

Non-adrenergic non-cholinergic (NANC)
Aging; Nitric oxide (NO); ATP; Ileum, rat (Smits, G.J.M. (303) 79)

Non-competitive agonist
Nicotinic acetylcholine receptor; Muscle, fetal, rat; Patch-clamp; Voltage-clamp; Molecular modelling; Nicotinic agonist (Cooper, J.C. (309) 287)

Non-depolarizing neuromuscular relaxant
Neuromuscular transmission; Suramin; P_2 purinoceptor; Ca^{2+} channel (Henning, R.H. (301) 91)

Non-narcotic antitussive drug
Cough reflex; Angiotensin-converting enzyme inhibitor; Enalapril; Moguisteine (Kamei, J. (312) 235)

Non-NMDA receptor
Haloperidol; NMDA receptor; Subsensitivity; Striatum; Contralateral turning (Ossowska, K. (294) 685)

Non-steroidal anti-inflammatory drug
Free radical; Hydrogen peroxide; Horseradish peroxidase; Glutathione peroxidase; Scavenging (Parij, N. (311) 259)

Noradrenaline
Cheek pouch, hamster; Microvascular flow; Hyperemia; Neuropeptide Y; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor; [Leu^{31},Pro^{34}] Neuropeptide Y; Neuropeptide Y-(13–36) (Boric, M.P. (294) 391)

5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

Epilepsy; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); GABA (γ-aminobutyric acid); Anticonvulsant (Löscher, W. (299) 61)

MK-801 dizocilpine; Vas deferens, rat; Uptake (Pubill, D. (303) 171)

β-Adrenoceptor; Propranolol; NMDA receptor; Hippocampus; Working memory (Ohno, M. (307) 21)

Vas deferens; Agmatine; Neurotransmission; Imidazoline receptor; Adrenoceptor (Jurkiewicz, N.H. (307) 299)

PAF (platelet-activating factor); Vasomotor tone; Endothelium; Arterial pressure; Blood flow; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

Ketotifen; Intestine; Nitric oxide (NO); Smooth muscle (Abu-Dalu, R. (309) 189)

Neuropeptide Y; Peptide; Blood vessel; Vascular control; Hemorrhage (Hunter, L.W. (313) 79)

5-HT_{1A} receptor; Dopamine D_1 receptor; SCH 23390; Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin) (Hajós-Korcsok, É. (314) 285)

Artery, human; Neuropeptide Y; Antisense oligodeoxynucleotide; BIBP3226; Reverse transcriptase-polymerase chain reaction (Bergdahl, A. (316) 59)

Melatonin; Myometrium, human; Pregnancy; Labor (Mårtensson, L.G.E. (316) 273)

Noradrenaline release
Vas deferens, guinea-pig; ATP release; Cotransmission; ANP (atrial natriuretic peptide); 8-Bromoguanosine 3′:5′-cyclic monophosphate (Driessen, B. (296) 261)

Chromaffin cell; Cell separation; Adrenaline release; Nicotinic acetylcholine receptor (Krause, W. (302) 223)

Parasympathetic; Pineal; Melatonin; Microdialysis; Muscarinic receptor agonist; Carbachol (Drijfhout, W.J. (308) 117)

Tail artery, rat; Adrenergic nerve stimulation; Gonadectomy (García-Villalón, A.L. (314) 339)

[^{3}H]Noradrenaline release
Spinal cord; NMDA receptor subtype (Klarica, M. (308) 135)

Noradrenaline uptake
Apigenin; Flavonoid; Monoamine oxidase (Lorenzo, P.S. (312) 203)

Noradrenergic mechanism
Colonic inflammation; Visceral nociception; Clonidine; S12813-4; Antinociceptive effect (Miampamba, M. (308) 251)

Nor-binaltorphimine
Analgesia; Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A (Reche, I. (301) 75)

Analgesia; Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; SR-141,716 A (Reche, I. (312) 391)

Nor-binaltorphimine dihydrochloride
Amnesia, delayed; κ-Opioid receptor; Cholinergic neuronal system; Carbon monoxide (CO); U-50488H, (trans-(±)-3,4-dichloro-*N*-methyl-*N*-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate salt) (Hiramatsu, M. (315) 119)

Norepinephrine
Vas deferens, guinea pig; Mn^{2+}; Contraction; Acetylcholine (Tsunobuchi-Ushijima, H. (295) 235)

Endothelin-1; Resistance artery; Conduit artery; (Human) (Miyauchi, T. (303) 193)

Risperidone; Primary olfactory cortex; Electrophysiology; Antipsychotic drug (Marek, G.J. (305) 95)

Aorta; Carotid artery; 5-HT (5-hydroxytryptamine, serotonin); Potassium chloride; Ca^{2+}; Cholesterol (Moreland, R.S. (307) 55)

Phospholipase C; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); Bombesin; LA-N-2 cell; β-Adrenoceptor; Metabotropic (Sorrentino, G. (308) 81)

Estrogen; Vascular endothelium (McNeill, A.M. (308) 305)

G-protein; β-Adrenoceptor density; Congestive heart failure (Lai, L.-P. (309) 201)

Na^+,K^+-ATPase; Digitalis; Heart failure (Lai, L.-P. (309) 235)

n–3 fatty acid; cAMP; Adrenoceptor; Pinealocyte; (Rat) (Delton-Vandenbroucke, I. (312) 379)

Rhythmic constriction; cAMP; Pial vein; 5-HT (5-hydroxytryptamine, serotonin); (Porcine) (Ishine, T. (313) 97)

Norharman
β-Carboline; Dopamine; Harman; Microdialysis; Nucleus accumbens; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

Noribogaine
Ibogaine; Adenylyl cyclase; 5-HT receptors; Opioid receptors; Muscarinic acetylcholine receptors (Rabin, R.A. (316) 343)

Normethylclozapine
5-HT_{2c} receptor; Quinpirole; Parkinson's disease (Fox, S. (301) 27)

Northern blot analysis
β-Adrenoceptor; mRNA; Hybridisation, in situ (Mak, J.C.W. (302) 215)

Novelty
Individual difference; $GABA_A$; Psychostimulant; Cortex; Locomotion; Basal ganglia (Gruen, R.J. (309) 115)

NPC 17742
NMDA receptor antagonist; ACEA 1021; *N*-Nitro-L-arginine methyl ester; Phencyclidine; Anxiolytic (Wiley, J.L. (294) 101)

NPC 18521
Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; Antinociception; Formalin; Capsaicin; Licking; Writhing test; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

NS-004
$[Ca^{2+}]_i$, free; K^+ channel, Ca^{2+}-activated; K^+ channel, delayed rectifier; Whole cell patch clamp; Membrane potential; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

NS-102
Cortical neuron; Excitotoxicity; LY293558; (*S*)-AMPA ((*S*)-α-amino-3-hydroxy-5-methylisoxazole-4-propionate); (*S*)-5-Fluorowillardiine (Larm, J.A. (314) 249)

Nuclear factor κB
Tetrahydrobiopterin; GTP cyclohydrolase I; Nitric oxide (NO); Smooth muscle cell, vascular; (Rat) (Hattori, Y. (296) 107)

Nucleoside transport
Nitrobenzylthioinosine; Adenosine; Propentofylline (Parkinson, F.E. (308) 97)

Nucleotide
ATP; Purinergic; Purinoceptor; Endothelial cell (Motte, S. (307) 201)

Nucleotide receptor
ATP receptor; UTP receptor; Aorta, rat; Endothelium; Smooth muscle, vascular (García-Velasco, G. (294) 521)

Nucleus accumbens
Nicotine; Isoarecolone; Microdialysis; Dopamine (Mirza, N.R. (295) 207)

Cocaine; Opioid; Caudate (Izenwasser, S. (297) 187)

Morphine; Deoxyglucose; Shell; Drug abuse (Orzi, F. (302) 49)

Mesolimbic system, rat; Ventral tegmental area; 5-HT_3 receptor; Dopaminergic modulation; Locomotor activity (Gillies, D.M. (303) 1)

Amphetamine; Microdialysis; Dopamine; Individual difference; (Rat) (Sills, T.L. (303) 177)

GABA (γ-aminobutyric acid); Dopamine release; Modafinil; Microdialysis (Ferraro, L. (306) 33)

Fluphenazine; Microdialysis; Caudate putamen; Glutamate; GABA (γ-aminobutyric acid) (See, R.E. (308) 279)

Striatum; Basal forebrain (Wallace, D.R. (308) 283)

Nicotine; L-DOPA (3,4-dihydroxyphenylalanine) release; Locomotor activity, rat; Ventral tegmental area; Microdialysis (Goshima, Y. (309) 229)

β-Carboline; Dopamine; Harman; Norharman; Microdialysis; 5-HT (5-hydroxytryptamine, serotonin) (Sällström Baum, S. (314) 75)

Haloperidol; Clozapine; Fos-protein; Cross-tolerance; Septum, lateral (Sebens, J.B. (315) 269)

Dopamine; Ethanol; Microdialysis; Tolerance; Animal model (Nurmi, M. (315) 277)

Nucleus accumbens stimulation
Dopamine receptor; Acetylcholine receptor; Ventrolateral striatum; Dopamine release; Turning behavior (Koshikawa, N. (303) 13)

Nucleus tractus solitarii
L-*threo*-DOPS (L-*threo*-dihydroxyphenylserine); L-DOPA (L-dihydroxyphenylalanine); L-DOPA methyl ester; Neurotransmitter; (Rat) (Miyamae, T. (300) 105)

Defense area; Perifornical area; GABA (γ-aminobutyric acid); Glutamate (Varga, K. (310) 145)

Δ^9-Tetrahydrocannabinol; Nausea; Glucose; Catecholaminergic neuron; 5-HT_3 receptor (Himmi, T. (312) 273)

Subdiaphragmatic vagus; Stomach; Opioid receptor; (In vitro); (Neonatal rat) (Yuan, C.-S. (314) 27)

O-823
Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

Occasion setting
Pavlovian conditioning; Conditioned immobility; Midazolam; Amphetamine; Flesinoxan (Maes, J.H.R. (309) 131)

7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin)
Dopamine release; Dopamine synthesis; Dopamine D_3 receptor; Dopamine D_2 receptor; Microdialysis (Gainetdinov, R.R. (308) 261)

7-OH-DPAT (7-hydroxy-*N*,*N*-2-(di-*n*-propylamino)tetralin)
Dopamine; Dopamine D_3 receptor; Locomotion; (Rat) (Frantz, K. (302) 1)

7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin)
Receptor reserve; Dopamine D_3 receptor (Aretha, C.W. (305) 119)

***R*-(+)-7-OH-DPAT (*R*-(+)-7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin)**
Dopamine D_3 receptor; Emesis; Area postrema; (Ferret) (Yoshikawa, T. (301) 143)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)
Antidepressant; Imipramine; 5-HT_{1A} receptor; 5-HT (5-hydroxytryptamine, serotonin); Baclofen; Hippocampal slice (Bijak, M. (305) 79)

5-HT_{1A} receptor; Adrenaline; Pituitary; ACTH (adrenocorticotrophin) (Korte, S.M. (309) 281)

8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin)
Myoclonic jerk; SKF 99101H; GR 127935; WAY 100635; 5-HT_{1D} receptor; 5-HT_{1A} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Antinociception; 5-HT_{1A} receptor; ATP-sensitive K^+ channel; Sulfonylurea; Gliquidone; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Stereoselectivity; 5-HT_{1D} receptor (Pauwels, P.J. (300) 137)

8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide)
Spinal reflex; 5-HT_{1A} receptor; Motor function; Spinal cord (Hasegawa, Y. (295) 211)

3-OH-PCP (1-[1(3-hydroxyphenyl)-cyclohexyl]piperidine)
Phencyclidine; NMDA receptor; Autoradiography; Brain, rat (Suzuki, T. (310) 243)

Olfactory bulb
Male pheromone; Glutamic acid decarboxylase; Ovariectomy; Estrogen; Progesterone; (Rat) (Navarro Becerra, N. (312) 83)

Oligodeoxynucleotide
Immediate-early gene; Growth factor (Sachinidis, A. (309) 95)

S-Oligodeoxynucleotide
Immobility behaviour; Forced swim test; Antisense; Glucocorticoid receptor; RU38486; Central nervous system (Korte, S.M. (301) 19)

One-way avoidance
Animal model; Anxiety; Chlorpromazine; Diazepam; Successive negative contrast; Thiopental sodium (Torres, C. (314) 269)

Ontogeny
Somatostatin receptor subtype; Autoradiography; Brain, rat (Thoss, V.S. (297) 145)

CCK_B/gastrin receptor; Pancreas; Cloning; Pharmacology (Dufresne, M. (297) 165)

OPC-14597
Ventral tegmental area; Extracellular recording in vivo; Whole-cell recording; Thin-slice preparation; Dopamine D_2 receptor (Momiyama, T. (310) 1)

OPC-18790
Positive inotropic agent; Systemic hemodynamics; Blood flow distribution; Mean circulatory filling pressure (Fujiki, H. (313) 191)

Open-field
Metabotropic glutamate receptors; D,L-Amphetamine; MK-801; Basal ganglia; Catalepsy (Kronthaler, U.O. (316) 129)

Open field behavior
Corticosterone; 5-HT receptor subtype; Lower lip retraction; Penile erection; Head shake (Berendsen, H.H.G. (308) 103)

Opiate
Opioid receptor, human; Binding site (Li, X. (300) R1)

(+)-Pentazocine; σ Site; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)

Dextromethorphan; Withdrawal; Naloxone; Excitatory amino acid (Rosen, M.I. (307) 251)

Tolerance; Withdrawal; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Locus ceruleus; (Mouse) (Dossin, O. (308) 271)

L-Arginine; Na^+ transport; K^+ transport; Cholinergic responses; Nitric oxide (NO) (Neumann, V. (316) 123)

Opiate abstinence
Lamotrigine; Nitric oxide (NO); Dizocilpine (MK-801) (Lizasoain, I. (299) 41)

Opiate detoxification
Withdrawal syndrome; Naltrexone (Muntoni, A.L. (301) R9)

Opiate receptor
Neuronal plasticity; Synapsin I; Pruning effect (Gorio, A. (303) 21)

Opioid
Breast cancer cell (T47D); Cell proliferation; Opioid receptor; Opioid receptor subtype (Hatzoglou, A. (296) 199)

κ-Opioid receptor agonist; Pregnancy; Blood pressure; Heart rate (Szeto, H.H. (297) 77)

Cocaine; Caudate; Nucleus accumbens (Izenwasser, S. (297) 187)

Adenosine; Spinal cord; Synergy (Cahill, C.M. (298) 45)

Sensitization; Morphine; Psychostimulant; Conditioned reward; Place preference conditioning (Shippenberg, T.S. (299) 33)

Analgesia; Dynorphin; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)

Morphine; Dyspnoea; Quenching; Autoradiography (Cabot, P.J. (310) 47)

Neuro-immune interaction; Analgesia; Nociception; Neuropeptide; Cytokine (Mousa, S.A. (311) 221)

Analgesia; Dynorphin; Δ^9-Tetrahydrocannabinol; SR-141,716 A; Nor-binaltorphimine (Reche, I. (312) 391)

Opioid dependence
Central nervous system; Glutamate; MK-801 (dizocilpine); Morphine; Butorphanol (Tokuyama, S. (295) 123)

Opioid receptor
κ-Opioid analgesia; σ Receptor; Haloperidol; Antisense; KOR-1; κ-Opioid receptor (Chien, C.-C. (294) 303)

Breast cancer cell (T47D); Cell proliferation; Opioid; Opioid receptor subtype (Hatzoglou, A. (296) 199)

NMDA receptor; Morphine tolerance; (Intrathecal administration) (Wong, C.-S. (297) 27)

Antinociception; Respiratory depression; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

Steroid; Nervous system; Neuroblastoma (Maggi, R. (301) 169)

Antinociception; Bioassay; Deltorphin; Peptide synthesis (Guerrini, R. (302) 37)

δ-Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Cold water swimming; Antinociception; Pertussis toxin; Gi/Go protein; (Mouse) (Mizoguchi, H. (309) 37)

α-Casomorphin; β-Casomorphin; Receptor subtype; Somatostastin receptor; Breast cancer cell, T47D (Hatzoglou, A. (310) 217)

Chimeric receptor; Mutagenesis; Structure-function relationship; δ-Opioid receptor ligand (Meng, F. (311) 285)

Binding characteristics; Partial agonist; cAMP; KT-90 ((−)-3-acetyl-6β-acetylthio-*N*-cyclopropylmethyl-normorphine) (Katsumata, S. (312) 349)

Antinociception; Respiratory depression; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Subdiaphragmatic vagus; Nucleus tractus solitarii; Stomach; (In vitro); (Neonatal rat) (Yuan, C.-S. (314) 27)

Opioid receptor antagonist
Opioids; Naltrindole; DAMGO ([D-Ala^2-MePhe^4-Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2, D-Pen^5]enkephalin) (Duvauchelle, C.L. (316) 137)

Opioid receptor, human
Opiate; Binding site (Li, X. (300) R1)

Opioid receptors
Ibogaine; Noribogaine; Adenylyl cyclase; 5-HT receptors; Muscarinic acetylcholine receptors (Rabin, R.A. (316) 343)

Opioid receptor subtype
Breast cancer cell (T47D); Cell proliferation; Opioid; Opioid receptor (Hatzoglou, A. (296) 199)

Opioid receptor type
Tramadol; Analgesia; Cloned human receptor (Lai, J. (316) 369)

δ-Opioid receptor
Cocaine; Enkephalin; Naltrindole; Sensitization (Heidbreder, C. (298) 207)

Naltrindole; Naltriben; Opioid withdrawal (Funada, M. (300) 17)

Adenylate cyclase; α_{2B}-Adrenoceptor; Muscarinic M_4 receptor; Prostaglandin E_1 receptor; Receptor cross-talk (Ammer, H. (302) 199)

Alcohol drinking; Food intake; μ-Opioid receptor; Reinforcement; (Selected rat line) (Honkanen, A. (304) 7)

Vas deferens, mouse; Cysteine sulfonamide enkephalin analog; Dalargin; Purinergic component; Adrenergic component; Electrical field stimulation (Pencheva, N. (304) 99)

Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

BW373U86; G-protein; Radioligand binding (Campa, M.J. (310) 263)

GTPase; Protein kinase C (Narita, M. (310) R1)

δ_1-Opioid receptor
δ-Opioid receptor, agonist, antagonist; δ_2-Opioid receptor; Antinociception; [^{3}H][D-Pen^2,D-Pen^5]Enkephalin (Bhargava, H.N. (311) 127)

δ_2-Opioid receptor
δ-Opioid receptor, agonist, antagonist; δ_1-Opioid receptor; Antinociception; [^{3}H][D-Pen^2,D-Pen^5]Enkephalin (Bhargava, H.N. (311) 127)

δ-Opioid receptor, agonist, antagonist
δ_1-Opioid receptor; δ_2-Opioid receptor; Antinociception; [^{3}H][D-Pen^2,D-Pen^5]Enkephalin (Bhargava, H.N. (311) 127)

δ-Opioid receptor antagonist
Peripheral antinociception; Mononeuropathic rat; Paw pressure; Systemic morphine; κ-Opioid receptor antagonist (Catheline, G. (315) 135)

δ-Opioid receptor ligand
Opioid receptor; Chimeric receptor; Mutagenesis; Structure-function relationship (Meng, F. (311) 285)

κ-Opioid receptor
κ-Opioid analgesia; Opioid receptor; σ Receptor; Haloperidol; Antisense; KOR-1 (Chien, C.-C. (294) 303)

Opioid receptor; δ-Opioid receptor; μ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Cardiovascular; Blood pressure; Phentolamine; Pregnancy (Szeto, H.H. (309) 183)

Tail-flick assay; Analgesia, peripheral (Kolesnikov, Y. (310) 141)

Nor-binaltorphimine dihydrochloride; Amnesia, delayed; Cholinergic neuronal system; Carbon monoxide (CO); U-50488H, (trans-(±)-3,4-dichloro-*N*-methyl-*N*-(2-[1-pyrrolidinyl] cyclohexyl) benzeneacetamide methanesulfonate salt) (Hiramatsu, M. (315) 119)

κ-Opioid receptor agonist
Opioid; Pregnancy; Blood pressure; Heart rate (Szeto, H.H. (297) 77)

Anticonflict effect; Diazepam; Vogel-type conflict test; (Mouse) (Tsuda, M. (307) 7)

κ-Opioid receptor agonist
Butorphanol; Glutamate; Locus coeruleus; Microdialysis; U-69,593 (Hoshi, K. (314) 301)

κ-Opioid analgesia
Opioid receptor; σ Receptor; Haloperidol; Antisense; KOR-1; κ-Opioid receptor (Chien, C.-C. (294) 303)

κ-Opioid receptor antagonist
Peripheral antinociception; Mononeuropathic rat; Paw pressure; Systemic morphine; δ-Opioid receptor antagonist (Catheline, G. (315) 135)

κ-Opioid receptor, tolerance
Ca^{2+}, intracellular, free; Inositol 1,4,5-trisphosphate; Myocyte, ventricular; U50,488H (Sheng, J.-Z. (307) 323)

μ-Opioid receptor
Analgesia; Spinal cord; Desipramine; α_2-Adrenoceptor; Neuropeptide (Gergen, K.A. (298) 235)

Alcohol drinking; Food intake; δ-Opioid receptor; Reinforcement; (Selected rat line) (Honkanen, A. (304) 7)

SH-SY5Y cell; Inositol(1,4,5)trisphosphate; Phospholipase C; Tyr-D-Arg^2-Phe-sarcosine^4 (TAPS) (Smart, D. (305) 235)

Opioid receptor; δ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Ventromedial nucleus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Analgesia; Tyr-W-MIF-1; Antinociception (Gergen, K.A. (316) 33)

μ_1-Opioid receptor
Respiratory depression; Fentanyl; Morphine; Muscle rigidity (Chen, S.-W. (312) 241)

μ-Opioid receptor, subtype
Morphine; Antitussive effect; Cough reflex; (Beige rat) (Kamei, J. (300) 75)

Opioids
Opioid receptor antagonist; Naltrindole; DAMGO ([D-Ala^2–MePhe^4–Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2, D-Pen^5]enkephalin) (Duvauchelle, C.L. (316) 137)

Opioid withdrawal
Naltrindole; Naltriben; δ-Opioid receptor (Funada, M. (300) 17)

Metabotropic glutamate receptor; Protein kinase C; Inositol-1,4,5-trisphosphate; Chelerythrine; Thapsigargin (Fundytus, M.E. (300) 173)

Oral administration, acute
Ceritizine; Chlorpheniramine; EEG (electroencephalogram), quantitative; Plasma concentration, drug; Neuropsychological status; (Healthy volunteer) (Sannita, W.G. (300) 33)

Oral dyskinesia
Reserpine; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Organ culture
FRG-8813; Histamine H_2 receptor antagonist; Gastric mucin biosynthesis; (Rat) (Ichikawa, T. (297) 87)

ORL_1
Nociceptin; Vas deferens, mouse (Berzetei-Gurske, I.P. (302) R1)

L-Ornithine
L-Arginine; Kyotorphin; Enkephalin; Pain; Antinociception (Kawabata, A. (296) 23)

Orphanin FQ
Nociceptin; Analgesia (Rossi, G.C. (311) R7)

Oscillatory potential
Streptozotocin-induced diabetes, rat; Electroretinogram; Propionyl-L-carnitine; Insulin; Carnitine; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Osmoregulation, central
Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Atropine; PD 123177; Vasopressin (Höhle, S. (300) 119)

Osteoarthritis
Synovial cell; Human; Glucose uptake; Anti-inflammatory drug; Rheumatoid arthritis (Hernvann, A. (314) 193)

Osthole
DNA synthesis; Cell cycle; Smooth muscle cell, rat, vascular; (*Angelica pubescens*) (Guh, J.-H. (298) 191)

Otilonium
Chromaffin cell; Ca^{2+} channel; Adrenal gland; Catecholamine release (Gandía, L. (298) 199)

Otsuka Long-Evans Tokushima Fatty rat
Cilostazol; Motor nerve conduction velocity; R-R interval, coefficient of variation; Sciatic nerve blood flow; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

Ouabain
Cytosolic Ca^{2+}; Chromaffin cell; Lithium chloride; Veratridine (De la Fuente, M.T. (306) 219)

[^{3}H]Ouabain
Thiamine deficiency; ATPase; Thalamus; Pyrithiamine; (Rat) (Mousseau, D.D. (300) 191)

Ovariectomy
Male pheromone; Glutamic acid decarboxylase; Olfactory bulb; Estrogen; Progesterone; (Rat) (Navarro Becerra, N. (312) 83)

Ovary
Puberty, female; Muscarinic receptor; Cholinergic system (Trkulja, V. (297) 93)

Oxatomide
RBL-2H3 cell; Signal transduction; Exocytosis; Protein tyrosine phosphorylation; Ca^{2+} flux; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

Oxidation
Catecholamine absorbing protein; Central nervous system; Free radical; Dopamine; Neurodegeneration; Parkinson's disease (Modi, P.I. (299) 213)

Oxidative hemolysis
N-Allylsecoboldine; Antioxidant; Lipid peroxidation; Peroxyl radical; Hydroxyl radical; Hypercoagulability; β-Thalassemia (Teng, C.-M. (303) 129)

Oxidative stress
Glutathione; Lipid peroxidation; Ischemia-reperfusion injury; 21-Aminosteroid; Kidney, rat (Paroni, R. (294) 737)

Oxime
Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Oxiracetam
Alaptide; Cyclodipeptide; 2,5-Piperazinedione; Elevated plus-maze test; Memory; (Mouse) (Hliňák, Z. (314) 1)

Oxotremorine
Learning; Memory; Synaptic plasticity; Cholinergic system; Muscarinic receptor agonist; AF102B (Iga, Y. (308) 13)

Oxygen free radical
Polyol pathway; Diabetes; Galactosemia; Nerve conduction; Nerve regeneration; Antioxidant; Metal chelator (Love, A. (314) 33)

Oxygen paradox
Ca^{2+} paradox; Caffeine; Extracellular K^+; Antiporter (Harding, R.J. (316) 223)

Oxymetazoline
α_1-Adrenoceptor; Positive inotropic effect; Phosphoinositide hydrolysis; Ventricular myocardium, rabbit; (±)-Tamsulosin [(±)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]-amino]propyl]-2-methoxybenzenesulfonamide-HCl] (Yang, H.-T. (312) 281)

Oxytocin
Structure-activity; Neuromodulation (Poulin, P. (294) 29)

Social recognition; Social memory, rat; PLG (prolyl-leucyl-glycinamide); Neurohypophyseal hormone; Structure activity (Popik, P. (308) 113)

Oxytocin receptor
Vasopressin receptor; Uterus; Pregnancy; (Rat) (Anouar, A. (308) 87)

PAF (platelet-activating factor)
Acetylcholine; Nitric oxide (NO); EDHF (endothelium-derived hyperpolarizing factor) (Kamata, K. (298) 129)

Desensitization; Spontaneously hypertensive rat (SHR); Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)

Arachidonic acid; Acyltransferase; Triacsin C; Zymosan (Naraba, H. (302) 117)

Heparin; Protamine; Platelet; PAF-acether; Thromboxane; BN 52021 (Aïssa, J. (302) 123)

Vasomotor tone; Endothelium; Arterial pressure; Blood flow; Noradrenaline; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

PAF-acether
Heparin; Protamine; Platelet; PAF (platelet-activating factor); Thromboxane; BN 52021 (Aïssa, J. (302) 123)

Pain
Prostaglandin E_2; Bradykinin; Nociceptor; Vein (Kindgen-Milles, D. (294) 491)

L-Ornithine; L-Arginine; Kyotorphin; Enkephalin; Antinociception (Kawabata, A. (296) 23)

Analgesia; Polyamine; NMDA receptor; Ifenprodil; Morphine; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

Inflammation; Adrenoceptor agonist; Adrenoceptor antagonist; Formalin test (Hong, Y. (301) 41)

Neurokinin; NK_1 receptor antagonist; Bronchoconstriction; Plasma extravasation; Neuropeptide (Bonnet, J. (310) 37)

C-fiber; Reflex; Clonidine; Blood pressure; (Rat) (Gozariu, M. (313) 51)

α_2-Adrenoceptor; Analgesia; (Amphibian) (Stevens, C.W. (316) 205)

Paired pulse facilitation
Spinal cord; Muscle relaxant; EPSC (excitatory postsynaptic current); IPSC (inhibitory postsynaptic current); (Slice) (Tanabe, M. (313) 187)

Paired-pulse method
CGP 35348; Transcallosal response; Pyramidal tract neuron; Motor cortex; (−)-Baclofen (Chowdhury, S.A. (314) 313)

Palatability
Benzodiazepine; Hyperphagia; Brain stem; Parabrachial nucleus; (Rat) (Higgs, S. (313) 1)

Pallidal slice
Tetrahydrocannabinol; GABA (γ-aminobutyric acid) transport; SR 141716A (Maneuf, Y.P. (308) 161)

Palmitoylethanolamide
N-Acylethanolamide; Autacoid local inflammatory antagonism; Cannabinoid receptor, peripheral; Neurogenic inflammation; Passive cutaneous anaphylaxis (Mazzari, S. (300) 227)

Pancreas
CCK_B/gastrin receptor; Cloning; Ontogeny; Pharmacology (Dufresne, M. (297) 165)

CCK_A receptor; Gallbladder; Amylase release; Gallbladder contraction; T-0632 (Taniguchi, H. (304) 147)

Capsaicin; Pancreatic islet; Insulin release; Blood flow; Peptidergic neuron (Carlsson, P.-O. (312) 75)

Pancreas, rat
Agmatine; Efaroxan; Imidazoline receptor; Insulin secretion; Vessel (Berdeu, D. (308) 301)

Pancreatic B-cell
Sulphonylurea; Tolbutamide; Glibenclamide; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Pancreatic islet
Capsaicin; Insulin release; Blood flow; Pancreas; Peptidergic neuron (Carlsson, P.-O. (312) 75)

Pancreatic islet, blood flow
Glucose; Insulin; Blood pressure; β-Adrenoceptor (Atef, N. (298) 287)

Pancreatic islet, rat
Insulin release; Hydroxylamine; K^+ channel, ATP-sensitive; Nitric oxide (NO) (Antoine, M.-H. (313) 229)

Pancreatic polypeptide
Binding protein; Neuropeptide Y (NPY); (*Conus* anemone); Neuropeptide Y-(18-36) (Czerwiec, E. (315) 355)

Pancreatic secretion
CCK_A receptor; Gallbladder contraction; Gastric emptying; T-0632 (Taniguchi, H. (312) 227)

Papillary muscle
Inotropic drug; Heart failure; K^+ channel, ATP-sensitive; Digoxin; Milrinone (Kocić, I. (301) 115)

Ethanol, chronic; Spontaneously hypertensive rat (SHR); Hypertension (Brown, R.A. (302) 61)

Parabrachial nucleus
Benzodiazepine; Hyperphagia; Brain stem; Palatability; (Rat) (Higgs, S. (313) 1)

Paracetamol
Antinociception; 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor, brain (Pini, L.A. (308) 31)

Parasympathetic
Pineal; Melatonin; Microdialysis; Muscarinic receptor agonist; Carbachol; Noradrenaline release (Drijfhout, W.J. (308) 117)

Parasympathetic nervous system
Acetylcholine; Chronotropism; Inotropism; Heart; PACAP-38 (pituitary adenylate cyclase-activating polypeptide-38); PACAP-(6–38) (pituitary adenylate cyclase-activating polypeptide-(6–38)); (Dog) (Yonezawa, T. (315) 289)

Parasympathetic neuron
Histamine H_3 receptor subtype; (*R*)-α-Methylhistamine; Sympathetic neuron (Rizzo, C.A. (294) 329)

Paraventricular nucleus
Nitric oxide (NO) donor; Penile erection; Yawning; Guanylate cyclase; (Rat) (Melis, M.R. (294) 1)

Sexual behavior; Nitric oxide (NO); Nitric oxide (NO) synthase; (Rat) (Benelli, A. (294) 505)

Paraventricular nucleus of the hypothalamus
Myocardial oxygen demand; MK-801; Memantine; (Rabbit) (Monassier, L. (305) 109)

Parietal cell, rabbit
Ca^{2+}; Cytosolic; Fura-2; Elutriation; CCK_B/gastrin receptor antagonist (Letari, O. (306) 325)

Parkinsonism
Nitric oxide (NO); 7-Nitroindazole; Harmaline; NMDA (*N*-methyl-D-aspartate); Epilepsy (Eblen, F. (299) 9)

Glutamate receptor antagonist; Dopamine; Reserpine; Microdialysis (Biggs, C.S. (299) 83)

Biperiden; Budipine; Muscarinic; NMDA (*N*-methyl-D-asparate) (Klockgether, T. (301) 67)

Parkinson's disease
Dopamine; Levodopa; Microdialysis; Dopamine receptor agonist; Dopamine receptor antagonist (Sarre, S. (296) 247)

Huntington's disease; Alzheimer's disease; Losartan; PD123177; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8] Angiotensin II; Brain, human (Ge, J. (297) 299)

Catecholamine absorbing protein; Central nervous system; Free radical; Oxidation; Dopamine; Neurodegeneration (Modi, P.I. (299) 213)

5-HT_{2c} receptor; Quinpirole; Normethylclozapine (Fox, S. (301) 27)

Dopamine D_1 receptor agonist; Desensitization; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) (Blanchet, P.J. (309) 13)

NMDA receptor antagonist; Haloperidol; Catalepsy; (Rat) (McAllister, K.H. (314) 307)

Partial agonist
BW A868C; DP receptor; Cl^- secretion (Liu, Y.J. (304) 117)

Opioid receptor; Binding characteristics; cAMP; KT-90 ((−)-3-acetyl-6β-acetylthio-*N*-cyclopropylmethyl-normorphine) (Katsumata, S. (312) 349)

Partial receptor agonist
Ethanol; Dopamine receptor agonist; Dependence (Bono, G. (296) 233)

Passive avoidance
Nicotine; Retrieval; (Mouse) (Zarrindast, M.-R. (295) 1)

α_1-Adrenoceptor; NMDA receptor; Water maze; Prazosin; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Riekkinen, M. (300) 9)

Scopolamine; Medial septum lesion; Aging; Metrifonate; Spatial navigation (Riekkinen Jr., P. (309) 121)

Passive avoidance task
JTP-4819; Prolyl endopeptidase; Morris water maze task; TRH (thyrotropin-releasing hormone); Middle cerebral artery occlusion (Shinoda, M. (305) 31)

σ_1 Receptor agonist; Cognitive enhancer; Scopolamine; Basal forebrain lesion; SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride); (Rat) (Senda, T. (315) 1)

Passive cutaneous anaphylaxis
N-Acylethanolamide; Palmitoylethanolamide; Autacoid local inflammatory antagonism; Cannabinoid receptor, peripheral; Neurogenic inflammation (Mazzari, S. (300) 227)

Patch clamp
Antiarrhythmic activity; Ischemic arrhythmia; Sparteine; BRB-I-28 (Pugsley, M.K. (294) 319)

Coronary arterial cell; BK_{Ca} channel; (Whole-cell recording); (Holding potential) (Hu, S. (294) 357)

Maitotoxin; Na^+-permeable channel; Ventricular cell, guinea-pig (Nishio, M. (297) 293)

Spinal neuron; Purinoceptor; K^+ channel; G-protein; Protein kinase C; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

K^+ channel, Ca^{2+}-dependent; Cl^- channel, Ca^{2+}-dependent; Smooth muscle cell; Trachea (Henmi, S. (306) 227)

Nicotinic acetylcholine receptor; Muscle, fetal, rat; Voltage-clamp; Molecular modelling; Nicotinic agonist; Non-competitive agonist (Cooper, J.C. (309) 287)

K^+ channel; Seizure; Ca^{2+} channel; Hippocampus; Levcromakalim (Katsumori, H. (311) 37)

Local anesthetic; *N*-butyl-*p*-aminobenzoate; Na^+ current inactivation; Dorsal root ganglion (Van den Berg, R.J. (316) 87)

Taurine; Na^+-Ca^{2+} exchange; Ventricular myocyte, rat (Katsube, Y. (316) 97)

Berberine; K^+ channel, ATP-sensitive; Microelectrode recording; Cardiac cell (Wang, Y.-X. (316) 307)

Patch clamp, dual
Gap junction; Cell-to-cell conductance; Dye diffusion; Trophoblast differentiation, human; Ca^{2+}, intracellular (Hervé, J.-C. (313) 243)

Patch clamp, whole-cell
Polyunsaturated fatty acid; Docosahexaenoic acid; K^+ channel, cloned (Garratt, J.C. (314) 393)

Pavlovian conditioning
Occasion setting; Conditioned immobility; Midazolam; Amphetamine; Flesinoxan (Maes, J.H.R. (309) 131)

Paw oedema
Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Licking; Writhing test; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

Paw pressure
Peripheral antinociception; Mononeuropathic rat; Systemic morphine; κ-Opioid receptor antagonist; δ-Opioid receptor antagonist (Catheline, G. (315) 135)

PC12 cell
CNTF (ciliary neurotrophic factor receptor α); cAMP; NB41A3 cell; mRNA (MacLennan, A.J. (295) 103)

ATP receptor; cAMP; Reactive blue 2 (Yakushi, Y. (314) 243)

PD123177
Parkinson's disease; Huntington's disease; Alzheimer's disease; Losartan; Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; [^{125}I][Sar^1,Ile^8] Angiotensin II; Brain, human (Ge, J. (297) 299)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Atropine; Osmoregulation, central; Vasopressin (Höhle, S. (300) 119)

PD123,319
Intestinal vascular bed; Angiotensin peptide; DuP532; Enalaprilat; Angiotensin II; Angiotensin IV; *p*-Aminophenylalanine^6-angiotensin II (Champion, H.C. (309) 251)

Penbutolol enantiomer
Microdialysis, in vivo; Citalopram; WAY-100635; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

Penile erection
Nitric oxide (NO) donor; Yawning; Guanylate cyclase; Paraventricular nucleus; (Rat) (Melis, M.R. (294) 1)

Corpus cavernosum; Endothelin; Nitric oxide (NO); (Rat) (Ari, G. (307) 69)

Corticosterone; 5-HT receptor subtype; Lower lip retraction; Head shake; Open field behavior (Berendsen, H.H.G. (308) 103)

Pentacaine
Local anesthetic; Pentacaine derivative; Smooth muscle, gastric; (Guinea-pig) (Mai, M.P. (315) 305)

Pentacaine derivative
Local anesthetic; Pentacaine; Smooth muscle, gastric; (Guinea-pig) (Mai, M.P. (315) 305)

Pentagastrin
Stomach; Angiotensin II; Gastric hemodynamics; Angiotensin AT_1 receptor; Renin-angiotensin system (Chow, L. (294) 309)

Pentazocine
Median eminence; Intermediate lobe; Haloperidol; Raclopride; Prolactin secretion; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

(+)-Pentazocine
σ Receptor; Dopamine release; BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine); DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl)piperidine HBr); BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl]cyclohexylamine) (Gonzalez-Alvear, G.M. (294) 713)

Opiate; σ Site; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)

σ Receptor; Liver, rat; Solubilization; CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate); DTG (1,3-di-*o*-tolylguanidine) (Torrence-Campbell, C. (304) 201)

Pentobarbital
$GABA_A$ receptor; Benzodiazepine binding; Drug tolerance; Substance dependence (Suzuki, T. (295) 169)

Pentobarbitone
GABA receptor antagonist; Bicuculline; SR95531; Etomidate; Hippocampal neuron (Uchida, I. (307) 89)

Pentylenetetrazole
Adenosine receptor; Adenosine A_1 receptor agonist; Adenosine A_{2A} receptor agonist; Seizure; (Rat) (Adami, M. (294) 383)

Peptide
Angiotensin I-converting enzyme; Angiotensin I-converting enzyme inhibitor; Hemoglobin; (Swine) (Mito, K. (304) 93)

Neuropeptide Y; Noradrenaline; Blood vessel; Vascular control; Hemorrhage (Hunter, L.W. (313) 79)

Peptide neurotransmitter
Achatin-I (Gly-D-Phe-Ala-Asp); Intracellular signal transduction system; H-89; KT5823; W-7; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

Peptide synthesis
Antinociception; Bioassay; Deltorphin; Opioid receptor (Guerrini, R. (302) 37)

Peptidergic neuron
Capsaicin; Pancreatic islet; Insulin release; Blood flow; Pancreas (Carlsson, P.-O. (312) 75)

Peptidohydrolase
Dynorphin A; Dynorphin B; Dynorphin-converting enzyme; Formalin test; Intrathecal administration; (Mouse) (Tan-No, K. (314) 61)

Perforant pathway stimulation
GABA (γ-aminobutyric acid); Epilepsy; Hippocampus; Neuroprotection (Halonen, T. (299) 69)

Perfusion
Dopamine; Placenta; β-Endorphin; Dynorphin; (Rat) (Stratakis, C.A. (315) 53)

Perifornical area
Defense area; GABA (γ-aminobutyric acid); Glutamate; Nucleus tractus solitarii (Varga, K. (310) 145)

Perinatal
Δ^9-Tetrahydrocannabinol; 5-HT (5-hydroxytryptamine, serotonin); 5-HTP (5-hydroxy-L-tryptophan); 5-HIAA (5-hydroxyindole-3-acetic acid); High-performance liquid chromatography with electrochemical detection (HPLC-ED) (Molina-Holgado, F. (316) 39)

Peripheral antinociception
Mononeuropathic rat; Paw pressure; Systemic morphine; κ-Opioid receptor antagonist; δ-Opioid receptor antagonist (Catheline, G. (315) 135)

Peripheral-type benzodiazepine receptor antagonist
Benzodiazepine; Diazepam; Heart preparation, isolated; Inotropy (Leeuwin, R.S. (299) 149)

Peristalsis
Neurotensin; Small intestine, guinea-pig; Apamin (Ohashi, H. (301) 129)

Peritoneal eosinophil
Migration, in vitro; Phosphodiesterase inhibition; β_2-Adrenoceptor agonist (Alves, A.C. (312) 89)

Peritumoral
Glycosphingolipid; Tumor; Recombinant interleukin-2; Adhesion (Tubaro, E. (294) 555)

Peroxyl radical
N-Allylsecoboldine; Antioxidant; Lipid peroxidation; Hydroxyl radical; Hypercoagulability; β-Thalassemia; Oxidative hemolysis (Teng, C.-M. (303) 129)

Peroxynitrite
Nitric oxide (NO); GABA (γ-aminobutyric acid) release; Superoxide; Cerebral cortical neuron (Ohkuma, S. (301) 179)

Carrageenan; Inflammation (Salvemini, D. (303) 217)

Tachyphylaxis; Hemodynamics, In vivo (Kooy, N.W. (307) R5)

Nitrotyrosine; Nitric oxide (NO); Superoxide; Hemodynamics, in vivo (Kooy, N.W. (310) 155)

Nitrotyrosine; Nitric oxide; Superoxide; Angiotensin II; Hemodynamics, in vivo (Kooy, N.W. (315) 165)

Pertussis toxin
Antinociception; Morphine; β-Endorphin; G-protein (Tseng, L.F. (294) 345)

[^{35}S]GTPγ[S] binding; Histamine H_3 receptor; G-protein (Clark, E.A. (296) 223)

Ancrod-generated fibrin; Integrin $\alpha_v\beta_3$; Prostacyclin; Phospholipase C (Chang, M.C. (297) 129)

Analgesia; Morphine; Diphenhydramine; Baclofen; Clomipramine; Physostigmine (Galeotti, N. (308) 125)

Cold water swimming; Antinociception; Gi/Go protein; Opioid receptor; (Mouse) (Mizoguchi, H. (309) 37)

PET (positron emission tomography)
[^{11}C]Flumazenil; Imidazopyridine; Benzodiazepine receptor, central (Abadie, P. (295) 35)

5-HT$_{1A}$ receptor, human; [*carbonyl*-^{11}C]WAY-100635 (Pike, V.W. (301) R5)

Atropine; Methyl-quinuclidinyl-benzylate; CGP-12177; Heart; β-Adrenoceptor; Muscarinic receptor (Valette, H. (306) 133)

P-glycoprotein
Chemotherapy; Modulator; Multidrug resistance (Demmer, A. (315) 339)

Phaclofen
GABA$_B$ receptor; (−)-Baclofen; 3-Amino-propylphosphinic acid; CGP 35348; 2-Hydroxy-saclofen; Gastric pepsinogen secretion; Gastric acid secretion (Blandizzi, C. (294) 191)

Pharmacokinetics
Melatonin; Continuous light; Circadian rhythm; 6-Sulfatoxymelatonin; (Intravenous) (Deprés-Brummer, P. (312) 171)

Pharmacological validation
Stress, chronic, mild; Depression, animal model (Papp, M. (296) 129)

Stress, chronic, mild; Depression, animal model (Papp, M. (310) 99)

Pharmacology
CCK$_B$/gastrin receptor; Pancreas; Cloning; Ontogeny (Dufresne, M. (297) 165)

Pharmacology, in vivo
Adenosine; Adenosine A$_{2A}$ receptor; ZM 241385 (Keddie, J.R. (301) 107)

***N*^{3}-Phenacyluridine**
Sedative; Hypnotic; Central nervous system; Benzodiazepine receptor (Kimura, T. (311) 265)

Phencyclidine
NMDA receptor antagonist; NPC 17742; ACEA 1021; *N*-Nitro-L-arginine methyl ester; Anxiolytic (Wiley, J.L. (294) 101)

5,7-Dichlorokynurenic acid; HA-966 (3-amino-l-hydroxy-2-pyrrolidone); Dizocilpine; Ifenprodil; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid); 5-HT$_{2C}$ receptor (Mazzola-Pomietto, P. (308) 329)

3-OH-PCP (1-[1(3-hydroxyphenyl)-cyclohexyl]piperidine); NMDA receptor; Autoradiography; Brain, rat (Suzuki, T. (310) 243)

Phencyclidine receptor
Conditioned fear stress; σ Receptor; Phenytoin; Motor suppression (Kamei, H. (299) 21)

Phencyclidine site
NMDA receptor; [^{3}H](+)-MK-801; Imidazoline drug; K$^+$ channel, ATP-sensitive (Olmos, G. (310) 273)

Phentolamine
κ-Opioid receptor; Cardiovascular; Blood pressure; Pregnancy (Szeto, H.H. (309) 183)

β-Phenylethylamine
Dopamine; Nigrostriatal system; Rotation (Barroso, N. (297) 195)

Phenylglycine
Metabotropic glutamate receptor; cAMP; Phosphoinositide hydrolysis; Cortex; Cerebellar granule cell (Bedingfield, J.S. (309) 71)

(−)-*N*^{6}-Phenylisopropyl-adenosine
Sodium fluoride; Carbachol; Phosphatase; Inotropy (Neumann, J. (294) 451)

8-Phenyltheophylline
Mucus secretion; Trachea; Theophylline; Enprofylline; 3-Isobutyl-methyl-xanthine; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Phenytoin
Conditioned fear stress; σ Receptor; Phencyclidine receptor; Motor suppression (Kamei, H. (299) 21)

Conditioned fear stress; σ Receptor; Dopaminergic system; Motor suppression (Kamei, H. (309) 149)

Pheochromocytoma (PC12) cell
Ca^{2+} uptake; Nicotine; NE-100 (*N,N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl); Binding assay; σ Receptor (Sagi, N. (304) 185)

Phorbol 12,13-dibutyrate (PDB)
Iris dilator, rabbit; Ca^{2+} mobilization; Protein kinase C; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

Phorbol ester
tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone); *N*-Formyl-Met-Leu-Phe; Superoxide anion; Ca^{2+}; BAPTA/AM (*O,O'*-bis(2-aminophenyl)ethyleneglycol-*N,N,N',N'*-tetraacetic acid, tetraacetoxymethyl ester) (Tsukii, K. (298) 87)

Phosphatase
Sodium fluoride; Carbachol; (−)-*N*^{6}-Phenylisopropyl-adenosine; Inotropy (Neumann, J. (294) 451)

Phosphodiesterase inhibition
Peritoneal eosinophil; Migration, in vitro; β_2-Adrenoceptor agonist (Alves, A.C. (312) 89)

Phosphodiesterase inhibitor
Intestinal erythrocyte extravasation; Lipopolysaccharide (Cardelús, I. (299) 153)

Platelet; Endothelin-3; Sodium nitroprusside; cGMP; Ca^{2+}, cytosolic; Ca^{2+} pump (Gagnet, C. (310) 67)

Nitroglycerin; Tolerance; cGMP monophosphate; Blood pressure; Zaprinast; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Phosphoinositide
Substance P; Neutrophil; Superoxide production; Ca^{2+}, intracellular (Tanabe, T. (299) 187)

Phosphoinositide hydrolysis
5-HT (5-hydroxytryptamine, serotonin); 5-HT$_{2A}$ receptor; 5-HT$_{2C}$ receptor; 5-HT receptor antagonist; Aryloxyalkylimidazoline (Siegel, B.W. (296) 307)

W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine); Thromboxane A_2; G-protein; Ca^{2+} (Ohkubo, S. (298) 175)

Metabotropic glutamate receptor; cAMP; Cortex; Cerebellar granule cell; Phenylglycine (Bedingfield, J.S. (309) 71)

α_1-Adrenoceptor; Positive inotropic effect; Oxymetazoline; Ventricular myocardium, rabbit; (±)-Tamsulosin [(±)-5-[2-[[2-(2-ethoxyphenoxy) ethyl]-amino]propyl]-2-methoxybenzenesulfonamide-HCl] (Yang, H.-T. (312) 281)

Thrombin receptor; G-protein; GTPase (Ogino, Y. (316) 105)

Phosphoinositide turnover
Protein kinase A; Endothelin; C_6 glioma cell; (ATP) (Lin, W.W. (296) 231)

Phospholipase A_2
Arachidonic acid; Long-term potentiation; NMDA (*N*-methyl-D-aspartate); ACPD ((1*S*,3*R*)-1-aminocyclopentane-1,3-dicarboxylic acid); Melittin (Collins, D.R. (294) 147)

Fenspiride; Lipopolysaccharide; TNF (tumor necrosis factor); Alveolar macrophage, guinea-pig (De Castro, C.M.M.B. (294) 669)

EGF (epidermal growth factor); Smooth muscle, airway; Leukotriene; Tyrosine kinase (Nasuhara, Y. (296) 161)

Interleukin 1β; cAMP; Tetranactin; Renal mesangial cell (Walker, G. (306) 265)

Inflammation; Transgenic mouse; Phospholipase inhibitor (Fox, N. (308) 195)

Antiflammin; Arachidonic acid; Chemotaxis; Inflammation; Anti-inflammatory drug (Moreno, J.J. (314) 129)

Phospholipase C
Ancrod-generated fibrin; Integrin $\alpha_v\beta_3$; Prostacyclin; Pertussis toxin (Chang, M.C. (297) 129)

Histamine H_1 receptor; Neomycin; Ca^{2+} entry (Sipma, H. (305) 207)

μ-Opioid receptor; SH-SY5Y cell; Inositol(1,4,5)trisphosphate; Tyr-D-Arg^2-Phe-sarcosine^4 (TAPS) (Smart, D. (305) 235)

Norepinephrine; *t*-ACPD (*trans*-1-amino-1,3-cyclopentanedicarboxylic acid); Bombesin; LA-N-2 cell; β-Adrenoceptor; Metabotropic (Sorrentino, G. (308) 81)

Desensitization; G-protein; Adenylyl cyclase (Galas, M.-C. (314) 157)

SK-N-BE(2)C human neuroblastoma; U-73122; cAMP production; Ca^{2+} mobilization; Inositol 1,4,5-triphosphate; Neomycin (Suh, B.-C. (314) 235)

Smooth muscle; Contraction; Muscarinic; G-protein; Antibody (Cuq, P. (315) 213)

Phospholipase D
α_2-Adrenoceptor; Smooth muscle, vascular; Tyrosine kinase; $pp60^{src}$; Hypertension; Protein kinase C (Jinsi, A. (302) 183)

Phospholipase inhibitor
Phospholipase A_2; Inflammation; Transgenic mouse (Fox, N. (308) 195)

Phospholipid
Azithromycin; Fluorescence polarization; NMR spectroscopy, ^{31}P; Conformational analysis; Gentamicin (Montenez, J.-P. (314) 215)

Phospholipidosis
Azithromycin; Macrolide; Gentamicin; Aminoglycoside; Lysosomal phospholipase; Membrane aggregation (Van Bambeke, F. (314) 203)

Phosphorylation
Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Oxime; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Glutamate release; Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Synaptophysin; Synapsin; Hippocampus; Ageing (Mullany, P. (309) 311)

Phosphoserine phosphatase
L-AP3 (L-2-amino-3-phosphonopropionic acid); D-AP3 (D-2-amino-3-phosphonopropionic acid); Serine; Glycine (Hawkinson, J.E. (307) 219)

Photoaffinity labeling
P-Glycoprotein; Chemosensitizer; Multidrug resistance (Boer, R. (295) 253)

Photochemically induced thrombosis
Tranilast; Endothelial injury; Smooth muscle cell proliferation; Intimal thickening (Kikuchi, S. (295) 221)

Aurintricarboxylic acid; Triflavin; Von Willebrand factor; Glycoprotein IIb/IIIa (Hisamichi, N. (312) 69)

Photolysis, ultraviolet
Ca^{2+} current; GTPγS; Baclofen; G-protein; Hippocampus, rat (Frank, C. (295) 87)

Physical dependence
Nicotine; Mecamylamine; Conditioned place preference paradigm; Place aversion (Suzuki, T. (314) 281)

Physostigmine
MF201; Tacrine; E2020; 8-Arm radial maze; (Rat) (Braida, D. (302) 13)

Pertussis toxin; Analgesia; Morphine; Diphenhydramine; Baclofen; Clomipramine (Galeotti, N. (308) 125)

Pial vein
Endothelin ET_A receptor; Endothelin ET_B receptor; IRL 1620; (Dog) (Fernández, N. (294) 483)

Rhythmic constriction; cAMP; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); (Porcine) (Ishine, T. (313) 97)

Picrotoxin
$GABA_A$ receptor; γ_2 Subunit; Antisense oligodeoxynucleotide; Methyl-β-carboline-3-carboxylate; Strychnine; Convulsion (Zhao, T.-j. (306) 61)

Pimozide
Neuroleptic withdrawal; Ca^{2+} channel blockade; Haloperidol; Nifedipine; Apomorphine (Antkiewicz-Michaluk, L. (294) 459)

Haloperidol; Dopamine metabolism; Catalepsy; Adaptation; (Chronic treatment) (Karolewicz, B. (313) 181)

Pinacidil
Hypothyroidism; K_{ATP} channel; Portal vein; Cromakalim; Glibenclamide (Jagadish, M. (309) 63)

(−)-Pindolol
5-HT_{1A} autoreceptor antagonism; Buspirone; Selective serotonin reuptake inhibitor (SSRI); Citalopram; 5-HT (5-hydroxytryptamine, serotonin), extracellular; Microdialysis, in vivo (Hjorth, S. (303) 183)

Pineal
Parasympathetic; Melatonin; Microdialysis; Muscarinic receptor agonist; Carbachol; Noradrenaline release (Drijfhout, W.J. (308) 117)

Pineal gland, ovine
Melatonin; 5-HT (hydroxytryptamine, serotonin)-*N*-acetyltransferase; Tryptamine (Shen, S. (307) 133)

Pinealocyte
n−3 fatty acid; cAMP; Adrenoceptor; Norepinephrine; (Rat) (Delton-Vandenbroucke, I. (312) 379)

2,5-Piperazinedione
Alaptide; Cyclodipeptide; Elevated plus-maze test; Memory; Oxiracetam; (Mouse) (Hliňák, Z. (314) 1)

Piper methysticum
Epilepsy; Kava pyrone; Na^+ channel; Synaptosome (Gleitz, J. (315) 83)

Piribedil
Dopamine receptor; Autoradiography (Cagnotto, A. (313) 63)

Pituitary
Pregnenolone sulfate; Steroid; Ca^{2+}; GH3 cell (Büküşoğlu, C. (298) 79)

5-HT_{1A} receptor; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Adrenaline; ACTH (adrenocorticotrophin) (Korte, S.M. (309) 281)

Ca^{2+} channel; Dihydropyridine; ω-Conotoxin; ω-Agatoxin; Melanotrope; α-MSH (α-melanocyte-stimulating hormone) (Mansvelder, H.D. (311) 293)

PK11195
Benzodiazepine receptor, peripheral; Porphyrin; Cholesterol; Metabolism; Liver (Tsankova, V. (299) 197)

Uterus, rat; Sex hormone, female; Diazepam; 4'-Chlorodiazepam; Clonazepam; Ca^{2+} channel (Yiu, M.-k. (302) 99)

Place aversion
Nicotine; Mecamylamine; Conditioned place preference paradigm; Physical dependence (Suzuki, T. (314) 281)

Place conditioning
Morphine; $GABA_B$ receptor; Ventral tegmental area; Reward (Tsuji, M. (313) 169)

Placenta
Dopamine; β-Endorphin; Dynorphin; Perfusion; (Rat) (Stratakis, C.A. (315) 53)

Place preference conditioning
Sensitization; Morphine; Opioid; Psychostimulant; Conditioned reward (Shippenberg, T.S. (299) 33)

Plasma catecholamine
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation (Vietor, I. (313) 119)

Plasma concentration, drug
Ceritizine; Chlorpheniramine; EEG (electroencephalogram), quantitative; Oral administration, acute; Neuropsychological status; (Healthy volunteer) (Sannita, W.G. (300) 33)

Plasma extravasation
Neurokinin; NK_1 receptor antagonist; Bronchoconstriction; Pain; Neuropeptide (Bonnet, J. (310) 37)

Plasma exudation
K^+ channel opener; Levcromakalim; HOE 234; Bronchoconstriction (Kidney, J.C. (296) 81)

Plasma membrane
P_{2Y} purinoceptor; ATP; Gastric mucosa (Vallejo, A.I. (312) 209)

Plasma nitrate
Endotoxin; Nitric oxide (NO) synthase; mRNA; Septic shock; Heart, rat (Bateson, A.N. (303) 141)

Plasticity
Glutamate; Long-term depression; Long-term potentiation; Metabotropic receptor; NMDA receptor; Posterior cingulate cortex (Hedberg, T.G. (310) 19)

Platelet
Heparin; Protamine; PAF (platelet-activating factor); PAF-acether; Thromboxane; BN 52021 (Aïssa, J. (302) 123)

Glyceryl trinitrate; Nitrite; Nitrate tolerance; Smooth muscle cell; Vascular (Weber, A.-A. (309) 209)

Endothelin-3; Sodium nitroprusside; cGMP; Phosphodiesterase inhibitor; Ca^{2+}, cytosolic; Ca^{2+} pump (Gagnet, C. (310) 67)

Platelet aggregation
Urokinase variant; Fibrinolysis; Thrombin inhibition; Clot specificity; (Rabbit) (Schneider, J. (302) 69)

Cilostazol; Otsuka Long-Evans Tokushima Fatty rat; Motor nerve conduction velocity; R-R interval, coefficient of variation; Sciatic nerve blood flow; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

Endotoxin; Adenine nucleotide; PAF (platelet-activating factor) (Jarvis, G.E. (315) 203)

Platelet, human
Prostaglandin endoperoxide synthase; Blood monocyte, human; Flurbiprofen; Flurbinitroxybutylester (Santini, G. (316) 65)

***cis*-Platinum (II) phosphonate complex**
Cisplatin; Murine mast cell; Histamine release (Brzezińska-Błaszczyk, E. (298) 155)

Pleurisy
N^{ω}-Nitro-L-arginine methyl ester; Eosinophil chemotaxis; Nitric oxide (NO); cGMP (Ferreira, H.H.A. (310) 201)

PLG (prolyl-leucyl-glycinamide)
Social recognition; Social memory, rat; Oxytocin; Neurohypophyseal hormone; Structure activity (Popik, P. (308) 113)

Plus-maze
5-HT_{1A} receptor; Defensive burying; Inescapable footshock; 5-HIAA/5-HT (5-hydroxy-indole acetic acid/5-hydroxytryptamine) ratio (Barf, T. (297) 205)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Substance P; Neurokinin A; FK 888; SR 48968; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Toluene; 1,1,1-Trichloroethane; Methoxyflurane; Flurothyl; Anxiolytic; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

PN 200-110
Lymphocyte; Ca^{2+} channel; Radioligand binding; Immune function; (Human) (Ricci, A. (301) 189)

[^{3}H](+)-PN200-110
Anandamide; Ca^{2+} channel; Arachidonic acid; [^{3}H]Diltiazem; [^{3}H](−)-Desmethoxyverapamil (Shimasue, K. (296) 347)

Pneumococcal meningitis
Bradykinin; Hoe140; Cerebral blood flow; Brain edema; Intracranial pressure (Lorenzl, S. (308) 335)

Polyamine
Pain; Analgesia; NMDA receptor; Ifenprodil; Morphine; Naloxone; α-MSH (α-melanocyte-stimulating hormone) (Bernardi, M. (298) 51)

Polymerase chain reaction
Preprotachykinin; mRNA; C-fiber activation; Release (Wang, Z.-Y. (297) 157)

Polymorphonuclear leukocyte influx
Propentofylline; Adenosine receptor; Xanthine; Myeloperoxidase (Zhang, Y. (313) 237)

Polymorphonuclear leukocyte migration
Seminal vesicle protein; Transglutaminase; Air-pouch inflammation (Mancuso, F. (312) 327)

Polyol pathway
Diabetic neuropathy; 2,3-Diphosphoglycerate; Hypoxia; Aldose reductase inhibitor (Nakamura, J. (294) 207)

Diabetes; Galactosemia; Nerve conduction; Nerve regeneration; Oxygen free radical; Antioxidant; Metal chelator (Love, A. (314) 33)

Polyunsaturated fatty acid
Docosahexaenoic acid; K^+ channel, cloned; Patch clamp, whole-cell (Garratt, J.C. (314) 393)

Porphyrin
Benzodiazepine receptor, peripheral; Mitochondria, liver; Cholesterol (Tsankova, V. (294) 601)

Benzodiazepine receptor, peripheral; PK11195; Cholesterol; Metabolism; Liver (Tsankova, V. (299) 197)

Portal hypertension
Baseline vascular tone; EDRF (endothelium-derived relaxing factor) (Pilette, C. (312) 63)

Portal vein
Hypothyroidism; K_{ATP} channel; Pinacidil; Cromakalim; Glibenclamide (Jagadish, M. (309) 63)

Portal vein, guinea-pig
P_{2x} purinoceptor; ATP; Suramin (Orre, M. (316) 229)

Positive inotropic agent
Systemic hemodynamics; Blood flow distribution; Mean circulatory filling pressure; OPC-18790 (Fujiki, H. (313) 191)

Positive inotropic effect
Methoxamine; α_1-Adrenoceptor; Endothelin; Ventricular myocardium, rabbit (Yang, H.-T. (296) 47)

α_1-Adrenoceptor; Phosphoinositide hydrolysis; Oxymetazoline; Ventricular myocardium, rabbit; (±)-Tamsulosin [(±)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]-amino]propyl]-2-methoxybenzenesulfonamide-HCl] (Yang, H.-T. (312) 281)

Posterior cingulate cortex
Glutamate; Long-term depression; Long-term potentiation; Metabotropic receptor; NMDA receptor; Plasticity (Hedberg, T.G. (310) 19)

Postjunctional potentiation
Endothelin-1; Endothelin ET_A receptor; Adrenergic nerve stimulation; Prejunctional inhibition; Mesenteric artery (Zhang, J.-X. (311) 169)

Potassium chloride
Aorta; Carotid artery; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin); Ca^{2+}; Cholesterol (Moreland, R.S. (307) 55)

Potentiation
Ketorolac; Caffeine; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (L-NAME); Antinociception (López-Muñoz, F.J. (308) 275)

PPAHV (phorbol 12-phenylacetate 13-acetate 20-homovanillate)
Vanilloid receptor; Binding cooperativity; Resiniferatoxin; Capsaicin (Szallasi, A. (299) 221)

pp60^{src}
α_2-Adrenoceptor; Phospholipase D; Smooth muscle, vascular; Tyrosine kinase; Hypertension; Protein kinase C (Jinsi, A. (302) 183)

P_1 purinoceptor
P_2 purinoceptor; Trachealis muscle, guinea-pig, isolated; Suramin; 8-Sulphophenyltheophylline; Adenosine 5′-triphosphate (Piper, A.S. (307) 183)

P_2 purinoceptor
Neuromuscular transmission; Suramin; Non-depolarizing neuromuscular relaxant; Ca^{2+} channel (Henning, R.H. (301) 91)

P_1 purinoceptor; Trachealis muscle, guinea-pig, isolated; Suramin; 8-Sulphophenyltheophylline; Adenosine 5′-triphosphate (Piper, A.S. (307) 183)

P_{2U} purinoceptor
CCK_A receptor; Adenosine A_1 receptor; 5-HT_{1B} receptor; Inositol phosphate; CHO (Chinese hamster ovary) cell (Dickenson, J.M. (302) 141)

P_{2X} purinoceptor
Purinergic transmission; α_2-Adrenoceptor; Autoinhibition; Electrical stimulation; Splenic artery; (Dog) (Ren, L.-M. (295) 61)

Cholesterol-feeding; Endothelium; Mesenteric arterial bed, rat; Sympathetic neurotransmission; Donryu rat (Ralevic, V. (313) 221)

P_{2x} purinoceptor
ATP; Suramin; Portal vein, guinea-pig (Orre, M. (316) 229)

P_{2Y} purinoceptor
G-protein; Protein kinase C; K^+ channel; Ca^{2+} release, cytosolic; Hippocampal neuron (Ikeuchi, Y. (304) 191)

ATP; Gastric mucosa; Plasma membrane (Vallejo, A.I. (312) 209)

P_3 purinoceptor
Adenosine A_{2A} receptor; Adenosine A_{2B} receptor; Adenosine A_3 receptor; Coronary vasculature; Heart, perfused, rat (Harden, F.A. (307) 49)

Pramipexole
D_3 receptor; Dopamine receptor agonist; Dopamine neuronal firing (Piercey, M.F. (312) 35)

Prazosin
α_1-Adrenoceptor; NMDA receptor; Water maze; Passive avoidance; CPP ((±)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Riekkinen, M. (300) 9)

α_1-Adrenoceptor subtype; JTH-601; α_{1L}-Adrenoceptor (Muramatsu, I. (300) 155)

[^{3}H]Prazosin
Spinal cord; α_1-Adrenoceptor subtype; BMY 7378; 5-Methyl-urapidil; (Rat) (Wada, T. (312) 263)

Preconditioning
Heart, rat; Capsaicin; Ruthenium red; CGRP (calcitonin gene-related peptide); CGRP-(8–37) (Li, Y.-J. (311) 163)

Preference
Dopamine; Ethanol; Nicotine; Nicotinic acetylcholine receptor; Sensitization; (Rat) (Blomqvist, O. (314) 257)

Prefrontal cortex
Desipramine; Maprotiline; Locus ceruleus; Extracellular recording; (Anesthetized rat) (Ceci, A. (312) 189)

Pregnancy
Opioid; κ-Opioid receptor agonist; Blood pressure; Heart rate (Szeto, H.H. (297) 77)

Uterus, rat; β_2-Adrenoceptor subtype; β_2-Adrenoceptor agonist (Ohashi, T. (307) 315)

Vasopressin receptor; Oxytocin receptor; Uterus; (Rat) (Anouar, A. (308) 87)

κ-Opioid receptor; Cardiovascular; Blood pressure; Phentolamine (Szeto, H.H. (309) 183)

α_1-Adrenoceptor; Uterine artery; Estrous cycle (Nair, R. (312) 45)

Melatonin; Myometrium, human; Labor; Noradrenaline (Mårtensson, L.G.E. (316) 273)

Pregnenolone
Neurosteroid; TNF (tumor necrosis factor); Glucocorticoid; Dehydroepiandrosterone sulfate (Di Santo, E. (299) 179)

Pregnenolone sulfate
Steroid; Ca^{2+}; GH3 cell; Pituitary (Büküşoğlu, C. (298) 79)

SR 95531; Neuroactive steroid; Neurosteroid; $GABA_A$ receptor; RU 5135; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

Prejunctional inhibition
Endothelin-1; Endothelin ET_A receptor; Adrenergic nerve stimulation; Postjunctional potentiation; Mesenteric artery (Zhang, J.-X. (311) 169)

Preload recruitable stroke work
Ventricular function; Diastolic function; Isovolumic relaxation; Superoxide dismutase; SC-55858; SC-54417 (Lowe, D. (304) 81)

Isovolumic relaxation; Ventricular filling; Myocardial contractility; Inotropes; Dobutamine; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

Preoptic area
$5\text{-}HT_{1A}$ receptor; Blood pressure; Heart rate; Forebrain; 8-OH-DPAT (*R*-(+)-8-hydroxy-2-(di-*n*-propylamino) tetralin) (Szabó, A. (315) 187)

Preprotachykinin
mRNA; Polymerase chain reaction; C-fiber activation; Release (Wang, Z.-Y. (297) 157)

Pressor response
Lipopolysaccharide; Nitric oxide (NO) synthase; Nitrosyl-hemoglobin (NO-hemoglobin) (Cai, M. (295) 215)

Angiotensin II; Medullary vasomotor neuron; Rostral ventrolateral medulla; Vasopressin (Sun, M.-K. (304) 63)

Presynaptic dopamine re-uptake site, presynaptic
Vesicular monoamine transporter; VMAT2 (vesicular monoamine transporter type 2); Dopamine D_2 receptor; Dopamine; Methoxytetrabenazine (Vander Borght, T. (294) 577)

Presynaptic receptor
NMDA receptor; 5-HT autoreceptor; 5-HT (5-hydroxytryptamine, serotonin) release; Cerebral cortex, guinea-pig; Serotoninergic axon terminal (Fink, K. (300) 79)

Primary culture
Endothelin-1; Angiotensin II; Atherosclerosis; Cell cycle progression; Ca^{2+}, cytosolic (Jahan, H. (295) 261)

Primary cultured neuron
β-CCE (ethyl β-carboline-3-carboxylate); Benzodiazepine receptor; Down-regulation; Inverse agonist (Katsura, M. (298) 71)

Primary neuronal culture
Flupirtine; Focal cerebral ischemia; Glutamate; Ca^{2+}, cytosolic; Fura-2 (Rupalla, K. (294) 469)

Primary olfactory cortex
Norepinephrine; Risperidone; Electrophysiology; Antipsychotic drug (Marek, G.J. (305) 95)

Progesterone
Mitogen-activated protein kinase; Smooth muscle, uterine; Steroid; Estradiol (Ruzycky, A.L. (300) 247)

Male pheromone; Glutamic acid decarboxylase; Olfactory bulb; Ovariectomy; Estrogen; (Rat) (Navarro Becerra, N. (312) 83)

Protein kinase C; Smooth muscle, uterine; Cardiac muscle; Steroid; Estradiol (Ruzycky, A.L. (313) 257)

Progesterone receptor
Neuroactive steroid; Neurosteroid; Gene expression (Rupprecht, R. (303) 227)

Prokinetic benzamide
$5\text{-}HT_3$ receptor; Intestinal transit; (Mouse) (Nagakura, Y. (311) 67)

Prolactin
Na^+-Ca^{2+} exchanger; Na^+-H^+ antiporter; Amiloride analog (Di Renzo, G. (294) 11)

Prolactin secretion
Median eminence; Intermediate lobe; Pentazocine; Haloperidol; Raclopride; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

Proliferation
Secretoneurin; Fibroblast; Migration (Kähler, C.M. (304) 135)

Prolyl endopeptidase
JTP-4819; Morris water maze task; Passive avoidance task; TRH (thyrotropin-releasing hormone); Middle cerebral artery occlusion (Shinoda, M. (305) 31)

Promethazine
Achatin-I (Gly-D-Phe-Ala-Asp); Excitatory neuropeptide; Triprolidine; Histamine H_1 receptor antagonist; Blocking effect; Neuron; (Snail) (Salunga, T.L. (304) 163)

Propafenone
AV-node; Ajmaline; Rate dependence; Time constant (Stark, G. (310) 29)

5-Hydroxypropafenone; Sinoatrial node automaticity; His bundle automaticity; Atrial myocardium refractoriness; AV node refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

Propentofylline
NGF (nerve growth factor); Learning; Memory; Choline acetyltransferase; Dementia model; (Rat) (Nitta, A. (307) 1)

Nitrobenzylthioinosine; Adenosine; Nucleoside transport (Parkinson, F.E. (308) 97)

Adenosine receptor; Xanthine; Myeloperoxidase; Polymorphonuclear leukocyte influx (Zhang, Y. (313) 237)

Propionyl-L-carnitine
Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Insulin; Carnitine; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Propofol
Benzodiazepine; $GABA_A$ receptor; Flurazepam; Anesthesia; *Xenopus* oocyte (Reynolds, J.N. (314) 151)

Propranolol
Noradrenaline; β-Adrenoceptor; NMDA receptor; Hippocampus; Working memory (Ohno, M. (307) 21)

β-Adrenoceptor antagonist; S100 protein; Cardiac muscle; Mg^{2+} (Nakatani, K. (315) 335)

Prostacyclin
Ancrod-generated fibrin; Integrin $\alpha_v\beta_3$; Pertussis toxin; Phospholipase C (Chang, M.C. (297) 129)

Ticlopidine; Thrombolysis; Anti-platelet potency; Nitric oxide (NO); Tissue plasminogen activator (Gryglewski, R.J. (308) 61)

Prostacyclin analog
SM-10902 ointment; Wound healing; Blood flow, skin; Angiogenesis; Diabetic mouse (*db/db* mouse), genitically (Yamamoto, T. (302) 53)

Prostaglandin
Carbamazepine; Edema; Inflammatory hyperalgesia; Nociception; Substance P (Bianchi, M. (294) 71)

Learning; Memory; Cyclooxygenase; Neurotransmitter; Retrograde messenger; Synaptic plasticity (Hölscher, C. (294) 253)

Vascular permeability; Lipopolysaccharide; Nitric oxide (NO); Skin; (Mouse) (Fujii, E. (297) 257)

Low-density lipoprotein, oxidized; Nitric oxide (NO); Macrophage; Atherosclerosis (Matthys, K.E. (298) 97)

Dolabrane; Anti-inflammatory; Neutrophil, human; Myeloperoxidase; Elastase; Leukotriene (Payá, M. (312) 97)

Prostaglandin D_2
BW A868C; BW245C; DP receptor; Antagonist affinity (Liu, Y.J. (303) 187)

Prostaglandin E_1
Pulmonary artery; ATP; Acetylcholine; Tolazoline; Nifedipine; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

Prostaglandin E_1 receptor
Adenylate cyclase; α_{2B}-Adrenoceptor; Muscarinic M_4 receptor; δ-Opioid receptor; Receptor cross-talk (Ammer, H. (302) 199)

Prostaglandin E_2
Bradykinin; Pain; Nociceptor; Vein (Kindgen-Milles, D. (294) 491)

TNF (tumor necrosis factor-α); Rolipram; Cicaprost (Greten, T.F. (299) 229)

CINC (cytokine-induced neutrophil chemoattractant); cAMP; Interleukin-1; Interleukin-6; Prostaglandin I_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Intestinal fluid transport; K^+ channels; *Escherichia coli* enterotoxin-induced secretion; Nitric oxide (NO); N^{ω}-nitro-L-arginine methyl ester (L-NAME) (Schirgi-Degen, A. (316) 257)

Prostaglandin I_2
CINC (cytokine-induced neutrophil chemoattractant); cAMP; Interleukin-1; Interleukin-6; Prostaglandin E_2; TNF (tumor necrosis factor) (Oh-ishi, S. (300) 255)

Prostanoid TP receptor
Benextramine; Mesenteric artery, small; SQ 30,741; U46619; (Rat) (Van der Graaf, P.H. (300) 211)

Prostaglandin endoperoxide synthase
Blood monocyte, human; Platelet, human; Flurbiprofen; Flurbinitroxybutylester (Santini, G. (316) 65)

Prostate
Endothelin receptor; Diabetes; (Rat) (Saito, M. (310) 197)

α-Adrenoceptor; cDNA; Fibroblast, rat-1; Doxazosin; (Enantiomer) (Hatano, A. (313) 135)

KMD-3213; α_1-Adrenoceptor subtype; α_{1a}-Adrenoceptor; Thoracic aorta (Yamagishi, R. (315) 73)

Prostate, human
Tamsulosin; Electrical field stimulation; α_1-Adrenoceptor stimulation (Chueh, S.-C. (305) 177)

Protamine
Heparin; Platelet; PAF (platelet-activating factor); PAF-acether; Thromboxane; BN 52021 (Aïssa, J. (302) 123)

Protection
Selegiline; Astrocyte, cultured; Hippocampal cell; Excitotoxicity; Cerebral ischemia; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Protein carbonyl
Apomorphine; Free radical; Lipid peroxidation; Iron; Ascorbate; Thiobarbituric acid (Gassen, M. (308) 219)

Protein kinase A
Phosphoinositide turnover; Endothelin; C_6 glioma cell; (ATP) (Lin, W.W. (296) 231)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Desensitization; Striatum; Protein kinase C; (Rat) (West, A.R. (298) 241)

Protein kinase C
Endothelin; Endothelin receptor; Ca^{2} sensitization; Smooth muscle, vascular (Sudjarwo, S.A. (294) 261)

Staurosporine; Calphostin C; Wortmannin; Myosin light chain kinase; Aorta; (Rabbit) (Asano, M. (294) 693)

Angiotensin AT_{1A} receptor; Receptor phosphorylation; Ca^{2+}, intracellular free; Angiotensin II (Thomas, W.G. (295) 119)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Desensitization; Striatum; Protein kinase A; (Rat) (West, A.R. (298) 241)

Opioid withdrawal; Metabotropic glutamate receptor; Inositol-1,4,5-trisphosphate; Chelerythrine; Thapsigargin (Fundytus, M.E. (300) 173)

Spinal neuron; Purinoceptor; K^+ channel; G-protein; Patch clamp; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

α_2-Adrenoceptor; Phospholipase D; Smooth muscle, vascular; Tyrosine kinase; $pp60^{src}$; Hypertension (Jinsi, A. (302) 183)

P_{2Y} purinoceptor; G-protein; K^+ channel; Ca^{2+} release, cytosolic; Hippocampal neuron (Ikeuchi, Y. (304) 191)

EGF (epidermal growth factor); MAPK (mitogen-activated protein kinase); Isoforms ($p42^{mapk}$ and $p44^{mapk}$); Dermal fibroblast, human (Le Panse, R. (307) 339)

Iris dilator, rabbit; Phorbol 12,13-dibutyrate (PDB); Ca^{2+} mobilization; GF 109203X (2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(-indol-3-yl)-maleimide); H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride); H-88 (*N*-(2-cinnamylaminoethyl)-5-isoquinolinesulfonamide) (Satoh, M. (308) 145)

Aging; ACPD (*trans*-1-amino-cyclopentyl-1,3-dicarboxylate); Arachidonic acid; Glutamate release; Inositol trisphosphate (McGahon, B. (309) 323)

δ-Opioid receptor; GTPase (Narita, M. (310) R1)

CGP 41251; Chromaffin cell; Tyrosine hydroxylase; Catecholamine secretion; Nicotinic receptor (Loneragan, K. (311) 87)

Hyperosmolarity; Genistein; Staurosporine; Uterus, rat (Ausina, P. (312) 309)

Jatrophone; Natural killer activity; Lymphocyte proliferation; 12-*O*-Tetradecanoylphorbol 13-acetate; CD69; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

Vascular endothelial cell, human; Thromboxane A_2 receptor; ICAM-1 (intercellular adhesion molecule-1) (Ishizuka, T. (312) 367)

Smooth muscle, uterine; Cardiac muscle; Steroid; Estradiol; Progesterone (Ruzycky, A.L. (313) 257)

Contraction; Human bronchus; Na^+/K^+-ATPase; Ca^{2+} channel (Yang, K.X.F. (315) 65)

Dopamine transporter; Dopamine uptake; WIN 35,428 binding; Arachidonic acid; Second messenger (Zhang, L. (315) 345)

Protein kinase C, cytosolic
Smooth muscle, vascular; Ca^{2+}; Protein kinase C, particulate (Bazan, E. (311) 101)

Protein kinase C, particulate
Smooth muscle, vascular; Ca^{2+}; Protein kinase C, cytosolic (Bazan, E. (311) 101)

Protein kinase inhibitor
Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Soman (Aas, P. (301) 59)

Respiratory burst; Degranulation; Ca^{2+} mobilization; Neutrophil, human (Ahn, S.K. (306) 175)

Protein mono-ADP-ribosylation
Diabetes; Nerve lesion; Corticosterone (Gorio, A. (311) 21)

Protein phosphatase 1G
S6 kinase, 90 kDa; Insulin; Glycogen synthesis; EGF (epidermal growth factor) (Yasui, K. (316) 317)

Protein tyrosine kinase
Colon, rat; Cl^- channel; K^+ channel; Ca^{2+}; Genistein (Diener, M. (299) 161)

Glutamate release; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synaptophysin; Synapsin; Hippocampus; Ageing (Mullany, P. (309) 311)

Protein tyrosine phosphorylation
Oxatomide; RBL-2H3 cell; Signal transduction; Exocytosis; Ca^{2+} flux; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

Proteinuria
Dietary fat; *n*–3 fatty acid; Arrhythmia; Blood pressure; Thromboxane (McLennan, P. (300) 83)

DP-1904; Thromboxane A_2 synthase inhibitor; Heymann nephritis (Nagao, T. (316) 73)

Proteoglycan
Endothelin-1; Fibronectin; Collagen (Gutierrez, S. (302) 191)

Pruning effect
Opiate receptor; Neuronal plasticity; Synapsin I (Gorio, A. (303) 21)

Pseudococaine
Local anesthetic; Cocaine; Lidocaine; Hemodynamics; Blood pressure; Heart rate; Desipramine (Bernards, C.M. (307) 33)

Psychomotor stimulant
d-Amphetamine; Dose response; Motor activity; Behavior (Gaytan, O. (300) 1)

Psychostimulant
Sensitization; Morphine; Opioid; Conditioned reward; Place preference conditioning (Shippenberg, T.S. (299) 33)

Individual difference; Novelty; $GABA_A$; Cortex; Locomotion; Basal ganglia (Gruen, R.J. (309) 115)

Psychostimulant abuse
[^{123}I]RTI-55; Cocaine analog; (Mouse) (Gatley, S.J. (296) 145)

Ptilomycalin A
Na^+,K^+-ATPase; Ca^{2+}-ATPase; ATPase inhibitor (Ohizumi, Y. (310) 95)

Puberty, female
Ovary; Muscarinic receptor; Cholinergic system (Trkulja, V. (297) 93)

Pulmonary artery
Hypoxia; K_{ATP} channel; Pulmonary vasoconstrictor; Hypoxic pulmonary vasoconstriction (Wanstall, J.C. (303) 71)

Prostaglandin E_1; ATP; Acetylcholine; Tolazoline; Nifedipine; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

Pulmonary artery smooth muscle cell
NS-004; $[Ca^{2+}]_i$, free; K^+ channel, Ca^{2+}-activated; K^+ channel, delayed rectifier; Whole cell patch clamp; Membrane potential (Vandier, C. (295) 53)

Pulmonary edema
Neuropeptide Y; Sympathetic nervous system; Capillary permeability (Hirabayashi, A. (296) 297)

Pulmonary eosinophilia
Inflammation; Leukotriene B_4; Leukotriene C_4; Leukotriene D_4; Leukotriene E_4; Bronchoalveolar lavage fluid; (Inbred Brown Norway rat) (Namovic, M.T. (315) 81)

Pulmonary hypertension
Semotiadil; Ventricular hypertrophy, right; Media thickening (Takahashi, T. (295) 229)

Pulmonary vasoconstrictor
Hypoxia; K_{ATP} channel; Pulmonary artery; Hypoxic pulmonary vasoconstriction (Wanstall, J.C. (303) 71)

Purinergic
ATP; Nucleotide; Purinoceptor; Endothelial cell (Motte, S. (307) 201)

Micturition volume threshold; Inhibition; Nitric oxide (NO) (Theobald Jr., R.J. (311) 73)

Purinergic component
δ-Opioid receptor; Vas deferens, mouse; Cysteine sulfonamide enkephalin analog; Dalargin; Adrenergic component; Electrical field stimulation (Pencheva, N. (304) 99)

Purinergic transmission
P_{2X} purinoceptor; α_2-Adrenoceptor; Autoinhibition; Electrical stimulation; Splenic artery; (Dog) (Ren, L.-M. (295) 61)

Purinoceptor
Spinal neuron; K^+ channel; G-protein; Protein kinase C; Patch clamp; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

ATP; Purinergic; Nucleotide; Endothelial cell (Motte, S. (307) 201)

Pyrimidinoceptor; Excitatory amino acid receptor; Locus coeruleus; Extracellular recording (Fröhlich, R. (315) 255)

Purinoceptor agonist
Kidney, perfused, rat; Purinoceptor P_{2X}; Purinoceptor P_{2Y}; Purinoceptor P_{2U}; Purinoceptor antagonist (Eltze, M. (306) 139)

Purinoceptor antagonist
Kidney, perfused, rat; Purinoceptor P_{2X}; Purinoceptor P_{2Y}; Purinoceptor P_{2U}; Purinoceptor agonist (Eltze, M. (306) 139)

Purinoceptor P_{2U}
Kidney, perfused, rat; Purinoceptor P_{2X}; Purinoceptor P_{2Y}; Purinoceptor agonist; Purinoceptor antagonist (Eltze, M. (306) 139)

Purinoceptor P_{2X}
Kidney, perfused, rat; Purinoceptor P_{2Y}; Purinoceptor P_{2U}; Purinoceptor agonist; Purinoceptor antagonist (Eltze, M. (306) 139)

Purinoceptor P_{2Y}
Kidney, perfused, rat; Purinoceptor P_{2X}; Purinoceptor P_{2U}; Purinoceptor agonist; Purinoceptor antagonist (Eltze, M. (306) 139)

Purkinje cell
cGMP; Cerebellum; MK-801; TRH tartrate (thyrotropin-releasing hormone tartrate); GABA (γ-aminobutyric acid) (Nakayama, T. (316) 157)

Push-pull cannula
5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia (Singewald, N. (294) 787)

Pylorus, rat
Motility; Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); NANC (non-adrenergic non-cholinergic) (Willis, S. (315) 59)

Pyramidal tract neuron
CGP 35348; Transcallosal response; Motor cortex; Paired-pulse method; (−)-Baclofen (Chowdhury, S.A. (314) 313)

Pyrimidinoceptor
Purinoceptor; Excitatory amino acid receptor; Locus coeruleus; Extracellular recording (Fröhlich, R. (315) 255)

1-(2-Pyrimidinyl)piperazine
5-HT (5-hydroxytryptamine, serotonin); Hippocampus; Excitatory synaptic transmission; Electrophysiology; $5\text{-}HT_{1A}$ receptor; Azapirone (Manahan-Vaughan, D. (294) 617)

Pyrithiamine
Thiamine deficiency; ATPase; Thalamus; [^{3}H]Ouabain; (Rat) (Mousseau, D.D. (300) 191)

Quadazocine
Antinociception; Respiratory depression; Opioid receptor; Naloxonazine; Levorphanol; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

Antinociception; Respiratory depression; Opioid receptor; Naloxonazine; Levorphanol; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Quality of life
Myocardial infarction; Anxiety; Exploration; Social behavior; (Rat) (Schoemaker, R.G. (298) 17)

Quantitative structure-activity relationship model
Melatonin receptor; Comparative molecular field analysis; Austin model 1; Binding site; G protein-coupled receptor (Navajas, C. (304) 173)

Quenching
Morphine; Dyspnoea; Autoradiography; Opioid (Cabot, P.J. (310) 47)

Quinolinic acid, i.c.v. infusion
Learning; Long-term potentiation; Memantine; MK-801 (Misztal, M. (296) 1)

Quinpirole
5-HT_{2c} receptor; Normethylclozapine; Parkinson's disease (Fox, S. (301) 27)

Quipazine
5-HT_{2A} receptor; 5-HT_{2C} receptor; MK-212; MDL 100,907; SB 200646A; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

Raclopride
Median eminence; Intermediate lobe; Pentazocine; Haloperidol; Prolactin secretion; α-MSH (α-melanocyte stimulating hormone) secretion (Eaton, M.J. (299) 171)

Dopamine D_4 receptor (Helmeste, D. (301) R1)

Conditioned place preference; Sulpiride; Dopamine; Dopamine D_2 receptor; Lordosis (Meisel, R.L. (309) 21)

[^{3}H]Raclopride
Dopamine D_2 receptor; [^{3}H]Spiperone; [^{125}I]NCQ-298; [^{3}H]YM-09151-2; Nemonapride; Receptor binding, in vitro (Malmberg, Å. (303) 123)

Radial maze learning
Entorhinal cortex lesion; NMDA receptor antagonist; Chronic infusion; Memantine; (+)-MK-801; (Rat) (Zajaczkowski, W. (296) 239)

Radioactive microsphere technique
CGS 21680; Adenosine A_{2A} receptor; Vascular conductance (Nekooeian, A.A. (307) 163)

Radioligand binding
α_{1D}-Adrenoceptor; Contractility; Aorta, rat (Buckner, S.A. (297) 241)

5-HT_4 receptor; [^{3}H]GR 113808; Desensitization (Ansanay, H. (298) 165)

Lymphocyte; Ca^{2+} channel; PN 200-110; Immune function; (Human) (Ricci, A. (301) 189)

5-HT_4 receptor; Splice variant; Affinity state (Adham, N. (304) 231)

Dopamine receptor; Adrenal medulla; Autoradiography; Chromaffin cell; (Rat) (Barili, P. (310) 129)

BW373U86; δ-Opioid receptor; G-protein (Campa, M.J. (310) 263)

Histamine H_3 receptor; [^{3}H]GR168320; Cerebral cortex, rat; [^{3}H]N^{α}-Methylhistamine (Brown, J.D. (311) 305)

CRF receptor; IMR-32 human neuroblastoma cell line; Differentiation; Adenylate cyclase (Hogg, J.E. (312) 257)

NMDA receptor; Competitive antagonist; Neuroprotection; Molecular modelling (Cheung, N.S. (313) 159)

Radiotelemetry
Acamprosate; Alcohol; Withdrawal; (Rat) (Spanagel, R. (305) 45)

Ramiprilat
Angiotensin-converting enzyme inhibitor; Bradykinin; Bradykinin B_2 receptor antagonism; HOE 140 (H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH); Cardiac myocyte; Hypoxia/reoxygenation injury (Wall, T.M. (306) 165)

Raphe magnum nucleus
Enkephalin; Methylnaloxonium; RB 101; Antinociception; Amygdala; Thalamus, ventro-basal; Central gray matter (Valverde, O. (312) 15)

Rat, conscious
Adenosine A_3 receptor; Hemodynamics; Histamine release; Tachyphylaxis; 2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA) (Van Schaick, E.A. (308) 311)

Rate dependence
AV-node; Ajmaline; Propafenone; Time constant (Stark, G. (310) 29)

RB 101
Enkephalin; Methylnaloxonium; Antinociception; Amygdala; Thalamus, ventro-basal; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

RBE4 cell
Nitric oxide (NO) synthase, inducible; Ethanol; Blood-brain barrier; Inflammation; Endotoxin; Nitric oxide (NO) (Naassila, M. (313) 273)

RBL-2H3 cell
Oxatomide; Signal transduction; Exocytosis; Protein tyrosine phosphorylation; Ca^{2+} flux; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

Reactive blue 2
PC12 cell; ATP receptor; cAMP (Yakushi, Y. (314) 243)

Reactive oxygen species
Endothelium-dependent relaxation; Electrolysis; L-Arginine; Aorta (Gumusel, B. (306) 107)

Rebamipide
Hepatic secretion; Drug metabolism; Ischemia/reperfusion (Lee, S.-M. (294) 41)

Receptor
Catalepsy; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); (Rat) (Wadenberg, M.-L. (294) 247)

EGF (epidermal growth factor); Mucosal protection; Tissue resistance; Epithelium (Rao, R. (303) 209)

TNF-α (tumor necrosis factor α) inhibition; Adenosine A_3 receptor; Macrophage; Cross-talk (McWhinney, C.D. (310) 209)

Receptor alkylation
Muscarinic receptor; Esophageal muscularis mucosae (Watson, N. (294) 779)

Receptor autoradiography
Melatonin; 2-[^{125}I]Iodomelatonin; Visual system; (Reptile) (Larson-Prior, L.J. (297) 181)

Dopamine D_1 receptor; Dopamine D_2 receptor; Dopamine uptake site; Cerebral ischemia (Araki, T. (306) 73)

Receptor binding
Antinociception; 5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Sulfonylurea; Gliquidone; Cromakalim (Robles, L.-I. (295) 181)

Molecular modeling; Three-dimensional structure; 5-HT_{2C} receptor; Subtype selectivity (Kristiansen, K. (306) 195)

Receptor binding, in vitro
Dopamine D_2 receptor; [^{3}H]Spiperone; [^{3}H]Raclopride; [^{125}I]NCQ-298; [^{3}H]YM-09151-2; Nemonapride (Malmberg, Å. (303) 123)

Receptor coupling
Muscarinic receptor; Heparin; Receptor subtype; Transfected cell; Allosteric interaction (Wang, S.Z. (296) 113)

Receptor cross-talk
Adenylate cyclase; α_{2B}-Adrenoceptor; Muscarinic M_4 receptor; δ-Opioid receptor; Prostaglandin E_1 receptor (Ammer, H. (302) 199)

Receptor desensitization
Bradykinin; Glomerular hemodynamics; Glomerular prostaglandin; Kinin antagonist; Glomerular receptor (Praddaude, F. (294) 173)

Receptor distribution
Vas deferens, rat; Adenosine receptor (Brownhill, V.R. (303) 87)

Receptor phosphorylation
Angiotensin AT_{1A} receptor; Protein kinase C; Ca^{2+}, intracellular free; Angiotensin II (Thomas, W.G. (295) 119)

Receptor-receptor interaction
Adenosine; Dopamine; Adenylyl cyclase; Fibroblast (Dasgupta, S. (316) 325)

Receptor reserve
Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin) (Aretha, C.W. (305) 119)

GR127935; 5-$HT_{1D\alpha}$ receptor; 5-$HT_{1D\beta}$ receptor; [^{35}S]GTPγS binding; cAMP accumulation (Watson, J.M. (314) 365)

Receptor selection and amplification technology
Muscarinic acetylcholine receptor; Cloned human receptor; Functional partial agonism; Functional receptor selectivity (Bräuner-Osborne, H. (313) 145)

Receptor sequestration
β_2-Adrenoceptor; Adenylyl cyclase; CHO (Chinese hamster ovary) cell (Gabilondo, A.M. (307) 243)

Receptor subtype
Muscarinic receptor; Heparin; Transfected cell; Allosteric interaction; Receptor coupling (Wang, S.Z. (296) 113)

α-Casomorphin; β-Casomorphin; Opioid receptor; Somatostastin receptor; Breast cancer cell, T47D (Hatzoglou, A. (310) 217)

σ Receptor
κ-Opioid analgesia; Opioid receptor; Haloperidol; Antisense; KOR-1; κ-Opioid receptor (Chien, C.-C. (294) 303)

Dopamine release; (+)-Pentazocine; BD737 (1*S*,2*R*-(−)-*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-(1-pyrrolidinyl)cyclohexylamine); DuP 734 (1-(cyclopropylmethyl)-4-(2′-(4″-fluorophenyl)-2′-oxoethyl)piperidine HBr); BD1008 (*N*-[2-(3,4-dichlorophenyl)ethyl]-*N*-methyl-2-pyrrodinyl)cyclohexylamine) (Gonzalez-Alvear, G.M. (294) 713)

Cardiac myocyte; Contractility (Ela, C. (295) 275)

Behavioral sensitization; Cocaine; BMY-14802; SR-31742A; Schizophrenia (Ujike, H. (296) 123)

Conditioned fear stress; Phenytoin; Phencyclidine receptor; Motor suppression (Kamei, H. (299) 21)

Pheochromocytoma (PC12) cell; Ca^{2+} uptake; Nicotine; NE-100 (*N*,*N*-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]-ethylamine HCl); Binding assay (Sagi, N. (304) 185)

Liver, rat; Solubilization; CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate); (+)-Pentazocine; DTG (1,3-di-*o*-tolylguanidine) (Torrence-Campbell, C. (304) 201)

(+)-SKF10047; Ketamine hydrochloride; (Guinea pig) (Jerram, A.H. (307) 269)

Conditioned fear stress; Phenytoin; Dopaminergic system; Motor suppression (Kamei, H. (309) 149)

Ryanodine; Inositol 1,4,5-trisphosphate) (Tsao, L.-I. (311) R1)

Dopamine D_4 receptor; Schizophrenia (Helmeste, D.M. (314) R3)

σ Receptor ligand
EMD 57445; Rimcazole; Central effect; Behavioral model (Maj, J. (315) 235)

σ Receptor subtype
σ Binding site; Smooth muscle; Ileum; (Guinea pig); (Rat) (Kinney, G.G. (294) 547)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor; Binding; Brain, rat (Narita, N. (307) 117)

σ_1 Receptor agonist
Antidepressive effect; Forced swimming test; SA4503; (Mouse) (Matsuno, K. (312) 267)

Cognitive enhancer; Scopolamine; Basal forebrain lesion; Passive avoidance task; SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine dihydrochloride); (Rat) (Senda, T. (315) 1)

σ_1 Receptor subtype
SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride); Agonistic property; Competitive inhibition (Matsuno, K. (306) 271)

Recombinant channel
ATP receptor channel; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); *Xenopus* oocyte (Nakazawa, K. (296) 119)

Recombinant interleukin-2
Glycosphingolipid; Tumor; Adhesion; Peritumoral (Tubaro, E. (294) 555)

Recombinant NMDA receptor
Xenopus oocyte; Ifenprodil stereoisomer; Voltage clamp (Avenet, P. (296) 209)

Recombinant protein
VIP receptor, human; VIP receptor antagonist; Desensitization; Internalization; Transfection (Gaudin, P. (302) 207)

Red nucleus
Opiate; (+)-Pentazocine; σ Site; Substantia nigra (Matsumoto, R.R. (301) 31)

Reflex
C-fiber; Pain; Clonidine; Blood pressure; (Rat) (Gozariu, M. (313) 51)

Refractory period
Vasorelaxation; Heart; ATP-sensitive K^+ channel; His bundle; Conduction; Electrophysiology (D'Alonzo, A.J. (294) 271)

Reinforcement
Alcohol drinking; Food intake; δ-Opioid receptor; μ-Opioid receptor; (Selected rat line) (Honkanen, A. (304) 7)

Reinforcing property
Morphine analgesia; Morphine dependence; Withdrawal; Antipain; Leupeptin (Lyupina, Y.V. (304) 23)

Relapse
Acamprosate; Alcohol; Alcohol-deprivation effect; Craving; (Rat) (Spanagel, R. (305) 39)

Relaxation
5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; Stomach; Contraction; (Guinea pig) (Tamura, T. (308) 315)

Nicorandil; Aorta, rat; cGMP; Tolerance; Levcromakalim (Trongvanichnam, K. (314) 83)

Relearning
[Arg^8]Vasopressin; Vasopressin V_1 receptor antagonist; Ventral hippocampus; Retrieval; Locomotor activity (Alescio-Lautier, B. (294) 763)

Release
Preprotachykinin; mRNA; Polymerase chain reaction; C-fiber activation (Wang, Z.-Y. (297) 157)

Remodeling
Myocardial infarction; Ischemia; Metabolism; Captopril (Kalkman, E.A.J. (298) 121)

Renal blood flow
Endothelin receptor antagonist; Hypertension (Bird, J.E. (294) 183)

Endothelin-1; Superior colliculus; Blood pressure (D'Amico, M. (316) 245)

Renal failure
Cyclosporine A; Endothelin; Nephrotoxicity (Brooks, D.P. (294) 571)

Renal hemodynamics
Bosentan; Congestive heart failure; Aorto-caval fistula (Gurbanov, K. (310) 193)

Renal hypertension
Blood pressure variability; HOE 140; Losartan; Spectral analysis (Ponchon, P. (297) 61)

Renal hypertensive rat (RHR)
PAF (platelet-activating factor); Desensitization; Spontaneously hypertensive rat (SHR); GTP-binding protein (Kamata, K. (301) 121)

Renal mesangial cell
Phospholipase A_2; Interleukin 1β; cAMP; Tetranactin (Walker, G. (306) 265)

Renin-angiotensin-aldosterone system
Heart failure; Angiotensin II; Angiotensin II receptor; Angiotensin-converting enzyme inhibitor (Lenz, O. (294) 17)

Renin-angiotensin system
Stomach; Angiotensin II; Gastric hemodynamics; Pentagastrin; Angiotensin AT_1 receptor (Chow, L. (294) 309)

Angiotensin II receptor subtype; Hypertension; L-163,017 (Chang, R.S.L. (294) 429)

Reparil
Cell activation; Hypoxia; Endothelium; Neutrophil adherence; Aescine (Arnould, T. (315) 227)

Repeated treatment
Antidepressant; Dopamine D_2 receptor binding; [^{3}H]N-0437 (Maj, J. (304) 49)

Reperfusion
Nicorandil; Myocardial ischemia; Ventricular arrhythmia; K_{ATP} channel; Nitric oxide (NO) (Vegh, A. (305) 163)

Cerebral ischemia; Nitric oxide (NO); DNA fragmentation; Chromatin condensation; Apoptotic body; TUNEL assay (Charriaut-Marlangue, C. (310) 137)

Ischemia; Angiotensin-converting enzyme; Idrapril; Captopril; Heart; (Rat) (Riva, E. (312) 293)

Reperfusion arrhythmia
Superoxide dismutase; Catalase; Dimethylthiourea; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Ohoi, I. (306) 123)

Reperfusion injury, lethal
Carvedilol; Myocardial ischaemia; (Cat) (Brunvand, H. (314) 99)

Reserpine
Dopamine transporter; [^{3}H]GBR 12935 binding; L-DOPA; Amantadine; Benztropine (Gordon, I. (298) 27)

Glutamate receptor antagonist; Dopamine; Parkinsonism; Microdialysis (Biggs, C.S. (299) 83)

Locomotion; Lamotrigine; Dopamine; (Mouse) (Kaur, S. (304) 1)

Oral dyskinesia; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Resiniferatoxin
Vanilloid receptor; Binding cooperativity; Capsaicin; PPAHV (phorbol 12-phenylacetate 13-acetate 20-homovanillate) (Szallasi, A. (299) 221)

Gastrointestinal microcirculation; Laser Doppler; Capsaicin (Abdel Salam, O.M.E. (305) 127)

Emesis; Morphine; Nicotine; Tachykinin NK_1 receptor; 5-HT_3 receptor; 5-HT_{1A} receptor; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

[^{3}H]Resiniferatoxin
Vanilloid receptor; Capsazepine; Neuroleptic; Cooperative binding (Szallasi, A. (298) 321)

Resistance arteriole, cerebral
Endothelin-1; BQ-123; BQ-3020; Endothelin receptor; Cerebral circulation (Patel, T.R. (307) 41)

Resistance artery
Endothelin-1; Norepinephrine; Conduit artery; (Human) (Miyauchi, T. (303) 193)

Resistance artery, small
Hyperthyroidism; Thromboxane A_2 receptor agonist; 5-HT (5-hydroxytryptamine, serotonin); Endothelial modulation (Zwaveling, J. (300) 91)

Respiratory burst
Protein kinase inhibitor; Degranulation; Ca^{2+} mobilization; Neutrophil, human (Ahn, S.K. (306) 175)

Respiratory depression
Antinociception; Opioid receptor; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (298) 31)

μ_1-Opioid receptor; Fentanyl; Morphine; Muscle rigidity (Chen, S.-W. (312) 241)

Antinociception; Opioid receptor; Naloxonazine; Levorphanol; Quadazocine; (*Macaca mulatta*) (Gatch, M.B. (312) 389)

Respiratory rhythm
Substance P; Tachykinin; (In vitro); (Newborn rat) (Monteau, R. (314) 41)

Restenosis
Balloon angioplasty; Neointima; Endothelium; Nitric oxide (NO); Nitric oxide (NO) synthase; Von Willebrand factor (Bosmans, J.M. (310) 163)

Retching
Emesis; Morphine; Nicotine; Tachykinin NK_1 receptor; 5-HT_3 receptor; 5-HT_{1A} receptor; Resiniferatoxin; Vomiting; (*Suncus murinus*) (Andrews, P. (307) 305)

Retinal cell
Glutamate receptor; Neurotoxicity; Ca^{2+}; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione) (Ferreira, I.L. (302) 153)

Retrieval
[Arg^8]Vasopressin; Vasopressin V_1 receptor antagonist; Ventral hippocampus; Relearning; Locomotor activity (Alescio-Lautier, B. (294) 763)

Nicotine; Passive avoidance; (Mouse) (Zarrindast, M.-R. (295) 1)

Retrograde messenger
Learning; Memory; Prostaglandin; Cyclooxygenase; Neurotransmitter; Synaptic plasticity (Hölscher, C. (294) 253)

Reverse tolerance
Cocaine; Sensitization (Wise, R.A. (307) 15)

Reverse transcriptase-polymerase chain reaction
Artery, human; Noradrenaline; Neuropeptide Y; Antisense oligodeoxynucleotide; BIBP3226 (Bergdahl, A. (316) 59)

Reward
Morphine; $GABA_B$ receptor; Ventral tegmental area; Place conditioning (Tsuji, M. (313) 169)

RGD (Arg-Gly-Asp)-containing peptide
Triflavin; Fibrinogen receptor antagonist; Bleeding time; Mesenteric artery; Thrombosis (Sheu, J.-R. (294) 231)

Rheumatoid arthritis
Synovial cell; Human; Glucose uptake; Anti-inflammatory drug; Osteoarthritis (Hernvann, A. (314) 193)

Rhythmic constriction
cAMP; Norepinephrine; Pial vein; 5-HT (5-hydroxytryptamine, serotonin); (Porcine) (Ishine, T. (313) 97)

Right atrial pressure
Cocaine; ANP (atrial natriuretic peptide); ANP, N-terminal; Mean arterial pressure; Heart rate (Pelkonen, M. (304) 55)

Rigor
Ca^{2+}; Myofilament; Ca^{2+} sensitiser; EMD 57033; Skinned fiber (Palmer, S. (294) 83)

Rimcazole
σ Receptor ligand; EMD 57445; Central effect; Behavioral model (Maj, J. (315) 235)

R-R interval, coefficient of variation
Cilostazol; Otsuka Long-Evans Tokushima Fatty rat; Motor nerve conduction velocity; Sciatic nerve blood flow; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

Risperidone
α_1-Adrenoceptor, subtypes A and B; Functional experiment (Eltze, M. (295) 69)

Norepinephrine; Primary olfactory cortex; Electrophysiology; Antipsychotic drug (Marek, G.J. (305) 95)

Ritanserin
α_2-Adrenoceptor; Dexmedetomidine; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Monoamine; Locus ceruleus; (Rat) (Rabin, B.C. (306) 51)

mRNA
α_1-Adrenoceptor, subtype; Heart; Thyroxine treatment (Han, C. (294) 593)

CNTF (ciliary neurotrophic factor receptor α); cAMP; NB41A3 cell; PC12 cell (MacLennan, A.J. (295) 103)

Preprotachykinin; Polymerase chain reaction; C-fiber activation; Release (Wang, Z.-Y. (297) 157)

β-Adrenoceptor; Hybridisation, in situ; Northern blot analysis (Mak, J.C.W. (302) 215)

Endotoxin; Nitric oxide (NO) synthase; Septic shock; Plasma nitrate; Heart, rat (Bateson, A.N. (303) 141)

Nodose ganglion; Guanylate cyclase; Electrophysiology; Enzyme; Nitric oxide (NO) (Lawrence, A.J. (315) 127)

mRNA expression
Nitric oxide (NO) synthase; Adenosine; Anti-inflammatory; Nitric oxide (NO) (Moochhala, S.M. (316) 287)

RO15-4513
Ethanol; $GABA_A$/benzodiazepine receptor complex; Ethanol dependence/withdrawal (Becker, H.C. (296) 43)

Ro 15-4513
$GABA_A$ receptor; Benzodiazepine; Flunitrazepam; Hydroxylamine (Duncalfe, L.L. (298) 313)

Ro 47-0203
Endothelin receptor antagonist; Endothelin receptor subtype; Bronchus, human; Trachea, guinea-pig; BQ123; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

Rolipram
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Motapizone; Zaprinast; Zardaverine (Wagner, U. (298) 265)

TNF (tumor necrosis factor-α); Cicaprost; Prostaglandin E_2 (Greten, T.F. (299) 229)

cAMP; Behavioral sensitization; Methamphetamine; Microdialysis, in vivo (Iyo, M. (312) 163)

Rostral ventrolateral medulla
Angiotensin II; Pressor response; Medullary vasomotor neuron; Vasopressin (Sun, M.-K. (304) 63)

Rotation
β-Phenylethylamine; Dopamine; Nigrostriatal system (Barroso, N. (297) 195)

RP 62203
Fananserin; Dopamine; Dopamine D_4 receptor; 5-HT_{2A} receptor; 5-HT (serotonin) (Heuillet, E. (314) 229)

RPR 104632
Glycine receptor antagonist; Glutamate; NMDA receptor-channel complex; Neurotoxicity (Boireau, A. (300) 237)

RPR-104,632
NMDA receptor; Glycine coagonist site; Desensitization; 5,7-Dichlorokynurenic acid; ACEA-1021; L-695,902; LY-294,619 (Molnár, P. (311) 311)

RS15385
Delequamine; α_2-Adrenoceptor; Lordosis; Sexual behavior, female; (Rat) (Gonzalez, M.I. (312) 1)

[^{123}I]RTI-55
Cocaine analog; Psychostimulant abuse; (Mouse) (Gatley, S.J. (296) 145)

RU 5135
SR 95531; Neuroactive steroid; Neurosteroid; $GABA_A$ receptor; Pregnenolone sulfate; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

RU38486
Immobility behaviour; Forced swim test; Antisense; S-Oligodeoxynucleotide; Glucocorticoid receptor; Central nervous system (Korte, S.M. (301) 19)

Ruthenium red
Ca^{2+} store; Ryanodine; Heparin; Thapsigargin; cGMP (Duridanova, D.B. (298) 159)

Heart, rat; Preconditioning; Capsaicin; CGRP (calcitonin gene-related peptide); CGRP-(8–37) (Li, Y.-J. (311) 163)

RX821002
α_2-Adrenoceptor subtype; Brain, human; Autoradiography; Frontal cortex; Hippocampus (Grijalba, B. (310) 83)

α_2-Adrenoceptors; Imidazoline binding sites; Kidney, rat (Callado, L.F. (316) 359)

Ryanodine
Ca^{2+} store; Heparin; Thapsigargin; Ruthenium red; cGMP (Duridanova, D.B. (298) 159)

Sarcoplasmic reticulum; Ca^{2+}-buffering function; Ca^{2+} channel, voltage-dependent; Arterial myogenic tone; Cerebral artery; (Dog) (Asano, M. (311) 53)

σ Receptor; Inositol 1,4,5-trisphosphate) (Tsao, L.-I. (311) R1)

Ca^{2+} store; Mn^{2+} influx; Ileum, rat; Thapsigargin (Tabo, M. (313) 151)

Ryanodine receptor
Synaptosome; Hippocampus; Ca^{2+}, intracellular; Subcellular localization (Padua, R.A. (298) 185)

Ryanodine store
Forskolin; 1,9-Dideoxyforskolin; Ca^{2+} current; Action potential; Cerebellar granule cell (Zerr, P. (303) 101)

S12813-4
Colonic inflammation; Visceral nociception; Clonidine; Antinociceptive effect; Noradrenergic mechanism (Miampamba, M. (308) 251)

S 14506
Haloperidol; Clozapine; BMY 14802; BMS-181100; Methylphenidate; Flesinoxan; Buspirone; Gnawing; 5-HT_{1A} receptor agonist; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin) (Kleven, M. (313) 25)

S 15535
WAY 100,635; 5-HT_{1A}; [^{35}S]GTPγS binding; (±)-8-OH-DPAT ((±)-hydroxy-2-(di-*n*-propylamino)tetralin) (Newman-Tancredi, A. (307) 107)

SA4503
σ_1 Receptor agonist; Antidepressive effect; Forced swimming test; (Mouse) (Matsuno, K. (312) 267)

SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride)
σ_1 Receptor subtype; Agonistic property; Competitive inhibition (Matsuno, K. (306) 271)

(*R*)-Saclofen
$GABA_B$ receptor; (*R,S*)-Baclofen (Kerr, D.I.B. (308) R1)

Salbutamol
Bt_2 cAMP (N^6,2′-*O*-dibutyryl adenosine 3′:5′-cyclic monophosphate); Allergic pleurisy (Diaz, B.L. (296) 173)

Saphenous vein, human
Vasoconstrictor sympathetic nerve; Nitric oxide (NO); L-N^{ω}-Nitro-L-arginine (L-NNA); cGMP (Fabi, F. (309) 41)

Sarafotoxin
Endothelin; Big endothelin-1; Inositol phosphate; Spinal cord; Endothelin ET_A receptor (Poulat, P. (315) 327)

Sarafotoxin S6c
IRL 1720; Endothelin ET_B receptor; FR139317; Hemodynamics (Kuwahara, M. (296) 55)

Endothelin receptor antagonist; Endothelin receptor subtype; Bronchus, human; Trachea, guinea-pig; Ro 47-0203; BQ123; Endothelin-1 (Gater, P.R. (304) 123)

Sarcoplasmic reticulum
Ryanodine; Ca^{2+}-buffering function; Ca^{2+} channel, voltage-dependent; Arterial myogenic tone; Cerebral artery; (Dog) (Asano, M. (311) 53)

Ca^{2+}; Myocardium; Dantrolene; Ca^{2+} indicators; Aequorin (Meissner, A. (316) 333)

Sauvagine
Urotensin I; CRF (corticotropin-releasing factor) receptor; Extravasation; Inflammation; ACTH (adrenocorticotropin) (Turnbull, A.V. (303) 213)

SB 200646A
5-HT_{2A} receptor; 5-HT_{2C} receptor; Quipazine; MK-212; MDL 100,907; Corticosterone, serum; (Rat) (Hemrick-Luecke, S.K. (311) 207)

SB 204070
5-HTP (5-hydroxytryptophan); 5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; 5-HT_4 receptor; Defecation; (Mouse) (Banner, S.E. (308) 181)

SB 204269
Anticonvulsant; Brain binding site (Herdon, H. (314) R7)

SC-54417
Ventricular function; Preload recruitable stroke work; Diastolic function; Isovolumic relaxation; Superoxide dismutase; SC-55858 (Lowe, D. (304) 81)

SC-55858
Ventricular function; Preload recruitable stroke work; Diastolic function; Isovolumic relaxation; Superoxide dismutase; SC-54417 (Lowe, D. (304) 81)

Scavenging
Free radical; Hydrogen peroxide; Non-steroidal anti-inflammatory drug; Horseradish peroxidase; Glutathione peroxidase (Parij, N. (311) 259)

SCH 23390
Dopamine; Haloperidol; MK-801; Self-stimulation (Olds, M.E. (306) 23)

Dopamine D_1 receptor; Development; Locomotor activity; SKF 38393; (Rat) (Shieh, G.-J. (311) 103)

5-HT_{1A} receptor; Noradrenaline; Dopamine D_1 receptor; Microdialysis; 8-OH-DPAT (8-hydroxy-2-(di-*N*-propylamino)tetralin) (Hajós-Korcsok, É. (314) 285)

Schizophrenia
Adenosine receptor agonist; Dopamine receptor antagonist; Behavioral interaction; Catalepsy (Kafka, S.H. (295) 147)

σ Receptor; Behavioral sensitization; Cocaine; BMY-14802; SR-31742A (Ujike, H. (296) 123)

Glutamate; Dentate gyrus; Dizocilpine; In situ hybridization (Healy, D.J. (306) 257)

σ Receptor; Dopamine D_4 receptor (Helmeste, D.M. (314) R3)

Sciatic nerve blood flow
Cilostazol; Otsuka Long-Evans Tokushima Fatty rat; Motor nerve conduction velocity; R-R interval, coefficient of variation; Platelet aggregation; 2,3-Diphosphoglycerate (Hotta, N. (313) 201)

Scopolamine
Medial septum lesion; Aging; Metrifonate; Spatial navigation; Passive avoidance (Riekkinen Jr., P. (309) 121)

Ginsenoside; Maze; (Rat) (Yamaguchi, Y. (312) 149)

σ_1 Receptor agonist; Cognitive enhancer; Basal forebrain lesion; Passive avoidance task; SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride); (Rat) (Senda, T. (315) 1)

(±)-SDZ NVI 085
Blood vessel; 5-HT_{2A} receptor; α_1-Adrenoceptor (Lachnit, W.G. (297) 83)

Second messenger
Dopamine transporter; Dopamine uptake; WIN 35,428 binding; Arachidonic acid; Protein kinase C (Zhang, L. (315) 345)

Secretin
Synaptosome; Isoproterenol; cAMP; VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Kurjak, M. (314) 165)

Secretion
Intestinal; 5-HT receptor; Short-circuit current; cAMP (Budhoo, M.R. (298) 137)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor; Colon; Mucosa; (Human) (Borman, R.A. (309) 271)

Secretoneurin
Fibroblast; Migration; Proliferation (Kähler, C.M. (304) 135)

Sedative
N^3-Phenacyluridine; Hypnotic; Central nervous system; Benzodiazepine receptor (Kimura, T. (311) 265)

Seizure
Lithium chloride; Tacrine; Nitric oxide (NO); Citrulline; L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (294) 341)

Adenosine receptor; Adenosine A_1 receptor agonist; Adenosine A_{2A} receptor agonist; Pentylenetetrazole; (Rat) (Adami, M. (294) 383)

Hippocampus; Cell death; Learning disorder; (Rat) (Lahtinen, H. (297) 213)

GABA (γ-aminobutyric acid); Excitatory amino acid; Ischemia; Neurological disorder; Drug screening; Antiepileptic (Kanthasamy, A.G. (297) 219)

5-HT (5-hydroxytryptamine, serotonin); Fluoxetine; Genetically epilepsy-prone rat; Substantia nigra (Statnick, M. (299) 93)

4-Aminopyridine; NMDA receptor antagonist; Excitatory amino acid neurotransmission (Morales-Villagrán, A. (305) 87)

Substantia nigra; GABA (γ-aminobutyric acid); $GABA_A$ receptor; Development; (Rat) (Velíšková, J. (309) 167)

K^+ channel; Ca^{2+} channel; Hippocampus; Levcromakalim; Patch clamp (Katsumori, H. (311) 37)

NMDA receptor antagonist; CGP 40116; CGP 43487; Ca^{2+} channel inhibitor; Flunarizine; Nicardipine; Nifedipine (Gasior, M. (312) 27)

Seizure threshold
NNC 14-0185; NNC 14-0189; Benzodiazepine receptor; Epilepsy (Jackson, H.C. (308) 21)

Selective breeding
Antidepressant; Depression, animal model (Vaugeois, J.-M. (316) R1)

Selective serotonin reuptake inhibitor (SSRI)
5-HT_{1A} autoreceptor antagonism; (−)-Pindolol; Buspirone; Citalopram; 5-HT (5-hydroxytryptamine, serotonin), extracellular; Microdialysis, in vivo (Hjorth, S. (303) 183)

Selectivity
Muscarinic receptor; Acetylcholine; Spare receptor; Adenylate cyclase (Heldman, E. (297) 283)

Selegiline
MPP^+ (1-methyl-4-phenylpyridinium); Astrocyte; Neuronal culture (Koutsilieri, E. (306) 181)

Astrocyte, cultured; Hippocampal cell; Excitotoxicity; Protection; Cerebral ischemia; Nerve growth factor (NGF) (Semkova, I. (315) 19)

Self-administration
Cocaine; Heart rate; Blood pressure (Ambrosio, E. (315) 43)

Self-administration, i.v.
Cocaine; Nimodipine; BayK 8644; (Rat); (Mouse) (Kuzmin, A. (295) 19)

Self-stimulation
Dopamine; Haloperidol; MK-801; SCH 23390 (Olds, M.E. (306) 23)

Seminal vesicle protein
Transglutaminase; Polymorphonuclear leukocyte migration; Air-pouch inflammation (Mancuso, F. (312) 327)

Semotiadil
Ventricular hypertrophy, right; Media thickening; Pulmonary hypertension (Takahashi, T. (295) 229)

Senna
Nitric oxide (NO); Cascara; Anthraquinone; Laxative; Intestinal secretion (Izzo, A.A. (301) 137)

Sensitization
Cocaine; Enkephalin; δ-Opioid receptor; Naltrindole (Heidbreder, C. (298) 207)

Morphine; Opioid; Psychostimulant; Conditioned reward; Place preference conditioning (Shippenberg, T.S. (299) 33)

Cocaine; Reverse tolerance (Wise, R.A. (307) 15)

Monosialoganglioside; Ethanol; Locomotor activity (Bellot, R.G. (313) 175)

Dopamine; Ethanol; Nicotine; Nicotinic acetylcholine receptor; Preference; (Rat) (Blomqvist, O. (314) 257)

Nicotine; D-CPPene (SDZ EAA 494; Dopamine, mesoaccumbens; Locomotor activity; 3-(2-carboxypiperazin-4-yl)-1-propenyl-1-phosphonic acid) (Balfour, D.J.K. (316) 153)

Sepsis
Indomethacin; Gram-negative sepsis; TMF (tumor necrosis factor); Cyclooxygenase inhibitor (Campanile, F. (307) 191)

Septic shock
Endotoxin; DNA fragmentation; K^+ channel; Systemic inflammatory response syndrome; Cerebral malaria (Gantner, F. (294) 353)

Endotoxin; Nitric oxide (NO) synthase; mRNA; Plasma nitrate; Heart, rat (Bateson, A.N. (303) 141)

L-Arginine; Nitric oxide (NO); Nitric oxide (NO) synthase; Lipopolysaccharide; Mesenteric vascular bed; (Rat) (Mitolo-Chieppa, D. (309) 175)

Septide
Substance P; Tachykinin NK_1 receptor antagonist; Superior cervical ganglion, rat, isolated; (Subtype); (Conformation) (Hawcock, A.B. (294) 163)

Septum, lateral
Haloperidol; Clozapine; Fos-protein; Cross-tolerance; Nucleus accumbens (Sebens, J.B. (315) 269)

Serine
Phosphoserine phosphatase; L-AP3 (L-2-amino-3-phosphonopropionic acid); D-AP3 (D-2-amino-3-phosphonopropionic acid); Glycine (Hawkinson, J.E. (307) 219)

Serine esterase
Anti-allergic drug; α-Chymotrypsin; Histamine; Mast cell (Emadi-Khiav, B. (295) 243)

Serotoninergic axon terminal
NMDA receptor; 5-HT autoreceptor; Presynaptic receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Cerebral cortex, guinea-pig (Fink, K. (300) 79)

Sertraline
Glutamic acid decarboxylase mRNA; Hybridization, in situ; Brain (Giardino, L. (312) 183)

Serum lipid
Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Insulin; Carnitine; Sorbitol; Diabetic retinopathy (Hotta, N. (311) 199)

Sex hormone, female
Uterus, rat; Diazepam; 4'-Chlorodiazepam; Clonazepam; PK 11195; Ca^{2+} channel (Yiu, M.-k. (302) 99)

Sexual behavior
Nitric oxide (NO); Nitric oxide (NO) synthase; Paraventricular nucleus; (Rat) (Benelli, A. (294) 505)

Sexual behavior, female
Delequamine; RS15385; α_2-Adrenoceptor; Lordosis; (Rat) (Gonzalez, M.I. (312) 1)

[^{35}S]GTPγS binding
GR127935; 5-$HT_{1D\alpha}$ receptor; 5-$HT_{1D\beta}$ receptor; cAMP accumulation; Receptor reserve (Watson, J.M. (314) 365)

Shell
Morphine; Deoxyglucose; Nucleus accumbens; Drug abuse (Orzi, F. (302) 49)

Shock
Superoxide; Mitochondrial respiration; Inflammation; Endotoxin; Nitric oxide (NO) (Szabó, C. (315) 221)

Short-circuit current
Intestinal; Secretion; 5-HT receptor; cAMP (Budhoo, M.R. (298) 137)

Short circuit current
Cl^-; Cl^- secretion; 5-HT receptor; Jejunum (Budhoo, M.R. (314) 109)

SH-SY5Y cell
μ-Opioid receptor; Inositol(1,4,5)trisphosphate; Phospholipase C; Tyr-D-Arg^2-Phe-sarcosine^4 (TAPS) (Smart, D. (305) 235)

Signal transducer and activator of transcription-1 (STAT1)
Nitric oxide (NO) synthase, inducible; Herbimycin A; Interferon-γ; Janus kinase; Microglia (Kitamura, Y. (306) 297)

Signal transduction
Oxatomide; RBL-2H3 cell; Exocytosis; Protein tyrosine phosphorylation; Ca^{2+} flux; Ca^{2+} channel (Paulussen, J.J.C. (312) 121)

Single channel current
Ag^+; Au^{3+}; Skeletal muscle contraction; Ca^{2+} release channel (Nihonyanagi, K. (311) 271)

Single-channel recording
K^+ channel, ATP-sensitive; Hypertension; Myocardial hypertrophy; Trypsin (Sodder, V.H. (315) 115)

Sinoatrial node
Falipamil; Alinidine; His bundle; Atrial myocardium; AV node; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (306) 93)

Sinoatrial node automaticity
Propafenone; 5-Hydroxypropafenone; His bundle automaticity; Atrial myocardium refractoriness; AV node refractoriness; Blood pressure; (Conscious intact dog); (AV-blocked dog) (Boucher, M. (315) 171)

σ Site
Opiate; (+)-Pentazocine; Red nucleus; Substantia nigra (Matsumoto, R.R. (301) 31)

Skeletal muscle
Taurine depletion; Mechanical threshold; Excitation-contraction coupling; Cl^- conductance; Ca^{2+} handling mechanism (De Luca, A. (296) 215)

K^+ channel opener; K^+ channel inhibitor; K^+ channel, ATP-sensitive; Adenosine; Diaphragm, guinea-pig (Wickenden, A.D. (302) 79)

Nicotinic receptor; Thermodynamics; *d*-Tubocurarine; Entropy; Enthalpy (Banerjee, B. (310) 13)

Skeletal muscle contraction
Ag^+; Au^{3+}; Ca^{2+} release channel; Single channel current (Nihonyanagi, K. (311) 271)

(+)-SKF10047
Ketamine hydrochloride; σ Receptor; (Guinea pig) (Jerram, A.H. (307) 269)

SKF 38393
Dopamine D_1 receptor; Development; Locomotor activity; SCH 23390; (Rat) (Shieh, G.-J. (311) 103)

SKF 99101H
Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); GR 127935; WAY 100635; 5-HT_{1D} receptor; 5-HT_{1A} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

Skin
Vascular permeability; Lipopolysaccharide; Nitric oxide (NO); Prostaglandin; (Mouse) (Fujii, E. (297) 257)

S6 kinase, 90 kDa
Insulin; Glycogen synthesis; Protein phosphatase 1G; EGF (epidermal growth factor) (Yasui, K. (316) 317)

Skin lesion, burn
2-Chloroethylethyl sulfide; Calmodulin antagonist; Anesthetic (Kim, Y.-B. (313) 107)

Skinned fiber
Ca^{2+}; Myofilament; Ca^{2+} sensitiser; EMD 57033; Rigor (Palmer, S. (294) 83)

SK-N-BE(2)C human neuroblastoma
Phospholipase C; U-73122; cAMP production; Ca^{2+} mobilization; Inositol 1,4,5-triphosphate; Neomycin (Suh, B.-C. (314) 235)

Sleep EEG (electroencephalogram)
Caffeine; Adenosine; Sleep regulation; (Rat) (Schwierin, B. (300) 163)

Sleep regulation
Caffeine; Adenosine; Sleep EEG (electroencephalogram); (Rat) (Schwierin, B. (300) 163)

Slow-onset potentiation
Hippocampus; Long-term potentiation; 1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid); MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Metabotropic glutamate receptor; Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

Slow wave
Stomach; Smooth muscle, gastric; Membrane potential; Junction potential; Trimebutine (Xue, L. (294) 75)

SM-9018
Antipsychotic; Haloperidol; c-*fos* mRNA; 5-HT_2 receptor; Striatum (Ishibashi, T. (303) 247)

SM-10902 ointment
Wound healing; Prostacyclin analog; Blood flow, skin; Angiogenesis; Diabetic mouse (*db*/*db* mouse), genitically (Yamamoto, T. (302) 53)

Small intestine
Cisapride; Electron probe X-ray microanalysis; (Mouse) (Spencer, A.J. (303) 205)

Small intestine, guinea-pig
Neurotensin; Peristalsis; Apamin (Ohashi, H. (301) 129)

Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; SR141716A; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation (Pertwee, R.G. (315) 195)

Smooth muscle
σ Binding site; Ileum; σ Receptor subtype; (Guinea pig); (Rat) (Kinney, G.G. (294) 547)

Ketotifen; Intestine; Noradrenaline; Nitric oxide (NO) (Abu-Dalu, R. (309) 189)

Contraction; Phospholipase C; Muscarinic; G-protein; Antibody (Cuq, P. (315) 213)

Smooth muscle, airway
EGF (epidermal growth factor); Leukotriene; Tyrosine kinase; Phospholipase A_2 (Nasuhara, Y. (296) 161)

Halothane; Ca^{2+}, intracellular; Ca^{2+} sensitivity (Kai, T. (315) 313)

Smooth muscle cell
Endothelial cell; Diabetes mellitus; Atherosclerosis; Aminoguanidine; Glutathione; Aldose-reductase (Graier, W.F. (294) 221)

K^+ channel, Ca^{2+}-dependent; Cl^- channel, Ca^{2+}-dependent; Patch clamp; Trachea (Henmi, S. (306) 227)

Angiotensin II; Thromboxane A_2; c-fos (Sachinidis, A. (307) 121)

Glyceryl trinitrate; Nitrite; Nitrate tolerance; Platelet; Vascular (Weber, A.-A. (309) 209)

Atherosclerosis; Cell proliferation; Cytokine; Gap junctional intercellular communication; Growth factor (Mensink, A. (310) 73)

Smooth muscle cell, aortic
Na^+,K^+ATPase, activity; Dopamine; Dopamine receptor; Dopamine signal transduction; Smooth muscle, vascular; (Rat) (Rashed, S.M.K. (305) 223)

Smooth muscle cell proliferation
Tranilast; Photochemically induced thrombosis; Endothelial injury; Intimal thickening (Kikuchi, S. (295) 221)

Smooth muscle cell, rat, vascular
DNA synthesis; Cell cycle; Osthole; (*Angelica pubescens*) (Guh, J.-H. (298) 191)

Smooth muscle cell, vascular
Nuclear factor κB; Tetrahydrobiopterin; GTP cyclohydrolase I; Nitric oxide (NO); (Rat) (Hattori, Y. (296) 107)

Angiotensin AT_1 receptor; Cell growth; Arteriosclerosis (Nickenig, G. (297) 307)

Diabetes; Interleukin-1β; Growth; Nitric oxide (NO) (Etienne, P. (311) 79)

Smooth muscle cells, vascular
Dipyridamole; Nitric oxide (NO); Interleukin-1β; Cyclic nucleotide (Iimura, O. (296) 319)

Smooth muscle, esophageal, rat
β/β_3-Adrenoceptor, atypical; β_3-Adrenoceptor; Trimetoquinol; Isomeric activity ratio; BRL 37344 (Lezama, E.J. (308) 69)

Smooth muscle, gastric
Stomach; Membrane potential; Junction potential; Slow wave; Trimebutine (Xue, L. (294) 75)

Local anesthetic; Pentacaine; Pentacaine derivative; (Guinea-pig) (Mai, M.P. (315) 305)

Smooth muscle, uterine
Mitogen-activated protein kinase; Steroid; Estradiol; Progesterone (Ruzycky, A.L. (300) 247)

Protein kinase C; Cardiac muscle; Steroid; Estradiol; Progesterone (Ruzycky, A.L. (313) 257)

Smooth muscle, vascular
Endothelin; Endothelin receptor; Protein kinase C; Ca^{2+} sensitization (Sudjarwo, S.A. (294) 261)

Nucleotide receptor; ATP receptor; UTP receptor; Aorta, rat; Endothelium (García-Velasco, G. (294) 521)

α_2-Adrenoceptor; Phospholipase D; Tyrosine kinase; $pp60^{v\text{-}src}$; Hypertension; Protein kinase C (Jinsi, A. (302) 183)

Na^+,K^+ATPase, activity; Dopamine; Dopamine receptor; Dopamine signal transduction; Smooth muscle cell, aortic; (Rat) (Rashed, S.M.K. (305) 223)

Ca^{2+}; Protein kinase C, cytosolic; Protein kinase C, particulate (Bazan, E. (311) 101)

CP-060*S*; Ca^{2+} overload; Veratridine; Cardiomyocyte; Ca^{2+} channel (Tamura, K. (312) 195)

Smooth muscle contraction
Jejunum, rat; 5-ht_7 receptor; 5-HT_3 receptor; Neurokinin, tachykinin NK_2 receptor; 5-HT (5-hydroxytryptamine, serotonin) (McLean, P.G. (312) 215)

Smooth muscle relaxation
Trachea; Endothelin; Charybdotoxin; Nitric oxide (NO); (Guinea-pig) (Hadj-Kaddour, K. (298) 145)

SMS 201-995
Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; Somatostatin receptor subtype; Gastric acid secretion; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Social behavior
Myocardial infarction; Quality of life; Anxiety; Exploration; (Rat) (Schoemaker, R.G. (298) 17)

Social memory, rat
Social recognition; Oxytocin; PLG (prolyl-leucyl-glycinamide); Neurohypophyseal hormone; Structure activity (Popik, P. (308) 113)

Social recognition
Social memory, rat; Oxytocin; PLG (prolyl-leucyl-glycinamide); Neurohypophyseal hormone; Structure activity (Popik, P. (308) 113)

Sodium fluoride
Carbachol; (−)-N^6-Phenylisopropyl-adenosine; Phosphatase; Inotropy (Neumann, J. (294) 451)

Sodium nitroprusside
Levcromakalim; Aorta, rat; Chronic treatment; Tolerance (Trongvanichnam, K. (303) 39)

Nitric oxide (NO) synthase; Arterial pressure, systemic; Acetylcholine; 7-Nitroindazole (Zagvazdin, Y. (303) 61)

Endothelium; Albumin transfer; Hydrogen peroxide; Glyceryl trinitrate (McQuaid, K.E. (307) 233)

Platelet; Endothelin-3; cGMP; Phosphodiesterase inhibitor; Ca^{2+}, cytosolic; Ca^{2+} pump (Gagnet, C. (310) 67)

Pulmonary artery; Prostaglandin E_1; ATP; Acetylcholine; Tolazoline; Nifedipine (Pérez-Vizcaíno, F. (314) 91)

Solubilization
σ Receptor; Liver, rat; CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate); (+)-Pentazocine; DTG (1,3-di-*o*-tolylguanidine) (Torrence-Campbell, C. (304) 201)

Solution hybridization
Methadone; CRF type 1 receptor; Corticosterone; POMC (proopiomelanocortin); CRF (corticotropin-releasing factor) (Zhou, Y. (315) 31)

Soman
Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Toxogonin; Oxime; Phosphorylation; Protein kinase inhibitor (Aas, P. (301) 59)

Somatostastin receptor
α-Casomorphin; β-Casomorphin; Opioid receptor; Receptor subtype; Breast cancer cell, T47D (Hatzoglou, A. (310) 217)

Somatostatin analog
Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; SMS 201-995; Somatostatin receptor subtype; Gastric acid secretion; Brain; (Rat) (Martínez, V. (296) 153)

Somatostatin receptor subtype
Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; SMS 201-995; Gastric acid secretion; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Autoradiography; Brain, rat; Ontogeny (Thoss, V.S. (297) 145)

Somatostatin sst_2 receptor
Somatostatin sst_3 receptor; Somatostatin sst_5 receptor; SMS 201-995; Somatostatin receptor subtype; Gastric acid secretion; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Somatostatin sst_3 receptor
Somatostatin sst_2 receptor; Somatostatin sst_5 receptor; SMS 201-995; Somatostatin receptor subtype; Gastric acid secretion; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Somatostatin sst_5 receptor
Somatostatin sst_2 receptor; Somatostatin sst_3 receptor; SMS 201-995; Somatostatin receptor subtype; Gastric acid secretion; Brain; Somatostatin analog; (Rat) (Martínez, V. (296) 153)

Sorbitol
Streptozotocin-induced diabetes, rat; Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Insulin; Carnitine; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Spare receptor
Muscarinic receptor; Acetylcholine; Adenylate cyclase; Selectivity (Heldman, E. (297) 283)

Agonist affinity; Agonist-antagonist combination, fixed; Carbachol; Tripitramine; (New methods) (Venter, D.P. (303) 235)

Sparteine
Antiarrhythmic activity; Ischemic arrhythmia; BRB-I-28; Patch-clamp (Pugsley, M.K. (294) 319)

Spatial learning
Dextromethorphan; NMDA receptor; Memory; Water maze (Bane, A. (302) 7)

Spatial memory
Cerebral ischemia; Adenosine receptor; Water maze; (Gerbil) (Von Lubitz, D.K.J.E. (302) 43)

Spatial navigation
Aging; Alzheimer's disease; 5-HT (5-hydroxytryptamine, serotonin); Nicotine; Tetrahydroaminoacridine (Riekkinen, M. (308) 243)

Scopolamine; Medial septum lesion; Aging; Metrifonate; Passive avoidance (Riekkinen Jr., P. (309) 121)

Species difference
Linopirdine; DuP 996; Brain; Membrane binding (Höfner, G. (298) 307)

Heart; Adenosine receptor; β-Adrenoceptor; (Guinea pig); (Pig); (Rabbit); (Rat) (Musser, B. (308) 357)

Spectral analysis
Blood pressure variability; HOE 140; Losartan; Renal hypertension (Ponchon, P. (297) 61)

Sphincter of Oddi
Nitric oxide (NO); Hypercholesterolemia (Szilvassy, Z. (301) R17)

Spider venom
Ca^{2+} channel blocker; K^+ channel blocker; Endothelin-1; Nitric oxide (NO); Hoe 140 (Costa, S.K.P. (298) 113)

Spinal cord
MK-801; Morphine tolerance; NMDA receptor antagonist; Ventral root potential (Bell, J.A. (294) 289)

MK-801; Morphine withdrawal; Naloxone; Morphine dependence (Bell, J.A. (294) 297)

C-fiber reflex; Buprenorphine; Nociception; Diffuse noxious inhibitory control; Descending inhibitory control; Morphine (Guirimand, F. (294) 651)

Spinal reflex; $5\text{-}HT_{1A}$ receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide); Motor function (Hasegawa, Y. (295) 211)

Central hyperalgesia; Atipamezole; Medetomidine; α_2-Adrenoceptor; Neurogenic pain; Lateral reticular nucleus of the medulla (Mansikka, H. (297) 19)

Adenosine; Opioid; Synergy (Cahill, C.M. (298) 45)

Analgesia; μ-Opioid receptor; Desipramine; α_2-Adrenoceptor; Neuropeptide (Gergen, K.A. (298) 235)

TRH (thyrotropin-releasing hormone); NMDA receptor; Nociception; 'Wind-up' (Chizh, B.A. (300) 183)

Carrageenan; c-Fos; Inflammatory pain; Niflumic acid; (+)-HA966; (Rat) (Buritova, J. (303) 91)

NMDA receptor; AMPA receptor; Hyperalgesia; (Mouse) (Brambilla, A. (305) 115)

Adenosine; Adenosine kinase; Adenosine deaminase (Golembiowska, K. (307) 157)

Excitatory amino acid; NMDA (*N*-methyl-D-aspartate); MK-801 binding (Souverbie, F. (307) 347)

[^{3}H]Noradrenaline release; NMDA receptor subtype (Klarica, M. (308) 135)

Dorsal horn; Intermediolateral cell column; Immunohistochemistry; Hyperalgesia; Tail-flick; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

Adenosine, pharmacology; Antinociception; Allodynia; (Mouse) (Keil II, G.J. (312) 7)

α_1-Adrenoceptor subtype; BMY 7378; 5-Methyl-urapidil; [^{3}H]Prazosin; (Rat) (Wada, T. (312) 263)

Paired pulse facilitation; Muscle relaxant; EPSC (excitatory postsynaptic current); IPSC (inhibitory postsynaptic current); (Slice) (Tanabe, M. (313) 187)

Blood pressure; Hypertension; Muscarinic receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester (L-NAME) (Feldman, D.S. (313) 211)

Endothelin; Sarafotoxin; Big endothelin-1; Inositol phosphate; Endothelin ET_A receptor (Poulat, P. (315) 327)

Mivazerol; α_2-Adrenoceptor agonist; Heart rate; NMDA receptor (Kim, S.Y. (316) 249)

Spinal cord, adult
α_2-Adrenoceptor; Spinal cord, neonatal; Cerebral cortex; Imidazole receptor; Imidazole-preferring binding site (Savola, M.K.T. (306) 315)

Spinal cord, mouse
DTG (1,3-di(2-tolyl)guanidine); Haloperidol (Hornfeldt, C.S. (306) 15)

Spinal cord, neonatal
α_2-Adrenoceptor; Spinal cord, adult; Cerebral cortex; Imidazole receptor; Imidazole-preferring binding site (Savola, M.K.T. (306) 315)

Spinal neuron
Purinoceptor; K^+ channel; G-protein; Protein kinase C; Patch clamp; Ca^{2+} assay (Ikeuchi, Y. (302) 163)

Spinal reflex
5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide); Motor function; Spinal cord (Hasegawa, Y. (295) 211)

Spinal trigeminal nucleus oralis
Nociception; C-fiber; Morphine (Dallel, R. (314) 19)

Spin trapping
Cerebral ischemia/reperfusion; ESR (electron spin resonance); Antioxidant; Free radical scavenger (Cowley, D.J. (298) 227)

[^{3}H]Spiperone
Dopamine D_2 receptor; [^{3}H]Raclopride; [^{125}I]NCQ-298; [^{3}H]YM-09151-2; Nemonapride; Receptor binding, in vitro (Malmberg, Å. (303) 123)

Spleen, mouse
α_1-Adrenoceptor, subtypes A, B and D (Eltze, M. (311) 187)

Splenic artery
Purinergic transmission; P_{2X} purinoceptor; α_2-Adrenoceptor; Autoinhibition; Electrical stimulation; (Dog) (Ren, L.-M. (295) 61)

Splice variant
5-HT_4 receptor; Affinity state; Radioligand binding (Adham, N. (304) 231)

Spontaneously hypertensive rat (SHR)
α_{1D}-Adrenoceptor; α_{1A}-Adrenoceptor; BMY 7378; Artery; Wistar Kyoto rat (WKY) (Villalobos-Molina, R. (298) 257)

PAF (platelet-activating factor); Desensitization; Renal hypertensive rat (RHR); GTP-binding protein (Kamata, K. (301) 121)

Ethanol, chronic; Hypertension; Papillary muscle (Brown, R.A. (302) 61)

Spreading depression
Taurine; Adenosine transport inhibitor; Adenosine; NMDA receptor; Hippocampus (Hada, J. (305) 101)

S100 protein
β-Adrenoceptor antagonist; Propranolol; Cardiac muscle; Mg^{2+} (Nakatani, K. (315) 335)

SQ 30,741
Benextramine; Prostanoid TP receptor; Mesenteric artery, small; U46619; (Rat) (Van der Graaf, P.H. (300) 211)

SR-31742A
σ Receptor; Behavioral sensitization; Cocaine; BMY-14802; Schizophrenia (Ujike, H. (296) 123)

SR48968
Cold air; Tachykinin; Kinin; Bronchoconstriction; HOE 140; Neurogenic inflammation (Yoshihara, S. (296) 291)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Substance P; Neurokinin A; FK 888; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

FK888; Citric acid; Bronchoconstriction; Cough; Tachykinin (Yasumitsu, R. (300) 215)

SR 49059
[Arg^8]Vasopressin; [Mpa^1,D-Arg^8]Vasopressin; Kidney, isolated, perfused, rat; Vasopressin V_{1A} receptor (Barthelmebs, M. (314) 325)

SR95531
Neuroactive steroid; Neurosteroid; $GABA_A$ receptor; RU 5135; Pregnenolone sulfate; 3α-Hydroxy-5β-pregnan-20-one (Hawkinson, J.E. (304) 141)

β-Endorphin; Morphine; 5-Aminovaleric acid; Tail-flick inhibition (Suh, H.-W. (307) 141)

GABA receptor antagonist; Bicuculline; Pentobarbitone; Etomidate; Hippocampal neuron (Uchida, I. (307) 89)

SR 120107A
Neuropeptide Y Y_1 receptor antagonist; Sympathetic vasoconstriction; (Pig) (Malmström, R.E. (305) 145)

SR 141716A
Marijuana; CP 55,940; Basal ganglion; Antipsychotic (Anderson, J.J. (295) 163)

Cannabinoid receptor; Cannabinoid receptor antagonist; Vas deferens, mouse; cAMP; Adenylate cyclase (Pertwee, R.G. (296) 169)

Cannabinoid receptor antagonist; Δ^9-Tetrahydrocannabinol (Gatley, S.J. (307) 331)

Tetrahydrocannabinol; GABA (γ-aminobutyric acid) transport; Pallidal slice (Maneuf, Y.P. (308) 161)

Cannabinoid; Cannabis; Ultrasonic vocalization; Anxiety; CP 55,940 (McGregor, I.S. (313) 43)

Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; Vas deferens, mouse; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

SR-141,716 A
Analgesia; Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; Nor-binaltorphimine (Reche, I. (301) 75)

Analgesia; Dynorphin; Opioid; Δ^9-Tetrahydrocannabinol; Nor-binaltorphimine (Reche, I. (312) 391)

1*S*,3*R*-ACPD (1*S*,3*R*-aminocyclopentane-2,3-dicarboxylic acid)
Hippocampus; Long-term potentiation; Slow-onset potentiation; MCPG ((*R*,*S*)-α-methyl-4-carboxyphenyl-glycine); Metabotropic glutamate receptor; Dentate gyrus; (In vivo) (Manahan-Vaughan, D. (294) 497)

Staurosporine
Calphostin C; Wortmannin; Protein kinase C; Myosin light chain kinase; Aorta; (Rabbit) (Asano, M. (294) 693)

4-Aminopyridine; α_1-Adrenoceptor subtype; Chloroethylclonidine; Cardiac muscle, isolated; WB4101 (Williamson, A.P. (304) 73)

Hyperosmolarity; Protein kinase C; Genistein; Uterus, rat (Ausina, P. (312) 309)

[^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate)
$GABA_A$ receptor, recombinant; [^{3}H]Flunitrazepam; [^{3}H]Muscimol; Allosteric binding site (Zezula, J. (301) 207)

Stereoisomer
S-Nitrosocysteine; Nitric oxide (NO) (Lewis, S.J. (312) R3)

Stereoselectivity
8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); $5\text{-}HT_{1D}$ receptor (Pauwels, P.J. (300) 137)

Stereoselectivity, at muscarinic receptor
Muscarinic receptor subtype; Muscarinic receptor antagonist; Carbon analog, uncharged; BS-6181; BS-7826, (*R*)- and (*S*)-enantiomer (Waelbroeck, M. (303) 221)

Stereotyped behavior
5-HT receptor; Locomotor activity; (Rat) (Hillegaart, V. (295) 155)

Steroid
Pregnenolone sulfate; Ca^{2+}; GH3 cell; Pituitary (Büküşoğlu, C. (298) 79)

Mitogen-activated protein kinase; Smooth muscle, uterine; Estradiol; Progesterone (Ruzycky, A.L. (300) 247)

Opioid receptor; Nervous system; Neuroblastoma (Maggi, R. (301) 169)

Protein kinase C; Smooth muscle, uterine; Cardiac muscle; Estradiol; Progesterone (Ruzycky, A.L. (313) 257)

Steroidogenesis
CGRP (calcitonin gene-related peptide); Amylin; Adrenomedullin; CGRP receptor, type 2; Corticosteroid secretion; Adenylyl cyclase activity (Esneu, M. (308) 187)

Stimulus intensity
Formalin test; Caffeine; 8-Cyclopentyltheophylline; 3,7-Dimethyl-1-propargylxanthine (Sawynok, J. (298) 105)

Stimulus-secretion coupling
Sulphonylurea; Tolbutamide; Glibenclamide; Pancreatic B-cell; Insulin release; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Stomach
Smooth muscle, gastric; Membrane potential; Junction potential; Slow wave; Trimebutine (Xue, L. (294) 75)

Angiotensin II; Gastric hemodynamics; Pentagastrin; Angiotensin AT_1 receptor; Renin-angiotensin system (Chow, L. (294) 309)

5-HT (5-hydroxytryptamine, serotonin); 5-HT receptor antagonist; Contraction; Relaxation; (Guinea pig) (Tamura, T. (308) 315)

Subdiaphragmatic vagus; Nucleus tractus solitarii; Opioid receptor; (In vitro); (Neonatal rat) (Yuan, C.-S. (314) 27)

Streptozotocin-induced diabetes, rat
Electroretinogram; Oscillatory potential; Propionyl-L-carnitine; Insulin; Carnitine; Sorbitol; Diabetic retinopathy; Serum lipid (Hotta, N. (311) 199)

Stress
Hyperthermia; Temperature; Anxiety; Benzodiazepine; $5\text{-}HT_{1A}$ receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_{1B}$ receptor; 5-HT release (Bolaños-Jiménez, F. (294) 531)

Forced swim test; $5\text{-}HT_2$ receptor; Wet-dog shake; β-Adrenoceptor (Takao, K. (294) 721)

Choline acetyltransferase; Ethanol; Dexamethasone; Acetyl coenzyme A; Enzyme affinity (Wattanathorn, J. (313) 69)

D-cycloserine; Imipramine; Chronic; Anhedonia; Antidepressant action; ACPC (1-aminocyclopropanecarboxylic acid) (Papp, M. (316) 145)

Stress, acute
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Stress, chronic, mild
Depression, animal model; Pharmacological validation (Papp, M. (296) 129)

Depression, animal model; Pharmacological validation (Papp, M. (310) 99)

Stress, repeated
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Stress, uncontrollable
Naloxone; Anhedonia (Zurita, A. (299) 1)

Stretch
Cardiac hypertrophy; Myocyte; Angiotensin (Miyata, S. (307) 81)

Stretch-activated channel
Na^+ dependence; Ca^{2+} uptake; Membrane potential; Ca^{2+} channel, L-type (Ruiz-Velasco, V. (296) 327)

Striatum
Haloperidol; NMDA receptor; Non-NMDA receptor; Subsensitivity; Contralateral turning (Ossowska, K. (294) 685)

Morphine; Dopamine release; Acetylcholine release; Dopamine D_2 receptor (Nestby, P. (294) 771)

Hippocampus; Acetylcholine; Microdialysis; NMDA receptor; NMDA receptor antagonist (Hutson, P.H. (295) 45)

Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Desensitization; Protein kinase A; Protein kinase C; (Rat) (West, A.R. (298) 241)

Light extinction test; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopamine; Substantia nigra (Messaoudi, M. (299) 17)

Glutamate; Turning; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Antipsychotic; SM-9018; Haloperidol; c-*fos* mRNA; $5\text{-}HT_2$ receptor (Ishibashi, T. (303) 247)

Nucleus accumbens; Basal forebrain (Wallace, D.R. (308) 283)

Dopamine; Aromatic L-amino acid decarboxylase; Tyrosine hydroxylase; Monoamine oxidase; (Modulation) (Cho, S. (314) 51)

Imidazoline-binding site; Monoamine oxidase; *Conus* venom; (Calf) (Czerwiec, E. (315) 99)

Dopamine; β-Carboline; Uptake; Microdialysis; MPP^+ (*N*-methyl-4-phenylpyridinium) (Matsubara, K. (315) 145)

Structure-activity
Oxytocin; Neuromodulation (Poulin, P. (294) 29)

γ_2-MSH (γ_2-melanocyte-stimulating hormone); ACTH-(4–10) (adrenocorticotropic hormone-(4–10)); Blood pressure; Heart rate; Melanocortin receptor; (Rat) (Van Bergen, P. (294) 795)

Structure activity
Social recognition; Social memory, rat; Oxytocin; PLG (prolyl-leucyl-glycinamide); Neurohypophyseal hormone (Popik, P. (308) 113)

Structure-activity relationship
CRF (corticotropin-releasing factor); CRF receptor; Anti-edema; ACTH (adrenocorticotropin) (Wei, E.T. (306) 161)

Muscarinic receptor; Allosteric modulation; Heart porcine (Kostenis, E. (314) 385)

Structure-function relationship
Opioid receptor; Chimeric receptor; Mutagenesis; δ-Opioid receptor ligand (Meng, F. (311) 285)

Structure-function study
Gastrin-releasing peptide; Neuromedin B; Bombesin (Lin, J.-T. (294) 55)

Strychnine
Muscarinic receptor, heart; Muscarinic receptor, allosteric control; Allosteric interaction; Eburnamonine; Vincamine; Alcuronium (Proška, J. (305) 201)

$GABA_A$ receptor; γ_2 Subunit; Antisense oligodeoxynucleotide; Methyl-β-carboline-3-carboxylate; Picrotoxin; Convulsion (Zhao, T.-j. (306) 61)

Subarachnoid hemorrhage
Endothelium-dependent relaxation; Lipid peroxidation; AJ-3941; Nimodipine; Ca^{2+} channel antagonist (Minato, H. (315) 297)

Subcellular localization
Ryanodine receptor; Synaptosome; Hippocampus; Ca^{2+}, intracellular (Padua, R.A. (298) 185)

Subdiaphragmatic vagus
Nucleus tractus solitarii; Stomach; Opioid receptor; (In vitro); (Neonatal rat) (Yuan, C.-S. (314) 27)

Submucosal neuron
Melatonin; Nicotinic channel; Cholinergic transmission; Synaptic modulation; Enteric neuron; Nerve terminal (Barajas-López, C. (312) 319)

Submucous plexus
Gastrointestinal tract; Intestine; Ganglion; Enteric nervous system; Myenteric plexus; Gastrointestinal motility; Intestinal prokinetic drug; Benzamide, substituted (Zafirov, D. (311) 61)

Subsensitivity
Haloperidol; NMDA receptor; Non-NMDA receptor; Striatum; Contralateral turning (Ossowska, K. (294) 685)

Substance dependence
Pentobarbital; $GABA_A$ receptor; Benzodiazepine binding; Drug tolerance (Suzuki, T. (295) 169)

Substance P
Carbamazepine; Edema; Inflammatory hyperalgesia; Nociception; Prostaglandin (Bianchi, M. (294) 71)

Septide; Tachykinin NK_1 receptor antagonist; Superior cervical ganglion, rat, isolated; (Subtype); (Conformation) (Hawcock, A.B. (294) 163)

Bronchoconstriction; Airway neurogenic inflammation; Neurokinin A; Capsaicin (Robineau, P. (294) 677)

Neutrophil; Superoxide production; Ca^{2+}, intracellular; Phosphoinositide (Tanabe, T. (299) 187)

Capsaicin treatment, neonatal; Superfusion; Autoradiography; Glutamate receptor; $GABA_B$ receptor (Teoh, H. (302) 27)

Neurokinin A; Tachykinin NK_1 receptor; Nociception; Analgesia; Hyperalgesia (Yashpal, K. (308) 41)

Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Neurokinin A; FK 888; SR 48968; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Autoradiography; NK_2 receptor; Airway; [^{125}I][Lys^5,Tyr(I$_2$)^7,MeLeu^9, Nle^{10}]Neurokinin A-(4–10) (Strigas, J. (311) 177)

Respiratory rhythm; Tachykinin; (In vitro); (Newborn rat) (Monteau, R. (314) 41)

Superoxide; Neutrophil; CGRP (calcitonin gene-related peptide) (Tanabe, T. (314) 175)

$5\text{-}HT_3$ receptor; Bezold-Jarisch reflex; Capsaicin; (+)-Tubocurarine (Malinowska, B. (315) 159)

Substantia nigra
Light extinction test; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Dopamine; Striatum (Messaoudi, M. (299) 17)

Seizure; 5-HT (5-hydroxytryptamine, serotonin); Fluoxetine; Genetically epilepsy-prone rat (Statnick, M. (299) 93)

Opiate; (+)-Pentazocine; σ Site; Red nucleus (Matsumoto, R.R. (301) 31)

Seizure; GABA (γ-aminobutyric acid); $GABA_A$ receptor; Development; (Rat) (Velíšková, J. (309) 167)

Substitution
Ca^{2+} channel, L-type; Nimodipine; Ethanol; Drug discrimination; Conditioned taste aversion (De Beun, R. (306) 5)

Subtype selectivity
Molecular modeling; Three-dimensional structure; $5\text{-}HT_{2C}$ receptor; Receptor binding (Kristiansen, K. (306) 195)

Subunit
Glutamate receptor; BHK cell; cDNA; AMPA (α-amino-3-hydroxy-5-methyl-isoxalazole-4-propionate) (Andersen, P.H. (311) 95)

γ_2 Subunit
$GABA_A$ receptor; Antisense oligodeoxynucleotide; Methyl-β-carboline-3-carboxylate; Strychnine; Picrotoxin; Convulsion (Zhao, T.-j. (306) 61)

Successive negative contrast
Animal model; Anxiety; Chlorpromazine; Diazepam; One-way avoidance; Thiopental sodium (Torres, C. (314) 269)

6-Sulfatoxymelatonin
Pharmacokinetics; Melatonin; Continuous light; Circadian rhythm; (Intravenous) (Deprés-Brummer, P. (312) 171)

Sulfonylurea
Antinociception; 5-HT_{1A} receptor; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); ATP-sensitive K^+ channel; Gliquidone; Cromakalim; Receptor binding (Robles, L.-I. (295) 181)

Tolbutamide; Glibenclamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Afterhyperpolarization; K^+ channel, Ca^{2+}-dependent (Erdemli, G. (304) 37)

Glimepiride; KK-Ay mouse (Takada, Y. (308) 205)

8-Sulphophenyltheophylline
P_1 purinoceptor; P_2 purinoceptor; Trachealis muscle, guinea-pig, isolated; Suramin; Adenosine 5′-triphosphate (Piper, A.S. (307) 183)

Sulpiride
ATP-sensitive K^+ channel; Nicorandil; Cromakalim; Dopamine autoreceptor; Microdialysis (Tanaka, T. (297) 35)

Conditioned place preference; Raclopride; Dopamine; Dopamine D_2 receptor; Lordosis (Meisel, R.L. (309) 21)

***l*-Sulpiride**
Dopamine neuron; Desipramine; Autoreceptor; Depression (Diana, M. (312) 179)

Sumatriptan
Alniditan; Ergotamine; Carotid arterial resistance (Van de Water, A. (299) 127)

Coronary artery, canine; Contraction; GR127935; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1D} receptor (Terrón, J.A. (300) 109)

5-HT_1-like receptor; Vasoconstriction; Vasoconstrictor synergy; Vascular tone; (Rabbit, anesthetised) (Choppin, A. (304) 87)

Trigeminal; Middle meningeal artery; Ergot alkaloid; Migraine (Lambert, G. (311) 141)

Antimigraine drug; Arteriovenous anastomosis; Carotid artery; GMC2021; Coronary artery, human; Migraine; (Human); (Pig) (Saxena, P.R. (312) 53)

[^{3}H]Sumatriptan
5-Carboxamidotryptamine; 5-HT_{1D} receptor; 5-HT_{1F} receptor; Metergoline; Migraine (Pascual, J. (295) 271)

Superfusion
Capsaicin treatment, neonatal; Autoradiography; Substance P; Glutamate receptor; $GABA_B$ receptor (Teoh, H. (302) 27)

Superior cervical ganglion, rat, isolated
Substance P; Septide; Tachykinin NK_1 receptor antagonist; (Subtype); (Conformation) (Hawcock, A.B. (294) 163)

Superior colliculus
Endothelin-1; Blood pressure; Renal blood flow (D'Amico, M. (316) 245)

Superoxide
Nitric oxide (NO); Peroxynitrite; GABA (γ-aminobutyric acid) release; Cerebral cortical neuron (Ohkuma, S. (301) 179)

Peroxynitrite; Nitrotyrosine; Nitric oxide (NO); Hemodynamics, in vivo (Kooy, N.W. (310) 155)

Substance P; Neutrophil; CGRP (calcitonin gene-related peptide) (Tanabe, T. (314) 175)

Peroxynitrite; Nitrotyrosine; Nitric oxide; Angiotensin II; Hemodynamics, in vivo (Kooy, N.W. (315) 165)

Mitochondrial respiration; Shock; Inflammation; Endotoxin; Nitric oxide (NO) (Szabó, C. (315) 221)

Superoxide anion
tBuBHQ (2,5-di-(tert-butyl)-1,4-benzohydroquinone); *N*-Formyl-Met-Leu-Phe; Phorbol ester; Ca^{2+}; BAPTA/AM (*O*,*O*′-bis(2-aminophenyl)ethyleneglycol-*N*,*N*,*N*′,*N*′-tetraacetic acid, tetraacetoxymethyl ester) (Tsukii, K. (298) 87)

Superoxide dismutase
Ventricular function; Preload recruitable stroke work; Diastolic function; Isovolumic relaxation; SC-55858; SC-54417 (Lowe, D. (304) 81)

Reperfusion arrhythmia; Catalase; Dimethylthiourea; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Ohoi, I. (306) 123)

Superoxide production
Substance P; Neutrophil; Ca^{2+}, intracellular; Phosphoinositide (Tanabe, T. (299) 187)

Superoxide radical
IT-066; Ischemia-reperfusion injury; Gastric mucosal acute injury; Histamine H_2 receptor antagonist; Hydroxyl radical (Naito, Y. (294) 47)

Cystathionine; Ischemia-reperfusion; Gastric mucosal injury; (Rat) (Wada, K. (294) 377)

Leukocyte, human; Cystathionine (Wada, K. (296) 335)

Suprachiasmatic nucleus
Melatonin; Intergeniculate leaflet; Electrophysiology; Light; Circadian rhythm; Entrainment (Ying, S.-W. (296) 33)

Suramin
Neuromuscular transmission; P_2 purinoceptor; Non-depolarizing neuromuscular relaxant; Ca^{2+} channel (Henning, R.H. (301) 91)

P_1 purinoceptor; P_2 purinoceptor; Trachealis muscle, guinea-pig, isolated; 8-Sulphophenyltheophylline; Adenosine 5′-triphosphate (Piper, A.S. (307) 183)

P_{2x} purinoceptor; ATP; Portal vein, guinea-pig (Orre, M. (316) 229)

Sympathetic nerve
6-Hydroxydopamine; Mast cell; Dorsal skin (Cambridge, H. (301) 151)

Sympathetic nerve activity
α_1-Adrenoceptor antagonist; Doxazosin; Terazosin; Bladder; (Anesthetized cat) (Ramage, A.G. (294) 645)

Sympathetic nervous system
Neuropeptide Y; Pulmonary edema; Capillary permeability (Hirabayashi, A. (296) 297)

Sympathetic neuron
Histamine H_3 receptor subtype; Parasympathetic neuron; (*R*)-α-Methylhistamine (Rizzo, C.A. (294) 329)

Sympathetic neurotransmission
Cholesterol-feeding; Endothelium; P_{2X} purinoceptor; Mesenteric arterial bed, rat; Donryu rat (Ralevic, V. (313) 221)

Sympathetic vasoconstriction
Neuropeptide Y Y_1 receptor antagonist; SR 120107A; (Pig) (Malmström, R.E. (305) 145)

Synapsin
Glutamate release; Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synaptophysin; Hippocampus; Ageing (Mullany, P. (309) 311)

Synapsin I
Opiate receptor; Neuronal plasticity; Pruning effect (Gorio, A. (303) 21)

Synaptic modulation
Melatonin; Nicotinic channel; Cholinergic transmission; Submucosal neuron; Enteric neuron; Nerve terminal (Barajas-López, C. (312) 319)

Synaptic plasticity
Learning; Memory; Prostaglandin; Cyclooxygenase; Neurotransmitter; Retrograde messenger (Hölscher, C. (294) 253)

Learning; Memory; Cholinergic system; Muscarinic receptor agonist; AF102B; Oxotremorine (Iga, Y. (308) 13)

Synaptic transmission
Hippocampus; Dentate gyrus; Glutamate metabotropic receptor; Electrophysiology, in vitro; Extracellular recording (Ugolini, A. (294) 403)

Synaptophysin
Glutamate release; Protein tyrosine kinase; Ca^{2+}/calmodulin-dependent protein kinase II; Phosphorylation; Synapsin; Hippocampus; Ageing (Mullany, P. (309) 311)

Synaptosome
Ryanodine receptor; Hippocampus; Ca^{2+}, intracellular; Subcellular localization (Padua, R.A. (298) 185)

Secretin; Isoproterenol; cAMP; VIP (vasoactive intestinal polypeptide); Nitric oxide (NO) (Kurjak, M. (314) 165)

Epilepsy; Kava pyrone; *Piper methysticum*; Na^+ channel (Gleitz, J. (315) 83)

Synergy
Adenosine; Opioid; Spinal cord (Cahill, C.M. (298) 45)

Synovial cell
Human; Glucose uptake; Anti-inflammatory drug; Osteoarthritis; Rheumatoid arthritis (Hernvann, A. (314) 193)

Synthetic impurity
Methamphetamine; Illicit synthesis; NMDA receptor; Dopamine transporter; BNMPA (α-benzyl-*N*-methylphenethylamine) (Moore, K.A. (311) 133)

Systemic hemodynamics
Positive inotropic agent; Blood flow distribution; Mean circulatory filling pressure; OPC-18790 (Fujiki, H. (313) 191)

Systemic inflammatory response syndrome
Endotoxin; Septic shock; DNA fragmentation; K^+ channel; Cerebral malaria (Gantner, F. (294) 353)

Systemic morphine
Peripheral antinociception; Mononeuropathic rat; Paw pressure; κ-Opioid receptor antagonist; δ-Opioid receptor antagonist (Catheline, G. (315) 135)

T-0509
β_1-Adrenoceptor agonist; β_3-Adrenoceptor; Intrinsic activity; Adenylyl cyclase (Sato, Y. (315) 363)

T-0632
CCK_A receptor; Pancreas; Gallbladder; Amylase release; Gallbladder contraction (Taniguchi, H. (304) 147)

CCK_A receptor; Pancreatic secretion; Gallbladder contraction; Gastric emptying (Taniguchi, H. (312) 227)

Tachykinin
Urinary bladder, hamster; [^{3}H][β-Ala^8]neurokinin A-(4–10); Tachykinin, NK_2 receptor; (Binding) (Goso, C. (294) 239)

Cold air; Kinin; Bronchoconstriction; SR 48968; HOE 140; Neurogenic inflammation (Yoshihara, S. (296) 291)

Angiogenesis; Basement membrane; Neurogenic inflammation; Wound healing (Wiedermann, C.J. (298) 335)

FK888; SR48968; Citric acid; Bronchoconstriction; Cough (Yasumitsu, R. (300) 215)

5-HT_3 receptor; 5-HT_4 receptor; Colon, guinea-pig; Tetrodotoxin; Enteric nerve (Briejer, M.R. (308) 173)

Respiratory rhythm; Substance P; (In vitro); (Newborn rat) (Monteau, R. (314) 41)

Tachykinin receptor
Bradykinin receptor; CP-99,994; Formaldehyde; Mast cell; Vascular permeability (Ito, K. (307) 291)

Tachykinin receptor antagonist
Microvascular leakage; (Guinea-pig) (Biyah, K. (308) 325)

Eicosanoid; Anaphylaxis, lung (Montuschi, P. (313) R1)

Tachykinin NK_1 receptor
Niflumic acid; Cl^- channel; Colon, rabbit (Patacchini, R. (303) 197)

Substance P; Neurokinin A; Nociception; Analgesia; Hyperalgesia (Yashpal, K. (308) 41)

Tachykinin NK_2 receptor; Substance P; Neurokinin A; FK 888; SR 48968; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Emesis; Morphine; Nicotine; 5-HT_3 receptor; 5-HT_{1A} receptor; Resiniferatoxin; Vomiting; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

Tachykinin NK_1 receptor antagonist
Substance P; Septide; Superior cervical ganglion, rat, isolated; (Subtype); (Conformation) (Hawcock, A.B. (294) 163)

Emesis; CP-122,721; (Ferret) (Gonsalves, S. (305) 181)

Tachykinin NK_2 receptor
Tachykinin NK_1 receptor; Substance P; Neurokinin A; FK 888; SR 48968; Plus-maze; Anxiety; (Intracerebroventricular injection) (Teixeira, R.M. (311) 7)

Urinary bladder, hamster; [^{3}H][β-Ala^8]neurokinin A-(4–10); Tachykinin; (Binding) (Goso, C. (294) 239)

Tachyphylaxis
Peroxynitrite; Hemodynamics, In vivo (Kooy, N.W. (307) R5)

Adenosine A_3 receptor; Hemodynamics; Histamine release; 2-Chloro-N^6-(3-iodobenzyl)adenosine-5-*N*-ethylcarboxamide (2-Cl-IB-MECA); Rat, conscious (Van Schaick, E.A. (308) 311)

Tacrine
Lithium chloride; Seizure; Nitric oxide (NO); Citrulline; L-NAME (N^{ω}-nitro-L-arginine methyl ester) (Bagetta, G. (294) 341)

MF201; E2020; Physostigmine; 8-Arm radial maze; (Rat) (Braida, D. (302) 13)

Tail artery, rat
Adrenergic nerve stimulation; Noradrenaline release; Gonadectomy (García-Villalón, A.L. (314) 339)

Tail-flick
Dorsal horn; Intermediolateral cell column; Immunohistochemistry; Hyperalgesia; Spinal cord; PACAP (pituitary adenylate cyclase-activating polypeptide) (Narita, M. (311) 121)

5-HT_{1A} receptor; 5-HT syndrome; Hyperphagia; Hypothermia; 5-HT (5-hydroxytryptamine, serotonin); 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin) (O'Connell, M.T. (312) 137)

Tail-flick assay
κ-Opioid receptor; Analgesia, peripheral (Kolesnikov, Y. (310) 141)

Tail-flick inhibition
β-Endorphin; Morphine; SR 95531; 5-Aminovaleric acid (Suh, H.-W. (307) 141)

Tail-flick test
Conditioned place preference; Formalin paw test; Charcoal meal (Singh, L. (307) 283)

TAK-044
Endothelin-1; Heart, perfused, rat; BQ-123; Endothelin ET_A receptor; Endothelin ET_B receptor (Kusumoto, K. (296) 65)

Endothelin; Myocardium, stunned; (Dog) (Kitayoshi, T. (305) 137)

Tamsulosin
Electrical field stimulation; α_1-Adrenoceptor stimulation; Prostate, human (Chueh, S.-C. (305) 177)

Tardive dyskinesia
Reserpine; Oral dyskinesia; Tongue protrusion; Dopamine; 6-Hydroxydopamine; Amphetamine; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Taurine
Hypercholesterolemia; Diabetes; Endothelium; LDL (low-density lipoprotein); Cholesterol (Kamata, K. (303) 47)

Adenosine transport inhibitor; Adenosine; Spreading depression; NMDA receptor; Hippocampus (Hada, J. (305) 101)

Na^+-Ca^{2+} exchange; Ventricular myocyte, rat; Patch-clamp (Katsube, Y. (316) 97)

Taurine depletion
Skeletal muscle; Mechanical threshold; Excitation-contraction coupling; Cl^- conductance; Ca^{2+} handling mechanism (De Luca, A. (296) 215)

T cell
15-Deoxyspergualin; B cell; Monocyte; Cytokine (Nicoletti, F. (311) 213)

Temperature
Stress; Hyperthermia; Anxiety; Benzodiazepine; 5-HT_{1A} receptor agonist; Antidepressant; 5-HT (5-hydroxytryptamine, seroronin); Dopamine (Zethof, T.J.J. (294) 125)

Terazosin
α_1-Adrenoceptor antagonist; Doxazosin; Sympathetic nerve activity; Bladder; (Anesthetized cat) (Ramage, A.G. (294) 645)

Testes
2-[^{125}I]MCA-NAT (2-[^{125}I]iodo-5-methoxy-carbonylamino-*N*-acetyltryptamine); Melatonin ML_2 receptor; Melatonin; Brain, hamster; Kidney; 2-[^{125}I]Iodomelatonin (Molinari, E.J. (301) 159)

12-*O*-Tetradecanoylphorbol 13-acetate
Jatrophone; Natural killer activity; Lymphocyte proliferation; Protein kinase C; CD69; Interleukin-2 (Gonçalves de Moraes, V.L. (312) 333)

Tetrahydroaminoacridine
Aging; Alzheimer's disease; Spatial navigation; 5-HT (5-hydroxytryptamine, serotonin); Nicotine (Riekkinen, M. (308) 243)

Tetrahydrobiopterin
Nuclear factor κB; GTP cyclohydrolase I; Nitric oxide (NO); Smooth muscle cell, vascular; (Rat) (Hattori, Y. (296) 107)

Tetrahydrocannabinol
Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; WIN 55,212-2; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

GABA (γ-aminobutyric acid) transport; Pallidal slice; SR 141716A (Maneuf, Y.P. (308) 161)

Δ^9-Tetrahydrocannabinol
Analgesia; Dynorphin; Opioid; SR-141,716 A; Nor-binaltorphimine (Reche, I. (301) 75)

Cannabinoid receptor antagonist; SR141617A (Gatley, S.J. (307) 331)

Nucleus tractus solitarii; Nausea; Glucose; Catecholaminergic neuron; 5-HT_3 receptor (Himmi, T. (312) 273)

Analgesia; Dynorphin; Opioid; SR-141,716 A; Nor-binaltorphimine (Reche, I. (312) 391)

Perinatal; 5-HT (5-hydroxytryptamine, serotonin); 5-HTP (5-hydroxy-L-tryptophan); 5-HIAA (5-hydroxyindole-3-acetic acid); High-performance liquid chromatography with electrochemical detection (HPLC-ED) (Molina-Holgado, F. (316) 39)

Tetranactin
Phospholipase A_2; Interleukin 1β; cAMP; Renal mesangial cell (Walker, G. (306) 265)

Tetrodotoxin
5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Veratridine; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

Glutamate; Turning; Striatum; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

5-HT_3 receptor; 5-HT_4 receptor; Tachykinin; Colon, guinea-pig; Enteric nerve (Briejer, M.R. (308) 173)

Thalamocortical oscillation
Nicotinic acetylcholine receptor; 5-HT_2 receptor; Neocortical high-voltage spindle; (Rat) (Jäkälä, P. (299) 47)

Anticholinesterase; Muscarinic acetylcholine receptor; 5-HT_2 receptor; Neocortical high-voltage spindle; (Rat) (Jäkälä, P. (316) 181)

Thalamus
Thiamine deficiency; ATPase; Pyrithiamine; [^{3}H]Ouabain; (Rat) (Mousseau, D.D. (300) 191)

$GABA_A$ receptor; $GABA_A$ receptor subunit; Heterogeneity; Cerebellum; Diazepam-insensitive (Huh, K.-H. (310) 225)

Thalamus, ventro-basal
Enkephalin; Methylnaloxonium; RB 101; Antinociception; Amygdala; Central gray matter; Raphe magnum nucleus (Valverde, O. (312) 15)

β-Thalassemia
N-Allylsecoboldine; Antioxidant; Lipid peroxidation; Peroxyl radical; Hydroxyl radical; Hypercoagulability; Oxidative hemolysis (Teng, C.-M. (303) 129)

Thapsigargin
Ca^{2+} store; Ryanodine; Heparin; Ruthenium red; cGMP (Duridanova, D.B. (298) 159)

Opioid withdrawal; Metabotropic glutamate receptor; Protein kinase C; Inositol-1,4,5-trisphosphate; Chelerythrine (Fundytus, M.E. (300) 173)

Atrial natriuretic peptide; Hormone secretion; Mechanical stretch (Taskinen, P. (308) 295)

Ca^{2+} store; Mn^{2+} influx; Ileum, rat; Ryanodine (Tabo, M. (313) 151)

Theophylline
Mucus secretion; Trachea; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

Dopamine receptor antagonist; Grooming; (Rat) (Zarrindast, M.-R. (306) 1)

Thermal hyperalgesia
Leukotriene; NGF (nerve growth factor) (Amann, R. (306) 89)

Thermodynamic compensation
5-HT_3 receptor; Binding thermodynamics; Agonist and antagonist discrimination (Borea, P.A. (298) 329)

Thermodynamics
Nicotinic receptor; *d*-Tubocurarine; Skeletal muscle; Entropy; Enthalpy (Banerjee, B. (310) 13)

Thermoregulation
Clozapine; Dopamine; Dopamine receptor; (Rat) (Salmi, P. (307) 27)

Thiamine deficiency
ATPase; Thalamus; Pyrithiamine; [^{3}H]Ouabain; (Rat) (Mousseau, D.D. (300) 191)

Thin-slice preparation
Ventral tegmental area; OPC-14597; Extracellular recording in vivo; Whole-cell recording; Dopamine D_2 receptor (Momiyama, T. (310) 1)

Thiobarbituric acid
Apomorphine; Free radical; Lipid peroxidation; Protein carbonyl; Iron; Ascorbate (Gassen, M. (308) 219)

Thiopental sodium
Animal model; Anxiety; Chlorpromazine; Diazepam; One-way avoidance; Successive negative contrast (Torres, C. (314) 269)

Thoracic aorta
KMD-3213; α_1-Adrenoceptor subtype; α_{1a}-Adrenoceptor; Prostate (Yamagishi, R. (315) 73)

Three-dimensional structure
Molecular modeling; 5-HT_{2C} receptor; Receptor binding; Subtype selectivity (Kristiansen, K. (306) 195)

Thrombin inhibition
Urokinase variant; Fibrinolysis; Platelet aggregation; Clot specificity; (Rabbit) (Schneider, J. (302) 69)

Thrombin receptor
Phosphoinositide hydrolysis; G-protein; GTPase (Ogino, Y. (316) 105)

Thrombolysis
Ticlopidine; Anti-platelet potency; Prostacyclin; Nitric oxide (NO); Tissue plasminogen activator (Gryglewski, R.J. (308) 61)

Thrombosis
Triflavin; RGD (Arg-Gly-Asp)-containing peptide; Fibrinogen receptor antagonist; Bleeding time; Mesenteric artery (Sheu, J.-R. (294) 231)

Thromboxane
Diabetes; Hindquarters; Endothelin; Arachidonic acid; 5-HT (5-hydroxytryptamine, serotonin) (James, G.M. (294) 109)

Dietary fat; *n*–3 fatty acid; Arrhythmia; Blood pressure; Proteinuria (McLennan, P. (300) 83)

Heparin; Protamine; Platelet; PAF (platelet-activating factor); PAF-acether; BN 52021 (Aïssa, J. (302) 123)

Thromboxane A_2
W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide); ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine); G-protein; Phosphoinositide hydrolysis; Ca^{2+} (Ohkubo, S. (298) 175)

Angiotensin II; c-fos; Smooth muscle cell (Sachinidis, A. (307) 121)

Thromboxane A_2 receptor
Vascular endothelial cell, human; Protein kinase C; ICAM-1 (intercellular adhesion molecule-1) (Ishizuka, T. (312) 367)

Thromboxane A_2 receptor agonist
Resistance artery, small; Hyperthyroidism; 5-HT (5-hydroxytryptamine, serotonin); Endothelial modulation (Zwaveling, J. (300) 91)

Thromboxane A_2 synthase inhibitor
DP-1904; Heymann nephritis; Proteinuria (Nagao, T. (316) 73)

Thyroid gland
K^+ channel (Yoshida, A. (312) 115)

Thyroid-stimulating antibody
Amitriptyline; Antidepressant; TSH (thyroid-stimulating hormone) (Yoshida, A. (312) 115)

Thyroxine treatment
α_1-Adrenoceptor, subtype; mRNA; Heart (Han, C. (294) 593)

Ticlopidine
Thrombolysis; Anti-platelet potency; Prostacyclin; Nitric oxide (NO); Tissue plasminogen activator (Gryglewski, R.J. (308) 61)

Time constant
AV-node; Ajmaline; Propafenone; Rate dependence (Stark, G. (310) 29)

Time course
Benzodiazepine; Drug discrimination; Bretazenil; Chlordiazepoxide; (Rat) (Bronson, M. (305) 7)

tis1
5-HT_{1A} receptor; 5-$HT_{2A/C}$ receptor; *c-fos*; *ngf1c* (Tilakaratne, N. (307) 211)

Tissue plasminogen activator
Ticlopidine; Thrombolysis; Anti-platelet potency; Prostacyclin; Nitric oxide (NO) (Gryglewski, R.J. (308) 61)

Tissue resistance
EGF (epidermal growth factor); Mucosal protection; Receptor; Epithelium (Rao, R. (303) 209)

3T3-L1 cell
Lovastatin; Isoprenoid (Nishio, E. (301) 203)

TMF (tumor necrosis factor)
Indomethacin; Gram-negative sepsis; Cyclooxygenase inhibitor; Sepsis (Campanile, F. (307) 191)

TNF (tumor necrosis factor)
Fenspiride; Lipopolysaccharide; Alveolar macrophage, guinea-pig; Phospholipase A_2 (De Castro, C.M.M.B. (294) 669)

Neurosteroid; Glucocorticoid; Dehydroepiandrosterone sulfate; Pregnenolone (Di Santo, E. (299) 179)

CINC (cytokine-induced neutrophil chemoattractant); cAMP; Interleukin-1; Interleukin-6; Prostaglandin E_2; Prostaglandin I_2 (Oh-ishi, S. (300) 255)

TNF (tumor necrosis factor-α)
Rolipram; Cicaprost; Prostaglandin E_2 (Greten, T.F. (299) 229)

TNF-α (tumor necrosis factor α) inhibition
Adenosine A_3 receptor; Macrophage; Receptor; Cross-talk (McWhinney, C.D. (310) 209)

α-Tocopherol analog (water-soluble)
Neuroprotection; Lipid peroxidation; Antioxidant; Vitamin E; Malondialdehyde; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

Tolazoline
Pulmonary artery; Prostaglandin E_1; ATP; Acetylcholine; Nifedipine; Sodium nitroprusside (Pérez-Vizcaíno, F. (314) 91)

Tolbutamide
Sulphonylurea; Glibenclamide; Pancreatic B-cell; Insulin release; Stimulus-secretion coupling; Ca^{2+}, cytoplasmic; K^+ channel, ATP-sensitive; Islet, mouse (Garcia-Barrado, M.-J. (298) 279)

Tolerance
Agmatine; Morphine; Analgesia (Kolesnikov, Y. (296) 17)

Nicotine; Epibatidine; Antinociception; (Mouse) (Damaj, M.I. (300) 51)

Levcromakalim; Sodium nitroprusside; Aorta, rat; Chronic treatment (Trongvanichnam, K. (303) 39)

Ethanol; IGF-I (insulin-like growth factor I); IGF binding protein 1; Ataxia; Hypothermia; Hypnosis; Blood alcohol concentration; (Transgenic mouse) (Pucilowski, O. (305) 57)

Opiate; Withdrawal; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Locus ceruleus; (Mouse) (Dossin, O. (308) 271)

Cannabinoid; CP-55,940; Biotransformation; Energetic metabolism (Costa, B. (313) 17)

Nitroglycerin; Phosphodiesterase inhibitor; cGMP monophosphate; Blood pressure; Zaprinast; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Nicorandil; Aorta, rat; Relaxation; cGMP; Levcromakalim (Trongvanichnam, K. (314) 83)

Ca^{2+} channel, P-type; Antinociception, spinal; Morphine; Clonidine; G-protein (Roerig, S.C. (314) 293)

Nucleus accumbens; Dopamine; Ethanol; Microdialysis; Animal model (Nurmi, M. (315) 277)

Toluene
1,1,1-Trichloroethane; Methoxyflurane; Flurothyl; Anxiolytic; Plus-maze; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

Tongue protrusion
Reserpine; Oral dyskinesia; Dopamine; 6-Hydroxydopamine; Amphetamine; Tardive dyskinesia; Nigrostriatal; Caudate-putamen; (Rat) (Neisewander, J.L. (305) 13)

Tonic periodontal masseteric reflex
NK433; Tonic vibration reflex; Jaw opening reflex (Ozawa, Y. (298) 57)

Tonic vibration reflex
NK433; Tonic periodontal masseteric reflex; Jaw opening reflex (Ozawa, Y. (298) 57)

Toxogonin
Acetylcholine; Ca^{2+} channel; HI-6; HLö-7; Oxime; Phosphorylation; Protein kinase inhibitor; Soman (Aas, P. (301) 59)

Trachea
Neutral endopeptidase; Acetylcholine; Epithelium; Cholinergic neurotransmission; (Rabbit) (Loenders, B. (296) 89)

Smooth muscle relaxation; Endothelin; Charybdotoxin; Nitric oxide (NO); (Guinea-pig) (Hadj-Kaddour, K. (298) 145)

Mucus secretion; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Motapizone; Rolipram; Zaprinast; Zardaverine (Wagner, U. (298) 265)

K^+ channel, Ca^{2+}-dependent; Cl^- channel, Ca^{2+}-dependent; Patch clamp; Smooth muscle cell (Henmi, S. (306) 227)

Trachea, guinea-pig
Endothelin receptor antagonist; Endothelin receptor subtype; Bronchus, human; Ro 47-0203; BQ123; Endothelin-1; Sarafotoxin S6c (Gater, P.R. (304) 123)

α-Mangostin; Histamine; Histamine H_1 receptor antagonist; Aorta, rabbit (Chairungsrilerd, N. (314) 351)

Trachea, rat
β-Adrenoceptor; β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Trimetoquinol; Atrium, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

Tracheal innervation
Vagal reflex; Bronchoconstriction; (Guinea-pig) (Takahashi, Y. (302) 89)

Trachealis muscle, guinea-pig, isolated
P_1 purinoceptor; P_2 purinoceptor; Suramin; 8-Sulphophenyltheophylline; Adenosine 5′-triphosphate (Piper, A.S. (307) 183)

Tracheal spirals
Bronchoconstriction, adenosine-induced; Cross-tachyphylaxis; Xanthine antagonist resistance; Transport inhibitors; (Sensitized guinea pigs) (Thorne, J.R. (316) 263)

Tramadol
Analgesia; Cloned human receptor; Opioid receptor type (Lai, J. (316) 369)

Tranilast
Photochemically induced thrombosis; Endothelial injury; Smooth muscle cell proliferation; Intimal thickening (Kikuchi, S. (295) 221)

Transcallosal response
CGP 35348; Pyramidal tract neuron; Motor cortex; Paired-pulse method; (−)-Baclofen (Chowdhury, S.A. (314) 313)

Transcription factor
Ethanol; NMDA (*N*-methyl-D-aspartate); AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole) propionic acid); AP-1 (activator protein-1) DNA binding; Granule cell, cerebellar (Hou, Y.-N. (309) 307)

Transfected cell
Muscarinic receptor; Heparin; Receptor subtype; Allosteric interaction; Receptor coupling (Wang, S.Z. (296) 113)

Transfection
VIP receptor, human; VIP receptor antagonist; Desensitization; Internalization; Recombinant protein (Gaudin, P. (302) 207)

Transgenic mouse
Phospholipase A_2; Inflammation; Phospholipase inhibitor (Fox, N. (308) 195)

Transglutaminase
Seminal vesicle protein; Polymorphonuclear leukocyte migration; Air-pouch inflammation (Mancuso, F. (312) 327)

Transporter
Dopamine; Dopamine efflux (Kitayama, S. (309) 107)

Transport inhibitors
Bronchoconstriction, adenosine-induced; Tracheal spirals; Cross-tachyphylaxis; Xanthine antagonist resistance; (Sensitized guinea pigs) (Thorne, J.R. (316) 263)

Traumatic brain injury
Felbamate; Long-term potentiation; CA1; Hippocampus (Wallis, R.A. (294) 475)

Azelastine; Leukotriene; NMDA (*N*-methyl-D-aspartate); Hippocampus; (In vitro) (Girard, J. (300) 43)

Tremorgenic indole alkaloid
Ca^{2+}-activated K^+ channel; Charybdotoxin; Iberiotoxin; Excitation-contraction coupling (DeFarias, F.P. (314) 123)

TRH (thyrotropin-releasing hormone)
NMDA receptor; Spinal cord; Nociception; 'Wind-up' (Chizh, B.A. (300) 183)

JTP-4819; Prolyl endopeptidase; Morris water maze task; Passive avoidance task; Middle cerebral artery occlusion (Shinoda, M. (305) 31)

Triacsin C
PAF (platelet-activating factor); Arachidonic acid; Acyltransferase; Zymosan (Naraba, H. (302) 117)

1,1,1-Trichloroethane
Toluene; Methoxyflurane; Flurothyl; Anxiolytic; Plus-maze; Inhalant abuse; (Mouse) (Bowen, S.E. (312) 131)

Triflavin
RGD (Arg-Gly-Asp)-containing peptide; Fibrinogen receptor antagonist; Bleeding time; Mesenteric artery; Thrombosis (Sheu, J.-R. (294) 231)

Aurintricarboxylic acid; Von Willebrand factor; Glycoprotein IIb/IIIa; Photochemically induced thrombosis (Hisamichi, N. (312) 69)

Trigeminal
Middle meningeal artery; Ergot alkaloid; Sumatriptan; Migraine (Lambert, G. (311) 141)

Trimebutine
Stomach; Smooth muscle, gastric; Membrane potential; Junction potential; Slow wave (Xue, L. (294) 75)

Trimetoquinol
β-Adrenoceptor; β-Adrenoceptor, atypical; β_3-Adrenoceptor; Isomeric activity ratio; Atrium, rat; Trachea, rat; Distal colon, rat; Brown adipose tissue, rat (Konkar, A.A. (305) 63)

β/β_3-Adrenoceptor, atypical; β_3-Adrenoceptor; Smooth muscle, esophageal, rat; Isomeric activity ratio; BRL 37344 (Lezama, E.J. (308) 69)

α-Trinositol
Antinociception; Intrathecal; Formalin test; Behavior; (Rat) (Malmberg, A.B. (294) 609)

Tripitramine
Agonist affinity; Agonist-antagonist combination, fixed; Carbachol; Spare receptor; (New methods) (Venter, D.P. (303) 235)

Triprolidine
Achatin-I (Gly-D-Phe-Ala-Asp); Excitatory neuropeptide; Promethazine; Histamine H_1 receptor antagonist; Blocking effect; Neuron; (Snail) (Salunga, T.L. (304) 163)

Trishomocubane
σ Binding site; 1,3-Di-*o*-tolylguanidine; Brain membrane; (+)-Pentazocine (Nguyen, V.H. (311) 233)

Troglitazone
K_{ATP} channel; β Cell; Insulin secretion (Lee, K. (313) 163)

Trophoblast differentiation, human
Gap junction; Cell-to-cell conductance; Dye diffusion; Ca^{2+}, intracellular; Patch clamp, dual (Hervé, J.-C. (313) 243)

Trypsin
K^+ channel, ATP-sensitive; Hypertension; Myocardial hypertrophy; Single-channel recording (Sodder, V.H. (315) 115)

Tryptamine
Melatonin; Pineal gland, ovine; 5-HT (hydroxytryptamine, serotonin)-*N*-acetyltransferase (Shen, S. (307) 133)

Tryptamine-4,5-dione
5-HT (5-hydroxytryptamine, serotonin); Neurotoxicity; Free radical; Fenton (Chen, J.-C. (303) 109)

***d*-Tubocurarine**
Nicotinic receptor; Thermodynamics; Skeletal muscle; Entropy; Enthalpy (Banerjee, B. (310) 13)

Tubulin
Appetite; Drinking; Food intake; Isatin; Motivation; 5-HT (5-hydroxytryptamine, serotonin); (Mouse) (Morley, J.E. (305) 23)

Tumor
Glycosphingolipid; Recombinant interleukin-2; Adhesion; Peritumoral (Tubaro, E. (294) 555)

TUNEL assay
Cerebral ischemia; Nitric oxide (NO); Reperfusion; DNA fragmentation; Chromatin condensation; Apoptotic body (Charriaut-Marlangue, C. (310) 137)

Turning
Glutamate; Striatum; Tetrodotoxin; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); *cis*-Flupenthixol (Smith, I.D. (301) 7)

Turning behavior
Nucleus accumbens stimulation; Dopamine receptor; Acetylcholine receptor; Ventrolateral striatum; Dopamine release (Koshikawa, N. (303) 13)

Accumbal shell; Accumbal core; Dopamine D_1/D_2 receptor interaction; Dopamine D_1/D_3 receptor interaction; (Rat) (Koshikawa, N. (308) 235)

Tyr-D-Arg^2-Phe-sarcosine^4 (TAPS)
μ-Opioid receptor; SH-SY5Y cell; Inositol(1,4,5)trisphosphate; Phospholipase C (Smart, D. (305) 235)

Tyrosine hydroxylase
Protein kinase C; CGP 41251; Chromaffin cell; Catecholamine secretion; Nicotinic receptor (Loneragan, K. (311) 87)

Dopamine; Aromatic L-amino acid decarboxylase; Monoamine oxidase; Striatum; (Modulation) (Cho, S. (314) 51)

Tyrosine hydroxylase gene expression
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase mRNA; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Tyrosine hydroxylase immunoprotein
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase mRNA; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Tyrosine hydroxylase mRNA
Insulin; 2-Deoxy-D-glucose; Glucoprivation; Tyrosine hydroxylase gene expression; Tyrosine hydroxylase immunoprotein; Stress, acute; Stress, repeated; Adrenal denervation; Plasma catecholamine (Vietor, I. (313) 119)

Tyrosine kinase
EGF (epidermal growth factor); Smooth muscle, airway; Leukotriene; Phospholipase A_2 (Nasuhara, Y. (296) 161)

α_2-Adrenoceptor; Phospholipase D; Smooth muscle, vascular; $pp60^{src}$; Hypertension; Protein kinase C (Jinsi, A. (302) 183)

Cerebellar granule cell; Cell death; Li^+ (Grignon, S. (315) 111)

Tyr-W-MIF-1
Analgesia; μ-Opioid receptor; Antinociception (Gergen, K.A. (316) 33)

U46619
Benextramine; Prostanoid TP receptor; Mesenteric artery, small; SQ 30,741; (Rat) (Van der Graaf, P.H. (300) 211)

U50,488H
κ-Opioid receptor, tolerance; Ca^{2+}, intracellular, free; Inositol 1,4,5-trisphosphate; Myocyte, ventricular (Sheng, J.-Z. (307) 323)

U-69,593
Butorphanol; Glutamate; κ-Opioid receptor agonist; Locus coeruleus; Microdialysis (Hoshi, K. (314) 301)

U-73122
SK-N-BE(2)C human neuroblastoma; Phospholipase C; cAMP production; Ca^{2+} mobilization; Inositol 1,4,5-triphosphate; Neomycin (Suh, B.-C. (314) 235)

Ultrasonic vocalization
Cannabinoid; Cannabis; Anxiety; SR 141716A; CP 55,940 (McGregor, I.S. (313) 43)

$5\text{-}HT_{1A}$ receptor; Efficacy; Drug discrimination; (Rat) (Sánchez, C. (315) 245)

Unilateral vagotomy
Gastric lesion, ethanol-induced; Benzodiazepine; (Rat) (Khadour, F. (298) 271)

Up-regulation
Adrenoceptor; Desensitization; Internalization; Intact cell binding (Zhu, S.-J. (299) 205)

Uptake
MK-801 dizocilpine; Vas deferens, rat; Noradrenaline (Pubill, D. (303) 171)

Dopamine; β-Carboline; Striatum; Microdialysis; MPP^+ (*N*-methyl-4-phenylpyridinium) (Matsubara, K. (315) 145)

Uptake carrier
Microdialysis; Hippocampus; Amino acid; Vesicular release; Ca^{2+} dependency (Zuiderwijk, M. (307) 275)

Urinary bladder, hamster
[^{3}H]β-Ala^8]neurokinin A-(4–10); Tachykinin, NK_2 receptor; Tachykinin; (Binding) (Goso, C. (294) 239)

Urokinase variant
Fibrinolysis; Thrombin inhibition; Platelet aggregation; Clot specificity; (Rabbit) (Schneider, J. (302) 69)

Urotensin I
Sauvagine; CRF (corticotropin-releasing factor) receptor; Extravasation; Inflammation; ACTH (adrenocorticotropin) (Turnbull, A.V. (303) 213)

Ursodeoxycholic acid
Nitric oxide (NO) synthase; Lipopolysaccharide; J774 macrophage (Hattori, Y. (300) 147)

Uterine artery
α_1-Adrenoceptor; Estrous cycle; Pregnancy (Nair, R. (312) 45)

Uterus
Vasopressin receptor; Oxytocin receptor; Pregnancy; (Rat) (Anouar, A. (308) 87)

Uterus, rat
Sex hormone, female; Diazepam; 4'-Chlorodiazepam; Clonazepam; PK 11195; Ca^{2+} channel (Yiu, M.-k. (302) 99)

β_2-Adrenoceptor subtype; β_2-Adrenoceptor agonist; Pregnancy (Ohashi, T. (307) 315)

Hyperosmolarity; Protein kinase C; Genistein; Staurosporine (Ausina, P. (312) 309)

UTP receptor
Nucleotide receptor; ATP receptor; Aorta, rat; Endothelium; Smooth muscle, vascular (García-Velasco, G. (294) 521)

Vacuous chewing movement
Cholecystokinin; Dopamine; Dopamine D_1 receptor; Grooming; (Rat) (Van Kampen, J. (298) 7)

Vagal reflex
Tracheal innervation; Bronchoconstriction; (Guinea-pig) (Takahashi, Y. (302) 89)

Valproic acid
D-23129; Amygdala kindling; Anti-epileptic drug; Afterdischarge threshold (Tober, C. (303) 163)

Lithium chloride; G-protein; Bipolar disorder; ADP ribosylation (Young, L.T. (309) 215)

Vanilloid receptor
[^{3}H]Resiniferatoxin; Capsazepine; Neuroleptic; Cooperative binding (Szallasi, A. (298) 321)

Binding cooperativity; Resiniferatoxin; Capsaicin; PPAHV (phorbol 12-phenylacetate 13-acetate 20-homovanillate) (Szallasi, A. (299) 221)

Vasa nervorum
Diabetic rat; Nerve blood flow; Adrenergic responsiveness; ACTH-(4–9) analog, Org 2766 (Van Buren, T. (296) 277)

Vascular
Glyceryl trinitrate; Nitrite; Nitrate tolerance; Platelet; Smooth muscle cell (Weber, A.-A. (309) 209)

Vascular conductance
CGS 21680; Adenosine A_{2A} receptor; Radioactive microsphere technique (Nekooeian, A.A. (307) 163)

Vascular control
Neuropeptide Y; Noradrenaline; Peptide; Blood vessel; Hemorrhage (Hunter, L.W. (313) 79)

Vascular endothelial cell, human
Thromboxane A_2 receptor; Protein kinase C; ICAM-1 (intercellular adhesion molecule-1) (Ishizuka, T. (312) 367)

Vascular endothelium
Estrogen; Norepinephrine (McNeill, A.M. (308) 305)

Vascular permeability
Lipopolysaccharide; Nitric oxide (NO); Prostaglandin; Skin; (Mouse) (Fujii, E. (297) 257)

Bradykinin; HOE140; Ketotifen; Bradykinin receptor; Mast cell (Morishita, M. (298) 149)

Bradykinin receptor; CP-99,994; Formaldehyde; Mast cell; Tachykinin receptor (Ito, K. (307) 291)

Lipopolysaccharide; Endotoxin tolerance; Cytokine; Adrenalectomy; Nitric oxide (NO) (Fujii, E. (313) 129)

Vascular reactivity
Intimal thickening; Glucocorticoid; Nitric oxide (NO); Endothelium; Carotid artery, rabbit (Van Put, D.J.M. (294) 753)

Vascular relaxation
HF-2035; W-7; Calmodulin antagonist; Nitric oxide (NO) synthase inhibitor (Win, N.H.H. (299) 119)

Ca^{2+} channel antagonist; Negative inotropic action; Negative chronotropic action; Ca^{2+} current, L-type; NB-818 (Hattori, Y. (301) 99)

Vascular smooth muscle
17β-Estradiol; Estrogen; Ca^{2+} current, L-type, voltage-dependent; Endothelin-1; Vasopressin; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Vascular tone
5-HT_1-like receptor; Vasoconstriction; Sumatriptan; Vasoconstrictor synergy; (Rabbit, anesthetised) (Choppin, A. (304) 87)

Vas deferens
Deferential artery, human; Vasopressin; Endothelium; Nitric oxide (NO) (Medina, P. (300) 221)

Noradrenaline; Agmatine; Neurotransmission; Imidazoline receptor; Adrenoceptor (Jurkiewicz, N.H. (307) 299)

Vas deferens, guinea-pig
Mn^{2+}; Contraction; Norepinephrine; Acetylcholine (Tsunobuchi-Ushijima, H. (295) 235)

Noradrenaline release; ATP release; Cotransmission; ANP (atrial natriuretic peptide); 8-Bromoguanosine 3':5'-cyclic monophosphate (Driessen, B. (296) 261)

Vas deferens, mouse
Cannabinoid receptor; Cannabinoid receptor antagonist; SR141716A; cAMP; Adenylate cyclase (Pertwee, R.G. (296) 169)

Nociceptin; ORL_1 (Berzetei-Gurske, I.P. (302) R1)

δ-Opioid receptor; Cysteine sulfonamide enkephalin analog; Dalargin; Purinergic component; Adrenergic component; Electrical field stimulation (Pencheva, N. (304) 99)

Nociceptin receptor; Bioassay (Calò, G. (311) R3)

Cannabinoid receptor antagonist; Cannabinoid receptor partial agonist; 6′-Cyanohex-2′-yne-Δ^8-tetrahydrocannabinol; O-823; SR141716A; Myenteric plexus-longitudinal muscle preparation; Small intestine, guinea-pig (Pertwee, R.G. (315) 195)

Vas deferens, rat
Adenosine receptor; Receptor distribution (Brownhill, V.R. (303) 87)

MK-801 dizocilpine; Noradrenaline; Uptake (Pubill, D. (303) 171)

Vasoconstriction
NH_4Cl; Coronary artery; Intracellular pH (Wakabayashi, I. (299) 139)

5-HT_1-like receptor; Sumatriptan; Vasoconstrictor synergy; Vascular tone; (Rabbit, anesthetised) (Choppin, A. (304) 87)

Vasoconstriction, sympathetic
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; BIBP 3226; Vena cava, guinea-pig (Malmström, R.E. (294) 661)

Vasoconstrictor sympathetic nerve
Nitric oxide (NO); Saphenous vein, human; L-N^{ω}-Nitro-L-arginine (L-NNA); cGMP (Fabi, F. (309) 41)

Vasoconstrictor synergy
5-HT_1-like receptor; Vasoconstriction; Sumatriptan; Vascular tone; (Rabbit, anesthetised) (Choppin, A. (304) 87)

Vasodilation
Nitric oxide (NO); Coronary circulation; Nitric oxide (NO) synthase (Abdul-Hussain, M.N. (305) 155)

Vasomotor tone
PAF (platelet-activating factor); Endothelium; Arterial pressure; Blood flow; Noradrenaline; Glutamate; Cyclooxygenase; (Rabbit) (Lopes-Martins, R. (308) 287)

Vasopressin
17β-Estradiol; Estrogen; Vascular smooth muscle; Ca^{2+} current, L-type, voltage-dependent; Endothelin-1; Ca^{2+}-permeable non-selective cation current (Nakajima, T. (294) 625)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Atropine; Osmoregulation, central; PD 123177 (Höhle, S. (300) 119)

Deferential artery, human; Vas deferens; Endothelium; Nitric oxide (NO) (Medina, P. (300) 221)

Angiotensin II; Pressor response; Medullary vasomotor neuron; Rostral ventrolateral medulla (Sun, M.-K. (304) 63)

Choline; Acetylcholine; Blood pressure; Hypotension; Nicotinic receptor (Savci, V. (311) 153)

[Arg^8]Vasopressin
Vasopressin V_1 receptor antagonist; Ventral hippocampus; Retrieval; Relearning; Locomotor activity (Alescio-Lautier, B. (294) 763)

Loop of Henle; Microperfusion, in vitro; Ion transport (Grider, J. (313) 115)

[Mpa^1,D-Arg^8]Vasopressin; SR 49059; Kidney, isolated, perfused, rat; Vasopressin V_{1A} receptor (Barthelmebs, M. (314) 325)

[Mpa^1,D-Arg^8]Vasopressin
[Arg^8]Vasopressin; SR 49059; Kidney, isolated, perfused, rat; Vasopressin V_{1A} receptor (Barthelmebs, M. (314) 325)

Vasopressin receptor
Oxytocin receptor; Uterus; Pregnancy; (Rat) (Anouar, A. (308) 87)

Vasopressin V_1 receptor antagonist
[Arg^8]Vasopressin; Ventral hippocampus; Retrieval; Relearning; Locomotor activity (Alescio-Lautier, B. (294) 763)

Vasopressin V_{1A} receptor
[Arg^8]Vasopressin; [Mpa^1,D-Arg^8]Vasopressin; SR 49059; Kidney, isolated, perfused, rat (Barthelmebs, M. (314) 325)

Vasorelaxation
Heart; ATP-sensitive K^+ channel; His bundle; Conduction; Refractory period; Electrophysiology (D'Alonzo, A.J. (294) 271)

Vein
Prostaglandin E_2; Bradykinin; Pain; Nociceptor (Kindgen-Milles, D. (294) 491)

Vena cava, guinea-pig
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; BIBP 3226; Vasoconstriction, sympathetic (Malmström, R.E. (294) 661)

Ventral hippocampus
[Arg^8]Vasopressin; Vasopressin V_1 receptor antagonist; Retrieval; Relearning; Locomotor activity (Alescio-Lautier, B. (294) 763)

Ventral root potential
MK-801; Spinal cord; Morphine tolerance; NMDA receptor antagonist (Bell, J.A. (294) 289)

Ventral tegmental area
Ethanol; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Microdialysis (Yan, Q.-S. (301) 49)

Mesolimbic system, rat; Nucleus accumbens; 5-HT_3 receptor; Dopaminergic modulation; Locomotor activity (Gillies, D.M. (303) 1)

Nicotine; L-DOPA (3,4-dihydroxyphenylalanine) release; Locomotor activity, rat; Nucleus accumbens; Microdialysis (Goshima, Y. (309) 229)

OPC-14597; Extracellular recording in vivo; Whole-cell recording; Thin-slice preparation; Dopamine D_2 receptor (Momiyama, T. (310) 1)

Morphine; $GABA_B$ receptor; Reward; Place conditioning (Tsuji, M. (313) 169)

Ventricular arrhythmia
Myocardial ischemia; α-Adrenoceptor subtype-selective blocker; Coronary occlusion; Heart rate; Arrhythmia (Geller, J.C. (294) 423)

MCI-154 (6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3-(2*H*)-pyridazinone); Heart failure; Ca^{2+} current (Eto, K. (298) 247)

Automaticity; Hyperpolarization-activated current (I_f); Zatebradine; Heart, dog (Furukawa, Y. (300) 203)

Nicorandil; Myocardial ischemia; K_{ATP} channel; Nitric oxide (NO); Reperfusion (Vegh, A. (305) 163)

Ventricular cardiomyocyte
Endothelin-1; Ca^{2+} current (Kelso, E. (308) 351)

Ventricular cell, guinea-pig
Maitotoxin; Na^+-permeable channel; Patch clamp (Nishio, M. (297) 293)

Ventricular fibrillation
ATP-dependent K^+ channel blocker; Cardiac arrhythmia (Friedrichs, G.S. (306) 99)

Ventricular filling
Isovolumic relaxation; Myocardial contractility; Preload recruitable stroke work; Inotropes; Dobutamine; Bradycardic agents, specific; Zatebradine (Hettrick, D.A. (316) 237)

Ventricular function
Preload recruitable stroke work; Diastolic function; Isovolumic relaxation; Superoxide dismutase; SC-55858; SC-54417 (Lowe, D. (304) 81)

Ventricular hypertrophy, right
Semotiadil; Media thickening; Pulmonary hypertension (Takahashi, T. (295) 229)

Ventricular myocardium, rabbit
Methoxamine; α_1-Adrenoceptor; Positive inotropic effect; Endothelin (Yang, H.-T. (296) 47)

α_1-Adrenoceptor; Positive inotropic effect; Phosphoinositide hydrolysis; Oxymetazoline; (±)-Tamsulosin [(±)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]-amino]propyl]-2-methoxybenzenesulfonamide-HCl] (Yang, H.-T. (312) 281)

Ventricular myocyte, rat
Taurine; Na^+-Ca^{2+} exchange; Patch-clamp (Katsube, Y. (316) 97)

Ventrolateral striatum
Nucleus accumbens stimulation; Dopamine receptor; Acetylcholine receptor; Dopamine release; Turning behavior (Koshikawa, N. (303) 13)

Ventromedial nucleus
Opioid receptor; δ-Opioid receptor; μ-Opioid receptor; κ-Opioid receptor; [Met^5]Enkephalin; Hypothalamus; Electrophysiology; (Rat) (Zhang, C. (308) 153)

Venular shear rate
Intravital microscopy; Flow cytometry; Blood pressure, mean arterial; Leukocyte rolling; Leukocyte adherence (Scalia, R. (296) 181)

Veratridine
5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindoleacetic acid); Blood pressure; Tetrodotoxin; Hypothalamus; Noradrenaline; Hypervolemia; Hypovolemia; Push-pull cannula (Singewald, N. (294) 787)

Ouabain; Cytosolic Ca^{2+}; Chromaffin cell; Lithium chloride (De la Fuente, M.T. (306) 219)

CP-060*S*; Ca^{2+} overload; Cardiomyocyte; Ca^{2+} channel; Smooth muscle, vascular (Tamura, K. (312) 195)

Verbascoside
Cyclic adenosine monophosphate; Langendorff heart preparation; (*Eremophila altermifolia*) (Pennacchio, M. (305) 169)

Vesicular monoamine transporter
VMAT2 (vesicular monoamine transporter type 2); Dopamine D_2 receptor; Presynaptic dopamine re-uptake site, presynaptic; Dopamine; Methoxytetrabenazine (Vander Borght, T. (294) 577)

VMAT2 (vesicular monoamine transporter type 2); MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Methoxytetrabenazine; Dihydrotetrabenazine (Kilbourn, M. (307) 227)

Vesicular release
Microdialysis; Hippocampus; Amino acid; Uptake carrier; Ca^{2+} dependency (Zuiderwijk, M. (307) 275)

Vessel
Agmatine; Efaroxan; Imidazoline receptor; Insulin secretion; Pancreas, rat (Berdeu, D. (308) 301)

Vincamine
Muscarinic receptor, heart; Muscarinic receptor, allosteric control; Allosteric interaction; Eburnamonine; Alcuronium; Strychnine (Proška, J. (305) 201)

Vincanol; Vinpocetine; Na^+ channel; Voltage-gated; Batrachotoxin; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

Vincanol
Vincamine; Vinpocetine; Na^+ channel; Voltage-gated; Batrachotoxin; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

Vinpocetine
Vincamine; Vincanol; Na^+ channel; Voltage-gated; Batrachotoxin; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

VIP (vasoactive intestinal peptide)
Glutamate receptor, metabotropic; cAMP; Adenosine deaminase; Forskolin; NECA (5′-*N*-ethylcarboxamidoadenosine); Hippocampus (Wright, R.A. (297) 275)

Lower esophageal sphincter; NANC (non-adrenergic non-cholinergic) neurotransmission; Electrical field stimulation; Nicotine; Nitric oxide (NO) (Kortezova, N. (304) 109)

VIP receptor, human
VIP receptor antagonist; Desensitization; Internalization; Recombinant protein; Transfection (Gaudin, P. (302) 207)

VIP receptor antagonist
VIP receptor, human; Desensitization; Internalization; Recombinant protein; Transfection (Gaudin, P. (302) 207)

Visceral nociception
Colonic inflammation; Clonidine; S12813-4; Antinociceptive effect; Noradrenergic mechanism (Miampamba, M. (308) 251)

Visual system
Melatonin; Receptor autoradiography; 2-[^{125}I]Iodomelatonin; (Reptile) (Larson-Prior, L.J. (297) 181)

Vitamin E
α-Tocopherol analog (water-soluble); Neuroprotection; Lipid peroxidation; Antioxidant; Malondialdehyde; Free radical; Cyclic voltammetry (Bolkenius, F.N. (298) 37)

VMAT2 (vesicular monoamine transporter type 2)
Vesicular monoamine transporter; Dopamine D_2 receptor; Presynaptic dopamine re-uptake site, presynaptic; Dopamine; Methoxytetrabenazine (Vander Borght, T. (294) 577)

Vesicular monoamine transporter; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Methoxytetrabenazine; Dihydrotetrabenazine (Kilbourn, M. (307) 227)

Vogel-type conflict test
κ-Opioid receptor agonist; Anticonflict effect; Diazepam; (Mouse) (Tsuda, M. (307) 7)

Voltage clamp
Recombinant NMDA receptor; *Xenopus* oocyte; Ifenprodil stereoisomer (Avenet, P. (296) 209)

Voltage-clamp
Nicotinic acetylcholine receptor; Muscle, fetal, rat; Patch-clamp; Molecular modelling; Nicotinic agonist; Non-competitive agonist (Cooper, J.C. (309) 287)

Voltage clamp, whole cell
Bepridil; Na^+ current; Myocyte, single, ventricular (Sato, N. (314) 373)

Voltage dependence
Ca^{2+} current, L-type; Niguldipine; Whole-cell recording; Enantioselectivity (Handrock, R. (309) 317)

Charybdotoxin; Dendrotoxin; Channel kinetics; Inactivation; Deactivation (Sprunger, L.K. (314) 357)

Voltage-gated
Vincamine; Vincanol; Vinpocetine; Na^+ channel; Batrachotoxin; Neuroprotection; Anticonvulsant (Erdő, S.L. (314) 69)

Vomiting
Emesis; Morphine; Nicotine; Tachykinin NK_1 receptor; 5-HT_3 receptor; 5-HT_{1A} receptor; Resiniferatoxin; Retching; (*Suncus murinus*) (Andrews, P. (307) 305)

Von Willebrand factor
Balloon angioplasty; Neointima; Restenosis; Endothelium; Nitric oxide (NO); Nitric oxide (NO) synthase (Bosmans, J.M. (310) 163)

Aurintricarboxylic acid; Triflavin; Glycoprotein IIb/IIIa; Photochemically induced thrombosis (Hisamichi, N. (312) 69)

W-7
HF-2035; Calmodulin antagonist; Vascular relaxation; Nitric oxide (NO) synthase inhibitor (Win, N.H.H. (299) 119)

Achatin-I (Gly-D-Phe-Ala-Asp); Peptide neurotransmitter; Intracellular signal transduction system; H-89; KT5823; IBMX (3-isobutyl-1-methylxanthine); Neurone; (Snail) (Emaduddin, M. (302) 129)

Water exchange
Amiodarone; NMR (nuclear magnetic resonance); Membrane (Federico, A. (304) 237)

Water intake
Lipopolysaccharide; Interleukin-1; Interleukin-1 receptor; Antagonist; (Human) (Nava, F. (309) 223)

Water maze
α_1-Adrenoceptor; NMDA receptor; Passive avoidance; Prazosin; CPP ((±))-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid) (Riekkinen, M. (300) 9)

Dextromethorphan; NMDA receptor; Spatial learning; Memory (Bane, A. (302) 7)

Cerebral ischemia; Adenosine receptor; Spatial memory; (Gerbil) (Von Lubitz, D.K.J.E. (302) 43)

WAY 100135
Dopamine; Cortex, prefrontal; 5-HT_{1A} receptor; Ipsapirone; NAN-190; Microdialysis (Wędzony, K. (305) 73)

[*carbonyl*-^{11}C]WAY 100635
5-HT_{1A} receptor, human; PET (positron emission tomography) (Pike, V.W. (301) R5)

(*S*)-WAY 100135
5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) level, extracellular; Microdialysis; WAY100635 (Assié, M.-B. (304) 15)

WAY 100,635
S 15535; 5-HT_{1A}; [^{35}S]GTPγS binding; (±)-8-OH-DPAT ((±)-hydroxy-2-(di-*n*-propylamino)tetralin) (Newman-Tancredi, A. (307) 107)

WAY 100635
Myoclonic jerk; 8-OH-DPAT ((±)-8-hydroxy-2-(di-*n*-propylamino)tetralin); SKF 99101H; GR 127935; 5-HT_{1D} receptor; 5-HT_{1A} receptor; 5-Hydroxytryptophan; (Guinea-pig) (Hagan, J.J. (294) 743)

5-HT_{1A} receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin) level, extracellular; Microdialysis; (*S*)-WAY100135 (Assié, M.-B. (304) 15)

Microdialysis, in vivo; Citalopram; Penbutolol enantiomer; 5-HT_{1A} autoreceptor, raphe; 5-HT_{1A} receptor, postsynaptic; β-Adrenoceptor; Antidepressant augmentation (Hjorth, S. (316) 43)

WB4101
4-Aminopyridine; α_1-Adrenoceptor subtype; Chloroethylclonidine; Cardiac muscle, isolated; Staurosporine (Williamson, A.P. (304) 73)

Wet-dog shake
Forced swim test; Stress; 5-HT_2 receptor; β-Adrenoceptor (Takao, K. (294) 721)

Whole-cell patch clamp
NS-004; [Ca^{2+}]$_i$, free; K^+ channel, Ca^{2+}-activated; K^+ channel, delayed rectifier; Membrane potential; Pulmonary artery smooth muscle cell (Vandier, C. (295) 53)

Whole-cell patch-clamp recording
CCK_B receptor; Neostriatal neuron; Cationic current; G-protein; Inositol 1,4,5-trisphosphate (Wu, T. (307) 125)

Whole-cell recording
Ca^{2+} current, L-type; Niguldipine; Voltage dependence; Enantioselectivity (Handrock, R. (309) 317)

Ventral tegmental area; OPC-14597; Extracellular recording in vivo; Thin-slice preparation; Dopamine D_2 receptor (Momiyama, T. (310) 1)

Whole-cell voltage-clamp
Ca^{2+} channel; Dissociated Purkinje neuron; Inactivation; Eliprodil (Biton, B. (294) 91)

WIN 55,212-2
Basal ganglia; Cannabinoid; Globus pallidus; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; Aminoalkylindole; Anandamide (Miller, A.S. (304) 29)

WIN 35,428 binding
Dopamine transporter; Dopamine uptake; Arachidonic acid; Protein kinase C; Second messenger (Zhang, L. (315) 345)

'Wind-up'
TRH (thyrotropin-releasing hormone); NMDA receptor; Spinal cord; Nociception (Chizh, B.A. (300) 183)

Wistar Kyoto rat (WKY)
α_{1D}-Adrenoceptor; α_{1A}-Adrenoceptor; BMY 7378; Spontaneously hypertensive rat (SHR); Artery (Villalobos-Molina, R. (298) 257)

Withdrawal
Morphine analgesia; Reinforcing property; Morphine dependence; Antipain; Leupeptin (Lyupina, Y.V. (304) 23)

Acamprosate; Alcohol; Radiotelemetry; (Rat) (Spanagel, R. (305) 45)

Dextromethorphan; Opiate; Naloxone; Excitatory amino acid (Rosen, M.I. (307) 251)

Opiate; Tolerance; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Locus ceruleus; (Mouse) (Dossin, O. (308) 271)

Withdrawal syndrome
Opiate detoxification; Naltrexone (Muntoni, A.L. (301) R9)

W-7 (*N*-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide)
ML-7 (1-(5-iodonaphthalene-1-sulfonyl)-1*H*-hexahydro-1,4-diazepine); Thromboxane A_2; G-protein; Phosphoinositide hydrolysis; Ca^{2+} (Ohkubo, S. (298) 175)

Working memory
Noradrenaline; β-Adrenoceptor; Propranolol; NMDA receptor; Hippocampus (Ohno, M. (307) 21)

Hippocampus; Acetylcholine release (Fadda, F. (307) R1)

Wortmannin
Staurosporine; Calphostin C; Protein kinase C; Myosin light chain kinase; Aorta; (Rabbit) (Asano, M. (294) 693)

Wound healing
Angiogenesis; Basement membrane; Neurogenic inflammation; Tachykinin (Wiedermann, C.J. (298) 335)

SM-10902 ointment; Prostacyclin analog; Blood flow, skin; Angiogenesis; Diabetic mouse (*db/db* mouse), genitically (Yamamoto, T. (302) 53)

Writhing test
Bradykinin; Bradykinin B_1 receptor; Bradykinin B_2 receptor; NPC 18521; Antinociception; Formalin; Capsaicin; Licking; Paw oedema; (Mouse); (Rat) (De Campos, R.O.P. (316) 277)

XAC
Adenosine A_{2A} receptor, human; Mutation; Glutamic acid; CGS21680; Amiloride (IJzerman, A.P. (310) 269)

Xanthine
Propentofylline; Adenosine receptor; Myeloperoxidase; Polymorphonuclear leukocyte influx (Zhang, Y. (313) 237)

Xanthine antagonist resistance
Bronchoconstriction, adenosine-induced; Tracheal spirals; Cross-tachyphylaxis; Transport inhibitors; (Sensitized guinea pigs) (Thorne, J.R. (316) 263)

***Xenopus* oocyte**
ATP receptor channel; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Recombinant channel (Nakazawa, K. (296) 119)

Recombinant NMDA receptor; Ifenprodil stereoisomer; Voltage clamp (Avenet, P. (296) 209)

Propofol; Benzodiazepine; $GABA_A$ receptor; Flurazepam; Anesthesia (Reynolds, J.N. (314) 151)

Yawning
Nitric oxide (NO) donor; Penile erection; Guanylate cyclase; Paraventricular nucleus; (Rat) (Melis, M.R. (294) 1)

[^{3}H]YM060 ([*methyl*-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride)
5-HT_3 receptor; Cerebral cortex; Ileum; Colon; 5-HT_3 receptor, cloned, rat (Akuzawa, S. (296) 227)

[^{3}H]YM-09151-2
Dopamine D_2 receptor; [^{3}H]Spiperone; [^{3}H]Raclopride; [^{125}I]NCQ-298; Nemonapride; Receptor binding, in vitro (Malmberg, Å. (303) 123)

Y_1 receptor antagonist
Neuropeptide Y; BIBP3226; Gastrointestinal epithelia (Tough, I.R. (310) 55)

[^{125}I]*S*-(−)-Zacopride
5-HT recognition site; Duodenum, rat; Ileum, rat; Autoradiography (Ge, J. (300) 113)

Zaleplon
Zolpidem; Hypnotic; BZ (ω) receptor (Sanger, D.J. (313) 35)

Zaprinast
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Motapizone; Rolipram; Zardaverine (Wagner, U. (298) 265)

Airway responsiveness; Nitric oxide (NO); Airway epithelium; Methylene blue; Guanylate cyclase (Sadeghi-Hashjin, G. (302) 109)

Nitroglycerin; Tolerance; Phosphodiesterase inhibitor; cGMP monophosphate; Blood pressure; Dipyridamole; Spontaneously hypertensive rat (SHR) (De Garavilla, L. (313) 89)

Zardaverine
Mucus secretion; Trachea; Theophylline; 8-Phenyltheophylline; Enprofylline; 3-Isobutyl-methylxanthine; Motapizone; Rolipram; Zaprinast (Wagner, U. (298) 265)

Zatebradine
AV node; E-4031; K^+ current, delayed rectifier; Heart, dog (Yamazaki, K. (297) 233)

Automaticity; Hyperpolarization-activated current (I_f); Ventricular arrhythmia; Heart, dog (Furukawa, Y. (300) 203)

Isovolumic relaxation; Ventricular filling; Myocardial contractility; Preload recruitable stroke work; Inotropes; Dobutamine; Bradycardic agents, specific (Hettrick, D.A. (316) 237)

ZD7114, partial agonist effect
Adipocyte, rat, white; Lipolysis; β_3-Adrenoceptor (Mayers, R.M. (295) 199)

ZM 241385
Adenosine; Adenosine A_{2A} receptor; Pharmacology, in vivo (Keddie, J.R. (301) 107)

Zolpidem
Zaleplon; Hypnotic; BZ (ω) receptor (Sanger, D.J. (313) 35)

Zymosan
PAF (platelet-activating factor); Arachidonic acid; Acyltransferase; Triacsin C (Naraba, H. (302) 117)

European Journal of Pharmacology

GENERAL INSTRUCTIONS

Complete instructions are given in the 'Notice to authors' (Vol. 319, No. 1, page v) or available as reprint, free on request. The 'Notice' must be followed to the letter so that papers conform to the style of the *European Journal of Pharmacology*.

The original and 3 copies, complete with 4 sets of figures and tables should be sent to:

The Editorial Office, European Journal of Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
Tel.: (31-30) 253-8833; Fax: (31-30) 253-9033

Acceptability of rapid communications will be decided by the editors, who will be advised by a member of the editorial board or by one of the consultants. Full-length manuscripts, short communications and short reviews are generally submitted to two referees who are chosen for their ability to evaluate the work. Authors may request that certain referees not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration from the referees. In order to reduce mailing costs, manuscripts will not be returned to the authors. Only the decision of the editors, together with the advise of the referees will be sent to the author(s). When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments they have incorporated and their reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editorial office. A revised manuscript should be received at the editorial office not later than 5 weeks (minor revision) or 10 weeks (extensive revision) after the editorial decision was postmarked to the author(s). Revised manuscripts received later than this will be processed as a new manuscript. Handwritten additions or corrections are not acceptable. Pages affected by revision must be retyped.

The preferred medium of final submission to the accepting editor is on disk with the accompanying reviewed and revised manuscript (see 'Electronic manuscripts' below). Manuscripts submitted by facsimile transmission will not be considered. Manuscripts should be typewritten or printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be processed by electronic scanning makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), type face, neither distorted nor reduced or enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable type face. Manuscripts should be written in English. Accepted manuscripts will, if necessary, have English style and language corrected. Manuscripts with extensive changes will be returned to the authors for retyping. Submission of a paper in clear, grammatical English will, therefore, shorten publication time considerably.

1. Electronic manuscripts

Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

2. Rapid communications

(a) Reports on exciting new results within the scope of the journal can be submitted for publication in the rapid communications section.
(b) A rapid communication should not exceed 700 words and should contain no or only one simple table or figure of not more than 8.4 cm = 1 column width.
(c) A maximum of 8 references may be used.
(d) The rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings, and preferably accompanied by a floppy disk (see section 1). The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done (all on 1 page); abstract (max. 75 words) and keywords (indexing terms, max. 3 items); text; acknowledgement(s); references; figure legend and figure; table (colour figures will delay publication). Name, full postal address, telephone, fax numbers, and e-mail address of author to whom correspondence is to be sent should be mentioned on the title page.
(e) Rapid communications have priority at the editorial office and publisher.
(f) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(g) Upon acceptance of a rapid communication a reprint order form will be sent to the author(s).

3. Full-length manuscripts

(a) The manuscript should be arranged as follows. First page: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done; name, full postal address, telephone and telefax numbers of author to whom proofs and other correspondence should be sent. Next page (2): abstract and keywords (indexing terms: normally 3–6 items). Pages 3 to end: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables. Both sections and their subdivisions should be numbered (2.1., 2.2., 2.3., etc.).
(b) Abstract and keywords: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. Below the abstract, type 3–6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from *Index Medicus* or *Excerpta Medica Index*. First category keywords (e.g., Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed and cross-indexed. Second category keywords (e.g., Rat, Cold, Metabolite) will only be listed under the index entry for the first category keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation of the author(s).
(c) Standard nomenclature should be used throughout. Avoid unnecessary abbreviations and symbols (see extensive 'Notice to authors', Vol. 319, No. 1, p. v). Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g., 8 or eight) should be consistent throughout the manuscript.

(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

4. Short communications should be prepared as described under 3, except for the following:
(a) The average length of a short communication should not exceed 4 pages in print (approx. 2000–2300 words including abstract, captions and references). A maximum of 2 illustrations (figures and tables) is allowed.
(b) An abstract of not more than 100 words should be provided and 3–6 keywords should be listed immediately below the abstract.
(c) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(d) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

5. References
References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1990) or (Hicks et al., 1988, 1989; Seeman et al., 1990; Stoof and Kebabian, 1991a,b,c). For three or more authors the name of the first author followed by et al. should be used. Journal names should be abbreviated according to the *List of Serial Title Word Abbreviations* (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed alphabetically. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references. Sample references:

Periodicals:
Paivio, A., Jansen, B., Becker, L.J., 1975. Comparisons through the mind's eye. Cognition 37, 635–647.
Strunk, W., White, E.B., 1979. The Elements of Style, third ed. MacMillan, New York, NY.
Gurman, A.S., Kniskern, D.P., 1981. Family therapy outcome research: knowns and unknowns. In: Gurman, A.S., Kniskern, D.P. (Eds.), Handbook of Family Therapy. Brunner/Maazel, New York, NY, pp. 742–775.

6. Illustrations, graphs and tables (see Notice to authors, Vol. 319, No. 1, p. v)
(a) Either the original drawings plus 3 good photographs, or 4 good photographs of the drawings (on glossy paper and unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.
(b) It is important to allow for reduction to fit a single column, 8.4 cm wide, or at most a double column, maximally 17.6 cm wide. Illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. The following symbols can be typeset and explained (as well as all lettering) in the legends: + × ■ □ ● ▲ ▼ ◀ ▶ ○ ◇ △ ▽ ▷ ◁ ⊕ ⊗ ⊖ ⊜ ⊛ * ★. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4–2 mm height when reduced to 8.4 cm width).
(c) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals. Kymograph records on sooted paper should be reversed photographically to ensure graphs in black on a white background.
(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.
(e) A calibration bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.
(f) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2, etc.).
(g) Legends to figures should make these comprehensible without reference to the text.
(h) Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).
(i) Colour reproduction of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission of the manuscript to the editors.

7. Proofs
One set of galley proofs will be sent to the author named on the title page (see section 3.). Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. Proofs should be returned within 48 hours to Elsevier Science B.V., Log-in Department, P.O. Box 2759, 1000 CT Amsterdam, The Netherlands, preferably by Fax ((31-20) 485-3239). If this period is exceeded no reminders will be sent, the manuscript will be read by the editorial staff of the publisher only and printed without the author's corrections. Authors of short and rapid communications will not receive galley proofs.

8. Page charges and reprints
There will be no page charge. Authors of a full-length paper will receive, together with the galley proofs, a reprint order form with must be completed and returned to the publisher with the proofs. Authors of short and rapid communications will receive a reprinted order form but no proofs: this order form should be mailed to the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered immediately.

© 1997 Elsevier Science B.V. All rights reserved

Printed in The Netherlands *Library of Congress Catalog Card Number 68-26539* Published weekly

EUROPEAN JOURNAL OF PHARMACOLOGY

Master Author and Keyword Indexes, Volumes 294–316, 1996

Cited in: Biological Abstracts – Chemical Abstracts – Current Contents/Life Sciences – Excerpta Medica (EMBASE) – Index Medicus – Pascal M – Reference Update – Unlisted Drugs – Current Awareness in Biological Sciences (CABS)

CONTENTS

Master author index to volumes 294–316 (1996) 1

Master keyword index to volumes 294–316 (1996) 53